<!DOCTYPE html>
 <!--[if lt IE 7]> <html dir="ltr" lang="en-US" class="aui ltr no-js lt-ie9 lt-ie8 lt-ie7"> <![endif]--> <!--[if IE 7]> <html dir="ltr" lang="en-US" class="aui ltr no-js lt-ie9 lt-ie8"> <![endif]--> <!--[if IE 8]> <html dir="ltr" lang="en-US" class="aui ltr no-js lt-ie9"> <![endif]--> <!--[if gt IE 8]><!--> <html class="aui ltr" dir="ltr" lang="en-US" prefix="og: http://ogp.me/ns#"> <!--<![endif]--> <head> <title>PARP (Poly ADP‐Ribose Polymerase) inhibitors for locally advanced or metastatic breast cancer - Taylor, AM - 2021 | Cochrane Library</title> <meta content="PARP (Poly ADP‐Ribose Polymerase) inhibitors for locally advanced or metastatic breast cancer - Taylor, AM - 2021 | Cochrane Library" property="og:title"/> <meta content="https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD011395.pub2/full" property="og:url"/> <meta content="article" property="og:type"/> <meta content="https://www.cochranelibrary.com/cochrane-theme/images/cochrane_circulargraphic.png" property="og:image"/> <meta content="summary_large_image" name="twitter:card"/> <meta content="PARP (Poly ADP‐Ribose Polymerase) inhibitors for locally advanced or metastatic breast cancer - Taylor, AM - 2021 | Cochrane Library" name="twitter:title"/> <meta content="https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD011395.pub2/full" name="twitter:url"/> <meta content="https://www.cochranelibrary.com/cochrane-theme/images/cochrane_circulargraphic.png" name="twitter:image"/> <meta content="initial-scale=1.0, width=device-width" name="viewport"/> <meta content="10.1002/14651858.CD011395.pub2" name="dc.identifier" scheme="DOI"/> <meta content="PARP (Poly ADP‐Ribose Polymerase) inhibitors for locally advanced or metastatic breast cancer" name="citation_title"/> <meta content="Amelia M Taylor" name="citation_author"/> <meta content="Royal North Shore Hospital" name="citation_author_institution"/> <meta content="David Lok Hang Chan" name="citation_author"/> <meta content="Martin Tio" name="citation_author"/> <meta content="Royal North Shore Hospital" name="citation_author_institution"/> <meta content="Sujata M Patil" name="citation_author"/> <meta content="Memorial Sloan Kettering Cancer Center" name="citation_author_institution"/> <meta content="Tiffany A Traina" name="citation_author"/> <meta content="Memorial Sloan Kettering Cancer Center, Weill Cornell Medical College" name="citation_author_institution"/> <meta content="Mark E Robson" name="citation_author"/> <meta content="Memorial Sloan Kettering Cancer Center, Weill Cornell Medical College" name="citation_author_institution"/> <meta content="Mustafa Khasraw" name="citation_author"/> <meta content="NHMRC Clinical Trials Centre, The University of Sydney" name="citation_author_institution"/> <meta content="mustafa.khasraw@duke.edu" name="citation_author_email"/> <meta content="Cochrane Database of Systematic Reviews" name="citation_journal_title"/> <meta content="John Wiley &amp; Sons, Ltd" name="citation_publisher"/> <meta content="4" name="citation_issue"/> <meta content="10.1002/14651858.CD011395.pub2" name="citation_doi"/> <meta content="2021" name="citation_date"/> <meta content="2021/04/22" name="citation_online_date"/> <meta content="https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD011395.pub2/abstract" name="citation_abstract_html_url"/> <meta content="https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD011395.pub2/full" name="citation_fulltext_html_url"/> <meta content="https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD011395.pub2/pdf/full" name="citation_pdf_url"/> <meta content="1465-1858" name="citation_issn"/> <meta content="en" name="citation_language"/> <meta content="Bias; Breast Neoplasms [chemistry, *drug therapy, genetics, pathology]; Genes, BRCA1; Genes, BRCA2; Germ-Line Mutation; Poly(ADP-ribose) Polymerase Inhibitors [adverse effects, *therapeutic use]; Quality of Life; Randomized Controlled Trials as Topic; Triple Negative Breast Neoplasms [drug therapy, genetics, pathology]" name="citation_keywords"/> <link href="https://fonts.googleapis.com/css?family=Source+Sans+Pro:400,700,600,900" rel="stylesheet"/> <script src="https://cmp.osano.com/AzZdRbSORDOOzF9W/d594efc1-9663-477d-9528-6576640e64fd/osano.js"></script> <style> .osano-cm-widget{display: none;} </style> <script src="https://static.addtoany.com/menu/page.js"></script> <script async="" charset="utf-8" src="https://platform.twitter.com/widgets.js"></script> <script async="async" src="//script.crazyegg.com/pages/scripts/0056/6375.js" type="text/javascript"></script> <script type="text/javascript">window.dataLayer={};var xtend=function(){var a={};var b=false;var c=0;var d=arguments.length;if(Object.prototype.toString.call(arguments[0])==="[object Boolean]"){b=arguments[0];c++}var f=function(g){for(var h in g){if(Object.prototype.hasOwnProperty.call(g,h)){if(b&&Object.prototype.toString.call(g[h])==="[object Object]"){a[h]=xtend(true,a[h],g[h])}else{a[h]=g[h]}}}};for(;c<d;c++){var e=arguments[c];f(e)}return a};</script> <!-- Global site tag (gtag.js) - Google Analytics --> <script src="https://www.googletagmanager.com/gtag/js?id=UA-189672-63&amp;l=gDataLayer"></script> <script>window.gDataLayer=window.gDataLayer||[];function gtag(){gDataLayer.push(arguments)}gtag("js",new Date());gtag("config","UA-189672-63");</script> <script type="text/javascript">var o={auth:{customerIds:[],individualId:null,brandedCustomer:null,roles:["Guest"]}};window.dataLayer=xtend(true,window.dataLayer,o);</script> <script type="text/javascript">var o={page:{siteSection:"Content",languageCode:"en",cms:{pageTitle:"Content"}}};window.dataLayer=xtend(true,window.dataLayer,o);</script> <meta content="text/html; charset=utf-8" http-equiv="content-type"/> <link href="https://www.cochranelibrary.com/cochrane-theme/images/favicon.ico" rel="Shortcut Icon"/> <link href="https://www.cochranelibrary.com/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD011395.pub2&amp;doi=10.1002/14651858.CD011395.pub2&amp;type=cdsr&amp;contentLanguage=" rel="canonical"/> <link href="https://www.cochranelibrary.com/zh/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD011395.pub2&amp;doi=10.1002/14651858.CD011395.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="zh-HANS" rel="alternate"/> <link href="https://www.cochranelibrary.com/zh_HANT/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD011395.pub2&amp;doi=10.1002/14651858.CD011395.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="zh-HANT" rel="alternate"/> <link href="https://www.cochranelibrary.com/hr/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD011395.pub2&amp;doi=10.1002/14651858.CD011395.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="hr-HR" rel="alternate"/> <link href="https://www.cochranelibrary.com/nl/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD011395.pub2&amp;doi=10.1002/14651858.CD011395.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="nl-NL" rel="alternate"/> <link href="https://www.cochranelibrary.com/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD011395.pub2&amp;doi=10.1002/14651858.CD011395.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="x-default" rel="alternate"/> <link href="https://www.cochranelibrary.com/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD011395.pub2&amp;doi=10.1002/14651858.CD011395.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="en-US" rel="alternate"/> <link href="https://www.cochranelibrary.com/fr/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD011395.pub2&amp;doi=10.1002/14651858.CD011395.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="fr-FR" rel="alternate"/> <link href="https://www.cochranelibrary.com/de/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD011395.pub2&amp;doi=10.1002/14651858.CD011395.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="de-DE" rel="alternate"/> <link href="https://www.cochranelibrary.com/hi/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD011395.pub2&amp;doi=10.1002/14651858.CD011395.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="hi-HI" rel="alternate"/> <link href="https://www.cochranelibrary.com/hu/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD011395.pub2&amp;doi=10.1002/14651858.CD011395.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="hu-HU" rel="alternate"/> <link href="https://www.cochranelibrary.com/in/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD011395.pub2&amp;doi=10.1002/14651858.CD011395.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="in-ID" rel="alternate"/> <link href="https://www.cochranelibrary.com/ja/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD011395.pub2&amp;doi=10.1002/14651858.CD011395.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="ja-JP" rel="alternate"/> <link href="https://www.cochranelibrary.com/ko/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD011395.pub2&amp;doi=10.1002/14651858.CD011395.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="ko-KR" rel="alternate"/> <link href="https://www.cochranelibrary.com/ms/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD011395.pub2&amp;doi=10.1002/14651858.CD011395.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="ms-MY" rel="alternate"/> <link href="https://www.cochranelibrary.com/fa/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD011395.pub2&amp;doi=10.1002/14651858.CD011395.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="fa-IR" rel="alternate"/> <link href="https://www.cochranelibrary.com/pl/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD011395.pub2&amp;doi=10.1002/14651858.CD011395.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="pl-PL" rel="alternate"/> <link href="https://www.cochranelibrary.com/pt/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD011395.pub2&amp;doi=10.1002/14651858.CD011395.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="pt-PT" rel="alternate"/> <link href="https://www.cochranelibrary.com/ro/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD011395.pub2&amp;doi=10.1002/14651858.CD011395.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="ro-RO" rel="alternate"/> <link href="https://www.cochranelibrary.com/ru/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD011395.pub2&amp;doi=10.1002/14651858.CD011395.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="ru-RU" rel="alternate"/> <link href="https://www.cochranelibrary.com/es/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD011395.pub2&amp;doi=10.1002/14651858.CD011395.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="es-ES" rel="alternate"/> <link href="https://www.cochranelibrary.com/ta/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD011395.pub2&amp;doi=10.1002/14651858.CD011395.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="ta-IN" rel="alternate"/> <link href="https://www.cochranelibrary.com/th/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD011395.pub2&amp;doi=10.1002/14651858.CD011395.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="th-TH" rel="alternate"/> <link class="lfr-css-file" href="https://www.cochranelibrary.com/cochrane-theme/css/main.css?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;minifierType=css&amp;languageId=en_US&amp;b=6210&amp;t=1738734739000" rel="stylesheet" type="text/css"/> <link class="lfr-css-file" href="https://www.cochranelibrary.com/cochrane-theme/css/aui.css?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;minifierType=css&amp;languageId=en_US&amp;b=6210&amp;t=1738734739000" rel="stylesheet" type="text/css"/> <link href="/html/css/main.css?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;minifierType=css&amp;languageId=en_US&amp;b=6210&amp;t=1739773519000" rel="stylesheet" type="text/css"/> <link href="https://www.cochranelibrary.com/scolaris-content-display/css/main.css?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;minifierType=css&amp;languageId=en_US&amp;b=6210&amp;t=1739773465000" rel="stylesheet" type="text/css"/> <link href="https://www.cochranelibrary.com/notifications-portlet/notifications/css/main.css?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;minifierType=css&amp;languageId=en_US&amp;b=6210&amp;t=1739773465000" rel="stylesheet" type="text/css"/> <link href="https://www.cochranelibrary.com/html/portlet/login/css/main.css?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;minifierType=css&amp;languageId=en_US&amp;b=6210&amp;t=1739773548000" rel="stylesheet" type="text/css"/> <script type="text/javascript">var Liferay={Browser:{acceptsGzip:function(){return false},getMajorVersion:function(){return 80},getRevision:function(){return"537.36"},getVersion:function(){return"80.0"},isAir:function(){return false},isChrome:function(){return true},isFirefox:function(){return false},isGecko:function(){return true},isIe:function(){return false},isIphone:function(){return false},isLinux:function(){return true},isMac:function(){return false},isMobile:function(){return false},isMozilla:function(){return false},isOpera:function(){return false},isRtf:function(){return true},isSafari:function(){return true},isSun:function(){return false},isWap:function(){return false},isWapXhtml:function(){return false},isWebKit:function(){return true},isWindows:function(){return false},isWml:function(){return false}},Data:{NAV_SELECTOR:"#navigation",isCustomizationView:function(){return false},notices:[null]},ThemeDisplay:{getLayoutId:function(){return"7"},getLayoutURL:function(){return"https://www.cochranelibrary.com/en/content"},getParentLayoutId:function(){return"0"},isPrivateLayout:function(){return"false"},isVirtualLayout:function(){return false},getBCP47LanguageId:function(){return"en-US"},getCDNBaseURL:function(){return"https://www.cochranelibrary.com"},getCDNDynamicResourcesHost:function(){return""},getCDNHost:function(){return""},getCompanyId:function(){return"20155"},getCompanyGroupId:function(){return"20195"},getDefaultLanguageId:function(){return"en_US"},getDoAsUserIdEncoded:function(){return""},getLanguageId:function(){return"en_US"},getParentGroupId:function(){return"20182"},getPathContext:function(){return""},getPathImage:function(){return"/image"},getPathJavaScript:function(){return"/html/js"},getPathMain:function(){return"/en/c"},getPathThemeImages:function(){return"https://www.cochranelibrary.com/cochrane-theme/images"},getPathThemeRoot:function(){return"/cochrane-theme"},getPlid:function(){return"20757"},getPortalURL:function(){return"https://www.cochranelibrary.com"},getPortletSetupShowBordersDefault:function(){return true},getScopeGroupId:function(){return"20182"},getScopeGroupIdOrLiveGroupId:function(){return"20182"},getSessionId:function(){return""},getSiteGroupId:function(){return"20182"},getURLControlPanel:function(){return"/group/control_panel?refererPlid=20757"},getURLHome:function(){return"https\x3a\x2f\x2fwww\x2ecochranelibrary\x2ecom\x2fweb\x2fcochrane"},getUserId:function(){return"20159"},getUserName:function(){return""},isAddSessionIdToURL:function(){return false},isFreeformLayout:function(){return false},isImpersonated:function(){return false},isSignedIn:function(){return false},isStateExclusive:function(){return false},isStateMaximized:function(){return false},isStatePopUp:function(){return false}},PropsValues:{NTLM_AUTH_ENABLED:false}};var themeDisplay=Liferay.ThemeDisplay;Liferay.AUI={getAvailableLangPath:function(){return"available_languages.jsp?browserId=other&themeId=cochrane_WAR_cochranetheme&colorSchemeId=01&minifierType=js&languageId=en_US&b=6210&t=1513680837000"},getCombine:function(){return true},getComboPath:function(){return"/combo/?browserId=other&minifierType=&languageId=en_US&b=6210&t=1513680837000&"},getFilter:function(){return"min"},getJavaScriptRootPath:function(){return"/html/js"},getLangPath:function(){return"aui_lang.jsp?browserId=other&themeId=cochrane_WAR_cochranetheme&colorSchemeId=01&minifierType=js&languageId=en_US&b=6210&t=1513680837000"},getStaticResourceURLParams:function(){return"?browserId=other&minifierType=&languageId=en_US&b=6210&t=1513680837000"}};Liferay.authToken="EBp84H4P";Liferay.currentURL="\x2fweb\x2fcochrane\x2fcontent\x3ftemplateType\x3dfull\x26urlTitle\x3d\x2fcdsr\x2fdoi\x2f10\x2e1002\x2f14651858\x2eCD011395\x2epub2\x26doi\x3d10\x2e1002\x2f14651858\x2eCD011395\x2epub2\x26type\x3dcdsr\x26contentLanguage\x3d";Liferay.currentURLEncoded="\x252Fweb\x252Fcochrane\x252Fcontent\x253FtemplateType\x253Dfull\x2526urlTitle\x253D\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD011395\x2epub2\x2526doi\x253D10\x2e1002\x252F14651858\x2eCD011395\x2epub2\x2526type\x253Dcdsr\x2526contentLanguage\x253D";</script> <script src="/html/js/barebone.jsp?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;colorSchemeId=01&amp;minifierType=js&amp;minifierBundleId=javascript.barebone.files&amp;languageId=en_US&amp;b=6210&amp;t=1513680837000" type="text/javascript"></script> <script type="text/javascript"></script> <script type="text/javascript">var o={database:"CDSR",page:{pageType:"Article Full Text HTML"},article:{availableLanguage:["en","es","zh_HANS","ru","th","ms","ja","fa","fr"],languageCode:"en",accessStatus:"delayed-free",doi:"10.1002/14651858.CD011395.pub2",title:"PARP (Poly ADP\\u2010Ribose Polymerase) inhibitors for locally advanced or metastatic breast cancer",firstPublishedDate:"Apr 22, 2021 12:00:00 AM",isCurrentVersion:true,editorialGroup:"Cochrane Breast Cancer Group",availableParts:["PDF Full","PDF Standard","PDF Abstract","HTML","Comments","Information","References","Stats","Related Content"]}};window.dataLayer=xtend(true,window.dataLayer,o);</script> <link class="lfr-css-file" href="https://www.cochranelibrary.com/cochrane-theme/css/custom.css?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;minifierType=css&amp;languageId=en_US&amp;b=6210&amp;t=1738734739000" rel="stylesheet" type="text/css"/> <style type="text/css"></style> <script async="" src="https://assets.adobedtm.com/59640f9fa510/7cad07cf7779/launch-a215d9c51521.min.js"></script> <!--[if lt IE 9]> <script src="/cochrane-theme/vendor/respond/dest/respond.min.js?t=1738734739000" type="text/javascript"></script> <![endif]--> </head> <body class="yui3-skin-sam controls-visible guest-site signed-out public-page site"> <div class="site-container"> <a href="#main-content" id="skip-to-content">Skip to Content</a> <div class="cookie-message cookie-message--hidden system-message-container" id="js-cookie-message"> <div class="container"> <a aria-label="Close cookies message" class="fa fa-times js-cookie-close pull-right" href="#"></a> <div class="system-message-wrapper container"> <i aria-hidden="true" class="fa fa-exclamation-triangle"></i> <div class="system-message-title">Cookies</div> <div class="system-message-description"> <p> Our site uses cookies to improve your experience. You can find out more about our use of cookies in About Cookies, including instructions on how to turn off cookies if you wish to do so. By continuing to browse this site you agree to us using cookies as described in <a href="http://olabout.wiley.com/WileyCDA/Section/id-813473.html">About Cookies</a>. </p> <a class="btn secondary js-cookie-close js-cookie-accept" href="#">I accept</a> </div> </div> </div> </div> <script>document.body.className=document.body.className+" js_enabled";</script><header> <div class="container"> <div class="branding"> <h1 class="brand-container"> <a href="https://www.cochranelibrary.com/en/"> <span class="brand-name">The Cochrane Library</span> <img alt="Cochrane Library logo" class="brand-logo" src="https://www.cochranelibrary.com/cochrane-theme/images/en-US_logo.png" title="Cochrane Library"/> </a> </h1> <span class="additional-branding"> <p class="brand-message"> <em>Trusted evidence.</em> <em>Informed decisions.</em> <em>Better health.</em> </p> </span> </div> <div class="desktop-search basic-search-container"> <div class="desktop-search-form"> <div class="portlet-boundary portlet-boundary_scolarissearchportlet_WAR_scolarissearch_ portlet-static portlet-static-end" id="p_p_id_scolarissearchportlet_WAR_scolarissearch_"> <span id="p_scolarissearchportlet_WAR_scolarissearch"></span> <section class="portlet" id="portlet_scolarissearchportlet_WAR_scolarissearch"> <header class="portlet-topper"> <h1 class="portlet-title"> <span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Search\x20Portlet')"> <img alt="" id="owel__null__null" src="/scolaris-search/icon.png"/> <span class="taglib-text hide-accessible">Scolaris Search Portlet</span> </span> <span class="portlet-title-text">Scolaris Search Portlet</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolarissearchportlet_WAR_scolarissearch" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <div class="header-search"> <form action="https://www.cochranelibrary.com/en/content?p_auth=EBp84H4P&amp;p_p_id=scolarissearchportlet_WAR_scolarissearch&amp;p_p_lifecycle=1&amp;p_p_state=normal&amp;p_p_mode=view&amp;_scolarissearchportlet_WAR_scolarissearch_scolarisAction=redirectSearchResult" method="post"> <input name="searchType" type="hidden" value="basic"/> <input name="facetDisplayName" type="hidden" value=""/> <input name="facetQueryTerm" type="hidden" value=""/> <input name="facetQueryField" type="hidden" value=""/> <input name="facetCategory" type="hidden" value=""/> <fieldset class="fieldset"> <legend class="sr-only">Basic Search</legend> <div class="select search-by"> <select aria-label="Search by options" class="custom-select-enabled search-type" name="searchBy" title="Search by options"> <option value="1">Title Abstract Keyword</option> <option value="2">Record Title</option> <option value="3">Abstract</option> <option value="4">Author</option> <option value="5">Keyword</option> <option value="6">All Text</option> <option value="7">Publication Type</option> <option value="8">Source</option> <option value="9">DOI</option> <option value="14">Language</option> <option value="10">Accession Number</option> <option value="11">Trial Registry Number</option> <option value="12">Cochrane Group</option> <option value="13">Cochrane Topic</option> </select> </div> <div class="search-select-crg-container select" style="display: none;"> <select class="search-select-crg-list"></select> </div> <div class="search-select-topic-container select" data-topic-list-url="https://www.cochranelibrary.com/en/content?p_p_id=scolaristopics_WAR_scolaristopics&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=topics-list&amp;p_p_cacheability=cacheLevelPage" style="display: none;"> <select class="search-select-topic-list"></select> </div> <div class="search-select-cl-container select" style="display: none;"> <select class="search-select-cl-list"></select> </div> <div class="search-text-container"> <div class="control-group control-group-inline search-input-wrapper"> <input aria-label="Enter search term" class="field browser-search search-text ui-autocomplete-input" id="searchText" name="searchText" placeholder="Search" size="30" type="text" value=""/>
<div id="autocomplete-results"></div>
</div>
<div class="control-group control-group-inline search-button-wrapper">
<button aria-label="Search" class="searchByBtn" type="submit">
<i aria-hidden="true" class="fa fa-search"></i>
</button>
</div>
</div>
</fieldset>
</form>
</div>
<script>
    window.displayResultURL = 'https://www.cochranelibrary.com/en/content?p_p_id=scolarissearchportlet_WAR_scolarissearch&p_p_lifecycle=2&p_p_state=normal&p_p_mode=view&p_p_resource_id=getSuggestions&p_p_cacheability=cacheLevelPage&_scolarissearchportlet_WAR_scolarissearch_templateType=full&_scolarissearchportlet_WAR_scolarissearch_urlTitle=%2Fcdsr%2Fdoi%2F10.1002%2F14651858.CD011395.pub2&_scolarissearchportlet_WAR_scolarissearch_contentLanguage=&_scolarissearchportlet_WAR_scolarissearch_type=cdsr&_scolarissearchportlet_WAR_scolarissearch_doi=10.1002%2F14651858.CD011395.pub2';
    window.searchByOption = '';
</script>
</div>
</div>
</div>
<div style="display:none">
<input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
</div>
<div class="search-tools-nav">
<a class="btn secondary" href="/en/browse-by-topic">Browse</a>
<a class="btn primary advanced-search-button" href="/en/advanced-search">Advanced search</a>
</div>
</div>
<a class="toggle-menu-switch" href="#"><i aria-hidden="true" class="fa fa-bars"></i> <div class="toggle-menu-text">Open menu</div></a>
</div>
<div class="auxiliary-container">
<div class="container">
<div class="header-auxiliary-menu">
<div class="auxiliary-menu-item language-selector">
<div class="portlet-boundary portlet-boundary_scolarislanguageselector_WAR_scolarislanguageportlet_ portlet-static portlet-static-end" id="p_p_id_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header_">
<span id="p_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header"></span>
<section class="portlet" id="portlet_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Language\x20Selector')">
<img alt="" id="bvrs__null__null" src="/scolaris-language-portlet/icon.png"/> <span class="taglib-text hide-accessible">Scolaris Language Selector</span> </span> <span class="portlet-title-text">Scolaris Language Selector</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <div class="language-display" data-content-languages="[de, en, es, fa, fr, hi, hr, id, ja, ko, hu, ms, nl, pl, pt, ru, ro, ta, th, zh_HANT, zh_HANS]"> <a class="open-language-modal" href="#" title="Select your preferred language"> <i class="fa fa-file-text"></i> Review language : English </a> <a class="open-language-modal" href="#" title="Select your preferred language"> <i class="fa fa-globe"></i> Website language : English </a> </div> <div class="language-selector-modal-content" data-modal-title="Language selection" data-size="large" style="display: none;"> <div class="form-content language-selector-modal"> <div class="row-fluid"> <div> <table class="mytable" style="border: 1px solid #f0f0f0" width="90%"> <tbody> <tr class="row-box"> <td><i class="fa fa-file-text icon-size"></i></td> <td><h3>Cochrane review language</h3> <p>Select your preferred language for Cochrane reviews and other content. Sections without translation will be in English.</p> </td> <td> <div> <select id="contentLanguageSelector" onchange="updateLang(this.value)"> <option class="content-language-option" data-languagecode="de" value="de"> Deutsch </option> <option class="content-language-option" data-languagecode="en" selected="" value="en"> English </option> <option class="content-language-option" data-languagecode="es" value="es"> Español </option> <option class="content-language-option" data-languagecode="fa" value="fa"> فارسی </option> <option class="content-language-option" data-languagecode="fr" value="fr"> Français </option> <option class="content-language-option" data-languagecode="hi" value="hi"> हिन्दी </option> <option class="content-language-option" data-languagecode="hr" value="hr"> Hrvatski </option> <option class="content-language-option" data-languagecode="id" value="id"> Bahasa Indonesia </option> <option class="content-language-option" data-languagecode="ja" value="ja"> 日本語 </option> <option class="content-language-option" data-languagecode="ko" value="ko"> 한국어 </option> <option class="content-language-option" data-languagecode="hu" value="hu"> Magyar </option> <option class="content-language-option" data-languagecode="ms" value="ms"> Bahasa Malaysia </option> <option class="content-language-option" data-languagecode="nl" value="nl"> Nederlands </option> <option class="content-language-option" data-languagecode="pl" value="pl"> Polski </option> <option class="content-language-option" data-languagecode="pt" value="pt"> Português </option> <option class="content-language-option" data-languagecode="ru" value="ru"> Русский </option> <option class="content-language-option" data-languagecode="ro" value="ro"> Română </option> <option class="content-language-option" data-languagecode="ta" value="ta"> தமிழ் </option> <option class="content-language-option" data-languagecode="th" value="th"> ภาษาไทย </option> <option class="content-language-option" data-languagecode="zh_HANT" value="zh_HANT"> 繁體中文 </option> <option class="content-language-option" data-languagecode="zh_HANS" value="zh_HANS"> 简体中文 </option> </select> </div> </td> </tr> <tr> <td colspan="1" style="height: 10px"></td> </tr> <tr class="row-box"> <td><i class="fa fa-globe icon-size"></i></td> <td> <div class="language-info"> <h3>Website language</h3> <p>Select your preferred language for the Cochrane Library website.</p> </div> </td> <td> <div class="language-dropdown"> <select id="portalLanguageSelector"> <option class="portal-language-selector" data-portallanguage="en" selected="" value="/en/cdsr/doi/10.1002/14651858.CD011395.pub2/full/en"> English </option> <option class="portal-language-selector" data-portallanguage="es" value="/es/cdsr/doi/10.1002/14651858.CD011395.pub2/full/es"> Español </option> </select> </div> </td> </tr> <tr> <td colspan="1" style="height: 10px"></td> </tr> </tbody> </table> </div> </div> <div style="text-align: right;"> <button class="btn primary btn-cancel" style="margin-left: 10px;" type="button">Cancel</button> <a class="btn secondary ok-btn" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage">Save</a> </div> </div> </div> </div> </div> </div> <div style="display:none"> <input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
</div>
<a class="auxiliary-menu-item signin last" href="https://www.cochranelibrary.com/c/portal/login?p_l_id=20757&amp;redirect=%2Fcdsr%2Fdoi%2F10.1002%2F14651858.CD011395.pub2%2Ffull" rel="nofollow">
<i class="icon fa fa-user"></i> Sign In
    </a>
<span class="auxiliary-container-extended"></span>
</div>
</div>
</div>
</header>
<div class="main-nav-wrapper">
<span class="main-nav-left-extended"></span>
<nav class="main container">
<ul>
<li class="nav-root-item parent">
<a href="#">Cochrane reviews<span class="icon fa fa-caret-down"></span></a>
<ul class="child">
<li class="child-nav-item" id="layout_nav_child_attr_14" role="presentation">
<a aria-labelledby="layout_14" href="https://www.cochranelibrary.com/en/cdsr/reviews" role="menuitem">
            Search reviews (CDSR)
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_15" role="presentation">
<a aria-labelledby="layout_15" href="https://www.cochranelibrary.com/en/cdsr/reviews/topics" role="menuitem">
            Browse reviews
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_18" role="presentation">
<a aria-labelledby="layout_18" href="https://www.cochranelibrary.com/en/cdsr/table-of-contents" role="menuitem">
            Issues
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_17" role="presentation">
<a aria-labelledby="layout_17" href="https://www.cochranelibrary.com/en/cdsr/editorials" role="menuitem">
            Editorials
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_19" role="presentation">
<a aria-labelledby="layout_19" href="https://www.cochranelibrary.com/en/special-collections" role="menuitem">
            Special Collections
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_20" role="presentation">
<a aria-labelledby="layout_20" href="https://www.cochranelibrary.com/en/cdsr/supplements" role="menuitem">
            Supplements
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_121" role="presentation">
<a aria-labelledby="layout_121" href="https://www.cochranelibrary.com/en/about/about-cochrane-reviews" role="menuitem">
            About Cochrane reviews
        </a>
</li>
</ul>
</li>
<li class="nav-root-item parent">
<a href="#">Searching for trials<span class="icon fa fa-caret-down"></span></a>
<ul class="child">
<li class="child-nav-item" id="layout_nav_child_attr_254" role="presentation">
<a aria-labelledby="layout_254" href="https://www.cochranelibrary.com/en/search/releases" role="menuitem">
            What's new (search and CENTRAL)
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_266" role="presentation">
<a aria-labelledby="layout_266" href="https://www.cochranelibrary.com/en/search-help" role="menuitem">
            Search help
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_252" role="presentation">
<a aria-labelledby="layout_252" href="https://www.cochranelibrary.com/en/search-help-quick-guides" role="menuitem">
            Search help quick guides
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_251" role="presentation">
<a aria-labelledby="layout_251" href="https://www.cochranelibrary.com/en/search-faqs" role="menuitem">
            Search FAQs
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_114" role="presentation">
<a aria-labelledby="layout_114" href="https://www.cochranelibrary.com/en/central/about-central" role="menuitem">
            About CENTRAL
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_115" role="presentation">
<a aria-labelledby="layout_115" href="https://www.cochranelibrary.com/en/central/central-creation" role="menuitem">
            How CENTRAL is created
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_241" role="presentation">
<a aria-labelledby="layout_241" href="https://www.cochranelibrary.com/en/retracted-trials" role="menuitem">
            Retracted publications in CENTRAL
        </a>
</li>
</ul>
</li>
<li class="nav-root-item parent">
<a href="#">Clinical Answers<span class="icon fa fa-caret-down"></span></a>
<ul class="child">
<li class="child-nav-item" id="layout_nav_child_attr_29" role="presentation">
<a aria-labelledby="layout_29" href="https://www.cochranelibrary.com/en/cca" role="menuitem">
            Browse Clinical Answers
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_91" role="presentation">
<a aria-labelledby="layout_91" href="https://www.cochranelibrary.com/en/cca/about" role="menuitem">
            About Clinical Answers
        </a>
</li>
</ul>
</li>
<li class="nav-root-item parent">
<a href="#">About<span class="icon fa fa-caret-down"></span></a>
<ul class="child">
<li class="child-nav-item" id="layout_nav_child_attr_116" role="presentation">
<a aria-labelledby="layout_116" href="https://www.cochranelibrary.com/en/about/about-cochrane-library" role="menuitem">
            About the Cochrane Library
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_13" role="presentation">
<a aria-labelledby="layout_13" href="https://www.cochranelibrary.com/en/cdsr/about-cdsr" role="menuitem">
            Cochrane Database of Systematic reviews
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_198" role="presentation">
<a aria-labelledby="layout_198" href="https://www.cochranelibrary.com/en/cdsr/editorial-policies" role="menuitem">
            Editorial policies
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_92" role="presentation">
<a aria-labelledby="layout_92" href="https://www.cochranelibrary.com/en/about/author-information" role="menuitem">
            Information for authors
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_212" role="presentation">
<a aria-labelledby="layout_212" href="https://www.cochranelibrary.com/en/about-pico" role="menuitem">
            About PICO
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_207" role="presentation">
<a aria-labelledby="layout_207" href="https://www.cochranelibrary.com/en/about/about-translations" role="menuitem">
            About translations
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_188" role="presentation">
<a aria-labelledby="layout_188" href="https://www.cochranelibrary.com/en/about/releases" role="menuitem">
            What's new
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_216" role="presentation">
<a aria-labelledby="layout_216" href="https://www.cochranelibrary.com/en/data" role="menuitem">
            Data reuse
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_235" role="presentation">
<a aria-labelledby="layout_235" href="https://www.cochranelibrary.com/en/about/about-cochrane-library/editorial-board" role="menuitem">
            Cochrane Library Editorial Board
        </a>
</li>
</ul>
</li>
<li class="nav-root-item parent">
<a href="#">Help<span class="icon fa fa-caret-down"></span></a>
<ul class="child">
<li class="child-nav-item" id="layout_nav_child_attr_259" role="presentation">
<a aria-labelledby="layout_259" href="https://m.info.wiley.com/webApp/cochranenewsletter?id=0" role="menuitem">
            Newsletter
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_177" role="presentation">
<a aria-labelledby="layout_177" href="https://www.wiley.com/en-us/customer-success/cochrane-library-training-hub" role="menuitem">
            Cochrane Library Training
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_44" role="presentation">
<a aria-labelledby="layout_44" href="https://www.cochranelibrary.com/en/help/access" role="menuitem">
            Access
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_150" role="presentation">
<a aria-labelledby="layout_150" href="https://www.cochranelibrary.com/en/help/permissions" role="menuitem">
            Permissions and reprints
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_93" role="presentation">
<a aria-labelledby="layout_93" href="https://www.cochranelibrary.com/en/help/media" role="menuitem">
            Media information
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_97" role="presentation">
<a aria-labelledby="layout_97" href="https://www.cochranelibrary.com/en/help/contact-us" role="menuitem">
            Contact us
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_125" role="presentation">
<a aria-labelledby="layout_125" href="https://www.cochranelibrary.com/en/about/terms-and-conditions" role="menuitem">
            Terms and conditions
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_176" role="presentation">
<a aria-labelledby="layout_176" href="https://cochranesupport.wiley.com/s/article/cochrane-library-known-issues" role="menuitem">
            Known issues
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_270" role="presentation">
<a aria-labelledby="layout_270" href="https://www.cochranelibrary.com/search-help" role="menuitem">
            Search help
        </a>
</li>
</ul>
</li>
<li class="about-link"><a href="https://www.cochrane.org/about-us" target="_blank"><span>About Cochrane</span><i class="fa fa-caret-right"></i></a></li>
</ul>
</nav>
</div>
<div class="portlet-boundary portlet-boundary_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_ portlet-static portlet-static-end" id="p_p_id_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_">
<span id="p_scolariscontentlanguagebanner_WAR_scolarislanguageportlet"></span>
<section class="portlet" id="portlet_scolariscontentlanguagebanner_WAR_scolarislanguageportlet">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Content\x20Language\x20Banner\x20Portlet')">
<img alt="" id="etlj__null__null" src="/scolaris-language-portlet/icon.png"/> <span class="taglib-text hide-accessible">Scolaris Content Language Banner Portlet</span> </span> <span class="portlet-title-text">Scolaris Content Language Banner Portlet</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolariscontentlanguagebanner_WAR_scolarislanguageportlet" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> </div> </div> </div> <div style="display:none"> <input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
<div class="" id="content">
<div class="columns-1" id="main-content" role="main">
<div class="portlet-layout row-fluid">
<div class="portlet-column portlet-column-only span12" id="column-1">
<div class="portlet-dropzone portlet-column-content portlet-column-content-only" id="layout-column_column-1">
<div class="portlet-boundary portlet-boundary_scolariscontentdisplay_WAR_scolariscontentdisplay_ portlet-static portlet-static-end scolaris-content-display-portlet" id="p_p_id_scolariscontentdisplay_WAR_scolariscontentdisplay_">
<span id="p_scolariscontentdisplay_WAR_scolariscontentdisplay"></span>
<section class="portlet" id="portlet_scolariscontentdisplay_WAR_scolariscontentdisplay">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Content\x20Display')">
<img alt="" id="rjus__column1__0" src="/scolaris-content-display/icon.png"/> <span class="taglib-text hide-accessible">Scolaris Content Display</span> </span> <span class="portlet-title-text">Scolaris Content Display</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolariscontentdisplay_WAR_scolariscontentdisplay" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <div class="publication cdsr container"> <div class="article-navigation-container" id="cdsr-nav"> <nav class="article-navigation"> <ul class="tools-row"> <li> <li class="tools pdf pulldown-menu readcube-menu closed en_US"> <a class="pulldown-menu-trigger" href="#0"> <span class="pdf-icon"> <i class="icon fa fa-file-pdf-o"></i> <span>Download PDF</span> </span> <i aria-hidden="true" class="fa fa-caret-down"></i> </a> <ul class="pulldown-menu-items"> <li class=""> <a class="download media pdf-link-full pdf-link" href="/cdsr/doi/10.1002/14651858.CD011395.pub2/pdf/full/en" title="Article in PDF format"> <span class="readcube-label"> Full </span> <span class="readcube-description"> All content </span> </a> <a class="download media pdf-link-full readcube-epdf-link" href="/cdsr/doi/10.1002/14651858.CD011395.pub2/epdf/full/en" title="Article in PDF format"> <span class="readcube-label"> Full </span> <span class="readcube-description"> All content </span> </a> </li> <li class=""> <a class="download media pdf-link-abstract pdf-link" href="/cdsr/doi/10.1002/14651858.CD011395.pub2/pdf/abstract/en" title="Article in PDF format"> <span class="readcube-label"> Summary </span> <span class="readcube-description"> Abstract and plain language summary only </span> </a> <a class="download media pdf-link-abstract readcube-epdf-link" href="/cdsr/doi/10.1002/14651858.CD011395.pub2/epdf/abstract/en" title="Article in PDF format"> <span class="readcube-label"> Summary </span> <span class="readcube-description"> Abstract and plain language summary only </span> </a> </li> </ul> </li> <li class="tools cite cite-article-link" data-article-id="CD011395.PUB2" data-modal-title="Cite this review"> <span><i aria-hidden="true" class="icon fa fa-share"></i></span> <span>Cite this review</span> </li> </li> </ul> <ul class="tools-row tools-secondary"> <li> <li class="tools print print-cdsr-link" data-content-language="en" data-indicator-tooltip="scolaris.print.modal.language.tooltip.en" data-print-options="[{&quot;param&quot;: &quot;abstract&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Abstract&quot;},{&quot;language&quot;:&quot;es&quot;,&quot;title&quot;:&quot;Resumen&quot;},{&quot;language&quot;:&quot;fa&quot;,&quot;title&quot;:&quot;چکیده&quot;},{&quot;language&quot;:&quot;fr&quot;,&quot;title&quot;:&quot;Résumé scientifique&quot;},{&quot;language&quot;:&quot;th&quot;,&quot;title&quot;:&quot;บทคัดย่อ&quot;},{&quot;language&quot;:&quot;zh_HANS&quot;,&quot;title&quot;:&quot;摘要&quot;}]},{&quot;param&quot;: &quot;pls&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Plain language summary&quot;},{&quot;language&quot;:&quot;es&quot;,&quot;title&quot;:&quot;Resumen en términos sencillos&quot;},{&quot;language&quot;:&quot;fa&quot;,&quot;title&quot;:&quot;خلاصه به زبان ساده&quot;},{&quot;language&quot;:&quot;fr&quot;,&quot;title&quot;:&quot;Résumé simplifié&quot;},{&quot;language&quot;:&quot;ja&quot;,&quot;title&quot;:&quot;一般語訳&quot;},{&quot;language&quot;:&quot;ms&quot;,&quot;title&quot;:&quot;Ringkasan bahasa mudah&quot;},{&quot;language&quot;:&quot;ru&quot;,&quot;title&quot;:&quot;Резюме на простом языке&quot;},{&quot;language&quot;:&quot;th&quot;,&quot;title&quot;:&quot;ข้้อสรุปภาษาธรรมดา&quot;},{&quot;language&quot;:&quot;zh_HANS&quot;,&quot;title&quot;:&quot;简语概要&quot;}]},{&quot;param&quot;: &quot;conclusions&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Authors' conclusions&quot;}]},{&quot;param&quot;: &quot;summaryOfFindings&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Summary of findings&quot;}]},{&quot;param&quot;: &quot;background&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Background&quot;}]},{&quot;param&quot;: &quot;objectives&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Objectives&quot;}]},{&quot;param&quot;: &quot;methods&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Methods&quot;}]},{&quot;param&quot;: &quot;results&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Results&quot;}]},{&quot;param&quot;: &quot;discussion&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Discussion&quot;}]},{&quot;param&quot;: &quot;references&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;References&quot;}]},{&quot;param&quot;: &quot;appendices&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Appendices&quot;},{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Search strategies&quot;}]},{&quot;param&quot;: &quot;characteristics&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Characteristics of studies&quot;}]},{&quot;param&quot;: &quot;data&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Analyses&quot;}]},{&quot;param&quot;: &quot;information&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Information&quot;}]},{&quot;param&quot;: &quot;authors&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Authors&quot;}]},{&quot;param&quot;: &quot;history&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;History&quot;},{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;History&quot;}]}]" data-print-urlbase="/cdsr/doi/10.1002/14651858.CD011395.pub2/print"> <span><i class="icon fa fa-print"></i></span> <span>Print</span> </li> <li class="js-old-version-modal-trigger tools comments comment-on-review" data-article-id="CD011395.PUB2" data-english-only-message="Please note, that commenting is available in English only. Apologies for any inconvenience." data-href="/cdsr/doi/10.1002/14651858.CD011395.pub2/read-comments" data-new-version="" id="comment-on-review"> <span class="comment-icon"><i class="icon fa fa-comment"></i></span> <span class="comments-count">0</span> <span>Comment</span> </li> <li class="tools share-cdsr-link" data-share-url="/cdsr/doi/10.1002/14651858.CD011395.pub2/full"> <span><i class="icon fa fa-share-alt"></i></span> <span>Share</span> </li> <li class="tools follow"> <span class="article-not-followed cochrane-link signin follow-wrapper"> <span> <i class="icon fa fa-plus"></i> </span> <span> Follow </span> </span> </li> </li> </ul> <div class="metrics-wrapper"> <div class="metrics-count"> <span>Full text views: </span> <span>6703 <i class="icon fa fa-info-circle custom-tooltip" style="padding-left: 2px;color: #962d91;" title="Usage represents full text views on Cochrane Library since January 2022 or 2023. For articles published after this date, the usage represents views since the article was first published on Cochrane Library."> </i> </span> </div> </div> <div class="metrics-wrapper nav-link-section"> <div class="altmetric-embed" data-badge-type="1" data-condensed="true" data-doi="10.1002/14651858.CD011395.pub2" data-link-target="_blank"></div> <div class="inline-status-wrapper guidelines-count" data-count-plural="Cited in $1 guidelines" data-count-single="Cited in 1 guideline"> <a href="related-content#guidelines_data" title="Guidelines"></a> </div> </div> <ul class="nav-section-header"> <li> <h3>Contents</h3> </li> </ul> <ul class="nav-long-form nav-link-section"> <li class="cdsr-nav-link bold-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD011395.pub2/full"> Abstract </a> </li> <li class="cdsr-nav-link bold-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD011395.pub2/full#pico"> PICOs </a> </li> <li class="cdsr-nav-link bold-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD011395.pub2/full#CD011395-abs-0002"> Plain language summary </a> </li> <li class="cdsr-nav-link bold-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD011395.pub2/full#CD011395-sec-0064"> Authors' conclusions </a> </li> <li class="cdsr-nav-link bold-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD011395.pub2/full#CD011395-sec-0008"> Summary of findings </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD011395.pub2/full#CD011395-sec-0009"> Background </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD011395.pub2/full#CD011395-sec-0014"> Objectives </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD011395.pub2/full#CD011395-sec-0015"> Methods </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD011395.pub2/full#CD011395-sec-0039"> Results </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD011395.pub2/full#CD011395-sec-0058"> Discussion </a> </li> <li class="cdsr-nav-link"> <a class="figures-and-tables-link" href="/cdsr/doi/10.1002/14651858.CD011395.pub2/#"> Figures and tables </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD011395.pub2/references"> References </a> </li> </ul> <div class="nav-section-header"> <h3>Supplementary materials</h3> </div> <ul class="nav-long-form nav-link-section"> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD011395.pub2/appendices#CD011395-sec-0069"> Search strategies </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD011395.pub2/references#characteristicStudies"> Characteristics of studies </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD011395.pub2/references#dataAndAnalyses"> Analyses </a> </li> <li class="cdsr-nav-link download-stats-data-link" data-download-href="/cdsr/doi/10.1002/14651858.CD011395.pub2/media/CDSR/CD011395/table_n/CD011395StatsDataOnly.rm5?content-disposition=attachment&amp;mime-type=application/octet-stream"> <a href="/cdsr/doi/10.1002/14651858.CD011395.pub2/media/CDSR/CD011395/table_n/CD011395StatsDataOnly.rm5?content-disposition=attachment&amp;mime-type=application/octet-stream"> Download data </a> </li> </ul> <ul class="tools-row"> <li> </li> </ul> <ul class="nav-section-header"> <li><h3>Related</h3></li> </ul> <ul class="linked-content linked-content-dropdown" id="linked-content-articles" tabindex="0"> <li class="linked-cca" data-type="cca"> <div class="linked-content-section"> <span class="linked-type">Cochrane Clinical Answers<span class="count"></span></span> <i aria-hidden="true" class="fa fa-caret-down"></i> </div> <div class="articles"></div> </li> <li class="linked-editorials" data-type="editorial"> <div class="linked-content-section"> <span class="linked-type">Editorials<span class="count"></span></span> <i aria-hidden="true" class="fa fa-caret-down"></i> </div> <div class="articles"></div> </li> <li class="linked-podcasts" data-type="podcast"> <div class="linked-content-section"> <span class="linked-type">Podcasts<span class="count"></span></span> <i aria-hidden="true" class="fa fa-caret-down"></i> </div> <div class="articles"></div> </li> <li class="linked-sc" data-type="sc"> <div class="linked-content-section"> <span class="linked-type">Special Collections<span class="count"></span></span> <i aria-hidden="true" class="fa fa-caret-down"></i> </div> <div class="articles"></div> </li> </ul> <div class="nav-section-header"> <h3>About this review</h3> </div> <ul class="nav-long-form nav-info nav-link-section"> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD011395.pub2/information"> <i> <svg viewbox="0 0 24 24"> <path d="M11,9H13V7H11M12,20C7.59,20 4,16.41 4,12C4,7.59 7.59,4 12,4C16.41,4 20,7.59 20,12C20,16.41 16.41,20 12,20M12,2A10,10 0 0,0 2,12A10,10 0 0,0 12,22A10,10 0 0,0 22,12A10,10 0 0,0 12,2M11,17H13V11H11V17Z"></path> </svg> </i> Information </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD011395.pub2/information#authors"> <i> <svg viewbox="0 0 24 24"> <path d="M12,5.5A3.5,3.5 0 0,1 15.5,9A3.5,3.5 0 0,1 12,12.5A3.5,3.5 0 0,1 8.5,9A3.5,3.5 0 0,1 12,5.5M5,8C5.56,8 6.08,8.15 6.53,8.42C6.38,9.85 6.8,11.27 7.66,12.38C7.16,13.34 6.16,14 5,14A3,3 0 0,1 2,11A3,3 0 0,1 5,8M19,8A3,3 0 0,1 22,11A3,3 0 0,1 19,14C17.84,14 16.84,13.34 16.34,12.38C17.2,11.27 17.62,9.85 17.47,8.42C17.92,8.15 18.44,8 19,8M5.5,18.25C5.5,16.18 8.41,14.5 12,14.5C15.59,14.5 18.5,16.18 18.5,18.25V20H5.5V18.25M0,20V18.5C0,17.11 1.89,15.94 4.45,15.6C3.86,16.28 3.5,17.22 3.5,18.25V20H0M24,20H20.5V18.25C20.5,17.22 20.14,16.28 19.55,15.6C22.11,15.94 24,17.11 24,18.5V20Z"></path> </svg> </i> Authors </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD011395.pub2/information#history"> <i> <svg viewbox="0 0 24 24"> <path d="M13.5,8H12V13L16.28,15.54L17,14.33L13.5,12.25V8M13,3A9,9 0 0,0 4,12H1L4.96,16.03L9,12H6A7,7 0 0,1 13,5A7,7 0 0,1 20,12A7,7 0 0,1 13,19C11.07,19 9.32,18.21 8.06,16.94L6.64,18.36C8.27,20 10.5,21 13,21A9,9 0 0,0 22,12A9,9 0 0,0 13,3"></path> </svg> </i> Version history </a> </li> <li class="cdsr-nav-link"> <a href="/cdsr/doi/10.1002/14651858.CD011395.pub2/information#keywords"> <i> <svg viewbox="0 0 24 24"> <path d="M11 3C10.18 3 9.44 3.5 9.14 4.27L3.64 18.27C3.12 19.58 4.09 21 5.5 21H7.75C8.59 21 9.33 20.5 9.62 19.7L10.26 18H13.74L14.38 19.7C14.67 20.5 15.42 21 16.25 21H18.5C19.91 21 20.88 19.58 20.36 18.27L14.86 4.27C14.56 3.5 13.82 3 13 3M11 5H13L18.5 19H16.25L15.12 16H8.87L7.75 19H5.5M12 7.67L9.62 14H14.37Z"></path> </svg> </i> Keywords (MeSH, PICOs) </a> </li> <li class="cdsr-nav-link"> <a href="/cdsr/doi/10.1002/14651858.CD011395.pub2/related-content"> <i class="icon fa fa-sitemap fa-rotate-270"></i> Related content </a> </li> <li class="cdsr-nav-link translation-notes-link"> <a href="/cdsr/doi/10.1002/14651858.CD011395.pub2/#"> <i> <svg viewbox="0 0 24 24"> <path d="M12.87,15.07L10.33,12.56L10.36,12.53C12.1,10.59 13.34,8.36 14.07,6H17V4H10V2H8V4H1V6H12.17C11.5,7.92 10.44,9.75 9,11.35C8.07,10.32 7.3,9.19 6.69,8H4.69C5.42,9.63 6.42,11.17 7.67,12.56L2.58,17.58L4,19L9,14L12.11,17.11L12.87,15.07M18.5,10H16.5L12,22H14L15.12,19H19.87L21,22H23L18.5,10M15.88,17L17.5,12.67L19.12,17H15.88Z"></path> </svg> </i> Translation notes </a> </li> <li class="cdsr-nav-link"> <a class="request-permissions" data-copyright="Copyright © 2021 The Cochrane Collaboration. Published by John Wiley &amp; Sons, Ltd." data-creative-commons="false" href="/cdsr/doi/10.1002/14651858.CD011395.pub2/#"> <span class="request-permissions-icon"></span> Request permissions </a> </li> <li class="cdsr-nav-link"> <a href="/data"> <i class="icon fa fa-database"></i> Request data reuse </a> </li> </ul> </nav> </div> <article> <div class="cdsr-header-top"> <div class="cdsr-header-left"> <a class="publish-database" href="/">Cochrane Database of Systematic reviews</a> <span class="publish-type">Review - Intervention</span> </div> <div class="cdsr-header-right"> </div> </div> <header class="publication-header"> <h1 class="publication-title" lang="en">PARP (Poly ADP‐Ribose Polymerase) inhibitors for locally advanced or metastatic breast cancer </h1> <div class="publication-metadata-block"> <div class="publication-authors"> <div class="publish-meta-wrapper"> <ul class="authors"> <li class="author"><a href="/cdsr/doi/10.1002/14651858.CD011395.pub2/information#CD011395-cr-0004">Amelia M Taylor</a></li> <li class="author"><a href="/cdsr/doi/10.1002/14651858.CD011395.pub2/information#CD011395-cr-0005">David Lok Hang Chan</a></li> <li class="author"><a href="/cdsr/doi/10.1002/14651858.CD011395.pub2/information#CD011395-cr-0006">Martin Tio</a></li> <li class="author"><a href="/cdsr/doi/10.1002/14651858.CD011395.pub2/information#CD011395-cr-0007">Sujata M Patil</a></li> <li class="author"><a href="/cdsr/doi/10.1002/14651858.CD011395.pub2/information#CD011395-cr-0008">Tiffany A Traina</a></li> <li class="author"><a href="/cdsr/doi/10.1002/14651858.CD011395.pub2/information#CD011395-cr-0009">Mark E Robson</a></li> <li class="author"><a href="/cdsr/doi/10.1002/14651858.CD011395.pub2/information#CD011395-cr-0010"><i class="icon corresponding-author fa fa-envelope"></i>Mustafa Khasraw</a></li> </ul> <span class="author declaration"> <a class="declarationsOfInterestLink" href="/cdsr/doi/10.1002/14651858.CD011395.pub2/information/en#CD011395-sec-0081">Authors' declarations of interest</a> </span> </div> </div> </div> <div class="publication-metadata-block"> <p> <span class="publish-date">Version published: 22 April 2021 </span> <a class="whatsNewLink" href="/cdsr/doi/10.1002/14651858.CD011395.pub2/information/en#versionTable">Version history</a> </p> <div class="doi-header"> <a href="https://doi.org/10.1002/14651858.CD011395.pub2">https://doi.org/10.1002/14651858.CD011395.pub2</a> </div> </div> </header> <div class="publication-control-bar"> <span class="publication-control-button publication-control-collapse"> Collapse all </span> <span class="publication-control-button publication-control-expand"> Expand all </span> </div> <section class="abstract"> <div class="section-header section-collapse-header" id="CD011395-abs-0001" lang="en"> <h2 class="title section-collapse-title"> Abstract <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> <div class="section-language-toggles"> <span class="section-languages-legend">available in</span> <nav class="section-languages"> <li class="section-language"> <a class="is-active" href="full/en#CD011395-abs-0001">English</a> </li> <li class="section-language"> <a class="" href="full/es#CD011395-abs-0014">Español</a> </li> <li class="section-language"> <a class="" href="full/fa#CD011395-abs-0010">فارسی</a> </li> <li class="section-language"> <a class="" href="full/fr#CD011395-abs-0012">Français</a> </li> <li class="section-language"> <a class="" href="full/th#CD011395-abs-0006">ภาษาไทย</a> </li> <li class="section-language"> <a class="" href="full/zh_HANS#CD011395-abs-0003">简体中文</a> </li> </nav> </div> </div> <div class="abstract full_abstract" id="CD011395-abs-0001" lang="en"> <section id="CD011395-sec-0001"> <h3 class="title" id="CD011395-sec-0001">Background</h3> <p>Locally advanced and metastatic breast cancer remains a challenge to treat. With emerging study results, it is important to interpret the available clinical data and apply the evidence offering the most effective treatment to the right patient. Poly(ADP Ribose) Polymerase (PARP) inhibitors are a new class of drug and their role in the treatment of locally advanced and metastatic breast cancer is being established. </p> </section> <section id="CD011395-sec-0002"> <h3 class="title" id="CD011395-sec-0002">Objectives</h3> <p>To determine the efficacy, safety profile, and potential harms of Poly(ADP‐Ribose) Polymerase (PARP) inhibitors in the treatment of patients with locally advanced or metastatic breast cancer. The primary outcome of interest was overall survival; secondary outcomes included progression‐free survival, tumour response rate, quality of life, and adverse events. </p> </section> <section id="CD011395-sec-0003"> <h3 class="title" id="CD011395-sec-0003">Search methods</h3> <p>On 8 June 2020, we searched the Cochrane Breast Cancer Group Specialised Register, the Cochrane Central Register of Controlled Trials (CENTRAL), MEDLINE via OvidSP, Embase via OvidSP, World Health Organization International Clinical Trials Registry Platform (WHO ICTRP) search portal and ClinicalTrials.gov. We also searched proceedings from the major oncology conferences as well as scanned reference lists from eligible publications and contacted corresponding authors of trials for further information, where needed. </p> </section> <section id="CD011395-sec-0004"> <h3 class="title" id="CD011395-sec-0004">Selection criteria</h3> <p>We included randomised controlled trials on participants with locally advanced or metastatic breast cancer comparing 1) chemotherapy in combination with PARP inhibitors, compared to the same chemotherapy without PARP inhibitors or 2) treatment with PARP inhibitors, compared to treatment with other chemotherapy. We included studies that reported on our primary outcome of overall survival and secondary outcomes including progression‐free survival, tumour response rate, quality of life, and adverse events. </p> </section> <section id="CD011395-sec-0005"> <h3 class="title" id="CD011395-sec-0005">Data collection and analysis</h3> <p>We used standard methodological procedures defined by Cochrane. Summary statistics for the endpoints used hazard ratios (HR) with 95% confidence intervals (CI) for overall survival and progression‐free survival, and odds ratios (OR) for response rate (RR) and toxicity. </p> </section> <section id="CD011395-sec-0006"> <h3 class="title" id="CD011395-sec-0006">Main results</h3> <p>We identified 49 articles for qualitative synthesis, describing five randomised controlled trials that were included in the quantitative synthesis (meta‐analysis). A sixth trial was assessed as eligible but had ended prematurely and no data were available for inclusion in our meta‐analysis. Risk of bias was predominately low to unclear across all studies except in regards to performance bias (3/5 high risk) and detection bias for the outcomes of quality of life (2/2 high risk) and reporting of adverse events (3/5 high risk).<br/>High‐certainty evidence shows there may be a small advantage in overall survival (HR 0.87, 95% CI 0.76 to 1.00; 4 studies; 1435 patients). High‐certainty evidence shows that PARP inhibitors offer an improvement in PFS in locally advanced/metastatic HER2‐negative, BRCA germline mutated breast cancer patients (HR 0.63, 95% CI 0.56 to 0.71; 5 studies; 1474 patients). There was no statistical heterogeneity for these outcomes. Subgroup analyses for PFS outcomes based on trial level data were performed for triple‐negative breast cancer, hormone‐positive and/or HER2‐positive breast cancer, BRCA1 and BRCA2 germline mutations, and patients who had received prior chemotherapy for advanced breast cancer or not. The subgroup analyses showed a persistent PFS benefit regardless of the subgroup chosen. Pooled analysis shows PARP inhibitors likely result in a moderate improvement in tumour response rate compared to other treatment arms (66.9% vs 48.9%; RR 1.39, 95% CI 1.24 to 1.54; 5 studies; 1185 participants; moderate‐certainty evidence).<br/>The most common adverse events reported across all five studies included neutropenia, anaemia and fatigue. Grade 3 or higher adverse events probably occur no less frequently in patients receiving PARP inhibitors (59.4% for PARP arm versus 64.5% for non‐PARP arm, RR 0.98, 95% CI 0.91 to 1.04; 5 studies; 1443 participants; moderate‐certainty evidence).<br/>Only two studies reported quality of life outcomes so this was not amenable to meta‐analysis. However, both studies that did assess quality of life showed PARP inhibitors were superior compared to physician’s choice of chemotherapy in terms of participant‐reported outcomes. </p> </section> <section id="CD011395-sec-0007"> <h3 class="title" id="CD011395-sec-0007">Authors' conclusions</h3> <p>In people with locally advanced or metastatic HER2‐negative, BRCA germline mutated breast cancer, PARP inhibitors offer an improvement in progression‐free survival, and likely improve overall survival and tumour response rates. This systematic review provides evidence supporting the use of PARP inhibitors as part of the therapeutic strategy for breast cancer patients in this subgroup. The toxicity profile for PARP inhibitors is probably no worse than chemotherapy but more information is required regarding quality of life outcomes, highlighting the importance of collecting such data in future studies. Future studies should also be powered to detect clinically important differences in overall survival and could focus on the role of PARP inhibitors in other relevant breast cancer populations, including HER2‐positive, BRCA‐negative/homologous recombination repair‐deficient and Programmed Death‐Ligand 1 (PDL1) positive. </p> </section> </div> </section> <section class="pico-section" id="pico"> <h2 class="title section-collapse-title">PICOs <i class="icon fa fa-info-circle" title="The PICO model is widely used and taught in evidence-based health care as a strategy for formulating questions and search strategies and for characterizing clinical studies or meta-analyses. PICO stands for four different potential components of a clinical question: Patient, Population or Problem; Intervention; Comparison; Outcome."></i> <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> <div class="section-content" style="display: block;"> <h3 class="keyword-heading">PICOs</h3> <div class="pico-table"> <div class="pico-column Population"> <h6>Population<span class="pico-count"></span></h6> <ul class="pico-terms"> </ul> </div> <div class="pico-column Intervention"> <h6>Intervention<span class="pico-count"></span></h6> <ul class="pico-terms"> </ul> </div> <div class="pico-column Comparison"> <h6>Comparison<span class="pico-count"></span></h6> <ul class="pico-terms"> </ul> </div> <div class="pico-column Outcome"> <h6>Outcome<span class="pico-count"></span></h6> <ul class="pico-terms"> </ul> </div> </div> <div class="pico-information"> <p><i class="icon fa fa-info-circle"></i> The PICO model is widely used and taught in evidence-based health care as a strategy for formulating questions and search strategies and for characterizing clinical studies or meta-analyses. PICO stands for four different potential components of a clinical question: Patient, Population or Problem; Intervention; Comparison; Outcome.</p> <p>See more on using PICO in the <a href="https://training.cochrane.org/handbook/current/chapter-02#section-2-3">Cochrane Handbook</a>.</p> </div> </div> </section> <section class="pls"> <div class="section-header section-collapse-header" id="CD011395-abs-0002" lang="en"> <h2 class="title section-collapse-title"> Plain language summary <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> <div class="section-language-toggles"> <span class="section-languages-legend">available in</span> <nav class="section-languages"> <li class="section-language"> <a class="is-active" href="full/en#CD011395-abs-0002">English</a> </li> <li class="section-language"> <a class="" href="full/es#CD011395-abs-0015">Español</a> </li> <li class="section-language"> <a class="" href="full/fa#CD011395-abs-0011">فارسی</a> </li> <li class="section-language"> <a class="" href="full/fr#CD011395-abs-0013">Français</a> </li> <li class="section-language"> <a class="" href="full/ja#CD011395-abs-0009">日本語</a> </li> <li class="section-language"> <a class="" href="full/ms#CD011395-abs-0008">Bahasa Malaysia</a> </li> <li class="section-language"> <a class="" href="full/ru#CD011395-abs-0005">Русский</a> </li> <li class="section-language"> <a class="" href="full/th#CD011395-abs-0007">ภาษาไทย</a> </li> <li class="section-language"> <a class="" href="full/zh_HANS#CD011395-abs-0004">简体中文</a> </li> </nav> </div> </div> <div class="abstract abstract_plainLanguageSummary" id="CD011395-abs-0002" lang="en"> <h3>PARP inhibitors for locally advanced or metastatic breast cancer</h3> <p><b>What is the aim of this review?</b> </p> <p>PARP inhibitors are a new class of drug that block DNA repair in tumour cells and hence lead to cell death. The aim of this Cochrane Review was to find out their efficacy and safety in the treatment of patients with locally advanced or metastatic breast cancer. The Cochrane review authors collected and analysed all relevant trials to answer this question and found five trials addressing this topic. Our primary aim was to look at whether PARP inhibitors prolonged survival. We also evaluated whether these drugs prolonged the time before disease progression (usually defined as growth of more than 20% or development of a new metastasis), caused the tumour to shrink, or resulted in more side effects. </p> <p><b>What was studied in the review?</b> </p> <p>We included randomised controlled trials of participants with locally advanced or metastatic breast cancer comparing 1) chemotherapy in combination with PARP inhibitors, compared to the same chemotherapy without PARP inhibitors or 2) treatment with PARP inhibitors, compared to treatment with other chemotherapy. We included trials that reported on our primary outcome of overall survival and secondary outcomes including progression‐free survival, tumour shrinkage rate, quality of life, and side effects. </p> <p><b>How up‐to‐date is this review?</b> </p> <p>We searched for published trials up to June 2020 and included the results of five trials involving 1474 participants. </p> <p><b>What are the main results of the review?</b> </p> <p>For people with locally advanced or metastatic HER2‐negative (people with breast cancer that tests negative for a protein called human epidermal growth factor receptor 2), BRCA germline mutated (participant carries a mutation in the BRCA gene) breast cancer, our systematic review found that PARP inhibitors: </p> <p>‐ may reduce the risk of death by 13% (i.e. people treated with these drugs live longer overall compared to those treated in the comparator treatment arm);<br/>‐ reduce the risk of disease growth by 37%; <br/>‐ may improve the chance of tumour shrinkage (66.9% for PARP inhibitors versus 48.9% for other treatments):<br/>‐ result in little to no difference in side effects compared to other treatment arms. </p> <p>Quality of life data were collected in two trials and the evidence available showed PARP inhibitors were superior compared to physician’s choice of chemotherapy in terms of participant‐reported outcomes. </p> </div> </section> <section id="vls" style="display: none"> <div class="section-header section-collapse-header"> <h2 class="title section-collapse-title">Visual summary<i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i></h2> </div> <a href="" target="_blank"><img alt="visual summary" src=""/></a> </section> <section class="conclusions"> <div class="section-header section-collapse-header" id="CD011395-sec-0064" lang="en"> <h2 class="title section-collapse-title"> Authors' conclusions <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> </div> <section class="authorsConclusions" lang="en"> <div class="section-header" id="CD011395-sec-0064"></div> <h3 class="title" id="CD011395-sec-0065">Implications for practice</h3> <section id="CD011395-sec-0065"> <p>Our systematic review shows PARP inhibitors offer a progression‐free survival advantage and there might be a small advantage in overall survival for patients with locally advanced/metastatic HER2‐negative, BRCA germline mutated breast cancer. Given PARP inhibitors did not have significantly increased toxicity and two studies that did look at quality of life outcomes showed an improvement, PARP inhibitors could be incorporated into the treatment paradigm for this subgroup of breast cancer patients. </p> <p>However, the optimum method of use of PARP inhibitors remains unclear. The small numbers of trials were insufficient for meta‐analysis to determine whether they should be used as a single agent or in combination with chemotherapy. </p> </section> <h3 class="title" id="CD011395-sec-0066">Implications for research</h3> <section id="CD011395-sec-0066"> <p>Our systematic review has raised a number of unanswered questions and helps guide direction for future studies. Certainly, future studies with sufficient power to detect meaningful improvements in overall survival are needed. </p> <p>HER2‐positive and BRCA‐negative/homologous recombination repair‐deficient populations were excluded from all studies, so further research with these populations is needed. Given the benefit seen in the metastatic setting, PARP inhibitors may also have a role in the neoadjuvant or the adjuvant settings. </p> <p>Data to help clinicians with sequencing of therapies is lacking and further research in this area is vital to help answer when are PARP inhibitors most effective and whether they should be given alone or in combination. We believe further investigation into the role of platinum chemotherapy in this group is needed and whether PARP inhibitors are superior for patients who have had prior platinum exposure. For the subgroup of BRCA‐mutated PDL1‐positive patients, especially those with triple‐negative disease, it remains unclear as to whether immunotherapy or PARP inhibitors may be most beneficial. Also, it is unclear whether previous immunotherapy impacts PARP inhibitor utility. </p> <p>Future studies need to collect data on quality of life to investigate the implications of using PARP inhibitors, especially in the palliative setting for patients with advanced breast cancer. In our current environment of scarce resources and a stressed health care system, it becomes even more apparent that assessing cost‐effectiveness of new interventions, in both health and economic terms, is essential. </p> </section> </section> </section> <section class="summaryOfFindings"> <div class="section-header section-collapse-header" id="CD011395-sec-0008" lang="en"> <h2 class="title section-collapse-title"> Summary of findings <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> </div> <section class="summaryOfFindings" lang="en"> <div class="section-header" id="CD011395-sec-0008"></div> <div class="table" id="CD011395-tbl-0001"> <table class="summary-of-findings framed"><a class="open-table-viewer open-in-figure-viewer" href="#0">Open in table viewer</a><div class="table-heading"><span class="table-label">Summary of findings 1.</span> <span class="table-title">PARPi‐containing regimen compared to non‐PARPi regimen for locally advanced or metastatic breast cancer</span></div> <tbody> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="7" rowspan="1" valign="top"> <p><b>PARPi‐containing regimen compared to non‐PARPi regimen for locally advanced or metastatic breast cancer</b> </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="7" rowspan="1" valign="top"> <p><b>Patient or population:</b> locally advanced or metastatic breast cancer<br/><b>Setting:</b> <br/><b>Intervention:</b> PARPi‐containing regimen<br/><b>Comparison:</b> non‐PARPi regimen </p> </td> </tr> <tr class="separated"> <th align="left" class="headercell" colspan="1" rowspan="2" scope="col" valign="top"> <p><b>Outcomes</b> </p> </th> <th align="left" class="headercell table-tint" colspan="2" rowspan="1" scope="col" valign="top"> <p><b>Anticipated absolute effects<sup>*</sup> (95% CI)</b> </p> </th> <th align="left" class="headercell" colspan="1" rowspan="2" scope="col" valign="top"> <p><b>Relative effect<br/>(95% CI)</b> </p> </th> <th align="left" class="headercell" colspan="1" rowspan="2" scope="col" valign="top"> <p><b>№ of participants<br/>(studies)</b> </p> </th> <th align="left" class="headercell" colspan="1" rowspan="2" scope="col" valign="top"> <p><b>Certainty of the evidence<br/>(GRADE)</b> </p> </th> <th align="left" class="headercell" colspan="1" rowspan="2" scope="col" valign="top"> <p><b>Comments</b> </p> </th> </tr> <tr class="separated"> <th align="left" class="headercell table-tint" colspan="1" rowspan="1" scope="col" valign="top"> <p><b>Risk with non‐PARPi regimen</b> </p> </th> <th align="left" class="headercell table-tint" colspan="1" rowspan="1" scope="col" valign="top"> <p><b>Risk with PARPi‐containing regimen</b> </p> </th> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>Overall Survival**<br/>follow up: 24 months </p> </td> <td align="left" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p>Study population</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>HR 0.84<br/>(0.76 to 1.00) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>1435<br/>(4 RCTs) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>⊕⊕⊕⊕<br/>HIGH <sup>1 2 3 4</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"></td> </tr> <tr class="separated"> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>550 per 1,000</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>497 per 1,000<br/>(446 to 550) </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>Progression Free Survival**<br/>follow up: 12 months </p> </td> <td align="left" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p>Study population</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>HR 0.63<br/>(0.56 to 0.71) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>1474<br/>(5 RCTs) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>⊕⊕⊕⊕<br/>HIGH <sup>1 3 5 6</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"></td> </tr> <tr class="separated"> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>625 per 1,000</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>461 per 1,000<br/>(423 to 502) </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>Response Rate</p> </td> <td align="left" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p>Study population</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>RR 1.39<br/>(1.24 to 1.54) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>1185<br/>(5 RCTs) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>⊕⊕⊝⊝<br/>LOW <sup>1 3 6 7</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"></td> </tr> <tr class="separated"> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>489 per 1,000</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>695 per 1,000<br/>(636 to 749) </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>Grade ≥3 AEs</p> </td> <td align="left" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p>Study population</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>RR 0.98<br/>(0.91 to 1.04) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>1443<br/>(5 RCTs) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>⊕⊕⊕⊝<br/>MODERATE <sup>1 3 8 9</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"></td> </tr> <tr class="separated"> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>645 per 1,000</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>620 per 1,000<br/>(555 to 684) </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p>*<b>The risk in the intervention group</b> (and its 95% confidence interval) is based on the assumed risk in the comparison group and the <b>relative effect</b> of the intervention (and its 95% CI). </p> <p>** Given i) overall survival and progression‐free survival are continuous endpoints in clinical practice but ii) that continuous measures are not easily quantifiable (even if the HR is available), we opted to estimate the percentage of patients with this outcome (e.g. death) at a predefined time interval to practically estimate the size of treatment benefit for readers. We extrapolated this information from Kaplan‐Meier curves from the included studies. We started with the OS at 2 years, then subtracted this from 1 to arrive at incidence of death at 2 years and similarly for PFS at 1 year (<a href="./references#CD011395-bbs2-0002" title="DiérasV , HanHS , RobsonME , PalacovaM , MarcomPK , JagerA , et al. Evaluation of veliparib (V) and temozolomide (TMZ) in a phase 2 randomized study of the efficacy and tolerability of V+TMZ or carboplatin (C) and paclitaxel (P) vs placebo (Plc)+C/P in patients (pts) with BRCA1 or BRCA2 mutations and metastatic breast cancer. Cancer Research2017;77(Suppl 4):Abstract nr SABCS16-P4-22-02. HanHS , DiérasV , RobsonM , PalácováM , MarcomPK , Jager A et al. Veliparib with temozolomide or carboplatin/paclitaxel versus placebo with carboplatin/paclitaxel in patients with BRCA1/2 locally recurrent/metastatic breast cancer: randomized phase II study. Annals of Oncology2018;29(1):154-61. HanHS , DiérasV , RobsonME , PalácováM , MarcomPK , JagerA , et al. Efficacy and tolerability of veliparib (V; ABT-888) in combination with carboplatin (C) and paclitaxel (P) vs placebo (Plc)+C/P in patients (pts) with BRCA1 or BRCA2 mutations and metastatic breast cancer: a randomized, phase 2 study. Cancer Research2017;77(Suppl 4):Abstract nr SABCS16-S2-05. IsakoffSJ , PuhallaS , DomchekSM , FriedlanderM , KaufmanB , RobsonM , et al. A randomized Phase II study of veliparib with temozolomide or carboplatin/paclitaxel versus placebo with carboplatin/paclitaxel in BRCA1/2 metastatic breast cancer: design and rationale. Future Oncology2017;13(4):307-20. ">BROCADE 2</a>; <a href="./references#CD011395-bbs2-0003" title="ArunBK , HanHS , KaufmanB , WildiersH , FriedlanderM , AyoubJP , et al. First-line veliparib plus carboplatin/paclitaxel in patients with HER2-negative advanced/metastatic gBRCA-associated breast cancer: planned subgroup analysis from the phase 3 BROCADE3 trial. Cancer Research2020;80(Suppl 4):Abstract nr PD4-01. AyoubJP , FriedlanderML , DierasVC , WildiersH , ArunB , HanHS , et al. Veliparib plus carboplatin-paclitaxel in patients with HER2-negative advanced/metastatic gBRCA-associated breast cancer: results in hormone receptor-positive and triple-negative breast cancer subgroups from the phase III BROCADE3 trial. Annals of Oncology2020;31(Suppl 2):S65. DierasV , HanH , KaufmanB , WildiersH , FriedlanderM , AyoubJ , et al. A Phase 3 randomized, placebo-controlled trial of carboplatin and paclitaxel with or without the PARP inhibitor veliparib (ABT-888) in HER2-negative metastatic or locally advanced unresectable BRCA-associated breast cancer. Annals of Oncology2019;30(Suppl 5):v851-v934. ">BROCADE 3</a>; <a href="./references#CD011395-bbs2-0004" title="DiabS , RugoHS , MinaLA , PuhallaS , MahtaniRL , HenryNL , et al. Efficacy and safety of talazoparib (TALA) or physician's choice of therapy (PCT) in United States patients (pts) with HER2- germline BRCA1/2-mutated (gBRCAm) locally advanced/metastatic breast cancer (LA/MBC) in the EMBRACA study. Journal of Clinical Oncology2019;37(Suppl 15):1044. EiermannW , RugoHS , DiabS , EttlJ , HurvitzSA , GoncalvesA , et al. Analysis of germline BRCA1/2 mutated (g BRCAmut) hormone receptor-positive (HR+) and triple-negative breast cancer (TNBC) treated with talazoparib (TALA). Journal of Clinical Oncology2018;36(Suppl 15):1070. EttlJ , HurvitzSA , RugoHS , LeeKH , MinaLA , WoodwardNE , et al. Outcomes of talazoparib (TALA) versus physician's choice of chemotherapy (PCT) in patients (pts) with advanced breast cancer (ABC) and a germline BRCA (gBRCA) mutation by line of chemotherapy (CT) in the EMBRACA trial. Journal of Clinical Oncology2019;37(Suppl 15):1071. EttlJ , QuekRG , BhattacharyyaH , RugoHS , HurvitzSA , GonçalvesA . Patient Reported Outcomes (PRO) in patients (pts) with HER2-advanced breast cancer (ABC) and a germline BRCA1/2 mutation (gBRCAm) receiving talazoparib (TALA) vs physician’s choice chemotherapy (PCT) in the EMBRACA trial: a focus on subgroups with/without visceral disease. Annals of Oncology2019;30(Suppl 5):v129–30. EttlJ , QuekRG , HurvitzSA , GoncalvesA , TudorIC , RugoHS . Hospitalization and supportive care medication (SCM) utilisation in patients (pts) with advanced breast cancer (ABC) and a germline BRCA1/2 mutation (gBRCAm) in EMBRACA. Annals of Oncology2019;30(Suppl 3):iii52. EttlJ , QuekRG , LeeKH , RugoHS , HurvitzS , GonçalvesA , et al. Quality of life with talazoparib versus physician’s choice of chemotherapy in patients with advanced breast cancer and germline BRCA1/2 mutation: patient-reported outcomes from the EMBRACA phase III trial. Annals of Oncology2018;29(9):1939-47. FaschingPA , QuekRG , BhattacharyyaH , HurvitzSA , RugoHS , EttlJ . Impact of objective response (OR) on patient-reported outcomes (PRO) in patients (pts) with advanced breast cancer (ABC) and a germline BRCA1/2 (gBRCA) mutation in the phase III EMBRACA trial. Annals of Oncology2019;30(Suppl 3):iii49. GonçalvesA , EiermannW , RugoHS , EttlJ , HurvitzSA , YerushalmiR , et al. EMBRACA: Efficacy and safety in comparing talazoparib (TALA) with physician's choice of therapy (PCT) in patients (pts) with advanced breast cancer (aBC) and a germline BRCA mutation (gBRCAm); BRCA1/BRCA2 subgroup analysis. Annals of Oncology2018;29(Suppl 8):viii96–7. GoncalvesA , QuekRGW , BhattacharyyaH , EttlJ , HurvitzSA , RugoHS . Patient-reported outcomes (PRO) in patients (pts) with Her2-advanced breast cancer (ABC) receiving talazoparib (TALA) vs physician's choice chemotherapy (PCT): a focus on EMBRACA germline BRCA1 and BRCA2 mutation (gBRCA1/2m) subgroups. Breast2019;48(Suppl 2):S71. HurvitzSA , GoncalvesA , RugoHS , LeeKH , FehrenbacherL , MinaLA , et al. Talazoparib in patients with a germline BRCA-mutated advanced breast cancer: detailed safety analyses from the phase III EMBRACA Trial. Oncologist2019;25(3):e439-50. LeeKH , KimSB , SohnJ , GoodwinA , UsariT , LanzaloneS , et al. Talazoparib (TALA) vs physician’s choice of chemotherapy (PCT) in Asian patients (Pts) with HER2- advanced breast cancer (ABC) and a germline BRCA1/2 mutation (gBRCA1/2mut): data from phase III EMBRACA. Annals of Oncology2019;30(9):ix14. LittonJ , EttlJ , HurvitzSA , MinaLA , RugoHS , LeeKH , et al. A phase 3, open-label, randomized, 2-arm international study of the oral dual PARP inhibitor talazoparib in germline BRCA mutation subjects with locally advanced and/or metastatic breast cancer (EMBRACA). Cancer Research2017;77(Suppl 4):Abstract nr OT2-01-13. LittonJ , RugoHS , EttlJ , HurvitzS , GoncalvesA , LeeKH , et al. EMBRACA: a phase 3 trial comparing talazoparib, an oral PARP inhibitor, to physicianʼs choice of therapy in patients with advanced breast cancer and a germline BRCA mutation [abstract]. In: San Antonio Breast Cancer Symposium; 2017 Dec 5-9; San Antonio (TX). San Antonio (TX), 2017. LittonJK , HurvitzSA , MinaLA , RugoHS , LeeKH , GonçalvesA , et al. Talazoparib (TALA) in germline BRCA1/2 (gBRCA1/2)-mutated human epidermal growth factor receptor 2 negative (HER2-) advanced breast cancer (ABC): final overall survival (OS) results from randomized phase 3 EMBRACA trial. Cancer Research2020;80(Suppl 16):Abstract no. CT071. LittonJK , RugoHS , EttlJ , HurvitzSA , GonçalvesA , LeeKH , et al. Talazoparib in patients with advanced breast cancer and a germline BRCA mutation. New England Journal of Medicine2018;379(8):753-63. MartínM , EiermannW , RugoHS , EttlJ , HurvitzSA , GonçalvesA , et al. EMBRACA: Comparison of efficacy and safety of talazoparib (TALA) and physician's choice of therapy (PCT) in patients (pts) with advanced breast cancer (aBC), a germline BRCA1/2 mutation (gBRCAm), and prior platinum treatment. Annals of Oncology2018;29(Suppl 8):viii96. MinaL , LeeKH , GoncalvesA , WoodwardN , HurvitzSA , DiabS , et al. EMBRACA: efficacy and safety of talazoparib or physician's choice of therapy in patients with advanced breast cancer and a germline BRCA1/2 mutation: a regional analysis. Cancer Research2019;79(Suppl 4):Abstract nr P6-18-12. QuekR , BhattacharyyaH , HurvitzS , GoncalvesA , EttlJ , RugoH . Patient-reported outcomes in patients with HER2-advanced breast cancer and a germline BRCA1/2 mutation receiving talazoparib versus physician's choice chemotherapy: a focus on EMBRACA age subgroups. Journal of Managed Care and Specialty Pharmacy2019;25(Suppl 10A):S37-8. QuekRGW , BhattacharyyaH , GoncalvesA , RugoHS , HurvitzSA , EttlJ . Pcn491 Patient reported outcomes (PRO) of talazoparib (TALA) versus physician's choice of chemotherapy (PCT) in patients (pts) with advanced breast cancer (aBC) and a germline BRCA (gBRCa) mutation: a focus on Embraca pts with/without prior chemotherapy (CT) subgroups. Value in Health2019;22(Suppl 3):S532. RugoHS , EttlJ , HurvitzSA , GoncalvesA , LeeKH , FehrenbacherL , et al. Outcomes in clinically relevant patient subgroups from the EMBRACA study: talazoparib vs physician's choice standard-of-care chemotherapy. Journal of the National Cancer Institute Cancer Spectrum2020;4(1):pkz085. RugoHS , EttlJ , WoodwardNE , HurvitzSA , GoncalvesA , LeeKH , et al. EMBRACA: efficacy outcomes in clinically relevant subgroups comparing talazoparib (TALA), an oral poly ADP ribose polymerase (PARP) inhibitor, to physician's choice of therapy (PCT) in patients with advanced breast cancer and a germline BRCA mutation. Journal of Clinical Oncology2018;36(Suppl 15):1069. RugoHS , QuekR , EttlJ , HurvitzSA , BhattacharyyaH , HannahAL , et al. Patient-reported outcomes (PRO) in patients (pts) with advanced breast cancer and a germline BRCA1/2 mutation (gBRCAm) receiving talazoparib (TALA) vs physician’s choice chemotherapy treatment (PCT): a focus on the EMBRACA triple negative (TNBC) subpopulation. Annals of Oncology2018;29(Suppl 8):viii91. YuY , ElmeliegyM , LittonJK , TudorIC , CzibereA , ZhengJ , et al. Exposure-efficacy progression-free survival (PFS) analyses of breast cancer patients with germline BRCA1/2 mutations receiving talazoparib in the phase III EMBRACA trial. Annals of Oncology2018;29(Suppl 8):viii97. YuY , ElmeliegyM , LittonJK , TudorIC , CzibereA , ZhengJ , et al. Talazoparib exposure-efficacy analysis in patients with advanced breast cancer and germline BRCA1/2 mutations in the EMBRACA trial. Journal of Clinical Pharmacology2020;60(10):1324-33. ">EMBRACA</a>; <a href="./references#CD011395-bbs2-0005" title="KummarS , WadeJL , OzaAM , SullivanD , ChenAP , GandaraDR , et al. Randomized phase II trial of cyclophosphamide and the oral poly (ADP-ribose) polymerase inhibitor veliparib in patients with recurrent, advanced triple-negative breast cancer. Investigational New Drugs2016;34(3):355–63. ">Kummar 2016</a>; <a href="./references#CD011395-bbs2-0006" title="DelalogeS , ContePF , ImS , Senkus-KonefkaE , XuB , DomchekSM , et al. OlympiAD: further efficacy outcomes in patients with HER2-negative metastatic breast cancer and a germline BRCA mutation receiving olaparib monotherapy vs standard single-agent chemotherapy treatment of physician’s choice. Annals of Oncology2017;28(Suppl 5):v74-v108. DomchekS , RobsonM , ImS , SenkusE , XuB , MasudaN , et al. Tolerability of olaparib monotherapy versus chemotherapy in patients with HER2-negative metastatic breast cancer and a germline BRCA mutation: OlympiAD. Cancer Research2018;78(Suppl 4):Abstract nr P5-21-12. ImSA , XuB , LiW , RobsonM , OuyangQ , YehDC , et al. Olaparib monotherapy for Asian patients with a germline BRCA mutation and HER2-negative metastatic breast cancer: OlympiAD randomized trial subgroup analysis. Scientific Reports2020;10(1):8753. ImSA , XuB , LiW , RobsonM , OuyangQ , YehDC , et al. Olaparib monotherapy versus chemotherapy for patients with HER2-negative metastatic breast cancer and a germline BRCA mutation: Asian subgroup analysis from the phase III OlympiAD trial. Cancer Research2018;78(Suppl 4):Abstract nr P5-21-13. MerensC , BannisterW , BergnerS , HettleR , McCreaC , McCutcheonS , et al. Impact of olaparib versus chemotherapy on the use of strong pain medications in gBRCA-mutated HER2-negative metastatic breast cancer and associated patient reported outcomes. Cancer Research2020;80(Suppl 4):Abstract nr P6-13-05. RobsonM , HettleR , DegboeA , SaundersO , CainT , KilvertH , et al. Estimating the health state utility of patients with HER2–gBRCA+ metastatic breast cancer treated with olaparib or chemotherapy via a mapping analysis of EORTC QLQ-C30 data collected in the Olympiad clinical trial. Value in Health2018;21(Suppl 1):S12. RobsonM , ImSA , SenkusE , XuB , DomchekS , MasudaN , et al. OlympiAD extended follow-up for overall survival and safety: olaparib versus chemotherapy treatment of physician’s choice in patients with a germline BRCA mutation and HER2-negative metastatic breast cancer. Cancer Research2020;80(Suppl 4):Abstract nr PD4-03. RobsonM , ImSA , SenkusE , XuB , DomchekSM , MasudaN , et al. Olaparib for metastatic breast cancer in patients with a germline BRCA mutation. New England Journal of Medicine2017;377(6):523-33. RobsonM , RuddyKJ , ImSA , SenkusE , XuB , DomchekSM , et al. Patient-reported outcomes in patients with a germline BRCA mutation and HER2-negative metastatic breast cancer receiving olaparib versus chemotherapy in the OlympiAD trial. European Journal of Cancer2019;120:20-30. RobsonM , RuddyKJ , ImSA , Senkus-KonefkaE , XuB , DomchekSM , et al. OlympiAD: health-related quality of life (HRQoL) in patients with HER2-negative metastatic breast cancer (mBC) and a germline BRCA mutation (gBRCAm) receiving olaparib monotherapy vs standard single-agent chemotherapy treatment of physician’s choice (TPC). Annals of Oncology2017;28(Suppl 5):v74-v108. RobsonME , ImSA , SenkusE , XuB , DomchekS , MasudaN , et al. Abstract CT038: OlympiAD final overall survival: olaparib versus chemotherapy treatment of physician's choice (TPC) in patients with HER2-negative metastatic breast cancer (mBC) and a germline BRCA mutation (gBRCAm). American Association for Cancer Research2018;78(Suppl 13):CT038. RobsonME , ImSA , SenkusE , XuB , DomchekSM , MasudaN , et al. OlympiAD: phase III trial of olaparib monotherapy versus chemotherapy for patients (pts) with HER2-negative metastatic breast cancer (mBC) and a germline BRCA mutation (gBRCAm). Journal of Clinical Oncology2017;35(Suppl 18):LBA4-LBA4. RobsonME , RuddyKJ , ImSA , Senkus-KonefkaE , XuB , DomchekSM , et al. EORTC QLQ-C30 (QLQ-C30) symptoms in patients (pts) with HER2-negative metastatic breast cancer (mBC) and a germline BRCA mutation (gBRCAm) receiving olaparib vs chemotherapy treatment of physician’s choice (TPC) in OlympiAD. Journal of Clinical Oncology2018;36(Suppl 15):1045. RobsonME , TungN , ConteP , ImSA , SenkusE , XuB , et al. OlympiAD final overall survival and tolerability results: olaparib versus chemotherapy treatment of physician’s choice in patients with a germline BRCA mutation and HER2-negative metastatic breast cancer. Annals of Oncology2019;30(4):558-66. Senkus-KonefkaE , DomchekSM , ImSA , XuB , ArmstrongA , MasudaN , et al. Subgroup analysis of olaparib monotherapy versus chemotherapy by hormone receptor and BRCA mutation status in patients with HER2-negative metastatic breast cancer and a germline BRCA mutation: OlympiAD. European Journal of Cancer2018;92:S19-20. TungNM , ImSA , Senkus-KonefkaE , XuB , DomchekSM , MasudaN , et al. Olaparib versus chemotherapy treatment of physician’s choice in patients with a germline BRCA mutation and HER2-negative metastatic breast cancer (OlympiAD): efficacy in patients with visceral metastases. Journal of Clinical Oncology2018;36(Suppl 15):1053. ">OLYMPIAD</a>).<br/><br/><b>CI:</b> Confidence interval; <b>HR:</b> Risk ratio; <b>OR:</b> Odds ratio; </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p><b>GRADE Working Group grades of evidence</b> <br/><b>High certainty:</b> We are very confident that the true effect lies close to that of the estimate of the effect<br/><b>Moderate certainty:</b> We are moderately confident in the effect estimate: The true effect is likely to be close to the estimate of the effect, but there is a possibility that it is substantially different<br/><b>Low certainty:</b> Our confidence in the effect estimate is limited: The true effect may be substantially different from the estimate of the effect<br/><b>Very low certainty:</b> We have very little confidence in the effect estimate: The true effect is likely to be substantially different from the estimate of effect </p> </td> </tr> </tbody> <tfoot> <tr> <td colspan="7"> <div class="table-footnote"> <p><sup>1</sup> All studies mostly graded as low to unclear risk of bias. This is based on the scores from each domain including 3/5 studies which had high risk of bias in terms of performance bias due to being open‐label. Also, detection bias for adverse events (3/5 studies) were judged as having high risk of bias. Overall, judged as unclear but not serious risk of bias. </p> <p><sup>2</sup> I<sup>2</sup>=0%, indicating low heterogeneity. </p> <p><sup>3</sup> No indirectness present. </p> <p><sup>4</sup> 95% CI did not extend past HR of 1.0 and the total number of patients exceeded 400. </p> <p><sup>5</sup> I<sup>2</sup>=2%, indicating low heterogeneity. </p> <p><sup>6</sup> 95% CI excluded a HR of 1.0 and the total number of events exceeded 400. </p> <p><sup>7</sup> Significant heterogeneity (I<sup>2</sup>=90%) without an obvious clinical explanation arising from differences in included trials. </p> <p><sup>8</sup> Significant heterogeneity (I<sup>2</sup>=73%). </p> <p><sup>9</sup> 95% CI crosses both 1 (the point of no effect) and 0.75 (the point of significantly reduced toxicity) </p> </div> </td> </tr> </tfoot> </table> </div> </section> </section> <section class="background"> <div class="section-header section-collapse-header" id="CD011395-sec-0009" lang="en"> <h2 class="title section-collapse-title"> Background <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> </div> <section class="background" lang="en"> <div class="section-header" id="CD011395-sec-0009"></div> <section id="CD011395-sec-0010"> <h3 class="title" id="CD011395-sec-0010">Description of the condition</h3> <p>Treatment of metastatic breast cancer remains a challenge to current patients and clinicians, with all patients eventually succumbing to the disease. Prognosis and survival rates vary greatly depending on the extent of the disease, performance status of the patients and the pathological tumour subtype, in particular, its immunohistochemical receptor status i.e. oestrogen receptor (ER), progesterone receptor (PR), and human epidermal growth factor receptor 2 (HER2). Expression of the ER and PR in tumours confers a better prognosis, while HER2‐positive and triple‐negative breast cancer (tumours without expression of ER/PR and HER2) tend to be indicative of a more aggressive cancer (<a href="./references#CD011395-bbs2-0021" title="FoulkesWD , SmithIE , Reis-FilhoJS . Triple-negative breast cancer. New England Journal of Medicine2010;363(20):1938-48.">Foulkes 2010</a>). Breast cancer phenotypes have also been described in terms of tumour gene expression profiles which have approximate immunohistochemical correlates (<a href="./references#CD011395-bbs2-0032" title="PerouCM , SørlieT , EisenMB , Van de RijnM , JeffreySS , ReesCA , et al. Molecular portraits of human breast tumours. Nature2000;406(6797):747-52.">Perou 2000</a>). Basal‐like breast cancer is one such group and has similar morphological and genetic features with triple‐negative breast cancer, but they are not completely identical. </p> <p>Breast cancers arising in patients with germline mutations in the BReast CAncer gene 1 (BRCA1) are more often triple‐negative and basal‐like, whereas BReast CAncer gene 2 (BRCA2)‐associated tumours are difficult to distinguish from sporadic cancers using standard histology techniques (<a href="./references#CD011395-bbs2-0021" title="FoulkesWD , SmithIE , Reis-FilhoJS . Triple-negative breast cancer. New England Journal of Medicine2010;363(20):1938-48.">Foulkes 2010</a>). </p> <p>Triple‐negative breast cancer and basal‐like breast cancer occur most frequently in young women and respond to conventional chemotherapy but relapse earlier and more frequently than hormone receptor‐positive breast cancer and are likely to have a less favourable overall outcome (<a href="./references#CD011395-bbs2-0021" title="FoulkesWD , SmithIE , Reis-FilhoJS . Triple-negative breast cancer. New England Journal of Medicine2010;363(20):1938-48.">Foulkes 2010</a>). </p> </section> <section id="CD011395-sec-0011"> <h3 class="title" id="CD011395-sec-0011">Description of the intervention</h3> <p>Novel therapeutic strategies for metastatic breast cancer are in clinical development. Poly ADP Ribose Polymerase (PARP) inhibitors are one new class of agents. PARP‐1 and PARP‐2 proteins are part of the complex that is assembled in response to single‐strand deoxyribonucleic acid (DNA) breaks and are integral to the repair of single‐strand DNA breaks (<a href="./references#CD011395-bbs2-0026" title="KhasrawM , RobsonM . Poly (ADP-ribose) polymerase inhibitors in breast cancer and other tumors: advances and challenges. Clinical Investigation2011;1(11):1545-54.">Khasraw 2011</a>). DNA damage induction is a common mode of action of many anti‐cancer drugs. </p> <p>BRCA1 and BRCA2 are part of the complex that permits homologous recombination, i.e. repairing of a double‐strand DNA break. If these genes are mutated, then DNA cannot be repaired via homologous recombination (<a href="./references#CD011395-bbs2-0020" title="DavarD , BeumerJH , HamiehL , TawbiH . Role of PARP inhibitors in cancer biology and therapy. Current Medicinal Chemistry2012;19(23):3907-21.">Davar 2012</a>). PARP inhibitors promote the progression of single‐strand DNA breaks to double‐strand DNA breaks and can induce synthetic lethality in cells with impaired homologous recombination mechanisms, such as those with a BRCA mutation (<a href="./references#CD011395-bbs2-0020" title="DavarD , BeumerJH , HamiehL , TawbiH . Role of PARP inhibitors in cancer biology and therapy. Current Medicinal Chemistry2012;19(23):3907-21.">Davar 2012</a>). </p> <p>Clinical trials of PARP inhibitors (PARPi) are ongoing in BRCA mutation‐associated cancers as well as sporadic breast cancers, ovarian cancers and other malignancies. </p> </section> <section id="CD011395-sec-0012"> <h3 class="title" id="CD011395-sec-0012">How the intervention might work</h3> <p>Ongoing studies have shed light on important genetic abnormalities in triple‐negative breast cancer, basal‐like breast cancer, and BRCA‐associated breast tumours. Treatment with PARP inhibitors has revealed encouraging data in early phase clinical studies in metastatic breast cancer including patients with triple‐negative breast cancer, basal‐like breast cancer and BRCA1‐associated tumours (<a href="./references#CD011395-bbs2-0026" title="KhasrawM , RobsonM . Poly (ADP-ribose) polymerase inhibitors in breast cancer and other tumors: advances and challenges. Clinical Investigation2011;1(11):1545-54.">Khasraw 2011</a>). There are several ongoing larger studies using PARP inhibitors in breast cancer either as a single agent or in combination with other cytotoxic medications. </p> </section> <section id="CD011395-sec-0013"> <h3 class="title" id="CD011395-sec-0013">Why it is important to do this review</h3> <p>With emerging study results, it is important to interpret the available clinical data and apply the evidence offering the most effective treatment to the right patient. It is hoped that these agents will play a significant role in the treatment of cancers including those arising in BRCA1/2 mutation carriers. The work that has been done so far raises the possibility that future studies will uncover additional relationships between PARP‐dependent pathways and tumour‐specific defects present in sporadic cancers (<a href="./references#CD011395-bbs2-0026" title="KhasrawM , RobsonM . Poly (ADP-ribose) polymerase inhibitors in breast cancer and other tumors: advances and challenges. Clinical Investigation2011;1(11):1545-54.">Khasraw 2011</a>). The optimal PARP inhibitor‐chemotherapy drug combination remains to be established, with a wide range of ongoing trials exploring these questions. </p> </section> </section> </section> <section class="objectives"> <div class="section-header section-collapse-header" id="CD011395-sec-0014" lang="en"> <h2 class="title section-collapse-title"> Objectives <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> </div> <section class="objectives" lang="en"> <div class="section-header" id="CD011395-sec-0014"></div> <p>To assess the effects of PARP inhibitors for patients with locally advanced or metastatic breast cancer<i>.</i> </p> </section> </section> <section class="methods"> <div class="section-header section-collapse-header" id="CD011395-sec-0015" lang="en"> <h2 class="title section-collapse-title"> Methods <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> </div> <section class="methods" lang="en"> <div class="section-header" id="CD011395-sec-0015"></div> <section id="CD011395-sec-0016"> <h3 class="title">Criteria for considering studies for this review</h3> <section id="CD011395-sec-0017"> <h4 class="title">Types of studies</h4> <p>Randomised controlled trials (RCTs). We only included RCTs when the agent evaluated was mechanistically described as a PARP inhibitor, used alone or in combination with chemotherapy or other biologic agents (or a combination of these treatment modalities). </p> </section> <section id="CD011395-sec-0018"> <h4 class="title">Types of participants</h4> <p>Patients with locally advanced or metastatic breast cancer.</p> </section> <section id="CD011395-sec-0019"> <h4 class="title">Types of interventions</h4> <p>The intervention was the use of PARP inhibitors for locally advanced or metastatic breast cancer treatment. The comparator involved treatment with chemotherapy without PARP inhibitors. </p> <p>We included trials involving:</p> <p> <ul id="CD011395-list-0001"> <li> <p>chemotherapy in combination with PARP inhibitors, compared to the same chemotherapy without PARP inhibitors; </p> </li> <li> <p>treatment with PARP inhibitors, compared to treatment with other chemotherapy</p> </li> </ul> </p> </section> <section id="CD011395-sec-0020"> <h4 class="title">Types of outcome measures</h4> <section id="CD011395-sec-0021"> <h5 class="title">Primary outcomes</h5> <p> <ul id="CD011395-list-0002"> <li> <p>Overall survival (OS), defined as the length of time from randomisation to death from any cause. </p> </li> </ul> </p> </section> <section id="CD011395-sec-0022"> <h5 class="title">Secondary outcomes</h5> <p> <ul id="CD011395-list-0003"> <li> <p>Progression‐free survival (PFS), defined as the time from randomisation to either death or disease progression, whichever occurs first: </p> <ul id="CD011395-list-0004"> <li> <p>Time To Progression (TTP) used if PFS was not reported</p> </li> </ul> </li> <li> <p>Disease progression, as defined according to the widely‐used 'Response Evaluation Criteria In Solid Tumors (RECIST)' criteria used for solid tumours (<a href="./references#CD011395-bbs2-0036" title="TherasseP , ArbuckSG , EisenhauerEA , WandersJ , KaplanRS , RubinsteinL , et al. New guidelines to evaluate the response to treatment in solid tumors. Journal of the National Cancer Institute2000;92(3):205-16.">Therasse 2000</a>): </p> <ul id="CD011395-list-0005"> <li> <p>Other response criteria also accepted if they are well defined in the study;</p> </li> <li> <p>Some currently‐open studies have abandoned RECIST scoring as the only method of assessing response and/or eligibility criteria partly due to recruitment issues, but also because it seems that it is not appropriate to assess response in some instances. This is similar to problems assessing activity of the biological (non‐cytotoxic) agents. </p> </li> </ul> </li> <li> <p>Quality of life (QoL), if a sufficient number of studies with adequate quality of life assessment are or become available and measured using a validated instrument e.g. the 36‐Item Short Form Health Survey (SF‐36), Functional Assessment of Cancer (FACT), the European Organisation for Research and Treatment of Cancer (EORTC) Quality of Life questionnaires </p> </li> <li> <p>Adverse events, classified according to the World Health Organization (WHO) or National Cancer Institute‐Common Terminology Criteria (NCI‐CTC), including the percentage of treatment‐related deaths. </p> </li> </ul> </p> </section> </section> </section> <section id="CD011395-sec-0023"> <h3 class="title">Search methods for identification of studies</h3> <section id="CD011395-sec-0024"> <h4 class="title">Electronic searches</h4> <p>We conducted systematic literature searches to identify published and unpublished RCTs. Due to the relatively recent availability of PARP inhibitors, the start date for the literature search was 2008, which was considered sufficient for the purpose of this review. We identified RCTs using the following key words: including but not restricted to PARP inhibitors (specific drugs: veliparib, olaparib), and breast cancer. </p> <p>We did not apply any language restriction in the searches.</p> <p>We searched the following databases on 18 June 2020:</p> <p> <ol id="CD011395-list-0006"> <li> <p>the Cochrane Breast Cancer Group Specialised Register;</p> </li> <li> <p>the Cochrane Central Register of Controlled Trials (CENTRAL) (<i>The Cochrane Library</i>) (<a href="./appendices#CD011395-sec-0070">Appendix 1</a>); </p> </li> <li> <p>MEDLINE via OvidSP (<a href="./appendices#CD011395-sec-0071">Appendix 2</a>); </p> </li> <li> <p>Embase via OvidSP (<a href="./appendices#CD011395-sec-0072">Appendix 3</a>); </p> </li> <li> <p>WHO International Clinical Trials Registry Platform (ICTRP) search portal for all prospectively registered and ongoing trials (<a href="http://apps.who.int/trialsearch/" target="_blank">http://apps.who.int/trialsearch/</a>) (<a href="./appendices#CD011395-sec-0073">Appendix 4</a>); </p> </li> <li> <p>ClinicalTrials.gov (<a href="http://clinicaltrials.gov/" target="_blank">http://clinicaltrials.gov/</a>) (<a href="./appendices#CD011395-sec-0076">Appendix 5</a>). </p> </li> </ol> </p> </section> <section id="CD011395-sec-0025"> <h4 class="title">Searching other resources</h4> <p>We screened reference lists from trial publications selected by electronic searching in order to identify further relevant trials. We also searched published conference abstracts from the following organisations: </p> <p> <ul id="CD011395-list-0007"> <li> <p>European Society for Medical Oncology (published in the Annals of Oncology);</p> </li> <li> <p>European Council for Clinical Oncology (published in the European Journal of Cancer);</p> </li> <li> <p>San Antonio Breast Cancer Symposium of the American Association of Cancer Research;</p> </li> <li> <p>St. Gallen International Breast Cancer Conference;</p> </li> <li> <p>American Society for Clinical Oncology;</p> </li> <li> <p>American Society for Clinical Oncology Breast Cancer Symposium.</p> </li> </ul> </p> <p>The search strategy was constructed using a combination of subject headings and text words relating to PARP inhibitors in breast cancer. In addition, we contacted members of the relevant cancer research groups, experts in the field, and manufacturers of relevant drugs for details of outstanding clinical trials and any relevant unpublished material. One conference abstract was provided by the editors. </p> </section> </section> <section id="CD011395-sec-0026"> <h3 class="title" id="CD011395-sec-0026">Data collection and analysis</h3> <section id="CD011395-sec-0027"> <h4 class="title">Selection of studies</h4> <p>Three review authors (AT, DC, MT) independently assessed the titles and abstracts retrieved by the search strategy for potential eligibility. We obtained full‐text articles of potentially eligible studies for further assessment (refer to <a href="#CD011395-sec-0019">Types of interventions</a>). The three authors assessed these full‐text articles for risk of bias independently and in a blinded fashion (to authors, journal, drug company, institutions and results), with disagreement resolved by consensus with a fourth review author (MK). </p> <p>We included abstracts or unpublished data only if sufficient information on the study design, characteristics of participants, interventions and outcomes was available. We attempted to obtain further information or final results from the primary trial author. </p> </section> <section id="CD011395-sec-0028"> <h4 class="title">Data extraction and management</h4> <p>Two authors (AT, DC) performed data extraction independently. We entered data into the Cochrane Collaboration statistical software, <a href="./references#CD011395-bbs2-0034" title="Nordic Cochrane Centre, The Cochrane CollaborationReview Manager (RevMan). Version 5.3 (accessed prior to 23 Feb 2021). Copenhagen: Nordic Cochrane Centre, The Cochrane Collaboration, 2014.">Review Manager 2014</a>. For each eligible trial, we recorded the following study characteristics: study design, participants, setting, interventions, 'Risk of bias' information, duration of follow‐up, efficacy outcomes, biomarker analyses and side‐effects. </p> <p>For studies with more than one publication, we extracted data on all outcomes from the most relevant publication. </p> <p>Two review authors (AT, DC) independently extracted details of study population, interventions and outcomes by using a standardised data extraction form. We resolved differences in data extraction by consensus with a third author (MK), referring back to the original article. </p> <p>Our data extraction form included at least the following items.</p> <p> <ul id="CD011395-list-0008"> <li> <p>General information: title, authors, source, contact address, country, published/unpublished, language and year of publication, sponsoring of trial. </p> </li> <li> <p>Trial characteristics: study design, duration/follow‐up, 'Risk of bias' assessment as specified above. </p> </li> <li> <p>Patients: inclusion and exclusion criteria, sample size, baseline characteristics, similarity of groups at baseline, withdrawals and losses to follow‐up. </p> </li> <li> <p>Interventions: dose, route and timing of chemotherapy, PARP inhibitors therapy and comparison intervention. </p> </li> <li> <p>Outcomes: hazard ratio (HRs) and 95% confidence intervals (CIs), log rank chi square, log rank P values, number of events, number of patients per group, median (one‐, two‐, three‐ and five‐year survival rates). </p> </li> </ul> </p> </section> <section id="CD011395-sec-0029"> <h4 class="title">Assessment of risk of bias in included studies</h4> <p>Two independent authors (AT, DC) assessed all studies that met the inclusion criteria for risk of bias, with disagreement resolved by the third review author (MK). We assessed the risk of bias for every included study using the Cochrane Collaboration's 'Risk of bias' tool (<a href="./references#CD011395-bbs2-0024" title="HigginsJPT , Green S (editors). Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0 [updated March 2011]. The Cochrane Collaboration, 2011. Available from training.cochrane.org/handbook/archive/v5.1.">Higgins 2011</a>). The Cochrane Collaboration's tool for assessing risk of bias encompasses seven domains, and our judgements on these domains for each trial will be reported in the 'Risk of bias' table. The seven domains are: </p> <p> <ol id="CD011395-list-0009"> <li> <p>sequence generation;</p> </li> <li> <p>allocation concealment;</p> </li> <li> <p>blinding of participants, personnel;</p> </li> <li> <p>blinding of outcome assessment (assessed separately for outcomes overall survival, progression‐free survival &amp; overall response rates, quality of life and adverse events); </p> </li> <li> <p>incomplete outcome data;</p> </li> <li> <p>selective outcome reporting (trial protocols and trial result publications will be cross‐checked); and </p> </li> <li> <p>other sources of bias (role of funding body considered).</p> </li> </ol> </p> <p>In addition, we also included trials which permitted a cross‐over for patients after disease progression. However, in these trials, the number of patients who crossed over has to be considered in the interpretation of the results for overall survival. We considered the following criteria. </p> <p> <ul id="CD011395-list-0010"> <li> <p>Was the allocation truly random?</p> </li> <li> <p>Were groups similar at baseline regarding the most important prognostic factors?</p> </li> <li> <p>Were the number of withdrawals, dropouts and losses to follow‐up in each group completely described? </p> </li> <li> <p>Was the analysis done by intention‐to‐treat?</p> </li> <li> <p>Were type and schedule of the follow‐up similar in the comparison group?</p> </li> </ul> </p> </section> <section id="CD011395-sec-0030"> <h4 class="title">Measures of treatment effect</h4> <p>We performed meta‐analysis on the basis of published data; unpublished or updated data provided will be used, when available. </p> <p>The summary statistics for time‐to‐event outcomes (i.e. overall survival and progression‐free survival) were hazard ratios (HRs) and their 95% confidence intervals (CIs) (<a href="./references#CD011395-bbs2-0019" title="CoxDR . Regression models and life tables. Journal of the Royal Statistical Society1972;34(2):187-220.">Cox 1972</a>). We estimated HRs and their 95% CIs directly or indirectly from the published data (<a href="./references#CD011395-bbs2-0016" title="AltmanDG . Systematic reviews of evaluations of prognostic variables. BMJ2001;323(7306):228-47.">Altman 2001</a>). HRs can be estimated (under some assumptions) from log rank Chi<sup>2</sup> values, from log rank P values, from observed to expected event ratios, from ratios of median survival times or time point survival rates (<a href="./references#CD011395-bbs2-0028" title="MachinD , StenningSP , ParmarMKP . Thirty years of Medical Research Council randomized trials in solid tumors. Journal of Clinical Oncology1997;9:100-14.">Machin 1997</a>; <a href="./references#CD011395-bbs2-0031" title="ParmarMKB , TorriV , StewardL . Extracting summary statistics to perform meta-analysis of the published literature for survival endpoints. Statistics in Medicine1998;17:2815-34.">Parmar 1998</a>). For overall survival and progression‐free survival, we calculated a statistical summary of the results of all individual trials performed with one PARP inhibitor, that was used to compare the results for different drugs. We used the fixed‐effect model for meta‐analyses to compare treatment differences. We performed statistical analysis of summary data using <a href="./references#CD011395-bbs2-0034" title="Nordic Cochrane Centre, The Cochrane CollaborationReview Manager (RevMan). Version 5.3 (accessed prior to 23 Feb 2021). Copenhagen: Nordic Cochrane Centre, The Cochrane Collaboration, 2014.">Review Manager 2014</a>. </p> <p>For dichotomous outcomes (e.g. tumour response rates, adverse events), we expressed the treatment effect as a risk ratio (RR) with 95% CIs. </p> <p>For continuous outcomes such as quality of life, we reported HRs comparing the time to achieve a clinically significant decrease in QoL. </p> <p>We carried out intention‐to‐treat analyses for all outcomes.</p> </section> <section id="CD011395-sec-0031"> <h4 class="title">Unit of analysis issues</h4> <p>There were no unit of analysis issues anticipated in this review.</p> </section> <section id="CD011395-sec-0032"> <h4 class="title">Dealing with missing data</h4> <p>We contacted study authors to request missing data, where possible. Studies with insufficient data for a particular outcome were not included for analysis of that outcome. </p> </section> <section id="CD011395-sec-0033"> <h4 class="title">Assessment of heterogeneity</h4> <p>We first inspected heterogeneity graphically using forest plots displaying effects of individual studies with 95% CIs. We also assessed heterogeneity of effects between studies using the Chi<sup>2</sup> test and the degree of inconsistency among results of included studies using the I<sup>2</sup> statistic (I<sup>2</sup> value &gt; 50% was considered as substantial heterogeneity and &gt; 75% represented considerable heterogeneity) (<a href="./references#CD011395-bbs2-0024" title="HigginsJPT , Green S (editors). Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0 [updated March 2011]. The Cochrane Collaboration, 2011. Available from training.cochrane.org/handbook/archive/v5.1.">Higgins 2011</a>). </p> </section> <section id="CD011395-sec-0034"> <h4 class="title">Assessment of reporting biases</h4> <p>We examined the possibility of publication bias using funnel plots as described in the <i>Cochrane Handbook for Systematic Reviews of Interventions</i> (<a href="./references#CD011395-bbs2-0024" title="HigginsJPT , Green S (editors). Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0 [updated March 2011]. The Cochrane Collaboration, 2011. Available from training.cochrane.org/handbook/archive/v5.1.">Higgins 2011</a>). </p> </section> <section id="CD011395-sec-0035"> <h4 class="title">Data synthesis</h4> <p>We extracted and entered the number of participants experiencing each outcome and total number of patients randomised to each study arm into <a href="./references#CD011395-bbs2-0034" title="Nordic Cochrane Centre, The Cochrane CollaborationReview Manager (RevMan). Version 5.3 (accessed prior to 23 Feb 2021). Copenhagen: Nordic Cochrane Centre, The Cochrane Collaboration, 2014.">Review Manager 2014</a> for statistical analysis. The data analysis adhered to the intention‐to‐treat principle. </p> <p>For time‐to‐event outcomes, we conducted a fixed‐effect (inverse‐variance method) analysis, if appropriate. For dichotomous outcomes, we used the fixed‐effect model (Mantel‐Haenszel method) to calculate pooled results. For continuous outcomes, we conducted a fixed‐effect (inverse‐variance method) analysis, if appropriate. </p> <p>We performed all analyses using <a href="./references#CD011395-bbs2-0034" title="Nordic Cochrane Centre, The Cochrane CollaborationReview Manager (RevMan). Version 5.3 (accessed prior to 23 Feb 2021). Copenhagen: Nordic Cochrane Centre, The Cochrane Collaboration, 2014.">Review Manager 2014</a> in accordance with the <i>Cochrane Handbook for Systematic Reviews of Interventions</i> (<a href="http://archie.cochrane.org/sections/documents/view?version=z1405020535096163505758311670816&amp;format=REVMAN#REF-Higgins-2011" target="_blank">Higgins 2011</a>). </p> <p>We described the quality of the available evidence in 'Summary of findings' tables in line with recommendations from the <i>Cochrane Handbook for Systematic Reviews of Interventions</i> (<a href="http://archie.cochrane.org/sections/documents/view?version=z1405020535096163505758311670816&amp;format=REVMAN#REF-Higgins-2011" target="_blank">Higgins 2011</a>). We used the GRADEprofiler (GRADEpro) software to develop the tables (<a href="./references#CD011395-bbs2-0022" title="McMaster UniversityGRADEprofiler (GRADEpro). Version accessed prior to 23 Feb 2021. McMaster University, 2014. www.gradepro.org.">GRADEpro 2014</a>). We selected four outcomes to include in the 'Summary of Findings' table: overall survival, progression‐free survival, tumour response rate and grade ≥ 3 adverse events. </p> </section> <section id="CD011395-sec-0036"> <h4 class="title">Subgroup analysis and investigation of heterogeneity</h4> <p>The subgroups analysed included:</p> <p> <ol id="CD011395-list-0011"> <li> <p>Patients with triple‐negative breast cancer</p> </li> <li> <p>Patients with hormone‐positive and/or HER2‐positive breast cancer</p> </li> <li> <p>Patients with BRCA1 and BRCA2 germline mutations</p> </li> <li> <p>Patients who had received prior chemotherapy for advanced breast cancer or not</p> </li> </ol> </p> <p>Our review was not able to report on subgroup analyses for OS outcomes as these data were not available for the included studies. Subgroup analyses for PFS outcomes was performed for triple‐negative breast cancer, hormone‐positive and/or HER2‐positive breast cancer, BRCA1 and BRCA2 germline mutations and patients who had received prior chemotherapy for advanced breast cancer or not. </p> <p>Other potentially planned subgroup analyses in the protocol including lines of therapy, performance status, PARP inhibitors as monotherapy, maintenance therapy or in combination with chemotherapy (or chemo‐radiotherapy) and position in the breast cancer treatment paradigm (first line, second line or third line) and different PARP inhibitors, were not performed due to the lack of these data in the included studies (see “<a href="#CD011395-sec-0082">Differences between protocol and review</a>”). </p> </section> <section id="CD011395-sec-0037"> <h4 class="title">Sensitivity analysis</h4> <p>We planned to perform a sensitivity analysis for the primary outcome excluding studies at high risk of bias. However, all studies contributing to the OS analysis were judged as having low risk of bias so sensitivity analysis was not performed. </p> </section> <section id="CD011395-sec-0038"> <h4 class="title">Summary of findings and assessment of the certainty of the evidence</h4> <p>We used the GRADE approach to assess the certainty of evidence of the key outcomes (<a href="./references#CD011395-bbs2-0023" title="GuyattGH , OxmanAD , VistGE , KunzR , Falck-YtterY , Alonso-CoelloP , SchünemannHJ . GRADE: an emerging consensus on rating quality of evidence and strength of recommendations. BMJ2008;336(7650):924-6.">Guyatt 2008</a>). GRADEpro GDT software was used to develop the 'Summary of findings' table. </p> <p>Two authors created the 'Summary of findings' tables using the following outcomes:</p> <p> <ul id="CD011395-list-0012"> <li> <p>overall survival;</p> </li> <li> <p>progression‐free survival;</p> </li> <li> <p>tumour response rate;</p> </li> <li> <p>grade 3 or higher adverse events.</p> </li> </ul> </p> </section> </section> </section> </section> <section class="results"> <div class="section-header section-collapse-header" id="CD011395-sec-0039" lang="en"> <h2 class="title section-collapse-title"> Results <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> </div> <section class="results" lang="en"> <div class="section-header" id="CD011395-sec-0039"></div> <section id="CD011395-sec-0040"> <h3 class="title">Description of studies</h3> <section id="CD011395-sec-0041"> <h4 class="title">Results of the search</h4> <p>We identified 3547 references in the initial search and additionally 86 from trials registries, nine from handsearching and one was provided by the editors. After excluding 122 duplicates and 3406 nonrelevant and/or nonrandomised studies, we selected 115 records for further evaluation (<a href="#CD011395-fig-0001">Figure 1</a>). We assessed these 115 records in full for eligibility. We excluded a further 11 that did not use PARP inhibitors, three that did not report PFS or OS, 19 nonrandomised studies, 26 neoadjuvant studies and six adjuvant studies. </p> <div class="figure" id="CD011395-fig-0001"> <div class="figure-caption-wrapper-top"> <nav class="inline-nav-list has-dividers"> <ul> <li><a class="open-in-figure-viewer" href="#0">Open in figure viewer</a></li> </ul> </nav> <div class="figure-label">Figure 1</div> </div> <hr class="top"/><img alt="Study flow diagram." data-id="CD011395-fig-0001" src="/cdsr/doi/10.1002/14651858.CD011395.pub2/media/CDSR/CD011395/image_n/nCD011395-FIG-01.png"/><hr class="bottom"/> <div class="figure-caption-wrapper-bottom"> <div class="figure-caption"> <p>Study flow diagram.</p> </div> </div> </div> <p>One ongoing trial was identified and described in the <a href="./references#CD011395-sec-0086" title="">Characteristics of ongoing studies</a> table. Overall, six studies (49 records) were eligible but only five were included in the quantitative synthesis as no data were available from one study. Each of the five studies produced multiple publications (<a href="#CD011395-fig-0001">Figure 1</a>). </p> </section> <section id="CD011395-sec-0042"> <h4 class="title">Included studies</h4> <p>See <a href="./references#CD011395-sec-0084" title="">Characteristics of included studies</a> table. </p> <p>Six studies were identified as eligible (<a href="./references#CD011395-bbs2-0001" title="BalmanaJ , TryfonidisK , AudehW , GouliotiT , SlaetsL , AgarwalS , et al. A phase III, randomized, open-label, multicenter, controlled trial of niraparib versus physician's choice in previously-treated, HER2-negative, germline BRCA mutation-positive breast cancer patients. An EORTC-BIG intergroup study (BRAVO study). Cancer Research2016;76(Suppl 4):Abstract nr OT1-03-05. ">BRAVO</a>; <a href="./references#CD011395-bbs2-0002" title="DiérasV , HanHS , RobsonME , PalacovaM , MarcomPK , JagerA , et al. Evaluation of veliparib (V) and temozolomide (TMZ) in a phase 2 randomized study of the efficacy and tolerability of V+TMZ or carboplatin (C) and paclitaxel (P) vs placebo (Plc)+C/P in patients (pts) with BRCA1 or BRCA2 mutations and metastatic breast cancer. Cancer Research2017;77(Suppl 4):Abstract nr SABCS16-P4-22-02. HanHS , DiérasV , RobsonM , PalácováM , MarcomPK , Jager A et al. Veliparib with temozolomide or carboplatin/paclitaxel versus placebo with carboplatin/paclitaxel in patients with BRCA1/2 locally recurrent/metastatic breast cancer: randomized phase II study. Annals of Oncology2018;29(1):154-61. HanHS , DiérasV , RobsonME , PalácováM , MarcomPK , JagerA , et al. Efficacy and tolerability of veliparib (V; ABT-888) in combination with carboplatin (C) and paclitaxel (P) vs placebo (Plc)+C/P in patients (pts) with BRCA1 or BRCA2 mutations and metastatic breast cancer: a randomized, phase 2 study. Cancer Research2017;77(Suppl 4):Abstract nr SABCS16-S2-05. IsakoffSJ , PuhallaS , DomchekSM , FriedlanderM , KaufmanB , RobsonM , et al. A randomized Phase II study of veliparib with temozolomide or carboplatin/paclitaxel versus placebo with carboplatin/paclitaxel in BRCA1/2 metastatic breast cancer: design and rationale. Future Oncology2017;13(4):307-20. ">BROCADE 2</a>; <a href="./references#CD011395-bbs2-0003" title="ArunBK , HanHS , KaufmanB , WildiersH , FriedlanderM , AyoubJP , et al. First-line veliparib plus carboplatin/paclitaxel in patients with HER2-negative advanced/metastatic gBRCA-associated breast cancer: planned subgroup analysis from the phase 3 BROCADE3 trial. Cancer Research2020;80(Suppl 4):Abstract nr PD4-01. AyoubJP , FriedlanderML , DierasVC , WildiersH , ArunB , HanHS , et al. Veliparib plus carboplatin-paclitaxel in patients with HER2-negative advanced/metastatic gBRCA-associated breast cancer: results in hormone receptor-positive and triple-negative breast cancer subgroups from the phase III BROCADE3 trial. Annals of Oncology2020;31(Suppl 2):S65. DierasV , HanH , KaufmanB , WildiersH , FriedlanderM , AyoubJ , et al. A Phase 3 randomized, placebo-controlled trial of carboplatin and paclitaxel with or without the PARP inhibitor veliparib (ABT-888) in HER2-negative metastatic or locally advanced unresectable BRCA-associated breast cancer. Annals of Oncology2019;30(Suppl 5):v851-v934. ">BROCADE 3</a>; <a href="./references#CD011395-bbs2-0004" title="DiabS , RugoHS , MinaLA , PuhallaS , MahtaniRL , HenryNL , et al. Efficacy and safety of talazoparib (TALA) or physician's choice of therapy (PCT) in United States patients (pts) with HER2- germline BRCA1/2-mutated (gBRCAm) locally advanced/metastatic breast cancer (LA/MBC) in the EMBRACA study. Journal of Clinical Oncology2019;37(Suppl 15):1044. EiermannW , RugoHS , DiabS , EttlJ , HurvitzSA , GoncalvesA , et al. Analysis of germline BRCA1/2 mutated (g BRCAmut) hormone receptor-positive (HR+) and triple-negative breast cancer (TNBC) treated with talazoparib (TALA). Journal of Clinical Oncology2018;36(Suppl 15):1070. EttlJ , HurvitzSA , RugoHS , LeeKH , MinaLA , WoodwardNE , et al. Outcomes of talazoparib (TALA) versus physician's choice of chemotherapy (PCT) in patients (pts) with advanced breast cancer (ABC) and a germline BRCA (gBRCA) mutation by line of chemotherapy (CT) in the EMBRACA trial. Journal of Clinical Oncology2019;37(Suppl 15):1071. EttlJ , QuekRG , BhattacharyyaH , RugoHS , HurvitzSA , GonçalvesA . Patient Reported Outcomes (PRO) in patients (pts) with HER2-advanced breast cancer (ABC) and a germline BRCA1/2 mutation (gBRCAm) receiving talazoparib (TALA) vs physician’s choice chemotherapy (PCT) in the EMBRACA trial: a focus on subgroups with/without visceral disease. Annals of Oncology2019;30(Suppl 5):v129–30. EttlJ , QuekRG , HurvitzSA , GoncalvesA , TudorIC , RugoHS . Hospitalization and supportive care medication (SCM) utilisation in patients (pts) with advanced breast cancer (ABC) and a germline BRCA1/2 mutation (gBRCAm) in EMBRACA. Annals of Oncology2019;30(Suppl 3):iii52. EttlJ , QuekRG , LeeKH , RugoHS , HurvitzS , GonçalvesA , et al. Quality of life with talazoparib versus physician’s choice of chemotherapy in patients with advanced breast cancer and germline BRCA1/2 mutation: patient-reported outcomes from the EMBRACA phase III trial. Annals of Oncology2018;29(9):1939-47. FaschingPA , QuekRG , BhattacharyyaH , HurvitzSA , RugoHS , EttlJ . Impact of objective response (OR) on patient-reported outcomes (PRO) in patients (pts) with advanced breast cancer (ABC) and a germline BRCA1/2 (gBRCA) mutation in the phase III EMBRACA trial. Annals of Oncology2019;30(Suppl 3):iii49. GonçalvesA , EiermannW , RugoHS , EttlJ , HurvitzSA , YerushalmiR , et al. EMBRACA: Efficacy and safety in comparing talazoparib (TALA) with physician's choice of therapy (PCT) in patients (pts) with advanced breast cancer (aBC) and a germline BRCA mutation (gBRCAm); BRCA1/BRCA2 subgroup analysis. Annals of Oncology2018;29(Suppl 8):viii96–7. GoncalvesA , QuekRGW , BhattacharyyaH , EttlJ , HurvitzSA , RugoHS . Patient-reported outcomes (PRO) in patients (pts) with Her2-advanced breast cancer (ABC) receiving talazoparib (TALA) vs physician's choice chemotherapy (PCT): a focus on EMBRACA germline BRCA1 and BRCA2 mutation (gBRCA1/2m) subgroups. Breast2019;48(Suppl 2):S71. HurvitzSA , GoncalvesA , RugoHS , LeeKH , FehrenbacherL , MinaLA , et al. Talazoparib in patients with a germline BRCA-mutated advanced breast cancer: detailed safety analyses from the phase III EMBRACA Trial. Oncologist2019;25(3):e439-50. LeeKH , KimSB , SohnJ , GoodwinA , UsariT , LanzaloneS , et al. Talazoparib (TALA) vs physician’s choice of chemotherapy (PCT) in Asian patients (Pts) with HER2- advanced breast cancer (ABC) and a germline BRCA1/2 mutation (gBRCA1/2mut): data from phase III EMBRACA. Annals of Oncology2019;30(9):ix14. LittonJ , EttlJ , HurvitzSA , MinaLA , RugoHS , LeeKH , et al. A phase 3, open-label, randomized, 2-arm international study of the oral dual PARP inhibitor talazoparib in germline BRCA mutation subjects with locally advanced and/or metastatic breast cancer (EMBRACA). Cancer Research2017;77(Suppl 4):Abstract nr OT2-01-13. LittonJ , RugoHS , EttlJ , HurvitzS , GoncalvesA , LeeKH , et al. EMBRACA: a phase 3 trial comparing talazoparib, an oral PARP inhibitor, to physicianʼs choice of therapy in patients with advanced breast cancer and a germline BRCA mutation [abstract]. In: San Antonio Breast Cancer Symposium; 2017 Dec 5-9; San Antonio (TX). San Antonio (TX), 2017. LittonJK , HurvitzSA , MinaLA , RugoHS , LeeKH , GonçalvesA , et al. Talazoparib (TALA) in germline BRCA1/2 (gBRCA1/2)-mutated human epidermal growth factor receptor 2 negative (HER2-) advanced breast cancer (ABC): final overall survival (OS) results from randomized phase 3 EMBRACA trial. Cancer Research2020;80(Suppl 16):Abstract no. CT071. LittonJK , RugoHS , EttlJ , HurvitzSA , GonçalvesA , LeeKH , et al. Talazoparib in patients with advanced breast cancer and a germline BRCA mutation. New England Journal of Medicine2018;379(8):753-63. MartínM , EiermannW , RugoHS , EttlJ , HurvitzSA , GonçalvesA , et al. EMBRACA: Comparison of efficacy and safety of talazoparib (TALA) and physician's choice of therapy (PCT) in patients (pts) with advanced breast cancer (aBC), a germline BRCA1/2 mutation (gBRCAm), and prior platinum treatment. Annals of Oncology2018;29(Suppl 8):viii96. MinaL , LeeKH , GoncalvesA , WoodwardN , HurvitzSA , DiabS , et al. EMBRACA: efficacy and safety of talazoparib or physician's choice of therapy in patients with advanced breast cancer and a germline BRCA1/2 mutation: a regional analysis. Cancer Research2019;79(Suppl 4):Abstract nr P6-18-12. QuekR , BhattacharyyaH , HurvitzS , GoncalvesA , EttlJ , RugoH . Patient-reported outcomes in patients with HER2-advanced breast cancer and a germline BRCA1/2 mutation receiving talazoparib versus physician's choice chemotherapy: a focus on EMBRACA age subgroups. Journal of Managed Care and Specialty Pharmacy2019;25(Suppl 10A):S37-8. QuekRGW , BhattacharyyaH , GoncalvesA , RugoHS , HurvitzSA , EttlJ . Pcn491 Patient reported outcomes (PRO) of talazoparib (TALA) versus physician's choice of chemotherapy (PCT) in patients (pts) with advanced breast cancer (aBC) and a germline BRCA (gBRCa) mutation: a focus on Embraca pts with/without prior chemotherapy (CT) subgroups. Value in Health2019;22(Suppl 3):S532. RugoHS , EttlJ , HurvitzSA , GoncalvesA , LeeKH , FehrenbacherL , et al. Outcomes in clinically relevant patient subgroups from the EMBRACA study: talazoparib vs physician's choice standard-of-care chemotherapy. Journal of the National Cancer Institute Cancer Spectrum2020;4(1):pkz085. RugoHS , EttlJ , WoodwardNE , HurvitzSA , GoncalvesA , LeeKH , et al. EMBRACA: efficacy outcomes in clinically relevant subgroups comparing talazoparib (TALA), an oral poly ADP ribose polymerase (PARP) inhibitor, to physician's choice of therapy (PCT) in patients with advanced breast cancer and a germline BRCA mutation. Journal of Clinical Oncology2018;36(Suppl 15):1069. RugoHS , QuekR , EttlJ , HurvitzSA , BhattacharyyaH , HannahAL , et al. Patient-reported outcomes (PRO) in patients (pts) with advanced breast cancer and a germline BRCA1/2 mutation (gBRCAm) receiving talazoparib (TALA) vs physician’s choice chemotherapy treatment (PCT): a focus on the EMBRACA triple negative (TNBC) subpopulation. Annals of Oncology2018;29(Suppl 8):viii91. YuY , ElmeliegyM , LittonJK , TudorIC , CzibereA , ZhengJ , et al. Exposure-efficacy progression-free survival (PFS) analyses of breast cancer patients with germline BRCA1/2 mutations receiving talazoparib in the phase III EMBRACA trial. Annals of Oncology2018;29(Suppl 8):viii97. YuY , ElmeliegyM , LittonJK , TudorIC , CzibereA , ZhengJ , et al. Talazoparib exposure-efficacy analysis in patients with advanced breast cancer and germline BRCA1/2 mutations in the EMBRACA trial. Journal of Clinical Pharmacology2020;60(10):1324-33. ">EMBRACA</a>; <a href="./references#CD011395-bbs2-0005" title="KummarS , WadeJL , OzaAM , SullivanD , ChenAP , GandaraDR , et al. Randomized phase II trial of cyclophosphamide and the oral poly (ADP-ribose) polymerase inhibitor veliparib in patients with recurrent, advanced triple-negative breast cancer. Investigational New Drugs2016;34(3):355–63. ">Kummar 2016</a>; <a href="./references#CD011395-bbs2-0006" title="DelalogeS , ContePF , ImS , Senkus-KonefkaE , XuB , DomchekSM , et al. OlympiAD: further efficacy outcomes in patients with HER2-negative metastatic breast cancer and a germline BRCA mutation receiving olaparib monotherapy vs standard single-agent chemotherapy treatment of physician’s choice. Annals of Oncology2017;28(Suppl 5):v74-v108. DomchekS , RobsonM , ImS , SenkusE , XuB , MasudaN , et al. Tolerability of olaparib monotherapy versus chemotherapy in patients with HER2-negative metastatic breast cancer and a germline BRCA mutation: OlympiAD. Cancer Research2018;78(Suppl 4):Abstract nr P5-21-12. ImSA , XuB , LiW , RobsonM , OuyangQ , YehDC , et al. Olaparib monotherapy for Asian patients with a germline BRCA mutation and HER2-negative metastatic breast cancer: OlympiAD randomized trial subgroup analysis. Scientific Reports2020;10(1):8753. ImSA , XuB , LiW , RobsonM , OuyangQ , YehDC , et al. Olaparib monotherapy versus chemotherapy for patients with HER2-negative metastatic breast cancer and a germline BRCA mutation: Asian subgroup analysis from the phase III OlympiAD trial. Cancer Research2018;78(Suppl 4):Abstract nr P5-21-13. MerensC , BannisterW , BergnerS , HettleR , McCreaC , McCutcheonS , et al. Impact of olaparib versus chemotherapy on the use of strong pain medications in gBRCA-mutated HER2-negative metastatic breast cancer and associated patient reported outcomes. Cancer Research2020;80(Suppl 4):Abstract nr P6-13-05. RobsonM , HettleR , DegboeA , SaundersO , CainT , KilvertH , et al. Estimating the health state utility of patients with HER2–gBRCA+ metastatic breast cancer treated with olaparib or chemotherapy via a mapping analysis of EORTC QLQ-C30 data collected in the Olympiad clinical trial. Value in Health2018;21(Suppl 1):S12. RobsonM , ImSA , SenkusE , XuB , DomchekS , MasudaN , et al. OlympiAD extended follow-up for overall survival and safety: olaparib versus chemotherapy treatment of physician’s choice in patients with a germline BRCA mutation and HER2-negative metastatic breast cancer. Cancer Research2020;80(Suppl 4):Abstract nr PD4-03. RobsonM , ImSA , SenkusE , XuB , DomchekSM , MasudaN , et al. Olaparib for metastatic breast cancer in patients with a germline BRCA mutation. New England Journal of Medicine2017;377(6):523-33. RobsonM , RuddyKJ , ImSA , SenkusE , XuB , DomchekSM , et al. Patient-reported outcomes in patients with a germline BRCA mutation and HER2-negative metastatic breast cancer receiving olaparib versus chemotherapy in the OlympiAD trial. European Journal of Cancer2019;120:20-30. RobsonM , RuddyKJ , ImSA , Senkus-KonefkaE , XuB , DomchekSM , et al. OlympiAD: health-related quality of life (HRQoL) in patients with HER2-negative metastatic breast cancer (mBC) and a germline BRCA mutation (gBRCAm) receiving olaparib monotherapy vs standard single-agent chemotherapy treatment of physician’s choice (TPC). Annals of Oncology2017;28(Suppl 5):v74-v108. RobsonME , ImSA , SenkusE , XuB , DomchekS , MasudaN , et al. Abstract CT038: OlympiAD final overall survival: olaparib versus chemotherapy treatment of physician's choice (TPC) in patients with HER2-negative metastatic breast cancer (mBC) and a germline BRCA mutation (gBRCAm). American Association for Cancer Research2018;78(Suppl 13):CT038. RobsonME , ImSA , SenkusE , XuB , DomchekSM , MasudaN , et al. OlympiAD: phase III trial of olaparib monotherapy versus chemotherapy for patients (pts) with HER2-negative metastatic breast cancer (mBC) and a germline BRCA mutation (gBRCAm). Journal of Clinical Oncology2017;35(Suppl 18):LBA4-LBA4. RobsonME , RuddyKJ , ImSA , Senkus-KonefkaE , XuB , DomchekSM , et al. EORTC QLQ-C30 (QLQ-C30) symptoms in patients (pts) with HER2-negative metastatic breast cancer (mBC) and a germline BRCA mutation (gBRCAm) receiving olaparib vs chemotherapy treatment of physician’s choice (TPC) in OlympiAD. Journal of Clinical Oncology2018;36(Suppl 15):1045. RobsonME , TungN , ConteP , ImSA , SenkusE , XuB , et al. OlympiAD final overall survival and tolerability results: olaparib versus chemotherapy treatment of physician’s choice in patients with a germline BRCA mutation and HER2-negative metastatic breast cancer. Annals of Oncology2019;30(4):558-66. Senkus-KonefkaE , DomchekSM , ImSA , XuB , ArmstrongA , MasudaN , et al. Subgroup analysis of olaparib monotherapy versus chemotherapy by hormone receptor and BRCA mutation status in patients with HER2-negative metastatic breast cancer and a germline BRCA mutation: OlympiAD. European Journal of Cancer2018;92:S19-20. TungNM , ImSA , Senkus-KonefkaE , XuB , DomchekSM , MasudaN , et al. Olaparib versus chemotherapy treatment of physician’s choice in patients with a germline BRCA mutation and HER2-negative metastatic breast cancer (OlympiAD): efficacy in patients with visceral metastases. Journal of Clinical Oncology2018;36(Suppl 15):1053. ">OLYMPIAD</a>). Four were identified by the systematic search and two by handsearching. All six trials are multicentre randomised trials that included patients with advanced or metastatic breast cancer and most had a germline BRCA mutation. </p> <p>The phase 3 <a href="./references#CD011395-bbs2-0001" title="BalmanaJ , TryfonidisK , AudehW , GouliotiT , SlaetsL , AgarwalS , et al. A phase III, randomized, open-label, multicenter, controlled trial of niraparib versus physician's choice in previously-treated, HER2-negative, germline BRCA mutation-positive breast cancer patients. An EORTC-BIG intergroup study (BRAVO study). Cancer Research2016;76(Suppl 4):Abstract nr OT1-03-05. ">BRAVO</a> trial (<a href="./references#CD011395-bbs2-0001" title="BalmanaJ , TryfonidisK , AudehW , GouliotiT , SlaetsL , AgarwalS , et al. A phase III, randomized, open-label, multicenter, controlled trial of niraparib versus physician's choice in previously-treated, HER2-negative, germline BRCA mutation-positive breast cancer patients. An EORTC-BIG intergroup study (BRAVO study). Cancer Research2016;76(Suppl 4):Abstract nr OT1-03-05. ">BRAVO</a>) of niraparib versus physician's choice in metastatic or locally advanced HER2‐negative, germline BRCA mutation‐positive breast cancer was set to determine whether niraparib had a similar beneficial effect in breast cancer as it has in ovarian cancer. This study ended prematurely because of poor patient adherence (<a href="./references#CD011395-bbs2-0030" title="ESMO. Breast Cancer. oncologypro.esmo.org/Oncology-in-Practice/Anti-Cancer-Agents-and-Biological-Therapy/PARP-inhibition-and-DNA-Damage-Response-DDR/PARP-inhibitors/Clinical-Activity/Breast-Cancer/Ongoing-Developments (accessed 29th March 2020).">OncologyPro 2020</a>). The authors made multiple attempts to access any available data from this trial, however, none was available at time of publication. As such, this trial was not included in the meta‐analysis and risk of bias was not able to be assessed.<br/><br/><a href="./references#CD011395-bbs2-0002" title="DiérasV , HanHS , RobsonME , PalacovaM , MarcomPK , JagerA , et al. Evaluation of veliparib (V) and temozolomide (TMZ) in a phase 2 randomized study of the efficacy and tolerability of V+TMZ or carboplatin (C) and paclitaxel (P) vs placebo (Plc)+C/P in patients (pts) with BRCA1 or BRCA2 mutations and metastatic breast cancer. Cancer Research2017;77(Suppl 4):Abstract nr SABCS16-P4-22-02. HanHS , DiérasV , RobsonM , PalácováM , MarcomPK , Jager A et al. Veliparib with temozolomide or carboplatin/paclitaxel versus placebo with carboplatin/paclitaxel in patients with BRCA1/2 locally recurrent/metastatic breast cancer: randomized phase II study. Annals of Oncology2018;29(1):154-61. HanHS , DiérasV , RobsonME , PalácováM , MarcomPK , JagerA , et al. Efficacy and tolerability of veliparib (V; ABT-888) in combination with carboplatin (C) and paclitaxel (P) vs placebo (Plc)+C/P in patients (pts) with BRCA1 or BRCA2 mutations and metastatic breast cancer: a randomized, phase 2 study. Cancer Research2017;77(Suppl 4):Abstract nr SABCS16-S2-05. IsakoffSJ , PuhallaS , DomchekSM , FriedlanderM , KaufmanB , RobsonM , et al. A randomized Phase II study of veliparib with temozolomide or carboplatin/paclitaxel versus placebo with carboplatin/paclitaxel in BRCA1/2 metastatic breast cancer: design and rationale. Future Oncology2017;13(4):307-20. ">BROCADE 2</a> is a phase 2 partially blinded, multicentre, randomised controlled trial. Two hundred and ninety patients with advanced or metastatic breast cancer with a germline BRCA mutation and who had received two or fewer prior lines of therapy were randomised 1:1:1 to receive veliparib, carboplatin and paclitaxel (arm 1), placebo, carboplatin and paclitaxel (arm 2) or veliparib and temozolamide (arm 3). The third treatment arm of <a href="./references#CD011395-bbs2-0002" title="DiérasV , HanHS , RobsonME , PalacovaM , MarcomPK , JagerA , et al. Evaluation of veliparib (V) and temozolomide (TMZ) in a phase 2 randomized study of the efficacy and tolerability of V+TMZ or carboplatin (C) and paclitaxel (P) vs placebo (Plc)+C/P in patients (pts) with BRCA1 or BRCA2 mutations and metastatic breast cancer. Cancer Research2017;77(Suppl 4):Abstract nr SABCS16-P4-22-02. HanHS , DiérasV , RobsonM , PalácováM , MarcomPK , Jager A et al. Veliparib with temozolomide or carboplatin/paclitaxel versus placebo with carboplatin/paclitaxel in patients with BRCA1/2 locally recurrent/metastatic breast cancer: randomized phase II study. Annals of Oncology2018;29(1):154-61. HanHS , DiérasV , RobsonME , PalácováM , MarcomPK , JagerA , et al. Efficacy and tolerability of veliparib (V; ABT-888) in combination with carboplatin (C) and paclitaxel (P) vs placebo (Plc)+C/P in patients (pts) with BRCA1 or BRCA2 mutations and metastatic breast cancer: a randomized, phase 2 study. Cancer Research2017;77(Suppl 4):Abstract nr SABCS16-S2-05. IsakoffSJ , PuhallaS , DomchekSM , FriedlanderM , KaufmanB , RobsonM , et al. A randomized Phase II study of veliparib with temozolomide or carboplatin/paclitaxel versus placebo with carboplatin/paclitaxel in BRCA1/2 metastatic breast cancer: design and rationale. Future Oncology2017;13(4):307-20. ">BROCADE 2</a> was not examined in any of our analyses, as it did not have a directly comparable control arm. The primary endpoint was PFS and secondary endpoints included OS, objective response rate, clinical benefit rate and safety.<br/><br/><a href="./references#CD011395-bbs2-0003" title="ArunBK , HanHS , KaufmanB , WildiersH , FriedlanderM , AyoubJP , et al. First-line veliparib plus carboplatin/paclitaxel in patients with HER2-negative advanced/metastatic gBRCA-associated breast cancer: planned subgroup analysis from the phase 3 BROCADE3 trial. Cancer Research2020;80(Suppl 4):Abstract nr PD4-01. AyoubJP , FriedlanderML , DierasVC , WildiersH , ArunB , HanHS , et al. Veliparib plus carboplatin-paclitaxel in patients with HER2-negative advanced/metastatic gBRCA-associated breast cancer: results in hormone receptor-positive and triple-negative breast cancer subgroups from the phase III BROCADE3 trial. Annals of Oncology2020;31(Suppl 2):S65. DierasV , HanH , KaufmanB , WildiersH , FriedlanderM , AyoubJ , et al. A Phase 3 randomized, placebo-controlled trial of carboplatin and paclitaxel with or without the PARP inhibitor veliparib (ABT-888) in HER2-negative metastatic or locally advanced unresectable BRCA-associated breast cancer. Annals of Oncology2019;30(Suppl 5):v851-v934. ">BROCADE 3</a> is a phase 3 version of <a href="./references#CD011395-bbs2-0002" title="DiérasV , HanHS , RobsonME , PalacovaM , MarcomPK , JagerA , et al. Evaluation of veliparib (V) and temozolomide (TMZ) in a phase 2 randomized study of the efficacy and tolerability of V+TMZ or carboplatin (C) and paclitaxel (P) vs placebo (Plc)+C/P in patients (pts) with BRCA1 or BRCA2 mutations and metastatic breast cancer. Cancer Research2017;77(Suppl 4):Abstract nr SABCS16-P4-22-02. HanHS , DiérasV , RobsonM , PalácováM , MarcomPK , Jager A et al. Veliparib with temozolomide or carboplatin/paclitaxel versus placebo with carboplatin/paclitaxel in patients with BRCA1/2 locally recurrent/metastatic breast cancer: randomized phase II study. Annals of Oncology2018;29(1):154-61. HanHS , DiérasV , RobsonME , PalácováM , MarcomPK , JagerA , et al. Efficacy and tolerability of veliparib (V; ABT-888) in combination with carboplatin (C) and paclitaxel (P) vs placebo (Plc)+C/P in patients (pts) with BRCA1 or BRCA2 mutations and metastatic breast cancer: a randomized, phase 2 study. Cancer Research2017;77(Suppl 4):Abstract nr SABCS16-S2-05. IsakoffSJ , PuhallaS , DomchekSM , FriedlanderM , KaufmanB , RobsonM , et al. A randomized Phase II study of veliparib with temozolomide or carboplatin/paclitaxel versus placebo with carboplatin/paclitaxel in BRCA1/2 metastatic breast cancer: design and rationale. Future Oncology2017;13(4):307-20. ">BROCADE 2</a>. It is a double‐blind, placebo‐controlled, multicentre, randomised trial. Five hundred and thirteen patients with advanced or metastatic HER2‐negative breast cancer with a germline BRCA mutation who had received two or fewer prior lines of therapy were randomised 2:1 to receive veliparib, carboplatin and paclitaxel (arm 1) or placebo, carboplatin and paclitaxel (arm 2). The primary endpoint was PFS and secondary endpoints included OS, clinical benefit rate, objective response rate, and progression on subsequent therapy (PFS2).<br/><br/><a href="./references#CD011395-bbs2-0004" title="DiabS , RugoHS , MinaLA , PuhallaS , MahtaniRL , HenryNL , et al. Efficacy and safety of talazoparib (TALA) or physician's choice of therapy (PCT) in United States patients (pts) with HER2- germline BRCA1/2-mutated (gBRCAm) locally advanced/metastatic breast cancer (LA/MBC) in the EMBRACA study. Journal of Clinical Oncology2019;37(Suppl 15):1044. EiermannW , RugoHS , DiabS , EttlJ , HurvitzSA , GoncalvesA , et al. Analysis of germline BRCA1/2 mutated (g BRCAmut) hormone receptor-positive (HR+) and triple-negative breast cancer (TNBC) treated with talazoparib (TALA). Journal of Clinical Oncology2018;36(Suppl 15):1070. EttlJ , HurvitzSA , RugoHS , LeeKH , MinaLA , WoodwardNE , et al. Outcomes of talazoparib (TALA) versus physician's choice of chemotherapy (PCT) in patients (pts) with advanced breast cancer (ABC) and a germline BRCA (gBRCA) mutation by line of chemotherapy (CT) in the EMBRACA trial. Journal of Clinical Oncology2019;37(Suppl 15):1071. EttlJ , QuekRG , BhattacharyyaH , RugoHS , HurvitzSA , GonçalvesA . Patient Reported Outcomes (PRO) in patients (pts) with HER2-advanced breast cancer (ABC) and a germline BRCA1/2 mutation (gBRCAm) receiving talazoparib (TALA) vs physician’s choice chemotherapy (PCT) in the EMBRACA trial: a focus on subgroups with/without visceral disease. Annals of Oncology2019;30(Suppl 5):v129–30. EttlJ , QuekRG , HurvitzSA , GoncalvesA , TudorIC , RugoHS . Hospitalization and supportive care medication (SCM) utilisation in patients (pts) with advanced breast cancer (ABC) and a germline BRCA1/2 mutation (gBRCAm) in EMBRACA. Annals of Oncology2019;30(Suppl 3):iii52. EttlJ , QuekRG , LeeKH , RugoHS , HurvitzS , GonçalvesA , et al. Quality of life with talazoparib versus physician’s choice of chemotherapy in patients with advanced breast cancer and germline BRCA1/2 mutation: patient-reported outcomes from the EMBRACA phase III trial. Annals of Oncology2018;29(9):1939-47. FaschingPA , QuekRG , BhattacharyyaH , HurvitzSA , RugoHS , EttlJ . Impact of objective response (OR) on patient-reported outcomes (PRO) in patients (pts) with advanced breast cancer (ABC) and a germline BRCA1/2 (gBRCA) mutation in the phase III EMBRACA trial. Annals of Oncology2019;30(Suppl 3):iii49. GonçalvesA , EiermannW , RugoHS , EttlJ , HurvitzSA , YerushalmiR , et al. EMBRACA: Efficacy and safety in comparing talazoparib (TALA) with physician's choice of therapy (PCT) in patients (pts) with advanced breast cancer (aBC) and a germline BRCA mutation (gBRCAm); BRCA1/BRCA2 subgroup analysis. Annals of Oncology2018;29(Suppl 8):viii96–7. GoncalvesA , QuekRGW , BhattacharyyaH , EttlJ , HurvitzSA , RugoHS . Patient-reported outcomes (PRO) in patients (pts) with Her2-advanced breast cancer (ABC) receiving talazoparib (TALA) vs physician's choice chemotherapy (PCT): a focus on EMBRACA germline BRCA1 and BRCA2 mutation (gBRCA1/2m) subgroups. Breast2019;48(Suppl 2):S71. HurvitzSA , GoncalvesA , RugoHS , LeeKH , FehrenbacherL , MinaLA , et al. Talazoparib in patients with a germline BRCA-mutated advanced breast cancer: detailed safety analyses from the phase III EMBRACA Trial. Oncologist2019;25(3):e439-50. LeeKH , KimSB , SohnJ , GoodwinA , UsariT , LanzaloneS , et al. Talazoparib (TALA) vs physician’s choice of chemotherapy (PCT) in Asian patients (Pts) with HER2- advanced breast cancer (ABC) and a germline BRCA1/2 mutation (gBRCA1/2mut): data from phase III EMBRACA. Annals of Oncology2019;30(9):ix14. LittonJ , EttlJ , HurvitzSA , MinaLA , RugoHS , LeeKH , et al. A phase 3, open-label, randomized, 2-arm international study of the oral dual PARP inhibitor talazoparib in germline BRCA mutation subjects with locally advanced and/or metastatic breast cancer (EMBRACA). Cancer Research2017;77(Suppl 4):Abstract nr OT2-01-13. LittonJ , RugoHS , EttlJ , HurvitzS , GoncalvesA , LeeKH , et al. EMBRACA: a phase 3 trial comparing talazoparib, an oral PARP inhibitor, to physicianʼs choice of therapy in patients with advanced breast cancer and a germline BRCA mutation [abstract]. In: San Antonio Breast Cancer Symposium; 2017 Dec 5-9; San Antonio (TX). San Antonio (TX), 2017. LittonJK , HurvitzSA , MinaLA , RugoHS , LeeKH , GonçalvesA , et al. Talazoparib (TALA) in germline BRCA1/2 (gBRCA1/2)-mutated human epidermal growth factor receptor 2 negative (HER2-) advanced breast cancer (ABC): final overall survival (OS) results from randomized phase 3 EMBRACA trial. Cancer Research2020;80(Suppl 16):Abstract no. CT071. LittonJK , RugoHS , EttlJ , HurvitzSA , GonçalvesA , LeeKH , et al. Talazoparib in patients with advanced breast cancer and a germline BRCA mutation. New England Journal of Medicine2018;379(8):753-63. MartínM , EiermannW , RugoHS , EttlJ , HurvitzSA , GonçalvesA , et al. EMBRACA: Comparison of efficacy and safety of talazoparib (TALA) and physician's choice of therapy (PCT) in patients (pts) with advanced breast cancer (aBC), a germline BRCA1/2 mutation (gBRCAm), and prior platinum treatment. Annals of Oncology2018;29(Suppl 8):viii96. MinaL , LeeKH , GoncalvesA , WoodwardN , HurvitzSA , DiabS , et al. EMBRACA: efficacy and safety of talazoparib or physician's choice of therapy in patients with advanced breast cancer and a germline BRCA1/2 mutation: a regional analysis. Cancer Research2019;79(Suppl 4):Abstract nr P6-18-12. QuekR , BhattacharyyaH , HurvitzS , GoncalvesA , EttlJ , RugoH . Patient-reported outcomes in patients with HER2-advanced breast cancer and a germline BRCA1/2 mutation receiving talazoparib versus physician's choice chemotherapy: a focus on EMBRACA age subgroups. Journal of Managed Care and Specialty Pharmacy2019;25(Suppl 10A):S37-8. QuekRGW , BhattacharyyaH , GoncalvesA , RugoHS , HurvitzSA , EttlJ . Pcn491 Patient reported outcomes (PRO) of talazoparib (TALA) versus physician's choice of chemotherapy (PCT) in patients (pts) with advanced breast cancer (aBC) and a germline BRCA (gBRCa) mutation: a focus on Embraca pts with/without prior chemotherapy (CT) subgroups. Value in Health2019;22(Suppl 3):S532. RugoHS , EttlJ , HurvitzSA , GoncalvesA , LeeKH , FehrenbacherL , et al. Outcomes in clinically relevant patient subgroups from the EMBRACA study: talazoparib vs physician's choice standard-of-care chemotherapy. Journal of the National Cancer Institute Cancer Spectrum2020;4(1):pkz085. RugoHS , EttlJ , WoodwardNE , HurvitzSA , GoncalvesA , LeeKH , et al. EMBRACA: efficacy outcomes in clinically relevant subgroups comparing talazoparib (TALA), an oral poly ADP ribose polymerase (PARP) inhibitor, to physician's choice of therapy (PCT) in patients with advanced breast cancer and a germline BRCA mutation. Journal of Clinical Oncology2018;36(Suppl 15):1069. RugoHS , QuekR , EttlJ , HurvitzSA , BhattacharyyaH , HannahAL , et al. Patient-reported outcomes (PRO) in patients (pts) with advanced breast cancer and a germline BRCA1/2 mutation (gBRCAm) receiving talazoparib (TALA) vs physician’s choice chemotherapy treatment (PCT): a focus on the EMBRACA triple negative (TNBC) subpopulation. Annals of Oncology2018;29(Suppl 8):viii91. YuY , ElmeliegyM , LittonJK , TudorIC , CzibereA , ZhengJ , et al. Exposure-efficacy progression-free survival (PFS) analyses of breast cancer patients with germline BRCA1/2 mutations receiving talazoparib in the phase III EMBRACA trial. Annals of Oncology2018;29(Suppl 8):viii97. YuY , ElmeliegyM , LittonJK , TudorIC , CzibereA , ZhengJ , et al. Talazoparib exposure-efficacy analysis in patients with advanced breast cancer and germline BRCA1/2 mutations in the EMBRACA trial. Journal of Clinical Pharmacology2020;60(10):1324-33. ">EMBRACA</a> is a phase 3 open‐label, multicentre, randomised controlled trial. Four hundred and thirty‐one patients with advanced or metastatic HER2‐negative breast cancer with a germline BRCA mutation who had received three or fewer prior lines of therapy were randomised 2:1 to talazoparib (arm 1) or physician’s choice of chemotherapy including capecitabine or eribulin or gemcitabine or vinorelbine (arm 2). The primary endpoint was PFS and secondary endpoints included OS, objective response rate, clinical benefit rate and safety.<br/><br/><a href="./references#CD011395-bbs2-0005" title="KummarS , WadeJL , OzaAM , SullivanD , ChenAP , GandaraDR , et al. Randomized phase II trial of cyclophosphamide and the oral poly (ADP-ribose) polymerase inhibitor veliparib in patients with recurrent, advanced triple-negative breast cancer. Investigational New Drugs2016;34(3):355–63. ">Kummar 2016</a> is a phase 2 open label, multi‐centre, randomised, controlled trial. 45 patients with metastatic triple‐negative breast cancer who had received at least one prior line of therapy were randomised 1:1 to veliparib and cyclophosphamide (Arm 1) or cyclophosphamide alone (Arm 2). Primary endpoint was response rate and secondary endpoints included PFS and safety.<br/><br/><a href="./references#CD011395-bbs2-0006" title="DelalogeS , ContePF , ImS , Senkus-KonefkaE , XuB , DomchekSM , et al. OlympiAD: further efficacy outcomes in patients with HER2-negative metastatic breast cancer and a germline BRCA mutation receiving olaparib monotherapy vs standard single-agent chemotherapy treatment of physician’s choice. Annals of Oncology2017;28(Suppl 5):v74-v108. DomchekS , RobsonM , ImS , SenkusE , XuB , MasudaN , et al. Tolerability of olaparib monotherapy versus chemotherapy in patients with HER2-negative metastatic breast cancer and a germline BRCA mutation: OlympiAD. Cancer Research2018;78(Suppl 4):Abstract nr P5-21-12. ImSA , XuB , LiW , RobsonM , OuyangQ , YehDC , et al. Olaparib monotherapy for Asian patients with a germline BRCA mutation and HER2-negative metastatic breast cancer: OlympiAD randomized trial subgroup analysis. Scientific Reports2020;10(1):8753. ImSA , XuB , LiW , RobsonM , OuyangQ , YehDC , et al. Olaparib monotherapy versus chemotherapy for patients with HER2-negative metastatic breast cancer and a germline BRCA mutation: Asian subgroup analysis from the phase III OlympiAD trial. Cancer Research2018;78(Suppl 4):Abstract nr P5-21-13. MerensC , BannisterW , BergnerS , HettleR , McCreaC , McCutcheonS , et al. Impact of olaparib versus chemotherapy on the use of strong pain medications in gBRCA-mutated HER2-negative metastatic breast cancer and associated patient reported outcomes. Cancer Research2020;80(Suppl 4):Abstract nr P6-13-05. RobsonM , HettleR , DegboeA , SaundersO , CainT , KilvertH , et al. Estimating the health state utility of patients with HER2–gBRCA+ metastatic breast cancer treated with olaparib or chemotherapy via a mapping analysis of EORTC QLQ-C30 data collected in the Olympiad clinical trial. Value in Health2018;21(Suppl 1):S12. RobsonM , ImSA , SenkusE , XuB , DomchekS , MasudaN , et al. OlympiAD extended follow-up for overall survival and safety: olaparib versus chemotherapy treatment of physician’s choice in patients with a germline BRCA mutation and HER2-negative metastatic breast cancer. Cancer Research2020;80(Suppl 4):Abstract nr PD4-03. RobsonM , ImSA , SenkusE , XuB , DomchekSM , MasudaN , et al. Olaparib for metastatic breast cancer in patients with a germline BRCA mutation. New England Journal of Medicine2017;377(6):523-33. RobsonM , RuddyKJ , ImSA , SenkusE , XuB , DomchekSM , et al. Patient-reported outcomes in patients with a germline BRCA mutation and HER2-negative metastatic breast cancer receiving olaparib versus chemotherapy in the OlympiAD trial. European Journal of Cancer2019;120:20-30. RobsonM , RuddyKJ , ImSA , Senkus-KonefkaE , XuB , DomchekSM , et al. OlympiAD: health-related quality of life (HRQoL) in patients with HER2-negative metastatic breast cancer (mBC) and a germline BRCA mutation (gBRCAm) receiving olaparib monotherapy vs standard single-agent chemotherapy treatment of physician’s choice (TPC). Annals of Oncology2017;28(Suppl 5):v74-v108. RobsonME , ImSA , SenkusE , XuB , DomchekS , MasudaN , et al. Abstract CT038: OlympiAD final overall survival: olaparib versus chemotherapy treatment of physician's choice (TPC) in patients with HER2-negative metastatic breast cancer (mBC) and a germline BRCA mutation (gBRCAm). American Association for Cancer Research2018;78(Suppl 13):CT038. RobsonME , ImSA , SenkusE , XuB , DomchekSM , MasudaN , et al. OlympiAD: phase III trial of olaparib monotherapy versus chemotherapy for patients (pts) with HER2-negative metastatic breast cancer (mBC) and a germline BRCA mutation (gBRCAm). Journal of Clinical Oncology2017;35(Suppl 18):LBA4-LBA4. RobsonME , RuddyKJ , ImSA , Senkus-KonefkaE , XuB , DomchekSM , et al. EORTC QLQ-C30 (QLQ-C30) symptoms in patients (pts) with HER2-negative metastatic breast cancer (mBC) and a germline BRCA mutation (gBRCAm) receiving olaparib vs chemotherapy treatment of physician’s choice (TPC) in OlympiAD. Journal of Clinical Oncology2018;36(Suppl 15):1045. RobsonME , TungN , ConteP , ImSA , SenkusE , XuB , et al. OlympiAD final overall survival and tolerability results: olaparib versus chemotherapy treatment of physician’s choice in patients with a germline BRCA mutation and HER2-negative metastatic breast cancer. Annals of Oncology2019;30(4):558-66. Senkus-KonefkaE , DomchekSM , ImSA , XuB , ArmstrongA , MasudaN , et al. Subgroup analysis of olaparib monotherapy versus chemotherapy by hormone receptor and BRCA mutation status in patients with HER2-negative metastatic breast cancer and a germline BRCA mutation: OlympiAD. European Journal of Cancer2018;92:S19-20. TungNM , ImSA , Senkus-KonefkaE , XuB , DomchekSM , MasudaN , et al. Olaparib versus chemotherapy treatment of physician’s choice in patients with a germline BRCA mutation and HER2-negative metastatic breast cancer (OlympiAD): efficacy in patients with visceral metastases. Journal of Clinical Oncology2018;36(Suppl 15):1053. ">OLYMPIAD</a> is a phase 3 open‐label, multicentre, randomised controlled trial. Three hundred and two patients with metastatic HER2‐negative breast cancer with a germline BRCA mutation who had received two or fewer prior lines of therapy were randomised 2:1 to olaparib (arm 1) or physician’s choice of chemotherapy including capecitabine or eribulin or vinorelbine (arm 2). The primary endpoint was PFS and secondary endpoints included OS, safety, time to second progression, death after first progression, objective response rate and health‐related quality of life.<br/><br/>As described, there were some differences in study design. <a href="./references#CD011395-bbs2-0006" title="DelalogeS , ContePF , ImS , Senkus-KonefkaE , XuB , DomchekSM , et al. OlympiAD: further efficacy outcomes in patients with HER2-negative metastatic breast cancer and a germline BRCA mutation receiving olaparib monotherapy vs standard single-agent chemotherapy treatment of physician’s choice. Annals of Oncology2017;28(Suppl 5):v74-v108. DomchekS , RobsonM , ImS , SenkusE , XuB , MasudaN , et al. Tolerability of olaparib monotherapy versus chemotherapy in patients with HER2-negative metastatic breast cancer and a germline BRCA mutation: OlympiAD. Cancer Research2018;78(Suppl 4):Abstract nr P5-21-12. ImSA , XuB , LiW , RobsonM , OuyangQ , YehDC , et al. Olaparib monotherapy for Asian patients with a germline BRCA mutation and HER2-negative metastatic breast cancer: OlympiAD randomized trial subgroup analysis. Scientific Reports2020;10(1):8753. ImSA , XuB , LiW , RobsonM , OuyangQ , YehDC , et al. Olaparib monotherapy versus chemotherapy for patients with HER2-negative metastatic breast cancer and a germline BRCA mutation: Asian subgroup analysis from the phase III OlympiAD trial. Cancer Research2018;78(Suppl 4):Abstract nr P5-21-13. MerensC , BannisterW , BergnerS , HettleR , McCreaC , McCutcheonS , et al. Impact of olaparib versus chemotherapy on the use of strong pain medications in gBRCA-mutated HER2-negative metastatic breast cancer and associated patient reported outcomes. Cancer Research2020;80(Suppl 4):Abstract nr P6-13-05. RobsonM , HettleR , DegboeA , SaundersO , CainT , KilvertH , et al. Estimating the health state utility of patients with HER2–gBRCA+ metastatic breast cancer treated with olaparib or chemotherapy via a mapping analysis of EORTC QLQ-C30 data collected in the Olympiad clinical trial. Value in Health2018;21(Suppl 1):S12. RobsonM , ImSA , SenkusE , XuB , DomchekS , MasudaN , et al. OlympiAD extended follow-up for overall survival and safety: olaparib versus chemotherapy treatment of physician’s choice in patients with a germline BRCA mutation and HER2-negative metastatic breast cancer. Cancer Research2020;80(Suppl 4):Abstract nr PD4-03. RobsonM , ImSA , SenkusE , XuB , DomchekSM , MasudaN , et al. Olaparib for metastatic breast cancer in patients with a germline BRCA mutation. New England Journal of Medicine2017;377(6):523-33. RobsonM , RuddyKJ , ImSA , SenkusE , XuB , DomchekSM , et al. Patient-reported outcomes in patients with a germline BRCA mutation and HER2-negative metastatic breast cancer receiving olaparib versus chemotherapy in the OlympiAD trial. European Journal of Cancer2019;120:20-30. RobsonM , RuddyKJ , ImSA , Senkus-KonefkaE , XuB , DomchekSM , et al. OlympiAD: health-related quality of life (HRQoL) in patients with HER2-negative metastatic breast cancer (mBC) and a germline BRCA mutation (gBRCAm) receiving olaparib monotherapy vs standard single-agent chemotherapy treatment of physician’s choice (TPC). Annals of Oncology2017;28(Suppl 5):v74-v108. RobsonME , ImSA , SenkusE , XuB , DomchekS , MasudaN , et al. Abstract CT038: OlympiAD final overall survival: olaparib versus chemotherapy treatment of physician's choice (TPC) in patients with HER2-negative metastatic breast cancer (mBC) and a germline BRCA mutation (gBRCAm). American Association for Cancer Research2018;78(Suppl 13):CT038. RobsonME , ImSA , SenkusE , XuB , DomchekSM , MasudaN , et al. OlympiAD: phase III trial of olaparib monotherapy versus chemotherapy for patients (pts) with HER2-negative metastatic breast cancer (mBC) and a germline BRCA mutation (gBRCAm). Journal of Clinical Oncology2017;35(Suppl 18):LBA4-LBA4. RobsonME , RuddyKJ , ImSA , Senkus-KonefkaE , XuB , DomchekSM , et al. EORTC QLQ-C30 (QLQ-C30) symptoms in patients (pts) with HER2-negative metastatic breast cancer (mBC) and a germline BRCA mutation (gBRCAm) receiving olaparib vs chemotherapy treatment of physician’s choice (TPC) in OlympiAD. Journal of Clinical Oncology2018;36(Suppl 15):1045. RobsonME , TungN , ConteP , ImSA , SenkusE , XuB , et al. OlympiAD final overall survival and tolerability results: olaparib versus chemotherapy treatment of physician’s choice in patients with a germline BRCA mutation and HER2-negative metastatic breast cancer. Annals of Oncology2019;30(4):558-66. Senkus-KonefkaE , DomchekSM , ImSA , XuB , ArmstrongA , MasudaN , et al. Subgroup analysis of olaparib monotherapy versus chemotherapy by hormone receptor and BRCA mutation status in patients with HER2-negative metastatic breast cancer and a germline BRCA mutation: OlympiAD. European Journal of Cancer2018;92:S19-20. TungNM , ImSA , Senkus-KonefkaE , XuB , DomchekSM , MasudaN , et al. Olaparib versus chemotherapy treatment of physician’s choice in patients with a germline BRCA mutation and HER2-negative metastatic breast cancer (OlympiAD): efficacy in patients with visceral metastases. Journal of Clinical Oncology2018;36(Suppl 15):1053. ">OLYMPIAD</a> and <a href="./references#CD011395-bbs2-0004" title="DiabS , RugoHS , MinaLA , PuhallaS , MahtaniRL , HenryNL , et al. Efficacy and safety of talazoparib (TALA) or physician's choice of therapy (PCT) in United States patients (pts) with HER2- germline BRCA1/2-mutated (gBRCAm) locally advanced/metastatic breast cancer (LA/MBC) in the EMBRACA study. Journal of Clinical Oncology2019;37(Suppl 15):1044. EiermannW , RugoHS , DiabS , EttlJ , HurvitzSA , GoncalvesA , et al. Analysis of germline BRCA1/2 mutated (g BRCAmut) hormone receptor-positive (HR+) and triple-negative breast cancer (TNBC) treated with talazoparib (TALA). Journal of Clinical Oncology2018;36(Suppl 15):1070. EttlJ , HurvitzSA , RugoHS , LeeKH , MinaLA , WoodwardNE , et al. Outcomes of talazoparib (TALA) versus physician's choice of chemotherapy (PCT) in patients (pts) with advanced breast cancer (ABC) and a germline BRCA (gBRCA) mutation by line of chemotherapy (CT) in the EMBRACA trial. Journal of Clinical Oncology2019;37(Suppl 15):1071. EttlJ , QuekRG , BhattacharyyaH , RugoHS , HurvitzSA , GonçalvesA . Patient Reported Outcomes (PRO) in patients (pts) with HER2-advanced breast cancer (ABC) and a germline BRCA1/2 mutation (gBRCAm) receiving talazoparib (TALA) vs physician’s choice chemotherapy (PCT) in the EMBRACA trial: a focus on subgroups with/without visceral disease. Annals of Oncology2019;30(Suppl 5):v129–30. EttlJ , QuekRG , HurvitzSA , GoncalvesA , TudorIC , RugoHS . Hospitalization and supportive care medication (SCM) utilisation in patients (pts) with advanced breast cancer (ABC) and a germline BRCA1/2 mutation (gBRCAm) in EMBRACA. Annals of Oncology2019;30(Suppl 3):iii52. EttlJ , QuekRG , LeeKH , RugoHS , HurvitzS , GonçalvesA , et al. Quality of life with talazoparib versus physician’s choice of chemotherapy in patients with advanced breast cancer and germline BRCA1/2 mutation: patient-reported outcomes from the EMBRACA phase III trial. Annals of Oncology2018;29(9):1939-47. FaschingPA , QuekRG , BhattacharyyaH , HurvitzSA , RugoHS , EttlJ . Impact of objective response (OR) on patient-reported outcomes (PRO) in patients (pts) with advanced breast cancer (ABC) and a germline BRCA1/2 (gBRCA) mutation in the phase III EMBRACA trial. Annals of Oncology2019;30(Suppl 3):iii49. GonçalvesA , EiermannW , RugoHS , EttlJ , HurvitzSA , YerushalmiR , et al. EMBRACA: Efficacy and safety in comparing talazoparib (TALA) with physician's choice of therapy (PCT) in patients (pts) with advanced breast cancer (aBC) and a germline BRCA mutation (gBRCAm); BRCA1/BRCA2 subgroup analysis. Annals of Oncology2018;29(Suppl 8):viii96–7. GoncalvesA , QuekRGW , BhattacharyyaH , EttlJ , HurvitzSA , RugoHS . Patient-reported outcomes (PRO) in patients (pts) with Her2-advanced breast cancer (ABC) receiving talazoparib (TALA) vs physician's choice chemotherapy (PCT): a focus on EMBRACA germline BRCA1 and BRCA2 mutation (gBRCA1/2m) subgroups. Breast2019;48(Suppl 2):S71. HurvitzSA , GoncalvesA , RugoHS , LeeKH , FehrenbacherL , MinaLA , et al. Talazoparib in patients with a germline BRCA-mutated advanced breast cancer: detailed safety analyses from the phase III EMBRACA Trial. Oncologist2019;25(3):e439-50. LeeKH , KimSB , SohnJ , GoodwinA , UsariT , LanzaloneS , et al. Talazoparib (TALA) vs physician’s choice of chemotherapy (PCT) in Asian patients (Pts) with HER2- advanced breast cancer (ABC) and a germline BRCA1/2 mutation (gBRCA1/2mut): data from phase III EMBRACA. Annals of Oncology2019;30(9):ix14. LittonJ , EttlJ , HurvitzSA , MinaLA , RugoHS , LeeKH , et al. A phase 3, open-label, randomized, 2-arm international study of the oral dual PARP inhibitor talazoparib in germline BRCA mutation subjects with locally advanced and/or metastatic breast cancer (EMBRACA). Cancer Research2017;77(Suppl 4):Abstract nr OT2-01-13. LittonJ , RugoHS , EttlJ , HurvitzS , GoncalvesA , LeeKH , et al. EMBRACA: a phase 3 trial comparing talazoparib, an oral PARP inhibitor, to physicianʼs choice of therapy in patients with advanced breast cancer and a germline BRCA mutation [abstract]. In: San Antonio Breast Cancer Symposium; 2017 Dec 5-9; San Antonio (TX). San Antonio (TX), 2017. LittonJK , HurvitzSA , MinaLA , RugoHS , LeeKH , GonçalvesA , et al. Talazoparib (TALA) in germline BRCA1/2 (gBRCA1/2)-mutated human epidermal growth factor receptor 2 negative (HER2-) advanced breast cancer (ABC): final overall survival (OS) results from randomized phase 3 EMBRACA trial. Cancer Research2020;80(Suppl 16):Abstract no. CT071. LittonJK , RugoHS , EttlJ , HurvitzSA , GonçalvesA , LeeKH , et al. Talazoparib in patients with advanced breast cancer and a germline BRCA mutation. New England Journal of Medicine2018;379(8):753-63. MartínM , EiermannW , RugoHS , EttlJ , HurvitzSA , GonçalvesA , et al. EMBRACA: Comparison of efficacy and safety of talazoparib (TALA) and physician's choice of therapy (PCT) in patients (pts) with advanced breast cancer (aBC), a germline BRCA1/2 mutation (gBRCAm), and prior platinum treatment. Annals of Oncology2018;29(Suppl 8):viii96. MinaL , LeeKH , GoncalvesA , WoodwardN , HurvitzSA , DiabS , et al. EMBRACA: efficacy and safety of talazoparib or physician's choice of therapy in patients with advanced breast cancer and a germline BRCA1/2 mutation: a regional analysis. Cancer Research2019;79(Suppl 4):Abstract nr P6-18-12. QuekR , BhattacharyyaH , HurvitzS , GoncalvesA , EttlJ , RugoH . Patient-reported outcomes in patients with HER2-advanced breast cancer and a germline BRCA1/2 mutation receiving talazoparib versus physician's choice chemotherapy: a focus on EMBRACA age subgroups. Journal of Managed Care and Specialty Pharmacy2019;25(Suppl 10A):S37-8. QuekRGW , BhattacharyyaH , GoncalvesA , RugoHS , HurvitzSA , EttlJ . Pcn491 Patient reported outcomes (PRO) of talazoparib (TALA) versus physician's choice of chemotherapy (PCT) in patients (pts) with advanced breast cancer (aBC) and a germline BRCA (gBRCa) mutation: a focus on Embraca pts with/without prior chemotherapy (CT) subgroups. Value in Health2019;22(Suppl 3):S532. RugoHS , EttlJ , HurvitzSA , GoncalvesA , LeeKH , FehrenbacherL , et al. Outcomes in clinically relevant patient subgroups from the EMBRACA study: talazoparib vs physician's choice standard-of-care chemotherapy. Journal of the National Cancer Institute Cancer Spectrum2020;4(1):pkz085. RugoHS , EttlJ , WoodwardNE , HurvitzSA , GoncalvesA , LeeKH , et al. EMBRACA: efficacy outcomes in clinically relevant subgroups comparing talazoparib (TALA), an oral poly ADP ribose polymerase (PARP) inhibitor, to physician's choice of therapy (PCT) in patients with advanced breast cancer and a germline BRCA mutation. Journal of Clinical Oncology2018;36(Suppl 15):1069. RugoHS , QuekR , EttlJ , HurvitzSA , BhattacharyyaH , HannahAL , et al. Patient-reported outcomes (PRO) in patients (pts) with advanced breast cancer and a germline BRCA1/2 mutation (gBRCAm) receiving talazoparib (TALA) vs physician’s choice chemotherapy treatment (PCT): a focus on the EMBRACA triple negative (TNBC) subpopulation. Annals of Oncology2018;29(Suppl 8):viii91. YuY , ElmeliegyM , LittonJK , TudorIC , CzibereA , ZhengJ , et al. Exposure-efficacy progression-free survival (PFS) analyses of breast cancer patients with germline BRCA1/2 mutations receiving talazoparib in the phase III EMBRACA trial. Annals of Oncology2018;29(Suppl 8):viii97. YuY , ElmeliegyM , LittonJK , TudorIC , CzibereA , ZhengJ , et al. Talazoparib exposure-efficacy analysis in patients with advanced breast cancer and germline BRCA1/2 mutations in the EMBRACA trial. Journal of Clinical Pharmacology2020;60(10):1324-33. ">EMBRACA</a> trials compared PARPi to physician's choice chemotherapy, whereas <a href="./references#CD011395-bbs2-0002" title="DiérasV , HanHS , RobsonME , PalacovaM , MarcomPK , JagerA , et al. Evaluation of veliparib (V) and temozolomide (TMZ) in a phase 2 randomized study of the efficacy and tolerability of V+TMZ or carboplatin (C) and paclitaxel (P) vs placebo (Plc)+C/P in patients (pts) with BRCA1 or BRCA2 mutations and metastatic breast cancer. Cancer Research2017;77(Suppl 4):Abstract nr SABCS16-P4-22-02. HanHS , DiérasV , RobsonM , PalácováM , MarcomPK , Jager A et al. Veliparib with temozolomide or carboplatin/paclitaxel versus placebo with carboplatin/paclitaxel in patients with BRCA1/2 locally recurrent/metastatic breast cancer: randomized phase II study. Annals of Oncology2018;29(1):154-61. HanHS , DiérasV , RobsonME , PalácováM , MarcomPK , JagerA , et al. Efficacy and tolerability of veliparib (V; ABT-888) in combination with carboplatin (C) and paclitaxel (P) vs placebo (Plc)+C/P in patients (pts) with BRCA1 or BRCA2 mutations and metastatic breast cancer: a randomized, phase 2 study. Cancer Research2017;77(Suppl 4):Abstract nr SABCS16-S2-05. IsakoffSJ , PuhallaS , DomchekSM , FriedlanderM , KaufmanB , RobsonM , et al. A randomized Phase II study of veliparib with temozolomide or carboplatin/paclitaxel versus placebo with carboplatin/paclitaxel in BRCA1/2 metastatic breast cancer: design and rationale. Future Oncology2017;13(4):307-20. ">BROCADE 2</a>, <a href="./references#CD011395-bbs2-0003" title="ArunBK , HanHS , KaufmanB , WildiersH , FriedlanderM , AyoubJP , et al. First-line veliparib plus carboplatin/paclitaxel in patients with HER2-negative advanced/metastatic gBRCA-associated breast cancer: planned subgroup analysis from the phase 3 BROCADE3 trial. Cancer Research2020;80(Suppl 4):Abstract nr PD4-01. AyoubJP , FriedlanderML , DierasVC , WildiersH , ArunB , HanHS , et al. Veliparib plus carboplatin-paclitaxel in patients with HER2-negative advanced/metastatic gBRCA-associated breast cancer: results in hormone receptor-positive and triple-negative breast cancer subgroups from the phase III BROCADE3 trial. Annals of Oncology2020;31(Suppl 2):S65. DierasV , HanH , KaufmanB , WildiersH , FriedlanderM , AyoubJ , et al. A Phase 3 randomized, placebo-controlled trial of carboplatin and paclitaxel with or without the PARP inhibitor veliparib (ABT-888) in HER2-negative metastatic or locally advanced unresectable BRCA-associated breast cancer. Annals of Oncology2019;30(Suppl 5):v851-v934. ">BROCADE 3</a> and <a href="./references#CD011395-bbs2-0005" title="KummarS , WadeJL , OzaAM , SullivanD , ChenAP , GandaraDR , et al. Randomized phase II trial of cyclophosphamide and the oral poly (ADP-ribose) polymerase inhibitor veliparib in patients with recurrent, advanced triple-negative breast cancer. Investigational New Drugs2016;34(3):355–63. ">Kummar 2016</a> compared PARP inhibitor in combination with chemotherapy to placebo plus chemotherapy. <a href="./references#CD011395-bbs2-0002" title="DiérasV , HanHS , RobsonME , PalacovaM , MarcomPK , JagerA , et al. Evaluation of veliparib (V) and temozolomide (TMZ) in a phase 2 randomized study of the efficacy and tolerability of V+TMZ or carboplatin (C) and paclitaxel (P) vs placebo (Plc)+C/P in patients (pts) with BRCA1 or BRCA2 mutations and metastatic breast cancer. Cancer Research2017;77(Suppl 4):Abstract nr SABCS16-P4-22-02. HanHS , DiérasV , RobsonM , PalácováM , MarcomPK , Jager A et al. Veliparib with temozolomide or carboplatin/paclitaxel versus placebo with carboplatin/paclitaxel in patients with BRCA1/2 locally recurrent/metastatic breast cancer: randomized phase II study. Annals of Oncology2018;29(1):154-61. HanHS , DiérasV , RobsonME , PalácováM , MarcomPK , JagerA , et al. Efficacy and tolerability of veliparib (V; ABT-888) in combination with carboplatin (C) and paclitaxel (P) vs placebo (Plc)+C/P in patients (pts) with BRCA1 or BRCA2 mutations and metastatic breast cancer: a randomized, phase 2 study. Cancer Research2017;77(Suppl 4):Abstract nr SABCS16-S2-05. IsakoffSJ , PuhallaS , DomchekSM , FriedlanderM , KaufmanB , RobsonM , et al. A randomized Phase II study of veliparib with temozolomide or carboplatin/paclitaxel versus placebo with carboplatin/paclitaxel in BRCA1/2 metastatic breast cancer: design and rationale. Future Oncology2017;13(4):307-20. ">BROCADE 2</a> included HER2‐positive patients if they had progression on or were intolerant to HER2‐directed therapies, while all other studies excluded HER2‐positive patients. </p> </section> <section id="CD011395-sec-0043"> <h4 class="title">Excluded studies</h4> <p>Three thousand five hundred and twenty‐one records were screened for eligibility. Three thousand four hundred and six were initially excluded as they were either nonrandomised or not relevant. One hundred and fifteen records were assessed in full for eligibility. Studies excluded included 11 that did not use PARP inhibitors, three that did not report PFS or OS and a further 19 that were nonrandomised. Studies examining PARP inhibitors in the neoadjuvant setting (26) and adjuvant setting (six) were also excluded and one ongoing trial was excluded. Below we have provided more detail regarding pertinent excluded studies.<br/><br/>The phase 2 and phase 3 studies by O'Shaughnessy and colleagues (<a href="./references#CD011395-bbs2-0009" title="O'ShaughnessyJ , OsborneC , PippenJE , YoffeM , PattD , RochaC , et al. Iniparib plus chemotherapy in metastatic triple-negative breast cancer. New England Journal of Medicine2011;364(3):205–14. ">O'Shaughnessy 2011</a>; <a href="./references#CD011395-bbs2-0010" title="O'ShaughnessyJ , SchwartzbergL , DansoMA , MillerKD , RugoHS , NeubauerM , et al. Phase III study of iniparib plus gemcitabine and carboplatin versus gemcitabine and carboplatin in patients with metastatic triple-negative breast cancer. Journal of Clinical Oncology2014;32(34):3840-7. ">O'Shaughnessy 2014</a>) investigated benefit for iniparib in patients with metastatic triple‐negative breast cancer by comparing iniparib plus gemcitabine and carboplatin versus gemcitabine and carboplatin alone. These studies were excluded as it was later discovered that iniparib is not a PARP inhibitor (<a href="./references#CD011395-bbs2-0027" title="LiuX , ShiY , MaggDX , PalmaJP , PattersonMJ , EllisPA , et al. Iniparib nonselectively modifies cysteine-containing proteins in tumor cells and is not a bona fide PARP inhibitor. Clinical Cancer Research2012;18(2):510-23.">Liu 2012</a>).<br/><br/>The phase 2 ABRAZO trial (<a href="./references#CD011395-bbs2-0013" title="TurnerNC , TelliML , RugoHS , MailliezA , EttlJ , GrischkeEM , et al. A phase II study of talazoparib after platinum or cytotoxic nonplatinum regimens in patients with advanced breast cancer and germline BRCA1/2 mutations (ABRAZO). Clinical Cancer Research2019;25(9):2717-24. ">Turner 2019</a>) investigated talazoparib in patients with locally advanced or metastatic breast cancer and a germline BRCA mutation with or without prior exposure to platinum agents. Response rates to talazoparib were higher in patients who had not had prior platinum exposure, suggesting some degree of cross‐resistance. This study was excluded as the intervention was prior exposure to platinum, not talazoparib.<br/><br/>The phase 2 RUBY trial (<a href="./references#CD011395-bbs2-0011" title="PatsourisA , TredanO , NenciuD , Tran-DienA , CampionL , GoncalvesA , et al. RUBY: A phase II study testing rucaparib in germline (g) BRCA wild-type patients presenting metastatic breast cancer (mBC) with homologous recombination deficiency (HRD). Journal of Clinical Oncology2019;37(Suppl 15):1092. ">Patsouris 2019</a>) reported clinical benefit in a subset of patients with germline BRCA wild‐type metastatic breast cancer whose tumour had high loss of heterozygosity scores. This study was excluded as it was a single‐arm study.<br/><br/>The phase 2 BRE09‐146 trial (<a href="./references#CD011395-bbs2-0007" title="DwadasiS , TongY , WalshT , DansoMA , MaCX , SilvermanP , et al. Cisplatin with or without rucaparib after preoperative chemotherapy in patients with triple-negative breast cancer (TNBC): Hoosier Oncology Group BRE09-146. Journal of Clinical Oncology2014;32(Suppl 15):1019. ">Dwadasi 2014</a>) reported that the addition of low dose rucaparib did not impact the toxicity of cisplatin or improve two‐year disease‐free survival in patients with BRCA mutations and/or triple‐negative breast cancer with residual disease after neoadjuvant therapy. The phase 3 randomised OlympiA trial (<a href="./references#CD011395-bbs2-0014" title="TuttA , KaufmanB , GarberJ , GelberR , McFaddenE , GoesslC , et al. OlympiA: a randomized phase III trial of olaparib as adjuvant therapy in patients with high-risk HER2-negative breast cancer (BC) and a germline BRCA1/2 mutation (gBRCAm). Annals of Oncology2017;28(Suppl 5):v67. ">Tutt 2017</a>) evaluated adjuvant use of olaparib in patients with high‐risk HER2‐negative breast cancer with germline BRCA mutations. These studies were excluded as they assessed PARP inhibition in the adjuvant setting.<br/><br/>Other trials of PARP inhibition in early stage breast cancer included the I‐SPY‐2 (<a href="./references#CD011395-bbs2-0012" title="RugoHS , OlopadeOI , DeMicheleA , YauC , Van 't VeerLJ , BuxtonMB , et al. Adaptive randomization of veliparib-carboplatin treatment in breast cancer. New England Journal of Medicine2016;375(1):23-34. ">Rugo 2016</a>) and BrighTNess trials (<a href="./references#CD011395-bbs2-0008" title="LoiblS , O'ShaughnessyJ , UntchM , SikovWM , RugoHS , McKeeMD , et al. Addition of the PARP inhibitor veliparib plus carboplatin or carboplatin alone to standard neoadjuvant chemotherapy in triple-negative breast cancer (BrighTNess): a randomised, phase 3 trial. Lancet Oncology2018;19(4):497-509. ">Loibl 2018</a>), which ultimately failed to show a benefit for adding the PARP inhibitor veliparib to standard neoadjuvant chemotherapy in patients with triple‐negative breast cancer. Both these studies were excluded from analysis as they looked at the role of PARP inhibitors in the neoadjuvant setting.<br/>Investigators are continuing to work on translating the success of the included studies showing benefit of PARP inhibition in advanced breast cancer in the early breast cancer setting where ongoing trials incorporate new dosing schedules, PARP inhibitor monotherapy, and novel PARP combinations. </p> </section> </section> <section id="CD011395-sec-0044"> <h3 class="title">Risk of bias in included studies</h3> <p>Five out of six included studies (<a href="./references#CD011395-bbs2-0002" title="DiérasV , HanHS , RobsonME , PalacovaM , MarcomPK , JagerA , et al. Evaluation of veliparib (V) and temozolomide (TMZ) in a phase 2 randomized study of the efficacy and tolerability of V+TMZ or carboplatin (C) and paclitaxel (P) vs placebo (Plc)+C/P in patients (pts) with BRCA1 or BRCA2 mutations and metastatic breast cancer. Cancer Research2017;77(Suppl 4):Abstract nr SABCS16-P4-22-02. HanHS , DiérasV , RobsonM , PalácováM , MarcomPK , Jager A et al. Veliparib with temozolomide or carboplatin/paclitaxel versus placebo with carboplatin/paclitaxel in patients with BRCA1/2 locally recurrent/metastatic breast cancer: randomized phase II study. Annals of Oncology2018;29(1):154-61. HanHS , DiérasV , RobsonME , PalácováM , MarcomPK , JagerA , et al. Efficacy and tolerability of veliparib (V; ABT-888) in combination with carboplatin (C) and paclitaxel (P) vs placebo (Plc)+C/P in patients (pts) with BRCA1 or BRCA2 mutations and metastatic breast cancer: a randomized, phase 2 study. Cancer Research2017;77(Suppl 4):Abstract nr SABCS16-S2-05. IsakoffSJ , PuhallaS , DomchekSM , FriedlanderM , KaufmanB , RobsonM , et al. A randomized Phase II study of veliparib with temozolomide or carboplatin/paclitaxel versus placebo with carboplatin/paclitaxel in BRCA1/2 metastatic breast cancer: design and rationale. Future Oncology2017;13(4):307-20. ">BROCADE 2</a>; <a href="./references#CD011395-bbs2-0003" title="ArunBK , HanHS , KaufmanB , WildiersH , FriedlanderM , AyoubJP , et al. First-line veliparib plus carboplatin/paclitaxel in patients with HER2-negative advanced/metastatic gBRCA-associated breast cancer: planned subgroup analysis from the phase 3 BROCADE3 trial. Cancer Research2020;80(Suppl 4):Abstract nr PD4-01. AyoubJP , FriedlanderML , DierasVC , WildiersH , ArunB , HanHS , et al. Veliparib plus carboplatin-paclitaxel in patients with HER2-negative advanced/metastatic gBRCA-associated breast cancer: results in hormone receptor-positive and triple-negative breast cancer subgroups from the phase III BROCADE3 trial. Annals of Oncology2020;31(Suppl 2):S65. DierasV , HanH , KaufmanB , WildiersH , FriedlanderM , AyoubJ , et al. A Phase 3 randomized, placebo-controlled trial of carboplatin and paclitaxel with or without the PARP inhibitor veliparib (ABT-888) in HER2-negative metastatic or locally advanced unresectable BRCA-associated breast cancer. Annals of Oncology2019;30(Suppl 5):v851-v934. ">BROCADE 3</a>; <a href="./references#CD011395-bbs2-0004" title="DiabS , RugoHS , MinaLA , PuhallaS , MahtaniRL , HenryNL , et al. Efficacy and safety of talazoparib (TALA) or physician's choice of therapy (PCT) in United States patients (pts) with HER2- germline BRCA1/2-mutated (gBRCAm) locally advanced/metastatic breast cancer (LA/MBC) in the EMBRACA study. Journal of Clinical Oncology2019;37(Suppl 15):1044. EiermannW , RugoHS , DiabS , EttlJ , HurvitzSA , GoncalvesA , et al. Analysis of germline BRCA1/2 mutated (g BRCAmut) hormone receptor-positive (HR+) and triple-negative breast cancer (TNBC) treated with talazoparib (TALA). Journal of Clinical Oncology2018;36(Suppl 15):1070. EttlJ , HurvitzSA , RugoHS , LeeKH , MinaLA , WoodwardNE , et al. Outcomes of talazoparib (TALA) versus physician's choice of chemotherapy (PCT) in patients (pts) with advanced breast cancer (ABC) and a germline BRCA (gBRCA) mutation by line of chemotherapy (CT) in the EMBRACA trial. Journal of Clinical Oncology2019;37(Suppl 15):1071. EttlJ , QuekRG , BhattacharyyaH , RugoHS , HurvitzSA , GonçalvesA . Patient Reported Outcomes (PRO) in patients (pts) with HER2-advanced breast cancer (ABC) and a germline BRCA1/2 mutation (gBRCAm) receiving talazoparib (TALA) vs physician’s choice chemotherapy (PCT) in the EMBRACA trial: a focus on subgroups with/without visceral disease. Annals of Oncology2019;30(Suppl 5):v129–30. EttlJ , QuekRG , HurvitzSA , GoncalvesA , TudorIC , RugoHS . Hospitalization and supportive care medication (SCM) utilisation in patients (pts) with advanced breast cancer (ABC) and a germline BRCA1/2 mutation (gBRCAm) in EMBRACA. Annals of Oncology2019;30(Suppl 3):iii52. EttlJ , QuekRG , LeeKH , RugoHS , HurvitzS , GonçalvesA , et al. Quality of life with talazoparib versus physician’s choice of chemotherapy in patients with advanced breast cancer and germline BRCA1/2 mutation: patient-reported outcomes from the EMBRACA phase III trial. Annals of Oncology2018;29(9):1939-47. FaschingPA , QuekRG , BhattacharyyaH , HurvitzSA , RugoHS , EttlJ . Impact of objective response (OR) on patient-reported outcomes (PRO) in patients (pts) with advanced breast cancer (ABC) and a germline BRCA1/2 (gBRCA) mutation in the phase III EMBRACA trial. Annals of Oncology2019;30(Suppl 3):iii49. GonçalvesA , EiermannW , RugoHS , EttlJ , HurvitzSA , YerushalmiR , et al. EMBRACA: Efficacy and safety in comparing talazoparib (TALA) with physician's choice of therapy (PCT) in patients (pts) with advanced breast cancer (aBC) and a germline BRCA mutation (gBRCAm); BRCA1/BRCA2 subgroup analysis. Annals of Oncology2018;29(Suppl 8):viii96–7. GoncalvesA , QuekRGW , BhattacharyyaH , EttlJ , HurvitzSA , RugoHS . Patient-reported outcomes (PRO) in patients (pts) with Her2-advanced breast cancer (ABC) receiving talazoparib (TALA) vs physician's choice chemotherapy (PCT): a focus on EMBRACA germline BRCA1 and BRCA2 mutation (gBRCA1/2m) subgroups. Breast2019;48(Suppl 2):S71. HurvitzSA , GoncalvesA , RugoHS , LeeKH , FehrenbacherL , MinaLA , et al. Talazoparib in patients with a germline BRCA-mutated advanced breast cancer: detailed safety analyses from the phase III EMBRACA Trial. Oncologist2019;25(3):e439-50. LeeKH , KimSB , SohnJ , GoodwinA , UsariT , LanzaloneS , et al. Talazoparib (TALA) vs physician’s choice of chemotherapy (PCT) in Asian patients (Pts) with HER2- advanced breast cancer (ABC) and a germline BRCA1/2 mutation (gBRCA1/2mut): data from phase III EMBRACA. Annals of Oncology2019;30(9):ix14. LittonJ , EttlJ , HurvitzSA , MinaLA , RugoHS , LeeKH , et al. A phase 3, open-label, randomized, 2-arm international study of the oral dual PARP inhibitor talazoparib in germline BRCA mutation subjects with locally advanced and/or metastatic breast cancer (EMBRACA). Cancer Research2017;77(Suppl 4):Abstract nr OT2-01-13. LittonJ , RugoHS , EttlJ , HurvitzS , GoncalvesA , LeeKH , et al. EMBRACA: a phase 3 trial comparing talazoparib, an oral PARP inhibitor, to physicianʼs choice of therapy in patients with advanced breast cancer and a germline BRCA mutation [abstract]. In: San Antonio Breast Cancer Symposium; 2017 Dec 5-9; San Antonio (TX). San Antonio (TX), 2017. LittonJK , HurvitzSA , MinaLA , RugoHS , LeeKH , GonçalvesA , et al. Talazoparib (TALA) in germline BRCA1/2 (gBRCA1/2)-mutated human epidermal growth factor receptor 2 negative (HER2-) advanced breast cancer (ABC): final overall survival (OS) results from randomized phase 3 EMBRACA trial. Cancer Research2020;80(Suppl 16):Abstract no. CT071. LittonJK , RugoHS , EttlJ , HurvitzSA , GonçalvesA , LeeKH , et al. Talazoparib in patients with advanced breast cancer and a germline BRCA mutation. New England Journal of Medicine2018;379(8):753-63. MartínM , EiermannW , RugoHS , EttlJ , HurvitzSA , GonçalvesA , et al. EMBRACA: Comparison of efficacy and safety of talazoparib (TALA) and physician's choice of therapy (PCT) in patients (pts) with advanced breast cancer (aBC), a germline BRCA1/2 mutation (gBRCAm), and prior platinum treatment. Annals of Oncology2018;29(Suppl 8):viii96. MinaL , LeeKH , GoncalvesA , WoodwardN , HurvitzSA , DiabS , et al. EMBRACA: efficacy and safety of talazoparib or physician's choice of therapy in patients with advanced breast cancer and a germline BRCA1/2 mutation: a regional analysis. Cancer Research2019;79(Suppl 4):Abstract nr P6-18-12. QuekR , BhattacharyyaH , HurvitzS , GoncalvesA , EttlJ , RugoH . Patient-reported outcomes in patients with HER2-advanced breast cancer and a germline BRCA1/2 mutation receiving talazoparib versus physician's choice chemotherapy: a focus on EMBRACA age subgroups. Journal of Managed Care and Specialty Pharmacy2019;25(Suppl 10A):S37-8. QuekRGW , BhattacharyyaH , GoncalvesA , RugoHS , HurvitzSA , EttlJ . Pcn491 Patient reported outcomes (PRO) of talazoparib (TALA) versus physician's choice of chemotherapy (PCT) in patients (pts) with advanced breast cancer (aBC) and a germline BRCA (gBRCa) mutation: a focus on Embraca pts with/without prior chemotherapy (CT) subgroups. Value in Health2019;22(Suppl 3):S532. RugoHS , EttlJ , HurvitzSA , GoncalvesA , LeeKH , FehrenbacherL , et al. Outcomes in clinically relevant patient subgroups from the EMBRACA study: talazoparib vs physician's choice standard-of-care chemotherapy. Journal of the National Cancer Institute Cancer Spectrum2020;4(1):pkz085. RugoHS , EttlJ , WoodwardNE , HurvitzSA , GoncalvesA , LeeKH , et al. EMBRACA: efficacy outcomes in clinically relevant subgroups comparing talazoparib (TALA), an oral poly ADP ribose polymerase (PARP) inhibitor, to physician's choice of therapy (PCT) in patients with advanced breast cancer and a germline BRCA mutation. Journal of Clinical Oncology2018;36(Suppl 15):1069. RugoHS , QuekR , EttlJ , HurvitzSA , BhattacharyyaH , HannahAL , et al. Patient-reported outcomes (PRO) in patients (pts) with advanced breast cancer and a germline BRCA1/2 mutation (gBRCAm) receiving talazoparib (TALA) vs physician’s choice chemotherapy treatment (PCT): a focus on the EMBRACA triple negative (TNBC) subpopulation. Annals of Oncology2018;29(Suppl 8):viii91. YuY , ElmeliegyM , LittonJK , TudorIC , CzibereA , ZhengJ , et al. Exposure-efficacy progression-free survival (PFS) analyses of breast cancer patients with germline BRCA1/2 mutations receiving talazoparib in the phase III EMBRACA trial. Annals of Oncology2018;29(Suppl 8):viii97. YuY , ElmeliegyM , LittonJK , TudorIC , CzibereA , ZhengJ , et al. Talazoparib exposure-efficacy analysis in patients with advanced breast cancer and germline BRCA1/2 mutations in the EMBRACA trial. Journal of Clinical Pharmacology2020;60(10):1324-33. ">EMBRACA</a>; <a href="./references#CD011395-bbs2-0005" title="KummarS , WadeJL , OzaAM , SullivanD , ChenAP , GandaraDR , et al. Randomized phase II trial of cyclophosphamide and the oral poly (ADP-ribose) polymerase inhibitor veliparib in patients with recurrent, advanced triple-negative breast cancer. Investigational New Drugs2016;34(3):355–63. ">Kummar 2016</a>; <a href="./references#CD011395-bbs2-0006" title="DelalogeS , ContePF , ImS , Senkus-KonefkaE , XuB , DomchekSM , et al. OlympiAD: further efficacy outcomes in patients with HER2-negative metastatic breast cancer and a germline BRCA mutation receiving olaparib monotherapy vs standard single-agent chemotherapy treatment of physician’s choice. Annals of Oncology2017;28(Suppl 5):v74-v108. DomchekS , RobsonM , ImS , SenkusE , XuB , MasudaN , et al. Tolerability of olaparib monotherapy versus chemotherapy in patients with HER2-negative metastatic breast cancer and a germline BRCA mutation: OlympiAD. Cancer Research2018;78(Suppl 4):Abstract nr P5-21-12. ImSA , XuB , LiW , RobsonM , OuyangQ , YehDC , et al. Olaparib monotherapy for Asian patients with a germline BRCA mutation and HER2-negative metastatic breast cancer: OlympiAD randomized trial subgroup analysis. Scientific Reports2020;10(1):8753. ImSA , XuB , LiW , RobsonM , OuyangQ , YehDC , et al. Olaparib monotherapy versus chemotherapy for patients with HER2-negative metastatic breast cancer and a germline BRCA mutation: Asian subgroup analysis from the phase III OlympiAD trial. Cancer Research2018;78(Suppl 4):Abstract nr P5-21-13. MerensC , BannisterW , BergnerS , HettleR , McCreaC , McCutcheonS , et al. Impact of olaparib versus chemotherapy on the use of strong pain medications in gBRCA-mutated HER2-negative metastatic breast cancer and associated patient reported outcomes. Cancer Research2020;80(Suppl 4):Abstract nr P6-13-05. RobsonM , HettleR , DegboeA , SaundersO , CainT , KilvertH , et al. Estimating the health state utility of patients with HER2–gBRCA+ metastatic breast cancer treated with olaparib or chemotherapy via a mapping analysis of EORTC QLQ-C30 data collected in the Olympiad clinical trial. Value in Health2018;21(Suppl 1):S12. RobsonM , ImSA , SenkusE , XuB , DomchekS , MasudaN , et al. OlympiAD extended follow-up for overall survival and safety: olaparib versus chemotherapy treatment of physician’s choice in patients with a germline BRCA mutation and HER2-negative metastatic breast cancer. Cancer Research2020;80(Suppl 4):Abstract nr PD4-03. RobsonM , ImSA , SenkusE , XuB , DomchekSM , MasudaN , et al. Olaparib for metastatic breast cancer in patients with a germline BRCA mutation. New England Journal of Medicine2017;377(6):523-33. RobsonM , RuddyKJ , ImSA , SenkusE , XuB , DomchekSM , et al. Patient-reported outcomes in patients with a germline BRCA mutation and HER2-negative metastatic breast cancer receiving olaparib versus chemotherapy in the OlympiAD trial. European Journal of Cancer2019;120:20-30. RobsonM , RuddyKJ , ImSA , Senkus-KonefkaE , XuB , DomchekSM , et al. OlympiAD: health-related quality of life (HRQoL) in patients with HER2-negative metastatic breast cancer (mBC) and a germline BRCA mutation (gBRCAm) receiving olaparib monotherapy vs standard single-agent chemotherapy treatment of physician’s choice (TPC). Annals of Oncology2017;28(Suppl 5):v74-v108. RobsonME , ImSA , SenkusE , XuB , DomchekS , MasudaN , et al. Abstract CT038: OlympiAD final overall survival: olaparib versus chemotherapy treatment of physician's choice (TPC) in patients with HER2-negative metastatic breast cancer (mBC) and a germline BRCA mutation (gBRCAm). American Association for Cancer Research2018;78(Suppl 13):CT038. RobsonME , ImSA , SenkusE , XuB , DomchekSM , MasudaN , et al. OlympiAD: phase III trial of olaparib monotherapy versus chemotherapy for patients (pts) with HER2-negative metastatic breast cancer (mBC) and a germline BRCA mutation (gBRCAm). Journal of Clinical Oncology2017;35(Suppl 18):LBA4-LBA4. RobsonME , RuddyKJ , ImSA , Senkus-KonefkaE , XuB , DomchekSM , et al. EORTC QLQ-C30 (QLQ-C30) symptoms in patients (pts) with HER2-negative metastatic breast cancer (mBC) and a germline BRCA mutation (gBRCAm) receiving olaparib vs chemotherapy treatment of physician’s choice (TPC) in OlympiAD. Journal of Clinical Oncology2018;36(Suppl 15):1045. RobsonME , TungN , ConteP , ImSA , SenkusE , XuB , et al. OlympiAD final overall survival and tolerability results: olaparib versus chemotherapy treatment of physician’s choice in patients with a germline BRCA mutation and HER2-negative metastatic breast cancer. Annals of Oncology2019;30(4):558-66. Senkus-KonefkaE , DomchekSM , ImSA , XuB , ArmstrongA , MasudaN , et al. Subgroup analysis of olaparib monotherapy versus chemotherapy by hormone receptor and BRCA mutation status in patients with HER2-negative metastatic breast cancer and a germline BRCA mutation: OlympiAD. European Journal of Cancer2018;92:S19-20. TungNM , ImSA , Senkus-KonefkaE , XuB , DomchekSM , MasudaN , et al. Olaparib versus chemotherapy treatment of physician’s choice in patients with a germline BRCA mutation and HER2-negative metastatic breast cancer (OlympiAD): efficacy in patients with visceral metastases. Journal of Clinical Oncology2018;36(Suppl 15):1053. ">OLYMPIAD</a>) were assessed with regard to risk of bias. <a href="./references#CD011395-bbs2-0001" title="BalmanaJ , TryfonidisK , AudehW , GouliotiT , SlaetsL , AgarwalS , et al. A phase III, randomized, open-label, multicenter, controlled trial of niraparib versus physician's choice in previously-treated, HER2-negative, germline BRCA mutation-positive breast cancer patients. An EORTC-BIG intergroup study (BRAVO study). Cancer Research2016;76(Suppl 4):Abstract nr OT1-03-05. ">BRAVO</a> was deemed as having unclear risk of bias across all domains as the study ended prematurely and minimal details regarding the study were available. <a href="#CD011395-fig-0002">Figure 2</a> illustrates the 'Risk of bias' summary. </p> <div class="figure" id="CD011395-fig-0002"> <div class="figure-caption-wrapper-top"> <nav class="inline-nav-list has-dividers"> <ul> <li><a class="open-in-figure-viewer" href="#0">Open in figure viewer</a></li> </ul> </nav> <div class="figure-label">Figure 2</div> </div> <hr class="top"/><img alt="Risk of bias summary: review authors' judgements about each risk of bias item for each included study." data-id="CD011395-fig-0002" src="/cdsr/doi/10.1002/14651858.CD011395.pub2/media/CDSR/CD011395/image_n/nCD011395-FIG-02.svg"/><hr class="bottom"/> <div class="figure-caption-wrapper-bottom"> <div class="figure-caption"> <p>Risk of bias summary: review authors' judgements about each risk of bias item for each included study. </p> </div> </div> </div> <section id="CD011395-sec-0045"> <h4 class="title">Allocation</h4> <p><a href="./references#CD011395-bbs2-0004" title="DiabS , RugoHS , MinaLA , PuhallaS , MahtaniRL , HenryNL , et al. Efficacy and safety of talazoparib (TALA) or physician's choice of therapy (PCT) in United States patients (pts) with HER2- germline BRCA1/2-mutated (gBRCAm) locally advanced/metastatic breast cancer (LA/MBC) in the EMBRACA study. Journal of Clinical Oncology2019;37(Suppl 15):1044. EiermannW , RugoHS , DiabS , EttlJ , HurvitzSA , GoncalvesA , et al. Analysis of germline BRCA1/2 mutated (g BRCAmut) hormone receptor-positive (HR+) and triple-negative breast cancer (TNBC) treated with talazoparib (TALA). Journal of Clinical Oncology2018;36(Suppl 15):1070. EttlJ , HurvitzSA , RugoHS , LeeKH , MinaLA , WoodwardNE , et al. Outcomes of talazoparib (TALA) versus physician's choice of chemotherapy (PCT) in patients (pts) with advanced breast cancer (ABC) and a germline BRCA (gBRCA) mutation by line of chemotherapy (CT) in the EMBRACA trial. Journal of Clinical Oncology2019;37(Suppl 15):1071. EttlJ , QuekRG , BhattacharyyaH , RugoHS , HurvitzSA , GonçalvesA . Patient Reported Outcomes (PRO) in patients (pts) with HER2-advanced breast cancer (ABC) and a germline BRCA1/2 mutation (gBRCAm) receiving talazoparib (TALA) vs physician’s choice chemotherapy (PCT) in the EMBRACA trial: a focus on subgroups with/without visceral disease. Annals of Oncology2019;30(Suppl 5):v129–30. EttlJ , QuekRG , HurvitzSA , GoncalvesA , TudorIC , RugoHS . Hospitalization and supportive care medication (SCM) utilisation in patients (pts) with advanced breast cancer (ABC) and a germline BRCA1/2 mutation (gBRCAm) in EMBRACA. Annals of Oncology2019;30(Suppl 3):iii52. EttlJ , QuekRG , LeeKH , RugoHS , HurvitzS , GonçalvesA , et al. Quality of life with talazoparib versus physician’s choice of chemotherapy in patients with advanced breast cancer and germline BRCA1/2 mutation: patient-reported outcomes from the EMBRACA phase III trial. Annals of Oncology2018;29(9):1939-47. FaschingPA , QuekRG , BhattacharyyaH , HurvitzSA , RugoHS , EttlJ . Impact of objective response (OR) on patient-reported outcomes (PRO) in patients (pts) with advanced breast cancer (ABC) and a germline BRCA1/2 (gBRCA) mutation in the phase III EMBRACA trial. Annals of Oncology2019;30(Suppl 3):iii49. GonçalvesA , EiermannW , RugoHS , EttlJ , HurvitzSA , YerushalmiR , et al. EMBRACA: Efficacy and safety in comparing talazoparib (TALA) with physician's choice of therapy (PCT) in patients (pts) with advanced breast cancer (aBC) and a germline BRCA mutation (gBRCAm); BRCA1/BRCA2 subgroup analysis. Annals of Oncology2018;29(Suppl 8):viii96–7. GoncalvesA , QuekRGW , BhattacharyyaH , EttlJ , HurvitzSA , RugoHS . Patient-reported outcomes (PRO) in patients (pts) with Her2-advanced breast cancer (ABC) receiving talazoparib (TALA) vs physician's choice chemotherapy (PCT): a focus on EMBRACA germline BRCA1 and BRCA2 mutation (gBRCA1/2m) subgroups. Breast2019;48(Suppl 2):S71. HurvitzSA , GoncalvesA , RugoHS , LeeKH , FehrenbacherL , MinaLA , et al. Talazoparib in patients with a germline BRCA-mutated advanced breast cancer: detailed safety analyses from the phase III EMBRACA Trial. Oncologist2019;25(3):e439-50. LeeKH , KimSB , SohnJ , GoodwinA , UsariT , LanzaloneS , et al. Talazoparib (TALA) vs physician’s choice of chemotherapy (PCT) in Asian patients (Pts) with HER2- advanced breast cancer (ABC) and a germline BRCA1/2 mutation (gBRCA1/2mut): data from phase III EMBRACA. Annals of Oncology2019;30(9):ix14. LittonJ , EttlJ , HurvitzSA , MinaLA , RugoHS , LeeKH , et al. A phase 3, open-label, randomized, 2-arm international study of the oral dual PARP inhibitor talazoparib in germline BRCA mutation subjects with locally advanced and/or metastatic breast cancer (EMBRACA). Cancer Research2017;77(Suppl 4):Abstract nr OT2-01-13. LittonJ , RugoHS , EttlJ , HurvitzS , GoncalvesA , LeeKH , et al. EMBRACA: a phase 3 trial comparing talazoparib, an oral PARP inhibitor, to physicianʼs choice of therapy in patients with advanced breast cancer and a germline BRCA mutation [abstract]. In: San Antonio Breast Cancer Symposium; 2017 Dec 5-9; San Antonio (TX). San Antonio (TX), 2017. LittonJK , HurvitzSA , MinaLA , RugoHS , LeeKH , GonçalvesA , et al. Talazoparib (TALA) in germline BRCA1/2 (gBRCA1/2)-mutated human epidermal growth factor receptor 2 negative (HER2-) advanced breast cancer (ABC): final overall survival (OS) results from randomized phase 3 EMBRACA trial. Cancer Research2020;80(Suppl 16):Abstract no. CT071. LittonJK , RugoHS , EttlJ , HurvitzSA , GonçalvesA , LeeKH , et al. Talazoparib in patients with advanced breast cancer and a germline BRCA mutation. New England Journal of Medicine2018;379(8):753-63. MartínM , EiermannW , RugoHS , EttlJ , HurvitzSA , GonçalvesA , et al. EMBRACA: Comparison of efficacy and safety of talazoparib (TALA) and physician's choice of therapy (PCT) in patients (pts) with advanced breast cancer (aBC), a germline BRCA1/2 mutation (gBRCAm), and prior platinum treatment. Annals of Oncology2018;29(Suppl 8):viii96. MinaL , LeeKH , GoncalvesA , WoodwardN , HurvitzSA , DiabS , et al. EMBRACA: efficacy and safety of talazoparib or physician's choice of therapy in patients with advanced breast cancer and a germline BRCA1/2 mutation: a regional analysis. Cancer Research2019;79(Suppl 4):Abstract nr P6-18-12. QuekR , BhattacharyyaH , HurvitzS , GoncalvesA , EttlJ , RugoH . Patient-reported outcomes in patients with HER2-advanced breast cancer and a germline BRCA1/2 mutation receiving talazoparib versus physician's choice chemotherapy: a focus on EMBRACA age subgroups. Journal of Managed Care and Specialty Pharmacy2019;25(Suppl 10A):S37-8. QuekRGW , BhattacharyyaH , GoncalvesA , RugoHS , HurvitzSA , EttlJ . Pcn491 Patient reported outcomes (PRO) of talazoparib (TALA) versus physician's choice of chemotherapy (PCT) in patients (pts) with advanced breast cancer (aBC) and a germline BRCA (gBRCa) mutation: a focus on Embraca pts with/without prior chemotherapy (CT) subgroups. Value in Health2019;22(Suppl 3):S532. RugoHS , EttlJ , HurvitzSA , GoncalvesA , LeeKH , FehrenbacherL , et al. Outcomes in clinically relevant patient subgroups from the EMBRACA study: talazoparib vs physician's choice standard-of-care chemotherapy. Journal of the National Cancer Institute Cancer Spectrum2020;4(1):pkz085. RugoHS , EttlJ , WoodwardNE , HurvitzSA , GoncalvesA , LeeKH , et al. EMBRACA: efficacy outcomes in clinically relevant subgroups comparing talazoparib (TALA), an oral poly ADP ribose polymerase (PARP) inhibitor, to physician's choice of therapy (PCT) in patients with advanced breast cancer and a germline BRCA mutation. Journal of Clinical Oncology2018;36(Suppl 15):1069. RugoHS , QuekR , EttlJ , HurvitzSA , BhattacharyyaH , HannahAL , et al. Patient-reported outcomes (PRO) in patients (pts) with advanced breast cancer and a germline BRCA1/2 mutation (gBRCAm) receiving talazoparib (TALA) vs physician’s choice chemotherapy treatment (PCT): a focus on the EMBRACA triple negative (TNBC) subpopulation. Annals of Oncology2018;29(Suppl 8):viii91. YuY , ElmeliegyM , LittonJK , TudorIC , CzibereA , ZhengJ , et al. Exposure-efficacy progression-free survival (PFS) analyses of breast cancer patients with germline BRCA1/2 mutations receiving talazoparib in the phase III EMBRACA trial. Annals of Oncology2018;29(Suppl 8):viii97. YuY , ElmeliegyM , LittonJK , TudorIC , CzibereA , ZhengJ , et al. Talazoparib exposure-efficacy analysis in patients with advanced breast cancer and germline BRCA1/2 mutations in the EMBRACA trial. Journal of Clinical Pharmacology2020;60(10):1324-33. ">EMBRACA</a> was the only study to report central randomisation as a means of allocation concealment, making it low risk. The other four studies (<a href="./references#CD011395-bbs2-0002" title="DiérasV , HanHS , RobsonME , PalacovaM , MarcomPK , JagerA , et al. Evaluation of veliparib (V) and temozolomide (TMZ) in a phase 2 randomized study of the efficacy and tolerability of V+TMZ or carboplatin (C) and paclitaxel (P) vs placebo (Plc)+C/P in patients (pts) with BRCA1 or BRCA2 mutations and metastatic breast cancer. Cancer Research2017;77(Suppl 4):Abstract nr SABCS16-P4-22-02. HanHS , DiérasV , RobsonM , PalácováM , MarcomPK , Jager A et al. Veliparib with temozolomide or carboplatin/paclitaxel versus placebo with carboplatin/paclitaxel in patients with BRCA1/2 locally recurrent/metastatic breast cancer: randomized phase II study. Annals of Oncology2018;29(1):154-61. HanHS , DiérasV , RobsonME , PalácováM , MarcomPK , JagerA , et al. Efficacy and tolerability of veliparib (V; ABT-888) in combination with carboplatin (C) and paclitaxel (P) vs placebo (Plc)+C/P in patients (pts) with BRCA1 or BRCA2 mutations and metastatic breast cancer: a randomized, phase 2 study. Cancer Research2017;77(Suppl 4):Abstract nr SABCS16-S2-05. IsakoffSJ , PuhallaS , DomchekSM , FriedlanderM , KaufmanB , RobsonM , et al. A randomized Phase II study of veliparib with temozolomide or carboplatin/paclitaxel versus placebo with carboplatin/paclitaxel in BRCA1/2 metastatic breast cancer: design and rationale. Future Oncology2017;13(4):307-20. ">BROCADE 2</a>; <a href="./references#CD011395-bbs2-0003" title="ArunBK , HanHS , KaufmanB , WildiersH , FriedlanderM , AyoubJP , et al. First-line veliparib plus carboplatin/paclitaxel in patients with HER2-negative advanced/metastatic gBRCA-associated breast cancer: planned subgroup analysis from the phase 3 BROCADE3 trial. Cancer Research2020;80(Suppl 4):Abstract nr PD4-01. AyoubJP , FriedlanderML , DierasVC , WildiersH , ArunB , HanHS , et al. Veliparib plus carboplatin-paclitaxel in patients with HER2-negative advanced/metastatic gBRCA-associated breast cancer: results in hormone receptor-positive and triple-negative breast cancer subgroups from the phase III BROCADE3 trial. Annals of Oncology2020;31(Suppl 2):S65. DierasV , HanH , KaufmanB , WildiersH , FriedlanderM , AyoubJ , et al. A Phase 3 randomized, placebo-controlled trial of carboplatin and paclitaxel with or without the PARP inhibitor veliparib (ABT-888) in HER2-negative metastatic or locally advanced unresectable BRCA-associated breast cancer. Annals of Oncology2019;30(Suppl 5):v851-v934. ">BROCADE 3</a>; <a href="./references#CD011395-bbs2-0005" title="KummarS , WadeJL , OzaAM , SullivanD , ChenAP , GandaraDR , et al. Randomized phase II trial of cyclophosphamide and the oral poly (ADP-ribose) polymerase inhibitor veliparib in patients with recurrent, advanced triple-negative breast cancer. Investigational New Drugs2016;34(3):355–63. ">Kummar 2016</a>; <a href="./references#CD011395-bbs2-0006" title="DelalogeS , ContePF , ImS , Senkus-KonefkaE , XuB , DomchekSM , et al. OlympiAD: further efficacy outcomes in patients with HER2-negative metastatic breast cancer and a germline BRCA mutation receiving olaparib monotherapy vs standard single-agent chemotherapy treatment of physician’s choice. Annals of Oncology2017;28(Suppl 5):v74-v108. DomchekS , RobsonM , ImS , SenkusE , XuB , MasudaN , et al. Tolerability of olaparib monotherapy versus chemotherapy in patients with HER2-negative metastatic breast cancer and a germline BRCA mutation: OlympiAD. Cancer Research2018;78(Suppl 4):Abstract nr P5-21-12. ImSA , XuB , LiW , RobsonM , OuyangQ , YehDC , et al. Olaparib monotherapy for Asian patients with a germline BRCA mutation and HER2-negative metastatic breast cancer: OlympiAD randomized trial subgroup analysis. Scientific Reports2020;10(1):8753. ImSA , XuB , LiW , RobsonM , OuyangQ , YehDC , et al. Olaparib monotherapy versus chemotherapy for patients with HER2-negative metastatic breast cancer and a germline BRCA mutation: Asian subgroup analysis from the phase III OlympiAD trial. Cancer Research2018;78(Suppl 4):Abstract nr P5-21-13. MerensC , BannisterW , BergnerS , HettleR , McCreaC , McCutcheonS , et al. Impact of olaparib versus chemotherapy on the use of strong pain medications in gBRCA-mutated HER2-negative metastatic breast cancer and associated patient reported outcomes. Cancer Research2020;80(Suppl 4):Abstract nr P6-13-05. RobsonM , HettleR , DegboeA , SaundersO , CainT , KilvertH , et al. Estimating the health state utility of patients with HER2–gBRCA+ metastatic breast cancer treated with olaparib or chemotherapy via a mapping analysis of EORTC QLQ-C30 data collected in the Olympiad clinical trial. Value in Health2018;21(Suppl 1):S12. RobsonM , ImSA , SenkusE , XuB , DomchekS , MasudaN , et al. OlympiAD extended follow-up for overall survival and safety: olaparib versus chemotherapy treatment of physician’s choice in patients with a germline BRCA mutation and HER2-negative metastatic breast cancer. Cancer Research2020;80(Suppl 4):Abstract nr PD4-03. RobsonM , ImSA , SenkusE , XuB , DomchekSM , MasudaN , et al. Olaparib for metastatic breast cancer in patients with a germline BRCA mutation. New England Journal of Medicine2017;377(6):523-33. RobsonM , RuddyKJ , ImSA , SenkusE , XuB , DomchekSM , et al. Patient-reported outcomes in patients with a germline BRCA mutation and HER2-negative metastatic breast cancer receiving olaparib versus chemotherapy in the OlympiAD trial. European Journal of Cancer2019;120:20-30. RobsonM , RuddyKJ , ImSA , Senkus-KonefkaE , XuB , DomchekSM , et al. OlympiAD: health-related quality of life (HRQoL) in patients with HER2-negative metastatic breast cancer (mBC) and a germline BRCA mutation (gBRCAm) receiving olaparib monotherapy vs standard single-agent chemotherapy treatment of physician’s choice (TPC). Annals of Oncology2017;28(Suppl 5):v74-v108. RobsonME , ImSA , SenkusE , XuB , DomchekS , MasudaN , et al. Abstract CT038: OlympiAD final overall survival: olaparib versus chemotherapy treatment of physician's choice (TPC) in patients with HER2-negative metastatic breast cancer (mBC) and a germline BRCA mutation (gBRCAm). American Association for Cancer Research2018;78(Suppl 13):CT038. RobsonME , ImSA , SenkusE , XuB , DomchekSM , MasudaN , et al. OlympiAD: phase III trial of olaparib monotherapy versus chemotherapy for patients (pts) with HER2-negative metastatic breast cancer (mBC) and a germline BRCA mutation (gBRCAm). Journal of Clinical Oncology2017;35(Suppl 18):LBA4-LBA4. RobsonME , RuddyKJ , ImSA , Senkus-KonefkaE , XuB , DomchekSM , et al. EORTC QLQ-C30 (QLQ-C30) symptoms in patients (pts) with HER2-negative metastatic breast cancer (mBC) and a germline BRCA mutation (gBRCAm) receiving olaparib vs chemotherapy treatment of physician’s choice (TPC) in OlympiAD. Journal of Clinical Oncology2018;36(Suppl 15):1045. RobsonME , TungN , ConteP , ImSA , SenkusE , XuB , et al. OlympiAD final overall survival and tolerability results: olaparib versus chemotherapy treatment of physician’s choice in patients with a germline BRCA mutation and HER2-negative metastatic breast cancer. Annals of Oncology2019;30(4):558-66. Senkus-KonefkaE , DomchekSM , ImSA , XuB , ArmstrongA , MasudaN , et al. Subgroup analysis of olaparib monotherapy versus chemotherapy by hormone receptor and BRCA mutation status in patients with HER2-negative metastatic breast cancer and a germline BRCA mutation: OlympiAD. European Journal of Cancer2018;92:S19-20. TungNM , ImSA , Senkus-KonefkaE , XuB , DomchekSM , MasudaN , et al. Olaparib versus chemotherapy treatment of physician’s choice in patients with a germline BRCA mutation and HER2-negative metastatic breast cancer (OlympiAD): efficacy in patients with visceral metastases. Journal of Clinical Oncology2018;36(Suppl 15):1053. ">OLYMPIAD</a>) did not describe their methods of concealment. However, similar to the other studies, <a href="./references#CD011395-bbs2-0004" title="DiabS , RugoHS , MinaLA , PuhallaS , MahtaniRL , HenryNL , et al. Efficacy and safety of talazoparib (TALA) or physician's choice of therapy (PCT) in United States patients (pts) with HER2- germline BRCA1/2-mutated (gBRCAm) locally advanced/metastatic breast cancer (LA/MBC) in the EMBRACA study. Journal of Clinical Oncology2019;37(Suppl 15):1044. EiermannW , RugoHS , DiabS , EttlJ , HurvitzSA , GoncalvesA , et al. Analysis of germline BRCA1/2 mutated (g BRCAmut) hormone receptor-positive (HR+) and triple-negative breast cancer (TNBC) treated with talazoparib (TALA). Journal of Clinical Oncology2018;36(Suppl 15):1070. EttlJ , HurvitzSA , RugoHS , LeeKH , MinaLA , WoodwardNE , et al. Outcomes of talazoparib (TALA) versus physician's choice of chemotherapy (PCT) in patients (pts) with advanced breast cancer (ABC) and a germline BRCA (gBRCA) mutation by line of chemotherapy (CT) in the EMBRACA trial. Journal of Clinical Oncology2019;37(Suppl 15):1071. EttlJ , QuekRG , BhattacharyyaH , RugoHS , HurvitzSA , GonçalvesA . Patient Reported Outcomes (PRO) in patients (pts) with HER2-advanced breast cancer (ABC) and a germline BRCA1/2 mutation (gBRCAm) receiving talazoparib (TALA) vs physician’s choice chemotherapy (PCT) in the EMBRACA trial: a focus on subgroups with/without visceral disease. Annals of Oncology2019;30(Suppl 5):v129–30. EttlJ , QuekRG , HurvitzSA , GoncalvesA , TudorIC , RugoHS . Hospitalization and supportive care medication (SCM) utilisation in patients (pts) with advanced breast cancer (ABC) and a germline BRCA1/2 mutation (gBRCAm) in EMBRACA. Annals of Oncology2019;30(Suppl 3):iii52. EttlJ , QuekRG , LeeKH , RugoHS , HurvitzS , GonçalvesA , et al. Quality of life with talazoparib versus physician’s choice of chemotherapy in patients with advanced breast cancer and germline BRCA1/2 mutation: patient-reported outcomes from the EMBRACA phase III trial. Annals of Oncology2018;29(9):1939-47. FaschingPA , QuekRG , BhattacharyyaH , HurvitzSA , RugoHS , EttlJ . Impact of objective response (OR) on patient-reported outcomes (PRO) in patients (pts) with advanced breast cancer (ABC) and a germline BRCA1/2 (gBRCA) mutation in the phase III EMBRACA trial. Annals of Oncology2019;30(Suppl 3):iii49. GonçalvesA , EiermannW , RugoHS , EttlJ , HurvitzSA , YerushalmiR , et al. EMBRACA: Efficacy and safety in comparing talazoparib (TALA) with physician's choice of therapy (PCT) in patients (pts) with advanced breast cancer (aBC) and a germline BRCA mutation (gBRCAm); BRCA1/BRCA2 subgroup analysis. Annals of Oncology2018;29(Suppl 8):viii96–7. GoncalvesA , QuekRGW , BhattacharyyaH , EttlJ , HurvitzSA , RugoHS . Patient-reported outcomes (PRO) in patients (pts) with Her2-advanced breast cancer (ABC) receiving talazoparib (TALA) vs physician's choice chemotherapy (PCT): a focus on EMBRACA germline BRCA1 and BRCA2 mutation (gBRCA1/2m) subgroups. Breast2019;48(Suppl 2):S71. HurvitzSA , GoncalvesA , RugoHS , LeeKH , FehrenbacherL , MinaLA , et al. Talazoparib in patients with a germline BRCA-mutated advanced breast cancer: detailed safety analyses from the phase III EMBRACA Trial. Oncologist2019;25(3):e439-50. LeeKH , KimSB , SohnJ , GoodwinA , UsariT , LanzaloneS , et al. Talazoparib (TALA) vs physician’s choice of chemotherapy (PCT) in Asian patients (Pts) with HER2- advanced breast cancer (ABC) and a germline BRCA1/2 mutation (gBRCA1/2mut): data from phase III EMBRACA. Annals of Oncology2019;30(9):ix14. LittonJ , EttlJ , HurvitzSA , MinaLA , RugoHS , LeeKH , et al. A phase 3, open-label, randomized, 2-arm international study of the oral dual PARP inhibitor talazoparib in germline BRCA mutation subjects with locally advanced and/or metastatic breast cancer (EMBRACA). Cancer Research2017;77(Suppl 4):Abstract nr OT2-01-13. LittonJ , RugoHS , EttlJ , HurvitzS , GoncalvesA , LeeKH , et al. EMBRACA: a phase 3 trial comparing talazoparib, an oral PARP inhibitor, to physicianʼs choice of therapy in patients with advanced breast cancer and a germline BRCA mutation [abstract]. In: San Antonio Breast Cancer Symposium; 2017 Dec 5-9; San Antonio (TX). San Antonio (TX), 2017. LittonJK , HurvitzSA , MinaLA , RugoHS , LeeKH , GonçalvesA , et al. Talazoparib (TALA) in germline BRCA1/2 (gBRCA1/2)-mutated human epidermal growth factor receptor 2 negative (HER2-) advanced breast cancer (ABC): final overall survival (OS) results from randomized phase 3 EMBRACA trial. Cancer Research2020;80(Suppl 16):Abstract no. CT071. LittonJK , RugoHS , EttlJ , HurvitzSA , GonçalvesA , LeeKH , et al. Talazoparib in patients with advanced breast cancer and a germline BRCA mutation. New England Journal of Medicine2018;379(8):753-63. MartínM , EiermannW , RugoHS , EttlJ , HurvitzSA , GonçalvesA , et al. EMBRACA: Comparison of efficacy and safety of talazoparib (TALA) and physician's choice of therapy (PCT) in patients (pts) with advanced breast cancer (aBC), a germline BRCA1/2 mutation (gBRCAm), and prior platinum treatment. Annals of Oncology2018;29(Suppl 8):viii96. MinaL , LeeKH , GoncalvesA , WoodwardN , HurvitzSA , DiabS , et al. EMBRACA: efficacy and safety of talazoparib or physician's choice of therapy in patients with advanced breast cancer and a germline BRCA1/2 mutation: a regional analysis. Cancer Research2019;79(Suppl 4):Abstract nr P6-18-12. QuekR , BhattacharyyaH , HurvitzS , GoncalvesA , EttlJ , RugoH . Patient-reported outcomes in patients with HER2-advanced breast cancer and a germline BRCA1/2 mutation receiving talazoparib versus physician's choice chemotherapy: a focus on EMBRACA age subgroups. Journal of Managed Care and Specialty Pharmacy2019;25(Suppl 10A):S37-8. QuekRGW , BhattacharyyaH , GoncalvesA , RugoHS , HurvitzSA , EttlJ . Pcn491 Patient reported outcomes (PRO) of talazoparib (TALA) versus physician's choice of chemotherapy (PCT) in patients (pts) with advanced breast cancer (aBC) and a germline BRCA (gBRCa) mutation: a focus on Embraca pts with/without prior chemotherapy (CT) subgroups. Value in Health2019;22(Suppl 3):S532. RugoHS , EttlJ , HurvitzSA , GoncalvesA , LeeKH , FehrenbacherL , et al. Outcomes in clinically relevant patient subgroups from the EMBRACA study: talazoparib vs physician's choice standard-of-care chemotherapy. Journal of the National Cancer Institute Cancer Spectrum2020;4(1):pkz085. RugoHS , EttlJ , WoodwardNE , HurvitzSA , GoncalvesA , LeeKH , et al. EMBRACA: efficacy outcomes in clinically relevant subgroups comparing talazoparib (TALA), an oral poly ADP ribose polymerase (PARP) inhibitor, to physician's choice of therapy (PCT) in patients with advanced breast cancer and a germline BRCA mutation. Journal of Clinical Oncology2018;36(Suppl 15):1069. RugoHS , QuekR , EttlJ , HurvitzSA , BhattacharyyaH , HannahAL , et al. Patient-reported outcomes (PRO) in patients (pts) with advanced breast cancer and a germline BRCA1/2 mutation (gBRCAm) receiving talazoparib (TALA) vs physician’s choice chemotherapy treatment (PCT): a focus on the EMBRACA triple negative (TNBC) subpopulation. Annals of Oncology2018;29(Suppl 8):viii91. YuY , ElmeliegyM , LittonJK , TudorIC , CzibereA , ZhengJ , et al. Exposure-efficacy progression-free survival (PFS) analyses of breast cancer patients with germline BRCA1/2 mutations receiving talazoparib in the phase III EMBRACA trial. Annals of Oncology2018;29(Suppl 8):viii97. YuY , ElmeliegyM , LittonJK , TudorIC , CzibereA , ZhengJ , et al. Talazoparib exposure-efficacy analysis in patients with advanced breast cancer and germline BRCA1/2 mutations in the EMBRACA trial. Journal of Clinical Pharmacology2020;60(10):1324-33. ">EMBRACA</a> did not provide sufficient information about the sequence generation process to permit judgement meaning all five studies were judged as unclear risk of bias in regards to their sequence generation processes. </p> </section> <section id="CD011395-sec-0046"> <h4 class="title">Blinding</h4> <p>In terms of performance bias, <a href="./references#CD011395-bbs2-0002" title="DiérasV , HanHS , RobsonME , PalacovaM , MarcomPK , JagerA , et al. Evaluation of veliparib (V) and temozolomide (TMZ) in a phase 2 randomized study of the efficacy and tolerability of V+TMZ or carboplatin (C) and paclitaxel (P) vs placebo (Plc)+C/P in patients (pts) with BRCA1 or BRCA2 mutations and metastatic breast cancer. Cancer Research2017;77(Suppl 4):Abstract nr SABCS16-P4-22-02. HanHS , DiérasV , RobsonM , PalácováM , MarcomPK , Jager A et al. Veliparib with temozolomide or carboplatin/paclitaxel versus placebo with carboplatin/paclitaxel in patients with BRCA1/2 locally recurrent/metastatic breast cancer: randomized phase II study. Annals of Oncology2018;29(1):154-61. HanHS , DiérasV , RobsonME , PalácováM , MarcomPK , JagerA , et al. Efficacy and tolerability of veliparib (V; ABT-888) in combination with carboplatin (C) and paclitaxel (P) vs placebo (Plc)+C/P in patients (pts) with BRCA1 or BRCA2 mutations and metastatic breast cancer: a randomized, phase 2 study. Cancer Research2017;77(Suppl 4):Abstract nr SABCS16-S2-05. IsakoffSJ , PuhallaS , DomchekSM , FriedlanderM , KaufmanB , RobsonM , et al. A randomized Phase II study of veliparib with temozolomide or carboplatin/paclitaxel versus placebo with carboplatin/paclitaxel in BRCA1/2 metastatic breast cancer: design and rationale. Future Oncology2017;13(4):307-20. ">BROCADE 2</a> and <a href="./references#CD011395-bbs2-0003" title="ArunBK , HanHS , KaufmanB , WildiersH , FriedlanderM , AyoubJP , et al. First-line veliparib plus carboplatin/paclitaxel in patients with HER2-negative advanced/metastatic gBRCA-associated breast cancer: planned subgroup analysis from the phase 3 BROCADE3 trial. Cancer Research2020;80(Suppl 4):Abstract nr PD4-01. AyoubJP , FriedlanderML , DierasVC , WildiersH , ArunB , HanHS , et al. Veliparib plus carboplatin-paclitaxel in patients with HER2-negative advanced/metastatic gBRCA-associated breast cancer: results in hormone receptor-positive and triple-negative breast cancer subgroups from the phase III BROCADE3 trial. Annals of Oncology2020;31(Suppl 2):S65. DierasV , HanH , KaufmanB , WildiersH , FriedlanderM , AyoubJ , et al. A Phase 3 randomized, placebo-controlled trial of carboplatin and paclitaxel with or without the PARP inhibitor veliparib (ABT-888) in HER2-negative metastatic or locally advanced unresectable BRCA-associated breast cancer. Annals of Oncology2019;30(Suppl 5):v851-v934. ">BROCADE 3</a> were judged as having low risk as the studies were double‐blinded, where blinding of participants and key study personnel were ensured. <a href="./references#CD011395-bbs2-0006" title="DelalogeS , ContePF , ImS , Senkus-KonefkaE , XuB , DomchekSM , et al. OlympiAD: further efficacy outcomes in patients with HER2-negative metastatic breast cancer and a germline BRCA mutation receiving olaparib monotherapy vs standard single-agent chemotherapy treatment of physician’s choice. Annals of Oncology2017;28(Suppl 5):v74-v108. DomchekS , RobsonM , ImS , SenkusE , XuB , MasudaN , et al. Tolerability of olaparib monotherapy versus chemotherapy in patients with HER2-negative metastatic breast cancer and a germline BRCA mutation: OlympiAD. Cancer Research2018;78(Suppl 4):Abstract nr P5-21-12. ImSA , XuB , LiW , RobsonM , OuyangQ , YehDC , et al. Olaparib monotherapy for Asian patients with a germline BRCA mutation and HER2-negative metastatic breast cancer: OlympiAD randomized trial subgroup analysis. Scientific Reports2020;10(1):8753. ImSA , XuB , LiW , RobsonM , OuyangQ , YehDC , et al. Olaparib monotherapy versus chemotherapy for patients with HER2-negative metastatic breast cancer and a germline BRCA mutation: Asian subgroup analysis from the phase III OlympiAD trial. Cancer Research2018;78(Suppl 4):Abstract nr P5-21-13. MerensC , BannisterW , BergnerS , HettleR , McCreaC , McCutcheonS , et al. Impact of olaparib versus chemotherapy on the use of strong pain medications in gBRCA-mutated HER2-negative metastatic breast cancer and associated patient reported outcomes. Cancer Research2020;80(Suppl 4):Abstract nr P6-13-05. RobsonM , HettleR , DegboeA , SaundersO , CainT , KilvertH , et al. Estimating the health state utility of patients with HER2–gBRCA+ metastatic breast cancer treated with olaparib or chemotherapy via a mapping analysis of EORTC QLQ-C30 data collected in the Olympiad clinical trial. Value in Health2018;21(Suppl 1):S12. RobsonM , ImSA , SenkusE , XuB , DomchekS , MasudaN , et al. OlympiAD extended follow-up for overall survival and safety: olaparib versus chemotherapy treatment of physician’s choice in patients with a germline BRCA mutation and HER2-negative metastatic breast cancer. Cancer Research2020;80(Suppl 4):Abstract nr PD4-03. RobsonM , ImSA , SenkusE , XuB , DomchekSM , MasudaN , et al. Olaparib for metastatic breast cancer in patients with a germline BRCA mutation. New England Journal of Medicine2017;377(6):523-33. RobsonM , RuddyKJ , ImSA , SenkusE , XuB , DomchekSM , et al. Patient-reported outcomes in patients with a germline BRCA mutation and HER2-negative metastatic breast cancer receiving olaparib versus chemotherapy in the OlympiAD trial. European Journal of Cancer2019;120:20-30. RobsonM , RuddyKJ , ImSA , Senkus-KonefkaE , XuB , DomchekSM , et al. OlympiAD: health-related quality of life (HRQoL) in patients with HER2-negative metastatic breast cancer (mBC) and a germline BRCA mutation (gBRCAm) receiving olaparib monotherapy vs standard single-agent chemotherapy treatment of physician’s choice (TPC). Annals of Oncology2017;28(Suppl 5):v74-v108. RobsonME , ImSA , SenkusE , XuB , DomchekS , MasudaN , et al. Abstract CT038: OlympiAD final overall survival: olaparib versus chemotherapy treatment of physician's choice (TPC) in patients with HER2-negative metastatic breast cancer (mBC) and a germline BRCA mutation (gBRCAm). American Association for Cancer Research2018;78(Suppl 13):CT038. RobsonME , ImSA , SenkusE , XuB , DomchekSM , MasudaN , et al. OlympiAD: phase III trial of olaparib monotherapy versus chemotherapy for patients (pts) with HER2-negative metastatic breast cancer (mBC) and a germline BRCA mutation (gBRCAm). Journal of Clinical Oncology2017;35(Suppl 18):LBA4-LBA4. RobsonME , RuddyKJ , ImSA , Senkus-KonefkaE , XuB , DomchekSM , et al. EORTC QLQ-C30 (QLQ-C30) symptoms in patients (pts) with HER2-negative metastatic breast cancer (mBC) and a germline BRCA mutation (gBRCAm) receiving olaparib vs chemotherapy treatment of physician’s choice (TPC) in OlympiAD. Journal of Clinical Oncology2018;36(Suppl 15):1045. RobsonME , TungN , ConteP , ImSA , SenkusE , XuB , et al. OlympiAD final overall survival and tolerability results: olaparib versus chemotherapy treatment of physician’s choice in patients with a germline BRCA mutation and HER2-negative metastatic breast cancer. Annals of Oncology2019;30(4):558-66. Senkus-KonefkaE , DomchekSM , ImSA , XuB , ArmstrongA , MasudaN , et al. Subgroup analysis of olaparib monotherapy versus chemotherapy by hormone receptor and BRCA mutation status in patients with HER2-negative metastatic breast cancer and a germline BRCA mutation: OlympiAD. European Journal of Cancer2018;92:S19-20. TungNM , ImSA , Senkus-KonefkaE , XuB , DomchekSM , MasudaN , et al. Olaparib versus chemotherapy treatment of physician’s choice in patients with a germline BRCA mutation and HER2-negative metastatic breast cancer (OlympiAD): efficacy in patients with visceral metastases. Journal of Clinical Oncology2018;36(Suppl 15):1053. ">OLYMPIAD</a>, <a href="./references#CD011395-bbs2-0004" title="DiabS , RugoHS , MinaLA , PuhallaS , MahtaniRL , HenryNL , et al. Efficacy and safety of talazoparib (TALA) or physician's choice of therapy (PCT) in United States patients (pts) with HER2- germline BRCA1/2-mutated (gBRCAm) locally advanced/metastatic breast cancer (LA/MBC) in the EMBRACA study. Journal of Clinical Oncology2019;37(Suppl 15):1044. EiermannW , RugoHS , DiabS , EttlJ , HurvitzSA , GoncalvesA , et al. Analysis of germline BRCA1/2 mutated (g BRCAmut) hormone receptor-positive (HR+) and triple-negative breast cancer (TNBC) treated with talazoparib (TALA). Journal of Clinical Oncology2018;36(Suppl 15):1070. EttlJ , HurvitzSA , RugoHS , LeeKH , MinaLA , WoodwardNE , et al. Outcomes of talazoparib (TALA) versus physician's choice of chemotherapy (PCT) in patients (pts) with advanced breast cancer (ABC) and a germline BRCA (gBRCA) mutation by line of chemotherapy (CT) in the EMBRACA trial. Journal of Clinical Oncology2019;37(Suppl 15):1071. EttlJ , QuekRG , BhattacharyyaH , RugoHS , HurvitzSA , GonçalvesA . Patient Reported Outcomes (PRO) in patients (pts) with HER2-advanced breast cancer (ABC) and a germline BRCA1/2 mutation (gBRCAm) receiving talazoparib (TALA) vs physician’s choice chemotherapy (PCT) in the EMBRACA trial: a focus on subgroups with/without visceral disease. Annals of Oncology2019;30(Suppl 5):v129–30. EttlJ , QuekRG , HurvitzSA , GoncalvesA , TudorIC , RugoHS . Hospitalization and supportive care medication (SCM) utilisation in patients (pts) with advanced breast cancer (ABC) and a germline BRCA1/2 mutation (gBRCAm) in EMBRACA. Annals of Oncology2019;30(Suppl 3):iii52. EttlJ , QuekRG , LeeKH , RugoHS , HurvitzS , GonçalvesA , et al. Quality of life with talazoparib versus physician’s choice of chemotherapy in patients with advanced breast cancer and germline BRCA1/2 mutation: patient-reported outcomes from the EMBRACA phase III trial. Annals of Oncology2018;29(9):1939-47. FaschingPA , QuekRG , BhattacharyyaH , HurvitzSA , RugoHS , EttlJ . Impact of objective response (OR) on patient-reported outcomes (PRO) in patients (pts) with advanced breast cancer (ABC) and a germline BRCA1/2 (gBRCA) mutation in the phase III EMBRACA trial. Annals of Oncology2019;30(Suppl 3):iii49. GonçalvesA , EiermannW , RugoHS , EttlJ , HurvitzSA , YerushalmiR , et al. EMBRACA: Efficacy and safety in comparing talazoparib (TALA) with physician's choice of therapy (PCT) in patients (pts) with advanced breast cancer (aBC) and a germline BRCA mutation (gBRCAm); BRCA1/BRCA2 subgroup analysis. Annals of Oncology2018;29(Suppl 8):viii96–7. GoncalvesA , QuekRGW , BhattacharyyaH , EttlJ , HurvitzSA , RugoHS . Patient-reported outcomes (PRO) in patients (pts) with Her2-advanced breast cancer (ABC) receiving talazoparib (TALA) vs physician's choice chemotherapy (PCT): a focus on EMBRACA germline BRCA1 and BRCA2 mutation (gBRCA1/2m) subgroups. Breast2019;48(Suppl 2):S71. HurvitzSA , GoncalvesA , RugoHS , LeeKH , FehrenbacherL , MinaLA , et al. Talazoparib in patients with a germline BRCA-mutated advanced breast cancer: detailed safety analyses from the phase III EMBRACA Trial. Oncologist2019;25(3):e439-50. LeeKH , KimSB , SohnJ , GoodwinA , UsariT , LanzaloneS , et al. Talazoparib (TALA) vs physician’s choice of chemotherapy (PCT) in Asian patients (Pts) with HER2- advanced breast cancer (ABC) and a germline BRCA1/2 mutation (gBRCA1/2mut): data from phase III EMBRACA. Annals of Oncology2019;30(9):ix14. LittonJ , EttlJ , HurvitzSA , MinaLA , RugoHS , LeeKH , et al. A phase 3, open-label, randomized, 2-arm international study of the oral dual PARP inhibitor talazoparib in germline BRCA mutation subjects with locally advanced and/or metastatic breast cancer (EMBRACA). Cancer Research2017;77(Suppl 4):Abstract nr OT2-01-13. LittonJ , RugoHS , EttlJ , HurvitzS , GoncalvesA , LeeKH , et al. EMBRACA: a phase 3 trial comparing talazoparib, an oral PARP inhibitor, to physicianʼs choice of therapy in patients with advanced breast cancer and a germline BRCA mutation [abstract]. In: San Antonio Breast Cancer Symposium; 2017 Dec 5-9; San Antonio (TX). San Antonio (TX), 2017. LittonJK , HurvitzSA , MinaLA , RugoHS , LeeKH , GonçalvesA , et al. Talazoparib (TALA) in germline BRCA1/2 (gBRCA1/2)-mutated human epidermal growth factor receptor 2 negative (HER2-) advanced breast cancer (ABC): final overall survival (OS) results from randomized phase 3 EMBRACA trial. Cancer Research2020;80(Suppl 16):Abstract no. CT071. LittonJK , RugoHS , EttlJ , HurvitzSA , GonçalvesA , LeeKH , et al. Talazoparib in patients with advanced breast cancer and a germline BRCA mutation. New England Journal of Medicine2018;379(8):753-63. MartínM , EiermannW , RugoHS , EttlJ , HurvitzSA , GonçalvesA , et al. EMBRACA: Comparison of efficacy and safety of talazoparib (TALA) and physician's choice of therapy (PCT) in patients (pts) with advanced breast cancer (aBC), a germline BRCA1/2 mutation (gBRCAm), and prior platinum treatment. Annals of Oncology2018;29(Suppl 8):viii96. MinaL , LeeKH , GoncalvesA , WoodwardN , HurvitzSA , DiabS , et al. EMBRACA: efficacy and safety of talazoparib or physician's choice of therapy in patients with advanced breast cancer and a germline BRCA1/2 mutation: a regional analysis. Cancer Research2019;79(Suppl 4):Abstract nr P6-18-12. QuekR , BhattacharyyaH , HurvitzS , GoncalvesA , EttlJ , RugoH . Patient-reported outcomes in patients with HER2-advanced breast cancer and a germline BRCA1/2 mutation receiving talazoparib versus physician's choice chemotherapy: a focus on EMBRACA age subgroups. Journal of Managed Care and Specialty Pharmacy2019;25(Suppl 10A):S37-8. QuekRGW , BhattacharyyaH , GoncalvesA , RugoHS , HurvitzSA , EttlJ . Pcn491 Patient reported outcomes (PRO) of talazoparib (TALA) versus physician's choice of chemotherapy (PCT) in patients (pts) with advanced breast cancer (aBC) and a germline BRCA (gBRCa) mutation: a focus on Embraca pts with/without prior chemotherapy (CT) subgroups. Value in Health2019;22(Suppl 3):S532. RugoHS , EttlJ , HurvitzSA , GoncalvesA , LeeKH , FehrenbacherL , et al. Outcomes in clinically relevant patient subgroups from the EMBRACA study: talazoparib vs physician's choice standard-of-care chemotherapy. Journal of the National Cancer Institute Cancer Spectrum2020;4(1):pkz085. RugoHS , EttlJ , WoodwardNE , HurvitzSA , GoncalvesA , LeeKH , et al. EMBRACA: efficacy outcomes in clinically relevant subgroups comparing talazoparib (TALA), an oral poly ADP ribose polymerase (PARP) inhibitor, to physician's choice of therapy (PCT) in patients with advanced breast cancer and a germline BRCA mutation. Journal of Clinical Oncology2018;36(Suppl 15):1069. RugoHS , QuekR , EttlJ , HurvitzSA , BhattacharyyaH , HannahAL , et al. Patient-reported outcomes (PRO) in patients (pts) with advanced breast cancer and a germline BRCA1/2 mutation (gBRCAm) receiving talazoparib (TALA) vs physician’s choice chemotherapy treatment (PCT): a focus on the EMBRACA triple negative (TNBC) subpopulation. Annals of Oncology2018;29(Suppl 8):viii91. YuY , ElmeliegyM , LittonJK , TudorIC , CzibereA , ZhengJ , et al. Exposure-efficacy progression-free survival (PFS) analyses of breast cancer patients with germline BRCA1/2 mutations receiving talazoparib in the phase III EMBRACA trial. Annals of Oncology2018;29(Suppl 8):viii97. YuY , ElmeliegyM , LittonJK , TudorIC , CzibereA , ZhengJ , et al. Talazoparib exposure-efficacy analysis in patients with advanced breast cancer and germline BRCA1/2 mutations in the EMBRACA trial. Journal of Clinical Pharmacology2020;60(10):1324-33. ">EMBRACA</a> and <a href="./references#CD011395-bbs2-0005" title="KummarS , WadeJL , OzaAM , SullivanD , ChenAP , GandaraDR , et al. Randomized phase II trial of cyclophosphamide and the oral poly (ADP-ribose) polymerase inhibitor veliparib in patients with recurrent, advanced triple-negative breast cancer. Investigational New Drugs2016;34(3):355–63. ">Kummar 2016</a> were all open‐label studies, meaning there was no blinding of participants and personnel. So, these three studies were judged as having high risk of performance bias. </p> <p>In terms of detection bias, individual outcomes were assessed for risk of bias. Overall survival is an objective measure and unaffected by lack of blinding so this outcome was judged as being at low risk for all five studies. <a href="./references#CD011395-bbs2-0002" title="DiérasV , HanHS , RobsonME , PalacovaM , MarcomPK , JagerA , et al. Evaluation of veliparib (V) and temozolomide (TMZ) in a phase 2 randomized study of the efficacy and tolerability of V+TMZ or carboplatin (C) and paclitaxel (P) vs placebo (Plc)+C/P in patients (pts) with BRCA1 or BRCA2 mutations and metastatic breast cancer. Cancer Research2017;77(Suppl 4):Abstract nr SABCS16-P4-22-02. HanHS , DiérasV , RobsonM , PalácováM , MarcomPK , Jager A et al. Veliparib with temozolomide or carboplatin/paclitaxel versus placebo with carboplatin/paclitaxel in patients with BRCA1/2 locally recurrent/metastatic breast cancer: randomized phase II study. Annals of Oncology2018;29(1):154-61. HanHS , DiérasV , RobsonME , PalácováM , MarcomPK , JagerA , et al. Efficacy and tolerability of veliparib (V; ABT-888) in combination with carboplatin (C) and paclitaxel (P) vs placebo (Plc)+C/P in patients (pts) with BRCA1 or BRCA2 mutations and metastatic breast cancer: a randomized, phase 2 study. Cancer Research2017;77(Suppl 4):Abstract nr SABCS16-S2-05. IsakoffSJ , PuhallaS , DomchekSM , FriedlanderM , KaufmanB , RobsonM , et al. A randomized Phase II study of veliparib with temozolomide or carboplatin/paclitaxel versus placebo with carboplatin/paclitaxel in BRCA1/2 metastatic breast cancer: design and rationale. Future Oncology2017;13(4):307-20. ">BROCADE 2</a> and <a href="./references#CD011395-bbs2-0003" title="ArunBK , HanHS , KaufmanB , WildiersH , FriedlanderM , AyoubJP , et al. First-line veliparib plus carboplatin/paclitaxel in patients with HER2-negative advanced/metastatic gBRCA-associated breast cancer: planned subgroup analysis from the phase 3 BROCADE3 trial. Cancer Research2020;80(Suppl 4):Abstract nr PD4-01. AyoubJP , FriedlanderML , DierasVC , WildiersH , ArunB , HanHS , et al. Veliparib plus carboplatin-paclitaxel in patients with HER2-negative advanced/metastatic gBRCA-associated breast cancer: results in hormone receptor-positive and triple-negative breast cancer subgroups from the phase III BROCADE3 trial. Annals of Oncology2020;31(Suppl 2):S65. DierasV , HanH , KaufmanB , WildiersH , FriedlanderM , AyoubJ , et al. A Phase 3 randomized, placebo-controlled trial of carboplatin and paclitaxel with or without the PARP inhibitor veliparib (ABT-888) in HER2-negative metastatic or locally advanced unresectable BRCA-associated breast cancer. Annals of Oncology2019;30(Suppl 5):v851-v934. ">BROCADE 3</a> were double‐blinded studies so blinding of outcome assessment was guaranteed, meaning progression‐free survival and overall response rates outcomes were judged as being at low risk of bias. Similarily, <a href="./references#CD011395-bbs2-0004" title="DiabS , RugoHS , MinaLA , PuhallaS , MahtaniRL , HenryNL , et al. Efficacy and safety of talazoparib (TALA) or physician's choice of therapy (PCT) in United States patients (pts) with HER2- germline BRCA1/2-mutated (gBRCAm) locally advanced/metastatic breast cancer (LA/MBC) in the EMBRACA study. Journal of Clinical Oncology2019;37(Suppl 15):1044. EiermannW , RugoHS , DiabS , EttlJ , HurvitzSA , GoncalvesA , et al. Analysis of germline BRCA1/2 mutated (g BRCAmut) hormone receptor-positive (HR+) and triple-negative breast cancer (TNBC) treated with talazoparib (TALA). Journal of Clinical Oncology2018;36(Suppl 15):1070. EttlJ , HurvitzSA , RugoHS , LeeKH , MinaLA , WoodwardNE , et al. Outcomes of talazoparib (TALA) versus physician's choice of chemotherapy (PCT) in patients (pts) with advanced breast cancer (ABC) and a germline BRCA (gBRCA) mutation by line of chemotherapy (CT) in the EMBRACA trial. Journal of Clinical Oncology2019;37(Suppl 15):1071. EttlJ , QuekRG , BhattacharyyaH , RugoHS , HurvitzSA , GonçalvesA . Patient Reported Outcomes (PRO) in patients (pts) with HER2-advanced breast cancer (ABC) and a germline BRCA1/2 mutation (gBRCAm) receiving talazoparib (TALA) vs physician’s choice chemotherapy (PCT) in the EMBRACA trial: a focus on subgroups with/without visceral disease. Annals of Oncology2019;30(Suppl 5):v129–30. EttlJ , QuekRG , HurvitzSA , GoncalvesA , TudorIC , RugoHS . Hospitalization and supportive care medication (SCM) utilisation in patients (pts) with advanced breast cancer (ABC) and a germline BRCA1/2 mutation (gBRCAm) in EMBRACA. Annals of Oncology2019;30(Suppl 3):iii52. EttlJ , QuekRG , LeeKH , RugoHS , HurvitzS , GonçalvesA , et al. Quality of life with talazoparib versus physician’s choice of chemotherapy in patients with advanced breast cancer and germline BRCA1/2 mutation: patient-reported outcomes from the EMBRACA phase III trial. Annals of Oncology2018;29(9):1939-47. FaschingPA , QuekRG , BhattacharyyaH , HurvitzSA , RugoHS , EttlJ . Impact of objective response (OR) on patient-reported outcomes (PRO) in patients (pts) with advanced breast cancer (ABC) and a germline BRCA1/2 (gBRCA) mutation in the phase III EMBRACA trial. Annals of Oncology2019;30(Suppl 3):iii49. GonçalvesA , EiermannW , RugoHS , EttlJ , HurvitzSA , YerushalmiR , et al. EMBRACA: Efficacy and safety in comparing talazoparib (TALA) with physician's choice of therapy (PCT) in patients (pts) with advanced breast cancer (aBC) and a germline BRCA mutation (gBRCAm); BRCA1/BRCA2 subgroup analysis. Annals of Oncology2018;29(Suppl 8):viii96–7. GoncalvesA , QuekRGW , BhattacharyyaH , EttlJ , HurvitzSA , RugoHS . Patient-reported outcomes (PRO) in patients (pts) with Her2-advanced breast cancer (ABC) receiving talazoparib (TALA) vs physician's choice chemotherapy (PCT): a focus on EMBRACA germline BRCA1 and BRCA2 mutation (gBRCA1/2m) subgroups. Breast2019;48(Suppl 2):S71. HurvitzSA , GoncalvesA , RugoHS , LeeKH , FehrenbacherL , MinaLA , et al. Talazoparib in patients with a germline BRCA-mutated advanced breast cancer: detailed safety analyses from the phase III EMBRACA Trial. Oncologist2019;25(3):e439-50. LeeKH , KimSB , SohnJ , GoodwinA , UsariT , LanzaloneS , et al. Talazoparib (TALA) vs physician’s choice of chemotherapy (PCT) in Asian patients (Pts) with HER2- advanced breast cancer (ABC) and a germline BRCA1/2 mutation (gBRCA1/2mut): data from phase III EMBRACA. Annals of Oncology2019;30(9):ix14. LittonJ , EttlJ , HurvitzSA , MinaLA , RugoHS , LeeKH , et al. A phase 3, open-label, randomized, 2-arm international study of the oral dual PARP inhibitor talazoparib in germline BRCA mutation subjects with locally advanced and/or metastatic breast cancer (EMBRACA). Cancer Research2017;77(Suppl 4):Abstract nr OT2-01-13. LittonJ , RugoHS , EttlJ , HurvitzS , GoncalvesA , LeeKH , et al. EMBRACA: a phase 3 trial comparing talazoparib, an oral PARP inhibitor, to physicianʼs choice of therapy in patients with advanced breast cancer and a germline BRCA mutation [abstract]. In: San Antonio Breast Cancer Symposium; 2017 Dec 5-9; San Antonio (TX). San Antonio (TX), 2017. LittonJK , HurvitzSA , MinaLA , RugoHS , LeeKH , GonçalvesA , et al. Talazoparib (TALA) in germline BRCA1/2 (gBRCA1/2)-mutated human epidermal growth factor receptor 2 negative (HER2-) advanced breast cancer (ABC): final overall survival (OS) results from randomized phase 3 EMBRACA trial. Cancer Research2020;80(Suppl 16):Abstract no. CT071. LittonJK , RugoHS , EttlJ , HurvitzSA , GonçalvesA , LeeKH , et al. Talazoparib in patients with advanced breast cancer and a germline BRCA mutation. New England Journal of Medicine2018;379(8):753-63. MartínM , EiermannW , RugoHS , EttlJ , HurvitzSA , GonçalvesA , et al. EMBRACA: Comparison of efficacy and safety of talazoparib (TALA) and physician's choice of therapy (PCT) in patients (pts) with advanced breast cancer (aBC), a germline BRCA1/2 mutation (gBRCAm), and prior platinum treatment. Annals of Oncology2018;29(Suppl 8):viii96. MinaL , LeeKH , GoncalvesA , WoodwardN , HurvitzSA , DiabS , et al. EMBRACA: efficacy and safety of talazoparib or physician's choice of therapy in patients with advanced breast cancer and a germline BRCA1/2 mutation: a regional analysis. Cancer Research2019;79(Suppl 4):Abstract nr P6-18-12. QuekR , BhattacharyyaH , HurvitzS , GoncalvesA , EttlJ , RugoH . Patient-reported outcomes in patients with HER2-advanced breast cancer and a germline BRCA1/2 mutation receiving talazoparib versus physician's choice chemotherapy: a focus on EMBRACA age subgroups. Journal of Managed Care and Specialty Pharmacy2019;25(Suppl 10A):S37-8. QuekRGW , BhattacharyyaH , GoncalvesA , RugoHS , HurvitzSA , EttlJ . Pcn491 Patient reported outcomes (PRO) of talazoparib (TALA) versus physician's choice of chemotherapy (PCT) in patients (pts) with advanced breast cancer (aBC) and a germline BRCA (gBRCa) mutation: a focus on Embraca pts with/without prior chemotherapy (CT) subgroups. Value in Health2019;22(Suppl 3):S532. RugoHS , EttlJ , HurvitzSA , GoncalvesA , LeeKH , FehrenbacherL , et al. Outcomes in clinically relevant patient subgroups from the EMBRACA study: talazoparib vs physician's choice standard-of-care chemotherapy. Journal of the National Cancer Institute Cancer Spectrum2020;4(1):pkz085. RugoHS , EttlJ , WoodwardNE , HurvitzSA , GoncalvesA , LeeKH , et al. EMBRACA: efficacy outcomes in clinically relevant subgroups comparing talazoparib (TALA), an oral poly ADP ribose polymerase (PARP) inhibitor, to physician's choice of therapy (PCT) in patients with advanced breast cancer and a germline BRCA mutation. Journal of Clinical Oncology2018;36(Suppl 15):1069. RugoHS , QuekR , EttlJ , HurvitzSA , BhattacharyyaH , HannahAL , et al. Patient-reported outcomes (PRO) in patients (pts) with advanced breast cancer and a germline BRCA1/2 mutation (gBRCAm) receiving talazoparib (TALA) vs physician’s choice chemotherapy treatment (PCT): a focus on the EMBRACA triple negative (TNBC) subpopulation. Annals of Oncology2018;29(Suppl 8):viii91. YuY , ElmeliegyM , LittonJK , TudorIC , CzibereA , ZhengJ , et al. Exposure-efficacy progression-free survival (PFS) analyses of breast cancer patients with germline BRCA1/2 mutations receiving talazoparib in the phase III EMBRACA trial. Annals of Oncology2018;29(Suppl 8):viii97. YuY , ElmeliegyM , LittonJK , TudorIC , CzibereA , ZhengJ , et al. Talazoparib exposure-efficacy analysis in patients with advanced breast cancer and germline BRCA1/2 mutations in the EMBRACA trial. Journal of Clinical Pharmacology2020;60(10):1324-33. ">EMBRACA</a> and <a href="./references#CD011395-bbs2-0006" title="DelalogeS , ContePF , ImS , Senkus-KonefkaE , XuB , DomchekSM , et al. OlympiAD: further efficacy outcomes in patients with HER2-negative metastatic breast cancer and a germline BRCA mutation receiving olaparib monotherapy vs standard single-agent chemotherapy treatment of physician’s choice. Annals of Oncology2017;28(Suppl 5):v74-v108. DomchekS , RobsonM , ImS , SenkusE , XuB , MasudaN , et al. Tolerability of olaparib monotherapy versus chemotherapy in patients with HER2-negative metastatic breast cancer and a germline BRCA mutation: OlympiAD. Cancer Research2018;78(Suppl 4):Abstract nr P5-21-12. ImSA , XuB , LiW , RobsonM , OuyangQ , YehDC , et al. Olaparib monotherapy for Asian patients with a germline BRCA mutation and HER2-negative metastatic breast cancer: OlympiAD randomized trial subgroup analysis. Scientific Reports2020;10(1):8753. ImSA , XuB , LiW , RobsonM , OuyangQ , YehDC , et al. Olaparib monotherapy versus chemotherapy for patients with HER2-negative metastatic breast cancer and a germline BRCA mutation: Asian subgroup analysis from the phase III OlympiAD trial. Cancer Research2018;78(Suppl 4):Abstract nr P5-21-13. MerensC , BannisterW , BergnerS , HettleR , McCreaC , McCutcheonS , et al. Impact of olaparib versus chemotherapy on the use of strong pain medications in gBRCA-mutated HER2-negative metastatic breast cancer and associated patient reported outcomes. Cancer Research2020;80(Suppl 4):Abstract nr P6-13-05. RobsonM , HettleR , DegboeA , SaundersO , CainT , KilvertH , et al. Estimating the health state utility of patients with HER2–gBRCA+ metastatic breast cancer treated with olaparib or chemotherapy via a mapping analysis of EORTC QLQ-C30 data collected in the Olympiad clinical trial. Value in Health2018;21(Suppl 1):S12. RobsonM , ImSA , SenkusE , XuB , DomchekS , MasudaN , et al. OlympiAD extended follow-up for overall survival and safety: olaparib versus chemotherapy treatment of physician’s choice in patients with a germline BRCA mutation and HER2-negative metastatic breast cancer. Cancer Research2020;80(Suppl 4):Abstract nr PD4-03. RobsonM , ImSA , SenkusE , XuB , DomchekSM , MasudaN , et al. Olaparib for metastatic breast cancer in patients with a germline BRCA mutation. New England Journal of Medicine2017;377(6):523-33. RobsonM , RuddyKJ , ImSA , SenkusE , XuB , DomchekSM , et al. Patient-reported outcomes in patients with a germline BRCA mutation and HER2-negative metastatic breast cancer receiving olaparib versus chemotherapy in the OlympiAD trial. European Journal of Cancer2019;120:20-30. RobsonM , RuddyKJ , ImSA , Senkus-KonefkaE , XuB , DomchekSM , et al. OlympiAD: health-related quality of life (HRQoL) in patients with HER2-negative metastatic breast cancer (mBC) and a germline BRCA mutation (gBRCAm) receiving olaparib monotherapy vs standard single-agent chemotherapy treatment of physician’s choice (TPC). Annals of Oncology2017;28(Suppl 5):v74-v108. RobsonME , ImSA , SenkusE , XuB , DomchekS , MasudaN , et al. Abstract CT038: OlympiAD final overall survival: olaparib versus chemotherapy treatment of physician's choice (TPC) in patients with HER2-negative metastatic breast cancer (mBC) and a germline BRCA mutation (gBRCAm). American Association for Cancer Research2018;78(Suppl 13):CT038. RobsonME , ImSA , SenkusE , XuB , DomchekSM , MasudaN , et al. OlympiAD: phase III trial of olaparib monotherapy versus chemotherapy for patients (pts) with HER2-negative metastatic breast cancer (mBC) and a germline BRCA mutation (gBRCAm). Journal of Clinical Oncology2017;35(Suppl 18):LBA4-LBA4. RobsonME , RuddyKJ , ImSA , Senkus-KonefkaE , XuB , DomchekSM , et al. EORTC QLQ-C30 (QLQ-C30) symptoms in patients (pts) with HER2-negative metastatic breast cancer (mBC) and a germline BRCA mutation (gBRCAm) receiving olaparib vs chemotherapy treatment of physician’s choice (TPC) in OlympiAD. Journal of Clinical Oncology2018;36(Suppl 15):1045. RobsonME , TungN , ConteP , ImSA , SenkusE , XuB , et al. OlympiAD final overall survival and tolerability results: olaparib versus chemotherapy treatment of physician’s choice in patients with a germline BRCA mutation and HER2-negative metastatic breast cancer. Annals of Oncology2019;30(4):558-66. Senkus-KonefkaE , DomchekSM , ImSA , XuB , ArmstrongA , MasudaN , et al. Subgroup analysis of olaparib monotherapy versus chemotherapy by hormone receptor and BRCA mutation status in patients with HER2-negative metastatic breast cancer and a germline BRCA mutation: OlympiAD. European Journal of Cancer2018;92:S19-20. TungNM , ImSA , Senkus-KonefkaE , XuB , DomchekSM , MasudaN , et al. Olaparib versus chemotherapy treatment of physician’s choice in patients with a germline BRCA mutation and HER2-negative metastatic breast cancer (OlympiAD): efficacy in patients with visceral metastases. Journal of Clinical Oncology2018;36(Suppl 15):1053. ">OLYMPIAD</a> for progression‐free survival and overall response rate outcomes were judged as being at low risk of bias as radiological assessment was performed by blinded independent central reviews. <a href="./references#CD011395-bbs2-0005" title="KummarS , WadeJL , OzaAM , SullivanD , ChenAP , GandaraDR , et al. Randomized phase II trial of cyclophosphamide and the oral poly (ADP-ribose) polymerase inhibitor veliparib in patients with recurrent, advanced triple-negative breast cancer. Investigational New Drugs2016;34(3):355–63. ">Kummar 2016</a> had an unclear risk of bias for this domain as it was not stated whether radiological assessment was performed in a blinded fashion or not. </p> <p>For the two studies that reported quality of life data (<a href="./references#CD011395-bbs2-0004" title="DiabS , RugoHS , MinaLA , PuhallaS , MahtaniRL , HenryNL , et al. Efficacy and safety of talazoparib (TALA) or physician's choice of therapy (PCT) in United States patients (pts) with HER2- germline BRCA1/2-mutated (gBRCAm) locally advanced/metastatic breast cancer (LA/MBC) in the EMBRACA study. Journal of Clinical Oncology2019;37(Suppl 15):1044. EiermannW , RugoHS , DiabS , EttlJ , HurvitzSA , GoncalvesA , et al. Analysis of germline BRCA1/2 mutated (g BRCAmut) hormone receptor-positive (HR+) and triple-negative breast cancer (TNBC) treated with talazoparib (TALA). Journal of Clinical Oncology2018;36(Suppl 15):1070. EttlJ , HurvitzSA , RugoHS , LeeKH , MinaLA , WoodwardNE , et al. Outcomes of talazoparib (TALA) versus physician's choice of chemotherapy (PCT) in patients (pts) with advanced breast cancer (ABC) and a germline BRCA (gBRCA) mutation by line of chemotherapy (CT) in the EMBRACA trial. Journal of Clinical Oncology2019;37(Suppl 15):1071. EttlJ , QuekRG , BhattacharyyaH , RugoHS , HurvitzSA , GonçalvesA . Patient Reported Outcomes (PRO) in patients (pts) with HER2-advanced breast cancer (ABC) and a germline BRCA1/2 mutation (gBRCAm) receiving talazoparib (TALA) vs physician’s choice chemotherapy (PCT) in the EMBRACA trial: a focus on subgroups with/without visceral disease. Annals of Oncology2019;30(Suppl 5):v129–30. EttlJ , QuekRG , HurvitzSA , GoncalvesA , TudorIC , RugoHS . Hospitalization and supportive care medication (SCM) utilisation in patients (pts) with advanced breast cancer (ABC) and a germline BRCA1/2 mutation (gBRCAm) in EMBRACA. Annals of Oncology2019;30(Suppl 3):iii52. EttlJ , QuekRG , LeeKH , RugoHS , HurvitzS , GonçalvesA , et al. Quality of life with talazoparib versus physician’s choice of chemotherapy in patients with advanced breast cancer and germline BRCA1/2 mutation: patient-reported outcomes from the EMBRACA phase III trial. Annals of Oncology2018;29(9):1939-47. FaschingPA , QuekRG , BhattacharyyaH , HurvitzSA , RugoHS , EttlJ . Impact of objective response (OR) on patient-reported outcomes (PRO) in patients (pts) with advanced breast cancer (ABC) and a germline BRCA1/2 (gBRCA) mutation in the phase III EMBRACA trial. Annals of Oncology2019;30(Suppl 3):iii49. GonçalvesA , EiermannW , RugoHS , EttlJ , HurvitzSA , YerushalmiR , et al. EMBRACA: Efficacy and safety in comparing talazoparib (TALA) with physician's choice of therapy (PCT) in patients (pts) with advanced breast cancer (aBC) and a germline BRCA mutation (gBRCAm); BRCA1/BRCA2 subgroup analysis. Annals of Oncology2018;29(Suppl 8):viii96–7. GoncalvesA , QuekRGW , BhattacharyyaH , EttlJ , HurvitzSA , RugoHS . Patient-reported outcomes (PRO) in patients (pts) with Her2-advanced breast cancer (ABC) receiving talazoparib (TALA) vs physician's choice chemotherapy (PCT): a focus on EMBRACA germline BRCA1 and BRCA2 mutation (gBRCA1/2m) subgroups. Breast2019;48(Suppl 2):S71. HurvitzSA , GoncalvesA , RugoHS , LeeKH , FehrenbacherL , MinaLA , et al. Talazoparib in patients with a germline BRCA-mutated advanced breast cancer: detailed safety analyses from the phase III EMBRACA Trial. Oncologist2019;25(3):e439-50. LeeKH , KimSB , SohnJ , GoodwinA , UsariT , LanzaloneS , et al. Talazoparib (TALA) vs physician’s choice of chemotherapy (PCT) in Asian patients (Pts) with HER2- advanced breast cancer (ABC) and a germline BRCA1/2 mutation (gBRCA1/2mut): data from phase III EMBRACA. Annals of Oncology2019;30(9):ix14. LittonJ , EttlJ , HurvitzSA , MinaLA , RugoHS , LeeKH , et al. A phase 3, open-label, randomized, 2-arm international study of the oral dual PARP inhibitor talazoparib in germline BRCA mutation subjects with locally advanced and/or metastatic breast cancer (EMBRACA). Cancer Research2017;77(Suppl 4):Abstract nr OT2-01-13. LittonJ , RugoHS , EttlJ , HurvitzS , GoncalvesA , LeeKH , et al. EMBRACA: a phase 3 trial comparing talazoparib, an oral PARP inhibitor, to physicianʼs choice of therapy in patients with advanced breast cancer and a germline BRCA mutation [abstract]. In: San Antonio Breast Cancer Symposium; 2017 Dec 5-9; San Antonio (TX). San Antonio (TX), 2017. LittonJK , HurvitzSA , MinaLA , RugoHS , LeeKH , GonçalvesA , et al. Talazoparib (TALA) in germline BRCA1/2 (gBRCA1/2)-mutated human epidermal growth factor receptor 2 negative (HER2-) advanced breast cancer (ABC): final overall survival (OS) results from randomized phase 3 EMBRACA trial. Cancer Research2020;80(Suppl 16):Abstract no. CT071. LittonJK , RugoHS , EttlJ , HurvitzSA , GonçalvesA , LeeKH , et al. Talazoparib in patients with advanced breast cancer and a germline BRCA mutation. New England Journal of Medicine2018;379(8):753-63. MartínM , EiermannW , RugoHS , EttlJ , HurvitzSA , GonçalvesA , et al. EMBRACA: Comparison of efficacy and safety of talazoparib (TALA) and physician's choice of therapy (PCT) in patients (pts) with advanced breast cancer (aBC), a germline BRCA1/2 mutation (gBRCAm), and prior platinum treatment. Annals of Oncology2018;29(Suppl 8):viii96. MinaL , LeeKH , GoncalvesA , WoodwardN , HurvitzSA , DiabS , et al. EMBRACA: efficacy and safety of talazoparib or physician's choice of therapy in patients with advanced breast cancer and a germline BRCA1/2 mutation: a regional analysis. Cancer Research2019;79(Suppl 4):Abstract nr P6-18-12. QuekR , BhattacharyyaH , HurvitzS , GoncalvesA , EttlJ , RugoH . Patient-reported outcomes in patients with HER2-advanced breast cancer and a germline BRCA1/2 mutation receiving talazoparib versus physician's choice chemotherapy: a focus on EMBRACA age subgroups. Journal of Managed Care and Specialty Pharmacy2019;25(Suppl 10A):S37-8. QuekRGW , BhattacharyyaH , GoncalvesA , RugoHS , HurvitzSA , EttlJ . Pcn491 Patient reported outcomes (PRO) of talazoparib (TALA) versus physician's choice of chemotherapy (PCT) in patients (pts) with advanced breast cancer (aBC) and a germline BRCA (gBRCa) mutation: a focus on Embraca pts with/without prior chemotherapy (CT) subgroups. Value in Health2019;22(Suppl 3):S532. RugoHS , EttlJ , HurvitzSA , GoncalvesA , LeeKH , FehrenbacherL , et al. Outcomes in clinically relevant patient subgroups from the EMBRACA study: talazoparib vs physician's choice standard-of-care chemotherapy. Journal of the National Cancer Institute Cancer Spectrum2020;4(1):pkz085. RugoHS , EttlJ , WoodwardNE , HurvitzSA , GoncalvesA , LeeKH , et al. EMBRACA: efficacy outcomes in clinically relevant subgroups comparing talazoparib (TALA), an oral poly ADP ribose polymerase (PARP) inhibitor, to physician's choice of therapy (PCT) in patients with advanced breast cancer and a germline BRCA mutation. Journal of Clinical Oncology2018;36(Suppl 15):1069. RugoHS , QuekR , EttlJ , HurvitzSA , BhattacharyyaH , HannahAL , et al. Patient-reported outcomes (PRO) in patients (pts) with advanced breast cancer and a germline BRCA1/2 mutation (gBRCAm) receiving talazoparib (TALA) vs physician’s choice chemotherapy treatment (PCT): a focus on the EMBRACA triple negative (TNBC) subpopulation. Annals of Oncology2018;29(Suppl 8):viii91. YuY , ElmeliegyM , LittonJK , TudorIC , CzibereA , ZhengJ , et al. Exposure-efficacy progression-free survival (PFS) analyses of breast cancer patients with germline BRCA1/2 mutations receiving talazoparib in the phase III EMBRACA trial. Annals of Oncology2018;29(Suppl 8):viii97. YuY , ElmeliegyM , LittonJK , TudorIC , CzibereA , ZhengJ , et al. Talazoparib exposure-efficacy analysis in patients with advanced breast cancer and germline BRCA1/2 mutations in the EMBRACA trial. Journal of Clinical Pharmacology2020;60(10):1324-33. ">EMBRACA</a>; <a href="./references#CD011395-bbs2-0006" title="DelalogeS , ContePF , ImS , Senkus-KonefkaE , XuB , DomchekSM , et al. OlympiAD: further efficacy outcomes in patients with HER2-negative metastatic breast cancer and a germline BRCA mutation receiving olaparib monotherapy vs standard single-agent chemotherapy treatment of physician’s choice. Annals of Oncology2017;28(Suppl 5):v74-v108. DomchekS , RobsonM , ImS , SenkusE , XuB , MasudaN , et al. Tolerability of olaparib monotherapy versus chemotherapy in patients with HER2-negative metastatic breast cancer and a germline BRCA mutation: OlympiAD. Cancer Research2018;78(Suppl 4):Abstract nr P5-21-12. ImSA , XuB , LiW , RobsonM , OuyangQ , YehDC , et al. Olaparib monotherapy for Asian patients with a germline BRCA mutation and HER2-negative metastatic breast cancer: OlympiAD randomized trial subgroup analysis. Scientific Reports2020;10(1):8753. ImSA , XuB , LiW , RobsonM , OuyangQ , YehDC , et al. Olaparib monotherapy versus chemotherapy for patients with HER2-negative metastatic breast cancer and a germline BRCA mutation: Asian subgroup analysis from the phase III OlympiAD trial. Cancer Research2018;78(Suppl 4):Abstract nr P5-21-13. MerensC , BannisterW , BergnerS , HettleR , McCreaC , McCutcheonS , et al. Impact of olaparib versus chemotherapy on the use of strong pain medications in gBRCA-mutated HER2-negative metastatic breast cancer and associated patient reported outcomes. Cancer Research2020;80(Suppl 4):Abstract nr P6-13-05. RobsonM , HettleR , DegboeA , SaundersO , CainT , KilvertH , et al. Estimating the health state utility of patients with HER2–gBRCA+ metastatic breast cancer treated with olaparib or chemotherapy via a mapping analysis of EORTC QLQ-C30 data collected in the Olympiad clinical trial. Value in Health2018;21(Suppl 1):S12. RobsonM , ImSA , SenkusE , XuB , DomchekS , MasudaN , et al. OlympiAD extended follow-up for overall survival and safety: olaparib versus chemotherapy treatment of physician’s choice in patients with a germline BRCA mutation and HER2-negative metastatic breast cancer. Cancer Research2020;80(Suppl 4):Abstract nr PD4-03. RobsonM , ImSA , SenkusE , XuB , DomchekSM , MasudaN , et al. Olaparib for metastatic breast cancer in patients with a germline BRCA mutation. New England Journal of Medicine2017;377(6):523-33. RobsonM , RuddyKJ , ImSA , SenkusE , XuB , DomchekSM , et al. Patient-reported outcomes in patients with a germline BRCA mutation and HER2-negative metastatic breast cancer receiving olaparib versus chemotherapy in the OlympiAD trial. European Journal of Cancer2019;120:20-30. RobsonM , RuddyKJ , ImSA , Senkus-KonefkaE , XuB , DomchekSM , et al. OlympiAD: health-related quality of life (HRQoL) in patients with HER2-negative metastatic breast cancer (mBC) and a germline BRCA mutation (gBRCAm) receiving olaparib monotherapy vs standard single-agent chemotherapy treatment of physician’s choice (TPC). Annals of Oncology2017;28(Suppl 5):v74-v108. RobsonME , ImSA , SenkusE , XuB , DomchekS , MasudaN , et al. Abstract CT038: OlympiAD final overall survival: olaparib versus chemotherapy treatment of physician's choice (TPC) in patients with HER2-negative metastatic breast cancer (mBC) and a germline BRCA mutation (gBRCAm). American Association for Cancer Research2018;78(Suppl 13):CT038. RobsonME , ImSA , SenkusE , XuB , DomchekSM , MasudaN , et al. OlympiAD: phase III trial of olaparib monotherapy versus chemotherapy for patients (pts) with HER2-negative metastatic breast cancer (mBC) and a germline BRCA mutation (gBRCAm). Journal of Clinical Oncology2017;35(Suppl 18):LBA4-LBA4. RobsonME , RuddyKJ , ImSA , Senkus-KonefkaE , XuB , DomchekSM , et al. EORTC QLQ-C30 (QLQ-C30) symptoms in patients (pts) with HER2-negative metastatic breast cancer (mBC) and a germline BRCA mutation (gBRCAm) receiving olaparib vs chemotherapy treatment of physician’s choice (TPC) in OlympiAD. Journal of Clinical Oncology2018;36(Suppl 15):1045. RobsonME , TungN , ConteP , ImSA , SenkusE , XuB , et al. OlympiAD final overall survival and tolerability results: olaparib versus chemotherapy treatment of physician’s choice in patients with a germline BRCA mutation and HER2-negative metastatic breast cancer. Annals of Oncology2019;30(4):558-66. Senkus-KonefkaE , DomchekSM , ImSA , XuB , ArmstrongA , MasudaN , et al. Subgroup analysis of olaparib monotherapy versus chemotherapy by hormone receptor and BRCA mutation status in patients with HER2-negative metastatic breast cancer and a germline BRCA mutation: OlympiAD. European Journal of Cancer2018;92:S19-20. TungNM , ImSA , Senkus-KonefkaE , XuB , DomchekSM , MasudaN , et al. Olaparib versus chemotherapy treatment of physician’s choice in patients with a germline BRCA mutation and HER2-negative metastatic breast cancer (OlympiAD): efficacy in patients with visceral metastases. Journal of Clinical Oncology2018;36(Suppl 15):1053. ">OLYMPIAD</a>), this outcome was judged as being at high risk of bias for both as both the studies were open‐label. In regards to adverse events, <a href="./references#CD011395-bbs2-0004" title="DiabS , RugoHS , MinaLA , PuhallaS , MahtaniRL , HenryNL , et al. Efficacy and safety of talazoparib (TALA) or physician's choice of therapy (PCT) in United States patients (pts) with HER2- germline BRCA1/2-mutated (gBRCAm) locally advanced/metastatic breast cancer (LA/MBC) in the EMBRACA study. Journal of Clinical Oncology2019;37(Suppl 15):1044. EiermannW , RugoHS , DiabS , EttlJ , HurvitzSA , GoncalvesA , et al. Analysis of germline BRCA1/2 mutated (g BRCAmut) hormone receptor-positive (HR+) and triple-negative breast cancer (TNBC) treated with talazoparib (TALA). Journal of Clinical Oncology2018;36(Suppl 15):1070. EttlJ , HurvitzSA , RugoHS , LeeKH , MinaLA , WoodwardNE , et al. Outcomes of talazoparib (TALA) versus physician's choice of chemotherapy (PCT) in patients (pts) with advanced breast cancer (ABC) and a germline BRCA (gBRCA) mutation by line of chemotherapy (CT) in the EMBRACA trial. Journal of Clinical Oncology2019;37(Suppl 15):1071. EttlJ , QuekRG , BhattacharyyaH , RugoHS , HurvitzSA , GonçalvesA . Patient Reported Outcomes (PRO) in patients (pts) with HER2-advanced breast cancer (ABC) and a germline BRCA1/2 mutation (gBRCAm) receiving talazoparib (TALA) vs physician’s choice chemotherapy (PCT) in the EMBRACA trial: a focus on subgroups with/without visceral disease. Annals of Oncology2019;30(Suppl 5):v129–30. EttlJ , QuekRG , HurvitzSA , GoncalvesA , TudorIC , RugoHS . Hospitalization and supportive care medication (SCM) utilisation in patients (pts) with advanced breast cancer (ABC) and a germline BRCA1/2 mutation (gBRCAm) in EMBRACA. Annals of Oncology2019;30(Suppl 3):iii52. EttlJ , QuekRG , LeeKH , RugoHS , HurvitzS , GonçalvesA , et al. Quality of life with talazoparib versus physician’s choice of chemotherapy in patients with advanced breast cancer and germline BRCA1/2 mutation: patient-reported outcomes from the EMBRACA phase III trial. Annals of Oncology2018;29(9):1939-47. FaschingPA , QuekRG , BhattacharyyaH , HurvitzSA , RugoHS , EttlJ . Impact of objective response (OR) on patient-reported outcomes (PRO) in patients (pts) with advanced breast cancer (ABC) and a germline BRCA1/2 (gBRCA) mutation in the phase III EMBRACA trial. Annals of Oncology2019;30(Suppl 3):iii49. GonçalvesA , EiermannW , RugoHS , EttlJ , HurvitzSA , YerushalmiR , et al. EMBRACA: Efficacy and safety in comparing talazoparib (TALA) with physician's choice of therapy (PCT) in patients (pts) with advanced breast cancer (aBC) and a germline BRCA mutation (gBRCAm); BRCA1/BRCA2 subgroup analysis. Annals of Oncology2018;29(Suppl 8):viii96–7. GoncalvesA , QuekRGW , BhattacharyyaH , EttlJ , HurvitzSA , RugoHS . Patient-reported outcomes (PRO) in patients (pts) with Her2-advanced breast cancer (ABC) receiving talazoparib (TALA) vs physician's choice chemotherapy (PCT): a focus on EMBRACA germline BRCA1 and BRCA2 mutation (gBRCA1/2m) subgroups. Breast2019;48(Suppl 2):S71. HurvitzSA , GoncalvesA , RugoHS , LeeKH , FehrenbacherL , MinaLA , et al. Talazoparib in patients with a germline BRCA-mutated advanced breast cancer: detailed safety analyses from the phase III EMBRACA Trial. Oncologist2019;25(3):e439-50. LeeKH , KimSB , SohnJ , GoodwinA , UsariT , LanzaloneS , et al. Talazoparib (TALA) vs physician’s choice of chemotherapy (PCT) in Asian patients (Pts) with HER2- advanced breast cancer (ABC) and a germline BRCA1/2 mutation (gBRCA1/2mut): data from phase III EMBRACA. Annals of Oncology2019;30(9):ix14. LittonJ , EttlJ , HurvitzSA , MinaLA , RugoHS , LeeKH , et al. A phase 3, open-label, randomized, 2-arm international study of the oral dual PARP inhibitor talazoparib in germline BRCA mutation subjects with locally advanced and/or metastatic breast cancer (EMBRACA). Cancer Research2017;77(Suppl 4):Abstract nr OT2-01-13. LittonJ , RugoHS , EttlJ , HurvitzS , GoncalvesA , LeeKH , et al. EMBRACA: a phase 3 trial comparing talazoparib, an oral PARP inhibitor, to physicianʼs choice of therapy in patients with advanced breast cancer and a germline BRCA mutation [abstract]. In: San Antonio Breast Cancer Symposium; 2017 Dec 5-9; San Antonio (TX). San Antonio (TX), 2017. LittonJK , HurvitzSA , MinaLA , RugoHS , LeeKH , GonçalvesA , et al. Talazoparib (TALA) in germline BRCA1/2 (gBRCA1/2)-mutated human epidermal growth factor receptor 2 negative (HER2-) advanced breast cancer (ABC): final overall survival (OS) results from randomized phase 3 EMBRACA trial. Cancer Research2020;80(Suppl 16):Abstract no. CT071. LittonJK , RugoHS , EttlJ , HurvitzSA , GonçalvesA , LeeKH , et al. Talazoparib in patients with advanced breast cancer and a germline BRCA mutation. New England Journal of Medicine2018;379(8):753-63. MartínM , EiermannW , RugoHS , EttlJ , HurvitzSA , GonçalvesA , et al. EMBRACA: Comparison of efficacy and safety of talazoparib (TALA) and physician's choice of therapy (PCT) in patients (pts) with advanced breast cancer (aBC), a germline BRCA1/2 mutation (gBRCAm), and prior platinum treatment. Annals of Oncology2018;29(Suppl 8):viii96. MinaL , LeeKH , GoncalvesA , WoodwardN , HurvitzSA , DiabS , et al. EMBRACA: efficacy and safety of talazoparib or physician's choice of therapy in patients with advanced breast cancer and a germline BRCA1/2 mutation: a regional analysis. Cancer Research2019;79(Suppl 4):Abstract nr P6-18-12. QuekR , BhattacharyyaH , HurvitzS , GoncalvesA , EttlJ , RugoH . Patient-reported outcomes in patients with HER2-advanced breast cancer and a germline BRCA1/2 mutation receiving talazoparib versus physician's choice chemotherapy: a focus on EMBRACA age subgroups. Journal of Managed Care and Specialty Pharmacy2019;25(Suppl 10A):S37-8. QuekRGW , BhattacharyyaH , GoncalvesA , RugoHS , HurvitzSA , EttlJ . Pcn491 Patient reported outcomes (PRO) of talazoparib (TALA) versus physician's choice of chemotherapy (PCT) in patients (pts) with advanced breast cancer (aBC) and a germline BRCA (gBRCa) mutation: a focus on Embraca pts with/without prior chemotherapy (CT) subgroups. Value in Health2019;22(Suppl 3):S532. RugoHS , EttlJ , HurvitzSA , GoncalvesA , LeeKH , FehrenbacherL , et al. Outcomes in clinically relevant patient subgroups from the EMBRACA study: talazoparib vs physician's choice standard-of-care chemotherapy. Journal of the National Cancer Institute Cancer Spectrum2020;4(1):pkz085. RugoHS , EttlJ , WoodwardNE , HurvitzSA , GoncalvesA , LeeKH , et al. EMBRACA: efficacy outcomes in clinically relevant subgroups comparing talazoparib (TALA), an oral poly ADP ribose polymerase (PARP) inhibitor, to physician's choice of therapy (PCT) in patients with advanced breast cancer and a germline BRCA mutation. Journal of Clinical Oncology2018;36(Suppl 15):1069. RugoHS , QuekR , EttlJ , HurvitzSA , BhattacharyyaH , HannahAL , et al. Patient-reported outcomes (PRO) in patients (pts) with advanced breast cancer and a germline BRCA1/2 mutation (gBRCAm) receiving talazoparib (TALA) vs physician’s choice chemotherapy treatment (PCT): a focus on the EMBRACA triple negative (TNBC) subpopulation. Annals of Oncology2018;29(Suppl 8):viii91. YuY , ElmeliegyM , LittonJK , TudorIC , CzibereA , ZhengJ , et al. Exposure-efficacy progression-free survival (PFS) analyses of breast cancer patients with germline BRCA1/2 mutations receiving talazoparib in the phase III EMBRACA trial. Annals of Oncology2018;29(Suppl 8):viii97. YuY , ElmeliegyM , LittonJK , TudorIC , CzibereA , ZhengJ , et al. Talazoparib exposure-efficacy analysis in patients with advanced breast cancer and germline BRCA1/2 mutations in the EMBRACA trial. Journal of Clinical Pharmacology2020;60(10):1324-33. ">EMBRACA</a>; <a href="./references#CD011395-bbs2-0005" title="KummarS , WadeJL , OzaAM , SullivanD , ChenAP , GandaraDR , et al. Randomized phase II trial of cyclophosphamide and the oral poly (ADP-ribose) polymerase inhibitor veliparib in patients with recurrent, advanced triple-negative breast cancer. Investigational New Drugs2016;34(3):355–63. ">Kummar 2016</a> and <a href="./references#CD011395-bbs2-0006" title="DelalogeS , ContePF , ImS , Senkus-KonefkaE , XuB , DomchekSM , et al. OlympiAD: further efficacy outcomes in patients with HER2-negative metastatic breast cancer and a germline BRCA mutation receiving olaparib monotherapy vs standard single-agent chemotherapy treatment of physician’s choice. Annals of Oncology2017;28(Suppl 5):v74-v108. DomchekS , RobsonM , ImS , SenkusE , XuB , MasudaN , et al. Tolerability of olaparib monotherapy versus chemotherapy in patients with HER2-negative metastatic breast cancer and a germline BRCA mutation: OlympiAD. Cancer Research2018;78(Suppl 4):Abstract nr P5-21-12. ImSA , XuB , LiW , RobsonM , OuyangQ , YehDC , et al. Olaparib monotherapy for Asian patients with a germline BRCA mutation and HER2-negative metastatic breast cancer: OlympiAD randomized trial subgroup analysis. Scientific Reports2020;10(1):8753. ImSA , XuB , LiW , RobsonM , OuyangQ , YehDC , et al. Olaparib monotherapy versus chemotherapy for patients with HER2-negative metastatic breast cancer and a germline BRCA mutation: Asian subgroup analysis from the phase III OlympiAD trial. Cancer Research2018;78(Suppl 4):Abstract nr P5-21-13. MerensC , BannisterW , BergnerS , HettleR , McCreaC , McCutcheonS , et al. Impact of olaparib versus chemotherapy on the use of strong pain medications in gBRCA-mutated HER2-negative metastatic breast cancer and associated patient reported outcomes. Cancer Research2020;80(Suppl 4):Abstract nr P6-13-05. RobsonM , HettleR , DegboeA , SaundersO , CainT , KilvertH , et al. Estimating the health state utility of patients with HER2–gBRCA+ metastatic breast cancer treated with olaparib or chemotherapy via a mapping analysis of EORTC QLQ-C30 data collected in the Olympiad clinical trial. Value in Health2018;21(Suppl 1):S12. RobsonM , ImSA , SenkusE , XuB , DomchekS , MasudaN , et al. OlympiAD extended follow-up for overall survival and safety: olaparib versus chemotherapy treatment of physician’s choice in patients with a germline BRCA mutation and HER2-negative metastatic breast cancer. Cancer Research2020;80(Suppl 4):Abstract nr PD4-03. RobsonM , ImSA , SenkusE , XuB , DomchekSM , MasudaN , et al. Olaparib for metastatic breast cancer in patients with a germline BRCA mutation. New England Journal of Medicine2017;377(6):523-33. RobsonM , RuddyKJ , ImSA , SenkusE , XuB , DomchekSM , et al. Patient-reported outcomes in patients with a germline BRCA mutation and HER2-negative metastatic breast cancer receiving olaparib versus chemotherapy in the OlympiAD trial. European Journal of Cancer2019;120:20-30. RobsonM , RuddyKJ , ImSA , Senkus-KonefkaE , XuB , DomchekSM , et al. OlympiAD: health-related quality of life (HRQoL) in patients with HER2-negative metastatic breast cancer (mBC) and a germline BRCA mutation (gBRCAm) receiving olaparib monotherapy vs standard single-agent chemotherapy treatment of physician’s choice (TPC). Annals of Oncology2017;28(Suppl 5):v74-v108. RobsonME , ImSA , SenkusE , XuB , DomchekS , MasudaN , et al. Abstract CT038: OlympiAD final overall survival: olaparib versus chemotherapy treatment of physician's choice (TPC) in patients with HER2-negative metastatic breast cancer (mBC) and a germline BRCA mutation (gBRCAm). American Association for Cancer Research2018;78(Suppl 13):CT038. RobsonME , ImSA , SenkusE , XuB , DomchekSM , MasudaN , et al. OlympiAD: phase III trial of olaparib monotherapy versus chemotherapy for patients (pts) with HER2-negative metastatic breast cancer (mBC) and a germline BRCA mutation (gBRCAm). Journal of Clinical Oncology2017;35(Suppl 18):LBA4-LBA4. RobsonME , RuddyKJ , ImSA , Senkus-KonefkaE , XuB , DomchekSM , et al. EORTC QLQ-C30 (QLQ-C30) symptoms in patients (pts) with HER2-negative metastatic breast cancer (mBC) and a germline BRCA mutation (gBRCAm) receiving olaparib vs chemotherapy treatment of physician’s choice (TPC) in OlympiAD. Journal of Clinical Oncology2018;36(Suppl 15):1045. RobsonME , TungN , ConteP , ImSA , SenkusE , XuB , et al. OlympiAD final overall survival and tolerability results: olaparib versus chemotherapy treatment of physician’s choice in patients with a germline BRCA mutation and HER2-negative metastatic breast cancer. Annals of Oncology2019;30(4):558-66. Senkus-KonefkaE , DomchekSM , ImSA , XuB , ArmstrongA , MasudaN , et al. Subgroup analysis of olaparib monotherapy versus chemotherapy by hormone receptor and BRCA mutation status in patients with HER2-negative metastatic breast cancer and a germline BRCA mutation: OlympiAD. European Journal of Cancer2018;92:S19-20. TungNM , ImSA , Senkus-KonefkaE , XuB , DomchekSM , MasudaN , et al. Olaparib versus chemotherapy treatment of physician’s choice in patients with a germline BRCA mutation and HER2-negative metastatic breast cancer (OlympiAD): efficacy in patients with visceral metastases. Journal of Clinical Oncology2018;36(Suppl 15):1053. ">OLYMPIAD</a> were judged as being at high risk of detection bias given the studies were open‐label. <a href="./references#CD011395-bbs2-0002" title="DiérasV , HanHS , RobsonME , PalacovaM , MarcomPK , JagerA , et al. Evaluation of veliparib (V) and temozolomide (TMZ) in a phase 2 randomized study of the efficacy and tolerability of V+TMZ or carboplatin (C) and paclitaxel (P) vs placebo (Plc)+C/P in patients (pts) with BRCA1 or BRCA2 mutations and metastatic breast cancer. Cancer Research2017;77(Suppl 4):Abstract nr SABCS16-P4-22-02. HanHS , DiérasV , RobsonM , PalácováM , MarcomPK , Jager A et al. Veliparib with temozolomide or carboplatin/paclitaxel versus placebo with carboplatin/paclitaxel in patients with BRCA1/2 locally recurrent/metastatic breast cancer: randomized phase II study. Annals of Oncology2018;29(1):154-61. HanHS , DiérasV , RobsonME , PalácováM , MarcomPK , JagerA , et al. Efficacy and tolerability of veliparib (V; ABT-888) in combination with carboplatin (C) and paclitaxel (P) vs placebo (Plc)+C/P in patients (pts) with BRCA1 or BRCA2 mutations and metastatic breast cancer: a randomized, phase 2 study. Cancer Research2017;77(Suppl 4):Abstract nr SABCS16-S2-05. IsakoffSJ , PuhallaS , DomchekSM , FriedlanderM , KaufmanB , RobsonM , et al. A randomized Phase II study of veliparib with temozolomide or carboplatin/paclitaxel versus placebo with carboplatin/paclitaxel in BRCA1/2 metastatic breast cancer: design and rationale. Future Oncology2017;13(4):307-20. ">BROCADE 2</a> and <a href="./references#CD011395-bbs2-0003" title="ArunBK , HanHS , KaufmanB , WildiersH , FriedlanderM , AyoubJP , et al. First-line veliparib plus carboplatin/paclitaxel in patients with HER2-negative advanced/metastatic gBRCA-associated breast cancer: planned subgroup analysis from the phase 3 BROCADE3 trial. Cancer Research2020;80(Suppl 4):Abstract nr PD4-01. AyoubJP , FriedlanderML , DierasVC , WildiersH , ArunB , HanHS , et al. Veliparib plus carboplatin-paclitaxel in patients with HER2-negative advanced/metastatic gBRCA-associated breast cancer: results in hormone receptor-positive and triple-negative breast cancer subgroups from the phase III BROCADE3 trial. Annals of Oncology2020;31(Suppl 2):S65. DierasV , HanH , KaufmanB , WildiersH , FriedlanderM , AyoubJ , et al. A Phase 3 randomized, placebo-controlled trial of carboplatin and paclitaxel with or without the PARP inhibitor veliparib (ABT-888) in HER2-negative metastatic or locally advanced unresectable BRCA-associated breast cancer. Annals of Oncology2019;30(Suppl 5):v851-v934. ">BROCADE 3</a> had low risk of detection bias for adverse event reporting given that they were double‐blinded studies. </p> </section> <section id="CD011395-sec-0047"> <h4 class="title">Incomplete outcome data</h4> <p><a href="./references#CD011395-bbs2-0002" title="DiérasV , HanHS , RobsonME , PalacovaM , MarcomPK , JagerA , et al. Evaluation of veliparib (V) and temozolomide (TMZ) in a phase 2 randomized study of the efficacy and tolerability of V+TMZ or carboplatin (C) and paclitaxel (P) vs placebo (Plc)+C/P in patients (pts) with BRCA1 or BRCA2 mutations and metastatic breast cancer. Cancer Research2017;77(Suppl 4):Abstract nr SABCS16-P4-22-02. HanHS , DiérasV , RobsonM , PalácováM , MarcomPK , Jager A et al. Veliparib with temozolomide or carboplatin/paclitaxel versus placebo with carboplatin/paclitaxel in patients with BRCA1/2 locally recurrent/metastatic breast cancer: randomized phase II study. Annals of Oncology2018;29(1):154-61. HanHS , DiérasV , RobsonME , PalácováM , MarcomPK , JagerA , et al. Efficacy and tolerability of veliparib (V; ABT-888) in combination with carboplatin (C) and paclitaxel (P) vs placebo (Plc)+C/P in patients (pts) with BRCA1 or BRCA2 mutations and metastatic breast cancer: a randomized, phase 2 study. Cancer Research2017;77(Suppl 4):Abstract nr SABCS16-S2-05. IsakoffSJ , PuhallaS , DomchekSM , FriedlanderM , KaufmanB , RobsonM , et al. A randomized Phase II study of veliparib with temozolomide or carboplatin/paclitaxel versus placebo with carboplatin/paclitaxel in BRCA1/2 metastatic breast cancer: design and rationale. Future Oncology2017;13(4):307-20. ">BROCADE 2</a> and <a href="./references#CD011395-bbs2-0006" title="DelalogeS , ContePF , ImS , Senkus-KonefkaE , XuB , DomchekSM , et al. OlympiAD: further efficacy outcomes in patients with HER2-negative metastatic breast cancer and a germline BRCA mutation receiving olaparib monotherapy vs standard single-agent chemotherapy treatment of physician’s choice. Annals of Oncology2017;28(Suppl 5):v74-v108. DomchekS , RobsonM , ImS , SenkusE , XuB , MasudaN , et al. Tolerability of olaparib monotherapy versus chemotherapy in patients with HER2-negative metastatic breast cancer and a germline BRCA mutation: OlympiAD. Cancer Research2018;78(Suppl 4):Abstract nr P5-21-12. ImSA , XuB , LiW , RobsonM , OuyangQ , YehDC , et al. Olaparib monotherapy for Asian patients with a germline BRCA mutation and HER2-negative metastatic breast cancer: OlympiAD randomized trial subgroup analysis. Scientific Reports2020;10(1):8753. ImSA , XuB , LiW , RobsonM , OuyangQ , YehDC , et al. Olaparib monotherapy versus chemotherapy for patients with HER2-negative metastatic breast cancer and a germline BRCA mutation: Asian subgroup analysis from the phase III OlympiAD trial. Cancer Research2018;78(Suppl 4):Abstract nr P5-21-13. MerensC , BannisterW , BergnerS , HettleR , McCreaC , McCutcheonS , et al. Impact of olaparib versus chemotherapy on the use of strong pain medications in gBRCA-mutated HER2-negative metastatic breast cancer and associated patient reported outcomes. Cancer Research2020;80(Suppl 4):Abstract nr P6-13-05. RobsonM , HettleR , DegboeA , SaundersO , CainT , KilvertH , et al. Estimating the health state utility of patients with HER2–gBRCA+ metastatic breast cancer treated with olaparib or chemotherapy via a mapping analysis of EORTC QLQ-C30 data collected in the Olympiad clinical trial. Value in Health2018;21(Suppl 1):S12. RobsonM , ImSA , SenkusE , XuB , DomchekS , MasudaN , et al. OlympiAD extended follow-up for overall survival and safety: olaparib versus chemotherapy treatment of physician’s choice in patients with a germline BRCA mutation and HER2-negative metastatic breast cancer. Cancer Research2020;80(Suppl 4):Abstract nr PD4-03. RobsonM , ImSA , SenkusE , XuB , DomchekSM , MasudaN , et al. Olaparib for metastatic breast cancer in patients with a germline BRCA mutation. New England Journal of Medicine2017;377(6):523-33. RobsonM , RuddyKJ , ImSA , SenkusE , XuB , DomchekSM , et al. Patient-reported outcomes in patients with a germline BRCA mutation and HER2-negative metastatic breast cancer receiving olaparib versus chemotherapy in the OlympiAD trial. European Journal of Cancer2019;120:20-30. RobsonM , RuddyKJ , ImSA , Senkus-KonefkaE , XuB , DomchekSM , et al. OlympiAD: health-related quality of life (HRQoL) in patients with HER2-negative metastatic breast cancer (mBC) and a germline BRCA mutation (gBRCAm) receiving olaparib monotherapy vs standard single-agent chemotherapy treatment of physician’s choice (TPC). Annals of Oncology2017;28(Suppl 5):v74-v108. RobsonME , ImSA , SenkusE , XuB , DomchekS , MasudaN , et al. Abstract CT038: OlympiAD final overall survival: olaparib versus chemotherapy treatment of physician's choice (TPC) in patients with HER2-negative metastatic breast cancer (mBC) and a germline BRCA mutation (gBRCAm). American Association for Cancer Research2018;78(Suppl 13):CT038. RobsonME , ImSA , SenkusE , XuB , DomchekSM , MasudaN , et al. OlympiAD: phase III trial of olaparib monotherapy versus chemotherapy for patients (pts) with HER2-negative metastatic breast cancer (mBC) and a germline BRCA mutation (gBRCAm). Journal of Clinical Oncology2017;35(Suppl 18):LBA4-LBA4. RobsonME , RuddyKJ , ImSA , Senkus-KonefkaE , XuB , DomchekSM , et al. EORTC QLQ-C30 (QLQ-C30) symptoms in patients (pts) with HER2-negative metastatic breast cancer (mBC) and a germline BRCA mutation (gBRCAm) receiving olaparib vs chemotherapy treatment of physician’s choice (TPC) in OlympiAD. Journal of Clinical Oncology2018;36(Suppl 15):1045. RobsonME , TungN , ConteP , ImSA , SenkusE , XuB , et al. OlympiAD final overall survival and tolerability results: olaparib versus chemotherapy treatment of physician’s choice in patients with a germline BRCA mutation and HER2-negative metastatic breast cancer. Annals of Oncology2019;30(4):558-66. Senkus-KonefkaE , DomchekSM , ImSA , XuB , ArmstrongA , MasudaN , et al. Subgroup analysis of olaparib monotherapy versus chemotherapy by hormone receptor and BRCA mutation status in patients with HER2-negative metastatic breast cancer and a germline BRCA mutation: OlympiAD. European Journal of Cancer2018;92:S19-20. TungNM , ImSA , Senkus-KonefkaE , XuB , DomchekSM , MasudaN , et al. Olaparib versus chemotherapy treatment of physician’s choice in patients with a germline BRCA mutation and HER2-negative metastatic breast cancer (OlympiAD): efficacy in patients with visceral metastases. Journal of Clinical Oncology2018;36(Suppl 15):1053. ">OLYMPIAD</a> were assessed as being at low risk since missing outcome data was balanced and small in numbers across intervention groups. <a href="./references#CD011395-bbs2-0005" title="KummarS , WadeJL , OzaAM , SullivanD , ChenAP , GandaraDR , et al. Randomized phase II trial of cyclophosphamide and the oral poly (ADP-ribose) polymerase inhibitor veliparib in patients with recurrent, advanced triple-negative breast cancer. Investigational New Drugs2016;34(3):355–63. ">Kummar 2016</a> was judged as being at unclear risk of attrition bias as six of the 45 enrolled patients (more than 10%) were not evaluable. Given <a href="./references#CD011395-bbs2-0003" title="ArunBK , HanHS , KaufmanB , WildiersH , FriedlanderM , AyoubJP , et al. First-line veliparib plus carboplatin/paclitaxel in patients with HER2-negative advanced/metastatic gBRCA-associated breast cancer: planned subgroup analysis from the phase 3 BROCADE3 trial. Cancer Research2020;80(Suppl 4):Abstract nr PD4-01. AyoubJP , FriedlanderML , DierasVC , WildiersH , ArunB , HanHS , et al. Veliparib plus carboplatin-paclitaxel in patients with HER2-negative advanced/metastatic gBRCA-associated breast cancer: results in hormone receptor-positive and triple-negative breast cancer subgroups from the phase III BROCADE3 trial. Annals of Oncology2020;31(Suppl 2):S65. DierasV , HanH , KaufmanB , WildiersH , FriedlanderM , AyoubJ , et al. A Phase 3 randomized, placebo-controlled trial of carboplatin and paclitaxel with or without the PARP inhibitor veliparib (ABT-888) in HER2-negative metastatic or locally advanced unresectable BRCA-associated breast cancer. Annals of Oncology2019;30(Suppl 5):v851-v934. ">BROCADE 3</a> has been published in abstract form only to date and participant attrition data were not provided by the lead author by time of submission, this was judged as being at unclear risk. <a href="./references#CD011395-bbs2-0004" title="DiabS , RugoHS , MinaLA , PuhallaS , MahtaniRL , HenryNL , et al. Efficacy and safety of talazoparib (TALA) or physician's choice of therapy (PCT) in United States patients (pts) with HER2- germline BRCA1/2-mutated (gBRCAm) locally advanced/metastatic breast cancer (LA/MBC) in the EMBRACA study. Journal of Clinical Oncology2019;37(Suppl 15):1044. EiermannW , RugoHS , DiabS , EttlJ , HurvitzSA , GoncalvesA , et al. Analysis of germline BRCA1/2 mutated (g BRCAmut) hormone receptor-positive (HR+) and triple-negative breast cancer (TNBC) treated with talazoparib (TALA). Journal of Clinical Oncology2018;36(Suppl 15):1070. EttlJ , HurvitzSA , RugoHS , LeeKH , MinaLA , WoodwardNE , et al. Outcomes of talazoparib (TALA) versus physician's choice of chemotherapy (PCT) in patients (pts) with advanced breast cancer (ABC) and a germline BRCA (gBRCA) mutation by line of chemotherapy (CT) in the EMBRACA trial. Journal of Clinical Oncology2019;37(Suppl 15):1071. EttlJ , QuekRG , BhattacharyyaH , RugoHS , HurvitzSA , GonçalvesA . Patient Reported Outcomes (PRO) in patients (pts) with HER2-advanced breast cancer (ABC) and a germline BRCA1/2 mutation (gBRCAm) receiving talazoparib (TALA) vs physician’s choice chemotherapy (PCT) in the EMBRACA trial: a focus on subgroups with/without visceral disease. Annals of Oncology2019;30(Suppl 5):v129–30. EttlJ , QuekRG , HurvitzSA , GoncalvesA , TudorIC , RugoHS . Hospitalization and supportive care medication (SCM) utilisation in patients (pts) with advanced breast cancer (ABC) and a germline BRCA1/2 mutation (gBRCAm) in EMBRACA. Annals of Oncology2019;30(Suppl 3):iii52. EttlJ , QuekRG , LeeKH , RugoHS , HurvitzS , GonçalvesA , et al. Quality of life with talazoparib versus physician’s choice of chemotherapy in patients with advanced breast cancer and germline BRCA1/2 mutation: patient-reported outcomes from the EMBRACA phase III trial. Annals of Oncology2018;29(9):1939-47. FaschingPA , QuekRG , BhattacharyyaH , HurvitzSA , RugoHS , EttlJ . Impact of objective response (OR) on patient-reported outcomes (PRO) in patients (pts) with advanced breast cancer (ABC) and a germline BRCA1/2 (gBRCA) mutation in the phase III EMBRACA trial. Annals of Oncology2019;30(Suppl 3):iii49. GonçalvesA , EiermannW , RugoHS , EttlJ , HurvitzSA , YerushalmiR , et al. EMBRACA: Efficacy and safety in comparing talazoparib (TALA) with physician's choice of therapy (PCT) in patients (pts) with advanced breast cancer (aBC) and a germline BRCA mutation (gBRCAm); BRCA1/BRCA2 subgroup analysis. Annals of Oncology2018;29(Suppl 8):viii96–7. GoncalvesA , QuekRGW , BhattacharyyaH , EttlJ , HurvitzSA , RugoHS . Patient-reported outcomes (PRO) in patients (pts) with Her2-advanced breast cancer (ABC) receiving talazoparib (TALA) vs physician's choice chemotherapy (PCT): a focus on EMBRACA germline BRCA1 and BRCA2 mutation (gBRCA1/2m) subgroups. Breast2019;48(Suppl 2):S71. HurvitzSA , GoncalvesA , RugoHS , LeeKH , FehrenbacherL , MinaLA , et al. Talazoparib in patients with a germline BRCA-mutated advanced breast cancer: detailed safety analyses from the phase III EMBRACA Trial. Oncologist2019;25(3):e439-50. LeeKH , KimSB , SohnJ , GoodwinA , UsariT , LanzaloneS , et al. Talazoparib (TALA) vs physician’s choice of chemotherapy (PCT) in Asian patients (Pts) with HER2- advanced breast cancer (ABC) and a germline BRCA1/2 mutation (gBRCA1/2mut): data from phase III EMBRACA. Annals of Oncology2019;30(9):ix14. LittonJ , EttlJ , HurvitzSA , MinaLA , RugoHS , LeeKH , et al. A phase 3, open-label, randomized, 2-arm international study of the oral dual PARP inhibitor talazoparib in germline BRCA mutation subjects with locally advanced and/or metastatic breast cancer (EMBRACA). Cancer Research2017;77(Suppl 4):Abstract nr OT2-01-13. LittonJ , RugoHS , EttlJ , HurvitzS , GoncalvesA , LeeKH , et al. EMBRACA: a phase 3 trial comparing talazoparib, an oral PARP inhibitor, to physicianʼs choice of therapy in patients with advanced breast cancer and a germline BRCA mutation [abstract]. In: San Antonio Breast Cancer Symposium; 2017 Dec 5-9; San Antonio (TX). San Antonio (TX), 2017. LittonJK , HurvitzSA , MinaLA , RugoHS , LeeKH , GonçalvesA , et al. Talazoparib (TALA) in germline BRCA1/2 (gBRCA1/2)-mutated human epidermal growth factor receptor 2 negative (HER2-) advanced breast cancer (ABC): final overall survival (OS) results from randomized phase 3 EMBRACA trial. Cancer Research2020;80(Suppl 16):Abstract no. CT071. LittonJK , RugoHS , EttlJ , HurvitzSA , GonçalvesA , LeeKH , et al. Talazoparib in patients with advanced breast cancer and a germline BRCA mutation. New England Journal of Medicine2018;379(8):753-63. MartínM , EiermannW , RugoHS , EttlJ , HurvitzSA , GonçalvesA , et al. EMBRACA: Comparison of efficacy and safety of talazoparib (TALA) and physician's choice of therapy (PCT) in patients (pts) with advanced breast cancer (aBC), a germline BRCA1/2 mutation (gBRCAm), and prior platinum treatment. Annals of Oncology2018;29(Suppl 8):viii96. MinaL , LeeKH , GoncalvesA , WoodwardN , HurvitzSA , DiabS , et al. EMBRACA: efficacy and safety of talazoparib or physician's choice of therapy in patients with advanced breast cancer and a germline BRCA1/2 mutation: a regional analysis. Cancer Research2019;79(Suppl 4):Abstract nr P6-18-12. QuekR , BhattacharyyaH , HurvitzS , GoncalvesA , EttlJ , RugoH . Patient-reported outcomes in patients with HER2-advanced breast cancer and a germline BRCA1/2 mutation receiving talazoparib versus physician's choice chemotherapy: a focus on EMBRACA age subgroups. Journal of Managed Care and Specialty Pharmacy2019;25(Suppl 10A):S37-8. QuekRGW , BhattacharyyaH , GoncalvesA , RugoHS , HurvitzSA , EttlJ . Pcn491 Patient reported outcomes (PRO) of talazoparib (TALA) versus physician's choice of chemotherapy (PCT) in patients (pts) with advanced breast cancer (aBC) and a germline BRCA (gBRCa) mutation: a focus on Embraca pts with/without prior chemotherapy (CT) subgroups. Value in Health2019;22(Suppl 3):S532. RugoHS , EttlJ , HurvitzSA , GoncalvesA , LeeKH , FehrenbacherL , et al. Outcomes in clinically relevant patient subgroups from the EMBRACA study: talazoparib vs physician's choice standard-of-care chemotherapy. Journal of the National Cancer Institute Cancer Spectrum2020;4(1):pkz085. RugoHS , EttlJ , WoodwardNE , HurvitzSA , GoncalvesA , LeeKH , et al. EMBRACA: efficacy outcomes in clinically relevant subgroups comparing talazoparib (TALA), an oral poly ADP ribose polymerase (PARP) inhibitor, to physician's choice of therapy (PCT) in patients with advanced breast cancer and a germline BRCA mutation. Journal of Clinical Oncology2018;36(Suppl 15):1069. RugoHS , QuekR , EttlJ , HurvitzSA , BhattacharyyaH , HannahAL , et al. Patient-reported outcomes (PRO) in patients (pts) with advanced breast cancer and a germline BRCA1/2 mutation (gBRCAm) receiving talazoparib (TALA) vs physician’s choice chemotherapy treatment (PCT): a focus on the EMBRACA triple negative (TNBC) subpopulation. Annals of Oncology2018;29(Suppl 8):viii91. YuY , ElmeliegyM , LittonJK , TudorIC , CzibereA , ZhengJ , et al. Exposure-efficacy progression-free survival (PFS) analyses of breast cancer patients with germline BRCA1/2 mutations receiving talazoparib in the phase III EMBRACA trial. Annals of Oncology2018;29(Suppl 8):viii97. YuY , ElmeliegyM , LittonJK , TudorIC , CzibereA , ZhengJ , et al. Talazoparib exposure-efficacy analysis in patients with advanced breast cancer and germline BRCA1/2 mutations in the EMBRACA trial. Journal of Clinical Pharmacology2020;60(10):1324-33. ">EMBRACA</a> reported 19 patients (18 in the standard therapy group and one in the talazoparib group) who withdrew consent; this imbalance of attrition between the two arms led to a judgement of unclear attrition bias risk. </p> </section> <section id="CD011395-sec-0048"> <h4 class="title">Selective reporting</h4> <p>All five studies were judged as being at low risk of selective reporting bias because they reported on all prespecified endpoints in the identified study records. </p> </section> <section id="CD011395-sec-0049"> <h4 class="title">Other potential sources of bias</h4> <p>No other potential sources of bias were identified.</p> </section> </section> <section id="CD011395-sec-0050"> <h3 class="title" id="CD011395-sec-0050">Effects of interventions</h3> <p>See: <a href="./full#CD011395-tbl-0001"><b>Summary of findings 1</b> PARPi‐containing regimen compared to non‐PARPi regimen for locally advanced or metastatic breast cancer</a> </p> <p>Five trials, involving 1474 patients, were included in this review (<a href="./references#CD011395-bbs2-0002" title="DiérasV , HanHS , RobsonME , PalacovaM , MarcomPK , JagerA , et al. Evaluation of veliparib (V) and temozolomide (TMZ) in a phase 2 randomized study of the efficacy and tolerability of V+TMZ or carboplatin (C) and paclitaxel (P) vs placebo (Plc)+C/P in patients (pts) with BRCA1 or BRCA2 mutations and metastatic breast cancer. Cancer Research2017;77(Suppl 4):Abstract nr SABCS16-P4-22-02. HanHS , DiérasV , RobsonM , PalácováM , MarcomPK , Jager A et al. Veliparib with temozolomide or carboplatin/paclitaxel versus placebo with carboplatin/paclitaxel in patients with BRCA1/2 locally recurrent/metastatic breast cancer: randomized phase II study. Annals of Oncology2018;29(1):154-61. HanHS , DiérasV , RobsonME , PalácováM , MarcomPK , JagerA , et al. Efficacy and tolerability of veliparib (V; ABT-888) in combination with carboplatin (C) and paclitaxel (P) vs placebo (Plc)+C/P in patients (pts) with BRCA1 or BRCA2 mutations and metastatic breast cancer: a randomized, phase 2 study. Cancer Research2017;77(Suppl 4):Abstract nr SABCS16-S2-05. IsakoffSJ , PuhallaS , DomchekSM , FriedlanderM , KaufmanB , RobsonM , et al. A randomized Phase II study of veliparib with temozolomide or carboplatin/paclitaxel versus placebo with carboplatin/paclitaxel in BRCA1/2 metastatic breast cancer: design and rationale. Future Oncology2017;13(4):307-20. ">BROCADE 2</a>; <a href="./references#CD011395-bbs2-0003" title="ArunBK , HanHS , KaufmanB , WildiersH , FriedlanderM , AyoubJP , et al. First-line veliparib plus carboplatin/paclitaxel in patients with HER2-negative advanced/metastatic gBRCA-associated breast cancer: planned subgroup analysis from the phase 3 BROCADE3 trial. Cancer Research2020;80(Suppl 4):Abstract nr PD4-01. AyoubJP , FriedlanderML , DierasVC , WildiersH , ArunB , HanHS , et al. Veliparib plus carboplatin-paclitaxel in patients with HER2-negative advanced/metastatic gBRCA-associated breast cancer: results in hormone receptor-positive and triple-negative breast cancer subgroups from the phase III BROCADE3 trial. Annals of Oncology2020;31(Suppl 2):S65. DierasV , HanH , KaufmanB , WildiersH , FriedlanderM , AyoubJ , et al. A Phase 3 randomized, placebo-controlled trial of carboplatin and paclitaxel with or without the PARP inhibitor veliparib (ABT-888) in HER2-negative metastatic or locally advanced unresectable BRCA-associated breast cancer. Annals of Oncology2019;30(Suppl 5):v851-v934. ">BROCADE 3</a>; <a href="./references#CD011395-bbs2-0004" title="DiabS , RugoHS , MinaLA , PuhallaS , MahtaniRL , HenryNL , et al. Efficacy and safety of talazoparib (TALA) or physician's choice of therapy (PCT) in United States patients (pts) with HER2- germline BRCA1/2-mutated (gBRCAm) locally advanced/metastatic breast cancer (LA/MBC) in the EMBRACA study. Journal of Clinical Oncology2019;37(Suppl 15):1044. EiermannW , RugoHS , DiabS , EttlJ , HurvitzSA , GoncalvesA , et al. Analysis of germline BRCA1/2 mutated (g BRCAmut) hormone receptor-positive (HR+) and triple-negative breast cancer (TNBC) treated with talazoparib (TALA). Journal of Clinical Oncology2018;36(Suppl 15):1070. EttlJ , HurvitzSA , RugoHS , LeeKH , MinaLA , WoodwardNE , et al. Outcomes of talazoparib (TALA) versus physician's choice of chemotherapy (PCT) in patients (pts) with advanced breast cancer (ABC) and a germline BRCA (gBRCA) mutation by line of chemotherapy (CT) in the EMBRACA trial. Journal of Clinical Oncology2019;37(Suppl 15):1071. EttlJ , QuekRG , BhattacharyyaH , RugoHS , HurvitzSA , GonçalvesA . Patient Reported Outcomes (PRO) in patients (pts) with HER2-advanced breast cancer (ABC) and a germline BRCA1/2 mutation (gBRCAm) receiving talazoparib (TALA) vs physician’s choice chemotherapy (PCT) in the EMBRACA trial: a focus on subgroups with/without visceral disease. Annals of Oncology2019;30(Suppl 5):v129–30. EttlJ , QuekRG , HurvitzSA , GoncalvesA , TudorIC , RugoHS . Hospitalization and supportive care medication (SCM) utilisation in patients (pts) with advanced breast cancer (ABC) and a germline BRCA1/2 mutation (gBRCAm) in EMBRACA. Annals of Oncology2019;30(Suppl 3):iii52. EttlJ , QuekRG , LeeKH , RugoHS , HurvitzS , GonçalvesA , et al. Quality of life with talazoparib versus physician’s choice of chemotherapy in patients with advanced breast cancer and germline BRCA1/2 mutation: patient-reported outcomes from the EMBRACA phase III trial. Annals of Oncology2018;29(9):1939-47. FaschingPA , QuekRG , BhattacharyyaH , HurvitzSA , RugoHS , EttlJ . Impact of objective response (OR) on patient-reported outcomes (PRO) in patients (pts) with advanced breast cancer (ABC) and a germline BRCA1/2 (gBRCA) mutation in the phase III EMBRACA trial. Annals of Oncology2019;30(Suppl 3):iii49. GonçalvesA , EiermannW , RugoHS , EttlJ , HurvitzSA , YerushalmiR , et al. EMBRACA: Efficacy and safety in comparing talazoparib (TALA) with physician's choice of therapy (PCT) in patients (pts) with advanced breast cancer (aBC) and a germline BRCA mutation (gBRCAm); BRCA1/BRCA2 subgroup analysis. Annals of Oncology2018;29(Suppl 8):viii96–7. GoncalvesA , QuekRGW , BhattacharyyaH , EttlJ , HurvitzSA , RugoHS . Patient-reported outcomes (PRO) in patients (pts) with Her2-advanced breast cancer (ABC) receiving talazoparib (TALA) vs physician's choice chemotherapy (PCT): a focus on EMBRACA germline BRCA1 and BRCA2 mutation (gBRCA1/2m) subgroups. Breast2019;48(Suppl 2):S71. HurvitzSA , GoncalvesA , RugoHS , LeeKH , FehrenbacherL , MinaLA , et al. Talazoparib in patients with a germline BRCA-mutated advanced breast cancer: detailed safety analyses from the phase III EMBRACA Trial. Oncologist2019;25(3):e439-50. LeeKH , KimSB , SohnJ , GoodwinA , UsariT , LanzaloneS , et al. Talazoparib (TALA) vs physician’s choice of chemotherapy (PCT) in Asian patients (Pts) with HER2- advanced breast cancer (ABC) and a germline BRCA1/2 mutation (gBRCA1/2mut): data from phase III EMBRACA. Annals of Oncology2019;30(9):ix14. LittonJ , EttlJ , HurvitzSA , MinaLA , RugoHS , LeeKH , et al. A phase 3, open-label, randomized, 2-arm international study of the oral dual PARP inhibitor talazoparib in germline BRCA mutation subjects with locally advanced and/or metastatic breast cancer (EMBRACA). Cancer Research2017;77(Suppl 4):Abstract nr OT2-01-13. LittonJ , RugoHS , EttlJ , HurvitzS , GoncalvesA , LeeKH , et al. EMBRACA: a phase 3 trial comparing talazoparib, an oral PARP inhibitor, to physicianʼs choice of therapy in patients with advanced breast cancer and a germline BRCA mutation [abstract]. In: San Antonio Breast Cancer Symposium; 2017 Dec 5-9; San Antonio (TX). San Antonio (TX), 2017. LittonJK , HurvitzSA , MinaLA , RugoHS , LeeKH , GonçalvesA , et al. Talazoparib (TALA) in germline BRCA1/2 (gBRCA1/2)-mutated human epidermal growth factor receptor 2 negative (HER2-) advanced breast cancer (ABC): final overall survival (OS) results from randomized phase 3 EMBRACA trial. Cancer Research2020;80(Suppl 16):Abstract no. CT071. LittonJK , RugoHS , EttlJ , HurvitzSA , GonçalvesA , LeeKH , et al. Talazoparib in patients with advanced breast cancer and a germline BRCA mutation. New England Journal of Medicine2018;379(8):753-63. MartínM , EiermannW , RugoHS , EttlJ , HurvitzSA , GonçalvesA , et al. EMBRACA: Comparison of efficacy and safety of talazoparib (TALA) and physician's choice of therapy (PCT) in patients (pts) with advanced breast cancer (aBC), a germline BRCA1/2 mutation (gBRCAm), and prior platinum treatment. Annals of Oncology2018;29(Suppl 8):viii96. MinaL , LeeKH , GoncalvesA , WoodwardN , HurvitzSA , DiabS , et al. EMBRACA: efficacy and safety of talazoparib or physician's choice of therapy in patients with advanced breast cancer and a germline BRCA1/2 mutation: a regional analysis. Cancer Research2019;79(Suppl 4):Abstract nr P6-18-12. QuekR , BhattacharyyaH , HurvitzS , GoncalvesA , EttlJ , RugoH . Patient-reported outcomes in patients with HER2-advanced breast cancer and a germline BRCA1/2 mutation receiving talazoparib versus physician's choice chemotherapy: a focus on EMBRACA age subgroups. Journal of Managed Care and Specialty Pharmacy2019;25(Suppl 10A):S37-8. QuekRGW , BhattacharyyaH , GoncalvesA , RugoHS , HurvitzSA , EttlJ . Pcn491 Patient reported outcomes (PRO) of talazoparib (TALA) versus physician's choice of chemotherapy (PCT) in patients (pts) with advanced breast cancer (aBC) and a germline BRCA (gBRCa) mutation: a focus on Embraca pts with/without prior chemotherapy (CT) subgroups. Value in Health2019;22(Suppl 3):S532. RugoHS , EttlJ , HurvitzSA , GoncalvesA , LeeKH , FehrenbacherL , et al. Outcomes in clinically relevant patient subgroups from the EMBRACA study: talazoparib vs physician's choice standard-of-care chemotherapy. Journal of the National Cancer Institute Cancer Spectrum2020;4(1):pkz085. RugoHS , EttlJ , WoodwardNE , HurvitzSA , GoncalvesA , LeeKH , et al. EMBRACA: efficacy outcomes in clinically relevant subgroups comparing talazoparib (TALA), an oral poly ADP ribose polymerase (PARP) inhibitor, to physician's choice of therapy (PCT) in patients with advanced breast cancer and a germline BRCA mutation. Journal of Clinical Oncology2018;36(Suppl 15):1069. RugoHS , QuekR , EttlJ , HurvitzSA , BhattacharyyaH , HannahAL , et al. Patient-reported outcomes (PRO) in patients (pts) with advanced breast cancer and a germline BRCA1/2 mutation (gBRCAm) receiving talazoparib (TALA) vs physician’s choice chemotherapy treatment (PCT): a focus on the EMBRACA triple negative (TNBC) subpopulation. Annals of Oncology2018;29(Suppl 8):viii91. YuY , ElmeliegyM , LittonJK , TudorIC , CzibereA , ZhengJ , et al. Exposure-efficacy progression-free survival (PFS) analyses of breast cancer patients with germline BRCA1/2 mutations receiving talazoparib in the phase III EMBRACA trial. Annals of Oncology2018;29(Suppl 8):viii97. YuY , ElmeliegyM , LittonJK , TudorIC , CzibereA , ZhengJ , et al. Talazoparib exposure-efficacy analysis in patients with advanced breast cancer and germline BRCA1/2 mutations in the EMBRACA trial. Journal of Clinical Pharmacology2020;60(10):1324-33. ">EMBRACA</a>; <a href="./references#CD011395-bbs2-0005" title="KummarS , WadeJL , OzaAM , SullivanD , ChenAP , GandaraDR , et al. Randomized phase II trial of cyclophosphamide and the oral poly (ADP-ribose) polymerase inhibitor veliparib in patients with recurrent, advanced triple-negative breast cancer. Investigational New Drugs2016;34(3):355–63. ">Kummar 2016</a>; <a href="./references#CD011395-bbs2-0006" title="DelalogeS , ContePF , ImS , Senkus-KonefkaE , XuB , DomchekSM , et al. OlympiAD: further efficacy outcomes in patients with HER2-negative metastatic breast cancer and a germline BRCA mutation receiving olaparib monotherapy vs standard single-agent chemotherapy treatment of physician’s choice. Annals of Oncology2017;28(Suppl 5):v74-v108. DomchekS , RobsonM , ImS , SenkusE , XuB , MasudaN , et al. Tolerability of olaparib monotherapy versus chemotherapy in patients with HER2-negative metastatic breast cancer and a germline BRCA mutation: OlympiAD. Cancer Research2018;78(Suppl 4):Abstract nr P5-21-12. ImSA , XuB , LiW , RobsonM , OuyangQ , YehDC , et al. Olaparib monotherapy for Asian patients with a germline BRCA mutation and HER2-negative metastatic breast cancer: OlympiAD randomized trial subgroup analysis. Scientific Reports2020;10(1):8753. ImSA , XuB , LiW , RobsonM , OuyangQ , YehDC , et al. Olaparib monotherapy versus chemotherapy for patients with HER2-negative metastatic breast cancer and a germline BRCA mutation: Asian subgroup analysis from the phase III OlympiAD trial. Cancer Research2018;78(Suppl 4):Abstract nr P5-21-13. MerensC , BannisterW , BergnerS , HettleR , McCreaC , McCutcheonS , et al. Impact of olaparib versus chemotherapy on the use of strong pain medications in gBRCA-mutated HER2-negative metastatic breast cancer and associated patient reported outcomes. Cancer Research2020;80(Suppl 4):Abstract nr P6-13-05. RobsonM , HettleR , DegboeA , SaundersO , CainT , KilvertH , et al. Estimating the health state utility of patients with HER2–gBRCA+ metastatic breast cancer treated with olaparib or chemotherapy via a mapping analysis of EORTC QLQ-C30 data collected in the Olympiad clinical trial. Value in Health2018;21(Suppl 1):S12. RobsonM , ImSA , SenkusE , XuB , DomchekS , MasudaN , et al. OlympiAD extended follow-up for overall survival and safety: olaparib versus chemotherapy treatment of physician’s choice in patients with a germline BRCA mutation and HER2-negative metastatic breast cancer. Cancer Research2020;80(Suppl 4):Abstract nr PD4-03. RobsonM , ImSA , SenkusE , XuB , DomchekSM , MasudaN , et al. Olaparib for metastatic breast cancer in patients with a germline BRCA mutation. New England Journal of Medicine2017;377(6):523-33. RobsonM , RuddyKJ , ImSA , SenkusE , XuB , DomchekSM , et al. Patient-reported outcomes in patients with a germline BRCA mutation and HER2-negative metastatic breast cancer receiving olaparib versus chemotherapy in the OlympiAD trial. European Journal of Cancer2019;120:20-30. RobsonM , RuddyKJ , ImSA , Senkus-KonefkaE , XuB , DomchekSM , et al. OlympiAD: health-related quality of life (HRQoL) in patients with HER2-negative metastatic breast cancer (mBC) and a germline BRCA mutation (gBRCAm) receiving olaparib monotherapy vs standard single-agent chemotherapy treatment of physician’s choice (TPC). Annals of Oncology2017;28(Suppl 5):v74-v108. RobsonME , ImSA , SenkusE , XuB , DomchekS , MasudaN , et al. Abstract CT038: OlympiAD final overall survival: olaparib versus chemotherapy treatment of physician's choice (TPC) in patients with HER2-negative metastatic breast cancer (mBC) and a germline BRCA mutation (gBRCAm). American Association for Cancer Research2018;78(Suppl 13):CT038. RobsonME , ImSA , SenkusE , XuB , DomchekSM , MasudaN , et al. OlympiAD: phase III trial of olaparib monotherapy versus chemotherapy for patients (pts) with HER2-negative metastatic breast cancer (mBC) and a germline BRCA mutation (gBRCAm). Journal of Clinical Oncology2017;35(Suppl 18):LBA4-LBA4. RobsonME , RuddyKJ , ImSA , Senkus-KonefkaE , XuB , DomchekSM , et al. EORTC QLQ-C30 (QLQ-C30) symptoms in patients (pts) with HER2-negative metastatic breast cancer (mBC) and a germline BRCA mutation (gBRCAm) receiving olaparib vs chemotherapy treatment of physician’s choice (TPC) in OlympiAD. Journal of Clinical Oncology2018;36(Suppl 15):1045. RobsonME , TungN , ConteP , ImSA , SenkusE , XuB , et al. OlympiAD final overall survival and tolerability results: olaparib versus chemotherapy treatment of physician’s choice in patients with a germline BRCA mutation and HER2-negative metastatic breast cancer. Annals of Oncology2019;30(4):558-66. Senkus-KonefkaE , DomchekSM , ImSA , XuB , ArmstrongA , MasudaN , et al. Subgroup analysis of olaparib monotherapy versus chemotherapy by hormone receptor and BRCA mutation status in patients with HER2-negative metastatic breast cancer and a germline BRCA mutation: OlympiAD. European Journal of Cancer2018;92:S19-20. TungNM , ImSA , Senkus-KonefkaE , XuB , DomchekSM , MasudaN , et al. Olaparib versus chemotherapy treatment of physician’s choice in patients with a germline BRCA mutation and HER2-negative metastatic breast cancer (OlympiAD): efficacy in patients with visceral metastases. Journal of Clinical Oncology2018;36(Suppl 15):1053. ">OLYMPIAD</a>). Refer to <a href="./full#CD011395-tbl-0001">summary of findings Table 1</a>. </p> <section id="CD011395-sec-0051"> <h4 class="title">Primary outcomes</h4> <section id="CD011395-sec-0052"> <h5 class="title">1.1 Overall survival</h5> <p>See: <a href="#CD011395-fig-0003">Figure 3</a>; <a href="./references#CD011395-fig-0007" title="">Analysis 1.1</a>. </p> <div class="figure" id="CD011395-fig-0003"> <div class="figure-caption-wrapper-top"> <nav class="inline-nav-list has-dividers"> <ul> <li><a class="open-in-figure-viewer" href="#0">Open in figure viewer</a></li> </ul> </nav> <div class="figure-label">Figure 3</div> </div> <hr class="top"/><img alt="Forest plot of comparison: 1 PARPi‐containing regimen vs non‐PARPi regimen, outcome: 1.1 Overall survival" data-id="CD011395-fig-0003" src="/cdsr/doi/10.1002/14651858.CD011395.pub2/media/CDSR/CD011395/image_n/nCD011395-FIG-03.svg"/><hr class="bottom"/> <div class="figure-caption-wrapper-bottom"> <div class="figure-caption"> <p>Forest plot of comparison: 1 PARPi‐containing regimen vs non‐PARPi regimen, outcome: 1.1 Overall survival </p> </div> </div> </div> <p>Four of the five studies reported on OS (<a href="./references#CD011395-bbs2-0002" title="DiérasV , HanHS , RobsonME , PalacovaM , MarcomPK , JagerA , et al. Evaluation of veliparib (V) and temozolomide (TMZ) in a phase 2 randomized study of the efficacy and tolerability of V+TMZ or carboplatin (C) and paclitaxel (P) vs placebo (Plc)+C/P in patients (pts) with BRCA1 or BRCA2 mutations and metastatic breast cancer. Cancer Research2017;77(Suppl 4):Abstract nr SABCS16-P4-22-02. HanHS , DiérasV , RobsonM , PalácováM , MarcomPK , Jager A et al. Veliparib with temozolomide or carboplatin/paclitaxel versus placebo with carboplatin/paclitaxel in patients with BRCA1/2 locally recurrent/metastatic breast cancer: randomized phase II study. Annals of Oncology2018;29(1):154-61. HanHS , DiérasV , RobsonME , PalácováM , MarcomPK , JagerA , et al. Efficacy and tolerability of veliparib (V; ABT-888) in combination with carboplatin (C) and paclitaxel (P) vs placebo (Plc)+C/P in patients (pts) with BRCA1 or BRCA2 mutations and metastatic breast cancer: a randomized, phase 2 study. Cancer Research2017;77(Suppl 4):Abstract nr SABCS16-S2-05. IsakoffSJ , PuhallaS , DomchekSM , FriedlanderM , KaufmanB , RobsonM , et al. A randomized Phase II study of veliparib with temozolomide or carboplatin/paclitaxel versus placebo with carboplatin/paclitaxel in BRCA1/2 metastatic breast cancer: design and rationale. Future Oncology2017;13(4):307-20. ">BROCADE 2</a>; <a href="./references#CD011395-bbs2-0003" title="ArunBK , HanHS , KaufmanB , WildiersH , FriedlanderM , AyoubJP , et al. First-line veliparib plus carboplatin/paclitaxel in patients with HER2-negative advanced/metastatic gBRCA-associated breast cancer: planned subgroup analysis from the phase 3 BROCADE3 trial. Cancer Research2020;80(Suppl 4):Abstract nr PD4-01. AyoubJP , FriedlanderML , DierasVC , WildiersH , ArunB , HanHS , et al. Veliparib plus carboplatin-paclitaxel in patients with HER2-negative advanced/metastatic gBRCA-associated breast cancer: results in hormone receptor-positive and triple-negative breast cancer subgroups from the phase III BROCADE3 trial. Annals of Oncology2020;31(Suppl 2):S65. DierasV , HanH , KaufmanB , WildiersH , FriedlanderM , AyoubJ , et al. A Phase 3 randomized, placebo-controlled trial of carboplatin and paclitaxel with or without the PARP inhibitor veliparib (ABT-888) in HER2-negative metastatic or locally advanced unresectable BRCA-associated breast cancer. Annals of Oncology2019;30(Suppl 5):v851-v934. ">BROCADE 3</a>; <a href="./references#CD011395-bbs2-0004" title="DiabS , RugoHS , MinaLA , PuhallaS , MahtaniRL , HenryNL , et al. Efficacy and safety of talazoparib (TALA) or physician's choice of therapy (PCT) in United States patients (pts) with HER2- germline BRCA1/2-mutated (gBRCAm) locally advanced/metastatic breast cancer (LA/MBC) in the EMBRACA study. Journal of Clinical Oncology2019;37(Suppl 15):1044. EiermannW , RugoHS , DiabS , EttlJ , HurvitzSA , GoncalvesA , et al. Analysis of germline BRCA1/2 mutated (g BRCAmut) hormone receptor-positive (HR+) and triple-negative breast cancer (TNBC) treated with talazoparib (TALA). Journal of Clinical Oncology2018;36(Suppl 15):1070. EttlJ , HurvitzSA , RugoHS , LeeKH , MinaLA , WoodwardNE , et al. Outcomes of talazoparib (TALA) versus physician's choice of chemotherapy (PCT) in patients (pts) with advanced breast cancer (ABC) and a germline BRCA (gBRCA) mutation by line of chemotherapy (CT) in the EMBRACA trial. Journal of Clinical Oncology2019;37(Suppl 15):1071. EttlJ , QuekRG , BhattacharyyaH , RugoHS , HurvitzSA , GonçalvesA . Patient Reported Outcomes (PRO) in patients (pts) with HER2-advanced breast cancer (ABC) and a germline BRCA1/2 mutation (gBRCAm) receiving talazoparib (TALA) vs physician’s choice chemotherapy (PCT) in the EMBRACA trial: a focus on subgroups with/without visceral disease. Annals of Oncology2019;30(Suppl 5):v129–30. EttlJ , QuekRG , HurvitzSA , GoncalvesA , TudorIC , RugoHS . Hospitalization and supportive care medication (SCM) utilisation in patients (pts) with advanced breast cancer (ABC) and a germline BRCA1/2 mutation (gBRCAm) in EMBRACA. Annals of Oncology2019;30(Suppl 3):iii52. EttlJ , QuekRG , LeeKH , RugoHS , HurvitzS , GonçalvesA , et al. Quality of life with talazoparib versus physician’s choice of chemotherapy in patients with advanced breast cancer and germline BRCA1/2 mutation: patient-reported outcomes from the EMBRACA phase III trial. Annals of Oncology2018;29(9):1939-47. FaschingPA , QuekRG , BhattacharyyaH , HurvitzSA , RugoHS , EttlJ . Impact of objective response (OR) on patient-reported outcomes (PRO) in patients (pts) with advanced breast cancer (ABC) and a germline BRCA1/2 (gBRCA) mutation in the phase III EMBRACA trial. Annals of Oncology2019;30(Suppl 3):iii49. GonçalvesA , EiermannW , RugoHS , EttlJ , HurvitzSA , YerushalmiR , et al. EMBRACA: Efficacy and safety in comparing talazoparib (TALA) with physician's choice of therapy (PCT) in patients (pts) with advanced breast cancer (aBC) and a germline BRCA mutation (gBRCAm); BRCA1/BRCA2 subgroup analysis. Annals of Oncology2018;29(Suppl 8):viii96–7. GoncalvesA , QuekRGW , BhattacharyyaH , EttlJ , HurvitzSA , RugoHS . Patient-reported outcomes (PRO) in patients (pts) with Her2-advanced breast cancer (ABC) receiving talazoparib (TALA) vs physician's choice chemotherapy (PCT): a focus on EMBRACA germline BRCA1 and BRCA2 mutation (gBRCA1/2m) subgroups. Breast2019;48(Suppl 2):S71. HurvitzSA , GoncalvesA , RugoHS , LeeKH , FehrenbacherL , MinaLA , et al. Talazoparib in patients with a germline BRCA-mutated advanced breast cancer: detailed safety analyses from the phase III EMBRACA Trial. Oncologist2019;25(3):e439-50. LeeKH , KimSB , SohnJ , GoodwinA , UsariT , LanzaloneS , et al. Talazoparib (TALA) vs physician’s choice of chemotherapy (PCT) in Asian patients (Pts) with HER2- advanced breast cancer (ABC) and a germline BRCA1/2 mutation (gBRCA1/2mut): data from phase III EMBRACA. Annals of Oncology2019;30(9):ix14. LittonJ , EttlJ , HurvitzSA , MinaLA , RugoHS , LeeKH , et al. A phase 3, open-label, randomized, 2-arm international study of the oral dual PARP inhibitor talazoparib in germline BRCA mutation subjects with locally advanced and/or metastatic breast cancer (EMBRACA). Cancer Research2017;77(Suppl 4):Abstract nr OT2-01-13. LittonJ , RugoHS , EttlJ , HurvitzS , GoncalvesA , LeeKH , et al. EMBRACA: a phase 3 trial comparing talazoparib, an oral PARP inhibitor, to physicianʼs choice of therapy in patients with advanced breast cancer and a germline BRCA mutation [abstract]. In: San Antonio Breast Cancer Symposium; 2017 Dec 5-9; San Antonio (TX). San Antonio (TX), 2017. LittonJK , HurvitzSA , MinaLA , RugoHS , LeeKH , GonçalvesA , et al. Talazoparib (TALA) in germline BRCA1/2 (gBRCA1/2)-mutated human epidermal growth factor receptor 2 negative (HER2-) advanced breast cancer (ABC): final overall survival (OS) results from randomized phase 3 EMBRACA trial. Cancer Research2020;80(Suppl 16):Abstract no. CT071. LittonJK , RugoHS , EttlJ , HurvitzSA , GonçalvesA , LeeKH , et al. Talazoparib in patients with advanced breast cancer and a germline BRCA mutation. New England Journal of Medicine2018;379(8):753-63. MartínM , EiermannW , RugoHS , EttlJ , HurvitzSA , GonçalvesA , et al. EMBRACA: Comparison of efficacy and safety of talazoparib (TALA) and physician's choice of therapy (PCT) in patients (pts) with advanced breast cancer (aBC), a germline BRCA1/2 mutation (gBRCAm), and prior platinum treatment. Annals of Oncology2018;29(Suppl 8):viii96. MinaL , LeeKH , GoncalvesA , WoodwardN , HurvitzSA , DiabS , et al. EMBRACA: efficacy and safety of talazoparib or physician's choice of therapy in patients with advanced breast cancer and a germline BRCA1/2 mutation: a regional analysis. Cancer Research2019;79(Suppl 4):Abstract nr P6-18-12. QuekR , BhattacharyyaH , HurvitzS , GoncalvesA , EttlJ , RugoH . Patient-reported outcomes in patients with HER2-advanced breast cancer and a germline BRCA1/2 mutation receiving talazoparib versus physician's choice chemotherapy: a focus on EMBRACA age subgroups. Journal of Managed Care and Specialty Pharmacy2019;25(Suppl 10A):S37-8. QuekRGW , BhattacharyyaH , GoncalvesA , RugoHS , HurvitzSA , EttlJ . Pcn491 Patient reported outcomes (PRO) of talazoparib (TALA) versus physician's choice of chemotherapy (PCT) in patients (pts) with advanced breast cancer (aBC) and a germline BRCA (gBRCa) mutation: a focus on Embraca pts with/without prior chemotherapy (CT) subgroups. Value in Health2019;22(Suppl 3):S532. RugoHS , EttlJ , HurvitzSA , GoncalvesA , LeeKH , FehrenbacherL , et al. Outcomes in clinically relevant patient subgroups from the EMBRACA study: talazoparib vs physician's choice standard-of-care chemotherapy. Journal of the National Cancer Institute Cancer Spectrum2020;4(1):pkz085. RugoHS , EttlJ , WoodwardNE , HurvitzSA , GoncalvesA , LeeKH , et al. EMBRACA: efficacy outcomes in clinically relevant subgroups comparing talazoparib (TALA), an oral poly ADP ribose polymerase (PARP) inhibitor, to physician's choice of therapy (PCT) in patients with advanced breast cancer and a germline BRCA mutation. Journal of Clinical Oncology2018;36(Suppl 15):1069. RugoHS , QuekR , EttlJ , HurvitzSA , BhattacharyyaH , HannahAL , et al. Patient-reported outcomes (PRO) in patients (pts) with advanced breast cancer and a germline BRCA1/2 mutation (gBRCAm) receiving talazoparib (TALA) vs physician’s choice chemotherapy treatment (PCT): a focus on the EMBRACA triple negative (TNBC) subpopulation. Annals of Oncology2018;29(Suppl 8):viii91. YuY , ElmeliegyM , LittonJK , TudorIC , CzibereA , ZhengJ , et al. Exposure-efficacy progression-free survival (PFS) analyses of breast cancer patients with germline BRCA1/2 mutations receiving talazoparib in the phase III EMBRACA trial. Annals of Oncology2018;29(Suppl 8):viii97. YuY , ElmeliegyM , LittonJK , TudorIC , CzibereA , ZhengJ , et al. Talazoparib exposure-efficacy analysis in patients with advanced breast cancer and germline BRCA1/2 mutations in the EMBRACA trial. Journal of Clinical Pharmacology2020;60(10):1324-33. ">EMBRACA</a>; <a href="./references#CD011395-bbs2-0006" title="DelalogeS , ContePF , ImS , Senkus-KonefkaE , XuB , DomchekSM , et al. OlympiAD: further efficacy outcomes in patients with HER2-negative metastatic breast cancer and a germline BRCA mutation receiving olaparib monotherapy vs standard single-agent chemotherapy treatment of physician’s choice. Annals of Oncology2017;28(Suppl 5):v74-v108. DomchekS , RobsonM , ImS , SenkusE , XuB , MasudaN , et al. Tolerability of olaparib monotherapy versus chemotherapy in patients with HER2-negative metastatic breast cancer and a germline BRCA mutation: OlympiAD. Cancer Research2018;78(Suppl 4):Abstract nr P5-21-12. ImSA , XuB , LiW , RobsonM , OuyangQ , YehDC , et al. Olaparib monotherapy for Asian patients with a germline BRCA mutation and HER2-negative metastatic breast cancer: OlympiAD randomized trial subgroup analysis. Scientific Reports2020;10(1):8753. ImSA , XuB , LiW , RobsonM , OuyangQ , YehDC , et al. Olaparib monotherapy versus chemotherapy for patients with HER2-negative metastatic breast cancer and a germline BRCA mutation: Asian subgroup analysis from the phase III OlympiAD trial. Cancer Research2018;78(Suppl 4):Abstract nr P5-21-13. MerensC , BannisterW , BergnerS , HettleR , McCreaC , McCutcheonS , et al. Impact of olaparib versus chemotherapy on the use of strong pain medications in gBRCA-mutated HER2-negative metastatic breast cancer and associated patient reported outcomes. Cancer Research2020;80(Suppl 4):Abstract nr P6-13-05. RobsonM , HettleR , DegboeA , SaundersO , CainT , KilvertH , et al. Estimating the health state utility of patients with HER2–gBRCA+ metastatic breast cancer treated with olaparib or chemotherapy via a mapping analysis of EORTC QLQ-C30 data collected in the Olympiad clinical trial. Value in Health2018;21(Suppl 1):S12. RobsonM , ImSA , SenkusE , XuB , DomchekS , MasudaN , et al. OlympiAD extended follow-up for overall survival and safety: olaparib versus chemotherapy treatment of physician’s choice in patients with a germline BRCA mutation and HER2-negative metastatic breast cancer. Cancer Research2020;80(Suppl 4):Abstract nr PD4-03. RobsonM , ImSA , SenkusE , XuB , DomchekSM , MasudaN , et al. Olaparib for metastatic breast cancer in patients with a germline BRCA mutation. New England Journal of Medicine2017;377(6):523-33. RobsonM , RuddyKJ , ImSA , SenkusE , XuB , DomchekSM , et al. Patient-reported outcomes in patients with a germline BRCA mutation and HER2-negative metastatic breast cancer receiving olaparib versus chemotherapy in the OlympiAD trial. European Journal of Cancer2019;120:20-30. RobsonM , RuddyKJ , ImSA , Senkus-KonefkaE , XuB , DomchekSM , et al. OlympiAD: health-related quality of life (HRQoL) in patients with HER2-negative metastatic breast cancer (mBC) and a germline BRCA mutation (gBRCAm) receiving olaparib monotherapy vs standard single-agent chemotherapy treatment of physician’s choice (TPC). Annals of Oncology2017;28(Suppl 5):v74-v108. RobsonME , ImSA , SenkusE , XuB , DomchekS , MasudaN , et al. Abstract CT038: OlympiAD final overall survival: olaparib versus chemotherapy treatment of physician's choice (TPC) in patients with HER2-negative metastatic breast cancer (mBC) and a germline BRCA mutation (gBRCAm). American Association for Cancer Research2018;78(Suppl 13):CT038. RobsonME , ImSA , SenkusE , XuB , DomchekSM , MasudaN , et al. OlympiAD: phase III trial of olaparib monotherapy versus chemotherapy for patients (pts) with HER2-negative metastatic breast cancer (mBC) and a germline BRCA mutation (gBRCAm). Journal of Clinical Oncology2017;35(Suppl 18):LBA4-LBA4. RobsonME , RuddyKJ , ImSA , Senkus-KonefkaE , XuB , DomchekSM , et al. EORTC QLQ-C30 (QLQ-C30) symptoms in patients (pts) with HER2-negative metastatic breast cancer (mBC) and a germline BRCA mutation (gBRCAm) receiving olaparib vs chemotherapy treatment of physician’s choice (TPC) in OlympiAD. Journal of Clinical Oncology2018;36(Suppl 15):1045. RobsonME , TungN , ConteP , ImSA , SenkusE , XuB , et al. OlympiAD final overall survival and tolerability results: olaparib versus chemotherapy treatment of physician’s choice in patients with a germline BRCA mutation and HER2-negative metastatic breast cancer. Annals of Oncology2019;30(4):558-66. Senkus-KonefkaE , DomchekSM , ImSA , XuB , ArmstrongA , MasudaN , et al. Subgroup analysis of olaparib monotherapy versus chemotherapy by hormone receptor and BRCA mutation status in patients with HER2-negative metastatic breast cancer and a germline BRCA mutation: OlympiAD. European Journal of Cancer2018;92:S19-20. TungNM , ImSA , Senkus-KonefkaE , XuB , DomchekSM , MasudaN , et al. Olaparib versus chemotherapy treatment of physician’s choice in patients with a germline BRCA mutation and HER2-negative metastatic breast cancer (OlympiAD): efficacy in patients with visceral metastases. Journal of Clinical Oncology2018;36(Suppl 15):1053. ">OLYMPIAD</a>). Pooled analysis of these trials with a sample size of 1435 patients showed PARP inhibitors may offer a small overall survival benefit, HR 0.87 (95% CI 0.76 to 1.00; P = 0.05; high‐certainty evidence), with no significant heterogeneity (I<sup>2</sup> = 0%, P = 0.81). </p> <p>Subgroup analyses for OS outcomes were not able to be performed as these data were not available for the included studies. </p> <p>All studies contributing to the OS analysis were at low risk of bias so sensitivity analysis was not performed. </p> <p>Cross‐over was only permitted in two trials (<a href="./references#CD011395-bbs2-0003" title="ArunBK , HanHS , KaufmanB , WildiersH , FriedlanderM , AyoubJP , et al. First-line veliparib plus carboplatin/paclitaxel in patients with HER2-negative advanced/metastatic gBRCA-associated breast cancer: planned subgroup analysis from the phase 3 BROCADE3 trial. Cancer Research2020;80(Suppl 4):Abstract nr PD4-01. AyoubJP , FriedlanderML , DierasVC , WildiersH , ArunB , HanHS , et al. Veliparib plus carboplatin-paclitaxel in patients with HER2-negative advanced/metastatic gBRCA-associated breast cancer: results in hormone receptor-positive and triple-negative breast cancer subgroups from the phase III BROCADE3 trial. Annals of Oncology2020;31(Suppl 2):S65. DierasV , HanH , KaufmanB , WildiersH , FriedlanderM , AyoubJ , et al. A Phase 3 randomized, placebo-controlled trial of carboplatin and paclitaxel with or without the PARP inhibitor veliparib (ABT-888) in HER2-negative metastatic or locally advanced unresectable BRCA-associated breast cancer. Annals of Oncology2019;30(Suppl 5):v851-v934. ">BROCADE 3</a>; <a href="./references#CD011395-bbs2-0005" title="KummarS , WadeJL , OzaAM , SullivanD , ChenAP , GandaraDR , et al. Randomized phase II trial of cyclophosphamide and the oral poly (ADP-ribose) polymerase inhibitor veliparib in patients with recurrent, advanced triple-negative breast cancer. Investigational New Drugs2016;34(3):355–63. ">Kummar 2016</a>), however, no hazard ratios were available regarding cross‐over analysis so no formal sensitivity analysis was done. </p> </section> </section> <section id="CD011395-sec-0053"> <h4 class="title">Secondary outcomes</h4> <section id="CD011395-sec-0054"> <h5 class="title">1.2 Progression‐free survival</h5> <p>See: <a href="#CD011395-fig-0004">Figure 4</a>; <a href="./references#CD011395-fig-0008" title="">Analysis 1.2</a>; <a href="./references#CD011395-fig-0009" title="">Analysis 1.3</a>; <a href="./references#CD011395-fig-0010" title="">Analysis 1.4</a>; <a href="./references#CD011395-fig-0011" title="">Analysis 1.5</a>; <a href="./references#CD011395-fig-0012" title="">Analysis 1.6</a>. </p> <div class="figure" id="CD011395-fig-0004"> <div class="figure-caption-wrapper-top"> <nav class="inline-nav-list has-dividers"> <ul> <li><a class="open-in-figure-viewer" href="#0">Open in figure viewer</a></li> </ul> </nav> <div class="figure-label">Figure 4</div> </div> <hr class="top"/><img alt="Forest plot of comparison: 1 PARPi‐containing regimen vs non‐PARPi regimen, outcome: 1.2 Progression‐free survival" data-id="CD011395-fig-0004" src="/cdsr/doi/10.1002/14651858.CD011395.pub2/media/CDSR/CD011395/image_n/nCD011395-FIG-04.svg"/><hr class="bottom"/> <div class="figure-caption-wrapper-bottom"> <div class="figure-caption"> <p>Forest plot of comparison: 1 PARPi‐containing regimen vs non‐PARPi regimen, outcome: 1.2 Progression‐free survival </p> </div> </div> </div> <p>Five of the trials reported PFS with a total of 1474 participants (<a href="./references#CD011395-bbs2-0002" title="DiérasV , HanHS , RobsonME , PalacovaM , MarcomPK , JagerA , et al. Evaluation of veliparib (V) and temozolomide (TMZ) in a phase 2 randomized study of the efficacy and tolerability of V+TMZ or carboplatin (C) and paclitaxel (P) vs placebo (Plc)+C/P in patients (pts) with BRCA1 or BRCA2 mutations and metastatic breast cancer. Cancer Research2017;77(Suppl 4):Abstract nr SABCS16-P4-22-02. HanHS , DiérasV , RobsonM , PalácováM , MarcomPK , Jager A et al. Veliparib with temozolomide or carboplatin/paclitaxel versus placebo with carboplatin/paclitaxel in patients with BRCA1/2 locally recurrent/metastatic breast cancer: randomized phase II study. Annals of Oncology2018;29(1):154-61. HanHS , DiérasV , RobsonME , PalácováM , MarcomPK , JagerA , et al. Efficacy and tolerability of veliparib (V; ABT-888) in combination with carboplatin (C) and paclitaxel (P) vs placebo (Plc)+C/P in patients (pts) with BRCA1 or BRCA2 mutations and metastatic breast cancer: a randomized, phase 2 study. Cancer Research2017;77(Suppl 4):Abstract nr SABCS16-S2-05. IsakoffSJ , PuhallaS , DomchekSM , FriedlanderM , KaufmanB , RobsonM , et al. A randomized Phase II study of veliparib with temozolomide or carboplatin/paclitaxel versus placebo with carboplatin/paclitaxel in BRCA1/2 metastatic breast cancer: design and rationale. Future Oncology2017;13(4):307-20. ">BROCADE 2</a>; <a href="./references#CD011395-bbs2-0003" title="ArunBK , HanHS , KaufmanB , WildiersH , FriedlanderM , AyoubJP , et al. First-line veliparib plus carboplatin/paclitaxel in patients with HER2-negative advanced/metastatic gBRCA-associated breast cancer: planned subgroup analysis from the phase 3 BROCADE3 trial. Cancer Research2020;80(Suppl 4):Abstract nr PD4-01. AyoubJP , FriedlanderML , DierasVC , WildiersH , ArunB , HanHS , et al. Veliparib plus carboplatin-paclitaxel in patients with HER2-negative advanced/metastatic gBRCA-associated breast cancer: results in hormone receptor-positive and triple-negative breast cancer subgroups from the phase III BROCADE3 trial. Annals of Oncology2020;31(Suppl 2):S65. DierasV , HanH , KaufmanB , WildiersH , FriedlanderM , AyoubJ , et al. A Phase 3 randomized, placebo-controlled trial of carboplatin and paclitaxel with or without the PARP inhibitor veliparib (ABT-888) in HER2-negative metastatic or locally advanced unresectable BRCA-associated breast cancer. Annals of Oncology2019;30(Suppl 5):v851-v934. ">BROCADE 3</a>; <a href="./references#CD011395-bbs2-0004" title="DiabS , RugoHS , MinaLA , PuhallaS , MahtaniRL , HenryNL , et al. Efficacy and safety of talazoparib (TALA) or physician's choice of therapy (PCT) in United States patients (pts) with HER2- germline BRCA1/2-mutated (gBRCAm) locally advanced/metastatic breast cancer (LA/MBC) in the EMBRACA study. Journal of Clinical Oncology2019;37(Suppl 15):1044. EiermannW , RugoHS , DiabS , EttlJ , HurvitzSA , GoncalvesA , et al. Analysis of germline BRCA1/2 mutated (g BRCAmut) hormone receptor-positive (HR+) and triple-negative breast cancer (TNBC) treated with talazoparib (TALA). Journal of Clinical Oncology2018;36(Suppl 15):1070. EttlJ , HurvitzSA , RugoHS , LeeKH , MinaLA , WoodwardNE , et al. Outcomes of talazoparib (TALA) versus physician's choice of chemotherapy (PCT) in patients (pts) with advanced breast cancer (ABC) and a germline BRCA (gBRCA) mutation by line of chemotherapy (CT) in the EMBRACA trial. Journal of Clinical Oncology2019;37(Suppl 15):1071. EttlJ , QuekRG , BhattacharyyaH , RugoHS , HurvitzSA , GonçalvesA . Patient Reported Outcomes (PRO) in patients (pts) with HER2-advanced breast cancer (ABC) and a germline BRCA1/2 mutation (gBRCAm) receiving talazoparib (TALA) vs physician’s choice chemotherapy (PCT) in the EMBRACA trial: a focus on subgroups with/without visceral disease. Annals of Oncology2019;30(Suppl 5):v129–30. EttlJ , QuekRG , HurvitzSA , GoncalvesA , TudorIC , RugoHS . Hospitalization and supportive care medication (SCM) utilisation in patients (pts) with advanced breast cancer (ABC) and a germline BRCA1/2 mutation (gBRCAm) in EMBRACA. Annals of Oncology2019;30(Suppl 3):iii52. EttlJ , QuekRG , LeeKH , RugoHS , HurvitzS , GonçalvesA , et al. Quality of life with talazoparib versus physician’s choice of chemotherapy in patients with advanced breast cancer and germline BRCA1/2 mutation: patient-reported outcomes from the EMBRACA phase III trial. Annals of Oncology2018;29(9):1939-47. FaschingPA , QuekRG , BhattacharyyaH , HurvitzSA , RugoHS , EttlJ . Impact of objective response (OR) on patient-reported outcomes (PRO) in patients (pts) with advanced breast cancer (ABC) and a germline BRCA1/2 (gBRCA) mutation in the phase III EMBRACA trial. Annals of Oncology2019;30(Suppl 3):iii49. GonçalvesA , EiermannW , RugoHS , EttlJ , HurvitzSA , YerushalmiR , et al. EMBRACA: Efficacy and safety in comparing talazoparib (TALA) with physician's choice of therapy (PCT) in patients (pts) with advanced breast cancer (aBC) and a germline BRCA mutation (gBRCAm); BRCA1/BRCA2 subgroup analysis. Annals of Oncology2018;29(Suppl 8):viii96–7. GoncalvesA , QuekRGW , BhattacharyyaH , EttlJ , HurvitzSA , RugoHS . Patient-reported outcomes (PRO) in patients (pts) with Her2-advanced breast cancer (ABC) receiving talazoparib (TALA) vs physician's choice chemotherapy (PCT): a focus on EMBRACA germline BRCA1 and BRCA2 mutation (gBRCA1/2m) subgroups. Breast2019;48(Suppl 2):S71. HurvitzSA , GoncalvesA , RugoHS , LeeKH , FehrenbacherL , MinaLA , et al. Talazoparib in patients with a germline BRCA-mutated advanced breast cancer: detailed safety analyses from the phase III EMBRACA Trial. Oncologist2019;25(3):e439-50. LeeKH , KimSB , SohnJ , GoodwinA , UsariT , LanzaloneS , et al. Talazoparib (TALA) vs physician’s choice of chemotherapy (PCT) in Asian patients (Pts) with HER2- advanced breast cancer (ABC) and a germline BRCA1/2 mutation (gBRCA1/2mut): data from phase III EMBRACA. Annals of Oncology2019;30(9):ix14. LittonJ , EttlJ , HurvitzSA , MinaLA , RugoHS , LeeKH , et al. A phase 3, open-label, randomized, 2-arm international study of the oral dual PARP inhibitor talazoparib in germline BRCA mutation subjects with locally advanced and/or metastatic breast cancer (EMBRACA). Cancer Research2017;77(Suppl 4):Abstract nr OT2-01-13. LittonJ , RugoHS , EttlJ , HurvitzS , GoncalvesA , LeeKH , et al. EMBRACA: a phase 3 trial comparing talazoparib, an oral PARP inhibitor, to physicianʼs choice of therapy in patients with advanced breast cancer and a germline BRCA mutation [abstract]. In: San Antonio Breast Cancer Symposium; 2017 Dec 5-9; San Antonio (TX). San Antonio (TX), 2017. LittonJK , HurvitzSA , MinaLA , RugoHS , LeeKH , GonçalvesA , et al. Talazoparib (TALA) in germline BRCA1/2 (gBRCA1/2)-mutated human epidermal growth factor receptor 2 negative (HER2-) advanced breast cancer (ABC): final overall survival (OS) results from randomized phase 3 EMBRACA trial. Cancer Research2020;80(Suppl 16):Abstract no. CT071. LittonJK , RugoHS , EttlJ , HurvitzSA , GonçalvesA , LeeKH , et al. Talazoparib in patients with advanced breast cancer and a germline BRCA mutation. New England Journal of Medicine2018;379(8):753-63. MartínM , EiermannW , RugoHS , EttlJ , HurvitzSA , GonçalvesA , et al. EMBRACA: Comparison of efficacy and safety of talazoparib (TALA) and physician's choice of therapy (PCT) in patients (pts) with advanced breast cancer (aBC), a germline BRCA1/2 mutation (gBRCAm), and prior platinum treatment. Annals of Oncology2018;29(Suppl 8):viii96. MinaL , LeeKH , GoncalvesA , WoodwardN , HurvitzSA , DiabS , et al. EMBRACA: efficacy and safety of talazoparib or physician's choice of therapy in patients with advanced breast cancer and a germline BRCA1/2 mutation: a regional analysis. Cancer Research2019;79(Suppl 4):Abstract nr P6-18-12. QuekR , BhattacharyyaH , HurvitzS , GoncalvesA , EttlJ , RugoH . Patient-reported outcomes in patients with HER2-advanced breast cancer and a germline BRCA1/2 mutation receiving talazoparib versus physician's choice chemotherapy: a focus on EMBRACA age subgroups. Journal of Managed Care and Specialty Pharmacy2019;25(Suppl 10A):S37-8. QuekRGW , BhattacharyyaH , GoncalvesA , RugoHS , HurvitzSA , EttlJ . Pcn491 Patient reported outcomes (PRO) of talazoparib (TALA) versus physician's choice of chemotherapy (PCT) in patients (pts) with advanced breast cancer (aBC) and a germline BRCA (gBRCa) mutation: a focus on Embraca pts with/without prior chemotherapy (CT) subgroups. Value in Health2019;22(Suppl 3):S532. RugoHS , EttlJ , HurvitzSA , GoncalvesA , LeeKH , FehrenbacherL , et al. Outcomes in clinically relevant patient subgroups from the EMBRACA study: talazoparib vs physician's choice standard-of-care chemotherapy. Journal of the National Cancer Institute Cancer Spectrum2020;4(1):pkz085. RugoHS , EttlJ , WoodwardNE , HurvitzSA , GoncalvesA , LeeKH , et al. EMBRACA: efficacy outcomes in clinically relevant subgroups comparing talazoparib (TALA), an oral poly ADP ribose polymerase (PARP) inhibitor, to physician's choice of therapy (PCT) in patients with advanced breast cancer and a germline BRCA mutation. Journal of Clinical Oncology2018;36(Suppl 15):1069. RugoHS , QuekR , EttlJ , HurvitzSA , BhattacharyyaH , HannahAL , et al. Patient-reported outcomes (PRO) in patients (pts) with advanced breast cancer and a germline BRCA1/2 mutation (gBRCAm) receiving talazoparib (TALA) vs physician’s choice chemotherapy treatment (PCT): a focus on the EMBRACA triple negative (TNBC) subpopulation. Annals of Oncology2018;29(Suppl 8):viii91. YuY , ElmeliegyM , LittonJK , TudorIC , CzibereA , ZhengJ , et al. Exposure-efficacy progression-free survival (PFS) analyses of breast cancer patients with germline BRCA1/2 mutations receiving talazoparib in the phase III EMBRACA trial. Annals of Oncology2018;29(Suppl 8):viii97. YuY , ElmeliegyM , LittonJK , TudorIC , CzibereA , ZhengJ , et al. Talazoparib exposure-efficacy analysis in patients with advanced breast cancer and germline BRCA1/2 mutations in the EMBRACA trial. Journal of Clinical Pharmacology2020;60(10):1324-33. ">EMBRACA</a>; <a href="./references#CD011395-bbs2-0005" title="KummarS , WadeJL , OzaAM , SullivanD , ChenAP , GandaraDR , et al. Randomized phase II trial of cyclophosphamide and the oral poly (ADP-ribose) polymerase inhibitor veliparib in patients with recurrent, advanced triple-negative breast cancer. Investigational New Drugs2016;34(3):355–63. ">Kummar 2016</a>; <a href="./references#CD011395-bbs2-0006" title="DelalogeS , ContePF , ImS , Senkus-KonefkaE , XuB , DomchekSM , et al. OlympiAD: further efficacy outcomes in patients with HER2-negative metastatic breast cancer and a germline BRCA mutation receiving olaparib monotherapy vs standard single-agent chemotherapy treatment of physician’s choice. Annals of Oncology2017;28(Suppl 5):v74-v108. DomchekS , RobsonM , ImS , SenkusE , XuB , MasudaN , et al. Tolerability of olaparib monotherapy versus chemotherapy in patients with HER2-negative metastatic breast cancer and a germline BRCA mutation: OlympiAD. Cancer Research2018;78(Suppl 4):Abstract nr P5-21-12. ImSA , XuB , LiW , RobsonM , OuyangQ , YehDC , et al. Olaparib monotherapy for Asian patients with a germline BRCA mutation and HER2-negative metastatic breast cancer: OlympiAD randomized trial subgroup analysis. Scientific Reports2020;10(1):8753. ImSA , XuB , LiW , RobsonM , OuyangQ , YehDC , et al. Olaparib monotherapy versus chemotherapy for patients with HER2-negative metastatic breast cancer and a germline BRCA mutation: Asian subgroup analysis from the phase III OlympiAD trial. Cancer Research2018;78(Suppl 4):Abstract nr P5-21-13. MerensC , BannisterW , BergnerS , HettleR , McCreaC , McCutcheonS , et al. Impact of olaparib versus chemotherapy on the use of strong pain medications in gBRCA-mutated HER2-negative metastatic breast cancer and associated patient reported outcomes. Cancer Research2020;80(Suppl 4):Abstract nr P6-13-05. RobsonM , HettleR , DegboeA , SaundersO , CainT , KilvertH , et al. Estimating the health state utility of patients with HER2–gBRCA+ metastatic breast cancer treated with olaparib or chemotherapy via a mapping analysis of EORTC QLQ-C30 data collected in the Olympiad clinical trial. Value in Health2018;21(Suppl 1):S12. RobsonM , ImSA , SenkusE , XuB , DomchekS , MasudaN , et al. OlympiAD extended follow-up for overall survival and safety: olaparib versus chemotherapy treatment of physician’s choice in patients with a germline BRCA mutation and HER2-negative metastatic breast cancer. Cancer Research2020;80(Suppl 4):Abstract nr PD4-03. RobsonM , ImSA , SenkusE , XuB , DomchekSM , MasudaN , et al. Olaparib for metastatic breast cancer in patients with a germline BRCA mutation. New England Journal of Medicine2017;377(6):523-33. RobsonM , RuddyKJ , ImSA , SenkusE , XuB , DomchekSM , et al. Patient-reported outcomes in patients with a germline BRCA mutation and HER2-negative metastatic breast cancer receiving olaparib versus chemotherapy in the OlympiAD trial. European Journal of Cancer2019;120:20-30. RobsonM , RuddyKJ , ImSA , Senkus-KonefkaE , XuB , DomchekSM , et al. OlympiAD: health-related quality of life (HRQoL) in patients with HER2-negative metastatic breast cancer (mBC) and a germline BRCA mutation (gBRCAm) receiving olaparib monotherapy vs standard single-agent chemotherapy treatment of physician’s choice (TPC). Annals of Oncology2017;28(Suppl 5):v74-v108. RobsonME , ImSA , SenkusE , XuB , DomchekS , MasudaN , et al. Abstract CT038: OlympiAD final overall survival: olaparib versus chemotherapy treatment of physician's choice (TPC) in patients with HER2-negative metastatic breast cancer (mBC) and a germline BRCA mutation (gBRCAm). American Association for Cancer Research2018;78(Suppl 13):CT038. RobsonME , ImSA , SenkusE , XuB , DomchekSM , MasudaN , et al. OlympiAD: phase III trial of olaparib monotherapy versus chemotherapy for patients (pts) with HER2-negative metastatic breast cancer (mBC) and a germline BRCA mutation (gBRCAm). Journal of Clinical Oncology2017;35(Suppl 18):LBA4-LBA4. RobsonME , RuddyKJ , ImSA , Senkus-KonefkaE , XuB , DomchekSM , et al. EORTC QLQ-C30 (QLQ-C30) symptoms in patients (pts) with HER2-negative metastatic breast cancer (mBC) and a germline BRCA mutation (gBRCAm) receiving olaparib vs chemotherapy treatment of physician’s choice (TPC) in OlympiAD. Journal of Clinical Oncology2018;36(Suppl 15):1045. RobsonME , TungN , ConteP , ImSA , SenkusE , XuB , et al. OlympiAD final overall survival and tolerability results: olaparib versus chemotherapy treatment of physician’s choice in patients with a germline BRCA mutation and HER2-negative metastatic breast cancer. Annals of Oncology2019;30(4):558-66. Senkus-KonefkaE , DomchekSM , ImSA , XuB , ArmstrongA , MasudaN , et al. Subgroup analysis of olaparib monotherapy versus chemotherapy by hormone receptor and BRCA mutation status in patients with HER2-negative metastatic breast cancer and a germline BRCA mutation: OlympiAD. European Journal of Cancer2018;92:S19-20. TungNM , ImSA , Senkus-KonefkaE , XuB , DomchekSM , MasudaN , et al. Olaparib versus chemotherapy treatment of physician’s choice in patients with a germline BRCA mutation and HER2-negative metastatic breast cancer (OlympiAD): efficacy in patients with visceral metastases. Journal of Clinical Oncology2018;36(Suppl 15):1053. ">OLYMPIAD</a>). Pooled analysis of five trials with a sample size of 1474 patients showed PARP inhibitors prolong PFS, with a HR of 0.63 (95% CI 0.56 to 0.71; P &lt; 0.00001; high‐certainty evidence), no significant heterogeneity (I<sup>2</sup> = 2%, P = 0.39). </p> <p>Subgroup analyses for PFS outcomes based on trial level data were performed for triple‐negative breast cancer, hormone‐positive and/or HER2‐positive breast cancer, BRCA1 and BRCA2 germline mutations and patients who had received prior chemotherapy for advanced breast cancer or not. Four trials were included for these pooled analyses (<a href="./references#CD011395-bbs2-0002" title="DiérasV , HanHS , RobsonME , PalacovaM , MarcomPK , JagerA , et al. Evaluation of veliparib (V) and temozolomide (TMZ) in a phase 2 randomized study of the efficacy and tolerability of V+TMZ or carboplatin (C) and paclitaxel (P) vs placebo (Plc)+C/P in patients (pts) with BRCA1 or BRCA2 mutations and metastatic breast cancer. Cancer Research2017;77(Suppl 4):Abstract nr SABCS16-P4-22-02. HanHS , DiérasV , RobsonM , PalácováM , MarcomPK , Jager A et al. Veliparib with temozolomide or carboplatin/paclitaxel versus placebo with carboplatin/paclitaxel in patients with BRCA1/2 locally recurrent/metastatic breast cancer: randomized phase II study. Annals of Oncology2018;29(1):154-61. HanHS , DiérasV , RobsonME , PalácováM , MarcomPK , JagerA , et al. Efficacy and tolerability of veliparib (V; ABT-888) in combination with carboplatin (C) and paclitaxel (P) vs placebo (Plc)+C/P in patients (pts) with BRCA1 or BRCA2 mutations and metastatic breast cancer: a randomized, phase 2 study. Cancer Research2017;77(Suppl 4):Abstract nr SABCS16-S2-05. IsakoffSJ , PuhallaS , DomchekSM , FriedlanderM , KaufmanB , RobsonM , et al. A randomized Phase II study of veliparib with temozolomide or carboplatin/paclitaxel versus placebo with carboplatin/paclitaxel in BRCA1/2 metastatic breast cancer: design and rationale. Future Oncology2017;13(4):307-20. ">BROCADE 2</a>; <a href="./references#CD011395-bbs2-0003" title="ArunBK , HanHS , KaufmanB , WildiersH , FriedlanderM , AyoubJP , et al. First-line veliparib plus carboplatin/paclitaxel in patients with HER2-negative advanced/metastatic gBRCA-associated breast cancer: planned subgroup analysis from the phase 3 BROCADE3 trial. Cancer Research2020;80(Suppl 4):Abstract nr PD4-01. AyoubJP , FriedlanderML , DierasVC , WildiersH , ArunB , HanHS , et al. Veliparib plus carboplatin-paclitaxel in patients with HER2-negative advanced/metastatic gBRCA-associated breast cancer: results in hormone receptor-positive and triple-negative breast cancer subgroups from the phase III BROCADE3 trial. Annals of Oncology2020;31(Suppl 2):S65. DierasV , HanH , KaufmanB , WildiersH , FriedlanderM , AyoubJ , et al. A Phase 3 randomized, placebo-controlled trial of carboplatin and paclitaxel with or without the PARP inhibitor veliparib (ABT-888) in HER2-negative metastatic or locally advanced unresectable BRCA-associated breast cancer. Annals of Oncology2019;30(Suppl 5):v851-v934. ">BROCADE 3</a>; <a href="./references#CD011395-bbs2-0004" title="DiabS , RugoHS , MinaLA , PuhallaS , MahtaniRL , HenryNL , et al. Efficacy and safety of talazoparib (TALA) or physician's choice of therapy (PCT) in United States patients (pts) with HER2- germline BRCA1/2-mutated (gBRCAm) locally advanced/metastatic breast cancer (LA/MBC) in the EMBRACA study. Journal of Clinical Oncology2019;37(Suppl 15):1044. EiermannW , RugoHS , DiabS , EttlJ , HurvitzSA , GoncalvesA , et al. Analysis of germline BRCA1/2 mutated (g BRCAmut) hormone receptor-positive (HR+) and triple-negative breast cancer (TNBC) treated with talazoparib (TALA). Journal of Clinical Oncology2018;36(Suppl 15):1070. EttlJ , HurvitzSA , RugoHS , LeeKH , MinaLA , WoodwardNE , et al. Outcomes of talazoparib (TALA) versus physician's choice of chemotherapy (PCT) in patients (pts) with advanced breast cancer (ABC) and a germline BRCA (gBRCA) mutation by line of chemotherapy (CT) in the EMBRACA trial. Journal of Clinical Oncology2019;37(Suppl 15):1071. EttlJ , QuekRG , BhattacharyyaH , RugoHS , HurvitzSA , GonçalvesA . Patient Reported Outcomes (PRO) in patients (pts) with HER2-advanced breast cancer (ABC) and a germline BRCA1/2 mutation (gBRCAm) receiving talazoparib (TALA) vs physician’s choice chemotherapy (PCT) in the EMBRACA trial: a focus on subgroups with/without visceral disease. Annals of Oncology2019;30(Suppl 5):v129–30. EttlJ , QuekRG , HurvitzSA , GoncalvesA , TudorIC , RugoHS . Hospitalization and supportive care medication (SCM) utilisation in patients (pts) with advanced breast cancer (ABC) and a germline BRCA1/2 mutation (gBRCAm) in EMBRACA. Annals of Oncology2019;30(Suppl 3):iii52. EttlJ , QuekRG , LeeKH , RugoHS , HurvitzS , GonçalvesA , et al. Quality of life with talazoparib versus physician’s choice of chemotherapy in patients with advanced breast cancer and germline BRCA1/2 mutation: patient-reported outcomes from the EMBRACA phase III trial. Annals of Oncology2018;29(9):1939-47. FaschingPA , QuekRG , BhattacharyyaH , HurvitzSA , RugoHS , EttlJ . Impact of objective response (OR) on patient-reported outcomes (PRO) in patients (pts) with advanced breast cancer (ABC) and a germline BRCA1/2 (gBRCA) mutation in the phase III EMBRACA trial. Annals of Oncology2019;30(Suppl 3):iii49. GonçalvesA , EiermannW , RugoHS , EttlJ , HurvitzSA , YerushalmiR , et al. EMBRACA: Efficacy and safety in comparing talazoparib (TALA) with physician's choice of therapy (PCT) in patients (pts) with advanced breast cancer (aBC) and a germline BRCA mutation (gBRCAm); BRCA1/BRCA2 subgroup analysis. Annals of Oncology2018;29(Suppl 8):viii96–7. GoncalvesA , QuekRGW , BhattacharyyaH , EttlJ , HurvitzSA , RugoHS . Patient-reported outcomes (PRO) in patients (pts) with Her2-advanced breast cancer (ABC) receiving talazoparib (TALA) vs physician's choice chemotherapy (PCT): a focus on EMBRACA germline BRCA1 and BRCA2 mutation (gBRCA1/2m) subgroups. Breast2019;48(Suppl 2):S71. HurvitzSA , GoncalvesA , RugoHS , LeeKH , FehrenbacherL , MinaLA , et al. Talazoparib in patients with a germline BRCA-mutated advanced breast cancer: detailed safety analyses from the phase III EMBRACA Trial. Oncologist2019;25(3):e439-50. LeeKH , KimSB , SohnJ , GoodwinA , UsariT , LanzaloneS , et al. Talazoparib (TALA) vs physician’s choice of chemotherapy (PCT) in Asian patients (Pts) with HER2- advanced breast cancer (ABC) and a germline BRCA1/2 mutation (gBRCA1/2mut): data from phase III EMBRACA. Annals of Oncology2019;30(9):ix14. LittonJ , EttlJ , HurvitzSA , MinaLA , RugoHS , LeeKH , et al. A phase 3, open-label, randomized, 2-arm international study of the oral dual PARP inhibitor talazoparib in germline BRCA mutation subjects with locally advanced and/or metastatic breast cancer (EMBRACA). Cancer Research2017;77(Suppl 4):Abstract nr OT2-01-13. LittonJ , RugoHS , EttlJ , HurvitzS , GoncalvesA , LeeKH , et al. EMBRACA: a phase 3 trial comparing talazoparib, an oral PARP inhibitor, to physicianʼs choice of therapy in patients with advanced breast cancer and a germline BRCA mutation [abstract]. In: San Antonio Breast Cancer Symposium; 2017 Dec 5-9; San Antonio (TX). San Antonio (TX), 2017. LittonJK , HurvitzSA , MinaLA , RugoHS , LeeKH , GonçalvesA , et al. Talazoparib (TALA) in germline BRCA1/2 (gBRCA1/2)-mutated human epidermal growth factor receptor 2 negative (HER2-) advanced breast cancer (ABC): final overall survival (OS) results from randomized phase 3 EMBRACA trial. Cancer Research2020;80(Suppl 16):Abstract no. CT071. LittonJK , RugoHS , EttlJ , HurvitzSA , GonçalvesA , LeeKH , et al. Talazoparib in patients with advanced breast cancer and a germline BRCA mutation. New England Journal of Medicine2018;379(8):753-63. MartínM , EiermannW , RugoHS , EttlJ , HurvitzSA , GonçalvesA , et al. EMBRACA: Comparison of efficacy and safety of talazoparib (TALA) and physician's choice of therapy (PCT) in patients (pts) with advanced breast cancer (aBC), a germline BRCA1/2 mutation (gBRCAm), and prior platinum treatment. Annals of Oncology2018;29(Suppl 8):viii96. MinaL , LeeKH , GoncalvesA , WoodwardN , HurvitzSA , DiabS , et al. EMBRACA: efficacy and safety of talazoparib or physician's choice of therapy in patients with advanced breast cancer and a germline BRCA1/2 mutation: a regional analysis. Cancer Research2019;79(Suppl 4):Abstract nr P6-18-12. QuekR , BhattacharyyaH , HurvitzS , GoncalvesA , EttlJ , RugoH . Patient-reported outcomes in patients with HER2-advanced breast cancer and a germline BRCA1/2 mutation receiving talazoparib versus physician's choice chemotherapy: a focus on EMBRACA age subgroups. Journal of Managed Care and Specialty Pharmacy2019;25(Suppl 10A):S37-8. QuekRGW , BhattacharyyaH , GoncalvesA , RugoHS , HurvitzSA , EttlJ . Pcn491 Patient reported outcomes (PRO) of talazoparib (TALA) versus physician's choice of chemotherapy (PCT) in patients (pts) with advanced breast cancer (aBC) and a germline BRCA (gBRCa) mutation: a focus on Embraca pts with/without prior chemotherapy (CT) subgroups. Value in Health2019;22(Suppl 3):S532. RugoHS , EttlJ , HurvitzSA , GoncalvesA , LeeKH , FehrenbacherL , et al. Outcomes in clinically relevant patient subgroups from the EMBRACA study: talazoparib vs physician's choice standard-of-care chemotherapy. Journal of the National Cancer Institute Cancer Spectrum2020;4(1):pkz085. RugoHS , EttlJ , WoodwardNE , HurvitzSA , GoncalvesA , LeeKH , et al. EMBRACA: efficacy outcomes in clinically relevant subgroups comparing talazoparib (TALA), an oral poly ADP ribose polymerase (PARP) inhibitor, to physician's choice of therapy (PCT) in patients with advanced breast cancer and a germline BRCA mutation. Journal of Clinical Oncology2018;36(Suppl 15):1069. RugoHS , QuekR , EttlJ , HurvitzSA , BhattacharyyaH , HannahAL , et al. Patient-reported outcomes (PRO) in patients (pts) with advanced breast cancer and a germline BRCA1/2 mutation (gBRCAm) receiving talazoparib (TALA) vs physician’s choice chemotherapy treatment (PCT): a focus on the EMBRACA triple negative (TNBC) subpopulation. Annals of Oncology2018;29(Suppl 8):viii91. YuY , ElmeliegyM , LittonJK , TudorIC , CzibereA , ZhengJ , et al. Exposure-efficacy progression-free survival (PFS) analyses of breast cancer patients with germline BRCA1/2 mutations receiving talazoparib in the phase III EMBRACA trial. Annals of Oncology2018;29(Suppl 8):viii97. YuY , ElmeliegyM , LittonJK , TudorIC , CzibereA , ZhengJ , et al. Talazoparib exposure-efficacy analysis in patients with advanced breast cancer and germline BRCA1/2 mutations in the EMBRACA trial. Journal of Clinical Pharmacology2020;60(10):1324-33. ">EMBRACA</a>; <a href="./references#CD011395-bbs2-0006" title="DelalogeS , ContePF , ImS , Senkus-KonefkaE , XuB , DomchekSM , et al. OlympiAD: further efficacy outcomes in patients with HER2-negative metastatic breast cancer and a germline BRCA mutation receiving olaparib monotherapy vs standard single-agent chemotherapy treatment of physician’s choice. Annals of Oncology2017;28(Suppl 5):v74-v108. DomchekS , RobsonM , ImS , SenkusE , XuB , MasudaN , et al. Tolerability of olaparib monotherapy versus chemotherapy in patients with HER2-negative metastatic breast cancer and a germline BRCA mutation: OlympiAD. Cancer Research2018;78(Suppl 4):Abstract nr P5-21-12. ImSA , XuB , LiW , RobsonM , OuyangQ , YehDC , et al. Olaparib monotherapy for Asian patients with a germline BRCA mutation and HER2-negative metastatic breast cancer: OlympiAD randomized trial subgroup analysis. Scientific Reports2020;10(1):8753. ImSA , XuB , LiW , RobsonM , OuyangQ , YehDC , et al. Olaparib monotherapy versus chemotherapy for patients with HER2-negative metastatic breast cancer and a germline BRCA mutation: Asian subgroup analysis from the phase III OlympiAD trial. Cancer Research2018;78(Suppl 4):Abstract nr P5-21-13. MerensC , BannisterW , BergnerS , HettleR , McCreaC , McCutcheonS , et al. Impact of olaparib versus chemotherapy on the use of strong pain medications in gBRCA-mutated HER2-negative metastatic breast cancer and associated patient reported outcomes. Cancer Research2020;80(Suppl 4):Abstract nr P6-13-05. RobsonM , HettleR , DegboeA , SaundersO , CainT , KilvertH , et al. Estimating the health state utility of patients with HER2–gBRCA+ metastatic breast cancer treated with olaparib or chemotherapy via a mapping analysis of EORTC QLQ-C30 data collected in the Olympiad clinical trial. Value in Health2018;21(Suppl 1):S12. RobsonM , ImSA , SenkusE , XuB , DomchekS , MasudaN , et al. OlympiAD extended follow-up for overall survival and safety: olaparib versus chemotherapy treatment of physician’s choice in patients with a germline BRCA mutation and HER2-negative metastatic breast cancer. Cancer Research2020;80(Suppl 4):Abstract nr PD4-03. RobsonM , ImSA , SenkusE , XuB , DomchekSM , MasudaN , et al. Olaparib for metastatic breast cancer in patients with a germline BRCA mutation. New England Journal of Medicine2017;377(6):523-33. RobsonM , RuddyKJ , ImSA , SenkusE , XuB , DomchekSM , et al. Patient-reported outcomes in patients with a germline BRCA mutation and HER2-negative metastatic breast cancer receiving olaparib versus chemotherapy in the OlympiAD trial. European Journal of Cancer2019;120:20-30. RobsonM , RuddyKJ , ImSA , Senkus-KonefkaE , XuB , DomchekSM , et al. OlympiAD: health-related quality of life (HRQoL) in patients with HER2-negative metastatic breast cancer (mBC) and a germline BRCA mutation (gBRCAm) receiving olaparib monotherapy vs standard single-agent chemotherapy treatment of physician’s choice (TPC). Annals of Oncology2017;28(Suppl 5):v74-v108. RobsonME , ImSA , SenkusE , XuB , DomchekS , MasudaN , et al. Abstract CT038: OlympiAD final overall survival: olaparib versus chemotherapy treatment of physician's choice (TPC) in patients with HER2-negative metastatic breast cancer (mBC) and a germline BRCA mutation (gBRCAm). American Association for Cancer Research2018;78(Suppl 13):CT038. RobsonME , ImSA , SenkusE , XuB , DomchekSM , MasudaN , et al. OlympiAD: phase III trial of olaparib monotherapy versus chemotherapy for patients (pts) with HER2-negative metastatic breast cancer (mBC) and a germline BRCA mutation (gBRCAm). Journal of Clinical Oncology2017;35(Suppl 18):LBA4-LBA4. RobsonME , RuddyKJ , ImSA , Senkus-KonefkaE , XuB , DomchekSM , et al. EORTC QLQ-C30 (QLQ-C30) symptoms in patients (pts) with HER2-negative metastatic breast cancer (mBC) and a germline BRCA mutation (gBRCAm) receiving olaparib vs chemotherapy treatment of physician’s choice (TPC) in OlympiAD. Journal of Clinical Oncology2018;36(Suppl 15):1045. RobsonME , TungN , ConteP , ImSA , SenkusE , XuB , et al. OlympiAD final overall survival and tolerability results: olaparib versus chemotherapy treatment of physician’s choice in patients with a germline BRCA mutation and HER2-negative metastatic breast cancer. Annals of Oncology2019;30(4):558-66. Senkus-KonefkaE , DomchekSM , ImSA , XuB , ArmstrongA , MasudaN , et al. Subgroup analysis of olaparib monotherapy versus chemotherapy by hormone receptor and BRCA mutation status in patients with HER2-negative metastatic breast cancer and a germline BRCA mutation: OlympiAD. European Journal of Cancer2018;92:S19-20. TungNM , ImSA , Senkus-KonefkaE , XuB , DomchekSM , MasudaN , et al. Olaparib versus chemotherapy treatment of physician’s choice in patients with a germline BRCA mutation and HER2-negative metastatic breast cancer (OlympiAD): efficacy in patients with visceral metastases. Journal of Clinical Oncology2018;36(Suppl 15):1053. ">OLYMPIAD</a>). <a href="./references#CD011395-bbs2-0005" title="KummarS , WadeJL , OzaAM , SullivanD , ChenAP , GandaraDR , et al. Randomized phase II trial of cyclophosphamide and the oral poly (ADP-ribose) polymerase inhibitor veliparib in patients with recurrent, advanced triple-negative breast cancer. Investigational New Drugs2016;34(3):355–63. ">Kummar 2016</a> did not report subgroup outcomes. </p> <p>All four trials included for subgroup analyses for PFS outcomes stipulated participants must carry a germline BRCA mutation as part of their inclusion criteria. For patients with BRCA1 mutated breast cancer (N = 717, 4 RCTs), there was evidence of PFS benefit on pooling of studies (HR 0.65, 95% CI 0.53 to 0.78; P &lt; 0.0001), with no significant heterogeneity (I<sup>2</sup> = 0.0%, P = 0.62). For patients with BRCA2 mutated breast cancer (N = 697, 4 RCTs), there was evidence of PFS benefit on pooling of studies (HR 0.62, 95% CI 0.51 to 0.76; P &lt; 0.0001) with no significant heterogeneity (I<sup>2</sup> = 0%, P = 0.42). There was no significant evidence of interaction between these two groups (subgroup interaction P = 0.78). </p> <p>For patients with triple‐negative breast cancer (N = 664, 4 RCTs), there was evidence of PFS benefit on pooling of studies (HR 0.61, 95% CI 0.47 to 0.80; P = 0.0003), with moderate heterogeneity (I<sup>2</sup> = 44%, P = 0.15). Examination of the relevant studies revealed no particular explanation for this statistical heterogeneity, and thus no relevant subgroups of this subgroup analysis were further analysed. </p> <p>For patients without triple‐negative breast cancer, that is, hormone‐positive and/or HER2‐positive breast cancer, (N = 771, 4 RCTs), there was evidence of PFS benefit on pooling of studies (HR 0.66, 95% CI 0.53 to 0.82; P &lt; 0.00001) with minimal heterogeneity (I<sup>2</sup> = 23%, P = 0.27). There was no significant evidence of interaction between these two groups (subgroup interaction P = 0.68). </p> <p>For patients who had received prior chemotherapy for advanced breast cancer (N = 729, 4 RCTs), there was evidence of PFS benefit on pooling of studies (HR 0.64, 95% CI 0.53 to 0.77; P &lt; 0.00001), with no significant heterogeneity (I<sup>2</sup> = 0%, P = 0.57). For patients who had not received prior chemotherapy for advanced breast cancer (N = 706, 4 RCTs), there was evidence of PFS benefit on pooling of studies (HR 0.66, 95% CI 0.55 to 0.79; P &lt; 0.00001), with no significant heterogeneity (I<sup>2</sup> = 0%, P = 0.51). Further, there was no significant evidence of interaction between these two groups (subgroup interaction P = 0.82). </p> <p>Although not prespecified, we also looked at PFS outcomes for patients who had received prior platinum chemotherapy compared to those who had not, as this is a clinically relevant distinction (see “<a href="#CD011395-sec-0082">Differences between protocol and review</a>”). Three trials were included for this pooled analysis (<a href="./references#CD011395-bbs2-0003" title="ArunBK , HanHS , KaufmanB , WildiersH , FriedlanderM , AyoubJP , et al. First-line veliparib plus carboplatin/paclitaxel in patients with HER2-negative advanced/metastatic gBRCA-associated breast cancer: planned subgroup analysis from the phase 3 BROCADE3 trial. Cancer Research2020;80(Suppl 4):Abstract nr PD4-01. AyoubJP , FriedlanderML , DierasVC , WildiersH , ArunB , HanHS , et al. Veliparib plus carboplatin-paclitaxel in patients with HER2-negative advanced/metastatic gBRCA-associated breast cancer: results in hormone receptor-positive and triple-negative breast cancer subgroups from the phase III BROCADE3 trial. Annals of Oncology2020;31(Suppl 2):S65. DierasV , HanH , KaufmanB , WildiersH , FriedlanderM , AyoubJ , et al. A Phase 3 randomized, placebo-controlled trial of carboplatin and paclitaxel with or without the PARP inhibitor veliparib (ABT-888) in HER2-negative metastatic or locally advanced unresectable BRCA-associated breast cancer. Annals of Oncology2019;30(Suppl 5):v851-v934. ">BROCADE 3</a>; <a href="./references#CD011395-bbs2-0004" title="DiabS , RugoHS , MinaLA , PuhallaS , MahtaniRL , HenryNL , et al. Efficacy and safety of talazoparib (TALA) or physician's choice of therapy (PCT) in United States patients (pts) with HER2- germline BRCA1/2-mutated (gBRCAm) locally advanced/metastatic breast cancer (LA/MBC) in the EMBRACA study. Journal of Clinical Oncology2019;37(Suppl 15):1044. EiermannW , RugoHS , DiabS , EttlJ , HurvitzSA , GoncalvesA , et al. Analysis of germline BRCA1/2 mutated (g BRCAmut) hormone receptor-positive (HR+) and triple-negative breast cancer (TNBC) treated with talazoparib (TALA). Journal of Clinical Oncology2018;36(Suppl 15):1070. EttlJ , HurvitzSA , RugoHS , LeeKH , MinaLA , WoodwardNE , et al. Outcomes of talazoparib (TALA) versus physician's choice of chemotherapy (PCT) in patients (pts) with advanced breast cancer (ABC) and a germline BRCA (gBRCA) mutation by line of chemotherapy (CT) in the EMBRACA trial. Journal of Clinical Oncology2019;37(Suppl 15):1071. EttlJ , QuekRG , BhattacharyyaH , RugoHS , HurvitzSA , GonçalvesA . Patient Reported Outcomes (PRO) in patients (pts) with HER2-advanced breast cancer (ABC) and a germline BRCA1/2 mutation (gBRCAm) receiving talazoparib (TALA) vs physician’s choice chemotherapy (PCT) in the EMBRACA trial: a focus on subgroups with/without visceral disease. Annals of Oncology2019;30(Suppl 5):v129–30. EttlJ , QuekRG , HurvitzSA , GoncalvesA , TudorIC , RugoHS . Hospitalization and supportive care medication (SCM) utilisation in patients (pts) with advanced breast cancer (ABC) and a germline BRCA1/2 mutation (gBRCAm) in EMBRACA. Annals of Oncology2019;30(Suppl 3):iii52. EttlJ , QuekRG , LeeKH , RugoHS , HurvitzS , GonçalvesA , et al. Quality of life with talazoparib versus physician’s choice of chemotherapy in patients with advanced breast cancer and germline BRCA1/2 mutation: patient-reported outcomes from the EMBRACA phase III trial. Annals of Oncology2018;29(9):1939-47. FaschingPA , QuekRG , BhattacharyyaH , HurvitzSA , RugoHS , EttlJ . Impact of objective response (OR) on patient-reported outcomes (PRO) in patients (pts) with advanced breast cancer (ABC) and a germline BRCA1/2 (gBRCA) mutation in the phase III EMBRACA trial. Annals of Oncology2019;30(Suppl 3):iii49. GonçalvesA , EiermannW , RugoHS , EttlJ , HurvitzSA , YerushalmiR , et al. EMBRACA: Efficacy and safety in comparing talazoparib (TALA) with physician's choice of therapy (PCT) in patients (pts) with advanced breast cancer (aBC) and a germline BRCA mutation (gBRCAm); BRCA1/BRCA2 subgroup analysis. Annals of Oncology2018;29(Suppl 8):viii96–7. GoncalvesA , QuekRGW , BhattacharyyaH , EttlJ , HurvitzSA , RugoHS . Patient-reported outcomes (PRO) in patients (pts) with Her2-advanced breast cancer (ABC) receiving talazoparib (TALA) vs physician's choice chemotherapy (PCT): a focus on EMBRACA germline BRCA1 and BRCA2 mutation (gBRCA1/2m) subgroups. Breast2019;48(Suppl 2):S71. HurvitzSA , GoncalvesA , RugoHS , LeeKH , FehrenbacherL , MinaLA , et al. Talazoparib in patients with a germline BRCA-mutated advanced breast cancer: detailed safety analyses from the phase III EMBRACA Trial. Oncologist2019;25(3):e439-50. LeeKH , KimSB , SohnJ , GoodwinA , UsariT , LanzaloneS , et al. Talazoparib (TALA) vs physician’s choice of chemotherapy (PCT) in Asian patients (Pts) with HER2- advanced breast cancer (ABC) and a germline BRCA1/2 mutation (gBRCA1/2mut): data from phase III EMBRACA. Annals of Oncology2019;30(9):ix14. LittonJ , EttlJ , HurvitzSA , MinaLA , RugoHS , LeeKH , et al. A phase 3, open-label, randomized, 2-arm international study of the oral dual PARP inhibitor talazoparib in germline BRCA mutation subjects with locally advanced and/or metastatic breast cancer (EMBRACA). Cancer Research2017;77(Suppl 4):Abstract nr OT2-01-13. LittonJ , RugoHS , EttlJ , HurvitzS , GoncalvesA , LeeKH , et al. EMBRACA: a phase 3 trial comparing talazoparib, an oral PARP inhibitor, to physicianʼs choice of therapy in patients with advanced breast cancer and a germline BRCA mutation [abstract]. In: San Antonio Breast Cancer Symposium; 2017 Dec 5-9; San Antonio (TX). San Antonio (TX), 2017. LittonJK , HurvitzSA , MinaLA , RugoHS , LeeKH , GonçalvesA , et al. Talazoparib (TALA) in germline BRCA1/2 (gBRCA1/2)-mutated human epidermal growth factor receptor 2 negative (HER2-) advanced breast cancer (ABC): final overall survival (OS) results from randomized phase 3 EMBRACA trial. Cancer Research2020;80(Suppl 16):Abstract no. CT071. LittonJK , RugoHS , EttlJ , HurvitzSA , GonçalvesA , LeeKH , et al. Talazoparib in patients with advanced breast cancer and a germline BRCA mutation. New England Journal of Medicine2018;379(8):753-63. MartínM , EiermannW , RugoHS , EttlJ , HurvitzSA , GonçalvesA , et al. EMBRACA: Comparison of efficacy and safety of talazoparib (TALA) and physician's choice of therapy (PCT) in patients (pts) with advanced breast cancer (aBC), a germline BRCA1/2 mutation (gBRCAm), and prior platinum treatment. Annals of Oncology2018;29(Suppl 8):viii96. MinaL , LeeKH , GoncalvesA , WoodwardN , HurvitzSA , DiabS , et al. EMBRACA: efficacy and safety of talazoparib or physician's choice of therapy in patients with advanced breast cancer and a germline BRCA1/2 mutation: a regional analysis. Cancer Research2019;79(Suppl 4):Abstract nr P6-18-12. QuekR , BhattacharyyaH , HurvitzS , GoncalvesA , EttlJ , RugoH . Patient-reported outcomes in patients with HER2-advanced breast cancer and a germline BRCA1/2 mutation receiving talazoparib versus physician's choice chemotherapy: a focus on EMBRACA age subgroups. Journal of Managed Care and Specialty Pharmacy2019;25(Suppl 10A):S37-8. QuekRGW , BhattacharyyaH , GoncalvesA , RugoHS , HurvitzSA , EttlJ . Pcn491 Patient reported outcomes (PRO) of talazoparib (TALA) versus physician's choice of chemotherapy (PCT) in patients (pts) with advanced breast cancer (aBC) and a germline BRCA (gBRCa) mutation: a focus on Embraca pts with/without prior chemotherapy (CT) subgroups. Value in Health2019;22(Suppl 3):S532. RugoHS , EttlJ , HurvitzSA , GoncalvesA , LeeKH , FehrenbacherL , et al. Outcomes in clinically relevant patient subgroups from the EMBRACA study: talazoparib vs physician's choice standard-of-care chemotherapy. Journal of the National Cancer Institute Cancer Spectrum2020;4(1):pkz085. RugoHS , EttlJ , WoodwardNE , HurvitzSA , GoncalvesA , LeeKH , et al. EMBRACA: efficacy outcomes in clinically relevant subgroups comparing talazoparib (TALA), an oral poly ADP ribose polymerase (PARP) inhibitor, to physician's choice of therapy (PCT) in patients with advanced breast cancer and a germline BRCA mutation. Journal of Clinical Oncology2018;36(Suppl 15):1069. RugoHS , QuekR , EttlJ , HurvitzSA , BhattacharyyaH , HannahAL , et al. Patient-reported outcomes (PRO) in patients (pts) with advanced breast cancer and a germline BRCA1/2 mutation (gBRCAm) receiving talazoparib (TALA) vs physician’s choice chemotherapy treatment (PCT): a focus on the EMBRACA triple negative (TNBC) subpopulation. Annals of Oncology2018;29(Suppl 8):viii91. YuY , ElmeliegyM , LittonJK , TudorIC , CzibereA , ZhengJ , et al. Exposure-efficacy progression-free survival (PFS) analyses of breast cancer patients with germline BRCA1/2 mutations receiving talazoparib in the phase III EMBRACA trial. Annals of Oncology2018;29(Suppl 8):viii97. YuY , ElmeliegyM , LittonJK , TudorIC , CzibereA , ZhengJ , et al. Talazoparib exposure-efficacy analysis in patients with advanced breast cancer and germline BRCA1/2 mutations in the EMBRACA trial. Journal of Clinical Pharmacology2020;60(10):1324-33. ">EMBRACA</a>; <a href="./references#CD011395-bbs2-0006" title="DelalogeS , ContePF , ImS , Senkus-KonefkaE , XuB , DomchekSM , et al. OlympiAD: further efficacy outcomes in patients with HER2-negative metastatic breast cancer and a germline BRCA mutation receiving olaparib monotherapy vs standard single-agent chemotherapy treatment of physician’s choice. Annals of Oncology2017;28(Suppl 5):v74-v108. DomchekS , RobsonM , ImS , SenkusE , XuB , MasudaN , et al. Tolerability of olaparib monotherapy versus chemotherapy in patients with HER2-negative metastatic breast cancer and a germline BRCA mutation: OlympiAD. Cancer Research2018;78(Suppl 4):Abstract nr P5-21-12. ImSA , XuB , LiW , RobsonM , OuyangQ , YehDC , et al. Olaparib monotherapy for Asian patients with a germline BRCA mutation and HER2-negative metastatic breast cancer: OlympiAD randomized trial subgroup analysis. Scientific Reports2020;10(1):8753. ImSA , XuB , LiW , RobsonM , OuyangQ , YehDC , et al. Olaparib monotherapy versus chemotherapy for patients with HER2-negative metastatic breast cancer and a germline BRCA mutation: Asian subgroup analysis from the phase III OlympiAD trial. Cancer Research2018;78(Suppl 4):Abstract nr P5-21-13. MerensC , BannisterW , BergnerS , HettleR , McCreaC , McCutcheonS , et al. Impact of olaparib versus chemotherapy on the use of strong pain medications in gBRCA-mutated HER2-negative metastatic breast cancer and associated patient reported outcomes. Cancer Research2020;80(Suppl 4):Abstract nr P6-13-05. RobsonM , HettleR , DegboeA , SaundersO , CainT , KilvertH , et al. Estimating the health state utility of patients with HER2–gBRCA+ metastatic breast cancer treated with olaparib or chemotherapy via a mapping analysis of EORTC QLQ-C30 data collected in the Olympiad clinical trial. Value in Health2018;21(Suppl 1):S12. RobsonM , ImSA , SenkusE , XuB , DomchekS , MasudaN , et al. OlympiAD extended follow-up for overall survival and safety: olaparib versus chemotherapy treatment of physician’s choice in patients with a germline BRCA mutation and HER2-negative metastatic breast cancer. Cancer Research2020;80(Suppl 4):Abstract nr PD4-03. RobsonM , ImSA , SenkusE , XuB , DomchekSM , MasudaN , et al. Olaparib for metastatic breast cancer in patients with a germline BRCA mutation. New England Journal of Medicine2017;377(6):523-33. RobsonM , RuddyKJ , ImSA , SenkusE , XuB , DomchekSM , et al. Patient-reported outcomes in patients with a germline BRCA mutation and HER2-negative metastatic breast cancer receiving olaparib versus chemotherapy in the OlympiAD trial. European Journal of Cancer2019;120:20-30. RobsonM , RuddyKJ , ImSA , Senkus-KonefkaE , XuB , DomchekSM , et al. OlympiAD: health-related quality of life (HRQoL) in patients with HER2-negative metastatic breast cancer (mBC) and a germline BRCA mutation (gBRCAm) receiving olaparib monotherapy vs standard single-agent chemotherapy treatment of physician’s choice (TPC). Annals of Oncology2017;28(Suppl 5):v74-v108. RobsonME , ImSA , SenkusE , XuB , DomchekS , MasudaN , et al. Abstract CT038: OlympiAD final overall survival: olaparib versus chemotherapy treatment of physician's choice (TPC) in patients with HER2-negative metastatic breast cancer (mBC) and a germline BRCA mutation (gBRCAm). American Association for Cancer Research2018;78(Suppl 13):CT038. RobsonME , ImSA , SenkusE , XuB , DomchekSM , MasudaN , et al. OlympiAD: phase III trial of olaparib monotherapy versus chemotherapy for patients (pts) with HER2-negative metastatic breast cancer (mBC) and a germline BRCA mutation (gBRCAm). Journal of Clinical Oncology2017;35(Suppl 18):LBA4-LBA4. RobsonME , RuddyKJ , ImSA , Senkus-KonefkaE , XuB , DomchekSM , et al. EORTC QLQ-C30 (QLQ-C30) symptoms in patients (pts) with HER2-negative metastatic breast cancer (mBC) and a germline BRCA mutation (gBRCAm) receiving olaparib vs chemotherapy treatment of physician’s choice (TPC) in OlympiAD. Journal of Clinical Oncology2018;36(Suppl 15):1045. RobsonME , TungN , ConteP , ImSA , SenkusE , XuB , et al. OlympiAD final overall survival and tolerability results: olaparib versus chemotherapy treatment of physician’s choice in patients with a germline BRCA mutation and HER2-negative metastatic breast cancer. Annals of Oncology2019;30(4):558-66. Senkus-KonefkaE , DomchekSM , ImSA , XuB , ArmstrongA , MasudaN , et al. Subgroup analysis of olaparib monotherapy versus chemotherapy by hormone receptor and BRCA mutation status in patients with HER2-negative metastatic breast cancer and a germline BRCA mutation: OlympiAD. European Journal of Cancer2018;92:S19-20. TungNM , ImSA , Senkus-KonefkaE , XuB , DomchekSM , MasudaN , et al. Olaparib versus chemotherapy treatment of physician’s choice in patients with a germline BRCA mutation and HER2-negative metastatic breast cancer (OlympiAD): efficacy in patients with visceral metastases. Journal of Clinical Oncology2018;36(Suppl 15):1053. ">OLYMPIAD</a>). For patients who had received prior platinum chemotherapy (N = 205, 3 RCTs), there was no significant evidence of PFS prolongation on pooling of studies (HR 0.71, 95% CI 0.50 to 1.01; P = 0.05), with no significant heterogeneity (I<sup>2</sup> = 0%, P = 0.97). For patients who had not received prior platinum chemotherapy (N=1037, 3 RCTs), there was evidence of PFS benefit on pooling of studies (HR 0.63, 95% CI 0.53 to 0.73; P &lt; 0.00001) with some heterogeneity (I<sup>2</sup> = 16%, P = 0.30). There was no significant evidence of interaction between these two groups (subgroup interaction P = 0.52). These results should be interpreted with caution given lack of subgroup interaction and differences in subgroup sizes. </p> <p>Other potentially planned subgroup analyses in the protocol, including lines of therapy, performance status, PARP inhibitors as monotherapy, maintenance therapy or in combination with chemotherapy (or chemo‐radiotherapy) and position in the breast cancer treatment paradigm (first‐line, second‐line or third‐line) and different PARP inhibitors, were not performed due to the lack of these data from the included studies (see “<a href="#CD011395-sec-0082">Differences between protocol and review</a>”). </p> </section> <section id="CD011395-sec-0055"> <h5 class="title">1.3 Tumour response rates</h5> <p>See: <a href="#CD011395-fig-0005">Figure 5</a>; <a href="./references#CD011395-fig-0013" title="">Analysis 1.7</a>. </p> <div class="figure" id="CD011395-fig-0005"> <div class="figure-caption-wrapper-top"> <nav class="inline-nav-list has-dividers"> <ul> <li><a class="open-in-figure-viewer" href="#0">Open in figure viewer</a></li> </ul> </nav> <div class="figure-label">Figure 5</div> </div> <hr class="top"/><img alt="Forest plot of comparison: 1 PARPi‐containing regimen vs non‐PARPi regimen, outcome: 1.3 Response rate" data-id="CD011395-fig-0005" src="/cdsr/doi/10.1002/14651858.CD011395.pub2/media/CDSR/CD011395/image_n/nCD011395-FIG-05.svg"/><hr class="bottom"/> <div class="figure-caption-wrapper-bottom"> <div class="figure-caption"> <p>Forest plot of comparison: 1 PARPi‐containing regimen vs non‐PARPi regimen, outcome: 1.3 Response rate </p> </div> </div> </div> <p>Five trials reported overall response rates (that is, complete response plus partial response as per RECIST v1.1) in patients with measurable disease with a total of 1185 participants (<a href="./references#CD011395-bbs2-0002" title="DiérasV , HanHS , RobsonME , PalacovaM , MarcomPK , JagerA , et al. Evaluation of veliparib (V) and temozolomide (TMZ) in a phase 2 randomized study of the efficacy and tolerability of V+TMZ or carboplatin (C) and paclitaxel (P) vs placebo (Plc)+C/P in patients (pts) with BRCA1 or BRCA2 mutations and metastatic breast cancer. Cancer Research2017;77(Suppl 4):Abstract nr SABCS16-P4-22-02. HanHS , DiérasV , RobsonM , PalácováM , MarcomPK , Jager A et al. Veliparib with temozolomide or carboplatin/paclitaxel versus placebo with carboplatin/paclitaxel in patients with BRCA1/2 locally recurrent/metastatic breast cancer: randomized phase II study. Annals of Oncology2018;29(1):154-61. HanHS , DiérasV , RobsonME , PalácováM , MarcomPK , JagerA , et al. Efficacy and tolerability of veliparib (V; ABT-888) in combination with carboplatin (C) and paclitaxel (P) vs placebo (Plc)+C/P in patients (pts) with BRCA1 or BRCA2 mutations and metastatic breast cancer: a randomized, phase 2 study. Cancer Research2017;77(Suppl 4):Abstract nr SABCS16-S2-05. IsakoffSJ , PuhallaS , DomchekSM , FriedlanderM , KaufmanB , RobsonM , et al. A randomized Phase II study of veliparib with temozolomide or carboplatin/paclitaxel versus placebo with carboplatin/paclitaxel in BRCA1/2 metastatic breast cancer: design and rationale. Future Oncology2017;13(4):307-20. ">BROCADE 2</a>; <a href="./references#CD011395-bbs2-0003" title="ArunBK , HanHS , KaufmanB , WildiersH , FriedlanderM , AyoubJP , et al. First-line veliparib plus carboplatin/paclitaxel in patients with HER2-negative advanced/metastatic gBRCA-associated breast cancer: planned subgroup analysis from the phase 3 BROCADE3 trial. Cancer Research2020;80(Suppl 4):Abstract nr PD4-01. AyoubJP , FriedlanderML , DierasVC , WildiersH , ArunB , HanHS , et al. Veliparib plus carboplatin-paclitaxel in patients with HER2-negative advanced/metastatic gBRCA-associated breast cancer: results in hormone receptor-positive and triple-negative breast cancer subgroups from the phase III BROCADE3 trial. Annals of Oncology2020;31(Suppl 2):S65. DierasV , HanH , KaufmanB , WildiersH , FriedlanderM , AyoubJ , et al. A Phase 3 randomized, placebo-controlled trial of carboplatin and paclitaxel with or without the PARP inhibitor veliparib (ABT-888) in HER2-negative metastatic or locally advanced unresectable BRCA-associated breast cancer. Annals of Oncology2019;30(Suppl 5):v851-v934. ">BROCADE 3</a>; <a href="./references#CD011395-bbs2-0004" title="DiabS , RugoHS , MinaLA , PuhallaS , MahtaniRL , HenryNL , et al. Efficacy and safety of talazoparib (TALA) or physician's choice of therapy (PCT) in United States patients (pts) with HER2- germline BRCA1/2-mutated (gBRCAm) locally advanced/metastatic breast cancer (LA/MBC) in the EMBRACA study. Journal of Clinical Oncology2019;37(Suppl 15):1044. EiermannW , RugoHS , DiabS , EttlJ , HurvitzSA , GoncalvesA , et al. Analysis of germline BRCA1/2 mutated (g BRCAmut) hormone receptor-positive (HR+) and triple-negative breast cancer (TNBC) treated with talazoparib (TALA). Journal of Clinical Oncology2018;36(Suppl 15):1070. EttlJ , HurvitzSA , RugoHS , LeeKH , MinaLA , WoodwardNE , et al. Outcomes of talazoparib (TALA) versus physician's choice of chemotherapy (PCT) in patients (pts) with advanced breast cancer (ABC) and a germline BRCA (gBRCA) mutation by line of chemotherapy (CT) in the EMBRACA trial. Journal of Clinical Oncology2019;37(Suppl 15):1071. EttlJ , QuekRG , BhattacharyyaH , RugoHS , HurvitzSA , GonçalvesA . Patient Reported Outcomes (PRO) in patients (pts) with HER2-advanced breast cancer (ABC) and a germline BRCA1/2 mutation (gBRCAm) receiving talazoparib (TALA) vs physician’s choice chemotherapy (PCT) in the EMBRACA trial: a focus on subgroups with/without visceral disease. Annals of Oncology2019;30(Suppl 5):v129–30. EttlJ , QuekRG , HurvitzSA , GoncalvesA , TudorIC , RugoHS . Hospitalization and supportive care medication (SCM) utilisation in patients (pts) with advanced breast cancer (ABC) and a germline BRCA1/2 mutation (gBRCAm) in EMBRACA. Annals of Oncology2019;30(Suppl 3):iii52. EttlJ , QuekRG , LeeKH , RugoHS , HurvitzS , GonçalvesA , et al. Quality of life with talazoparib versus physician’s choice of chemotherapy in patients with advanced breast cancer and germline BRCA1/2 mutation: patient-reported outcomes from the EMBRACA phase III trial. Annals of Oncology2018;29(9):1939-47. FaschingPA , QuekRG , BhattacharyyaH , HurvitzSA , RugoHS , EttlJ . Impact of objective response (OR) on patient-reported outcomes (PRO) in patients (pts) with advanced breast cancer (ABC) and a germline BRCA1/2 (gBRCA) mutation in the phase III EMBRACA trial. Annals of Oncology2019;30(Suppl 3):iii49. GonçalvesA , EiermannW , RugoHS , EttlJ , HurvitzSA , YerushalmiR , et al. EMBRACA: Efficacy and safety in comparing talazoparib (TALA) with physician's choice of therapy (PCT) in patients (pts) with advanced breast cancer (aBC) and a germline BRCA mutation (gBRCAm); BRCA1/BRCA2 subgroup analysis. Annals of Oncology2018;29(Suppl 8):viii96–7. GoncalvesA , QuekRGW , BhattacharyyaH , EttlJ , HurvitzSA , RugoHS . Patient-reported outcomes (PRO) in patients (pts) with Her2-advanced breast cancer (ABC) receiving talazoparib (TALA) vs physician's choice chemotherapy (PCT): a focus on EMBRACA germline BRCA1 and BRCA2 mutation (gBRCA1/2m) subgroups. Breast2019;48(Suppl 2):S71. HurvitzSA , GoncalvesA , RugoHS , LeeKH , FehrenbacherL , MinaLA , et al. Talazoparib in patients with a germline BRCA-mutated advanced breast cancer: detailed safety analyses from the phase III EMBRACA Trial. Oncologist2019;25(3):e439-50. LeeKH , KimSB , SohnJ , GoodwinA , UsariT , LanzaloneS , et al. Talazoparib (TALA) vs physician’s choice of chemotherapy (PCT) in Asian patients (Pts) with HER2- advanced breast cancer (ABC) and a germline BRCA1/2 mutation (gBRCA1/2mut): data from phase III EMBRACA. Annals of Oncology2019;30(9):ix14. LittonJ , EttlJ , HurvitzSA , MinaLA , RugoHS , LeeKH , et al. A phase 3, open-label, randomized, 2-arm international study of the oral dual PARP inhibitor talazoparib in germline BRCA mutation subjects with locally advanced and/or metastatic breast cancer (EMBRACA). Cancer Research2017;77(Suppl 4):Abstract nr OT2-01-13. LittonJ , RugoHS , EttlJ , HurvitzS , GoncalvesA , LeeKH , et al. EMBRACA: a phase 3 trial comparing talazoparib, an oral PARP inhibitor, to physicianʼs choice of therapy in patients with advanced breast cancer and a germline BRCA mutation [abstract]. In: San Antonio Breast Cancer Symposium; 2017 Dec 5-9; San Antonio (TX). San Antonio (TX), 2017. LittonJK , HurvitzSA , MinaLA , RugoHS , LeeKH , GonçalvesA , et al. Talazoparib (TALA) in germline BRCA1/2 (gBRCA1/2)-mutated human epidermal growth factor receptor 2 negative (HER2-) advanced breast cancer (ABC): final overall survival (OS) results from randomized phase 3 EMBRACA trial. Cancer Research2020;80(Suppl 16):Abstract no. CT071. LittonJK , RugoHS , EttlJ , HurvitzSA , GonçalvesA , LeeKH , et al. Talazoparib in patients with advanced breast cancer and a germline BRCA mutation. New England Journal of Medicine2018;379(8):753-63. MartínM , EiermannW , RugoHS , EttlJ , HurvitzSA , GonçalvesA , et al. EMBRACA: Comparison of efficacy and safety of talazoparib (TALA) and physician's choice of therapy (PCT) in patients (pts) with advanced breast cancer (aBC), a germline BRCA1/2 mutation (gBRCAm), and prior platinum treatment. Annals of Oncology2018;29(Suppl 8):viii96. MinaL , LeeKH , GoncalvesA , WoodwardN , HurvitzSA , DiabS , et al. EMBRACA: efficacy and safety of talazoparib or physician's choice of therapy in patients with advanced breast cancer and a germline BRCA1/2 mutation: a regional analysis. Cancer Research2019;79(Suppl 4):Abstract nr P6-18-12. QuekR , BhattacharyyaH , HurvitzS , GoncalvesA , EttlJ , RugoH . Patient-reported outcomes in patients with HER2-advanced breast cancer and a germline BRCA1/2 mutation receiving talazoparib versus physician's choice chemotherapy: a focus on EMBRACA age subgroups. Journal of Managed Care and Specialty Pharmacy2019;25(Suppl 10A):S37-8. QuekRGW , BhattacharyyaH , GoncalvesA , RugoHS , HurvitzSA , EttlJ . Pcn491 Patient reported outcomes (PRO) of talazoparib (TALA) versus physician's choice of chemotherapy (PCT) in patients (pts) with advanced breast cancer (aBC) and a germline BRCA (gBRCa) mutation: a focus on Embraca pts with/without prior chemotherapy (CT) subgroups. Value in Health2019;22(Suppl 3):S532. RugoHS , EttlJ , HurvitzSA , GoncalvesA , LeeKH , FehrenbacherL , et al. Outcomes in clinically relevant patient subgroups from the EMBRACA study: talazoparib vs physician's choice standard-of-care chemotherapy. Journal of the National Cancer Institute Cancer Spectrum2020;4(1):pkz085. RugoHS , EttlJ , WoodwardNE , HurvitzSA , GoncalvesA , LeeKH , et al. EMBRACA: efficacy outcomes in clinically relevant subgroups comparing talazoparib (TALA), an oral poly ADP ribose polymerase (PARP) inhibitor, to physician's choice of therapy (PCT) in patients with advanced breast cancer and a germline BRCA mutation. Journal of Clinical Oncology2018;36(Suppl 15):1069. RugoHS , QuekR , EttlJ , HurvitzSA , BhattacharyyaH , HannahAL , et al. Patient-reported outcomes (PRO) in patients (pts) with advanced breast cancer and a germline BRCA1/2 mutation (gBRCAm) receiving talazoparib (TALA) vs physician’s choice chemotherapy treatment (PCT): a focus on the EMBRACA triple negative (TNBC) subpopulation. Annals of Oncology2018;29(Suppl 8):viii91. YuY , ElmeliegyM , LittonJK , TudorIC , CzibereA , ZhengJ , et al. Exposure-efficacy progression-free survival (PFS) analyses of breast cancer patients with germline BRCA1/2 mutations receiving talazoparib in the phase III EMBRACA trial. Annals of Oncology2018;29(Suppl 8):viii97. YuY , ElmeliegyM , LittonJK , TudorIC , CzibereA , ZhengJ , et al. Talazoparib exposure-efficacy analysis in patients with advanced breast cancer and germline BRCA1/2 mutations in the EMBRACA trial. Journal of Clinical Pharmacology2020;60(10):1324-33. ">EMBRACA</a>; <a href="./references#CD011395-bbs2-0005" title="KummarS , WadeJL , OzaAM , SullivanD , ChenAP , GandaraDR , et al. Randomized phase II trial of cyclophosphamide and the oral poly (ADP-ribose) polymerase inhibitor veliparib in patients with recurrent, advanced triple-negative breast cancer. Investigational New Drugs2016;34(3):355–63. ">Kummar 2016</a>; <a href="./references#CD011395-bbs2-0006" title="DelalogeS , ContePF , ImS , Senkus-KonefkaE , XuB , DomchekSM , et al. OlympiAD: further efficacy outcomes in patients with HER2-negative metastatic breast cancer and a germline BRCA mutation receiving olaparib monotherapy vs standard single-agent chemotherapy treatment of physician’s choice. Annals of Oncology2017;28(Suppl 5):v74-v108. DomchekS , RobsonM , ImS , SenkusE , XuB , MasudaN , et al. Tolerability of olaparib monotherapy versus chemotherapy in patients with HER2-negative metastatic breast cancer and a germline BRCA mutation: OlympiAD. Cancer Research2018;78(Suppl 4):Abstract nr P5-21-12. ImSA , XuB , LiW , RobsonM , OuyangQ , YehDC , et al. Olaparib monotherapy for Asian patients with a germline BRCA mutation and HER2-negative metastatic breast cancer: OlympiAD randomized trial subgroup analysis. Scientific Reports2020;10(1):8753. ImSA , XuB , LiW , RobsonM , OuyangQ , YehDC , et al. Olaparib monotherapy versus chemotherapy for patients with HER2-negative metastatic breast cancer and a germline BRCA mutation: Asian subgroup analysis from the phase III OlympiAD trial. Cancer Research2018;78(Suppl 4):Abstract nr P5-21-13. MerensC , BannisterW , BergnerS , HettleR , McCreaC , McCutcheonS , et al. Impact of olaparib versus chemotherapy on the use of strong pain medications in gBRCA-mutated HER2-negative metastatic breast cancer and associated patient reported outcomes. Cancer Research2020;80(Suppl 4):Abstract nr P6-13-05. RobsonM , HettleR , DegboeA , SaundersO , CainT , KilvertH , et al. Estimating the health state utility of patients with HER2–gBRCA+ metastatic breast cancer treated with olaparib or chemotherapy via a mapping analysis of EORTC QLQ-C30 data collected in the Olympiad clinical trial. Value in Health2018;21(Suppl 1):S12. RobsonM , ImSA , SenkusE , XuB , DomchekS , MasudaN , et al. OlympiAD extended follow-up for overall survival and safety: olaparib versus chemotherapy treatment of physician’s choice in patients with a germline BRCA mutation and HER2-negative metastatic breast cancer. Cancer Research2020;80(Suppl 4):Abstract nr PD4-03. RobsonM , ImSA , SenkusE , XuB , DomchekSM , MasudaN , et al. Olaparib for metastatic breast cancer in patients with a germline BRCA mutation. New England Journal of Medicine2017;377(6):523-33. RobsonM , RuddyKJ , ImSA , SenkusE , XuB , DomchekSM , et al. Patient-reported outcomes in patients with a germline BRCA mutation and HER2-negative metastatic breast cancer receiving olaparib versus chemotherapy in the OlympiAD trial. European Journal of Cancer2019;120:20-30. RobsonM , RuddyKJ , ImSA , Senkus-KonefkaE , XuB , DomchekSM , et al. OlympiAD: health-related quality of life (HRQoL) in patients with HER2-negative metastatic breast cancer (mBC) and a germline BRCA mutation (gBRCAm) receiving olaparib monotherapy vs standard single-agent chemotherapy treatment of physician’s choice (TPC). Annals of Oncology2017;28(Suppl 5):v74-v108. RobsonME , ImSA , SenkusE , XuB , DomchekS , MasudaN , et al. Abstract CT038: OlympiAD final overall survival: olaparib versus chemotherapy treatment of physician's choice (TPC) in patients with HER2-negative metastatic breast cancer (mBC) and a germline BRCA mutation (gBRCAm). American Association for Cancer Research2018;78(Suppl 13):CT038. RobsonME , ImSA , SenkusE , XuB , DomchekSM , MasudaN , et al. OlympiAD: phase III trial of olaparib monotherapy versus chemotherapy for patients (pts) with HER2-negative metastatic breast cancer (mBC) and a germline BRCA mutation (gBRCAm). Journal of Clinical Oncology2017;35(Suppl 18):LBA4-LBA4. RobsonME , RuddyKJ , ImSA , Senkus-KonefkaE , XuB , DomchekSM , et al. EORTC QLQ-C30 (QLQ-C30) symptoms in patients (pts) with HER2-negative metastatic breast cancer (mBC) and a germline BRCA mutation (gBRCAm) receiving olaparib vs chemotherapy treatment of physician’s choice (TPC) in OlympiAD. Journal of Clinical Oncology2018;36(Suppl 15):1045. RobsonME , TungN , ConteP , ImSA , SenkusE , XuB , et al. OlympiAD final overall survival and tolerability results: olaparib versus chemotherapy treatment of physician’s choice in patients with a germline BRCA mutation and HER2-negative metastatic breast cancer. Annals of Oncology2019;30(4):558-66. Senkus-KonefkaE , DomchekSM , ImSA , XuB , ArmstrongA , MasudaN , et al. Subgroup analysis of olaparib monotherapy versus chemotherapy by hormone receptor and BRCA mutation status in patients with HER2-negative metastatic breast cancer and a germline BRCA mutation: OlympiAD. European Journal of Cancer2018;92:S19-20. TungNM , ImSA , Senkus-KonefkaE , XuB , DomchekSM , MasudaN , et al. Olaparib versus chemotherapy treatment of physician’s choice in patients with a germline BRCA mutation and HER2-negative metastatic breast cancer (OlympiAD): efficacy in patients with visceral metastases. Journal of Clinical Oncology2018;36(Suppl 15):1053. ">OLYMPIAD</a>). In two studies (<a href="./references#CD011395-bbs2-0006" title="DelalogeS , ContePF , ImS , Senkus-KonefkaE , XuB , DomchekSM , et al. OlympiAD: further efficacy outcomes in patients with HER2-negative metastatic breast cancer and a germline BRCA mutation receiving olaparib monotherapy vs standard single-agent chemotherapy treatment of physician’s choice. Annals of Oncology2017;28(Suppl 5):v74-v108. DomchekS , RobsonM , ImS , SenkusE , XuB , MasudaN , et al. Tolerability of olaparib monotherapy versus chemotherapy in patients with HER2-negative metastatic breast cancer and a germline BRCA mutation: OlympiAD. Cancer Research2018;78(Suppl 4):Abstract nr P5-21-12. ImSA , XuB , LiW , RobsonM , OuyangQ , YehDC , et al. Olaparib monotherapy for Asian patients with a germline BRCA mutation and HER2-negative metastatic breast cancer: OlympiAD randomized trial subgroup analysis. Scientific Reports2020;10(1):8753. ImSA , XuB , LiW , RobsonM , OuyangQ , YehDC , et al. Olaparib monotherapy versus chemotherapy for patients with HER2-negative metastatic breast cancer and a germline BRCA mutation: Asian subgroup analysis from the phase III OlympiAD trial. Cancer Research2018;78(Suppl 4):Abstract nr P5-21-13. MerensC , BannisterW , BergnerS , HettleR , McCreaC , McCutcheonS , et al. Impact of olaparib versus chemotherapy on the use of strong pain medications in gBRCA-mutated HER2-negative metastatic breast cancer and associated patient reported outcomes. Cancer Research2020;80(Suppl 4):Abstract nr P6-13-05. RobsonM , HettleR , DegboeA , SaundersO , CainT , KilvertH , et al. Estimating the health state utility of patients with HER2–gBRCA+ metastatic breast cancer treated with olaparib or chemotherapy via a mapping analysis of EORTC QLQ-C30 data collected in the Olympiad clinical trial. Value in Health2018;21(Suppl 1):S12. RobsonM , ImSA , SenkusE , XuB , DomchekS , MasudaN , et al. OlympiAD extended follow-up for overall survival and safety: olaparib versus chemotherapy treatment of physician’s choice in patients with a germline BRCA mutation and HER2-negative metastatic breast cancer. Cancer Research2020;80(Suppl 4):Abstract nr PD4-03. RobsonM , ImSA , SenkusE , XuB , DomchekSM , MasudaN , et al. Olaparib for metastatic breast cancer in patients with a germline BRCA mutation. New England Journal of Medicine2017;377(6):523-33. RobsonM , RuddyKJ , ImSA , SenkusE , XuB , DomchekSM , et al. Patient-reported outcomes in patients with a germline BRCA mutation and HER2-negative metastatic breast cancer receiving olaparib versus chemotherapy in the OlympiAD trial. European Journal of Cancer2019;120:20-30. RobsonM , RuddyKJ , ImSA , Senkus-KonefkaE , XuB , DomchekSM , et al. OlympiAD: health-related quality of life (HRQoL) in patients with HER2-negative metastatic breast cancer (mBC) and a germline BRCA mutation (gBRCAm) receiving olaparib monotherapy vs standard single-agent chemotherapy treatment of physician’s choice (TPC). Annals of Oncology2017;28(Suppl 5):v74-v108. RobsonME , ImSA , SenkusE , XuB , DomchekS , MasudaN , et al. Abstract CT038: OlympiAD final overall survival: olaparib versus chemotherapy treatment of physician's choice (TPC) in patients with HER2-negative metastatic breast cancer (mBC) and a germline BRCA mutation (gBRCAm). American Association for Cancer Research2018;78(Suppl 13):CT038. RobsonME , ImSA , SenkusE , XuB , DomchekSM , MasudaN , et al. OlympiAD: phase III trial of olaparib monotherapy versus chemotherapy for patients (pts) with HER2-negative metastatic breast cancer (mBC) and a germline BRCA mutation (gBRCAm). Journal of Clinical Oncology2017;35(Suppl 18):LBA4-LBA4. RobsonME , RuddyKJ , ImSA , Senkus-KonefkaE , XuB , DomchekSM , et al. EORTC QLQ-C30 (QLQ-C30) symptoms in patients (pts) with HER2-negative metastatic breast cancer (mBC) and a germline BRCA mutation (gBRCAm) receiving olaparib vs chemotherapy treatment of physician’s choice (TPC) in OlympiAD. Journal of Clinical Oncology2018;36(Suppl 15):1045. RobsonME , TungN , ConteP , ImSA , SenkusE , XuB , et al. OlympiAD final overall survival and tolerability results: olaparib versus chemotherapy treatment of physician’s choice in patients with a germline BRCA mutation and HER2-negative metastatic breast cancer. Annals of Oncology2019;30(4):558-66. Senkus-KonefkaE , DomchekSM , ImSA , XuB , ArmstrongA , MasudaN , et al. Subgroup analysis of olaparib monotherapy versus chemotherapy by hormone receptor and BRCA mutation status in patients with HER2-negative metastatic breast cancer and a germline BRCA mutation: OlympiAD. European Journal of Cancer2018;92:S19-20. TungNM , ImSA , Senkus-KonefkaE , XuB , DomchekSM , MasudaN , et al. Olaparib versus chemotherapy treatment of physician’s choice in patients with a germline BRCA mutation and HER2-negative metastatic breast cancer (OlympiAD): efficacy in patients with visceral metastases. Journal of Clinical Oncology2018;36(Suppl 15):1053. ">OLYMPIAD</a>; <a href="./references#CD011395-bbs2-0002" title="DiérasV , HanHS , RobsonME , PalacovaM , MarcomPK , JagerA , et al. Evaluation of veliparib (V) and temozolomide (TMZ) in a phase 2 randomized study of the efficacy and tolerability of V+TMZ or carboplatin (C) and paclitaxel (P) vs placebo (Plc)+C/P in patients (pts) with BRCA1 or BRCA2 mutations and metastatic breast cancer. Cancer Research2017;77(Suppl 4):Abstract nr SABCS16-P4-22-02. HanHS , DiérasV , RobsonM , PalácováM , MarcomPK , Jager A et al. Veliparib with temozolomide or carboplatin/paclitaxel versus placebo with carboplatin/paclitaxel in patients with BRCA1/2 locally recurrent/metastatic breast cancer: randomized phase II study. Annals of Oncology2018;29(1):154-61. HanHS , DiérasV , RobsonME , PalácováM , MarcomPK , JagerA , et al. Efficacy and tolerability of veliparib (V; ABT-888) in combination with carboplatin (C) and paclitaxel (P) vs placebo (Plc)+C/P in patients (pts) with BRCA1 or BRCA2 mutations and metastatic breast cancer: a randomized, phase 2 study. Cancer Research2017;77(Suppl 4):Abstract nr SABCS16-S2-05. IsakoffSJ , PuhallaS , DomchekSM , FriedlanderM , KaufmanB , RobsonM , et al. A randomized Phase II study of veliparib with temozolomide or carboplatin/paclitaxel versus placebo with carboplatin/paclitaxel in BRCA1/2 metastatic breast cancer: design and rationale. Future Oncology2017;13(4):307-20. ">BROCADE 2</a>), this was assessed by independent review and, in two studies (<a href="./references#CD011395-bbs2-0004" title="DiabS , RugoHS , MinaLA , PuhallaS , MahtaniRL , HenryNL , et al. Efficacy and safety of talazoparib (TALA) or physician's choice of therapy (PCT) in United States patients (pts) with HER2- germline BRCA1/2-mutated (gBRCAm) locally advanced/metastatic breast cancer (LA/MBC) in the EMBRACA study. Journal of Clinical Oncology2019;37(Suppl 15):1044. EiermannW , RugoHS , DiabS , EttlJ , HurvitzSA , GoncalvesA , et al. Analysis of germline BRCA1/2 mutated (g BRCAmut) hormone receptor-positive (HR+) and triple-negative breast cancer (TNBC) treated with talazoparib (TALA). Journal of Clinical Oncology2018;36(Suppl 15):1070. EttlJ , HurvitzSA , RugoHS , LeeKH , MinaLA , WoodwardNE , et al. Outcomes of talazoparib (TALA) versus physician's choice of chemotherapy (PCT) in patients (pts) with advanced breast cancer (ABC) and a germline BRCA (gBRCA) mutation by line of chemotherapy (CT) in the EMBRACA trial. Journal of Clinical Oncology2019;37(Suppl 15):1071. EttlJ , QuekRG , BhattacharyyaH , RugoHS , HurvitzSA , GonçalvesA . Patient Reported Outcomes (PRO) in patients (pts) with HER2-advanced breast cancer (ABC) and a germline BRCA1/2 mutation (gBRCAm) receiving talazoparib (TALA) vs physician’s choice chemotherapy (PCT) in the EMBRACA trial: a focus on subgroups with/without visceral disease. Annals of Oncology2019;30(Suppl 5):v129–30. EttlJ , QuekRG , HurvitzSA , GoncalvesA , TudorIC , RugoHS . Hospitalization and supportive care medication (SCM) utilisation in patients (pts) with advanced breast cancer (ABC) and a germline BRCA1/2 mutation (gBRCAm) in EMBRACA. Annals of Oncology2019;30(Suppl 3):iii52. EttlJ , QuekRG , LeeKH , RugoHS , HurvitzS , GonçalvesA , et al. Quality of life with talazoparib versus physician’s choice of chemotherapy in patients with advanced breast cancer and germline BRCA1/2 mutation: patient-reported outcomes from the EMBRACA phase III trial. Annals of Oncology2018;29(9):1939-47. FaschingPA , QuekRG , BhattacharyyaH , HurvitzSA , RugoHS , EttlJ . Impact of objective response (OR) on patient-reported outcomes (PRO) in patients (pts) with advanced breast cancer (ABC) and a germline BRCA1/2 (gBRCA) mutation in the phase III EMBRACA trial. Annals of Oncology2019;30(Suppl 3):iii49. GonçalvesA , EiermannW , RugoHS , EttlJ , HurvitzSA , YerushalmiR , et al. EMBRACA: Efficacy and safety in comparing talazoparib (TALA) with physician's choice of therapy (PCT) in patients (pts) with advanced breast cancer (aBC) and a germline BRCA mutation (gBRCAm); BRCA1/BRCA2 subgroup analysis. Annals of Oncology2018;29(Suppl 8):viii96–7. GoncalvesA , QuekRGW , BhattacharyyaH , EttlJ , HurvitzSA , RugoHS . Patient-reported outcomes (PRO) in patients (pts) with Her2-advanced breast cancer (ABC) receiving talazoparib (TALA) vs physician's choice chemotherapy (PCT): a focus on EMBRACA germline BRCA1 and BRCA2 mutation (gBRCA1/2m) subgroups. Breast2019;48(Suppl 2):S71. HurvitzSA , GoncalvesA , RugoHS , LeeKH , FehrenbacherL , MinaLA , et al. Talazoparib in patients with a germline BRCA-mutated advanced breast cancer: detailed safety analyses from the phase III EMBRACA Trial. Oncologist2019;25(3):e439-50. LeeKH , KimSB , SohnJ , GoodwinA , UsariT , LanzaloneS , et al. Talazoparib (TALA) vs physician’s choice of chemotherapy (PCT) in Asian patients (Pts) with HER2- advanced breast cancer (ABC) and a germline BRCA1/2 mutation (gBRCA1/2mut): data from phase III EMBRACA. Annals of Oncology2019;30(9):ix14. LittonJ , EttlJ , HurvitzSA , MinaLA , RugoHS , LeeKH , et al. A phase 3, open-label, randomized, 2-arm international study of the oral dual PARP inhibitor talazoparib in germline BRCA mutation subjects with locally advanced and/or metastatic breast cancer (EMBRACA). Cancer Research2017;77(Suppl 4):Abstract nr OT2-01-13. LittonJ , RugoHS , EttlJ , HurvitzS , GoncalvesA , LeeKH , et al. EMBRACA: a phase 3 trial comparing talazoparib, an oral PARP inhibitor, to physicianʼs choice of therapy in patients with advanced breast cancer and a germline BRCA mutation [abstract]. In: San Antonio Breast Cancer Symposium; 2017 Dec 5-9; San Antonio (TX). San Antonio (TX), 2017. LittonJK , HurvitzSA , MinaLA , RugoHS , LeeKH , GonçalvesA , et al. Talazoparib (TALA) in germline BRCA1/2 (gBRCA1/2)-mutated human epidermal growth factor receptor 2 negative (HER2-) advanced breast cancer (ABC): final overall survival (OS) results from randomized phase 3 EMBRACA trial. Cancer Research2020;80(Suppl 16):Abstract no. CT071. LittonJK , RugoHS , EttlJ , HurvitzSA , GonçalvesA , LeeKH , et al. Talazoparib in patients with advanced breast cancer and a germline BRCA mutation. New England Journal of Medicine2018;379(8):753-63. MartínM , EiermannW , RugoHS , EttlJ , HurvitzSA , GonçalvesA , et al. EMBRACA: Comparison of efficacy and safety of talazoparib (TALA) and physician's choice of therapy (PCT) in patients (pts) with advanced breast cancer (aBC), a germline BRCA1/2 mutation (gBRCAm), and prior platinum treatment. Annals of Oncology2018;29(Suppl 8):viii96. MinaL , LeeKH , GoncalvesA , WoodwardN , HurvitzSA , DiabS , et al. EMBRACA: efficacy and safety of talazoparib or physician's choice of therapy in patients with advanced breast cancer and a germline BRCA1/2 mutation: a regional analysis. Cancer Research2019;79(Suppl 4):Abstract nr P6-18-12. QuekR , BhattacharyyaH , HurvitzS , GoncalvesA , EttlJ , RugoH . Patient-reported outcomes in patients with HER2-advanced breast cancer and a germline BRCA1/2 mutation receiving talazoparib versus physician's choice chemotherapy: a focus on EMBRACA age subgroups. Journal of Managed Care and Specialty Pharmacy2019;25(Suppl 10A):S37-8. QuekRGW , BhattacharyyaH , GoncalvesA , RugoHS , HurvitzSA , EttlJ . Pcn491 Patient reported outcomes (PRO) of talazoparib (TALA) versus physician's choice of chemotherapy (PCT) in patients (pts) with advanced breast cancer (aBC) and a germline BRCA (gBRCa) mutation: a focus on Embraca pts with/without prior chemotherapy (CT) subgroups. Value in Health2019;22(Suppl 3):S532. RugoHS , EttlJ , HurvitzSA , GoncalvesA , LeeKH , FehrenbacherL , et al. Outcomes in clinically relevant patient subgroups from the EMBRACA study: talazoparib vs physician's choice standard-of-care chemotherapy. Journal of the National Cancer Institute Cancer Spectrum2020;4(1):pkz085. RugoHS , EttlJ , WoodwardNE , HurvitzSA , GoncalvesA , LeeKH , et al. EMBRACA: efficacy outcomes in clinically relevant subgroups comparing talazoparib (TALA), an oral poly ADP ribose polymerase (PARP) inhibitor, to physician's choice of therapy (PCT) in patients with advanced breast cancer and a germline BRCA mutation. Journal of Clinical Oncology2018;36(Suppl 15):1069. RugoHS , QuekR , EttlJ , HurvitzSA , BhattacharyyaH , HannahAL , et al. Patient-reported outcomes (PRO) in patients (pts) with advanced breast cancer and a germline BRCA1/2 mutation (gBRCAm) receiving talazoparib (TALA) vs physician’s choice chemotherapy treatment (PCT): a focus on the EMBRACA triple negative (TNBC) subpopulation. Annals of Oncology2018;29(Suppl 8):viii91. YuY , ElmeliegyM , LittonJK , TudorIC , CzibereA , ZhengJ , et al. Exposure-efficacy progression-free survival (PFS) analyses of breast cancer patients with germline BRCA1/2 mutations receiving talazoparib in the phase III EMBRACA trial. Annals of Oncology2018;29(Suppl 8):viii97. YuY , ElmeliegyM , LittonJK , TudorIC , CzibereA , ZhengJ , et al. Talazoparib exposure-efficacy analysis in patients with advanced breast cancer and germline BRCA1/2 mutations in the EMBRACA trial. Journal of Clinical Pharmacology2020;60(10):1324-33. ">EMBRACA</a> and <a href="./references#CD011395-bbs2-0003" title="ArunBK , HanHS , KaufmanB , WildiersH , FriedlanderM , AyoubJP , et al. First-line veliparib plus carboplatin/paclitaxel in patients with HER2-negative advanced/metastatic gBRCA-associated breast cancer: planned subgroup analysis from the phase 3 BROCADE3 trial. Cancer Research2020;80(Suppl 4):Abstract nr PD4-01. AyoubJP , FriedlanderML , DierasVC , WildiersH , ArunB , HanHS , et al. Veliparib plus carboplatin-paclitaxel in patients with HER2-negative advanced/metastatic gBRCA-associated breast cancer: results in hormone receptor-positive and triple-negative breast cancer subgroups from the phase III BROCADE3 trial. Annals of Oncology2020;31(Suppl 2):S65. DierasV , HanH , KaufmanB , WildiersH , FriedlanderM , AyoubJ , et al. A Phase 3 randomized, placebo-controlled trial of carboplatin and paclitaxel with or without the PARP inhibitor veliparib (ABT-888) in HER2-negative metastatic or locally advanced unresectable BRCA-associated breast cancer. Annals of Oncology2019;30(Suppl 5):v851-v934. ">BROCADE 3</a>), this was assessed by investigators. <a href="./references#CD011395-bbs2-0005" title="KummarS , WadeJL , OzaAM , SullivanD , ChenAP , GandaraDR , et al. Randomized phase II trial of cyclophosphamide and the oral poly (ADP-ribose) polymerase inhibitor veliparib in patients with recurrent, advanced triple-negative breast cancer. Investigational New Drugs2016;34(3):355–63. ">Kummar 2016</a> did not specify the method of analysis. Pooled analysis shows PARP inhibitors likely improve response rates from 48.9% to 66.9% (RR 1.39, 95% CI 1.24 to 1.54; P &lt; 0.00001; moderate‐certainty evidence). However, significant statistical heterogeneity was present (I<sup>2</sup>= 90%, P &lt; 0.00001). </p> </section> <section id="CD011395-sec-0056"> <h5 class="title">1.4 Quality of life</h5> <p>Two studies (<a href="./references#CD011395-bbs2-0004" title="DiabS , RugoHS , MinaLA , PuhallaS , MahtaniRL , HenryNL , et al. Efficacy and safety of talazoparib (TALA) or physician's choice of therapy (PCT) in United States patients (pts) with HER2- germline BRCA1/2-mutated (gBRCAm) locally advanced/metastatic breast cancer (LA/MBC) in the EMBRACA study. Journal of Clinical Oncology2019;37(Suppl 15):1044. EiermannW , RugoHS , DiabS , EttlJ , HurvitzSA , GoncalvesA , et al. Analysis of germline BRCA1/2 mutated (g BRCAmut) hormone receptor-positive (HR+) and triple-negative breast cancer (TNBC) treated with talazoparib (TALA). Journal of Clinical Oncology2018;36(Suppl 15):1070. EttlJ , HurvitzSA , RugoHS , LeeKH , MinaLA , WoodwardNE , et al. Outcomes of talazoparib (TALA) versus physician's choice of chemotherapy (PCT) in patients (pts) with advanced breast cancer (ABC) and a germline BRCA (gBRCA) mutation by line of chemotherapy (CT) in the EMBRACA trial. Journal of Clinical Oncology2019;37(Suppl 15):1071. EttlJ , QuekRG , BhattacharyyaH , RugoHS , HurvitzSA , GonçalvesA . Patient Reported Outcomes (PRO) in patients (pts) with HER2-advanced breast cancer (ABC) and a germline BRCA1/2 mutation (gBRCAm) receiving talazoparib (TALA) vs physician’s choice chemotherapy (PCT) in the EMBRACA trial: a focus on subgroups with/without visceral disease. Annals of Oncology2019;30(Suppl 5):v129–30. EttlJ , QuekRG , HurvitzSA , GoncalvesA , TudorIC , RugoHS . Hospitalization and supportive care medication (SCM) utilisation in patients (pts) with advanced breast cancer (ABC) and a germline BRCA1/2 mutation (gBRCAm) in EMBRACA. Annals of Oncology2019;30(Suppl 3):iii52. EttlJ , QuekRG , LeeKH , RugoHS , HurvitzS , GonçalvesA , et al. Quality of life with talazoparib versus physician’s choice of chemotherapy in patients with advanced breast cancer and germline BRCA1/2 mutation: patient-reported outcomes from the EMBRACA phase III trial. Annals of Oncology2018;29(9):1939-47. FaschingPA , QuekRG , BhattacharyyaH , HurvitzSA , RugoHS , EttlJ . Impact of objective response (OR) on patient-reported outcomes (PRO) in patients (pts) with advanced breast cancer (ABC) and a germline BRCA1/2 (gBRCA) mutation in the phase III EMBRACA trial. Annals of Oncology2019;30(Suppl 3):iii49. GonçalvesA , EiermannW , RugoHS , EttlJ , HurvitzSA , YerushalmiR , et al. EMBRACA: Efficacy and safety in comparing talazoparib (TALA) with physician's choice of therapy (PCT) in patients (pts) with advanced breast cancer (aBC) and a germline BRCA mutation (gBRCAm); BRCA1/BRCA2 subgroup analysis. Annals of Oncology2018;29(Suppl 8):viii96–7. GoncalvesA , QuekRGW , BhattacharyyaH , EttlJ , HurvitzSA , RugoHS . Patient-reported outcomes (PRO) in patients (pts) with Her2-advanced breast cancer (ABC) receiving talazoparib (TALA) vs physician's choice chemotherapy (PCT): a focus on EMBRACA germline BRCA1 and BRCA2 mutation (gBRCA1/2m) subgroups. Breast2019;48(Suppl 2):S71. HurvitzSA , GoncalvesA , RugoHS , LeeKH , FehrenbacherL , MinaLA , et al. Talazoparib in patients with a germline BRCA-mutated advanced breast cancer: detailed safety analyses from the phase III EMBRACA Trial. Oncologist2019;25(3):e439-50. LeeKH , KimSB , SohnJ , GoodwinA , UsariT , LanzaloneS , et al. Talazoparib (TALA) vs physician’s choice of chemotherapy (PCT) in Asian patients (Pts) with HER2- advanced breast cancer (ABC) and a germline BRCA1/2 mutation (gBRCA1/2mut): data from phase III EMBRACA. Annals of Oncology2019;30(9):ix14. LittonJ , EttlJ , HurvitzSA , MinaLA , RugoHS , LeeKH , et al. A phase 3, open-label, randomized, 2-arm international study of the oral dual PARP inhibitor talazoparib in germline BRCA mutation subjects with locally advanced and/or metastatic breast cancer (EMBRACA). Cancer Research2017;77(Suppl 4):Abstract nr OT2-01-13. LittonJ , RugoHS , EttlJ , HurvitzS , GoncalvesA , LeeKH , et al. EMBRACA: a phase 3 trial comparing talazoparib, an oral PARP inhibitor, to physicianʼs choice of therapy in patients with advanced breast cancer and a germline BRCA mutation [abstract]. In: San Antonio Breast Cancer Symposium; 2017 Dec 5-9; San Antonio (TX). San Antonio (TX), 2017. LittonJK , HurvitzSA , MinaLA , RugoHS , LeeKH , GonçalvesA , et al. Talazoparib (TALA) in germline BRCA1/2 (gBRCA1/2)-mutated human epidermal growth factor receptor 2 negative (HER2-) advanced breast cancer (ABC): final overall survival (OS) results from randomized phase 3 EMBRACA trial. Cancer Research2020;80(Suppl 16):Abstract no. CT071. LittonJK , RugoHS , EttlJ , HurvitzSA , GonçalvesA , LeeKH , et al. Talazoparib in patients with advanced breast cancer and a germline BRCA mutation. New England Journal of Medicine2018;379(8):753-63. MartínM , EiermannW , RugoHS , EttlJ , HurvitzSA , GonçalvesA , et al. EMBRACA: Comparison of efficacy and safety of talazoparib (TALA) and physician's choice of therapy (PCT) in patients (pts) with advanced breast cancer (aBC), a germline BRCA1/2 mutation (gBRCAm), and prior platinum treatment. Annals of Oncology2018;29(Suppl 8):viii96. MinaL , LeeKH , GoncalvesA , WoodwardN , HurvitzSA , DiabS , et al. EMBRACA: efficacy and safety of talazoparib or physician's choice of therapy in patients with advanced breast cancer and a germline BRCA1/2 mutation: a regional analysis. Cancer Research2019;79(Suppl 4):Abstract nr P6-18-12. QuekR , BhattacharyyaH , HurvitzS , GoncalvesA , EttlJ , RugoH . Patient-reported outcomes in patients with HER2-advanced breast cancer and a germline BRCA1/2 mutation receiving talazoparib versus physician's choice chemotherapy: a focus on EMBRACA age subgroups. Journal of Managed Care and Specialty Pharmacy2019;25(Suppl 10A):S37-8. QuekRGW , BhattacharyyaH , GoncalvesA , RugoHS , HurvitzSA , EttlJ . Pcn491 Patient reported outcomes (PRO) of talazoparib (TALA) versus physician's choice of chemotherapy (PCT) in patients (pts) with advanced breast cancer (aBC) and a germline BRCA (gBRCa) mutation: a focus on Embraca pts with/without prior chemotherapy (CT) subgroups. Value in Health2019;22(Suppl 3):S532. RugoHS , EttlJ , HurvitzSA , GoncalvesA , LeeKH , FehrenbacherL , et al. Outcomes in clinically relevant patient subgroups from the EMBRACA study: talazoparib vs physician's choice standard-of-care chemotherapy. Journal of the National Cancer Institute Cancer Spectrum2020;4(1):pkz085. RugoHS , EttlJ , WoodwardNE , HurvitzSA , GoncalvesA , LeeKH , et al. EMBRACA: efficacy outcomes in clinically relevant subgroups comparing talazoparib (TALA), an oral poly ADP ribose polymerase (PARP) inhibitor, to physician's choice of therapy (PCT) in patients with advanced breast cancer and a germline BRCA mutation. Journal of Clinical Oncology2018;36(Suppl 15):1069. RugoHS , QuekR , EttlJ , HurvitzSA , BhattacharyyaH , HannahAL , et al. Patient-reported outcomes (PRO) in patients (pts) with advanced breast cancer and a germline BRCA1/2 mutation (gBRCAm) receiving talazoparib (TALA) vs physician’s choice chemotherapy treatment (PCT): a focus on the EMBRACA triple negative (TNBC) subpopulation. Annals of Oncology2018;29(Suppl 8):viii91. YuY , ElmeliegyM , LittonJK , TudorIC , CzibereA , ZhengJ , et al. Exposure-efficacy progression-free survival (PFS) analyses of breast cancer patients with germline BRCA1/2 mutations receiving talazoparib in the phase III EMBRACA trial. Annals of Oncology2018;29(Suppl 8):viii97. YuY , ElmeliegyM , LittonJK , TudorIC , CzibereA , ZhengJ , et al. Talazoparib exposure-efficacy analysis in patients with advanced breast cancer and germline BRCA1/2 mutations in the EMBRACA trial. Journal of Clinical Pharmacology2020;60(10):1324-33. ">EMBRACA</a> and <a href="./references#CD011395-bbs2-0006" title="DelalogeS , ContePF , ImS , Senkus-KonefkaE , XuB , DomchekSM , et al. OlympiAD: further efficacy outcomes in patients with HER2-negative metastatic breast cancer and a germline BRCA mutation receiving olaparib monotherapy vs standard single-agent chemotherapy treatment of physician’s choice. Annals of Oncology2017;28(Suppl 5):v74-v108. DomchekS , RobsonM , ImS , SenkusE , XuB , MasudaN , et al. Tolerability of olaparib monotherapy versus chemotherapy in patients with HER2-negative metastatic breast cancer and a germline BRCA mutation: OlympiAD. Cancer Research2018;78(Suppl 4):Abstract nr P5-21-12. ImSA , XuB , LiW , RobsonM , OuyangQ , YehDC , et al. Olaparib monotherapy for Asian patients with a germline BRCA mutation and HER2-negative metastatic breast cancer: OlympiAD randomized trial subgroup analysis. Scientific Reports2020;10(1):8753. ImSA , XuB , LiW , RobsonM , OuyangQ , YehDC , et al. Olaparib monotherapy versus chemotherapy for patients with HER2-negative metastatic breast cancer and a germline BRCA mutation: Asian subgroup analysis from the phase III OlympiAD trial. Cancer Research2018;78(Suppl 4):Abstract nr P5-21-13. MerensC , BannisterW , BergnerS , HettleR , McCreaC , McCutcheonS , et al. Impact of olaparib versus chemotherapy on the use of strong pain medications in gBRCA-mutated HER2-negative metastatic breast cancer and associated patient reported outcomes. Cancer Research2020;80(Suppl 4):Abstract nr P6-13-05. RobsonM , HettleR , DegboeA , SaundersO , CainT , KilvertH , et al. Estimating the health state utility of patients with HER2–gBRCA+ metastatic breast cancer treated with olaparib or chemotherapy via a mapping analysis of EORTC QLQ-C30 data collected in the Olympiad clinical trial. Value in Health2018;21(Suppl 1):S12. RobsonM , ImSA , SenkusE , XuB , DomchekS , MasudaN , et al. OlympiAD extended follow-up for overall survival and safety: olaparib versus chemotherapy treatment of physician’s choice in patients with a germline BRCA mutation and HER2-negative metastatic breast cancer. Cancer Research2020;80(Suppl 4):Abstract nr PD4-03. RobsonM , ImSA , SenkusE , XuB , DomchekSM , MasudaN , et al. Olaparib for metastatic breast cancer in patients with a germline BRCA mutation. New England Journal of Medicine2017;377(6):523-33. RobsonM , RuddyKJ , ImSA , SenkusE , XuB , DomchekSM , et al. Patient-reported outcomes in patients with a germline BRCA mutation and HER2-negative metastatic breast cancer receiving olaparib versus chemotherapy in the OlympiAD trial. European Journal of Cancer2019;120:20-30. RobsonM , RuddyKJ , ImSA , Senkus-KonefkaE , XuB , DomchekSM , et al. OlympiAD: health-related quality of life (HRQoL) in patients with HER2-negative metastatic breast cancer (mBC) and a germline BRCA mutation (gBRCAm) receiving olaparib monotherapy vs standard single-agent chemotherapy treatment of physician’s choice (TPC). Annals of Oncology2017;28(Suppl 5):v74-v108. RobsonME , ImSA , SenkusE , XuB , DomchekS , MasudaN , et al. Abstract CT038: OlympiAD final overall survival: olaparib versus chemotherapy treatment of physician's choice (TPC) in patients with HER2-negative metastatic breast cancer (mBC) and a germline BRCA mutation (gBRCAm). American Association for Cancer Research2018;78(Suppl 13):CT038. RobsonME , ImSA , SenkusE , XuB , DomchekSM , MasudaN , et al. OlympiAD: phase III trial of olaparib monotherapy versus chemotherapy for patients (pts) with HER2-negative metastatic breast cancer (mBC) and a germline BRCA mutation (gBRCAm). Journal of Clinical Oncology2017;35(Suppl 18):LBA4-LBA4. RobsonME , RuddyKJ , ImSA , Senkus-KonefkaE , XuB , DomchekSM , et al. EORTC QLQ-C30 (QLQ-C30) symptoms in patients (pts) with HER2-negative metastatic breast cancer (mBC) and a germline BRCA mutation (gBRCAm) receiving olaparib vs chemotherapy treatment of physician’s choice (TPC) in OlympiAD. Journal of Clinical Oncology2018;36(Suppl 15):1045. RobsonME , TungN , ConteP , ImSA , SenkusE , XuB , et al. OlympiAD final overall survival and tolerability results: olaparib versus chemotherapy treatment of physician’s choice in patients with a germline BRCA mutation and HER2-negative metastatic breast cancer. Annals of Oncology2019;30(4):558-66. Senkus-KonefkaE , DomchekSM , ImSA , XuB , ArmstrongA , MasudaN , et al. Subgroup analysis of olaparib monotherapy versus chemotherapy by hormone receptor and BRCA mutation status in patients with HER2-negative metastatic breast cancer and a germline BRCA mutation: OlympiAD. European Journal of Cancer2018;92:S19-20. TungNM , ImSA , Senkus-KonefkaE , XuB , DomchekSM , MasudaN , et al. Olaparib versus chemotherapy treatment of physician’s choice in patients with a germline BRCA mutation and HER2-negative metastatic breast cancer (OlympiAD): efficacy in patients with visceral metastases. Journal of Clinical Oncology2018;36(Suppl 15):1053. ">OLYMPIAD</a>) reported quality of life outcomes so this was not amenable to meta‐analysis. <a href="./references#CD011395-bbs2-0006" title="DelalogeS , ContePF , ImS , Senkus-KonefkaE , XuB , DomchekSM , et al. OlympiAD: further efficacy outcomes in patients with HER2-negative metastatic breast cancer and a germline BRCA mutation receiving olaparib monotherapy vs standard single-agent chemotherapy treatment of physician’s choice. Annals of Oncology2017;28(Suppl 5):v74-v108. DomchekS , RobsonM , ImS , SenkusE , XuB , MasudaN , et al. Tolerability of olaparib monotherapy versus chemotherapy in patients with HER2-negative metastatic breast cancer and a germline BRCA mutation: OlympiAD. Cancer Research2018;78(Suppl 4):Abstract nr P5-21-12. ImSA , XuB , LiW , RobsonM , OuyangQ , YehDC , et al. Olaparib monotherapy for Asian patients with a germline BRCA mutation and HER2-negative metastatic breast cancer: OlympiAD randomized trial subgroup analysis. Scientific Reports2020;10(1):8753. ImSA , XuB , LiW , RobsonM , OuyangQ , YehDC , et al. Olaparib monotherapy versus chemotherapy for patients with HER2-negative metastatic breast cancer and a germline BRCA mutation: Asian subgroup analysis from the phase III OlympiAD trial. Cancer Research2018;78(Suppl 4):Abstract nr P5-21-13. MerensC , BannisterW , BergnerS , HettleR , McCreaC , McCutcheonS , et al. Impact of olaparib versus chemotherapy on the use of strong pain medications in gBRCA-mutated HER2-negative metastatic breast cancer and associated patient reported outcomes. Cancer Research2020;80(Suppl 4):Abstract nr P6-13-05. RobsonM , HettleR , DegboeA , SaundersO , CainT , KilvertH , et al. Estimating the health state utility of patients with HER2–gBRCA+ metastatic breast cancer treated with olaparib or chemotherapy via a mapping analysis of EORTC QLQ-C30 data collected in the Olympiad clinical trial. Value in Health2018;21(Suppl 1):S12. RobsonM , ImSA , SenkusE , XuB , DomchekS , MasudaN , et al. OlympiAD extended follow-up for overall survival and safety: olaparib versus chemotherapy treatment of physician’s choice in patients with a germline BRCA mutation and HER2-negative metastatic breast cancer. Cancer Research2020;80(Suppl 4):Abstract nr PD4-03. RobsonM , ImSA , SenkusE , XuB , DomchekSM , MasudaN , et al. Olaparib for metastatic breast cancer in patients with a germline BRCA mutation. New England Journal of Medicine2017;377(6):523-33. RobsonM , RuddyKJ , ImSA , SenkusE , XuB , DomchekSM , et al. Patient-reported outcomes in patients with a germline BRCA mutation and HER2-negative metastatic breast cancer receiving olaparib versus chemotherapy in the OlympiAD trial. European Journal of Cancer2019;120:20-30. RobsonM , RuddyKJ , ImSA , Senkus-KonefkaE , XuB , DomchekSM , et al. OlympiAD: health-related quality of life (HRQoL) in patients with HER2-negative metastatic breast cancer (mBC) and a germline BRCA mutation (gBRCAm) receiving olaparib monotherapy vs standard single-agent chemotherapy treatment of physician’s choice (TPC). Annals of Oncology2017;28(Suppl 5):v74-v108. RobsonME , ImSA , SenkusE , XuB , DomchekS , MasudaN , et al. Abstract CT038: OlympiAD final overall survival: olaparib versus chemotherapy treatment of physician's choice (TPC) in patients with HER2-negative metastatic breast cancer (mBC) and a germline BRCA mutation (gBRCAm). American Association for Cancer Research2018;78(Suppl 13):CT038. RobsonME , ImSA , SenkusE , XuB , DomchekSM , MasudaN , et al. OlympiAD: phase III trial of olaparib monotherapy versus chemotherapy for patients (pts) with HER2-negative metastatic breast cancer (mBC) and a germline BRCA mutation (gBRCAm). Journal of Clinical Oncology2017;35(Suppl 18):LBA4-LBA4. RobsonME , RuddyKJ , ImSA , Senkus-KonefkaE , XuB , DomchekSM , et al. EORTC QLQ-C30 (QLQ-C30) symptoms in patients (pts) with HER2-negative metastatic breast cancer (mBC) and a germline BRCA mutation (gBRCAm) receiving olaparib vs chemotherapy treatment of physician’s choice (TPC) in OlympiAD. Journal of Clinical Oncology2018;36(Suppl 15):1045. RobsonME , TungN , ConteP , ImSA , SenkusE , XuB , et al. OlympiAD final overall survival and tolerability results: olaparib versus chemotherapy treatment of physician’s choice in patients with a germline BRCA mutation and HER2-negative metastatic breast cancer. Annals of Oncology2019;30(4):558-66. Senkus-KonefkaE , DomchekSM , ImSA , XuB , ArmstrongA , MasudaN , et al. Subgroup analysis of olaparib monotherapy versus chemotherapy by hormone receptor and BRCA mutation status in patients with HER2-negative metastatic breast cancer and a germline BRCA mutation: OlympiAD. European Journal of Cancer2018;92:S19-20. TungNM , ImSA , Senkus-KonefkaE , XuB , DomchekSM , MasudaN , et al. Olaparib versus chemotherapy treatment of physician’s choice in patients with a germline BRCA mutation and HER2-negative metastatic breast cancer (OlympiAD): efficacy in patients with visceral metastases. Journal of Clinical Oncology2018;36(Suppl 15):1053. ">OLYMPIAD</a> and <a href="./references#CD011395-bbs2-0004" title="DiabS , RugoHS , MinaLA , PuhallaS , MahtaniRL , HenryNL , et al. Efficacy and safety of talazoparib (TALA) or physician's choice of therapy (PCT) in United States patients (pts) with HER2- germline BRCA1/2-mutated (gBRCAm) locally advanced/metastatic breast cancer (LA/MBC) in the EMBRACA study. Journal of Clinical Oncology2019;37(Suppl 15):1044. EiermannW , RugoHS , DiabS , EttlJ , HurvitzSA , GoncalvesA , et al. Analysis of germline BRCA1/2 mutated (g BRCAmut) hormone receptor-positive (HR+) and triple-negative breast cancer (TNBC) treated with talazoparib (TALA). Journal of Clinical Oncology2018;36(Suppl 15):1070. EttlJ , HurvitzSA , RugoHS , LeeKH , MinaLA , WoodwardNE , et al. Outcomes of talazoparib (TALA) versus physician's choice of chemotherapy (PCT) in patients (pts) with advanced breast cancer (ABC) and a germline BRCA (gBRCA) mutation by line of chemotherapy (CT) in the EMBRACA trial. Journal of Clinical Oncology2019;37(Suppl 15):1071. EttlJ , QuekRG , BhattacharyyaH , RugoHS , HurvitzSA , GonçalvesA . Patient Reported Outcomes (PRO) in patients (pts) with HER2-advanced breast cancer (ABC) and a germline BRCA1/2 mutation (gBRCAm) receiving talazoparib (TALA) vs physician’s choice chemotherapy (PCT) in the EMBRACA trial: a focus on subgroups with/without visceral disease. Annals of Oncology2019;30(Suppl 5):v129–30. EttlJ , QuekRG , HurvitzSA , GoncalvesA , TudorIC , RugoHS . Hospitalization and supportive care medication (SCM) utilisation in patients (pts) with advanced breast cancer (ABC) and a germline BRCA1/2 mutation (gBRCAm) in EMBRACA. Annals of Oncology2019;30(Suppl 3):iii52. EttlJ , QuekRG , LeeKH , RugoHS , HurvitzS , GonçalvesA , et al. Quality of life with talazoparib versus physician’s choice of chemotherapy in patients with advanced breast cancer and germline BRCA1/2 mutation: patient-reported outcomes from the EMBRACA phase III trial. Annals of Oncology2018;29(9):1939-47. FaschingPA , QuekRG , BhattacharyyaH , HurvitzSA , RugoHS , EttlJ . Impact of objective response (OR) on patient-reported outcomes (PRO) in patients (pts) with advanced breast cancer (ABC) and a germline BRCA1/2 (gBRCA) mutation in the phase III EMBRACA trial. Annals of Oncology2019;30(Suppl 3):iii49. GonçalvesA , EiermannW , RugoHS , EttlJ , HurvitzSA , YerushalmiR , et al. EMBRACA: Efficacy and safety in comparing talazoparib (TALA) with physician's choice of therapy (PCT) in patients (pts) with advanced breast cancer (aBC) and a germline BRCA mutation (gBRCAm); BRCA1/BRCA2 subgroup analysis. Annals of Oncology2018;29(Suppl 8):viii96–7. GoncalvesA , QuekRGW , BhattacharyyaH , EttlJ , HurvitzSA , RugoHS . Patient-reported outcomes (PRO) in patients (pts) with Her2-advanced breast cancer (ABC) receiving talazoparib (TALA) vs physician's choice chemotherapy (PCT): a focus on EMBRACA germline BRCA1 and BRCA2 mutation (gBRCA1/2m) subgroups. Breast2019;48(Suppl 2):S71. HurvitzSA , GoncalvesA , RugoHS , LeeKH , FehrenbacherL , MinaLA , et al. Talazoparib in patients with a germline BRCA-mutated advanced breast cancer: detailed safety analyses from the phase III EMBRACA Trial. Oncologist2019;25(3):e439-50. LeeKH , KimSB , SohnJ , GoodwinA , UsariT , LanzaloneS , et al. Talazoparib (TALA) vs physician’s choice of chemotherapy (PCT) in Asian patients (Pts) with HER2- advanced breast cancer (ABC) and a germline BRCA1/2 mutation (gBRCA1/2mut): data from phase III EMBRACA. Annals of Oncology2019;30(9):ix14. LittonJ , EttlJ , HurvitzSA , MinaLA , RugoHS , LeeKH , et al. A phase 3, open-label, randomized, 2-arm international study of the oral dual PARP inhibitor talazoparib in germline BRCA mutation subjects with locally advanced and/or metastatic breast cancer (EMBRACA). Cancer Research2017;77(Suppl 4):Abstract nr OT2-01-13. LittonJ , RugoHS , EttlJ , HurvitzS , GoncalvesA , LeeKH , et al. EMBRACA: a phase 3 trial comparing talazoparib, an oral PARP inhibitor, to physicianʼs choice of therapy in patients with advanced breast cancer and a germline BRCA mutation [abstract]. In: San Antonio Breast Cancer Symposium; 2017 Dec 5-9; San Antonio (TX). San Antonio (TX), 2017. LittonJK , HurvitzSA , MinaLA , RugoHS , LeeKH , GonçalvesA , et al. Talazoparib (TALA) in germline BRCA1/2 (gBRCA1/2)-mutated human epidermal growth factor receptor 2 negative (HER2-) advanced breast cancer (ABC): final overall survival (OS) results from randomized phase 3 EMBRACA trial. Cancer Research2020;80(Suppl 16):Abstract no. CT071. LittonJK , RugoHS , EttlJ , HurvitzSA , GonçalvesA , LeeKH , et al. Talazoparib in patients with advanced breast cancer and a germline BRCA mutation. New England Journal of Medicine2018;379(8):753-63. MartínM , EiermannW , RugoHS , EttlJ , HurvitzSA , GonçalvesA , et al. EMBRACA: Comparison of efficacy and safety of talazoparib (TALA) and physician's choice of therapy (PCT) in patients (pts) with advanced breast cancer (aBC), a germline BRCA1/2 mutation (gBRCAm), and prior platinum treatment. Annals of Oncology2018;29(Suppl 8):viii96. MinaL , LeeKH , GoncalvesA , WoodwardN , HurvitzSA , DiabS , et al. EMBRACA: efficacy and safety of talazoparib or physician's choice of therapy in patients with advanced breast cancer and a germline BRCA1/2 mutation: a regional analysis. Cancer Research2019;79(Suppl 4):Abstract nr P6-18-12. QuekR , BhattacharyyaH , HurvitzS , GoncalvesA , EttlJ , RugoH . Patient-reported outcomes in patients with HER2-advanced breast cancer and a germline BRCA1/2 mutation receiving talazoparib versus physician's choice chemotherapy: a focus on EMBRACA age subgroups. Journal of Managed Care and Specialty Pharmacy2019;25(Suppl 10A):S37-8. QuekRGW , BhattacharyyaH , GoncalvesA , RugoHS , HurvitzSA , EttlJ . Pcn491 Patient reported outcomes (PRO) of talazoparib (TALA) versus physician's choice of chemotherapy (PCT) in patients (pts) with advanced breast cancer (aBC) and a germline BRCA (gBRCa) mutation: a focus on Embraca pts with/without prior chemotherapy (CT) subgroups. Value in Health2019;22(Suppl 3):S532. RugoHS , EttlJ , HurvitzSA , GoncalvesA , LeeKH , FehrenbacherL , et al. Outcomes in clinically relevant patient subgroups from the EMBRACA study: talazoparib vs physician's choice standard-of-care chemotherapy. Journal of the National Cancer Institute Cancer Spectrum2020;4(1):pkz085. RugoHS , EttlJ , WoodwardNE , HurvitzSA , GoncalvesA , LeeKH , et al. EMBRACA: efficacy outcomes in clinically relevant subgroups comparing talazoparib (TALA), an oral poly ADP ribose polymerase (PARP) inhibitor, to physician's choice of therapy (PCT) in patients with advanced breast cancer and a germline BRCA mutation. Journal of Clinical Oncology2018;36(Suppl 15):1069. RugoHS , QuekR , EttlJ , HurvitzSA , BhattacharyyaH , HannahAL , et al. Patient-reported outcomes (PRO) in patients (pts) with advanced breast cancer and a germline BRCA1/2 mutation (gBRCAm) receiving talazoparib (TALA) vs physician’s choice chemotherapy treatment (PCT): a focus on the EMBRACA triple negative (TNBC) subpopulation. Annals of Oncology2018;29(Suppl 8):viii91. YuY , ElmeliegyM , LittonJK , TudorIC , CzibereA , ZhengJ , et al. Exposure-efficacy progression-free survival (PFS) analyses of breast cancer patients with germline BRCA1/2 mutations receiving talazoparib in the phase III EMBRACA trial. Annals of Oncology2018;29(Suppl 8):viii97. YuY , ElmeliegyM , LittonJK , TudorIC , CzibereA , ZhengJ , et al. Talazoparib exposure-efficacy analysis in patients with advanced breast cancer and germline BRCA1/2 mutations in the EMBRACA trial. Journal of Clinical Pharmacology2020;60(10):1324-33. ">EMBRACA</a> showed PARP inhibitors were superior compared to physician’s choice of chemotherapy in terms of patient‐reported outcomes. Both studies used the 30‐item EORTC Quality of Life Questionnaire (QLQ‐C30) to assess health‐related quality of life. In both studies, clinically meaningful deterioration was defined as a decrease of 10 points or more on the QLQ‐C30 and no subsequent observations with a decrease of less than 10 points from baseline. <a href="./references#CD011395-bbs2-0006" title="DelalogeS , ContePF , ImS , Senkus-KonefkaE , XuB , DomchekSM , et al. OlympiAD: further efficacy outcomes in patients with HER2-negative metastatic breast cancer and a germline BRCA mutation receiving olaparib monotherapy vs standard single-agent chemotherapy treatment of physician’s choice. Annals of Oncology2017;28(Suppl 5):v74-v108. DomchekS , RobsonM , ImS , SenkusE , XuB , MasudaN , et al. Tolerability of olaparib monotherapy versus chemotherapy in patients with HER2-negative metastatic breast cancer and a germline BRCA mutation: OlympiAD. Cancer Research2018;78(Suppl 4):Abstract nr P5-21-12. ImSA , XuB , LiW , RobsonM , OuyangQ , YehDC , et al. Olaparib monotherapy for Asian patients with a germline BRCA mutation and HER2-negative metastatic breast cancer: OlympiAD randomized trial subgroup analysis. Scientific Reports2020;10(1):8753. ImSA , XuB , LiW , RobsonM , OuyangQ , YehDC , et al. Olaparib monotherapy versus chemotherapy for patients with HER2-negative metastatic breast cancer and a germline BRCA mutation: Asian subgroup analysis from the phase III OlympiAD trial. Cancer Research2018;78(Suppl 4):Abstract nr P5-21-13. MerensC , BannisterW , BergnerS , HettleR , McCreaC , McCutcheonS , et al. Impact of olaparib versus chemotherapy on the use of strong pain medications in gBRCA-mutated HER2-negative metastatic breast cancer and associated patient reported outcomes. Cancer Research2020;80(Suppl 4):Abstract nr P6-13-05. RobsonM , HettleR , DegboeA , SaundersO , CainT , KilvertH , et al. Estimating the health state utility of patients with HER2–gBRCA+ metastatic breast cancer treated with olaparib or chemotherapy via a mapping analysis of EORTC QLQ-C30 data collected in the Olympiad clinical trial. Value in Health2018;21(Suppl 1):S12. RobsonM , ImSA , SenkusE , XuB , DomchekS , MasudaN , et al. OlympiAD extended follow-up for overall survival and safety: olaparib versus chemotherapy treatment of physician’s choice in patients with a germline BRCA mutation and HER2-negative metastatic breast cancer. Cancer Research2020;80(Suppl 4):Abstract nr PD4-03. RobsonM , ImSA , SenkusE , XuB , DomchekSM , MasudaN , et al. Olaparib for metastatic breast cancer in patients with a germline BRCA mutation. New England Journal of Medicine2017;377(6):523-33. RobsonM , RuddyKJ , ImSA , SenkusE , XuB , DomchekSM , et al. Patient-reported outcomes in patients with a germline BRCA mutation and HER2-negative metastatic breast cancer receiving olaparib versus chemotherapy in the OlympiAD trial. European Journal of Cancer2019;120:20-30. RobsonM , RuddyKJ , ImSA , Senkus-KonefkaE , XuB , DomchekSM , et al. OlympiAD: health-related quality of life (HRQoL) in patients with HER2-negative metastatic breast cancer (mBC) and a germline BRCA mutation (gBRCAm) receiving olaparib monotherapy vs standard single-agent chemotherapy treatment of physician’s choice (TPC). Annals of Oncology2017;28(Suppl 5):v74-v108. RobsonME , ImSA , SenkusE , XuB , DomchekS , MasudaN , et al. Abstract CT038: OlympiAD final overall survival: olaparib versus chemotherapy treatment of physician's choice (TPC) in patients with HER2-negative metastatic breast cancer (mBC) and a germline BRCA mutation (gBRCAm). American Association for Cancer Research2018;78(Suppl 13):CT038. RobsonME , ImSA , SenkusE , XuB , DomchekSM , MasudaN , et al. OlympiAD: phase III trial of olaparib monotherapy versus chemotherapy for patients (pts) with HER2-negative metastatic breast cancer (mBC) and a germline BRCA mutation (gBRCAm). Journal of Clinical Oncology2017;35(Suppl 18):LBA4-LBA4. RobsonME , RuddyKJ , ImSA , Senkus-KonefkaE , XuB , DomchekSM , et al. EORTC QLQ-C30 (QLQ-C30) symptoms in patients (pts) with HER2-negative metastatic breast cancer (mBC) and a germline BRCA mutation (gBRCAm) receiving olaparib vs chemotherapy treatment of physician’s choice (TPC) in OlympiAD. Journal of Clinical Oncology2018;36(Suppl 15):1045. RobsonME , TungN , ConteP , ImSA , SenkusE , XuB , et al. OlympiAD final overall survival and tolerability results: olaparib versus chemotherapy treatment of physician’s choice in patients with a germline BRCA mutation and HER2-negative metastatic breast cancer. Annals of Oncology2019;30(4):558-66. Senkus-KonefkaE , DomchekSM , ImSA , XuB , ArmstrongA , MasudaN , et al. Subgroup analysis of olaparib monotherapy versus chemotherapy by hormone receptor and BRCA mutation status in patients with HER2-negative metastatic breast cancer and a germline BRCA mutation: OlympiAD. European Journal of Cancer2018;92:S19-20. TungNM , ImSA , Senkus-KonefkaE , XuB , DomchekSM , MasudaN , et al. Olaparib versus chemotherapy treatment of physician’s choice in patients with a germline BRCA mutation and HER2-negative metastatic breast cancer (OlympiAD): efficacy in patients with visceral metastases. Journal of Clinical Oncology2018;36(Suppl 15):1053. ">OLYMPIAD</a> showed a small significant difference between treatment groups in the adjusted mean QLQ‐C30 score across all time points, and a clinically meaningful decrease in the QLQ‐ C30 score was delayed in the olaparib group (HR 0.44, 95% CI 0.25 to 0.77, P = 0.004). Similarly, <a href="./references#CD011395-bbs2-0004" title="DiabS , RugoHS , MinaLA , PuhallaS , MahtaniRL , HenryNL , et al. Efficacy and safety of talazoparib (TALA) or physician's choice of therapy (PCT) in United States patients (pts) with HER2- germline BRCA1/2-mutated (gBRCAm) locally advanced/metastatic breast cancer (LA/MBC) in the EMBRACA study. Journal of Clinical Oncology2019;37(Suppl 15):1044. EiermannW , RugoHS , DiabS , EttlJ , HurvitzSA , GoncalvesA , et al. Analysis of germline BRCA1/2 mutated (g BRCAmut) hormone receptor-positive (HR+) and triple-negative breast cancer (TNBC) treated with talazoparib (TALA). Journal of Clinical Oncology2018;36(Suppl 15):1070. EttlJ , HurvitzSA , RugoHS , LeeKH , MinaLA , WoodwardNE , et al. Outcomes of talazoparib (TALA) versus physician's choice of chemotherapy (PCT) in patients (pts) with advanced breast cancer (ABC) and a germline BRCA (gBRCA) mutation by line of chemotherapy (CT) in the EMBRACA trial. Journal of Clinical Oncology2019;37(Suppl 15):1071. EttlJ , QuekRG , BhattacharyyaH , RugoHS , HurvitzSA , GonçalvesA . Patient Reported Outcomes (PRO) in patients (pts) with HER2-advanced breast cancer (ABC) and a germline BRCA1/2 mutation (gBRCAm) receiving talazoparib (TALA) vs physician’s choice chemotherapy (PCT) in the EMBRACA trial: a focus on subgroups with/without visceral disease. Annals of Oncology2019;30(Suppl 5):v129–30. EttlJ , QuekRG , HurvitzSA , GoncalvesA , TudorIC , RugoHS . Hospitalization and supportive care medication (SCM) utilisation in patients (pts) with advanced breast cancer (ABC) and a germline BRCA1/2 mutation (gBRCAm) in EMBRACA. Annals of Oncology2019;30(Suppl 3):iii52. EttlJ , QuekRG , LeeKH , RugoHS , HurvitzS , GonçalvesA , et al. Quality of life with talazoparib versus physician’s choice of chemotherapy in patients with advanced breast cancer and germline BRCA1/2 mutation: patient-reported outcomes from the EMBRACA phase III trial. Annals of Oncology2018;29(9):1939-47. FaschingPA , QuekRG , BhattacharyyaH , HurvitzSA , RugoHS , EttlJ . Impact of objective response (OR) on patient-reported outcomes (PRO) in patients (pts) with advanced breast cancer (ABC) and a germline BRCA1/2 (gBRCA) mutation in the phase III EMBRACA trial. Annals of Oncology2019;30(Suppl 3):iii49. GonçalvesA , EiermannW , RugoHS , EttlJ , HurvitzSA , YerushalmiR , et al. EMBRACA: Efficacy and safety in comparing talazoparib (TALA) with physician's choice of therapy (PCT) in patients (pts) with advanced breast cancer (aBC) and a germline BRCA mutation (gBRCAm); BRCA1/BRCA2 subgroup analysis. Annals of Oncology2018;29(Suppl 8):viii96–7. GoncalvesA , QuekRGW , BhattacharyyaH , EttlJ , HurvitzSA , RugoHS . Patient-reported outcomes (PRO) in patients (pts) with Her2-advanced breast cancer (ABC) receiving talazoparib (TALA) vs physician's choice chemotherapy (PCT): a focus on EMBRACA germline BRCA1 and BRCA2 mutation (gBRCA1/2m) subgroups. Breast2019;48(Suppl 2):S71. HurvitzSA , GoncalvesA , RugoHS , LeeKH , FehrenbacherL , MinaLA , et al. Talazoparib in patients with a germline BRCA-mutated advanced breast cancer: detailed safety analyses from the phase III EMBRACA Trial. Oncologist2019;25(3):e439-50. LeeKH , KimSB , SohnJ , GoodwinA , UsariT , LanzaloneS , et al. Talazoparib (TALA) vs physician’s choice of chemotherapy (PCT) in Asian patients (Pts) with HER2- advanced breast cancer (ABC) and a germline BRCA1/2 mutation (gBRCA1/2mut): data from phase III EMBRACA. Annals of Oncology2019;30(9):ix14. LittonJ , EttlJ , HurvitzSA , MinaLA , RugoHS , LeeKH , et al. A phase 3, open-label, randomized, 2-arm international study of the oral dual PARP inhibitor talazoparib in germline BRCA mutation subjects with locally advanced and/or metastatic breast cancer (EMBRACA). Cancer Research2017;77(Suppl 4):Abstract nr OT2-01-13. LittonJ , RugoHS , EttlJ , HurvitzS , GoncalvesA , LeeKH , et al. EMBRACA: a phase 3 trial comparing talazoparib, an oral PARP inhibitor, to physicianʼs choice of therapy in patients with advanced breast cancer and a germline BRCA mutation [abstract]. In: San Antonio Breast Cancer Symposium; 2017 Dec 5-9; San Antonio (TX). San Antonio (TX), 2017. LittonJK , HurvitzSA , MinaLA , RugoHS , LeeKH , GonçalvesA , et al. Talazoparib (TALA) in germline BRCA1/2 (gBRCA1/2)-mutated human epidermal growth factor receptor 2 negative (HER2-) advanced breast cancer (ABC): final overall survival (OS) results from randomized phase 3 EMBRACA trial. Cancer Research2020;80(Suppl 16):Abstract no. CT071. LittonJK , RugoHS , EttlJ , HurvitzSA , GonçalvesA , LeeKH , et al. Talazoparib in patients with advanced breast cancer and a germline BRCA mutation. New England Journal of Medicine2018;379(8):753-63. MartínM , EiermannW , RugoHS , EttlJ , HurvitzSA , GonçalvesA , et al. EMBRACA: Comparison of efficacy and safety of talazoparib (TALA) and physician's choice of therapy (PCT) in patients (pts) with advanced breast cancer (aBC), a germline BRCA1/2 mutation (gBRCAm), and prior platinum treatment. Annals of Oncology2018;29(Suppl 8):viii96. MinaL , LeeKH , GoncalvesA , WoodwardN , HurvitzSA , DiabS , et al. EMBRACA: efficacy and safety of talazoparib or physician's choice of therapy in patients with advanced breast cancer and a germline BRCA1/2 mutation: a regional analysis. Cancer Research2019;79(Suppl 4):Abstract nr P6-18-12. QuekR , BhattacharyyaH , HurvitzS , GoncalvesA , EttlJ , RugoH . Patient-reported outcomes in patients with HER2-advanced breast cancer and a germline BRCA1/2 mutation receiving talazoparib versus physician's choice chemotherapy: a focus on EMBRACA age subgroups. Journal of Managed Care and Specialty Pharmacy2019;25(Suppl 10A):S37-8. QuekRGW , BhattacharyyaH , GoncalvesA , RugoHS , HurvitzSA , EttlJ . Pcn491 Patient reported outcomes (PRO) of talazoparib (TALA) versus physician's choice of chemotherapy (PCT) in patients (pts) with advanced breast cancer (aBC) and a germline BRCA (gBRCa) mutation: a focus on Embraca pts with/without prior chemotherapy (CT) subgroups. Value in Health2019;22(Suppl 3):S532. RugoHS , EttlJ , HurvitzSA , GoncalvesA , LeeKH , FehrenbacherL , et al. Outcomes in clinically relevant patient subgroups from the EMBRACA study: talazoparib vs physician's choice standard-of-care chemotherapy. Journal of the National Cancer Institute Cancer Spectrum2020;4(1):pkz085. RugoHS , EttlJ , WoodwardNE , HurvitzSA , GoncalvesA , LeeKH , et al. EMBRACA: efficacy outcomes in clinically relevant subgroups comparing talazoparib (TALA), an oral poly ADP ribose polymerase (PARP) inhibitor, to physician's choice of therapy (PCT) in patients with advanced breast cancer and a germline BRCA mutation. Journal of Clinical Oncology2018;36(Suppl 15):1069. RugoHS , QuekR , EttlJ , HurvitzSA , BhattacharyyaH , HannahAL , et al. Patient-reported outcomes (PRO) in patients (pts) with advanced breast cancer and a germline BRCA1/2 mutation (gBRCAm) receiving talazoparib (TALA) vs physician’s choice chemotherapy treatment (PCT): a focus on the EMBRACA triple negative (TNBC) subpopulation. Annals of Oncology2018;29(Suppl 8):viii91. YuY , ElmeliegyM , LittonJK , TudorIC , CzibereA , ZhengJ , et al. Exposure-efficacy progression-free survival (PFS) analyses of breast cancer patients with germline BRCA1/2 mutations receiving talazoparib in the phase III EMBRACA trial. Annals of Oncology2018;29(Suppl 8):viii97. YuY , ElmeliegyM , LittonJK , TudorIC , CzibereA , ZhengJ , et al. Talazoparib exposure-efficacy analysis in patients with advanced breast cancer and germline BRCA1/2 mutations in the EMBRACA trial. Journal of Clinical Pharmacology2020;60(10):1324-33. ">EMBRACA</a> showed significant overall improvements in global health status quality of life and significant delays in the times to clinically meaningful deterioration (HR 0.38, 95% CI 0.26 to 0.55, P &lt; 0.0001). </p> </section> <section id="CD011395-sec-0057"> <h5 class="title">1.5 Adverse events</h5> <p>See: <a href="#CD011395-fig-0006">Figure 6</a>; <a href="./references#CD011395-fig-0014" title="">Analysis 1.8</a>; <a href="./references#CD011395-fig-0015" title="">Analysis 1.9</a>; <a href="./references#CD011395-fig-0016" title="">Analysis 1.10</a>; <a href="./references#CD011395-fig-0017" title="">Analysis 1.11</a>; <a href="./references#CD011395-fig-0018" title="">Analysis 1.12</a>.<br/><br/>All five trials reported on adverse events (<a href="./references#CD011395-bbs2-0002" title="DiérasV , HanHS , RobsonME , PalacovaM , MarcomPK , JagerA , et al. Evaluation of veliparib (V) and temozolomide (TMZ) in a phase 2 randomized study of the efficacy and tolerability of V+TMZ or carboplatin (C) and paclitaxel (P) vs placebo (Plc)+C/P in patients (pts) with BRCA1 or BRCA2 mutations and metastatic breast cancer. Cancer Research2017;77(Suppl 4):Abstract nr SABCS16-P4-22-02. HanHS , DiérasV , RobsonM , PalácováM , MarcomPK , Jager A et al. Veliparib with temozolomide or carboplatin/paclitaxel versus placebo with carboplatin/paclitaxel in patients with BRCA1/2 locally recurrent/metastatic breast cancer: randomized phase II study. Annals of Oncology2018;29(1):154-61. HanHS , DiérasV , RobsonME , PalácováM , MarcomPK , JagerA , et al. Efficacy and tolerability of veliparib (V; ABT-888) in combination with carboplatin (C) and paclitaxel (P) vs placebo (Plc)+C/P in patients (pts) with BRCA1 or BRCA2 mutations and metastatic breast cancer: a randomized, phase 2 study. Cancer Research2017;77(Suppl 4):Abstract nr SABCS16-S2-05. IsakoffSJ , PuhallaS , DomchekSM , FriedlanderM , KaufmanB , RobsonM , et al. A randomized Phase II study of veliparib with temozolomide or carboplatin/paclitaxel versus placebo with carboplatin/paclitaxel in BRCA1/2 metastatic breast cancer: design and rationale. Future Oncology2017;13(4):307-20. ">BROCADE 2</a>; <a href="./references#CD011395-bbs2-0003" title="ArunBK , HanHS , KaufmanB , WildiersH , FriedlanderM , AyoubJP , et al. First-line veliparib plus carboplatin/paclitaxel in patients with HER2-negative advanced/metastatic gBRCA-associated breast cancer: planned subgroup analysis from the phase 3 BROCADE3 trial. Cancer Research2020;80(Suppl 4):Abstract nr PD4-01. AyoubJP , FriedlanderML , DierasVC , WildiersH , ArunB , HanHS , et al. Veliparib plus carboplatin-paclitaxel in patients with HER2-negative advanced/metastatic gBRCA-associated breast cancer: results in hormone receptor-positive and triple-negative breast cancer subgroups from the phase III BROCADE3 trial. Annals of Oncology2020;31(Suppl 2):S65. DierasV , HanH , KaufmanB , WildiersH , FriedlanderM , AyoubJ , et al. A Phase 3 randomized, placebo-controlled trial of carboplatin and paclitaxel with or without the PARP inhibitor veliparib (ABT-888) in HER2-negative metastatic or locally advanced unresectable BRCA-associated breast cancer. Annals of Oncology2019;30(Suppl 5):v851-v934. ">BROCADE 3</a>; <a href="./references#CD011395-bbs2-0004" title="DiabS , RugoHS , MinaLA , PuhallaS , MahtaniRL , HenryNL , et al. Efficacy and safety of talazoparib (TALA) or physician's choice of therapy (PCT) in United States patients (pts) with HER2- germline BRCA1/2-mutated (gBRCAm) locally advanced/metastatic breast cancer (LA/MBC) in the EMBRACA study. Journal of Clinical Oncology2019;37(Suppl 15):1044. EiermannW , RugoHS , DiabS , EttlJ , HurvitzSA , GoncalvesA , et al. Analysis of germline BRCA1/2 mutated (g BRCAmut) hormone receptor-positive (HR+) and triple-negative breast cancer (TNBC) treated with talazoparib (TALA). Journal of Clinical Oncology2018;36(Suppl 15):1070. EttlJ , HurvitzSA , RugoHS , LeeKH , MinaLA , WoodwardNE , et al. Outcomes of talazoparib (TALA) versus physician's choice of chemotherapy (PCT) in patients (pts) with advanced breast cancer (ABC) and a germline BRCA (gBRCA) mutation by line of chemotherapy (CT) in the EMBRACA trial. Journal of Clinical Oncology2019;37(Suppl 15):1071. EttlJ , QuekRG , BhattacharyyaH , RugoHS , HurvitzSA , GonçalvesA . Patient Reported Outcomes (PRO) in patients (pts) with HER2-advanced breast cancer (ABC) and a germline BRCA1/2 mutation (gBRCAm) receiving talazoparib (TALA) vs physician’s choice chemotherapy (PCT) in the EMBRACA trial: a focus on subgroups with/without visceral disease. Annals of Oncology2019;30(Suppl 5):v129–30. EttlJ , QuekRG , HurvitzSA , GoncalvesA , TudorIC , RugoHS . Hospitalization and supportive care medication (SCM) utilisation in patients (pts) with advanced breast cancer (ABC) and a germline BRCA1/2 mutation (gBRCAm) in EMBRACA. Annals of Oncology2019;30(Suppl 3):iii52. EttlJ , QuekRG , LeeKH , RugoHS , HurvitzS , GonçalvesA , et al. Quality of life with talazoparib versus physician’s choice of chemotherapy in patients with advanced breast cancer and germline BRCA1/2 mutation: patient-reported outcomes from the EMBRACA phase III trial. Annals of Oncology2018;29(9):1939-47. FaschingPA , QuekRG , BhattacharyyaH , HurvitzSA , RugoHS , EttlJ . Impact of objective response (OR) on patient-reported outcomes (PRO) in patients (pts) with advanced breast cancer (ABC) and a germline BRCA1/2 (gBRCA) mutation in the phase III EMBRACA trial. Annals of Oncology2019;30(Suppl 3):iii49. GonçalvesA , EiermannW , RugoHS , EttlJ , HurvitzSA , YerushalmiR , et al. EMBRACA: Efficacy and safety in comparing talazoparib (TALA) with physician's choice of therapy (PCT) in patients (pts) with advanced breast cancer (aBC) and a germline BRCA mutation (gBRCAm); BRCA1/BRCA2 subgroup analysis. Annals of Oncology2018;29(Suppl 8):viii96–7. GoncalvesA , QuekRGW , BhattacharyyaH , EttlJ , HurvitzSA , RugoHS . Patient-reported outcomes (PRO) in patients (pts) with Her2-advanced breast cancer (ABC) receiving talazoparib (TALA) vs physician's choice chemotherapy (PCT): a focus on EMBRACA germline BRCA1 and BRCA2 mutation (gBRCA1/2m) subgroups. Breast2019;48(Suppl 2):S71. HurvitzSA , GoncalvesA , RugoHS , LeeKH , FehrenbacherL , MinaLA , et al. Talazoparib in patients with a germline BRCA-mutated advanced breast cancer: detailed safety analyses from the phase III EMBRACA Trial. Oncologist2019;25(3):e439-50. LeeKH , KimSB , SohnJ , GoodwinA , UsariT , LanzaloneS , et al. Talazoparib (TALA) vs physician’s choice of chemotherapy (PCT) in Asian patients (Pts) with HER2- advanced breast cancer (ABC) and a germline BRCA1/2 mutation (gBRCA1/2mut): data from phase III EMBRACA. Annals of Oncology2019;30(9):ix14. LittonJ , EttlJ , HurvitzSA , MinaLA , RugoHS , LeeKH , et al. A phase 3, open-label, randomized, 2-arm international study of the oral dual PARP inhibitor talazoparib in germline BRCA mutation subjects with locally advanced and/or metastatic breast cancer (EMBRACA). Cancer Research2017;77(Suppl 4):Abstract nr OT2-01-13. LittonJ , RugoHS , EttlJ , HurvitzS , GoncalvesA , LeeKH , et al. EMBRACA: a phase 3 trial comparing talazoparib, an oral PARP inhibitor, to physicianʼs choice of therapy in patients with advanced breast cancer and a germline BRCA mutation [abstract]. In: San Antonio Breast Cancer Symposium; 2017 Dec 5-9; San Antonio (TX). San Antonio (TX), 2017. LittonJK , HurvitzSA , MinaLA , RugoHS , LeeKH , GonçalvesA , et al. Talazoparib (TALA) in germline BRCA1/2 (gBRCA1/2)-mutated human epidermal growth factor receptor 2 negative (HER2-) advanced breast cancer (ABC): final overall survival (OS) results from randomized phase 3 EMBRACA trial. Cancer Research2020;80(Suppl 16):Abstract no. CT071. LittonJK , RugoHS , EttlJ , HurvitzSA , GonçalvesA , LeeKH , et al. Talazoparib in patients with advanced breast cancer and a germline BRCA mutation. New England Journal of Medicine2018;379(8):753-63. MartínM , EiermannW , RugoHS , EttlJ , HurvitzSA , GonçalvesA , et al. EMBRACA: Comparison of efficacy and safety of talazoparib (TALA) and physician's choice of therapy (PCT) in patients (pts) with advanced breast cancer (aBC), a germline BRCA1/2 mutation (gBRCAm), and prior platinum treatment. Annals of Oncology2018;29(Suppl 8):viii96. MinaL , LeeKH , GoncalvesA , WoodwardN , HurvitzSA , DiabS , et al. EMBRACA: efficacy and safety of talazoparib or physician's choice of therapy in patients with advanced breast cancer and a germline BRCA1/2 mutation: a regional analysis. Cancer Research2019;79(Suppl 4):Abstract nr P6-18-12. QuekR , BhattacharyyaH , HurvitzS , GoncalvesA , EttlJ , RugoH . Patient-reported outcomes in patients with HER2-advanced breast cancer and a germline BRCA1/2 mutation receiving talazoparib versus physician's choice chemotherapy: a focus on EMBRACA age subgroups. Journal of Managed Care and Specialty Pharmacy2019;25(Suppl 10A):S37-8. QuekRGW , BhattacharyyaH , GoncalvesA , RugoHS , HurvitzSA , EttlJ . Pcn491 Patient reported outcomes (PRO) of talazoparib (TALA) versus physician's choice of chemotherapy (PCT) in patients (pts) with advanced breast cancer (aBC) and a germline BRCA (gBRCa) mutation: a focus on Embraca pts with/without prior chemotherapy (CT) subgroups. Value in Health2019;22(Suppl 3):S532. RugoHS , EttlJ , HurvitzSA , GoncalvesA , LeeKH , FehrenbacherL , et al. Outcomes in clinically relevant patient subgroups from the EMBRACA study: talazoparib vs physician's choice standard-of-care chemotherapy. Journal of the National Cancer Institute Cancer Spectrum2020;4(1):pkz085. RugoHS , EttlJ , WoodwardNE , HurvitzSA , GoncalvesA , LeeKH , et al. EMBRACA: efficacy outcomes in clinically relevant subgroups comparing talazoparib (TALA), an oral poly ADP ribose polymerase (PARP) inhibitor, to physician's choice of therapy (PCT) in patients with advanced breast cancer and a germline BRCA mutation. Journal of Clinical Oncology2018;36(Suppl 15):1069. RugoHS , QuekR , EttlJ , HurvitzSA , BhattacharyyaH , HannahAL , et al. Patient-reported outcomes (PRO) in patients (pts) with advanced breast cancer and a germline BRCA1/2 mutation (gBRCAm) receiving talazoparib (TALA) vs physician’s choice chemotherapy treatment (PCT): a focus on the EMBRACA triple negative (TNBC) subpopulation. Annals of Oncology2018;29(Suppl 8):viii91. YuY , ElmeliegyM , LittonJK , TudorIC , CzibereA , ZhengJ , et al. Exposure-efficacy progression-free survival (PFS) analyses of breast cancer patients with germline BRCA1/2 mutations receiving talazoparib in the phase III EMBRACA trial. Annals of Oncology2018;29(Suppl 8):viii97. YuY , ElmeliegyM , LittonJK , TudorIC , CzibereA , ZhengJ , et al. Talazoparib exposure-efficacy analysis in patients with advanced breast cancer and germline BRCA1/2 mutations in the EMBRACA trial. Journal of Clinical Pharmacology2020;60(10):1324-33. ">EMBRACA</a>; <a href="./references#CD011395-bbs2-0005" title="KummarS , WadeJL , OzaAM , SullivanD , ChenAP , GandaraDR , et al. Randomized phase II trial of cyclophosphamide and the oral poly (ADP-ribose) polymerase inhibitor veliparib in patients with recurrent, advanced triple-negative breast cancer. Investigational New Drugs2016;34(3):355–63. ">Kummar 2016</a>; <a href="./references#CD011395-bbs2-0006" title="DelalogeS , ContePF , ImS , Senkus-KonefkaE , XuB , DomchekSM , et al. OlympiAD: further efficacy outcomes in patients with HER2-negative metastatic breast cancer and a germline BRCA mutation receiving olaparib monotherapy vs standard single-agent chemotherapy treatment of physician’s choice. Annals of Oncology2017;28(Suppl 5):v74-v108. DomchekS , RobsonM , ImS , SenkusE , XuB , MasudaN , et al. Tolerability of olaparib monotherapy versus chemotherapy in patients with HER2-negative metastatic breast cancer and a germline BRCA mutation: OlympiAD. Cancer Research2018;78(Suppl 4):Abstract nr P5-21-12. ImSA , XuB , LiW , RobsonM , OuyangQ , YehDC , et al. Olaparib monotherapy for Asian patients with a germline BRCA mutation and HER2-negative metastatic breast cancer: OlympiAD randomized trial subgroup analysis. Scientific Reports2020;10(1):8753. ImSA , XuB , LiW , RobsonM , OuyangQ , YehDC , et al. Olaparib monotherapy versus chemotherapy for patients with HER2-negative metastatic breast cancer and a germline BRCA mutation: Asian subgroup analysis from the phase III OlympiAD trial. Cancer Research2018;78(Suppl 4):Abstract nr P5-21-13. MerensC , BannisterW , BergnerS , HettleR , McCreaC , McCutcheonS , et al. Impact of olaparib versus chemotherapy on the use of strong pain medications in gBRCA-mutated HER2-negative metastatic breast cancer and associated patient reported outcomes. Cancer Research2020;80(Suppl 4):Abstract nr P6-13-05. RobsonM , HettleR , DegboeA , SaundersO , CainT , KilvertH , et al. Estimating the health state utility of patients with HER2–gBRCA+ metastatic breast cancer treated with olaparib or chemotherapy via a mapping analysis of EORTC QLQ-C30 data collected in the Olympiad clinical trial. Value in Health2018;21(Suppl 1):S12. RobsonM , ImSA , SenkusE , XuB , DomchekS , MasudaN , et al. OlympiAD extended follow-up for overall survival and safety: olaparib versus chemotherapy treatment of physician’s choice in patients with a germline BRCA mutation and HER2-negative metastatic breast cancer. Cancer Research2020;80(Suppl 4):Abstract nr PD4-03. RobsonM , ImSA , SenkusE , XuB , DomchekSM , MasudaN , et al. Olaparib for metastatic breast cancer in patients with a germline BRCA mutation. New England Journal of Medicine2017;377(6):523-33. RobsonM , RuddyKJ , ImSA , SenkusE , XuB , DomchekSM , et al. Patient-reported outcomes in patients with a germline BRCA mutation and HER2-negative metastatic breast cancer receiving olaparib versus chemotherapy in the OlympiAD trial. European Journal of Cancer2019;120:20-30. RobsonM , RuddyKJ , ImSA , Senkus-KonefkaE , XuB , DomchekSM , et al. OlympiAD: health-related quality of life (HRQoL) in patients with HER2-negative metastatic breast cancer (mBC) and a germline BRCA mutation (gBRCAm) receiving olaparib monotherapy vs standard single-agent chemotherapy treatment of physician’s choice (TPC). Annals of Oncology2017;28(Suppl 5):v74-v108. RobsonME , ImSA , SenkusE , XuB , DomchekS , MasudaN , et al. Abstract CT038: OlympiAD final overall survival: olaparib versus chemotherapy treatment of physician's choice (TPC) in patients with HER2-negative metastatic breast cancer (mBC) and a germline BRCA mutation (gBRCAm). American Association for Cancer Research2018;78(Suppl 13):CT038. RobsonME , ImSA , SenkusE , XuB , DomchekSM , MasudaN , et al. OlympiAD: phase III trial of olaparib monotherapy versus chemotherapy for patients (pts) with HER2-negative metastatic breast cancer (mBC) and a germline BRCA mutation (gBRCAm). Journal of Clinical Oncology2017;35(Suppl 18):LBA4-LBA4. RobsonME , RuddyKJ , ImSA , Senkus-KonefkaE , XuB , DomchekSM , et al. EORTC QLQ-C30 (QLQ-C30) symptoms in patients (pts) with HER2-negative metastatic breast cancer (mBC) and a germline BRCA mutation (gBRCAm) receiving olaparib vs chemotherapy treatment of physician’s choice (TPC) in OlympiAD. Journal of Clinical Oncology2018;36(Suppl 15):1045. RobsonME , TungN , ConteP , ImSA , SenkusE , XuB , et al. OlympiAD final overall survival and tolerability results: olaparib versus chemotherapy treatment of physician’s choice in patients with a germline BRCA mutation and HER2-negative metastatic breast cancer. Annals of Oncology2019;30(4):558-66. Senkus-KonefkaE , DomchekSM , ImSA , XuB , ArmstrongA , MasudaN , et al. Subgroup analysis of olaparib monotherapy versus chemotherapy by hormone receptor and BRCA mutation status in patients with HER2-negative metastatic breast cancer and a germline BRCA mutation: OlympiAD. European Journal of Cancer2018;92:S19-20. TungNM , ImSA , Senkus-KonefkaE , XuB , DomchekSM , MasudaN , et al. Olaparib versus chemotherapy treatment of physician’s choice in patients with a germline BRCA mutation and HER2-negative metastatic breast cancer (OlympiAD): efficacy in patients with visceral metastases. Journal of Clinical Oncology2018;36(Suppl 15):1053. ">OLYMPIAD</a>). Pooled analysis of a sample size of 1443 patients showed likely little to no difference in rates of grade 3 or higher adverse events (59.4% for PARPi arm vs 64.5% for non‐PARPi arm, RR 0.98, 95% CI 0.91 to 1.04, P = 0.47; moderate‐certainty evidence). Significant statistical heterogeneity was present (I<sup>2</sup>= 73%, P = 0.005). </p> <div class="figure" id="CD011395-fig-0006"> <div class="figure-caption-wrapper-top"> <nav class="inline-nav-list has-dividers"> <ul> <li><a class="open-in-figure-viewer" href="#0">Open in figure viewer</a></li> </ul> </nav> <div class="figure-label">Figure 6</div> </div> <hr class="top"/><img alt="Forest plot of comparison: 1 PARPi‐containing regimen vs non‐PARPi regimen, outcome: 1.4 Grade ≥ 3 AEs" data-id="CD011395-fig-0006" src="/cdsr/doi/10.1002/14651858.CD011395.pub2/media/CDSR/CD011395/image_n/nCD011395-FIG-06.svg"/><hr class="bottom"/> <div class="figure-caption-wrapper-bottom"> <div class="figure-caption"> <p>Forest plot of comparison: 1 PARPi‐containing regimen vs non‐PARPi regimen, outcome: 1.4 Grade ≥ 3 AEs </p> </div> </div> </div> <p>The most common adverse events reported across all five studies included neutropenia, anaemia and fatigue. Neutropaenia was significantly less common in patients receiving PARP inhibitors (32.7% versus 52.0%, RR 0.67, 95% CI 0.60 to 0.76; P &lt; 0.00001). Anaemia was more common in patients receiving PARP inhibitors (39.2% versus 33.7%, RR 1.21, 95% CI 1.04 to 1.41, P = 0.01). Fatigue was non‐significantly less common in patients receiving PARP inhibitors (32.0% versus 36.7%, RR 0.90, 95% CI 0.78 to 1.05, P = 0.18). Only four studies reported thrombocytopaenia event rates (<a href="./references#CD011395-bbs2-0002" title="DiérasV , HanHS , RobsonME , PalacovaM , MarcomPK , JagerA , et al. Evaluation of veliparib (V) and temozolomide (TMZ) in a phase 2 randomized study of the efficacy and tolerability of V+TMZ or carboplatin (C) and paclitaxel (P) vs placebo (Plc)+C/P in patients (pts) with BRCA1 or BRCA2 mutations and metastatic breast cancer. Cancer Research2017;77(Suppl 4):Abstract nr SABCS16-P4-22-02. HanHS , DiérasV , RobsonM , PalácováM , MarcomPK , Jager A et al. Veliparib with temozolomide or carboplatin/paclitaxel versus placebo with carboplatin/paclitaxel in patients with BRCA1/2 locally recurrent/metastatic breast cancer: randomized phase II study. Annals of Oncology2018;29(1):154-61. HanHS , DiérasV , RobsonME , PalácováM , MarcomPK , JagerA , et al. Efficacy and tolerability of veliparib (V; ABT-888) in combination with carboplatin (C) and paclitaxel (P) vs placebo (Plc)+C/P in patients (pts) with BRCA1 or BRCA2 mutations and metastatic breast cancer: a randomized, phase 2 study. Cancer Research2017;77(Suppl 4):Abstract nr SABCS16-S2-05. IsakoffSJ , PuhallaS , DomchekSM , FriedlanderM , KaufmanB , RobsonM , et al. A randomized Phase II study of veliparib with temozolomide or carboplatin/paclitaxel versus placebo with carboplatin/paclitaxel in BRCA1/2 metastatic breast cancer: design and rationale. Future Oncology2017;13(4):307-20. ">BROCADE 2</a>; <a href="./references#CD011395-bbs2-0003" title="ArunBK , HanHS , KaufmanB , WildiersH , FriedlanderM , AyoubJP , et al. First-line veliparib plus carboplatin/paclitaxel in patients with HER2-negative advanced/metastatic gBRCA-associated breast cancer: planned subgroup analysis from the phase 3 BROCADE3 trial. Cancer Research2020;80(Suppl 4):Abstract nr PD4-01. AyoubJP , FriedlanderML , DierasVC , WildiersH , ArunB , HanHS , et al. Veliparib plus carboplatin-paclitaxel in patients with HER2-negative advanced/metastatic gBRCA-associated breast cancer: results in hormone receptor-positive and triple-negative breast cancer subgroups from the phase III BROCADE3 trial. Annals of Oncology2020;31(Suppl 2):S65. DierasV , HanH , KaufmanB , WildiersH , FriedlanderM , AyoubJ , et al. A Phase 3 randomized, placebo-controlled trial of carboplatin and paclitaxel with or without the PARP inhibitor veliparib (ABT-888) in HER2-negative metastatic or locally advanced unresectable BRCA-associated breast cancer. Annals of Oncology2019;30(Suppl 5):v851-v934. ">BROCADE 3</a>; <a href="./references#CD011395-bbs2-0004" title="DiabS , RugoHS , MinaLA , PuhallaS , MahtaniRL , HenryNL , et al. Efficacy and safety of talazoparib (TALA) or physician's choice of therapy (PCT) in United States patients (pts) with HER2- germline BRCA1/2-mutated (gBRCAm) locally advanced/metastatic breast cancer (LA/MBC) in the EMBRACA study. Journal of Clinical Oncology2019;37(Suppl 15):1044. EiermannW , RugoHS , DiabS , EttlJ , HurvitzSA , GoncalvesA , et al. Analysis of germline BRCA1/2 mutated (g BRCAmut) hormone receptor-positive (HR+) and triple-negative breast cancer (TNBC) treated with talazoparib (TALA). Journal of Clinical Oncology2018;36(Suppl 15):1070. EttlJ , HurvitzSA , RugoHS , LeeKH , MinaLA , WoodwardNE , et al. Outcomes of talazoparib (TALA) versus physician's choice of chemotherapy (PCT) in patients (pts) with advanced breast cancer (ABC) and a germline BRCA (gBRCA) mutation by line of chemotherapy (CT) in the EMBRACA trial. Journal of Clinical Oncology2019;37(Suppl 15):1071. EttlJ , QuekRG , BhattacharyyaH , RugoHS , HurvitzSA , GonçalvesA . Patient Reported Outcomes (PRO) in patients (pts) with HER2-advanced breast cancer (ABC) and a germline BRCA1/2 mutation (gBRCAm) receiving talazoparib (TALA) vs physician’s choice chemotherapy (PCT) in the EMBRACA trial: a focus on subgroups with/without visceral disease. Annals of Oncology2019;30(Suppl 5):v129–30. EttlJ , QuekRG , HurvitzSA , GoncalvesA , TudorIC , RugoHS . Hospitalization and supportive care medication (SCM) utilisation in patients (pts) with advanced breast cancer (ABC) and a germline BRCA1/2 mutation (gBRCAm) in EMBRACA. Annals of Oncology2019;30(Suppl 3):iii52. EttlJ , QuekRG , LeeKH , RugoHS , HurvitzS , GonçalvesA , et al. Quality of life with talazoparib versus physician’s choice of chemotherapy in patients with advanced breast cancer and germline BRCA1/2 mutation: patient-reported outcomes from the EMBRACA phase III trial. Annals of Oncology2018;29(9):1939-47. FaschingPA , QuekRG , BhattacharyyaH , HurvitzSA , RugoHS , EttlJ . Impact of objective response (OR) on patient-reported outcomes (PRO) in patients (pts) with advanced breast cancer (ABC) and a germline BRCA1/2 (gBRCA) mutation in the phase III EMBRACA trial. Annals of Oncology2019;30(Suppl 3):iii49. GonçalvesA , EiermannW , RugoHS , EttlJ , HurvitzSA , YerushalmiR , et al. EMBRACA: Efficacy and safety in comparing talazoparib (TALA) with physician's choice of therapy (PCT) in patients (pts) with advanced breast cancer (aBC) and a germline BRCA mutation (gBRCAm); BRCA1/BRCA2 subgroup analysis. Annals of Oncology2018;29(Suppl 8):viii96–7. GoncalvesA , QuekRGW , BhattacharyyaH , EttlJ , HurvitzSA , RugoHS . Patient-reported outcomes (PRO) in patients (pts) with Her2-advanced breast cancer (ABC) receiving talazoparib (TALA) vs physician's choice chemotherapy (PCT): a focus on EMBRACA germline BRCA1 and BRCA2 mutation (gBRCA1/2m) subgroups. Breast2019;48(Suppl 2):S71. HurvitzSA , GoncalvesA , RugoHS , LeeKH , FehrenbacherL , MinaLA , et al. Talazoparib in patients with a germline BRCA-mutated advanced breast cancer: detailed safety analyses from the phase III EMBRACA Trial. Oncologist2019;25(3):e439-50. LeeKH , KimSB , SohnJ , GoodwinA , UsariT , LanzaloneS , et al. Talazoparib (TALA) vs physician’s choice of chemotherapy (PCT) in Asian patients (Pts) with HER2- advanced breast cancer (ABC) and a germline BRCA1/2 mutation (gBRCA1/2mut): data from phase III EMBRACA. Annals of Oncology2019;30(9):ix14. LittonJ , EttlJ , HurvitzSA , MinaLA , RugoHS , LeeKH , et al. A phase 3, open-label, randomized, 2-arm international study of the oral dual PARP inhibitor talazoparib in germline BRCA mutation subjects with locally advanced and/or metastatic breast cancer (EMBRACA). Cancer Research2017;77(Suppl 4):Abstract nr OT2-01-13. LittonJ , RugoHS , EttlJ , HurvitzS , GoncalvesA , LeeKH , et al. EMBRACA: a phase 3 trial comparing talazoparib, an oral PARP inhibitor, to physicianʼs choice of therapy in patients with advanced breast cancer and a germline BRCA mutation [abstract]. In: San Antonio Breast Cancer Symposium; 2017 Dec 5-9; San Antonio (TX). San Antonio (TX), 2017. LittonJK , HurvitzSA , MinaLA , RugoHS , LeeKH , GonçalvesA , et al. Talazoparib (TALA) in germline BRCA1/2 (gBRCA1/2)-mutated human epidermal growth factor receptor 2 negative (HER2-) advanced breast cancer (ABC): final overall survival (OS) results from randomized phase 3 EMBRACA trial. Cancer Research2020;80(Suppl 16):Abstract no. CT071. LittonJK , RugoHS , EttlJ , HurvitzSA , GonçalvesA , LeeKH , et al. Talazoparib in patients with advanced breast cancer and a germline BRCA mutation. New England Journal of Medicine2018;379(8):753-63. MartínM , EiermannW , RugoHS , EttlJ , HurvitzSA , GonçalvesA , et al. EMBRACA: Comparison of efficacy and safety of talazoparib (TALA) and physician's choice of therapy (PCT) in patients (pts) with advanced breast cancer (aBC), a germline BRCA1/2 mutation (gBRCAm), and prior platinum treatment. Annals of Oncology2018;29(Suppl 8):viii96. MinaL , LeeKH , GoncalvesA , WoodwardN , HurvitzSA , DiabS , et al. EMBRACA: efficacy and safety of talazoparib or physician's choice of therapy in patients with advanced breast cancer and a germline BRCA1/2 mutation: a regional analysis. Cancer Research2019;79(Suppl 4):Abstract nr P6-18-12. QuekR , BhattacharyyaH , HurvitzS , GoncalvesA , EttlJ , RugoH . Patient-reported outcomes in patients with HER2-advanced breast cancer and a germline BRCA1/2 mutation receiving talazoparib versus physician's choice chemotherapy: a focus on EMBRACA age subgroups. Journal of Managed Care and Specialty Pharmacy2019;25(Suppl 10A):S37-8. QuekRGW , BhattacharyyaH , GoncalvesA , RugoHS , HurvitzSA , EttlJ . Pcn491 Patient reported outcomes (PRO) of talazoparib (TALA) versus physician's choice of chemotherapy (PCT) in patients (pts) with advanced breast cancer (aBC) and a germline BRCA (gBRCa) mutation: a focus on Embraca pts with/without prior chemotherapy (CT) subgroups. Value in Health2019;22(Suppl 3):S532. RugoHS , EttlJ , HurvitzSA , GoncalvesA , LeeKH , FehrenbacherL , et al. Outcomes in clinically relevant patient subgroups from the EMBRACA study: talazoparib vs physician's choice standard-of-care chemotherapy. Journal of the National Cancer Institute Cancer Spectrum2020;4(1):pkz085. RugoHS , EttlJ , WoodwardNE , HurvitzSA , GoncalvesA , LeeKH , et al. EMBRACA: efficacy outcomes in clinically relevant subgroups comparing talazoparib (TALA), an oral poly ADP ribose polymerase (PARP) inhibitor, to physician's choice of therapy (PCT) in patients with advanced breast cancer and a germline BRCA mutation. Journal of Clinical Oncology2018;36(Suppl 15):1069. RugoHS , QuekR , EttlJ , HurvitzSA , BhattacharyyaH , HannahAL , et al. Patient-reported outcomes (PRO) in patients (pts) with advanced breast cancer and a germline BRCA1/2 mutation (gBRCAm) receiving talazoparib (TALA) vs physician’s choice chemotherapy treatment (PCT): a focus on the EMBRACA triple negative (TNBC) subpopulation. Annals of Oncology2018;29(Suppl 8):viii91. YuY , ElmeliegyM , LittonJK , TudorIC , CzibereA , ZhengJ , et al. Exposure-efficacy progression-free survival (PFS) analyses of breast cancer patients with germline BRCA1/2 mutations receiving talazoparib in the phase III EMBRACA trial. Annals of Oncology2018;29(Suppl 8):viii97. YuY , ElmeliegyM , LittonJK , TudorIC , CzibereA , ZhengJ , et al. Talazoparib exposure-efficacy analysis in patients with advanced breast cancer and germline BRCA1/2 mutations in the EMBRACA trial. Journal of Clinical Pharmacology2020;60(10):1324-33. ">EMBRACA</a>; <a href="./references#CD011395-bbs2-0005" title="KummarS , WadeJL , OzaAM , SullivanD , ChenAP , GandaraDR , et al. Randomized phase II trial of cyclophosphamide and the oral poly (ADP-ribose) polymerase inhibitor veliparib in patients with recurrent, advanced triple-negative breast cancer. Investigational New Drugs2016;34(3):355–63. ">Kummar 2016</a>). Thrombocytopaenia was non‐significantly less common in patients receiving PARP inhibitors (30.6% versus 35.8%, RR 0.98, 95% CI 0.84 to 1.15, P = 0.84). </p> </section> </section> </section> </section> </section> <section class="discussion"> <div class="section-header section-collapse-header" id="CD011395-sec-0058" lang="en"> <h2 class="title section-collapse-title"> Discussion <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> </div> <section class="discussion" lang="en"> <div class="section-header" id="CD011395-sec-0058"></div> <section id="CD011395-sec-0059"> <h3 class="title" id="CD011395-sec-0059">Summary of main results</h3> <p>We identified a total of 49 articles describing six eligible studies for qualitative analysis. Five studies comprising a total of 1474 participants were included in the meta‐analyses. Three studies were large phase 3 randomised controlled trials (<a href="./references#CD011395-bbs2-0003" title="ArunBK , HanHS , KaufmanB , WildiersH , FriedlanderM , AyoubJP , et al. First-line veliparib plus carboplatin/paclitaxel in patients with HER2-negative advanced/metastatic gBRCA-associated breast cancer: planned subgroup analysis from the phase 3 BROCADE3 trial. Cancer Research2020;80(Suppl 4):Abstract nr PD4-01. AyoubJP , FriedlanderML , DierasVC , WildiersH , ArunB , HanHS , et al. Veliparib plus carboplatin-paclitaxel in patients with HER2-negative advanced/metastatic gBRCA-associated breast cancer: results in hormone receptor-positive and triple-negative breast cancer subgroups from the phase III BROCADE3 trial. Annals of Oncology2020;31(Suppl 2):S65. DierasV , HanH , KaufmanB , WildiersH , FriedlanderM , AyoubJ , et al. A Phase 3 randomized, placebo-controlled trial of carboplatin and paclitaxel with or without the PARP inhibitor veliparib (ABT-888) in HER2-negative metastatic or locally advanced unresectable BRCA-associated breast cancer. Annals of Oncology2019;30(Suppl 5):v851-v934. ">BROCADE 3</a>; <a href="./references#CD011395-bbs2-0004" title="DiabS , RugoHS , MinaLA , PuhallaS , MahtaniRL , HenryNL , et al. Efficacy and safety of talazoparib (TALA) or physician's choice of therapy (PCT) in United States patients (pts) with HER2- germline BRCA1/2-mutated (gBRCAm) locally advanced/metastatic breast cancer (LA/MBC) in the EMBRACA study. Journal of Clinical Oncology2019;37(Suppl 15):1044. EiermannW , RugoHS , DiabS , EttlJ , HurvitzSA , GoncalvesA , et al. Analysis of germline BRCA1/2 mutated (g BRCAmut) hormone receptor-positive (HR+) and triple-negative breast cancer (TNBC) treated with talazoparib (TALA). Journal of Clinical Oncology2018;36(Suppl 15):1070. EttlJ , HurvitzSA , RugoHS , LeeKH , MinaLA , WoodwardNE , et al. Outcomes of talazoparib (TALA) versus physician's choice of chemotherapy (PCT) in patients (pts) with advanced breast cancer (ABC) and a germline BRCA (gBRCA) mutation by line of chemotherapy (CT) in the EMBRACA trial. Journal of Clinical Oncology2019;37(Suppl 15):1071. EttlJ , QuekRG , BhattacharyyaH , RugoHS , HurvitzSA , GonçalvesA . Patient Reported Outcomes (PRO) in patients (pts) with HER2-advanced breast cancer (ABC) and a germline BRCA1/2 mutation (gBRCAm) receiving talazoparib (TALA) vs physician’s choice chemotherapy (PCT) in the EMBRACA trial: a focus on subgroups with/without visceral disease. Annals of Oncology2019;30(Suppl 5):v129–30. EttlJ , QuekRG , HurvitzSA , GoncalvesA , TudorIC , RugoHS . Hospitalization and supportive care medication (SCM) utilisation in patients (pts) with advanced breast cancer (ABC) and a germline BRCA1/2 mutation (gBRCAm) in EMBRACA. Annals of Oncology2019;30(Suppl 3):iii52. EttlJ , QuekRG , LeeKH , RugoHS , HurvitzS , GonçalvesA , et al. Quality of life with talazoparib versus physician’s choice of chemotherapy in patients with advanced breast cancer and germline BRCA1/2 mutation: patient-reported outcomes from the EMBRACA phase III trial. Annals of Oncology2018;29(9):1939-47. FaschingPA , QuekRG , BhattacharyyaH , HurvitzSA , RugoHS , EttlJ . Impact of objective response (OR) on patient-reported outcomes (PRO) in patients (pts) with advanced breast cancer (ABC) and a germline BRCA1/2 (gBRCA) mutation in the phase III EMBRACA trial. Annals of Oncology2019;30(Suppl 3):iii49. GonçalvesA , EiermannW , RugoHS , EttlJ , HurvitzSA , YerushalmiR , et al. EMBRACA: Efficacy and safety in comparing talazoparib (TALA) with physician's choice of therapy (PCT) in patients (pts) with advanced breast cancer (aBC) and a germline BRCA mutation (gBRCAm); BRCA1/BRCA2 subgroup analysis. Annals of Oncology2018;29(Suppl 8):viii96–7. GoncalvesA , QuekRGW , BhattacharyyaH , EttlJ , HurvitzSA , RugoHS . Patient-reported outcomes (PRO) in patients (pts) with Her2-advanced breast cancer (ABC) receiving talazoparib (TALA) vs physician's choice chemotherapy (PCT): a focus on EMBRACA germline BRCA1 and BRCA2 mutation (gBRCA1/2m) subgroups. Breast2019;48(Suppl 2):S71. HurvitzSA , GoncalvesA , RugoHS , LeeKH , FehrenbacherL , MinaLA , et al. Talazoparib in patients with a germline BRCA-mutated advanced breast cancer: detailed safety analyses from the phase III EMBRACA Trial. Oncologist2019;25(3):e439-50. LeeKH , KimSB , SohnJ , GoodwinA , UsariT , LanzaloneS , et al. Talazoparib (TALA) vs physician’s choice of chemotherapy (PCT) in Asian patients (Pts) with HER2- advanced breast cancer (ABC) and a germline BRCA1/2 mutation (gBRCA1/2mut): data from phase III EMBRACA. Annals of Oncology2019;30(9):ix14. LittonJ , EttlJ , HurvitzSA , MinaLA , RugoHS , LeeKH , et al. A phase 3, open-label, randomized, 2-arm international study of the oral dual PARP inhibitor talazoparib in germline BRCA mutation subjects with locally advanced and/or metastatic breast cancer (EMBRACA). Cancer Research2017;77(Suppl 4):Abstract nr OT2-01-13. LittonJ , RugoHS , EttlJ , HurvitzS , GoncalvesA , LeeKH , et al. EMBRACA: a phase 3 trial comparing talazoparib, an oral PARP inhibitor, to physicianʼs choice of therapy in patients with advanced breast cancer and a germline BRCA mutation [abstract]. In: San Antonio Breast Cancer Symposium; 2017 Dec 5-9; San Antonio (TX). San Antonio (TX), 2017. LittonJK , HurvitzSA , MinaLA , RugoHS , LeeKH , GonçalvesA , et al. Talazoparib (TALA) in germline BRCA1/2 (gBRCA1/2)-mutated human epidermal growth factor receptor 2 negative (HER2-) advanced breast cancer (ABC): final overall survival (OS) results from randomized phase 3 EMBRACA trial. Cancer Research2020;80(Suppl 16):Abstract no. CT071. LittonJK , RugoHS , EttlJ , HurvitzSA , GonçalvesA , LeeKH , et al. Talazoparib in patients with advanced breast cancer and a germline BRCA mutation. New England Journal of Medicine2018;379(8):753-63. MartínM , EiermannW , RugoHS , EttlJ , HurvitzSA , GonçalvesA , et al. EMBRACA: Comparison of efficacy and safety of talazoparib (TALA) and physician's choice of therapy (PCT) in patients (pts) with advanced breast cancer (aBC), a germline BRCA1/2 mutation (gBRCAm), and prior platinum treatment. Annals of Oncology2018;29(Suppl 8):viii96. MinaL , LeeKH , GoncalvesA , WoodwardN , HurvitzSA , DiabS , et al. EMBRACA: efficacy and safety of talazoparib or physician's choice of therapy in patients with advanced breast cancer and a germline BRCA1/2 mutation: a regional analysis. Cancer Research2019;79(Suppl 4):Abstract nr P6-18-12. QuekR , BhattacharyyaH , HurvitzS , GoncalvesA , EttlJ , RugoH . Patient-reported outcomes in patients with HER2-advanced breast cancer and a germline BRCA1/2 mutation receiving talazoparib versus physician's choice chemotherapy: a focus on EMBRACA age subgroups. Journal of Managed Care and Specialty Pharmacy2019;25(Suppl 10A):S37-8. QuekRGW , BhattacharyyaH , GoncalvesA , RugoHS , HurvitzSA , EttlJ . Pcn491 Patient reported outcomes (PRO) of talazoparib (TALA) versus physician's choice of chemotherapy (PCT) in patients (pts) with advanced breast cancer (aBC) and a germline BRCA (gBRCa) mutation: a focus on Embraca pts with/without prior chemotherapy (CT) subgroups. Value in Health2019;22(Suppl 3):S532. RugoHS , EttlJ , HurvitzSA , GoncalvesA , LeeKH , FehrenbacherL , et al. Outcomes in clinically relevant patient subgroups from the EMBRACA study: talazoparib vs physician's choice standard-of-care chemotherapy. Journal of the National Cancer Institute Cancer Spectrum2020;4(1):pkz085. RugoHS , EttlJ , WoodwardNE , HurvitzSA , GoncalvesA , LeeKH , et al. EMBRACA: efficacy outcomes in clinically relevant subgroups comparing talazoparib (TALA), an oral poly ADP ribose polymerase (PARP) inhibitor, to physician's choice of therapy (PCT) in patients with advanced breast cancer and a germline BRCA mutation. Journal of Clinical Oncology2018;36(Suppl 15):1069. RugoHS , QuekR , EttlJ , HurvitzSA , BhattacharyyaH , HannahAL , et al. Patient-reported outcomes (PRO) in patients (pts) with advanced breast cancer and a germline BRCA1/2 mutation (gBRCAm) receiving talazoparib (TALA) vs physician’s choice chemotherapy treatment (PCT): a focus on the EMBRACA triple negative (TNBC) subpopulation. Annals of Oncology2018;29(Suppl 8):viii91. YuY , ElmeliegyM , LittonJK , TudorIC , CzibereA , ZhengJ , et al. Exposure-efficacy progression-free survival (PFS) analyses of breast cancer patients with germline BRCA1/2 mutations receiving talazoparib in the phase III EMBRACA trial. Annals of Oncology2018;29(Suppl 8):viii97. YuY , ElmeliegyM , LittonJK , TudorIC , CzibereA , ZhengJ , et al. Talazoparib exposure-efficacy analysis in patients with advanced breast cancer and germline BRCA1/2 mutations in the EMBRACA trial. Journal of Clinical Pharmacology2020;60(10):1324-33. ">EMBRACA</a>; <a href="./references#CD011395-bbs2-0006" title="DelalogeS , ContePF , ImS , Senkus-KonefkaE , XuB , DomchekSM , et al. OlympiAD: further efficacy outcomes in patients with HER2-negative metastatic breast cancer and a germline BRCA mutation receiving olaparib monotherapy vs standard single-agent chemotherapy treatment of physician’s choice. Annals of Oncology2017;28(Suppl 5):v74-v108. DomchekS , RobsonM , ImS , SenkusE , XuB , MasudaN , et al. Tolerability of olaparib monotherapy versus chemotherapy in patients with HER2-negative metastatic breast cancer and a germline BRCA mutation: OlympiAD. Cancer Research2018;78(Suppl 4):Abstract nr P5-21-12. ImSA , XuB , LiW , RobsonM , OuyangQ , YehDC , et al. Olaparib monotherapy for Asian patients with a germline BRCA mutation and HER2-negative metastatic breast cancer: OlympiAD randomized trial subgroup analysis. Scientific Reports2020;10(1):8753. ImSA , XuB , LiW , RobsonM , OuyangQ , YehDC , et al. Olaparib monotherapy versus chemotherapy for patients with HER2-negative metastatic breast cancer and a germline BRCA mutation: Asian subgroup analysis from the phase III OlympiAD trial. Cancer Research2018;78(Suppl 4):Abstract nr P5-21-13. MerensC , BannisterW , BergnerS , HettleR , McCreaC , McCutcheonS , et al. Impact of olaparib versus chemotherapy on the use of strong pain medications in gBRCA-mutated HER2-negative metastatic breast cancer and associated patient reported outcomes. Cancer Research2020;80(Suppl 4):Abstract nr P6-13-05. RobsonM , HettleR , DegboeA , SaundersO , CainT , KilvertH , et al. Estimating the health state utility of patients with HER2–gBRCA+ metastatic breast cancer treated with olaparib or chemotherapy via a mapping analysis of EORTC QLQ-C30 data collected in the Olympiad clinical trial. Value in Health2018;21(Suppl 1):S12. RobsonM , ImSA , SenkusE , XuB , DomchekS , MasudaN , et al. OlympiAD extended follow-up for overall survival and safety: olaparib versus chemotherapy treatment of physician’s choice in patients with a germline BRCA mutation and HER2-negative metastatic breast cancer. Cancer Research2020;80(Suppl 4):Abstract nr PD4-03. RobsonM , ImSA , SenkusE , XuB , DomchekSM , MasudaN , et al. Olaparib for metastatic breast cancer in patients with a germline BRCA mutation. New England Journal of Medicine2017;377(6):523-33. RobsonM , RuddyKJ , ImSA , SenkusE , XuB , DomchekSM , et al. Patient-reported outcomes in patients with a germline BRCA mutation and HER2-negative metastatic breast cancer receiving olaparib versus chemotherapy in the OlympiAD trial. European Journal of Cancer2019;120:20-30. RobsonM , RuddyKJ , ImSA , Senkus-KonefkaE , XuB , DomchekSM , et al. OlympiAD: health-related quality of life (HRQoL) in patients with HER2-negative metastatic breast cancer (mBC) and a germline BRCA mutation (gBRCAm) receiving olaparib monotherapy vs standard single-agent chemotherapy treatment of physician’s choice (TPC). Annals of Oncology2017;28(Suppl 5):v74-v108. RobsonME , ImSA , SenkusE , XuB , DomchekS , MasudaN , et al. Abstract CT038: OlympiAD final overall survival: olaparib versus chemotherapy treatment of physician's choice (TPC) in patients with HER2-negative metastatic breast cancer (mBC) and a germline BRCA mutation (gBRCAm). American Association for Cancer Research2018;78(Suppl 13):CT038. RobsonME , ImSA , SenkusE , XuB , DomchekSM , MasudaN , et al. OlympiAD: phase III trial of olaparib monotherapy versus chemotherapy for patients (pts) with HER2-negative metastatic breast cancer (mBC) and a germline BRCA mutation (gBRCAm). Journal of Clinical Oncology2017;35(Suppl 18):LBA4-LBA4. RobsonME , RuddyKJ , ImSA , Senkus-KonefkaE , XuB , DomchekSM , et al. EORTC QLQ-C30 (QLQ-C30) symptoms in patients (pts) with HER2-negative metastatic breast cancer (mBC) and a germline BRCA mutation (gBRCAm) receiving olaparib vs chemotherapy treatment of physician’s choice (TPC) in OlympiAD. Journal of Clinical Oncology2018;36(Suppl 15):1045. RobsonME , TungN , ConteP , ImSA , SenkusE , XuB , et al. OlympiAD final overall survival and tolerability results: olaparib versus chemotherapy treatment of physician’s choice in patients with a germline BRCA mutation and HER2-negative metastatic breast cancer. Annals of Oncology2019;30(4):558-66. Senkus-KonefkaE , DomchekSM , ImSA , XuB , ArmstrongA , MasudaN , et al. Subgroup analysis of olaparib monotherapy versus chemotherapy by hormone receptor and BRCA mutation status in patients with HER2-negative metastatic breast cancer and a germline BRCA mutation: OlympiAD. European Journal of Cancer2018;92:S19-20. TungNM , ImSA , Senkus-KonefkaE , XuB , DomchekSM , MasudaN , et al. Olaparib versus chemotherapy treatment of physician’s choice in patients with a germline BRCA mutation and HER2-negative metastatic breast cancer (OlympiAD): efficacy in patients with visceral metastases. Journal of Clinical Oncology2018;36(Suppl 15):1053. ">OLYMPIAD</a>) and two were phase 2 trials (<a href="./references#CD011395-bbs2-0002" title="DiérasV , HanHS , RobsonME , PalacovaM , MarcomPK , JagerA , et al. Evaluation of veliparib (V) and temozolomide (TMZ) in a phase 2 randomized study of the efficacy and tolerability of V+TMZ or carboplatin (C) and paclitaxel (P) vs placebo (Plc)+C/P in patients (pts) with BRCA1 or BRCA2 mutations and metastatic breast cancer. Cancer Research2017;77(Suppl 4):Abstract nr SABCS16-P4-22-02. HanHS , DiérasV , RobsonM , PalácováM , MarcomPK , Jager A et al. Veliparib with temozolomide or carboplatin/paclitaxel versus placebo with carboplatin/paclitaxel in patients with BRCA1/2 locally recurrent/metastatic breast cancer: randomized phase II study. Annals of Oncology2018;29(1):154-61. HanHS , DiérasV , RobsonME , PalácováM , MarcomPK , JagerA , et al. Efficacy and tolerability of veliparib (V; ABT-888) in combination with carboplatin (C) and paclitaxel (P) vs placebo (Plc)+C/P in patients (pts) with BRCA1 or BRCA2 mutations and metastatic breast cancer: a randomized, phase 2 study. Cancer Research2017;77(Suppl 4):Abstract nr SABCS16-S2-05. IsakoffSJ , PuhallaS , DomchekSM , FriedlanderM , KaufmanB , RobsonM , et al. A randomized Phase II study of veliparib with temozolomide or carboplatin/paclitaxel versus placebo with carboplatin/paclitaxel in BRCA1/2 metastatic breast cancer: design and rationale. Future Oncology2017;13(4):307-20. ">BROCADE 2</a>; <a href="./references#CD011395-bbs2-0005" title="KummarS , WadeJL , OzaAM , SullivanD , ChenAP , GandaraDR , et al. Randomized phase II trial of cyclophosphamide and the oral poly (ADP-ribose) polymerase inhibitor veliparib in patients with recurrent, advanced triple-negative breast cancer. Investigational New Drugs2016;34(3):355–63. ">Kummar 2016</a>). Trial design differed in that two of the phase 3 studies compared single agent PARP inhibitors to physician’s choice of chemotherapy (<a href="./references#CD011395-bbs2-0004" title="DiabS , RugoHS , MinaLA , PuhallaS , MahtaniRL , HenryNL , et al. Efficacy and safety of talazoparib (TALA) or physician's choice of therapy (PCT) in United States patients (pts) with HER2- germline BRCA1/2-mutated (gBRCAm) locally advanced/metastatic breast cancer (LA/MBC) in the EMBRACA study. Journal of Clinical Oncology2019;37(Suppl 15):1044. EiermannW , RugoHS , DiabS , EttlJ , HurvitzSA , GoncalvesA , et al. Analysis of germline BRCA1/2 mutated (g BRCAmut) hormone receptor-positive (HR+) and triple-negative breast cancer (TNBC) treated with talazoparib (TALA). Journal of Clinical Oncology2018;36(Suppl 15):1070. EttlJ , HurvitzSA , RugoHS , LeeKH , MinaLA , WoodwardNE , et al. Outcomes of talazoparib (TALA) versus physician's choice of chemotherapy (PCT) in patients (pts) with advanced breast cancer (ABC) and a germline BRCA (gBRCA) mutation by line of chemotherapy (CT) in the EMBRACA trial. Journal of Clinical Oncology2019;37(Suppl 15):1071. EttlJ , QuekRG , BhattacharyyaH , RugoHS , HurvitzSA , GonçalvesA . Patient Reported Outcomes (PRO) in patients (pts) with HER2-advanced breast cancer (ABC) and a germline BRCA1/2 mutation (gBRCAm) receiving talazoparib (TALA) vs physician’s choice chemotherapy (PCT) in the EMBRACA trial: a focus on subgroups with/without visceral disease. Annals of Oncology2019;30(Suppl 5):v129–30. EttlJ , QuekRG , HurvitzSA , GoncalvesA , TudorIC , RugoHS . Hospitalization and supportive care medication (SCM) utilisation in patients (pts) with advanced breast cancer (ABC) and a germline BRCA1/2 mutation (gBRCAm) in EMBRACA. Annals of Oncology2019;30(Suppl 3):iii52. EttlJ , QuekRG , LeeKH , RugoHS , HurvitzS , GonçalvesA , et al. Quality of life with talazoparib versus physician’s choice of chemotherapy in patients with advanced breast cancer and germline BRCA1/2 mutation: patient-reported outcomes from the EMBRACA phase III trial. Annals of Oncology2018;29(9):1939-47. FaschingPA , QuekRG , BhattacharyyaH , HurvitzSA , RugoHS , EttlJ . Impact of objective response (OR) on patient-reported outcomes (PRO) in patients (pts) with advanced breast cancer (ABC) and a germline BRCA1/2 (gBRCA) mutation in the phase III EMBRACA trial. Annals of Oncology2019;30(Suppl 3):iii49. GonçalvesA , EiermannW , RugoHS , EttlJ , HurvitzSA , YerushalmiR , et al. EMBRACA: Efficacy and safety in comparing talazoparib (TALA) with physician's choice of therapy (PCT) in patients (pts) with advanced breast cancer (aBC) and a germline BRCA mutation (gBRCAm); BRCA1/BRCA2 subgroup analysis. Annals of Oncology2018;29(Suppl 8):viii96–7. GoncalvesA , QuekRGW , BhattacharyyaH , EttlJ , HurvitzSA , RugoHS . Patient-reported outcomes (PRO) in patients (pts) with Her2-advanced breast cancer (ABC) receiving talazoparib (TALA) vs physician's choice chemotherapy (PCT): a focus on EMBRACA germline BRCA1 and BRCA2 mutation (gBRCA1/2m) subgroups. Breast2019;48(Suppl 2):S71. HurvitzSA , GoncalvesA , RugoHS , LeeKH , FehrenbacherL , MinaLA , et al. Talazoparib in patients with a germline BRCA-mutated advanced breast cancer: detailed safety analyses from the phase III EMBRACA Trial. Oncologist2019;25(3):e439-50. LeeKH , KimSB , SohnJ , GoodwinA , UsariT , LanzaloneS , et al. Talazoparib (TALA) vs physician’s choice of chemotherapy (PCT) in Asian patients (Pts) with HER2- advanced breast cancer (ABC) and a germline BRCA1/2 mutation (gBRCA1/2mut): data from phase III EMBRACA. Annals of Oncology2019;30(9):ix14. LittonJ , EttlJ , HurvitzSA , MinaLA , RugoHS , LeeKH , et al. A phase 3, open-label, randomized, 2-arm international study of the oral dual PARP inhibitor talazoparib in germline BRCA mutation subjects with locally advanced and/or metastatic breast cancer (EMBRACA). Cancer Research2017;77(Suppl 4):Abstract nr OT2-01-13. LittonJ , RugoHS , EttlJ , HurvitzS , GoncalvesA , LeeKH , et al. EMBRACA: a phase 3 trial comparing talazoparib, an oral PARP inhibitor, to physicianʼs choice of therapy in patients with advanced breast cancer and a germline BRCA mutation [abstract]. In: San Antonio Breast Cancer Symposium; 2017 Dec 5-9; San Antonio (TX). San Antonio (TX), 2017. LittonJK , HurvitzSA , MinaLA , RugoHS , LeeKH , GonçalvesA , et al. Talazoparib (TALA) in germline BRCA1/2 (gBRCA1/2)-mutated human epidermal growth factor receptor 2 negative (HER2-) advanced breast cancer (ABC): final overall survival (OS) results from randomized phase 3 EMBRACA trial. Cancer Research2020;80(Suppl 16):Abstract no. CT071. LittonJK , RugoHS , EttlJ , HurvitzSA , GonçalvesA , LeeKH , et al. Talazoparib in patients with advanced breast cancer and a germline BRCA mutation. New England Journal of Medicine2018;379(8):753-63. MartínM , EiermannW , RugoHS , EttlJ , HurvitzSA , GonçalvesA , et al. EMBRACA: Comparison of efficacy and safety of talazoparib (TALA) and physician's choice of therapy (PCT) in patients (pts) with advanced breast cancer (aBC), a germline BRCA1/2 mutation (gBRCAm), and prior platinum treatment. Annals of Oncology2018;29(Suppl 8):viii96. MinaL , LeeKH , GoncalvesA , WoodwardN , HurvitzSA , DiabS , et al. EMBRACA: efficacy and safety of talazoparib or physician's choice of therapy in patients with advanced breast cancer and a germline BRCA1/2 mutation: a regional analysis. Cancer Research2019;79(Suppl 4):Abstract nr P6-18-12. QuekR , BhattacharyyaH , HurvitzS , GoncalvesA , EttlJ , RugoH . Patient-reported outcomes in patients with HER2-advanced breast cancer and a germline BRCA1/2 mutation receiving talazoparib versus physician's choice chemotherapy: a focus on EMBRACA age subgroups. Journal of Managed Care and Specialty Pharmacy2019;25(Suppl 10A):S37-8. QuekRGW , BhattacharyyaH , GoncalvesA , RugoHS , HurvitzSA , EttlJ . Pcn491 Patient reported outcomes (PRO) of talazoparib (TALA) versus physician's choice of chemotherapy (PCT) in patients (pts) with advanced breast cancer (aBC) and a germline BRCA (gBRCa) mutation: a focus on Embraca pts with/without prior chemotherapy (CT) subgroups. Value in Health2019;22(Suppl 3):S532. RugoHS , EttlJ , HurvitzSA , GoncalvesA , LeeKH , FehrenbacherL , et al. Outcomes in clinically relevant patient subgroups from the EMBRACA study: talazoparib vs physician's choice standard-of-care chemotherapy. Journal of the National Cancer Institute Cancer Spectrum2020;4(1):pkz085. RugoHS , EttlJ , WoodwardNE , HurvitzSA , GoncalvesA , LeeKH , et al. EMBRACA: efficacy outcomes in clinically relevant subgroups comparing talazoparib (TALA), an oral poly ADP ribose polymerase (PARP) inhibitor, to physician's choice of therapy (PCT) in patients with advanced breast cancer and a germline BRCA mutation. Journal of Clinical Oncology2018;36(Suppl 15):1069. RugoHS , QuekR , EttlJ , HurvitzSA , BhattacharyyaH , HannahAL , et al. Patient-reported outcomes (PRO) in patients (pts) with advanced breast cancer and a germline BRCA1/2 mutation (gBRCAm) receiving talazoparib (TALA) vs physician’s choice chemotherapy treatment (PCT): a focus on the EMBRACA triple negative (TNBC) subpopulation. Annals of Oncology2018;29(Suppl 8):viii91. YuY , ElmeliegyM , LittonJK , TudorIC , CzibereA , ZhengJ , et al. Exposure-efficacy progression-free survival (PFS) analyses of breast cancer patients with germline BRCA1/2 mutations receiving talazoparib in the phase III EMBRACA trial. Annals of Oncology2018;29(Suppl 8):viii97. YuY , ElmeliegyM , LittonJK , TudorIC , CzibereA , ZhengJ , et al. Talazoparib exposure-efficacy analysis in patients with advanced breast cancer and germline BRCA1/2 mutations in the EMBRACA trial. Journal of Clinical Pharmacology2020;60(10):1324-33. ">EMBRACA</a>; <a href="./references#CD011395-bbs2-0006" title="DelalogeS , ContePF , ImS , Senkus-KonefkaE , XuB , DomchekSM , et al. OlympiAD: further efficacy outcomes in patients with HER2-negative metastatic breast cancer and a germline BRCA mutation receiving olaparib monotherapy vs standard single-agent chemotherapy treatment of physician’s choice. Annals of Oncology2017;28(Suppl 5):v74-v108. DomchekS , RobsonM , ImS , SenkusE , XuB , MasudaN , et al. Tolerability of olaparib monotherapy versus chemotherapy in patients with HER2-negative metastatic breast cancer and a germline BRCA mutation: OlympiAD. Cancer Research2018;78(Suppl 4):Abstract nr P5-21-12. ImSA , XuB , LiW , RobsonM , OuyangQ , YehDC , et al. Olaparib monotherapy for Asian patients with a germline BRCA mutation and HER2-negative metastatic breast cancer: OlympiAD randomized trial subgroup analysis. Scientific Reports2020;10(1):8753. ImSA , XuB , LiW , RobsonM , OuyangQ , YehDC , et al. Olaparib monotherapy versus chemotherapy for patients with HER2-negative metastatic breast cancer and a germline BRCA mutation: Asian subgroup analysis from the phase III OlympiAD trial. Cancer Research2018;78(Suppl 4):Abstract nr P5-21-13. MerensC , BannisterW , BergnerS , HettleR , McCreaC , McCutcheonS , et al. Impact of olaparib versus chemotherapy on the use of strong pain medications in gBRCA-mutated HER2-negative metastatic breast cancer and associated patient reported outcomes. Cancer Research2020;80(Suppl 4):Abstract nr P6-13-05. RobsonM , HettleR , DegboeA , SaundersO , CainT , KilvertH , et al. Estimating the health state utility of patients with HER2–gBRCA+ metastatic breast cancer treated with olaparib or chemotherapy via a mapping analysis of EORTC QLQ-C30 data collected in the Olympiad clinical trial. Value in Health2018;21(Suppl 1):S12. RobsonM , ImSA , SenkusE , XuB , DomchekS , MasudaN , et al. OlympiAD extended follow-up for overall survival and safety: olaparib versus chemotherapy treatment of physician’s choice in patients with a germline BRCA mutation and HER2-negative metastatic breast cancer. Cancer Research2020;80(Suppl 4):Abstract nr PD4-03. RobsonM , ImSA , SenkusE , XuB , DomchekSM , MasudaN , et al. Olaparib for metastatic breast cancer in patients with a germline BRCA mutation. New England Journal of Medicine2017;377(6):523-33. RobsonM , RuddyKJ , ImSA , SenkusE , XuB , DomchekSM , et al. Patient-reported outcomes in patients with a germline BRCA mutation and HER2-negative metastatic breast cancer receiving olaparib versus chemotherapy in the OlympiAD trial. European Journal of Cancer2019;120:20-30. RobsonM , RuddyKJ , ImSA , Senkus-KonefkaE , XuB , DomchekSM , et al. OlympiAD: health-related quality of life (HRQoL) in patients with HER2-negative metastatic breast cancer (mBC) and a germline BRCA mutation (gBRCAm) receiving olaparib monotherapy vs standard single-agent chemotherapy treatment of physician’s choice (TPC). Annals of Oncology2017;28(Suppl 5):v74-v108. RobsonME , ImSA , SenkusE , XuB , DomchekS , MasudaN , et al. Abstract CT038: OlympiAD final overall survival: olaparib versus chemotherapy treatment of physician's choice (TPC) in patients with HER2-negative metastatic breast cancer (mBC) and a germline BRCA mutation (gBRCAm). American Association for Cancer Research2018;78(Suppl 13):CT038. RobsonME , ImSA , SenkusE , XuB , DomchekSM , MasudaN , et al. OlympiAD: phase III trial of olaparib monotherapy versus chemotherapy for patients (pts) with HER2-negative metastatic breast cancer (mBC) and a germline BRCA mutation (gBRCAm). Journal of Clinical Oncology2017;35(Suppl 18):LBA4-LBA4. RobsonME , RuddyKJ , ImSA , Senkus-KonefkaE , XuB , DomchekSM , et al. EORTC QLQ-C30 (QLQ-C30) symptoms in patients (pts) with HER2-negative metastatic breast cancer (mBC) and a germline BRCA mutation (gBRCAm) receiving olaparib vs chemotherapy treatment of physician’s choice (TPC) in OlympiAD. Journal of Clinical Oncology2018;36(Suppl 15):1045. RobsonME , TungN , ConteP , ImSA , SenkusE , XuB , et al. OlympiAD final overall survival and tolerability results: olaparib versus chemotherapy treatment of physician’s choice in patients with a germline BRCA mutation and HER2-negative metastatic breast cancer. Annals of Oncology2019;30(4):558-66. Senkus-KonefkaE , DomchekSM , ImSA , XuB , ArmstrongA , MasudaN , et al. Subgroup analysis of olaparib monotherapy versus chemotherapy by hormone receptor and BRCA mutation status in patients with HER2-negative metastatic breast cancer and a germline BRCA mutation: OlympiAD. European Journal of Cancer2018;92:S19-20. TungNM , ImSA , Senkus-KonefkaE , XuB , DomchekSM , MasudaN , et al. Olaparib versus chemotherapy treatment of physician’s choice in patients with a germline BRCA mutation and HER2-negative metastatic breast cancer (OlympiAD): efficacy in patients with visceral metastases. Journal of Clinical Oncology2018;36(Suppl 15):1053. ">OLYMPIAD</a>) and the other three studies compared PARP inhibitors plus chemotherapy to placebo plus chemotherapy (<a href="./references#CD011395-bbs2-0002" title="DiérasV , HanHS , RobsonME , PalacovaM , MarcomPK , JagerA , et al. Evaluation of veliparib (V) and temozolomide (TMZ) in a phase 2 randomized study of the efficacy and tolerability of V+TMZ or carboplatin (C) and paclitaxel (P) vs placebo (Plc)+C/P in patients (pts) with BRCA1 or BRCA2 mutations and metastatic breast cancer. Cancer Research2017;77(Suppl 4):Abstract nr SABCS16-P4-22-02. HanHS , DiérasV , RobsonM , PalácováM , MarcomPK , Jager A et al. Veliparib with temozolomide or carboplatin/paclitaxel versus placebo with carboplatin/paclitaxel in patients with BRCA1/2 locally recurrent/metastatic breast cancer: randomized phase II study. Annals of Oncology2018;29(1):154-61. HanHS , DiérasV , RobsonME , PalácováM , MarcomPK , JagerA , et al. Efficacy and tolerability of veliparib (V; ABT-888) in combination with carboplatin (C) and paclitaxel (P) vs placebo (Plc)+C/P in patients (pts) with BRCA1 or BRCA2 mutations and metastatic breast cancer: a randomized, phase 2 study. Cancer Research2017;77(Suppl 4):Abstract nr SABCS16-S2-05. IsakoffSJ , PuhallaS , DomchekSM , FriedlanderM , KaufmanB , RobsonM , et al. A randomized Phase II study of veliparib with temozolomide or carboplatin/paclitaxel versus placebo with carboplatin/paclitaxel in BRCA1/2 metastatic breast cancer: design and rationale. Future Oncology2017;13(4):307-20. ">BROCADE 2</a>; <a href="./references#CD011395-bbs2-0003" title="ArunBK , HanHS , KaufmanB , WildiersH , FriedlanderM , AyoubJP , et al. First-line veliparib plus carboplatin/paclitaxel in patients with HER2-negative advanced/metastatic gBRCA-associated breast cancer: planned subgroup analysis from the phase 3 BROCADE3 trial. Cancer Research2020;80(Suppl 4):Abstract nr PD4-01. AyoubJP , FriedlanderML , DierasVC , WildiersH , ArunB , HanHS , et al. Veliparib plus carboplatin-paclitaxel in patients with HER2-negative advanced/metastatic gBRCA-associated breast cancer: results in hormone receptor-positive and triple-negative breast cancer subgroups from the phase III BROCADE3 trial. Annals of Oncology2020;31(Suppl 2):S65. DierasV , HanH , KaufmanB , WildiersH , FriedlanderM , AyoubJ , et al. A Phase 3 randomized, placebo-controlled trial of carboplatin and paclitaxel with or without the PARP inhibitor veliparib (ABT-888) in HER2-negative metastatic or locally advanced unresectable BRCA-associated breast cancer. Annals of Oncology2019;30(Suppl 5):v851-v934. ">BROCADE 3</a>; <a href="./references#CD011395-bbs2-0005" title="KummarS , WadeJL , OzaAM , SullivanD , ChenAP , GandaraDR , et al. Randomized phase II trial of cyclophosphamide and the oral poly (ADP-ribose) polymerase inhibitor veliparib in patients with recurrent, advanced triple-negative breast cancer. Investigational New Drugs2016;34(3):355–63. ">Kummar 2016</a>. Three studies used veliparib (<a href="./references#CD011395-bbs2-0002" title="DiérasV , HanHS , RobsonME , PalacovaM , MarcomPK , JagerA , et al. Evaluation of veliparib (V) and temozolomide (TMZ) in a phase 2 randomized study of the efficacy and tolerability of V+TMZ or carboplatin (C) and paclitaxel (P) vs placebo (Plc)+C/P in patients (pts) with BRCA1 or BRCA2 mutations and metastatic breast cancer. Cancer Research2017;77(Suppl 4):Abstract nr SABCS16-P4-22-02. HanHS , DiérasV , RobsonM , PalácováM , MarcomPK , Jager A et al. Veliparib with temozolomide or carboplatin/paclitaxel versus placebo with carboplatin/paclitaxel in patients with BRCA1/2 locally recurrent/metastatic breast cancer: randomized phase II study. Annals of Oncology2018;29(1):154-61. HanHS , DiérasV , RobsonME , PalácováM , MarcomPK , JagerA , et al. Efficacy and tolerability of veliparib (V; ABT-888) in combination with carboplatin (C) and paclitaxel (P) vs placebo (Plc)+C/P in patients (pts) with BRCA1 or BRCA2 mutations and metastatic breast cancer: a randomized, phase 2 study. Cancer Research2017;77(Suppl 4):Abstract nr SABCS16-S2-05. IsakoffSJ , PuhallaS , DomchekSM , FriedlanderM , KaufmanB , RobsonM , et al. A randomized Phase II study of veliparib with temozolomide or carboplatin/paclitaxel versus placebo with carboplatin/paclitaxel in BRCA1/2 metastatic breast cancer: design and rationale. Future Oncology2017;13(4):307-20. ">BROCADE 2</a>; <a href="./references#CD011395-bbs2-0003" title="ArunBK , HanHS , KaufmanB , WildiersH , FriedlanderM , AyoubJP , et al. First-line veliparib plus carboplatin/paclitaxel in patients with HER2-negative advanced/metastatic gBRCA-associated breast cancer: planned subgroup analysis from the phase 3 BROCADE3 trial. Cancer Research2020;80(Suppl 4):Abstract nr PD4-01. AyoubJP , FriedlanderML , DierasVC , WildiersH , ArunB , HanHS , et al. Veliparib plus carboplatin-paclitaxel in patients with HER2-negative advanced/metastatic gBRCA-associated breast cancer: results in hormone receptor-positive and triple-negative breast cancer subgroups from the phase III BROCADE3 trial. Annals of Oncology2020;31(Suppl 2):S65. DierasV , HanH , KaufmanB , WildiersH , FriedlanderM , AyoubJ , et al. A Phase 3 randomized, placebo-controlled trial of carboplatin and paclitaxel with or without the PARP inhibitor veliparib (ABT-888) in HER2-negative metastatic or locally advanced unresectable BRCA-associated breast cancer. Annals of Oncology2019;30(Suppl 5):v851-v934. ">BROCADE 3</a>; <a href="./references#CD011395-bbs2-0005" title="KummarS , WadeJL , OzaAM , SullivanD , ChenAP , GandaraDR , et al. Randomized phase II trial of cyclophosphamide and the oral poly (ADP-ribose) polymerase inhibitor veliparib in patients with recurrent, advanced triple-negative breast cancer. Investigational New Drugs2016;34(3):355–63. ">Kummar 2016</a>) and the others used olaparib (<a href="./references#CD011395-bbs2-0006" title="DelalogeS , ContePF , ImS , Senkus-KonefkaE , XuB , DomchekSM , et al. OlympiAD: further efficacy outcomes in patients with HER2-negative metastatic breast cancer and a germline BRCA mutation receiving olaparib monotherapy vs standard single-agent chemotherapy treatment of physician’s choice. Annals of Oncology2017;28(Suppl 5):v74-v108. DomchekS , RobsonM , ImS , SenkusE , XuB , MasudaN , et al. Tolerability of olaparib monotherapy versus chemotherapy in patients with HER2-negative metastatic breast cancer and a germline BRCA mutation: OlympiAD. Cancer Research2018;78(Suppl 4):Abstract nr P5-21-12. ImSA , XuB , LiW , RobsonM , OuyangQ , YehDC , et al. Olaparib monotherapy for Asian patients with a germline BRCA mutation and HER2-negative metastatic breast cancer: OlympiAD randomized trial subgroup analysis. Scientific Reports2020;10(1):8753. ImSA , XuB , LiW , RobsonM , OuyangQ , YehDC , et al. Olaparib monotherapy versus chemotherapy for patients with HER2-negative metastatic breast cancer and a germline BRCA mutation: Asian subgroup analysis from the phase III OlympiAD trial. Cancer Research2018;78(Suppl 4):Abstract nr P5-21-13. MerensC , BannisterW , BergnerS , HettleR , McCreaC , McCutcheonS , et al. Impact of olaparib versus chemotherapy on the use of strong pain medications in gBRCA-mutated HER2-negative metastatic breast cancer and associated patient reported outcomes. Cancer Research2020;80(Suppl 4):Abstract nr P6-13-05. RobsonM , HettleR , DegboeA , SaundersO , CainT , KilvertH , et al. Estimating the health state utility of patients with HER2–gBRCA+ metastatic breast cancer treated with olaparib or chemotherapy via a mapping analysis of EORTC QLQ-C30 data collected in the Olympiad clinical trial. Value in Health2018;21(Suppl 1):S12. RobsonM , ImSA , SenkusE , XuB , DomchekS , MasudaN , et al. OlympiAD extended follow-up for overall survival and safety: olaparib versus chemotherapy treatment of physician’s choice in patients with a germline BRCA mutation and HER2-negative metastatic breast cancer. Cancer Research2020;80(Suppl 4):Abstract nr PD4-03. RobsonM , ImSA , SenkusE , XuB , DomchekSM , MasudaN , et al. Olaparib for metastatic breast cancer in patients with a germline BRCA mutation. New England Journal of Medicine2017;377(6):523-33. RobsonM , RuddyKJ , ImSA , SenkusE , XuB , DomchekSM , et al. Patient-reported outcomes in patients with a germline BRCA mutation and HER2-negative metastatic breast cancer receiving olaparib versus chemotherapy in the OlympiAD trial. European Journal of Cancer2019;120:20-30. RobsonM , RuddyKJ , ImSA , Senkus-KonefkaE , XuB , DomchekSM , et al. OlympiAD: health-related quality of life (HRQoL) in patients with HER2-negative metastatic breast cancer (mBC) and a germline BRCA mutation (gBRCAm) receiving olaparib monotherapy vs standard single-agent chemotherapy treatment of physician’s choice (TPC). Annals of Oncology2017;28(Suppl 5):v74-v108. RobsonME , ImSA , SenkusE , XuB , DomchekS , MasudaN , et al. Abstract CT038: OlympiAD final overall survival: olaparib versus chemotherapy treatment of physician's choice (TPC) in patients with HER2-negative metastatic breast cancer (mBC) and a germline BRCA mutation (gBRCAm). American Association for Cancer Research2018;78(Suppl 13):CT038. RobsonME , ImSA , SenkusE , XuB , DomchekSM , MasudaN , et al. OlympiAD: phase III trial of olaparib monotherapy versus chemotherapy for patients (pts) with HER2-negative metastatic breast cancer (mBC) and a germline BRCA mutation (gBRCAm). Journal of Clinical Oncology2017;35(Suppl 18):LBA4-LBA4. RobsonME , RuddyKJ , ImSA , Senkus-KonefkaE , XuB , DomchekSM , et al. EORTC QLQ-C30 (QLQ-C30) symptoms in patients (pts) with HER2-negative metastatic breast cancer (mBC) and a germline BRCA mutation (gBRCAm) receiving olaparib vs chemotherapy treatment of physician’s choice (TPC) in OlympiAD. Journal of Clinical Oncology2018;36(Suppl 15):1045. RobsonME , TungN , ConteP , ImSA , SenkusE , XuB , et al. OlympiAD final overall survival and tolerability results: olaparib versus chemotherapy treatment of physician’s choice in patients with a germline BRCA mutation and HER2-negative metastatic breast cancer. Annals of Oncology2019;30(4):558-66. Senkus-KonefkaE , DomchekSM , ImSA , XuB , ArmstrongA , MasudaN , et al. Subgroup analysis of olaparib monotherapy versus chemotherapy by hormone receptor and BRCA mutation status in patients with HER2-negative metastatic breast cancer and a germline BRCA mutation: OlympiAD. European Journal of Cancer2018;92:S19-20. TungNM , ImSA , Senkus-KonefkaE , XuB , DomchekSM , MasudaN , et al. Olaparib versus chemotherapy treatment of physician’s choice in patients with a germline BRCA mutation and HER2-negative metastatic breast cancer (OlympiAD): efficacy in patients with visceral metastases. Journal of Clinical Oncology2018;36(Suppl 15):1053. ">OLYMPIAD</a>) and talazoparib (<a href="./references#CD011395-bbs2-0004" title="DiabS , RugoHS , MinaLA , PuhallaS , MahtaniRL , HenryNL , et al. Efficacy and safety of talazoparib (TALA) or physician's choice of therapy (PCT) in United States patients (pts) with HER2- germline BRCA1/2-mutated (gBRCAm) locally advanced/metastatic breast cancer (LA/MBC) in the EMBRACA study. Journal of Clinical Oncology2019;37(Suppl 15):1044. EiermannW , RugoHS , DiabS , EttlJ , HurvitzSA , GoncalvesA , et al. Analysis of germline BRCA1/2 mutated (g BRCAmut) hormone receptor-positive (HR+) and triple-negative breast cancer (TNBC) treated with talazoparib (TALA). Journal of Clinical Oncology2018;36(Suppl 15):1070. EttlJ , HurvitzSA , RugoHS , LeeKH , MinaLA , WoodwardNE , et al. Outcomes of talazoparib (TALA) versus physician's choice of chemotherapy (PCT) in patients (pts) with advanced breast cancer (ABC) and a germline BRCA (gBRCA) mutation by line of chemotherapy (CT) in the EMBRACA trial. Journal of Clinical Oncology2019;37(Suppl 15):1071. EttlJ , QuekRG , BhattacharyyaH , RugoHS , HurvitzSA , GonçalvesA . Patient Reported Outcomes (PRO) in patients (pts) with HER2-advanced breast cancer (ABC) and a germline BRCA1/2 mutation (gBRCAm) receiving talazoparib (TALA) vs physician’s choice chemotherapy (PCT) in the EMBRACA trial: a focus on subgroups with/without visceral disease. Annals of Oncology2019;30(Suppl 5):v129–30. EttlJ , QuekRG , HurvitzSA , GoncalvesA , TudorIC , RugoHS . Hospitalization and supportive care medication (SCM) utilisation in patients (pts) with advanced breast cancer (ABC) and a germline BRCA1/2 mutation (gBRCAm) in EMBRACA. Annals of Oncology2019;30(Suppl 3):iii52. EttlJ , QuekRG , LeeKH , RugoHS , HurvitzS , GonçalvesA , et al. Quality of life with talazoparib versus physician’s choice of chemotherapy in patients with advanced breast cancer and germline BRCA1/2 mutation: patient-reported outcomes from the EMBRACA phase III trial. Annals of Oncology2018;29(9):1939-47. FaschingPA , QuekRG , BhattacharyyaH , HurvitzSA , RugoHS , EttlJ . Impact of objective response (OR) on patient-reported outcomes (PRO) in patients (pts) with advanced breast cancer (ABC) and a germline BRCA1/2 (gBRCA) mutation in the phase III EMBRACA trial. Annals of Oncology2019;30(Suppl 3):iii49. GonçalvesA , EiermannW , RugoHS , EttlJ , HurvitzSA , YerushalmiR , et al. EMBRACA: Efficacy and safety in comparing talazoparib (TALA) with physician's choice of therapy (PCT) in patients (pts) with advanced breast cancer (aBC) and a germline BRCA mutation (gBRCAm); BRCA1/BRCA2 subgroup analysis. Annals of Oncology2018;29(Suppl 8):viii96–7. GoncalvesA , QuekRGW , BhattacharyyaH , EttlJ , HurvitzSA , RugoHS . Patient-reported outcomes (PRO) in patients (pts) with Her2-advanced breast cancer (ABC) receiving talazoparib (TALA) vs physician's choice chemotherapy (PCT): a focus on EMBRACA germline BRCA1 and BRCA2 mutation (gBRCA1/2m) subgroups. Breast2019;48(Suppl 2):S71. HurvitzSA , GoncalvesA , RugoHS , LeeKH , FehrenbacherL , MinaLA , et al. Talazoparib in patients with a germline BRCA-mutated advanced breast cancer: detailed safety analyses from the phase III EMBRACA Trial. Oncologist2019;25(3):e439-50. LeeKH , KimSB , SohnJ , GoodwinA , UsariT , LanzaloneS , et al. Talazoparib (TALA) vs physician’s choice of chemotherapy (PCT) in Asian patients (Pts) with HER2- advanced breast cancer (ABC) and a germline BRCA1/2 mutation (gBRCA1/2mut): data from phase III EMBRACA. Annals of Oncology2019;30(9):ix14. LittonJ , EttlJ , HurvitzSA , MinaLA , RugoHS , LeeKH , et al. A phase 3, open-label, randomized, 2-arm international study of the oral dual PARP inhibitor talazoparib in germline BRCA mutation subjects with locally advanced and/or metastatic breast cancer (EMBRACA). Cancer Research2017;77(Suppl 4):Abstract nr OT2-01-13. LittonJ , RugoHS , EttlJ , HurvitzS , GoncalvesA , LeeKH , et al. EMBRACA: a phase 3 trial comparing talazoparib, an oral PARP inhibitor, to physicianʼs choice of therapy in patients with advanced breast cancer and a germline BRCA mutation [abstract]. In: San Antonio Breast Cancer Symposium; 2017 Dec 5-9; San Antonio (TX). San Antonio (TX), 2017. LittonJK , HurvitzSA , MinaLA , RugoHS , LeeKH , GonçalvesA , et al. Talazoparib (TALA) in germline BRCA1/2 (gBRCA1/2)-mutated human epidermal growth factor receptor 2 negative (HER2-) advanced breast cancer (ABC): final overall survival (OS) results from randomized phase 3 EMBRACA trial. Cancer Research2020;80(Suppl 16):Abstract no. CT071. LittonJK , RugoHS , EttlJ , HurvitzSA , GonçalvesA , LeeKH , et al. Talazoparib in patients with advanced breast cancer and a germline BRCA mutation. New England Journal of Medicine2018;379(8):753-63. MartínM , EiermannW , RugoHS , EttlJ , HurvitzSA , GonçalvesA , et al. EMBRACA: Comparison of efficacy and safety of talazoparib (TALA) and physician's choice of therapy (PCT) in patients (pts) with advanced breast cancer (aBC), a germline BRCA1/2 mutation (gBRCAm), and prior platinum treatment. Annals of Oncology2018;29(Suppl 8):viii96. MinaL , LeeKH , GoncalvesA , WoodwardN , HurvitzSA , DiabS , et al. EMBRACA: efficacy and safety of talazoparib or physician's choice of therapy in patients with advanced breast cancer and a germline BRCA1/2 mutation: a regional analysis. Cancer Research2019;79(Suppl 4):Abstract nr P6-18-12. QuekR , BhattacharyyaH , HurvitzS , GoncalvesA , EttlJ , RugoH . Patient-reported outcomes in patients with HER2-advanced breast cancer and a germline BRCA1/2 mutation receiving talazoparib versus physician's choice chemotherapy: a focus on EMBRACA age subgroups. Journal of Managed Care and Specialty Pharmacy2019;25(Suppl 10A):S37-8. QuekRGW , BhattacharyyaH , GoncalvesA , RugoHS , HurvitzSA , EttlJ . Pcn491 Patient reported outcomes (PRO) of talazoparib (TALA) versus physician's choice of chemotherapy (PCT) in patients (pts) with advanced breast cancer (aBC) and a germline BRCA (gBRCa) mutation: a focus on Embraca pts with/without prior chemotherapy (CT) subgroups. Value in Health2019;22(Suppl 3):S532. RugoHS , EttlJ , HurvitzSA , GoncalvesA , LeeKH , FehrenbacherL , et al. Outcomes in clinically relevant patient subgroups from the EMBRACA study: talazoparib vs physician's choice standard-of-care chemotherapy. Journal of the National Cancer Institute Cancer Spectrum2020;4(1):pkz085. RugoHS , EttlJ , WoodwardNE , HurvitzSA , GoncalvesA , LeeKH , et al. EMBRACA: efficacy outcomes in clinically relevant subgroups comparing talazoparib (TALA), an oral poly ADP ribose polymerase (PARP) inhibitor, to physician's choice of therapy (PCT) in patients with advanced breast cancer and a germline BRCA mutation. Journal of Clinical Oncology2018;36(Suppl 15):1069. RugoHS , QuekR , EttlJ , HurvitzSA , BhattacharyyaH , HannahAL , et al. Patient-reported outcomes (PRO) in patients (pts) with advanced breast cancer and a germline BRCA1/2 mutation (gBRCAm) receiving talazoparib (TALA) vs physician’s choice chemotherapy treatment (PCT): a focus on the EMBRACA triple negative (TNBC) subpopulation. Annals of Oncology2018;29(Suppl 8):viii91. YuY , ElmeliegyM , LittonJK , TudorIC , CzibereA , ZhengJ , et al. Exposure-efficacy progression-free survival (PFS) analyses of breast cancer patients with germline BRCA1/2 mutations receiving talazoparib in the phase III EMBRACA trial. Annals of Oncology2018;29(Suppl 8):viii97. YuY , ElmeliegyM , LittonJK , TudorIC , CzibereA , ZhengJ , et al. Talazoparib exposure-efficacy analysis in patients with advanced breast cancer and germline BRCA1/2 mutations in the EMBRACA trial. Journal of Clinical Pharmacology2020;60(10):1324-33. ">EMBRACA</a>) in their PARP inhibitor intervention arms. Four of the five studies (<a href="./references#CD011395-bbs2-0002" title="DiérasV , HanHS , RobsonME , PalacovaM , MarcomPK , JagerA , et al. Evaluation of veliparib (V) and temozolomide (TMZ) in a phase 2 randomized study of the efficacy and tolerability of V+TMZ or carboplatin (C) and paclitaxel (P) vs placebo (Plc)+C/P in patients (pts) with BRCA1 or BRCA2 mutations and metastatic breast cancer. Cancer Research2017;77(Suppl 4):Abstract nr SABCS16-P4-22-02. HanHS , DiérasV , RobsonM , PalácováM , MarcomPK , Jager A et al. Veliparib with temozolomide or carboplatin/paclitaxel versus placebo with carboplatin/paclitaxel in patients with BRCA1/2 locally recurrent/metastatic breast cancer: randomized phase II study. Annals of Oncology2018;29(1):154-61. HanHS , DiérasV , RobsonME , PalácováM , MarcomPK , JagerA , et al. Efficacy and tolerability of veliparib (V; ABT-888) in combination with carboplatin (C) and paclitaxel (P) vs placebo (Plc)+C/P in patients (pts) with BRCA1 or BRCA2 mutations and metastatic breast cancer: a randomized, phase 2 study. Cancer Research2017;77(Suppl 4):Abstract nr SABCS16-S2-05. IsakoffSJ , PuhallaS , DomchekSM , FriedlanderM , KaufmanB , RobsonM , et al. A randomized Phase II study of veliparib with temozolomide or carboplatin/paclitaxel versus placebo with carboplatin/paclitaxel in BRCA1/2 metastatic breast cancer: design and rationale. Future Oncology2017;13(4):307-20. ">BROCADE 2</a>; <a href="./references#CD011395-bbs2-0003" title="ArunBK , HanHS , KaufmanB , WildiersH , FriedlanderM , AyoubJP , et al. First-line veliparib plus carboplatin/paclitaxel in patients with HER2-negative advanced/metastatic gBRCA-associated breast cancer: planned subgroup analysis from the phase 3 BROCADE3 trial. Cancer Research2020;80(Suppl 4):Abstract nr PD4-01. AyoubJP , FriedlanderML , DierasVC , WildiersH , ArunB , HanHS , et al. Veliparib plus carboplatin-paclitaxel in patients with HER2-negative advanced/metastatic gBRCA-associated breast cancer: results in hormone receptor-positive and triple-negative breast cancer subgroups from the phase III BROCADE3 trial. Annals of Oncology2020;31(Suppl 2):S65. DierasV , HanH , KaufmanB , WildiersH , FriedlanderM , AyoubJ , et al. A Phase 3 randomized, placebo-controlled trial of carboplatin and paclitaxel with or without the PARP inhibitor veliparib (ABT-888) in HER2-negative metastatic or locally advanced unresectable BRCA-associated breast cancer. Annals of Oncology2019;30(Suppl 5):v851-v934. ">BROCADE 3</a>; <a href="./references#CD011395-bbs2-0004" title="DiabS , RugoHS , MinaLA , PuhallaS , MahtaniRL , HenryNL , et al. Efficacy and safety of talazoparib (TALA) or physician's choice of therapy (PCT) in United States patients (pts) with HER2- germline BRCA1/2-mutated (gBRCAm) locally advanced/metastatic breast cancer (LA/MBC) in the EMBRACA study. Journal of Clinical Oncology2019;37(Suppl 15):1044. EiermannW , RugoHS , DiabS , EttlJ , HurvitzSA , GoncalvesA , et al. Analysis of germline BRCA1/2 mutated (g BRCAmut) hormone receptor-positive (HR+) and triple-negative breast cancer (TNBC) treated with talazoparib (TALA). Journal of Clinical Oncology2018;36(Suppl 15):1070. EttlJ , HurvitzSA , RugoHS , LeeKH , MinaLA , WoodwardNE , et al. Outcomes of talazoparib (TALA) versus physician's choice of chemotherapy (PCT) in patients (pts) with advanced breast cancer (ABC) and a germline BRCA (gBRCA) mutation by line of chemotherapy (CT) in the EMBRACA trial. Journal of Clinical Oncology2019;37(Suppl 15):1071. EttlJ , QuekRG , BhattacharyyaH , RugoHS , HurvitzSA , GonçalvesA . Patient Reported Outcomes (PRO) in patients (pts) with HER2-advanced breast cancer (ABC) and a germline BRCA1/2 mutation (gBRCAm) receiving talazoparib (TALA) vs physician’s choice chemotherapy (PCT) in the EMBRACA trial: a focus on subgroups with/without visceral disease. Annals of Oncology2019;30(Suppl 5):v129–30. EttlJ , QuekRG , HurvitzSA , GoncalvesA , TudorIC , RugoHS . Hospitalization and supportive care medication (SCM) utilisation in patients (pts) with advanced breast cancer (ABC) and a germline BRCA1/2 mutation (gBRCAm) in EMBRACA. Annals of Oncology2019;30(Suppl 3):iii52. EttlJ , QuekRG , LeeKH , RugoHS , HurvitzS , GonçalvesA , et al. Quality of life with talazoparib versus physician’s choice of chemotherapy in patients with advanced breast cancer and germline BRCA1/2 mutation: patient-reported outcomes from the EMBRACA phase III trial. Annals of Oncology2018;29(9):1939-47. FaschingPA , QuekRG , BhattacharyyaH , HurvitzSA , RugoHS , EttlJ . Impact of objective response (OR) on patient-reported outcomes (PRO) in patients (pts) with advanced breast cancer (ABC) and a germline BRCA1/2 (gBRCA) mutation in the phase III EMBRACA trial. Annals of Oncology2019;30(Suppl 3):iii49. GonçalvesA , EiermannW , RugoHS , EttlJ , HurvitzSA , YerushalmiR , et al. EMBRACA: Efficacy and safety in comparing talazoparib (TALA) with physician's choice of therapy (PCT) in patients (pts) with advanced breast cancer (aBC) and a germline BRCA mutation (gBRCAm); BRCA1/BRCA2 subgroup analysis. Annals of Oncology2018;29(Suppl 8):viii96–7. GoncalvesA , QuekRGW , BhattacharyyaH , EttlJ , HurvitzSA , RugoHS . Patient-reported outcomes (PRO) in patients (pts) with Her2-advanced breast cancer (ABC) receiving talazoparib (TALA) vs physician's choice chemotherapy (PCT): a focus on EMBRACA germline BRCA1 and BRCA2 mutation (gBRCA1/2m) subgroups. Breast2019;48(Suppl 2):S71. HurvitzSA , GoncalvesA , RugoHS , LeeKH , FehrenbacherL , MinaLA , et al. Talazoparib in patients with a germline BRCA-mutated advanced breast cancer: detailed safety analyses from the phase III EMBRACA Trial. Oncologist2019;25(3):e439-50. LeeKH , KimSB , SohnJ , GoodwinA , UsariT , LanzaloneS , et al. Talazoparib (TALA) vs physician’s choice of chemotherapy (PCT) in Asian patients (Pts) with HER2- advanced breast cancer (ABC) and a germline BRCA1/2 mutation (gBRCA1/2mut): data from phase III EMBRACA. Annals of Oncology2019;30(9):ix14. LittonJ , EttlJ , HurvitzSA , MinaLA , RugoHS , LeeKH , et al. A phase 3, open-label, randomized, 2-arm international study of the oral dual PARP inhibitor talazoparib in germline BRCA mutation subjects with locally advanced and/or metastatic breast cancer (EMBRACA). Cancer Research2017;77(Suppl 4):Abstract nr OT2-01-13. LittonJ , RugoHS , EttlJ , HurvitzS , GoncalvesA , LeeKH , et al. EMBRACA: a phase 3 trial comparing talazoparib, an oral PARP inhibitor, to physicianʼs choice of therapy in patients with advanced breast cancer and a germline BRCA mutation [abstract]. In: San Antonio Breast Cancer Symposium; 2017 Dec 5-9; San Antonio (TX). San Antonio (TX), 2017. LittonJK , HurvitzSA , MinaLA , RugoHS , LeeKH , GonçalvesA , et al. Talazoparib (TALA) in germline BRCA1/2 (gBRCA1/2)-mutated human epidermal growth factor receptor 2 negative (HER2-) advanced breast cancer (ABC): final overall survival (OS) results from randomized phase 3 EMBRACA trial. Cancer Research2020;80(Suppl 16):Abstract no. CT071. LittonJK , RugoHS , EttlJ , HurvitzSA , GonçalvesA , LeeKH , et al. Talazoparib in patients with advanced breast cancer and a germline BRCA mutation. New England Journal of Medicine2018;379(8):753-63. MartínM , EiermannW , RugoHS , EttlJ , HurvitzSA , GonçalvesA , et al. EMBRACA: Comparison of efficacy and safety of talazoparib (TALA) and physician's choice of therapy (PCT) in patients (pts) with advanced breast cancer (aBC), a germline BRCA1/2 mutation (gBRCAm), and prior platinum treatment. Annals of Oncology2018;29(Suppl 8):viii96. MinaL , LeeKH , GoncalvesA , WoodwardN , HurvitzSA , DiabS , et al. EMBRACA: efficacy and safety of talazoparib or physician's choice of therapy in patients with advanced breast cancer and a germline BRCA1/2 mutation: a regional analysis. Cancer Research2019;79(Suppl 4):Abstract nr P6-18-12. QuekR , BhattacharyyaH , HurvitzS , GoncalvesA , EttlJ , RugoH . Patient-reported outcomes in patients with HER2-advanced breast cancer and a germline BRCA1/2 mutation receiving talazoparib versus physician's choice chemotherapy: a focus on EMBRACA age subgroups. Journal of Managed Care and Specialty Pharmacy2019;25(Suppl 10A):S37-8. QuekRGW , BhattacharyyaH , GoncalvesA , RugoHS , HurvitzSA , EttlJ . Pcn491 Patient reported outcomes (PRO) of talazoparib (TALA) versus physician's choice of chemotherapy (PCT) in patients (pts) with advanced breast cancer (aBC) and a germline BRCA (gBRCa) mutation: a focus on Embraca pts with/without prior chemotherapy (CT) subgroups. Value in Health2019;22(Suppl 3):S532. RugoHS , EttlJ , HurvitzSA , GoncalvesA , LeeKH , FehrenbacherL , et al. Outcomes in clinically relevant patient subgroups from the EMBRACA study: talazoparib vs physician's choice standard-of-care chemotherapy. Journal of the National Cancer Institute Cancer Spectrum2020;4(1):pkz085. RugoHS , EttlJ , WoodwardNE , HurvitzSA , GoncalvesA , LeeKH , et al. EMBRACA: efficacy outcomes in clinically relevant subgroups comparing talazoparib (TALA), an oral poly ADP ribose polymerase (PARP) inhibitor, to physician's choice of therapy (PCT) in patients with advanced breast cancer and a germline BRCA mutation. Journal of Clinical Oncology2018;36(Suppl 15):1069. RugoHS , QuekR , EttlJ , HurvitzSA , BhattacharyyaH , HannahAL , et al. Patient-reported outcomes (PRO) in patients (pts) with advanced breast cancer and a germline BRCA1/2 mutation (gBRCAm) receiving talazoparib (TALA) vs physician’s choice chemotherapy treatment (PCT): a focus on the EMBRACA triple negative (TNBC) subpopulation. Annals of Oncology2018;29(Suppl 8):viii91. YuY , ElmeliegyM , LittonJK , TudorIC , CzibereA , ZhengJ , et al. Exposure-efficacy progression-free survival (PFS) analyses of breast cancer patients with germline BRCA1/2 mutations receiving talazoparib in the phase III EMBRACA trial. Annals of Oncology2018;29(Suppl 8):viii97. YuY , ElmeliegyM , LittonJK , TudorIC , CzibereA , ZhengJ , et al. Talazoparib exposure-efficacy analysis in patients with advanced breast cancer and germline BRCA1/2 mutations in the EMBRACA trial. Journal of Clinical Pharmacology2020;60(10):1324-33. ">EMBRACA</a>; <a href="./references#CD011395-bbs2-0006" title="DelalogeS , ContePF , ImS , Senkus-KonefkaE , XuB , DomchekSM , et al. OlympiAD: further efficacy outcomes in patients with HER2-negative metastatic breast cancer and a germline BRCA mutation receiving olaparib monotherapy vs standard single-agent chemotherapy treatment of physician’s choice. Annals of Oncology2017;28(Suppl 5):v74-v108. DomchekS , RobsonM , ImS , SenkusE , XuB , MasudaN , et al. Tolerability of olaparib monotherapy versus chemotherapy in patients with HER2-negative metastatic breast cancer and a germline BRCA mutation: OlympiAD. Cancer Research2018;78(Suppl 4):Abstract nr P5-21-12. ImSA , XuB , LiW , RobsonM , OuyangQ , YehDC , et al. Olaparib monotherapy for Asian patients with a germline BRCA mutation and HER2-negative metastatic breast cancer: OlympiAD randomized trial subgroup analysis. Scientific Reports2020;10(1):8753. ImSA , XuB , LiW , RobsonM , OuyangQ , YehDC , et al. Olaparib monotherapy versus chemotherapy for patients with HER2-negative metastatic breast cancer and a germline BRCA mutation: Asian subgroup analysis from the phase III OlympiAD trial. Cancer Research2018;78(Suppl 4):Abstract nr P5-21-13. MerensC , BannisterW , BergnerS , HettleR , McCreaC , McCutcheonS , et al. Impact of olaparib versus chemotherapy on the use of strong pain medications in gBRCA-mutated HER2-negative metastatic breast cancer and associated patient reported outcomes. Cancer Research2020;80(Suppl 4):Abstract nr P6-13-05. RobsonM , HettleR , DegboeA , SaundersO , CainT , KilvertH , et al. Estimating the health state utility of patients with HER2–gBRCA+ metastatic breast cancer treated with olaparib or chemotherapy via a mapping analysis of EORTC QLQ-C30 data collected in the Olympiad clinical trial. Value in Health2018;21(Suppl 1):S12. RobsonM , ImSA , SenkusE , XuB , DomchekS , MasudaN , et al. OlympiAD extended follow-up for overall survival and safety: olaparib versus chemotherapy treatment of physician’s choice in patients with a germline BRCA mutation and HER2-negative metastatic breast cancer. Cancer Research2020;80(Suppl 4):Abstract nr PD4-03. RobsonM , ImSA , SenkusE , XuB , DomchekSM , MasudaN , et al. Olaparib for metastatic breast cancer in patients with a germline BRCA mutation. New England Journal of Medicine2017;377(6):523-33. RobsonM , RuddyKJ , ImSA , SenkusE , XuB , DomchekSM , et al. Patient-reported outcomes in patients with a germline BRCA mutation and HER2-negative metastatic breast cancer receiving olaparib versus chemotherapy in the OlympiAD trial. European Journal of Cancer2019;120:20-30. RobsonM , RuddyKJ , ImSA , Senkus-KonefkaE , XuB , DomchekSM , et al. OlympiAD: health-related quality of life (HRQoL) in patients with HER2-negative metastatic breast cancer (mBC) and a germline BRCA mutation (gBRCAm) receiving olaparib monotherapy vs standard single-agent chemotherapy treatment of physician’s choice (TPC). Annals of Oncology2017;28(Suppl 5):v74-v108. RobsonME , ImSA , SenkusE , XuB , DomchekS , MasudaN , et al. Abstract CT038: OlympiAD final overall survival: olaparib versus chemotherapy treatment of physician's choice (TPC) in patients with HER2-negative metastatic breast cancer (mBC) and a germline BRCA mutation (gBRCAm). American Association for Cancer Research2018;78(Suppl 13):CT038. RobsonME , ImSA , SenkusE , XuB , DomchekSM , MasudaN , et al. OlympiAD: phase III trial of olaparib monotherapy versus chemotherapy for patients (pts) with HER2-negative metastatic breast cancer (mBC) and a germline BRCA mutation (gBRCAm). Journal of Clinical Oncology2017;35(Suppl 18):LBA4-LBA4. RobsonME , RuddyKJ , ImSA , Senkus-KonefkaE , XuB , DomchekSM , et al. EORTC QLQ-C30 (QLQ-C30) symptoms in patients (pts) with HER2-negative metastatic breast cancer (mBC) and a germline BRCA mutation (gBRCAm) receiving olaparib vs chemotherapy treatment of physician’s choice (TPC) in OlympiAD. Journal of Clinical Oncology2018;36(Suppl 15):1045. RobsonME , TungN , ConteP , ImSA , SenkusE , XuB , et al. OlympiAD final overall survival and tolerability results: olaparib versus chemotherapy treatment of physician’s choice in patients with a germline BRCA mutation and HER2-negative metastatic breast cancer. Annals of Oncology2019;30(4):558-66. Senkus-KonefkaE , DomchekSM , ImSA , XuB , ArmstrongA , MasudaN , et al. Subgroup analysis of olaparib monotherapy versus chemotherapy by hormone receptor and BRCA mutation status in patients with HER2-negative metastatic breast cancer and a germline BRCA mutation: OlympiAD. European Journal of Cancer2018;92:S19-20. TungNM , ImSA , Senkus-KonefkaE , XuB , DomchekSM , MasudaN , et al. Olaparib versus chemotherapy treatment of physician’s choice in patients with a germline BRCA mutation and HER2-negative metastatic breast cancer (OlympiAD): efficacy in patients with visceral metastases. Journal of Clinical Oncology2018;36(Suppl 15):1053. ">OLYMPIAD</a>) were powered to assess progression‐free survival, with overall survival being a secondary outcome and one phase 2 study, the smallest, (<a href="./references#CD011395-bbs2-0005" title="KummarS , WadeJL , OzaAM , SullivanD , ChenAP , GandaraDR , et al. Randomized phase II trial of cyclophosphamide and the oral poly (ADP-ribose) polymerase inhibitor veliparib in patients with recurrent, advanced triple-negative breast cancer. Investigational New Drugs2016;34(3):355–63. ">Kummar 2016</a>) assessed tumour response rate as the primary outcome and progression‐free survival as a secondary outcome.<br/><br/>The primary objective of this review was to assess the effects of PARP inhibitors for patients with locally advanced or metastatic breast cancer. Four out of five studies (1435/1474 patients) included only women with a germline BRCA mutation and similarly most participants were HER2‐negative (only 10 patients in <a href="./references#CD011395-bbs2-0002" title="DiérasV , HanHS , RobsonME , PalacovaM , MarcomPK , JagerA , et al. Evaluation of veliparib (V) and temozolomide (TMZ) in a phase 2 randomized study of the efficacy and tolerability of V+TMZ or carboplatin (C) and paclitaxel (P) vs placebo (Plc)+C/P in patients (pts) with BRCA1 or BRCA2 mutations and metastatic breast cancer. Cancer Research2017;77(Suppl 4):Abstract nr SABCS16-P4-22-02. HanHS , DiérasV , RobsonM , PalácováM , MarcomPK , Jager A et al. Veliparib with temozolomide or carboplatin/paclitaxel versus placebo with carboplatin/paclitaxel in patients with BRCA1/2 locally recurrent/metastatic breast cancer: randomized phase II study. Annals of Oncology2018;29(1):154-61. HanHS , DiérasV , RobsonME , PalácováM , MarcomPK , JagerA , et al. Efficacy and tolerability of veliparib (V; ABT-888) in combination with carboplatin (C) and paclitaxel (P) vs placebo (Plc)+C/P in patients (pts) with BRCA1 or BRCA2 mutations and metastatic breast cancer: a randomized, phase 2 study. Cancer Research2017;77(Suppl 4):Abstract nr SABCS16-S2-05. IsakoffSJ , PuhallaS , DomchekSM , FriedlanderM , KaufmanB , RobsonM , et al. A randomized Phase II study of veliparib with temozolomide or carboplatin/paclitaxel versus placebo with carboplatin/paclitaxel in BRCA1/2 metastatic breast cancer: design and rationale. Future Oncology2017;13(4):307-20. ">BROCADE 2</a> were HER2‐positive) so our results pertain to these groups predominantly.<br/><br/>Our systematic review indicates that PARP inhibitors offer a PFS benefit in advanced/metastatic HER2‐negative, BRCA germline mutated breast cancer patients. Importantly, to the authors' knowledge, our systematic review provides the first evidence that PARP inhibitors may also offer a small advantage in overall survival. Pooled analysis also showed a likely improved response rate with PARP inhibitors. There was little to no heterogeneity in the overall analyses and most of the subgroup analyses, consistent with the observation that included studies were largely designed in a similar fashion. This provides evidence that the use of PARP inhibitors can form part of the therapeutic strategy for this subgroup of breast cancer patients. The risk of death at two years is 55% for patients not treated with PARPi, and 49.7% for patients treated with PARPi (equivalent to a number needed to treat for an additional beneficial outcome of 18.9). The risk of progression or death at one year was 62.5% for patients not treated with PARPi, and 46.1% for patients treated with PARPi (equivalent to a number needed to treat for an additional beneficial outcome of 6.1) (See <a href="./full#CD011395-tbl-0001">summary of findings Table 1</a>).<br/><br/>These positive overall findings are supported by the subgroup analyses all showing consistent findings of a persistent PFS benefit. We showed that PARP inhibitors confer a PFS benefit in advanced HER2‐negative, BRCA germline mutated breast cancer regardless of whether the patient carries a BRCA 1 or 2 mutation, whether the tumour is triple‐negative or not and regardless of whether chemotherapy was previously given in the metastatic setting.<br/><br/>Several studies have evaluated the use of platinum agents in patients with germline BRCA mutations. In particular, the TNT trial (<a href="./references#CD011395-bbs2-0037" title="TuttA , ToveyH , CheangMC , KernaghanS , KilburnL , GazinskaP , et al. A randomised phase III trial of carboplatin compared with docetaxel in BRCA1/2 mutated and pre-specified triple negative breast cancer “BRCAness” subgroups: the TNT Trial. Nature Medicine2018;24(5):628.">Tutt 2018</a>) showed an objective response rate of 68% with carboplatin versus 33% with docetaxel among 43 patients with metastatic triple‐negative breast cancer and a known BRCA mutation. That is, platinum chemotherapy is also an effective treatment for our patient population. Platinum‐based agents were not included as an option in the standard‐therapy groups of <a href="./references#CD011395-bbs2-0006" title="DelalogeS , ContePF , ImS , Senkus-KonefkaE , XuB , DomchekSM , et al. OlympiAD: further efficacy outcomes in patients with HER2-negative metastatic breast cancer and a germline BRCA mutation receiving olaparib monotherapy vs standard single-agent chemotherapy treatment of physician’s choice. Annals of Oncology2017;28(Suppl 5):v74-v108. DomchekS , RobsonM , ImS , SenkusE , XuB , MasudaN , et al. Tolerability of olaparib monotherapy versus chemotherapy in patients with HER2-negative metastatic breast cancer and a germline BRCA mutation: OlympiAD. Cancer Research2018;78(Suppl 4):Abstract nr P5-21-12. ImSA , XuB , LiW , RobsonM , OuyangQ , YehDC , et al. Olaparib monotherapy for Asian patients with a germline BRCA mutation and HER2-negative metastatic breast cancer: OlympiAD randomized trial subgroup analysis. Scientific Reports2020;10(1):8753. ImSA , XuB , LiW , RobsonM , OuyangQ , YehDC , et al. Olaparib monotherapy versus chemotherapy for patients with HER2-negative metastatic breast cancer and a germline BRCA mutation: Asian subgroup analysis from the phase III OlympiAD trial. Cancer Research2018;78(Suppl 4):Abstract nr P5-21-13. MerensC , BannisterW , BergnerS , HettleR , McCreaC , McCutcheonS , et al. Impact of olaparib versus chemotherapy on the use of strong pain medications in gBRCA-mutated HER2-negative metastatic breast cancer and associated patient reported outcomes. Cancer Research2020;80(Suppl 4):Abstract nr P6-13-05. RobsonM , HettleR , DegboeA , SaundersO , CainT , KilvertH , et al. Estimating the health state utility of patients with HER2–gBRCA+ metastatic breast cancer treated with olaparib or chemotherapy via a mapping analysis of EORTC QLQ-C30 data collected in the Olympiad clinical trial. Value in Health2018;21(Suppl 1):S12. RobsonM , ImSA , SenkusE , XuB , DomchekS , MasudaN , et al. OlympiAD extended follow-up for overall survival and safety: olaparib versus chemotherapy treatment of physician’s choice in patients with a germline BRCA mutation and HER2-negative metastatic breast cancer. Cancer Research2020;80(Suppl 4):Abstract nr PD4-03. RobsonM , ImSA , SenkusE , XuB , DomchekSM , MasudaN , et al. Olaparib for metastatic breast cancer in patients with a germline BRCA mutation. New England Journal of Medicine2017;377(6):523-33. RobsonM , RuddyKJ , ImSA , SenkusE , XuB , DomchekSM , et al. Patient-reported outcomes in patients with a germline BRCA mutation and HER2-negative metastatic breast cancer receiving olaparib versus chemotherapy in the OlympiAD trial. European Journal of Cancer2019;120:20-30. RobsonM , RuddyKJ , ImSA , Senkus-KonefkaE , XuB , DomchekSM , et al. OlympiAD: health-related quality of life (HRQoL) in patients with HER2-negative metastatic breast cancer (mBC) and a germline BRCA mutation (gBRCAm) receiving olaparib monotherapy vs standard single-agent chemotherapy treatment of physician’s choice (TPC). Annals of Oncology2017;28(Suppl 5):v74-v108. RobsonME , ImSA , SenkusE , XuB , DomchekS , MasudaN , et al. Abstract CT038: OlympiAD final overall survival: olaparib versus chemotherapy treatment of physician's choice (TPC) in patients with HER2-negative metastatic breast cancer (mBC) and a germline BRCA mutation (gBRCAm). American Association for Cancer Research2018;78(Suppl 13):CT038. RobsonME , ImSA , SenkusE , XuB , DomchekSM , MasudaN , et al. OlympiAD: phase III trial of olaparib monotherapy versus chemotherapy for patients (pts) with HER2-negative metastatic breast cancer (mBC) and a germline BRCA mutation (gBRCAm). Journal of Clinical Oncology2017;35(Suppl 18):LBA4-LBA4. RobsonME , RuddyKJ , ImSA , Senkus-KonefkaE , XuB , DomchekSM , et al. EORTC QLQ-C30 (QLQ-C30) symptoms in patients (pts) with HER2-negative metastatic breast cancer (mBC) and a germline BRCA mutation (gBRCAm) receiving olaparib vs chemotherapy treatment of physician’s choice (TPC) in OlympiAD. Journal of Clinical Oncology2018;36(Suppl 15):1045. RobsonME , TungN , ConteP , ImSA , SenkusE , XuB , et al. OlympiAD final overall survival and tolerability results: olaparib versus chemotherapy treatment of physician’s choice in patients with a germline BRCA mutation and HER2-negative metastatic breast cancer. Annals of Oncology2019;30(4):558-66. Senkus-KonefkaE , DomchekSM , ImSA , XuB , ArmstrongA , MasudaN , et al. Subgroup analysis of olaparib monotherapy versus chemotherapy by hormone receptor and BRCA mutation status in patients with HER2-negative metastatic breast cancer and a germline BRCA mutation: OlympiAD. European Journal of Cancer2018;92:S19-20. TungNM , ImSA , Senkus-KonefkaE , XuB , DomchekSM , MasudaN , et al. Olaparib versus chemotherapy treatment of physician’s choice in patients with a germline BRCA mutation and HER2-negative metastatic breast cancer (OlympiAD): efficacy in patients with visceral metastases. Journal of Clinical Oncology2018;36(Suppl 15):1053. ">OLYMPIAD</a> or <a href="./references#CD011395-bbs2-0004" title="DiabS , RugoHS , MinaLA , PuhallaS , MahtaniRL , HenryNL , et al. Efficacy and safety of talazoparib (TALA) or physician's choice of therapy (PCT) in United States patients (pts) with HER2- germline BRCA1/2-mutated (gBRCAm) locally advanced/metastatic breast cancer (LA/MBC) in the EMBRACA study. Journal of Clinical Oncology2019;37(Suppl 15):1044. EiermannW , RugoHS , DiabS , EttlJ , HurvitzSA , GoncalvesA , et al. Analysis of germline BRCA1/2 mutated (g BRCAmut) hormone receptor-positive (HR+) and triple-negative breast cancer (TNBC) treated with talazoparib (TALA). Journal of Clinical Oncology2018;36(Suppl 15):1070. EttlJ , HurvitzSA , RugoHS , LeeKH , MinaLA , WoodwardNE , et al. Outcomes of talazoparib (TALA) versus physician's choice of chemotherapy (PCT) in patients (pts) with advanced breast cancer (ABC) and a germline BRCA (gBRCA) mutation by line of chemotherapy (CT) in the EMBRACA trial. Journal of Clinical Oncology2019;37(Suppl 15):1071. EttlJ , QuekRG , BhattacharyyaH , RugoHS , HurvitzSA , GonçalvesA . Patient Reported Outcomes (PRO) in patients (pts) with HER2-advanced breast cancer (ABC) and a germline BRCA1/2 mutation (gBRCAm) receiving talazoparib (TALA) vs physician’s choice chemotherapy (PCT) in the EMBRACA trial: a focus on subgroups with/without visceral disease. Annals of Oncology2019;30(Suppl 5):v129–30. EttlJ , QuekRG , HurvitzSA , GoncalvesA , TudorIC , RugoHS . Hospitalization and supportive care medication (SCM) utilisation in patients (pts) with advanced breast cancer (ABC) and a germline BRCA1/2 mutation (gBRCAm) in EMBRACA. Annals of Oncology2019;30(Suppl 3):iii52. EttlJ , QuekRG , LeeKH , RugoHS , HurvitzS , GonçalvesA , et al. Quality of life with talazoparib versus physician’s choice of chemotherapy in patients with advanced breast cancer and germline BRCA1/2 mutation: patient-reported outcomes from the EMBRACA phase III trial. Annals of Oncology2018;29(9):1939-47. FaschingPA , QuekRG , BhattacharyyaH , HurvitzSA , RugoHS , EttlJ . Impact of objective response (OR) on patient-reported outcomes (PRO) in patients (pts) with advanced breast cancer (ABC) and a germline BRCA1/2 (gBRCA) mutation in the phase III EMBRACA trial. Annals of Oncology2019;30(Suppl 3):iii49. GonçalvesA , EiermannW , RugoHS , EttlJ , HurvitzSA , YerushalmiR , et al. EMBRACA: Efficacy and safety in comparing talazoparib (TALA) with physician's choice of therapy (PCT) in patients (pts) with advanced breast cancer (aBC) and a germline BRCA mutation (gBRCAm); BRCA1/BRCA2 subgroup analysis. Annals of Oncology2018;29(Suppl 8):viii96–7. GoncalvesA , QuekRGW , BhattacharyyaH , EttlJ , HurvitzSA , RugoHS . Patient-reported outcomes (PRO) in patients (pts) with Her2-advanced breast cancer (ABC) receiving talazoparib (TALA) vs physician's choice chemotherapy (PCT): a focus on EMBRACA germline BRCA1 and BRCA2 mutation (gBRCA1/2m) subgroups. Breast2019;48(Suppl 2):S71. HurvitzSA , GoncalvesA , RugoHS , LeeKH , FehrenbacherL , MinaLA , et al. Talazoparib in patients with a germline BRCA-mutated advanced breast cancer: detailed safety analyses from the phase III EMBRACA Trial. Oncologist2019;25(3):e439-50. LeeKH , KimSB , SohnJ , GoodwinA , UsariT , LanzaloneS , et al. Talazoparib (TALA) vs physician’s choice of chemotherapy (PCT) in Asian patients (Pts) with HER2- advanced breast cancer (ABC) and a germline BRCA1/2 mutation (gBRCA1/2mut): data from phase III EMBRACA. Annals of Oncology2019;30(9):ix14. LittonJ , EttlJ , HurvitzSA , MinaLA , RugoHS , LeeKH , et al. A phase 3, open-label, randomized, 2-arm international study of the oral dual PARP inhibitor talazoparib in germline BRCA mutation subjects with locally advanced and/or metastatic breast cancer (EMBRACA). Cancer Research2017;77(Suppl 4):Abstract nr OT2-01-13. LittonJ , RugoHS , EttlJ , HurvitzS , GoncalvesA , LeeKH , et al. EMBRACA: a phase 3 trial comparing talazoparib, an oral PARP inhibitor, to physicianʼs choice of therapy in patients with advanced breast cancer and a germline BRCA mutation [abstract]. In: San Antonio Breast Cancer Symposium; 2017 Dec 5-9; San Antonio (TX). San Antonio (TX), 2017. LittonJK , HurvitzSA , MinaLA , RugoHS , LeeKH , GonçalvesA , et al. Talazoparib (TALA) in germline BRCA1/2 (gBRCA1/2)-mutated human epidermal growth factor receptor 2 negative (HER2-) advanced breast cancer (ABC): final overall survival (OS) results from randomized phase 3 EMBRACA trial. Cancer Research2020;80(Suppl 16):Abstract no. CT071. LittonJK , RugoHS , EttlJ , HurvitzSA , GonçalvesA , LeeKH , et al. Talazoparib in patients with advanced breast cancer and a germline BRCA mutation. New England Journal of Medicine2018;379(8):753-63. MartínM , EiermannW , RugoHS , EttlJ , HurvitzSA , GonçalvesA , et al. EMBRACA: Comparison of efficacy and safety of talazoparib (TALA) and physician's choice of therapy (PCT) in patients (pts) with advanced breast cancer (aBC), a germline BRCA1/2 mutation (gBRCAm), and prior platinum treatment. Annals of Oncology2018;29(Suppl 8):viii96. MinaL , LeeKH , GoncalvesA , WoodwardN , HurvitzSA , DiabS , et al. EMBRACA: efficacy and safety of talazoparib or physician's choice of therapy in patients with advanced breast cancer and a germline BRCA1/2 mutation: a regional analysis. Cancer Research2019;79(Suppl 4):Abstract nr P6-18-12. QuekR , BhattacharyyaH , HurvitzS , GoncalvesA , EttlJ , RugoH . Patient-reported outcomes in patients with HER2-advanced breast cancer and a germline BRCA1/2 mutation receiving talazoparib versus physician's choice chemotherapy: a focus on EMBRACA age subgroups. Journal of Managed Care and Specialty Pharmacy2019;25(Suppl 10A):S37-8. QuekRGW , BhattacharyyaH , GoncalvesA , RugoHS , HurvitzSA , EttlJ . Pcn491 Patient reported outcomes (PRO) of talazoparib (TALA) versus physician's choice of chemotherapy (PCT) in patients (pts) with advanced breast cancer (aBC) and a germline BRCA (gBRCa) mutation: a focus on Embraca pts with/without prior chemotherapy (CT) subgroups. Value in Health2019;22(Suppl 3):S532. RugoHS , EttlJ , HurvitzSA , GoncalvesA , LeeKH , FehrenbacherL , et al. Outcomes in clinically relevant patient subgroups from the EMBRACA study: talazoparib vs physician's choice standard-of-care chemotherapy. Journal of the National Cancer Institute Cancer Spectrum2020;4(1):pkz085. RugoHS , EttlJ , WoodwardNE , HurvitzSA , GoncalvesA , LeeKH , et al. EMBRACA: efficacy outcomes in clinically relevant subgroups comparing talazoparib (TALA), an oral poly ADP ribose polymerase (PARP) inhibitor, to physician's choice of therapy (PCT) in patients with advanced breast cancer and a germline BRCA mutation. Journal of Clinical Oncology2018;36(Suppl 15):1069. RugoHS , QuekR , EttlJ , HurvitzSA , BhattacharyyaH , HannahAL , et al. Patient-reported outcomes (PRO) in patients (pts) with advanced breast cancer and a germline BRCA1/2 mutation (gBRCAm) receiving talazoparib (TALA) vs physician’s choice chemotherapy treatment (PCT): a focus on the EMBRACA triple negative (TNBC) subpopulation. Annals of Oncology2018;29(Suppl 8):viii91. YuY , ElmeliegyM , LittonJK , TudorIC , CzibereA , ZhengJ , et al. Exposure-efficacy progression-free survival (PFS) analyses of breast cancer patients with germline BRCA1/2 mutations receiving talazoparib in the phase III EMBRACA trial. Annals of Oncology2018;29(Suppl 8):viii97. YuY , ElmeliegyM , LittonJK , TudorIC , CzibereA , ZhengJ , et al. Talazoparib exposure-efficacy analysis in patients with advanced breast cancer and germline BRCA1/2 mutations in the EMBRACA trial. Journal of Clinical Pharmacology2020;60(10):1324-33. ">EMBRACA</a> so, given the results of the TNT study, the trials realistically only compared PARP inhibitors against second‐line therapies which is a limitation. It is unknown how PARP inhibitors would compare with first‐line drugs. In our systematic review, four out of the five studies (<a href="./references#CD011395-bbs2-0005" title="KummarS , WadeJL , OzaAM , SullivanD , ChenAP , GandaraDR , et al. Randomized phase II trial of cyclophosphamide and the oral poly (ADP-ribose) polymerase inhibitor veliparib in patients with recurrent, advanced triple-negative breast cancer. Investigational New Drugs2016;34(3):355–63. ">Kummar 2016</a> did not specify) excluded patients who failed prior treatment with platinum chemotherapy but patients were allowed prior platinum exposure in <a href="./references#CD011395-bbs2-0004" title="DiabS , RugoHS , MinaLA , PuhallaS , MahtaniRL , HenryNL , et al. Efficacy and safety of talazoparib (TALA) or physician's choice of therapy (PCT) in United States patients (pts) with HER2- germline BRCA1/2-mutated (gBRCAm) locally advanced/metastatic breast cancer (LA/MBC) in the EMBRACA study. Journal of Clinical Oncology2019;37(Suppl 15):1044. EiermannW , RugoHS , DiabS , EttlJ , HurvitzSA , GoncalvesA , et al. Analysis of germline BRCA1/2 mutated (g BRCAmut) hormone receptor-positive (HR+) and triple-negative breast cancer (TNBC) treated with talazoparib (TALA). Journal of Clinical Oncology2018;36(Suppl 15):1070. EttlJ , HurvitzSA , RugoHS , LeeKH , MinaLA , WoodwardNE , et al. Outcomes of talazoparib (TALA) versus physician's choice of chemotherapy (PCT) in patients (pts) with advanced breast cancer (ABC) and a germline BRCA (gBRCA) mutation by line of chemotherapy (CT) in the EMBRACA trial. Journal of Clinical Oncology2019;37(Suppl 15):1071. EttlJ , QuekRG , BhattacharyyaH , RugoHS , HurvitzSA , GonçalvesA . Patient Reported Outcomes (PRO) in patients (pts) with HER2-advanced breast cancer (ABC) and a germline BRCA1/2 mutation (gBRCAm) receiving talazoparib (TALA) vs physician’s choice chemotherapy (PCT) in the EMBRACA trial: a focus on subgroups with/without visceral disease. Annals of Oncology2019;30(Suppl 5):v129–30. EttlJ , QuekRG , HurvitzSA , GoncalvesA , TudorIC , RugoHS . Hospitalization and supportive care medication (SCM) utilisation in patients (pts) with advanced breast cancer (ABC) and a germline BRCA1/2 mutation (gBRCAm) in EMBRACA. Annals of Oncology2019;30(Suppl 3):iii52. EttlJ , QuekRG , LeeKH , RugoHS , HurvitzS , GonçalvesA , et al. Quality of life with talazoparib versus physician’s choice of chemotherapy in patients with advanced breast cancer and germline BRCA1/2 mutation: patient-reported outcomes from the EMBRACA phase III trial. Annals of Oncology2018;29(9):1939-47. FaschingPA , QuekRG , BhattacharyyaH , HurvitzSA , RugoHS , EttlJ . Impact of objective response (OR) on patient-reported outcomes (PRO) in patients (pts) with advanced breast cancer (ABC) and a germline BRCA1/2 (gBRCA) mutation in the phase III EMBRACA trial. Annals of Oncology2019;30(Suppl 3):iii49. GonçalvesA , EiermannW , RugoHS , EttlJ , HurvitzSA , YerushalmiR , et al. EMBRACA: Efficacy and safety in comparing talazoparib (TALA) with physician's choice of therapy (PCT) in patients (pts) with advanced breast cancer (aBC) and a germline BRCA mutation (gBRCAm); BRCA1/BRCA2 subgroup analysis. Annals of Oncology2018;29(Suppl 8):viii96–7. GoncalvesA , QuekRGW , BhattacharyyaH , EttlJ , HurvitzSA , RugoHS . Patient-reported outcomes (PRO) in patients (pts) with Her2-advanced breast cancer (ABC) receiving talazoparib (TALA) vs physician's choice chemotherapy (PCT): a focus on EMBRACA germline BRCA1 and BRCA2 mutation (gBRCA1/2m) subgroups. Breast2019;48(Suppl 2):S71. HurvitzSA , GoncalvesA , RugoHS , LeeKH , FehrenbacherL , MinaLA , et al. Talazoparib in patients with a germline BRCA-mutated advanced breast cancer: detailed safety analyses from the phase III EMBRACA Trial. Oncologist2019;25(3):e439-50. LeeKH , KimSB , SohnJ , GoodwinA , UsariT , LanzaloneS , et al. Talazoparib (TALA) vs physician’s choice of chemotherapy (PCT) in Asian patients (Pts) with HER2- advanced breast cancer (ABC) and a germline BRCA1/2 mutation (gBRCA1/2mut): data from phase III EMBRACA. Annals of Oncology2019;30(9):ix14. LittonJ , EttlJ , HurvitzSA , MinaLA , RugoHS , LeeKH , et al. A phase 3, open-label, randomized, 2-arm international study of the oral dual PARP inhibitor talazoparib in germline BRCA mutation subjects with locally advanced and/or metastatic breast cancer (EMBRACA). Cancer Research2017;77(Suppl 4):Abstract nr OT2-01-13. LittonJ , RugoHS , EttlJ , HurvitzS , GoncalvesA , LeeKH , et al. EMBRACA: a phase 3 trial comparing talazoparib, an oral PARP inhibitor, to physicianʼs choice of therapy in patients with advanced breast cancer and a germline BRCA mutation [abstract]. In: San Antonio Breast Cancer Symposium; 2017 Dec 5-9; San Antonio (TX). San Antonio (TX), 2017. LittonJK , HurvitzSA , MinaLA , RugoHS , LeeKH , GonçalvesA , et al. Talazoparib (TALA) in germline BRCA1/2 (gBRCA1/2)-mutated human epidermal growth factor receptor 2 negative (HER2-) advanced breast cancer (ABC): final overall survival (OS) results from randomized phase 3 EMBRACA trial. Cancer Research2020;80(Suppl 16):Abstract no. CT071. LittonJK , RugoHS , EttlJ , HurvitzSA , GonçalvesA , LeeKH , et al. Talazoparib in patients with advanced breast cancer and a germline BRCA mutation. New England Journal of Medicine2018;379(8):753-63. MartínM , EiermannW , RugoHS , EttlJ , HurvitzSA , GonçalvesA , et al. EMBRACA: Comparison of efficacy and safety of talazoparib (TALA) and physician's choice of therapy (PCT) in patients (pts) with advanced breast cancer (aBC), a germline BRCA1/2 mutation (gBRCAm), and prior platinum treatment. Annals of Oncology2018;29(Suppl 8):viii96. MinaL , LeeKH , GoncalvesA , WoodwardN , HurvitzSA , DiabS , et al. EMBRACA: efficacy and safety of talazoparib or physician's choice of therapy in patients with advanced breast cancer and a germline BRCA1/2 mutation: a regional analysis. Cancer Research2019;79(Suppl 4):Abstract nr P6-18-12. QuekR , BhattacharyyaH , HurvitzS , GoncalvesA , EttlJ , RugoH . Patient-reported outcomes in patients with HER2-advanced breast cancer and a germline BRCA1/2 mutation receiving talazoparib versus physician's choice chemotherapy: a focus on EMBRACA age subgroups. Journal of Managed Care and Specialty Pharmacy2019;25(Suppl 10A):S37-8. QuekRGW , BhattacharyyaH , GoncalvesA , RugoHS , HurvitzSA , EttlJ . Pcn491 Patient reported outcomes (PRO) of talazoparib (TALA) versus physician's choice of chemotherapy (PCT) in patients (pts) with advanced breast cancer (aBC) and a germline BRCA (gBRCa) mutation: a focus on Embraca pts with/without prior chemotherapy (CT) subgroups. Value in Health2019;22(Suppl 3):S532. RugoHS , EttlJ , HurvitzSA , GoncalvesA , LeeKH , FehrenbacherL , et al. Outcomes in clinically relevant patient subgroups from the EMBRACA study: talazoparib vs physician's choice standard-of-care chemotherapy. Journal of the National Cancer Institute Cancer Spectrum2020;4(1):pkz085. RugoHS , EttlJ , WoodwardNE , HurvitzSA , GoncalvesA , LeeKH , et al. EMBRACA: efficacy outcomes in clinically relevant subgroups comparing talazoparib (TALA), an oral poly ADP ribose polymerase (PARP) inhibitor, to physician's choice of therapy (PCT) in patients with advanced breast cancer and a germline BRCA mutation. Journal of Clinical Oncology2018;36(Suppl 15):1069. RugoHS , QuekR , EttlJ , HurvitzSA , BhattacharyyaH , HannahAL , et al. Patient-reported outcomes (PRO) in patients (pts) with advanced breast cancer and a germline BRCA1/2 mutation (gBRCAm) receiving talazoparib (TALA) vs physician’s choice chemotherapy treatment (PCT): a focus on the EMBRACA triple negative (TNBC) subpopulation. Annals of Oncology2018;29(Suppl 8):viii91. YuY , ElmeliegyM , LittonJK , TudorIC , CzibereA , ZhengJ , et al. Exposure-efficacy progression-free survival (PFS) analyses of breast cancer patients with germline BRCA1/2 mutations receiving talazoparib in the phase III EMBRACA trial. Annals of Oncology2018;29(Suppl 8):viii97. YuY , ElmeliegyM , LittonJK , TudorIC , CzibereA , ZhengJ , et al. Talazoparib exposure-efficacy analysis in patients with advanced breast cancer and germline BRCA1/2 mutations in the EMBRACA trial. Journal of Clinical Pharmacology2020;60(10):1324-33. ">EMBRACA</a>, <a href="./references#CD011395-bbs2-0006" title="DelalogeS , ContePF , ImS , Senkus-KonefkaE , XuB , DomchekSM , et al. OlympiAD: further efficacy outcomes in patients with HER2-negative metastatic breast cancer and a germline BRCA mutation receiving olaparib monotherapy vs standard single-agent chemotherapy treatment of physician’s choice. Annals of Oncology2017;28(Suppl 5):v74-v108. DomchekS , RobsonM , ImS , SenkusE , XuB , MasudaN , et al. Tolerability of olaparib monotherapy versus chemotherapy in patients with HER2-negative metastatic breast cancer and a germline BRCA mutation: OlympiAD. Cancer Research2018;78(Suppl 4):Abstract nr P5-21-12. ImSA , XuB , LiW , RobsonM , OuyangQ , YehDC , et al. Olaparib monotherapy for Asian patients with a germline BRCA mutation and HER2-negative metastatic breast cancer: OlympiAD randomized trial subgroup analysis. Scientific Reports2020;10(1):8753. ImSA , XuB , LiW , RobsonM , OuyangQ , YehDC , et al. Olaparib monotherapy versus chemotherapy for patients with HER2-negative metastatic breast cancer and a germline BRCA mutation: Asian subgroup analysis from the phase III OlympiAD trial. Cancer Research2018;78(Suppl 4):Abstract nr P5-21-13. MerensC , BannisterW , BergnerS , HettleR , McCreaC , McCutcheonS , et al. Impact of olaparib versus chemotherapy on the use of strong pain medications in gBRCA-mutated HER2-negative metastatic breast cancer and associated patient reported outcomes. Cancer Research2020;80(Suppl 4):Abstract nr P6-13-05. RobsonM , HettleR , DegboeA , SaundersO , CainT , KilvertH , et al. Estimating the health state utility of patients with HER2–gBRCA+ metastatic breast cancer treated with olaparib or chemotherapy via a mapping analysis of EORTC QLQ-C30 data collected in the Olympiad clinical trial. Value in Health2018;21(Suppl 1):S12. RobsonM , ImSA , SenkusE , XuB , DomchekS , MasudaN , et al. OlympiAD extended follow-up for overall survival and safety: olaparib versus chemotherapy treatment of physician’s choice in patients with a germline BRCA mutation and HER2-negative metastatic breast cancer. Cancer Research2020;80(Suppl 4):Abstract nr PD4-03. RobsonM , ImSA , SenkusE , XuB , DomchekSM , MasudaN , et al. Olaparib for metastatic breast cancer in patients with a germline BRCA mutation. New England Journal of Medicine2017;377(6):523-33. RobsonM , RuddyKJ , ImSA , SenkusE , XuB , DomchekSM , et al. Patient-reported outcomes in patients with a germline BRCA mutation and HER2-negative metastatic breast cancer receiving olaparib versus chemotherapy in the OlympiAD trial. European Journal of Cancer2019;120:20-30. RobsonM , RuddyKJ , ImSA , Senkus-KonefkaE , XuB , DomchekSM , et al. OlympiAD: health-related quality of life (HRQoL) in patients with HER2-negative metastatic breast cancer (mBC) and a germline BRCA mutation (gBRCAm) receiving olaparib monotherapy vs standard single-agent chemotherapy treatment of physician’s choice (TPC). Annals of Oncology2017;28(Suppl 5):v74-v108. RobsonME , ImSA , SenkusE , XuB , DomchekS , MasudaN , et al. Abstract CT038: OlympiAD final overall survival: olaparib versus chemotherapy treatment of physician's choice (TPC) in patients with HER2-negative metastatic breast cancer (mBC) and a germline BRCA mutation (gBRCAm). American Association for Cancer Research2018;78(Suppl 13):CT038. RobsonME , ImSA , SenkusE , XuB , DomchekSM , MasudaN , et al. OlympiAD: phase III trial of olaparib monotherapy versus chemotherapy for patients (pts) with HER2-negative metastatic breast cancer (mBC) and a germline BRCA mutation (gBRCAm). Journal of Clinical Oncology2017;35(Suppl 18):LBA4-LBA4. RobsonME , RuddyKJ , ImSA , Senkus-KonefkaE , XuB , DomchekSM , et al. EORTC QLQ-C30 (QLQ-C30) symptoms in patients (pts) with HER2-negative metastatic breast cancer (mBC) and a germline BRCA mutation (gBRCAm) receiving olaparib vs chemotherapy treatment of physician’s choice (TPC) in OlympiAD. Journal of Clinical Oncology2018;36(Suppl 15):1045. RobsonME , TungN , ConteP , ImSA , SenkusE , XuB , et al. OlympiAD final overall survival and tolerability results: olaparib versus chemotherapy treatment of physician’s choice in patients with a germline BRCA mutation and HER2-negative metastatic breast cancer. Annals of Oncology2019;30(4):558-66. Senkus-KonefkaE , DomchekSM , ImSA , XuB , ArmstrongA , MasudaN , et al. Subgroup analysis of olaparib monotherapy versus chemotherapy by hormone receptor and BRCA mutation status in patients with HER2-negative metastatic breast cancer and a germline BRCA mutation: OlympiAD. European Journal of Cancer2018;92:S19-20. TungNM , ImSA , Senkus-KonefkaE , XuB , DomchekSM , MasudaN , et al. Olaparib versus chemotherapy treatment of physician’s choice in patients with a germline BRCA mutation and HER2-negative metastatic breast cancer (OlympiAD): efficacy in patients with visceral metastases. Journal of Clinical Oncology2018;36(Suppl 15):1053. ">OLYMPIAD</a> and <a href="./references#CD011395-bbs2-0003" title="ArunBK , HanHS , KaufmanB , WildiersH , FriedlanderM , AyoubJP , et al. First-line veliparib plus carboplatin/paclitaxel in patients with HER2-negative advanced/metastatic gBRCA-associated breast cancer: planned subgroup analysis from the phase 3 BROCADE3 trial. Cancer Research2020;80(Suppl 4):Abstract nr PD4-01. AyoubJP , FriedlanderML , DierasVC , WildiersH , ArunB , HanHS , et al. Veliparib plus carboplatin-paclitaxel in patients with HER2-negative advanced/metastatic gBRCA-associated breast cancer: results in hormone receptor-positive and triple-negative breast cancer subgroups from the phase III BROCADE3 trial. Annals of Oncology2020;31(Suppl 2):S65. DierasV , HanH , KaufmanB , WildiersH , FriedlanderM , AyoubJ , et al. A Phase 3 randomized, placebo-controlled trial of carboplatin and paclitaxel with or without the PARP inhibitor veliparib (ABT-888) in HER2-negative metastatic or locally advanced unresectable BRCA-associated breast cancer. Annals of Oncology2019;30(Suppl 5):v851-v934. ">BROCADE 3</a>. In this admittedly small subgroup of patients who had prior exposure to platinum‐based agents (205 patients), there was no significant PFS benefit demonstrated with PARP inhibitors, however, a 29% risk reduction was shown. As mentioned, these results need to be interpreted with caution and, given the small numbers, benefit from a PARP inhibitor in this particular subgroup should be confirmed in future studies. <a href="./references#CD011395-bbs2-0002" title="DiérasV , HanHS , RobsonME , PalacovaM , MarcomPK , JagerA , et al. Evaluation of veliparib (V) and temozolomide (TMZ) in a phase 2 randomized study of the efficacy and tolerability of V+TMZ or carboplatin (C) and paclitaxel (P) vs placebo (Plc)+C/P in patients (pts) with BRCA1 or BRCA2 mutations and metastatic breast cancer. Cancer Research2017;77(Suppl 4):Abstract nr SABCS16-P4-22-02. HanHS , DiérasV , RobsonM , PalácováM , MarcomPK , Jager A et al. Veliparib with temozolomide or carboplatin/paclitaxel versus placebo with carboplatin/paclitaxel in patients with BRCA1/2 locally recurrent/metastatic breast cancer: randomized phase II study. Annals of Oncology2018;29(1):154-61. HanHS , DiérasV , RobsonME , PalácováM , MarcomPK , JagerA , et al. Efficacy and tolerability of veliparib (V; ABT-888) in combination with carboplatin (C) and paclitaxel (P) vs placebo (Plc)+C/P in patients (pts) with BRCA1 or BRCA2 mutations and metastatic breast cancer: a randomized, phase 2 study. Cancer Research2017;77(Suppl 4):Abstract nr SABCS16-S2-05. IsakoffSJ , PuhallaS , DomchekSM , FriedlanderM , KaufmanB , RobsonM , et al. A randomized Phase II study of veliparib with temozolomide or carboplatin/paclitaxel versus placebo with carboplatin/paclitaxel in BRCA1/2 metastatic breast cancer: design and rationale. Future Oncology2017;13(4):307-20. ">BROCADE 2</a> and <a href="./references#CD011395-bbs2-0003" title="ArunBK , HanHS , KaufmanB , WildiersH , FriedlanderM , AyoubJP , et al. First-line veliparib plus carboplatin/paclitaxel in patients with HER2-negative advanced/metastatic gBRCA-associated breast cancer: planned subgroup analysis from the phase 3 BROCADE3 trial. Cancer Research2020;80(Suppl 4):Abstract nr PD4-01. AyoubJP , FriedlanderML , DierasVC , WildiersH , ArunB , HanHS , et al. Veliparib plus carboplatin-paclitaxel in patients with HER2-negative advanced/metastatic gBRCA-associated breast cancer: results in hormone receptor-positive and triple-negative breast cancer subgroups from the phase III BROCADE3 trial. Annals of Oncology2020;31(Suppl 2):S65. DierasV , HanH , KaufmanB , WildiersH , FriedlanderM , AyoubJ , et al. A Phase 3 randomized, placebo-controlled trial of carboplatin and paclitaxel with or without the PARP inhibitor veliparib (ABT-888) in HER2-negative metastatic or locally advanced unresectable BRCA-associated breast cancer. Annals of Oncology2019;30(Suppl 5):v851-v934. ">BROCADE 3</a> assessed the efficacy of the combination of a PARP inhibitor and platinum chemotherapy acknowledging shared mechanisms of resistance and showed superiority with the combination compared to platinum chemotherapy alone. Head‐to‐head studies to compare platinum‐based agents with PARP inhibitors and to compare the response rates after progression among classes of inhibitors are lacking. A further limitation is the lack of taxane in the comparator arms of trials comparing PARP inhibitors to physicians' choice, such that it is unclear whether a patient should have a taxane or PARP inhibitor if taxane is being considered either first‐line (e.g. when platinum was given adjuvantly) or after platinum. This research is necessary to provide important insight into efficacy and sequencing.<br/><br/>Our systematic review indicates there is likely to be no increase in toxicity with PARP inhibitors when looking at overall grade 3 or above adverse events. Combining this with the added advantages of ease of administration and convenience of oral administration, PARP inhibitors are an appealing alternative to intravenous chemotherapy. It is important to note that our systematic review included studies using three different PARP inhibitors. Common toxicities for all PARP inhibitors included fatigue, gastrointestinal toxicities and cytopenias (<a href="./references#CD011395-bbs2-0025" title="HoT , RiazIB , AkhterM , MalikSU , RiazA , FarooqMZ , et al. Incidence of adverse events following use of different PARP inhibitors: systematic review and meta-analysis. Journal of the National Comprehensive Cancer Network: National Compehensive Cancer Network Annual Conference: Improving the Quality, Effectiveness, and Efficiency of Cancer Care, NCCN2019;17(3-5):Abstract HSR19-091.">Ho 2019</a>, <a href="./references#CD011395-bbs2-0029" title="MurthyP , MuggiaF . PARP inhibitors: clinical development, emerging differences, and the current therapeutic issues. Cancer Drug Resistance2019;2:665-79.">Murthy 2019</a>). However, differences in toxicities between PARP inhibitors have emerged from the studies included in this review as well as other clinical trials (<a href="./references#CD011395-bbs2-0029" title="MurthyP , MuggiaF . PARP inhibitors: clinical development, emerging differences, and the current therapeutic issues. Cancer Drug Resistance2019;2:665-79.">Murthy 2019</a>). Olaparib’s most common grade 3 toxicity is anaemia (<a href="./references#CD011395-bbs2-0006" title="DelalogeS , ContePF , ImS , Senkus-KonefkaE , XuB , DomchekSM , et al. OlympiAD: further efficacy outcomes in patients with HER2-negative metastatic breast cancer and a germline BRCA mutation receiving olaparib monotherapy vs standard single-agent chemotherapy treatment of physician’s choice. Annals of Oncology2017;28(Suppl 5):v74-v108. DomchekS , RobsonM , ImS , SenkusE , XuB , MasudaN , et al. Tolerability of olaparib monotherapy versus chemotherapy in patients with HER2-negative metastatic breast cancer and a germline BRCA mutation: OlympiAD. Cancer Research2018;78(Suppl 4):Abstract nr P5-21-12. ImSA , XuB , LiW , RobsonM , OuyangQ , YehDC , et al. Olaparib monotherapy for Asian patients with a germline BRCA mutation and HER2-negative metastatic breast cancer: OlympiAD randomized trial subgroup analysis. Scientific Reports2020;10(1):8753. ImSA , XuB , LiW , RobsonM , OuyangQ , YehDC , et al. Olaparib monotherapy versus chemotherapy for patients with HER2-negative metastatic breast cancer and a germline BRCA mutation: Asian subgroup analysis from the phase III OlympiAD trial. Cancer Research2018;78(Suppl 4):Abstract nr P5-21-13. MerensC , BannisterW , BergnerS , HettleR , McCreaC , McCutcheonS , et al. Impact of olaparib versus chemotherapy on the use of strong pain medications in gBRCA-mutated HER2-negative metastatic breast cancer and associated patient reported outcomes. Cancer Research2020;80(Suppl 4):Abstract nr P6-13-05. RobsonM , HettleR , DegboeA , SaundersO , CainT , KilvertH , et al. Estimating the health state utility of patients with HER2–gBRCA+ metastatic breast cancer treated with olaparib or chemotherapy via a mapping analysis of EORTC QLQ-C30 data collected in the Olympiad clinical trial. Value in Health2018;21(Suppl 1):S12. RobsonM , ImSA , SenkusE , XuB , DomchekS , MasudaN , et al. OlympiAD extended follow-up for overall survival and safety: olaparib versus chemotherapy treatment of physician’s choice in patients with a germline BRCA mutation and HER2-negative metastatic breast cancer. Cancer Research2020;80(Suppl 4):Abstract nr PD4-03. RobsonM , ImSA , SenkusE , XuB , DomchekSM , MasudaN , et al. Olaparib for metastatic breast cancer in patients with a germline BRCA mutation. New England Journal of Medicine2017;377(6):523-33. RobsonM , RuddyKJ , ImSA , SenkusE , XuB , DomchekSM , et al. Patient-reported outcomes in patients with a germline BRCA mutation and HER2-negative metastatic breast cancer receiving olaparib versus chemotherapy in the OlympiAD trial. European Journal of Cancer2019;120:20-30. RobsonM , RuddyKJ , ImSA , Senkus-KonefkaE , XuB , DomchekSM , et al. OlympiAD: health-related quality of life (HRQoL) in patients with HER2-negative metastatic breast cancer (mBC) and a germline BRCA mutation (gBRCAm) receiving olaparib monotherapy vs standard single-agent chemotherapy treatment of physician’s choice (TPC). Annals of Oncology2017;28(Suppl 5):v74-v108. RobsonME , ImSA , SenkusE , XuB , DomchekS , MasudaN , et al. Abstract CT038: OlympiAD final overall survival: olaparib versus chemotherapy treatment of physician's choice (TPC) in patients with HER2-negative metastatic breast cancer (mBC) and a germline BRCA mutation (gBRCAm). American Association for Cancer Research2018;78(Suppl 13):CT038. RobsonME , ImSA , SenkusE , XuB , DomchekSM , MasudaN , et al. OlympiAD: phase III trial of olaparib monotherapy versus chemotherapy for patients (pts) with HER2-negative metastatic breast cancer (mBC) and a germline BRCA mutation (gBRCAm). Journal of Clinical Oncology2017;35(Suppl 18):LBA4-LBA4. RobsonME , RuddyKJ , ImSA , Senkus-KonefkaE , XuB , DomchekSM , et al. EORTC QLQ-C30 (QLQ-C30) symptoms in patients (pts) with HER2-negative metastatic breast cancer (mBC) and a germline BRCA mutation (gBRCAm) receiving olaparib vs chemotherapy treatment of physician’s choice (TPC) in OlympiAD. Journal of Clinical Oncology2018;36(Suppl 15):1045. RobsonME , TungN , ConteP , ImSA , SenkusE , XuB , et al. OlympiAD final overall survival and tolerability results: olaparib versus chemotherapy treatment of physician’s choice in patients with a germline BRCA mutation and HER2-negative metastatic breast cancer. Annals of Oncology2019;30(4):558-66. Senkus-KonefkaE , DomchekSM , ImSA , XuB , ArmstrongA , MasudaN , et al. Subgroup analysis of olaparib monotherapy versus chemotherapy by hormone receptor and BRCA mutation status in patients with HER2-negative metastatic breast cancer and a germline BRCA mutation: OlympiAD. European Journal of Cancer2018;92:S19-20. TungNM , ImSA , Senkus-KonefkaE , XuB , DomchekSM , MasudaN , et al. Olaparib versus chemotherapy treatment of physician’s choice in patients with a germline BRCA mutation and HER2-negative metastatic breast cancer (OlympiAD): efficacy in patients with visceral metastases. Journal of Clinical Oncology2018;36(Suppl 15):1053. ">OLYMPIAD</a>). The most frequent grade 3 or 4 toxicity for talazoparib was anaemia (<a href="./references#CD011395-bbs2-0004" title="DiabS , RugoHS , MinaLA , PuhallaS , MahtaniRL , HenryNL , et al. Efficacy and safety of talazoparib (TALA) or physician's choice of therapy (PCT) in United States patients (pts) with HER2- germline BRCA1/2-mutated (gBRCAm) locally advanced/metastatic breast cancer (LA/MBC) in the EMBRACA study. Journal of Clinical Oncology2019;37(Suppl 15):1044. EiermannW , RugoHS , DiabS , EttlJ , HurvitzSA , GoncalvesA , et al. Analysis of germline BRCA1/2 mutated (g BRCAmut) hormone receptor-positive (HR+) and triple-negative breast cancer (TNBC) treated with talazoparib (TALA). Journal of Clinical Oncology2018;36(Suppl 15):1070. EttlJ , HurvitzSA , RugoHS , LeeKH , MinaLA , WoodwardNE , et al. Outcomes of talazoparib (TALA) versus physician's choice of chemotherapy (PCT) in patients (pts) with advanced breast cancer (ABC) and a germline BRCA (gBRCA) mutation by line of chemotherapy (CT) in the EMBRACA trial. Journal of Clinical Oncology2019;37(Suppl 15):1071. EttlJ , QuekRG , BhattacharyyaH , RugoHS , HurvitzSA , GonçalvesA . Patient Reported Outcomes (PRO) in patients (pts) with HER2-advanced breast cancer (ABC) and a germline BRCA1/2 mutation (gBRCAm) receiving talazoparib (TALA) vs physician’s choice chemotherapy (PCT) in the EMBRACA trial: a focus on subgroups with/without visceral disease. Annals of Oncology2019;30(Suppl 5):v129–30. EttlJ , QuekRG , HurvitzSA , GoncalvesA , TudorIC , RugoHS . Hospitalization and supportive care medication (SCM) utilisation in patients (pts) with advanced breast cancer (ABC) and a germline BRCA1/2 mutation (gBRCAm) in EMBRACA. Annals of Oncology2019;30(Suppl 3):iii52. EttlJ , QuekRG , LeeKH , RugoHS , HurvitzS , GonçalvesA , et al. Quality of life with talazoparib versus physician’s choice of chemotherapy in patients with advanced breast cancer and germline BRCA1/2 mutation: patient-reported outcomes from the EMBRACA phase III trial. Annals of Oncology2018;29(9):1939-47. FaschingPA , QuekRG , BhattacharyyaH , HurvitzSA , RugoHS , EttlJ . Impact of objective response (OR) on patient-reported outcomes (PRO) in patients (pts) with advanced breast cancer (ABC) and a germline BRCA1/2 (gBRCA) mutation in the phase III EMBRACA trial. Annals of Oncology2019;30(Suppl 3):iii49. GonçalvesA , EiermannW , RugoHS , EttlJ , HurvitzSA , YerushalmiR , et al. EMBRACA: Efficacy and safety in comparing talazoparib (TALA) with physician's choice of therapy (PCT) in patients (pts) with advanced breast cancer (aBC) and a germline BRCA mutation (gBRCAm); BRCA1/BRCA2 subgroup analysis. Annals of Oncology2018;29(Suppl 8):viii96–7. GoncalvesA , QuekRGW , BhattacharyyaH , EttlJ , HurvitzSA , RugoHS . Patient-reported outcomes (PRO) in patients (pts) with Her2-advanced breast cancer (ABC) receiving talazoparib (TALA) vs physician's choice chemotherapy (PCT): a focus on EMBRACA germline BRCA1 and BRCA2 mutation (gBRCA1/2m) subgroups. Breast2019;48(Suppl 2):S71. HurvitzSA , GoncalvesA , RugoHS , LeeKH , FehrenbacherL , MinaLA , et al. Talazoparib in patients with a germline BRCA-mutated advanced breast cancer: detailed safety analyses from the phase III EMBRACA Trial. Oncologist2019;25(3):e439-50. LeeKH , KimSB , SohnJ , GoodwinA , UsariT , LanzaloneS , et al. Talazoparib (TALA) vs physician’s choice of chemotherapy (PCT) in Asian patients (Pts) with HER2- advanced breast cancer (ABC) and a germline BRCA1/2 mutation (gBRCA1/2mut): data from phase III EMBRACA. Annals of Oncology2019;30(9):ix14. LittonJ , EttlJ , HurvitzSA , MinaLA , RugoHS , LeeKH , et al. A phase 3, open-label, randomized, 2-arm international study of the oral dual PARP inhibitor talazoparib in germline BRCA mutation subjects with locally advanced and/or metastatic breast cancer (EMBRACA). Cancer Research2017;77(Suppl 4):Abstract nr OT2-01-13. LittonJ , RugoHS , EttlJ , HurvitzS , GoncalvesA , LeeKH , et al. EMBRACA: a phase 3 trial comparing talazoparib, an oral PARP inhibitor, to physicianʼs choice of therapy in patients with advanced breast cancer and a germline BRCA mutation [abstract]. In: San Antonio Breast Cancer Symposium; 2017 Dec 5-9; San Antonio (TX). San Antonio (TX), 2017. LittonJK , HurvitzSA , MinaLA , RugoHS , LeeKH , GonçalvesA , et al. Talazoparib (TALA) in germline BRCA1/2 (gBRCA1/2)-mutated human epidermal growth factor receptor 2 negative (HER2-) advanced breast cancer (ABC): final overall survival (OS) results from randomized phase 3 EMBRACA trial. Cancer Research2020;80(Suppl 16):Abstract no. CT071. LittonJK , RugoHS , EttlJ , HurvitzSA , GonçalvesA , LeeKH , et al. Talazoparib in patients with advanced breast cancer and a germline BRCA mutation. New England Journal of Medicine2018;379(8):753-63. MartínM , EiermannW , RugoHS , EttlJ , HurvitzSA , GonçalvesA , et al. EMBRACA: Comparison of efficacy and safety of talazoparib (TALA) and physician's choice of therapy (PCT) in patients (pts) with advanced breast cancer (aBC), a germline BRCA1/2 mutation (gBRCAm), and prior platinum treatment. Annals of Oncology2018;29(Suppl 8):viii96. MinaL , LeeKH , GoncalvesA , WoodwardN , HurvitzSA , DiabS , et al. EMBRACA: efficacy and safety of talazoparib or physician's choice of therapy in patients with advanced breast cancer and a germline BRCA1/2 mutation: a regional analysis. Cancer Research2019;79(Suppl 4):Abstract nr P6-18-12. QuekR , BhattacharyyaH , HurvitzS , GoncalvesA , EttlJ , RugoH . Patient-reported outcomes in patients with HER2-advanced breast cancer and a germline BRCA1/2 mutation receiving talazoparib versus physician's choice chemotherapy: a focus on EMBRACA age subgroups. Journal of Managed Care and Specialty Pharmacy2019;25(Suppl 10A):S37-8. QuekRGW , BhattacharyyaH , GoncalvesA , RugoHS , HurvitzSA , EttlJ . Pcn491 Patient reported outcomes (PRO) of talazoparib (TALA) versus physician's choice of chemotherapy (PCT) in patients (pts) with advanced breast cancer (aBC) and a germline BRCA (gBRCa) mutation: a focus on Embraca pts with/without prior chemotherapy (CT) subgroups. Value in Health2019;22(Suppl 3):S532. RugoHS , EttlJ , HurvitzSA , GoncalvesA , LeeKH , FehrenbacherL , et al. Outcomes in clinically relevant patient subgroups from the EMBRACA study: talazoparib vs physician's choice standard-of-care chemotherapy. Journal of the National Cancer Institute Cancer Spectrum2020;4(1):pkz085. RugoHS , EttlJ , WoodwardNE , HurvitzSA , GoncalvesA , LeeKH , et al. EMBRACA: efficacy outcomes in clinically relevant subgroups comparing talazoparib (TALA), an oral poly ADP ribose polymerase (PARP) inhibitor, to physician's choice of therapy (PCT) in patients with advanced breast cancer and a germline BRCA mutation. Journal of Clinical Oncology2018;36(Suppl 15):1069. RugoHS , QuekR , EttlJ , HurvitzSA , BhattacharyyaH , HannahAL , et al. Patient-reported outcomes (PRO) in patients (pts) with advanced breast cancer and a germline BRCA1/2 mutation (gBRCAm) receiving talazoparib (TALA) vs physician’s choice chemotherapy treatment (PCT): a focus on the EMBRACA triple negative (TNBC) subpopulation. Annals of Oncology2018;29(Suppl 8):viii91. YuY , ElmeliegyM , LittonJK , TudorIC , CzibereA , ZhengJ , et al. Exposure-efficacy progression-free survival (PFS) analyses of breast cancer patients with germline BRCA1/2 mutations receiving talazoparib in the phase III EMBRACA trial. Annals of Oncology2018;29(Suppl 8):viii97. YuY , ElmeliegyM , LittonJK , TudorIC , CzibereA , ZhengJ , et al. Talazoparib exposure-efficacy analysis in patients with advanced breast cancer and germline BRCA1/2 mutations in the EMBRACA trial. Journal of Clinical Pharmacology2020;60(10):1324-33. ">EMBRACA</a>). A phase 2 trial evaluating single agent veliparib in recurrent ovarian cancer patients showed the main grade 4 toxicity was thrombocytopenia (<a href="./references#CD011395-bbs2-0018" title="ColemanRL , SillMW , Bell-McGuinnK , AghajanianC , GrayHJ , TewariKS , et al. A phase II evaluation of the potent, highly selective PARP inhibitor veliparib in the treatment of persistent or recurrent epithelial ovarian, fallopian tube, or primary peritoneal cancer in patients who carry a germline BRCA1 or BRCA2 mutation — an NRG oncology/gynecologic oncology group study. Gynecologic Oncology2015;137(3):386-91.">Coleman 2015</a>). Our systematic review showed neutropenia was significantly less common and anaemia was significantly more common in patients receiving PARP inhibitors but there was not a meaningful difference in rates of other adverse events of any grade including thrombocytopaenia and fatigue. An upcoming systematic review and meta‐analysis may shed further light on the incidence of adverse events following use of different PARP inhibitors (<a href="./references#CD011395-bbs2-0025" title="HoT , RiazIB , AkhterM , MalikSU , RiazA , FarooqMZ , et al. Incidence of adverse events following use of different PARP inhibitors: systematic review and meta-analysis. Journal of the National Comprehensive Cancer Network: National Compehensive Cancer Network Annual Conference: Improving the Quality, Effectiveness, and Efficiency of Cancer Care, NCCN2019;17(3-5):Abstract HSR19-091.">Ho 2019</a>).<br/>Quality of life data were not easily available and were not amenable to quantitative analysis (only reported in two studies). This is obviously an important issue for both patients and clinicians, for objective quality of life indices help determine whether the adverse events from PARP inhibitors are outweighed by the known clinical benefit. This highlights the importance of collecting such data in future studies. </p> </section> <section id="CD011395-sec-0060"> <h3 class="title" id="CD011395-sec-0060">Overall completeness and applicability of evidence</h3> <p>The studies identified are relevant to the aims of this review and the clinical needs of the defined subgroup of patients with advanced breast cancer. This review allowed evaluation of all protocol‐defined endpoints, some fully and some partially. In terms of efficacy endpoints, OS, PFS, and response rates have been well reported with sufficient statistical information to allow meta‐analysis. On the other hand, documentation of quality of life outcomes was inadequate for meta‐analysis.<br/><br/>The overall survival results, our primary outcome, were limited by the lack of trials powered for overall survival as a primary endpoint. Also, only four out of five studies reported overall survival.<br/><br/>Our results were also limited by availability of only three phase 3 clinical trials, as well as the differing comparator arms of PARP inhibitor plus chemotherapy versus chemotherapy alone (<a href="./references#CD011395-bbs2-0002" title="DiérasV , HanHS , RobsonME , PalacovaM , MarcomPK , JagerA , et al. Evaluation of veliparib (V) and temozolomide (TMZ) in a phase 2 randomized study of the efficacy and tolerability of V+TMZ or carboplatin (C) and paclitaxel (P) vs placebo (Plc)+C/P in patients (pts) with BRCA1 or BRCA2 mutations and metastatic breast cancer. Cancer Research2017;77(Suppl 4):Abstract nr SABCS16-P4-22-02. HanHS , DiérasV , RobsonM , PalácováM , MarcomPK , Jager A et al. Veliparib with temozolomide or carboplatin/paclitaxel versus placebo with carboplatin/paclitaxel in patients with BRCA1/2 locally recurrent/metastatic breast cancer: randomized phase II study. Annals of Oncology2018;29(1):154-61. HanHS , DiérasV , RobsonME , PalácováM , MarcomPK , JagerA , et al. Efficacy and tolerability of veliparib (V; ABT-888) in combination with carboplatin (C) and paclitaxel (P) vs placebo (Plc)+C/P in patients (pts) with BRCA1 or BRCA2 mutations and metastatic breast cancer: a randomized, phase 2 study. Cancer Research2017;77(Suppl 4):Abstract nr SABCS16-S2-05. IsakoffSJ , PuhallaS , DomchekSM , FriedlanderM , KaufmanB , RobsonM , et al. A randomized Phase II study of veliparib with temozolomide or carboplatin/paclitaxel versus placebo with carboplatin/paclitaxel in BRCA1/2 metastatic breast cancer: design and rationale. Future Oncology2017;13(4):307-20. ">BROCADE 2</a>; <a href="./references#CD011395-bbs2-0003" title="ArunBK , HanHS , KaufmanB , WildiersH , FriedlanderM , AyoubJP , et al. First-line veliparib plus carboplatin/paclitaxel in patients with HER2-negative advanced/metastatic gBRCA-associated breast cancer: planned subgroup analysis from the phase 3 BROCADE3 trial. Cancer Research2020;80(Suppl 4):Abstract nr PD4-01. AyoubJP , FriedlanderML , DierasVC , WildiersH , ArunB , HanHS , et al. Veliparib plus carboplatin-paclitaxel in patients with HER2-negative advanced/metastatic gBRCA-associated breast cancer: results in hormone receptor-positive and triple-negative breast cancer subgroups from the phase III BROCADE3 trial. Annals of Oncology2020;31(Suppl 2):S65. DierasV , HanH , KaufmanB , WildiersH , FriedlanderM , AyoubJ , et al. A Phase 3 randomized, placebo-controlled trial of carboplatin and paclitaxel with or without the PARP inhibitor veliparib (ABT-888) in HER2-negative metastatic or locally advanced unresectable BRCA-associated breast cancer. Annals of Oncology2019;30(Suppl 5):v851-v934. ">BROCADE 3</a>; <a href="./references#CD011395-bbs2-0005" title="KummarS , WadeJL , OzaAM , SullivanD , ChenAP , GandaraDR , et al. Randomized phase II trial of cyclophosphamide and the oral poly (ADP-ribose) polymerase inhibitor veliparib in patients with recurrent, advanced triple-negative breast cancer. Investigational New Drugs2016;34(3):355–63. ">Kummar 2016</a>) compared to single agent PARP inhibitor versus physician’s choice of chemotherapy (<a href="./references#CD011395-bbs2-0004" title="DiabS , RugoHS , MinaLA , PuhallaS , MahtaniRL , HenryNL , et al. Efficacy and safety of talazoparib (TALA) or physician's choice of therapy (PCT) in United States patients (pts) with HER2- germline BRCA1/2-mutated (gBRCAm) locally advanced/metastatic breast cancer (LA/MBC) in the EMBRACA study. Journal of Clinical Oncology2019;37(Suppl 15):1044. EiermannW , RugoHS , DiabS , EttlJ , HurvitzSA , GoncalvesA , et al. Analysis of germline BRCA1/2 mutated (g BRCAmut) hormone receptor-positive (HR+) and triple-negative breast cancer (TNBC) treated with talazoparib (TALA). Journal of Clinical Oncology2018;36(Suppl 15):1070. EttlJ , HurvitzSA , RugoHS , LeeKH , MinaLA , WoodwardNE , et al. Outcomes of talazoparib (TALA) versus physician's choice of chemotherapy (PCT) in patients (pts) with advanced breast cancer (ABC) and a germline BRCA (gBRCA) mutation by line of chemotherapy (CT) in the EMBRACA trial. Journal of Clinical Oncology2019;37(Suppl 15):1071. EttlJ , QuekRG , BhattacharyyaH , RugoHS , HurvitzSA , GonçalvesA . Patient Reported Outcomes (PRO) in patients (pts) with HER2-advanced breast cancer (ABC) and a germline BRCA1/2 mutation (gBRCAm) receiving talazoparib (TALA) vs physician’s choice chemotherapy (PCT) in the EMBRACA trial: a focus on subgroups with/without visceral disease. Annals of Oncology2019;30(Suppl 5):v129–30. EttlJ , QuekRG , HurvitzSA , GoncalvesA , TudorIC , RugoHS . Hospitalization and supportive care medication (SCM) utilisation in patients (pts) with advanced breast cancer (ABC) and a germline BRCA1/2 mutation (gBRCAm) in EMBRACA. Annals of Oncology2019;30(Suppl 3):iii52. EttlJ , QuekRG , LeeKH , RugoHS , HurvitzS , GonçalvesA , et al. Quality of life with talazoparib versus physician’s choice of chemotherapy in patients with advanced breast cancer and germline BRCA1/2 mutation: patient-reported outcomes from the EMBRACA phase III trial. Annals of Oncology2018;29(9):1939-47. FaschingPA , QuekRG , BhattacharyyaH , HurvitzSA , RugoHS , EttlJ . Impact of objective response (OR) on patient-reported outcomes (PRO) in patients (pts) with advanced breast cancer (ABC) and a germline BRCA1/2 (gBRCA) mutation in the phase III EMBRACA trial. Annals of Oncology2019;30(Suppl 3):iii49. GonçalvesA , EiermannW , RugoHS , EttlJ , HurvitzSA , YerushalmiR , et al. EMBRACA: Efficacy and safety in comparing talazoparib (TALA) with physician's choice of therapy (PCT) in patients (pts) with advanced breast cancer (aBC) and a germline BRCA mutation (gBRCAm); BRCA1/BRCA2 subgroup analysis. Annals of Oncology2018;29(Suppl 8):viii96–7. GoncalvesA , QuekRGW , BhattacharyyaH , EttlJ , HurvitzSA , RugoHS . Patient-reported outcomes (PRO) in patients (pts) with Her2-advanced breast cancer (ABC) receiving talazoparib (TALA) vs physician's choice chemotherapy (PCT): a focus on EMBRACA germline BRCA1 and BRCA2 mutation (gBRCA1/2m) subgroups. Breast2019;48(Suppl 2):S71. HurvitzSA , GoncalvesA , RugoHS , LeeKH , FehrenbacherL , MinaLA , et al. Talazoparib in patients with a germline BRCA-mutated advanced breast cancer: detailed safety analyses from the phase III EMBRACA Trial. Oncologist2019;25(3):e439-50. LeeKH , KimSB , SohnJ , GoodwinA , UsariT , LanzaloneS , et al. Talazoparib (TALA) vs physician’s choice of chemotherapy (PCT) in Asian patients (Pts) with HER2- advanced breast cancer (ABC) and a germline BRCA1/2 mutation (gBRCA1/2mut): data from phase III EMBRACA. Annals of Oncology2019;30(9):ix14. LittonJ , EttlJ , HurvitzSA , MinaLA , RugoHS , LeeKH , et al. A phase 3, open-label, randomized, 2-arm international study of the oral dual PARP inhibitor talazoparib in germline BRCA mutation subjects with locally advanced and/or metastatic breast cancer (EMBRACA). Cancer Research2017;77(Suppl 4):Abstract nr OT2-01-13. LittonJ , RugoHS , EttlJ , HurvitzS , GoncalvesA , LeeKH , et al. EMBRACA: a phase 3 trial comparing talazoparib, an oral PARP inhibitor, to physicianʼs choice of therapy in patients with advanced breast cancer and a germline BRCA mutation [abstract]. In: San Antonio Breast Cancer Symposium; 2017 Dec 5-9; San Antonio (TX). San Antonio (TX), 2017. LittonJK , HurvitzSA , MinaLA , RugoHS , LeeKH , GonçalvesA , et al. Talazoparib (TALA) in germline BRCA1/2 (gBRCA1/2)-mutated human epidermal growth factor receptor 2 negative (HER2-) advanced breast cancer (ABC): final overall survival (OS) results from randomized phase 3 EMBRACA trial. Cancer Research2020;80(Suppl 16):Abstract no. CT071. LittonJK , RugoHS , EttlJ , HurvitzSA , GonçalvesA , LeeKH , et al. Talazoparib in patients with advanced breast cancer and a germline BRCA mutation. New England Journal of Medicine2018;379(8):753-63. MartínM , EiermannW , RugoHS , EttlJ , HurvitzSA , GonçalvesA , et al. EMBRACA: Comparison of efficacy and safety of talazoparib (TALA) and physician's choice of therapy (PCT) in patients (pts) with advanced breast cancer (aBC), a germline BRCA1/2 mutation (gBRCAm), and prior platinum treatment. Annals of Oncology2018;29(Suppl 8):viii96. MinaL , LeeKH , GoncalvesA , WoodwardN , HurvitzSA , DiabS , et al. EMBRACA: efficacy and safety of talazoparib or physician's choice of therapy in patients with advanced breast cancer and a germline BRCA1/2 mutation: a regional analysis. Cancer Research2019;79(Suppl 4):Abstract nr P6-18-12. QuekR , BhattacharyyaH , HurvitzS , GoncalvesA , EttlJ , RugoH . Patient-reported outcomes in patients with HER2-advanced breast cancer and a germline BRCA1/2 mutation receiving talazoparib versus physician's choice chemotherapy: a focus on EMBRACA age subgroups. Journal of Managed Care and Specialty Pharmacy2019;25(Suppl 10A):S37-8. QuekRGW , BhattacharyyaH , GoncalvesA , RugoHS , HurvitzSA , EttlJ . Pcn491 Patient reported outcomes (PRO) of talazoparib (TALA) versus physician's choice of chemotherapy (PCT) in patients (pts) with advanced breast cancer (aBC) and a germline BRCA (gBRCa) mutation: a focus on Embraca pts with/without prior chemotherapy (CT) subgroups. Value in Health2019;22(Suppl 3):S532. RugoHS , EttlJ , HurvitzSA , GoncalvesA , LeeKH , FehrenbacherL , et al. Outcomes in clinically relevant patient subgroups from the EMBRACA study: talazoparib vs physician's choice standard-of-care chemotherapy. Journal of the National Cancer Institute Cancer Spectrum2020;4(1):pkz085. RugoHS , EttlJ , WoodwardNE , HurvitzSA , GoncalvesA , LeeKH , et al. EMBRACA: efficacy outcomes in clinically relevant subgroups comparing talazoparib (TALA), an oral poly ADP ribose polymerase (PARP) inhibitor, to physician's choice of therapy (PCT) in patients with advanced breast cancer and a germline BRCA mutation. Journal of Clinical Oncology2018;36(Suppl 15):1069. RugoHS , QuekR , EttlJ , HurvitzSA , BhattacharyyaH , HannahAL , et al. Patient-reported outcomes (PRO) in patients (pts) with advanced breast cancer and a germline BRCA1/2 mutation (gBRCAm) receiving talazoparib (TALA) vs physician’s choice chemotherapy treatment (PCT): a focus on the EMBRACA triple negative (TNBC) subpopulation. Annals of Oncology2018;29(Suppl 8):viii91. YuY , ElmeliegyM , LittonJK , TudorIC , CzibereA , ZhengJ , et al. Exposure-efficacy progression-free survival (PFS) analyses of breast cancer patients with germline BRCA1/2 mutations receiving talazoparib in the phase III EMBRACA trial. Annals of Oncology2018;29(Suppl 8):viii97. YuY , ElmeliegyM , LittonJK , TudorIC , CzibereA , ZhengJ , et al. Talazoparib exposure-efficacy analysis in patients with advanced breast cancer and germline BRCA1/2 mutations in the EMBRACA trial. Journal of Clinical Pharmacology2020;60(10):1324-33. ">EMBRACA</a>; <a href="./references#CD011395-bbs2-0006" title="DelalogeS , ContePF , ImS , Senkus-KonefkaE , XuB , DomchekSM , et al. OlympiAD: further efficacy outcomes in patients with HER2-negative metastatic breast cancer and a germline BRCA mutation receiving olaparib monotherapy vs standard single-agent chemotherapy treatment of physician’s choice. Annals of Oncology2017;28(Suppl 5):v74-v108. DomchekS , RobsonM , ImS , SenkusE , XuB , MasudaN , et al. Tolerability of olaparib monotherapy versus chemotherapy in patients with HER2-negative metastatic breast cancer and a germline BRCA mutation: OlympiAD. Cancer Research2018;78(Suppl 4):Abstract nr P5-21-12. ImSA , XuB , LiW , RobsonM , OuyangQ , YehDC , et al. Olaparib monotherapy for Asian patients with a germline BRCA mutation and HER2-negative metastatic breast cancer: OlympiAD randomized trial subgroup analysis. Scientific Reports2020;10(1):8753. ImSA , XuB , LiW , RobsonM , OuyangQ , YehDC , et al. Olaparib monotherapy versus chemotherapy for patients with HER2-negative metastatic breast cancer and a germline BRCA mutation: Asian subgroup analysis from the phase III OlympiAD trial. Cancer Research2018;78(Suppl 4):Abstract nr P5-21-13. MerensC , BannisterW , BergnerS , HettleR , McCreaC , McCutcheonS , et al. Impact of olaparib versus chemotherapy on the use of strong pain medications in gBRCA-mutated HER2-negative metastatic breast cancer and associated patient reported outcomes. Cancer Research2020;80(Suppl 4):Abstract nr P6-13-05. RobsonM , HettleR , DegboeA , SaundersO , CainT , KilvertH , et al. Estimating the health state utility of patients with HER2–gBRCA+ metastatic breast cancer treated with olaparib or chemotherapy via a mapping analysis of EORTC QLQ-C30 data collected in the Olympiad clinical trial. Value in Health2018;21(Suppl 1):S12. RobsonM , ImSA , SenkusE , XuB , DomchekS , MasudaN , et al. OlympiAD extended follow-up for overall survival and safety: olaparib versus chemotherapy treatment of physician’s choice in patients with a germline BRCA mutation and HER2-negative metastatic breast cancer. Cancer Research2020;80(Suppl 4):Abstract nr PD4-03. RobsonM , ImSA , SenkusE , XuB , DomchekSM , MasudaN , et al. Olaparib for metastatic breast cancer in patients with a germline BRCA mutation. New England Journal of Medicine2017;377(6):523-33. RobsonM , RuddyKJ , ImSA , SenkusE , XuB , DomchekSM , et al. Patient-reported outcomes in patients with a germline BRCA mutation and HER2-negative metastatic breast cancer receiving olaparib versus chemotherapy in the OlympiAD trial. European Journal of Cancer2019;120:20-30. RobsonM , RuddyKJ , ImSA , Senkus-KonefkaE , XuB , DomchekSM , et al. OlympiAD: health-related quality of life (HRQoL) in patients with HER2-negative metastatic breast cancer (mBC) and a germline BRCA mutation (gBRCAm) receiving olaparib monotherapy vs standard single-agent chemotherapy treatment of physician’s choice (TPC). Annals of Oncology2017;28(Suppl 5):v74-v108. RobsonME , ImSA , SenkusE , XuB , DomchekS , MasudaN , et al. Abstract CT038: OlympiAD final overall survival: olaparib versus chemotherapy treatment of physician's choice (TPC) in patients with HER2-negative metastatic breast cancer (mBC) and a germline BRCA mutation (gBRCAm). American Association for Cancer Research2018;78(Suppl 13):CT038. RobsonME , ImSA , SenkusE , XuB , DomchekSM , MasudaN , et al. OlympiAD: phase III trial of olaparib monotherapy versus chemotherapy for patients (pts) with HER2-negative metastatic breast cancer (mBC) and a germline BRCA mutation (gBRCAm). Journal of Clinical Oncology2017;35(Suppl 18):LBA4-LBA4. RobsonME , RuddyKJ , ImSA , Senkus-KonefkaE , XuB , DomchekSM , et al. EORTC QLQ-C30 (QLQ-C30) symptoms in patients (pts) with HER2-negative metastatic breast cancer (mBC) and a germline BRCA mutation (gBRCAm) receiving olaparib vs chemotherapy treatment of physician’s choice (TPC) in OlympiAD. Journal of Clinical Oncology2018;36(Suppl 15):1045. RobsonME , TungN , ConteP , ImSA , SenkusE , XuB , et al. OlympiAD final overall survival and tolerability results: olaparib versus chemotherapy treatment of physician’s choice in patients with a germline BRCA mutation and HER2-negative metastatic breast cancer. Annals of Oncology2019;30(4):558-66. Senkus-KonefkaE , DomchekSM , ImSA , XuB , ArmstrongA , MasudaN , et al. Subgroup analysis of olaparib monotherapy versus chemotherapy by hormone receptor and BRCA mutation status in patients with HER2-negative metastatic breast cancer and a germline BRCA mutation: OlympiAD. European Journal of Cancer2018;92:S19-20. TungNM , ImSA , Senkus-KonefkaE , XuB , DomchekSM , MasudaN , et al. Olaparib versus chemotherapy treatment of physician’s choice in patients with a germline BRCA mutation and HER2-negative metastatic breast cancer (OlympiAD): efficacy in patients with visceral metastases. Journal of Clinical Oncology2018;36(Suppl 15):1053. ">OLYMPIAD</a>). Although there was minimal statistical heterogeneity, there is obvious clinical heterogeneity when combining outcomes from single‐agent PARP inhibitor studies and those from combination chemotherapy and PARP inhibitor studies. Potential ways to shed light on this heterogeneity would include between‐study analysis using individual patient data and/or a network meta‐analysis, however, data were not available to do this.<br/><br/>Our review identified studies that used three different PARP inhibitors. Given there were only five studies included, this means that there was a small number of studies for each PARP inhibitor. In pooling outcome data for the current study, we determined that there was an insufficient number of studies and no methodological grounds to perform analyses comparing the effects of individual PARP inhibitors. Therefore, investigation of which PARP inhibitor may be superior to another (and particularly in differing clinical settings) is outside the scope of the current study.<br/><br/>Baseline characteristics differed slightly in the trial populations. <a href="./references#CD011395-bbs2-0002" title="DiérasV , HanHS , RobsonME , PalacovaM , MarcomPK , JagerA , et al. Evaluation of veliparib (V) and temozolomide (TMZ) in a phase 2 randomized study of the efficacy and tolerability of V+TMZ or carboplatin (C) and paclitaxel (P) vs placebo (Plc)+C/P in patients (pts) with BRCA1 or BRCA2 mutations and metastatic breast cancer. Cancer Research2017;77(Suppl 4):Abstract nr SABCS16-P4-22-02. HanHS , DiérasV , RobsonM , PalácováM , MarcomPK , Jager A et al. Veliparib with temozolomide or carboplatin/paclitaxel versus placebo with carboplatin/paclitaxel in patients with BRCA1/2 locally recurrent/metastatic breast cancer: randomized phase II study. Annals of Oncology2018;29(1):154-61. HanHS , DiérasV , RobsonME , PalácováM , MarcomPK , JagerA , et al. Efficacy and tolerability of veliparib (V; ABT-888) in combination with carboplatin (C) and paclitaxel (P) vs placebo (Plc)+C/P in patients (pts) with BRCA1 or BRCA2 mutations and metastatic breast cancer: a randomized, phase 2 study. Cancer Research2017;77(Suppl 4):Abstract nr SABCS16-S2-05. IsakoffSJ , PuhallaS , DomchekSM , FriedlanderM , KaufmanB , RobsonM , et al. A randomized Phase II study of veliparib with temozolomide or carboplatin/paclitaxel versus placebo with carboplatin/paclitaxel in BRCA1/2 metastatic breast cancer: design and rationale. Future Oncology2017;13(4):307-20. ">BROCADE 2</a>; <a href="./references#CD011395-bbs2-0003" title="ArunBK , HanHS , KaufmanB , WildiersH , FriedlanderM , AyoubJP , et al. First-line veliparib plus carboplatin/paclitaxel in patients with HER2-negative advanced/metastatic gBRCA-associated breast cancer: planned subgroup analysis from the phase 3 BROCADE3 trial. Cancer Research2020;80(Suppl 4):Abstract nr PD4-01. AyoubJP , FriedlanderML , DierasVC , WildiersH , ArunB , HanHS , et al. Veliparib plus carboplatin-paclitaxel in patients with HER2-negative advanced/metastatic gBRCA-associated breast cancer: results in hormone receptor-positive and triple-negative breast cancer subgroups from the phase III BROCADE3 trial. Annals of Oncology2020;31(Suppl 2):S65. DierasV , HanH , KaufmanB , WildiersH , FriedlanderM , AyoubJ , et al. A Phase 3 randomized, placebo-controlled trial of carboplatin and paclitaxel with or without the PARP inhibitor veliparib (ABT-888) in HER2-negative metastatic or locally advanced unresectable BRCA-associated breast cancer. Annals of Oncology2019;30(Suppl 5):v851-v934. ">BROCADE 3</a> and <a href="./references#CD011395-bbs2-0004" title="DiabS , RugoHS , MinaLA , PuhallaS , MahtaniRL , HenryNL , et al. Efficacy and safety of talazoparib (TALA) or physician's choice of therapy (PCT) in United States patients (pts) with HER2- germline BRCA1/2-mutated (gBRCAm) locally advanced/metastatic breast cancer (LA/MBC) in the EMBRACA study. Journal of Clinical Oncology2019;37(Suppl 15):1044. EiermannW , RugoHS , DiabS , EttlJ , HurvitzSA , GoncalvesA , et al. Analysis of germline BRCA1/2 mutated (g BRCAmut) hormone receptor-positive (HR+) and triple-negative breast cancer (TNBC) treated with talazoparib (TALA). Journal of Clinical Oncology2018;36(Suppl 15):1070. EttlJ , HurvitzSA , RugoHS , LeeKH , MinaLA , WoodwardNE , et al. Outcomes of talazoparib (TALA) versus physician's choice of chemotherapy (PCT) in patients (pts) with advanced breast cancer (ABC) and a germline BRCA (gBRCA) mutation by line of chemotherapy (CT) in the EMBRACA trial. Journal of Clinical Oncology2019;37(Suppl 15):1071. EttlJ , QuekRG , BhattacharyyaH , RugoHS , HurvitzSA , GonçalvesA . Patient Reported Outcomes (PRO) in patients (pts) with HER2-advanced breast cancer (ABC) and a germline BRCA1/2 mutation (gBRCAm) receiving talazoparib (TALA) vs physician’s choice chemotherapy (PCT) in the EMBRACA trial: a focus on subgroups with/without visceral disease. Annals of Oncology2019;30(Suppl 5):v129–30. EttlJ , QuekRG , HurvitzSA , GoncalvesA , TudorIC , RugoHS . Hospitalization and supportive care medication (SCM) utilisation in patients (pts) with advanced breast cancer (ABC) and a germline BRCA1/2 mutation (gBRCAm) in EMBRACA. Annals of Oncology2019;30(Suppl 3):iii52. EttlJ , QuekRG , LeeKH , RugoHS , HurvitzS , GonçalvesA , et al. Quality of life with talazoparib versus physician’s choice of chemotherapy in patients with advanced breast cancer and germline BRCA1/2 mutation: patient-reported outcomes from the EMBRACA phase III trial. Annals of Oncology2018;29(9):1939-47. FaschingPA , QuekRG , BhattacharyyaH , HurvitzSA , RugoHS , EttlJ . Impact of objective response (OR) on patient-reported outcomes (PRO) in patients (pts) with advanced breast cancer (ABC) and a germline BRCA1/2 (gBRCA) mutation in the phase III EMBRACA trial. Annals of Oncology2019;30(Suppl 3):iii49. GonçalvesA , EiermannW , RugoHS , EttlJ , HurvitzSA , YerushalmiR , et al. EMBRACA: Efficacy and safety in comparing talazoparib (TALA) with physician's choice of therapy (PCT) in patients (pts) with advanced breast cancer (aBC) and a germline BRCA mutation (gBRCAm); BRCA1/BRCA2 subgroup analysis. Annals of Oncology2018;29(Suppl 8):viii96–7. GoncalvesA , QuekRGW , BhattacharyyaH , EttlJ , HurvitzSA , RugoHS . Patient-reported outcomes (PRO) in patients (pts) with Her2-advanced breast cancer (ABC) receiving talazoparib (TALA) vs physician's choice chemotherapy (PCT): a focus on EMBRACA germline BRCA1 and BRCA2 mutation (gBRCA1/2m) subgroups. Breast2019;48(Suppl 2):S71. HurvitzSA , GoncalvesA , RugoHS , LeeKH , FehrenbacherL , MinaLA , et al. Talazoparib in patients with a germline BRCA-mutated advanced breast cancer: detailed safety analyses from the phase III EMBRACA Trial. Oncologist2019;25(3):e439-50. LeeKH , KimSB , SohnJ , GoodwinA , UsariT , LanzaloneS , et al. Talazoparib (TALA) vs physician’s choice of chemotherapy (PCT) in Asian patients (Pts) with HER2- advanced breast cancer (ABC) and a germline BRCA1/2 mutation (gBRCA1/2mut): data from phase III EMBRACA. Annals of Oncology2019;30(9):ix14. LittonJ , EttlJ , HurvitzSA , MinaLA , RugoHS , LeeKH , et al. A phase 3, open-label, randomized, 2-arm international study of the oral dual PARP inhibitor talazoparib in germline BRCA mutation subjects with locally advanced and/or metastatic breast cancer (EMBRACA). Cancer Research2017;77(Suppl 4):Abstract nr OT2-01-13. LittonJ , RugoHS , EttlJ , HurvitzS , GoncalvesA , LeeKH , et al. EMBRACA: a phase 3 trial comparing talazoparib, an oral PARP inhibitor, to physicianʼs choice of therapy in patients with advanced breast cancer and a germline BRCA mutation [abstract]. In: San Antonio Breast Cancer Symposium; 2017 Dec 5-9; San Antonio (TX). San Antonio (TX), 2017. LittonJK , HurvitzSA , MinaLA , RugoHS , LeeKH , GonçalvesA , et al. Talazoparib (TALA) in germline BRCA1/2 (gBRCA1/2)-mutated human epidermal growth factor receptor 2 negative (HER2-) advanced breast cancer (ABC): final overall survival (OS) results from randomized phase 3 EMBRACA trial. Cancer Research2020;80(Suppl 16):Abstract no. CT071. LittonJK , RugoHS , EttlJ , HurvitzSA , GonçalvesA , LeeKH , et al. Talazoparib in patients with advanced breast cancer and a germline BRCA mutation. New England Journal of Medicine2018;379(8):753-63. MartínM , EiermannW , RugoHS , EttlJ , HurvitzSA , GonçalvesA , et al. EMBRACA: Comparison of efficacy and safety of talazoparib (TALA) and physician's choice of therapy (PCT) in patients (pts) with advanced breast cancer (aBC), a germline BRCA1/2 mutation (gBRCAm), and prior platinum treatment. Annals of Oncology2018;29(Suppl 8):viii96. MinaL , LeeKH , GoncalvesA , WoodwardN , HurvitzSA , DiabS , et al. EMBRACA: efficacy and safety of talazoparib or physician's choice of therapy in patients with advanced breast cancer and a germline BRCA1/2 mutation: a regional analysis. Cancer Research2019;79(Suppl 4):Abstract nr P6-18-12. QuekR , BhattacharyyaH , HurvitzS , GoncalvesA , EttlJ , RugoH . Patient-reported outcomes in patients with HER2-advanced breast cancer and a germline BRCA1/2 mutation receiving talazoparib versus physician's choice chemotherapy: a focus on EMBRACA age subgroups. Journal of Managed Care and Specialty Pharmacy2019;25(Suppl 10A):S37-8. QuekRGW , BhattacharyyaH , GoncalvesA , RugoHS , HurvitzSA , EttlJ . Pcn491 Patient reported outcomes (PRO) of talazoparib (TALA) versus physician's choice of chemotherapy (PCT) in patients (pts) with advanced breast cancer (aBC) and a germline BRCA (gBRCa) mutation: a focus on Embraca pts with/without prior chemotherapy (CT) subgroups. Value in Health2019;22(Suppl 3):S532. RugoHS , EttlJ , HurvitzSA , GoncalvesA , LeeKH , FehrenbacherL , et al. Outcomes in clinically relevant patient subgroups from the EMBRACA study: talazoparib vs physician's choice standard-of-care chemotherapy. Journal of the National Cancer Institute Cancer Spectrum2020;4(1):pkz085. RugoHS , EttlJ , WoodwardNE , HurvitzSA , GoncalvesA , LeeKH , et al. EMBRACA: efficacy outcomes in clinically relevant subgroups comparing talazoparib (TALA), an oral poly ADP ribose polymerase (PARP) inhibitor, to physician's choice of therapy (PCT) in patients with advanced breast cancer and a germline BRCA mutation. Journal of Clinical Oncology2018;36(Suppl 15):1069. RugoHS , QuekR , EttlJ , HurvitzSA , BhattacharyyaH , HannahAL , et al. Patient-reported outcomes (PRO) in patients (pts) with advanced breast cancer and a germline BRCA1/2 mutation (gBRCAm) receiving talazoparib (TALA) vs physician’s choice chemotherapy treatment (PCT): a focus on the EMBRACA triple negative (TNBC) subpopulation. Annals of Oncology2018;29(Suppl 8):viii91. YuY , ElmeliegyM , LittonJK , TudorIC , CzibereA , ZhengJ , et al. Exposure-efficacy progression-free survival (PFS) analyses of breast cancer patients with germline BRCA1/2 mutations receiving talazoparib in the phase III EMBRACA trial. Annals of Oncology2018;29(Suppl 8):viii97. YuY , ElmeliegyM , LittonJK , TudorIC , CzibereA , ZhengJ , et al. Talazoparib exposure-efficacy analysis in patients with advanced breast cancer and germline BRCA1/2 mutations in the EMBRACA trial. Journal of Clinical Pharmacology2020;60(10):1324-33. ">EMBRACA</a> included patients with locally advanced breast cancer whereas <a href="./references#CD011395-bbs2-0005" title="KummarS , WadeJL , OzaAM , SullivanD , ChenAP , GandaraDR , et al. Randomized phase II trial of cyclophosphamide and the oral poly (ADP-ribose) polymerase inhibitor veliparib in patients with recurrent, advanced triple-negative breast cancer. Investigational New Drugs2016;34(3):355–63. ">Kummar 2016</a> and <a href="./references#CD011395-bbs2-0006" title="DelalogeS , ContePF , ImS , Senkus-KonefkaE , XuB , DomchekSM , et al. OlympiAD: further efficacy outcomes in patients with HER2-negative metastatic breast cancer and a germline BRCA mutation receiving olaparib monotherapy vs standard single-agent chemotherapy treatment of physician’s choice. Annals of Oncology2017;28(Suppl 5):v74-v108. DomchekS , RobsonM , ImS , SenkusE , XuB , MasudaN , et al. Tolerability of olaparib monotherapy versus chemotherapy in patients with HER2-negative metastatic breast cancer and a germline BRCA mutation: OlympiAD. Cancer Research2018;78(Suppl 4):Abstract nr P5-21-12. ImSA , XuB , LiW , RobsonM , OuyangQ , YehDC , et al. Olaparib monotherapy for Asian patients with a germline BRCA mutation and HER2-negative metastatic breast cancer: OlympiAD randomized trial subgroup analysis. Scientific Reports2020;10(1):8753. ImSA , XuB , LiW , RobsonM , OuyangQ , YehDC , et al. Olaparib monotherapy versus chemotherapy for patients with HER2-negative metastatic breast cancer and a germline BRCA mutation: Asian subgroup analysis from the phase III OlympiAD trial. Cancer Research2018;78(Suppl 4):Abstract nr P5-21-13. MerensC , BannisterW , BergnerS , HettleR , McCreaC , McCutcheonS , et al. Impact of olaparib versus chemotherapy on the use of strong pain medications in gBRCA-mutated HER2-negative metastatic breast cancer and associated patient reported outcomes. Cancer Research2020;80(Suppl 4):Abstract nr P6-13-05. RobsonM , HettleR , DegboeA , SaundersO , CainT , KilvertH , et al. Estimating the health state utility of patients with HER2–gBRCA+ metastatic breast cancer treated with olaparib or chemotherapy via a mapping analysis of EORTC QLQ-C30 data collected in the Olympiad clinical trial. Value in Health2018;21(Suppl 1):S12. RobsonM , ImSA , SenkusE , XuB , DomchekS , MasudaN , et al. OlympiAD extended follow-up for overall survival and safety: olaparib versus chemotherapy treatment of physician’s choice in patients with a germline BRCA mutation and HER2-negative metastatic breast cancer. Cancer Research2020;80(Suppl 4):Abstract nr PD4-03. RobsonM , ImSA , SenkusE , XuB , DomchekSM , MasudaN , et al. Olaparib for metastatic breast cancer in patients with a germline BRCA mutation. New England Journal of Medicine2017;377(6):523-33. RobsonM , RuddyKJ , ImSA , SenkusE , XuB , DomchekSM , et al. Patient-reported outcomes in patients with a germline BRCA mutation and HER2-negative metastatic breast cancer receiving olaparib versus chemotherapy in the OlympiAD trial. European Journal of Cancer2019;120:20-30. RobsonM , RuddyKJ , ImSA , Senkus-KonefkaE , XuB , DomchekSM , et al. OlympiAD: health-related quality of life (HRQoL) in patients with HER2-negative metastatic breast cancer (mBC) and a germline BRCA mutation (gBRCAm) receiving olaparib monotherapy vs standard single-agent chemotherapy treatment of physician’s choice (TPC). Annals of Oncology2017;28(Suppl 5):v74-v108. RobsonME , ImSA , SenkusE , XuB , DomchekS , MasudaN , et al. Abstract CT038: OlympiAD final overall survival: olaparib versus chemotherapy treatment of physician's choice (TPC) in patients with HER2-negative metastatic breast cancer (mBC) and a germline BRCA mutation (gBRCAm). American Association for Cancer Research2018;78(Suppl 13):CT038. RobsonME , ImSA , SenkusE , XuB , DomchekSM , MasudaN , et al. OlympiAD: phase III trial of olaparib monotherapy versus chemotherapy for patients (pts) with HER2-negative metastatic breast cancer (mBC) and a germline BRCA mutation (gBRCAm). Journal of Clinical Oncology2017;35(Suppl 18):LBA4-LBA4. RobsonME , RuddyKJ , ImSA , Senkus-KonefkaE , XuB , DomchekSM , et al. EORTC QLQ-C30 (QLQ-C30) symptoms in patients (pts) with HER2-negative metastatic breast cancer (mBC) and a germline BRCA mutation (gBRCAm) receiving olaparib vs chemotherapy treatment of physician’s choice (TPC) in OlympiAD. Journal of Clinical Oncology2018;36(Suppl 15):1045. RobsonME , TungN , ConteP , ImSA , SenkusE , XuB , et al. OlympiAD final overall survival and tolerability results: olaparib versus chemotherapy treatment of physician’s choice in patients with a germline BRCA mutation and HER2-negative metastatic breast cancer. Annals of Oncology2019;30(4):558-66. Senkus-KonefkaE , DomchekSM , ImSA , XuB , ArmstrongA , MasudaN , et al. Subgroup analysis of olaparib monotherapy versus chemotherapy by hormone receptor and BRCA mutation status in patients with HER2-negative metastatic breast cancer and a germline BRCA mutation: OlympiAD. European Journal of Cancer2018;92:S19-20. TungNM , ImSA , Senkus-KonefkaE , XuB , DomchekSM , MasudaN , et al. Olaparib versus chemotherapy treatment of physician’s choice in patients with a germline BRCA mutation and HER2-negative metastatic breast cancer (OlympiAD): efficacy in patients with visceral metastases. Journal of Clinical Oncology2018;36(Suppl 15):1053. ">OLYMPIAD</a> only included metastatic patients. <a href="./references#CD011395-bbs2-0002" title="DiérasV , HanHS , RobsonME , PalacovaM , MarcomPK , JagerA , et al. Evaluation of veliparib (V) and temozolomide (TMZ) in a phase 2 randomized study of the efficacy and tolerability of V+TMZ or carboplatin (C) and paclitaxel (P) vs placebo (Plc)+C/P in patients (pts) with BRCA1 or BRCA2 mutations and metastatic breast cancer. Cancer Research2017;77(Suppl 4):Abstract nr SABCS16-P4-22-02. HanHS , DiérasV , RobsonM , PalácováM , MarcomPK , Jager A et al. Veliparib with temozolomide or carboplatin/paclitaxel versus placebo with carboplatin/paclitaxel in patients with BRCA1/2 locally recurrent/metastatic breast cancer: randomized phase II study. Annals of Oncology2018;29(1):154-61. HanHS , DiérasV , RobsonME , PalácováM , MarcomPK , JagerA , et al. Efficacy and tolerability of veliparib (V; ABT-888) in combination with carboplatin (C) and paclitaxel (P) vs placebo (Plc)+C/P in patients (pts) with BRCA1 or BRCA2 mutations and metastatic breast cancer: a randomized, phase 2 study. Cancer Research2017;77(Suppl 4):Abstract nr SABCS16-S2-05. IsakoffSJ , PuhallaS , DomchekSM , FriedlanderM , KaufmanB , RobsonM , et al. A randomized Phase II study of veliparib with temozolomide or carboplatin/paclitaxel versus placebo with carboplatin/paclitaxel in BRCA1/2 metastatic breast cancer: design and rationale. Future Oncology2017;13(4):307-20. ">BROCADE 2</a> and <a href="./references#CD011395-bbs2-0003" title="ArunBK , HanHS , KaufmanB , WildiersH , FriedlanderM , AyoubJP , et al. First-line veliparib plus carboplatin/paclitaxel in patients with HER2-negative advanced/metastatic gBRCA-associated breast cancer: planned subgroup analysis from the phase 3 BROCADE3 trial. Cancer Research2020;80(Suppl 4):Abstract nr PD4-01. AyoubJP , FriedlanderML , DierasVC , WildiersH , ArunB , HanHS , et al. Veliparib plus carboplatin-paclitaxel in patients with HER2-negative advanced/metastatic gBRCA-associated breast cancer: results in hormone receptor-positive and triple-negative breast cancer subgroups from the phase III BROCADE3 trial. Annals of Oncology2020;31(Suppl 2):S65. DierasV , HanH , KaufmanB , WildiersH , FriedlanderM , AyoubJ , et al. A Phase 3 randomized, placebo-controlled trial of carboplatin and paclitaxel with or without the PARP inhibitor veliparib (ABT-888) in HER2-negative metastatic or locally advanced unresectable BRCA-associated breast cancer. Annals of Oncology2019;30(Suppl 5):v851-v934. ">BROCADE 3</a> had a higher proportion of patients without any prior chemotherapy treatment for metastatic disease compared to the other trials. <a href="./references#CD011395-bbs2-0002" title="DiérasV , HanHS , RobsonME , PalacovaM , MarcomPK , JagerA , et al. Evaluation of veliparib (V) and temozolomide (TMZ) in a phase 2 randomized study of the efficacy and tolerability of V+TMZ or carboplatin (C) and paclitaxel (P) vs placebo (Plc)+C/P in patients (pts) with BRCA1 or BRCA2 mutations and metastatic breast cancer. Cancer Research2017;77(Suppl 4):Abstract nr SABCS16-P4-22-02. HanHS , DiérasV , RobsonM , PalácováM , MarcomPK , Jager A et al. Veliparib with temozolomide or carboplatin/paclitaxel versus placebo with carboplatin/paclitaxel in patients with BRCA1/2 locally recurrent/metastatic breast cancer: randomized phase II study. Annals of Oncology2018;29(1):154-61. HanHS , DiérasV , RobsonME , PalácováM , MarcomPK , JagerA , et al. Efficacy and tolerability of veliparib (V; ABT-888) in combination with carboplatin (C) and paclitaxel (P) vs placebo (Plc)+C/P in patients (pts) with BRCA1 or BRCA2 mutations and metastatic breast cancer: a randomized, phase 2 study. Cancer Research2017;77(Suppl 4):Abstract nr SABCS16-S2-05. IsakoffSJ , PuhallaS , DomchekSM , FriedlanderM , KaufmanB , RobsonM , et al. A randomized Phase II study of veliparib with temozolomide or carboplatin/paclitaxel versus placebo with carboplatin/paclitaxel in BRCA1/2 metastatic breast cancer: design and rationale. Future Oncology2017;13(4):307-20. ">BROCADE 2</a> is the only study to include HER2‐positive patients, albeit very small numbers (three in the PARP inhibitor arm and seven in the control arm).<br/><br/>In terms of applicability to current practice, our results support the use of PARP inhibitors in advanced/metastatic HER2‐negative, BRCA germline mutated breast cancer patients. This is in line with current FDA approvals. Olaparib was approved by the FDA in January 2018 for the treatment of patients with previously treated advanced or metastatic HER2‐negative, BRCA germline mutated breast cancer, on the basis of the progression‐free survival benefits published in the OlympiAD trial (<a href="./references#CD011395-bbs2-0006" title="DelalogeS , ContePF , ImS , Senkus-KonefkaE , XuB , DomchekSM , et al. OlympiAD: further efficacy outcomes in patients with HER2-negative metastatic breast cancer and a germline BRCA mutation receiving olaparib monotherapy vs standard single-agent chemotherapy treatment of physician’s choice. Annals of Oncology2017;28(Suppl 5):v74-v108. DomchekS , RobsonM , ImS , SenkusE , XuB , MasudaN , et al. Tolerability of olaparib monotherapy versus chemotherapy in patients with HER2-negative metastatic breast cancer and a germline BRCA mutation: OlympiAD. Cancer Research2018;78(Suppl 4):Abstract nr P5-21-12. ImSA , XuB , LiW , RobsonM , OuyangQ , YehDC , et al. Olaparib monotherapy for Asian patients with a germline BRCA mutation and HER2-negative metastatic breast cancer: OlympiAD randomized trial subgroup analysis. Scientific Reports2020;10(1):8753. ImSA , XuB , LiW , RobsonM , OuyangQ , YehDC , et al. Olaparib monotherapy versus chemotherapy for patients with HER2-negative metastatic breast cancer and a germline BRCA mutation: Asian subgroup analysis from the phase III OlympiAD trial. Cancer Research2018;78(Suppl 4):Abstract nr P5-21-13. MerensC , BannisterW , BergnerS , HettleR , McCreaC , McCutcheonS , et al. Impact of olaparib versus chemotherapy on the use of strong pain medications in gBRCA-mutated HER2-negative metastatic breast cancer and associated patient reported outcomes. Cancer Research2020;80(Suppl 4):Abstract nr P6-13-05. RobsonM , HettleR , DegboeA , SaundersO , CainT , KilvertH , et al. Estimating the health state utility of patients with HER2–gBRCA+ metastatic breast cancer treated with olaparib or chemotherapy via a mapping analysis of EORTC QLQ-C30 data collected in the Olympiad clinical trial. Value in Health2018;21(Suppl 1):S12. RobsonM , ImSA , SenkusE , XuB , DomchekS , MasudaN , et al. OlympiAD extended follow-up for overall survival and safety: olaparib versus chemotherapy treatment of physician’s choice in patients with a germline BRCA mutation and HER2-negative metastatic breast cancer. Cancer Research2020;80(Suppl 4):Abstract nr PD4-03. RobsonM , ImSA , SenkusE , XuB , DomchekSM , MasudaN , et al. Olaparib for metastatic breast cancer in patients with a germline BRCA mutation. New England Journal of Medicine2017;377(6):523-33. RobsonM , RuddyKJ , ImSA , SenkusE , XuB , DomchekSM , et al. Patient-reported outcomes in patients with a germline BRCA mutation and HER2-negative metastatic breast cancer receiving olaparib versus chemotherapy in the OlympiAD trial. European Journal of Cancer2019;120:20-30. RobsonM , RuddyKJ , ImSA , Senkus-KonefkaE , XuB , DomchekSM , et al. OlympiAD: health-related quality of life (HRQoL) in patients with HER2-negative metastatic breast cancer (mBC) and a germline BRCA mutation (gBRCAm) receiving olaparib monotherapy vs standard single-agent chemotherapy treatment of physician’s choice (TPC). Annals of Oncology2017;28(Suppl 5):v74-v108. RobsonME , ImSA , SenkusE , XuB , DomchekS , MasudaN , et al. Abstract CT038: OlympiAD final overall survival: olaparib versus chemotherapy treatment of physician's choice (TPC) in patients with HER2-negative metastatic breast cancer (mBC) and a germline BRCA mutation (gBRCAm). American Association for Cancer Research2018;78(Suppl 13):CT038. RobsonME , ImSA , SenkusE , XuB , DomchekSM , MasudaN , et al. OlympiAD: phase III trial of olaparib monotherapy versus chemotherapy for patients (pts) with HER2-negative metastatic breast cancer (mBC) and a germline BRCA mutation (gBRCAm). Journal of Clinical Oncology2017;35(Suppl 18):LBA4-LBA4. RobsonME , RuddyKJ , ImSA , Senkus-KonefkaE , XuB , DomchekSM , et al. EORTC QLQ-C30 (QLQ-C30) symptoms in patients (pts) with HER2-negative metastatic breast cancer (mBC) and a germline BRCA mutation (gBRCAm) receiving olaparib vs chemotherapy treatment of physician’s choice (TPC) in OlympiAD. Journal of Clinical Oncology2018;36(Suppl 15):1045. RobsonME , TungN , ConteP , ImSA , SenkusE , XuB , et al. OlympiAD final overall survival and tolerability results: olaparib versus chemotherapy treatment of physician’s choice in patients with a germline BRCA mutation and HER2-negative metastatic breast cancer. Annals of Oncology2019;30(4):558-66. Senkus-KonefkaE , DomchekSM , ImSA , XuB , ArmstrongA , MasudaN , et al. Subgroup analysis of olaparib monotherapy versus chemotherapy by hormone receptor and BRCA mutation status in patients with HER2-negative metastatic breast cancer and a germline BRCA mutation: OlympiAD. European Journal of Cancer2018;92:S19-20. TungNM , ImSA , Senkus-KonefkaE , XuB , DomchekSM , MasudaN , et al. Olaparib versus chemotherapy treatment of physician’s choice in patients with a germline BRCA mutation and HER2-negative metastatic breast cancer (OlympiAD): efficacy in patients with visceral metastases. Journal of Clinical Oncology2018;36(Suppl 15):1053. ">OLYMPIAD</a>). Talazoparib was approved for the same indication, based on the <a href="./references#CD011395-bbs2-0004" title="DiabS , RugoHS , MinaLA , PuhallaS , MahtaniRL , HenryNL , et al. Efficacy and safety of talazoparib (TALA) or physician's choice of therapy (PCT) in United States patients (pts) with HER2- germline BRCA1/2-mutated (gBRCAm) locally advanced/metastatic breast cancer (LA/MBC) in the EMBRACA study. Journal of Clinical Oncology2019;37(Suppl 15):1044. EiermannW , RugoHS , DiabS , EttlJ , HurvitzSA , GoncalvesA , et al. Analysis of germline BRCA1/2 mutated (g BRCAmut) hormone receptor-positive (HR+) and triple-negative breast cancer (TNBC) treated with talazoparib (TALA). Journal of Clinical Oncology2018;36(Suppl 15):1070. EttlJ , HurvitzSA , RugoHS , LeeKH , MinaLA , WoodwardNE , et al. Outcomes of talazoparib (TALA) versus physician's choice of chemotherapy (PCT) in patients (pts) with advanced breast cancer (ABC) and a germline BRCA (gBRCA) mutation by line of chemotherapy (CT) in the EMBRACA trial. Journal of Clinical Oncology2019;37(Suppl 15):1071. EttlJ , QuekRG , BhattacharyyaH , RugoHS , HurvitzSA , GonçalvesA . Patient Reported Outcomes (PRO) in patients (pts) with HER2-advanced breast cancer (ABC) and a germline BRCA1/2 mutation (gBRCAm) receiving talazoparib (TALA) vs physician’s choice chemotherapy (PCT) in the EMBRACA trial: a focus on subgroups with/without visceral disease. Annals of Oncology2019;30(Suppl 5):v129–30. EttlJ , QuekRG , HurvitzSA , GoncalvesA , TudorIC , RugoHS . Hospitalization and supportive care medication (SCM) utilisation in patients (pts) with advanced breast cancer (ABC) and a germline BRCA1/2 mutation (gBRCAm) in EMBRACA. Annals of Oncology2019;30(Suppl 3):iii52. EttlJ , QuekRG , LeeKH , RugoHS , HurvitzS , GonçalvesA , et al. Quality of life with talazoparib versus physician’s choice of chemotherapy in patients with advanced breast cancer and germline BRCA1/2 mutation: patient-reported outcomes from the EMBRACA phase III trial. Annals of Oncology2018;29(9):1939-47. FaschingPA , QuekRG , BhattacharyyaH , HurvitzSA , RugoHS , EttlJ . Impact of objective response (OR) on patient-reported outcomes (PRO) in patients (pts) with advanced breast cancer (ABC) and a germline BRCA1/2 (gBRCA) mutation in the phase III EMBRACA trial. Annals of Oncology2019;30(Suppl 3):iii49. GonçalvesA , EiermannW , RugoHS , EttlJ , HurvitzSA , YerushalmiR , et al. EMBRACA: Efficacy and safety in comparing talazoparib (TALA) with physician's choice of therapy (PCT) in patients (pts) with advanced breast cancer (aBC) and a germline BRCA mutation (gBRCAm); BRCA1/BRCA2 subgroup analysis. Annals of Oncology2018;29(Suppl 8):viii96–7. GoncalvesA , QuekRGW , BhattacharyyaH , EttlJ , HurvitzSA , RugoHS . Patient-reported outcomes (PRO) in patients (pts) with Her2-advanced breast cancer (ABC) receiving talazoparib (TALA) vs physician's choice chemotherapy (PCT): a focus on EMBRACA germline BRCA1 and BRCA2 mutation (gBRCA1/2m) subgroups. Breast2019;48(Suppl 2):S71. HurvitzSA , GoncalvesA , RugoHS , LeeKH , FehrenbacherL , MinaLA , et al. Talazoparib in patients with a germline BRCA-mutated advanced breast cancer: detailed safety analyses from the phase III EMBRACA Trial. Oncologist2019;25(3):e439-50. LeeKH , KimSB , SohnJ , GoodwinA , UsariT , LanzaloneS , et al. Talazoparib (TALA) vs physician’s choice of chemotherapy (PCT) in Asian patients (Pts) with HER2- advanced breast cancer (ABC) and a germline BRCA1/2 mutation (gBRCA1/2mut): data from phase III EMBRACA. Annals of Oncology2019;30(9):ix14. LittonJ , EttlJ , HurvitzSA , MinaLA , RugoHS , LeeKH , et al. A phase 3, open-label, randomized, 2-arm international study of the oral dual PARP inhibitor talazoparib in germline BRCA mutation subjects with locally advanced and/or metastatic breast cancer (EMBRACA). Cancer Research2017;77(Suppl 4):Abstract nr OT2-01-13. LittonJ , RugoHS , EttlJ , HurvitzS , GoncalvesA , LeeKH , et al. EMBRACA: a phase 3 trial comparing talazoparib, an oral PARP inhibitor, to physicianʼs choice of therapy in patients with advanced breast cancer and a germline BRCA mutation [abstract]. In: San Antonio Breast Cancer Symposium; 2017 Dec 5-9; San Antonio (TX). San Antonio (TX), 2017. LittonJK , HurvitzSA , MinaLA , RugoHS , LeeKH , GonçalvesA , et al. Talazoparib (TALA) in germline BRCA1/2 (gBRCA1/2)-mutated human epidermal growth factor receptor 2 negative (HER2-) advanced breast cancer (ABC): final overall survival (OS) results from randomized phase 3 EMBRACA trial. Cancer Research2020;80(Suppl 16):Abstract no. CT071. LittonJK , RugoHS , EttlJ , HurvitzSA , GonçalvesA , LeeKH , et al. Talazoparib in patients with advanced breast cancer and a germline BRCA mutation. New England Journal of Medicine2018;379(8):753-63. MartínM , EiermannW , RugoHS , EttlJ , HurvitzSA , GonçalvesA , et al. EMBRACA: Comparison of efficacy and safety of talazoparib (TALA) and physician's choice of therapy (PCT) in patients (pts) with advanced breast cancer (aBC), a germline BRCA1/2 mutation (gBRCAm), and prior platinum treatment. Annals of Oncology2018;29(Suppl 8):viii96. MinaL , LeeKH , GoncalvesA , WoodwardN , HurvitzSA , DiabS , et al. EMBRACA: efficacy and safety of talazoparib or physician's choice of therapy in patients with advanced breast cancer and a germline BRCA1/2 mutation: a regional analysis. Cancer Research2019;79(Suppl 4):Abstract nr P6-18-12. QuekR , BhattacharyyaH , HurvitzS , GoncalvesA , EttlJ , RugoH . Patient-reported outcomes in patients with HER2-advanced breast cancer and a germline BRCA1/2 mutation receiving talazoparib versus physician's choice chemotherapy: a focus on EMBRACA age subgroups. Journal of Managed Care and Specialty Pharmacy2019;25(Suppl 10A):S37-8. QuekRGW , BhattacharyyaH , GoncalvesA , RugoHS , HurvitzSA , EttlJ . Pcn491 Patient reported outcomes (PRO) of talazoparib (TALA) versus physician's choice of chemotherapy (PCT) in patients (pts) with advanced breast cancer (aBC) and a germline BRCA (gBRCa) mutation: a focus on Embraca pts with/without prior chemotherapy (CT) subgroups. Value in Health2019;22(Suppl 3):S532. RugoHS , EttlJ , HurvitzSA , GoncalvesA , LeeKH , FehrenbacherL , et al. Outcomes in clinically relevant patient subgroups from the EMBRACA study: talazoparib vs physician's choice standard-of-care chemotherapy. Journal of the National Cancer Institute Cancer Spectrum2020;4(1):pkz085. RugoHS , EttlJ , WoodwardNE , HurvitzSA , GoncalvesA , LeeKH , et al. EMBRACA: efficacy outcomes in clinically relevant subgroups comparing talazoparib (TALA), an oral poly ADP ribose polymerase (PARP) inhibitor, to physician's choice of therapy (PCT) in patients with advanced breast cancer and a germline BRCA mutation. Journal of Clinical Oncology2018;36(Suppl 15):1069. RugoHS , QuekR , EttlJ , HurvitzSA , BhattacharyyaH , HannahAL , et al. Patient-reported outcomes (PRO) in patients (pts) with advanced breast cancer and a germline BRCA1/2 mutation (gBRCAm) receiving talazoparib (TALA) vs physician’s choice chemotherapy treatment (PCT): a focus on the EMBRACA triple negative (TNBC) subpopulation. Annals of Oncology2018;29(Suppl 8):viii91. YuY , ElmeliegyM , LittonJK , TudorIC , CzibereA , ZhengJ , et al. Exposure-efficacy progression-free survival (PFS) analyses of breast cancer patients with germline BRCA1/2 mutations receiving talazoparib in the phase III EMBRACA trial. Annals of Oncology2018;29(Suppl 8):viii97. YuY , ElmeliegyM , LittonJK , TudorIC , CzibereA , ZhengJ , et al. Talazoparib exposure-efficacy analysis in patients with advanced breast cancer and germline BRCA1/2 mutations in the EMBRACA trial. Journal of Clinical Pharmacology2020;60(10):1324-33. ">EMBRACA</a> results, in October 2018. The third PARP inhibitor identified by our review, veliparib, has not yet been approved but the complete results of <a href="./references#CD011395-bbs2-0003" title="ArunBK , HanHS , KaufmanB , WildiersH , FriedlanderM , AyoubJP , et al. First-line veliparib plus carboplatin/paclitaxel in patients with HER2-negative advanced/metastatic gBRCA-associated breast cancer: planned subgroup analysis from the phase 3 BROCADE3 trial. Cancer Research2020;80(Suppl 4):Abstract nr PD4-01. AyoubJP , FriedlanderML , DierasVC , WildiersH , ArunB , HanHS , et al. Veliparib plus carboplatin-paclitaxel in patients with HER2-negative advanced/metastatic gBRCA-associated breast cancer: results in hormone receptor-positive and triple-negative breast cancer subgroups from the phase III BROCADE3 trial. Annals of Oncology2020;31(Suppl 2):S65. DierasV , HanH , KaufmanB , WildiersH , FriedlanderM , AyoubJ , et al. A Phase 3 randomized, placebo-controlled trial of carboplatin and paclitaxel with or without the PARP inhibitor veliparib (ABT-888) in HER2-negative metastatic or locally advanced unresectable BRCA-associated breast cancer. Annals of Oncology2019;30(Suppl 5):v851-v934. ">BROCADE 3</a> are yet to be formally published. </p> </section> <section id="CD011395-sec-0061"> <h3 class="title" id="CD011395-sec-0061">Quality of the evidence</h3> <p>Although only five studies were included for meta‐analysis and only three of these were phase 3 studies, there were a large number of patients (1474) and we believe that the conclusions drawn are clinically meaningful. We acknowledge the different choice of PARP inhibitors and difference in study design. However, there was homogeneity of results and minimal statistical heterogeneity, with each study individually concluding PARP inhibitors are superior to their comparator treatments and our meta‐analysis adds weight to this.<br/><br/>The results included in this systematic review allow a robust conclusion regarding the primary objective addressed in the overview, that of overall survival benefit in advanced/metastatic HER2‐negative, BRCA germline mutated breast cancer patients. Similar high‐quality evidence was available for the outcome of PFS. See <a href="./full#CD011395-tbl-0001">summary of findings Table 1</a>. </p> <p>Lower quality evidence was available for the outcomes of response rates and grade 3 to 4 overall toxicity. We considered the quality of evidence for response rates to be low and was downgraded due to inconsistency. We considered the quality of evidence for grade 3 to 4 overall toxicity to be moderate and was downgraded due to imprecision. See <a href="./full#CD011395-tbl-0001">summary of findings Table 1</a>. </p> </section> <section id="CD011395-sec-0062"> <h3 class="title" id="CD011395-sec-0062">Potential biases in the review process</h3> <p>A thorough search was conducted to find all relevant studies including searching relevant databases and handsearching other resources. Relevant data were obtained from published sources, as well as an unpublished source in the case of <a href="./references#CD011395-bbs2-0003" title="ArunBK , HanHS , KaufmanB , WildiersH , FriedlanderM , AyoubJP , et al. First-line veliparib plus carboplatin/paclitaxel in patients with HER2-negative advanced/metastatic gBRCA-associated breast cancer: planned subgroup analysis from the phase 3 BROCADE3 trial. Cancer Research2020;80(Suppl 4):Abstract nr PD4-01. AyoubJP , FriedlanderML , DierasVC , WildiersH , ArunB , HanHS , et al. Veliparib plus carboplatin-paclitaxel in patients with HER2-negative advanced/metastatic gBRCA-associated breast cancer: results in hormone receptor-positive and triple-negative breast cancer subgroups from the phase III BROCADE3 trial. Annals of Oncology2020;31(Suppl 2):S65. DierasV , HanH , KaufmanB , WildiersH , FriedlanderM , AyoubJ , et al. A Phase 3 randomized, placebo-controlled trial of carboplatin and paclitaxel with or without the PARP inhibitor veliparib (ABT-888) in HER2-negative metastatic or locally advanced unresectable BRCA-associated breast cancer. Annals of Oncology2019;30(Suppl 5):v851-v934. ">BROCADE 3</a>. We attempted to obtain complete data by contacting the authors, including data on overall survival from <a href="./references#CD011395-bbs2-0005" title="KummarS , WadeJL , OzaAM , SullivanD , ChenAP , GandaraDR , et al. Randomized phase II trial of cyclophosphamide and the oral poly (ADP-ribose) polymerase inhibitor veliparib in patients with recurrent, advanced triple-negative breast cancer. Investigational New Drugs2016;34(3):355–63. ">Kummar 2016</a>. Methods used for the meta‐analysis were standard and unlikely to have introduced bias. We believe our systematic review and meta‐analysis has a low risk of bias. </p> </section> <section id="CD011395-sec-0063"> <h3 class="title" id="CD011395-sec-0063">Agreements and disagreements with other studies or reviews</h3> <p>There are a number of other meta‐analyses looking at PARP inhibitors in all tumour types but very few meta‐analyses looking at the role of PARP inhibitors in breast cancer specifically.<br/><br/>We note that Bao and colleagues (<a href="./references#CD011395-bbs2-0017" title="BaoZ , CaoC , GengX , TianB , WuY , ZhangC , et al. Effectiveness and safety of poly (ADP-ribose) polymerase inhibitors in cancer therapy: a systematic review and meta-analysis. Oncotarget2016;7(7):7629.">Bao 2016</a>) published a meta‐analysis on the effectiveness and safety of PARP inhibitors in cancer therapy and concluded that PARP inhibitors do well in improving PFS with little toxicity, especially in patients with BRCA deficiency. However, no significant difference in overall survival between the PARP inhibitors and controls, even in the BRCA mutation group, was found. This meta‐analysis did not include the studies we have included for our meta‐analysis. In fact, the only studies that were included looking at PARP inhibitors in breast cancer specifically were two studies using iniparib (<a href="./references#CD011395-bbs2-0009" title="O'ShaughnessyJ , OsborneC , PippenJE , YoffeM , PattD , RochaC , et al. Iniparib plus chemotherapy in metastatic triple-negative breast cancer. New England Journal of Medicine2011;364(3):205–14. ">O'Shaughnessy 2011</a>; <a href="./references#CD011395-bbs2-0010" title="O'ShaughnessyJ , SchwartzbergL , DansoMA , MillerKD , RugoHS , NeubauerM , et al. Phase III study of iniparib plus gemcitabine and carboplatin versus gemcitabine and carboplatin in patients with metastatic triple-negative breast cancer. Journal of Clinical Oncology2014;32(34):3840-7. ">O'Shaughnessy 2014</a>), which has since been disproved to be a PARP inhibitor mechanistically (<a href="./references#CD011395-bbs2-0027" title="LiuX , ShiY , MaggDX , PalmaJP , PattersonMJ , EllisPA , et al. Iniparib nonselectively modifies cysteine-containing proteins in tumor cells and is not a bona fide PARP inhibitor. Clinical Cancer Research2012;18(2):510-23.">Liu 2012</a>).<br/><br/>We note that Poggio and colleagues published a meta‐analysis on single‐agent PARP inhibitors for the treatment of patients with BRCA‐mutated HER 2‐negative metastatic breast cancer (<a href="./references#CD011395-bbs2-0033" title="PoggioF , BruzzoneM , CeppiM , ConteB , MartelS , MaurerC , et al. Single-agent PARP inhibitors for the treatment of patients with BRCA-mutated HER2-negative metastatic breast cancer: a systematic review and meta-analysis. European Society for Medical Oncology Open2018;3(4):e000361.">Poggio 2018</a>) and included two RCTs (<a href="./references#CD011395-bbs2-0004" title="DiabS , RugoHS , MinaLA , PuhallaS , MahtaniRL , HenryNL , et al. Efficacy and safety of talazoparib (TALA) or physician's choice of therapy (PCT) in United States patients (pts) with HER2- germline BRCA1/2-mutated (gBRCAm) locally advanced/metastatic breast cancer (LA/MBC) in the EMBRACA study. Journal of Clinical Oncology2019;37(Suppl 15):1044. EiermannW , RugoHS , DiabS , EttlJ , HurvitzSA , GoncalvesA , et al. Analysis of germline BRCA1/2 mutated (g BRCAmut) hormone receptor-positive (HR+) and triple-negative breast cancer (TNBC) treated with talazoparib (TALA). Journal of Clinical Oncology2018;36(Suppl 15):1070. EttlJ , HurvitzSA , RugoHS , LeeKH , MinaLA , WoodwardNE , et al. Outcomes of talazoparib (TALA) versus physician's choice of chemotherapy (PCT) in patients (pts) with advanced breast cancer (ABC) and a germline BRCA (gBRCA) mutation by line of chemotherapy (CT) in the EMBRACA trial. Journal of Clinical Oncology2019;37(Suppl 15):1071. EttlJ , QuekRG , BhattacharyyaH , RugoHS , HurvitzSA , GonçalvesA . Patient Reported Outcomes (PRO) in patients (pts) with HER2-advanced breast cancer (ABC) and a germline BRCA1/2 mutation (gBRCAm) receiving talazoparib (TALA) vs physician’s choice chemotherapy (PCT) in the EMBRACA trial: a focus on subgroups with/without visceral disease. Annals of Oncology2019;30(Suppl 5):v129–30. EttlJ , QuekRG , HurvitzSA , GoncalvesA , TudorIC , RugoHS . Hospitalization and supportive care medication (SCM) utilisation in patients (pts) with advanced breast cancer (ABC) and a germline BRCA1/2 mutation (gBRCAm) in EMBRACA. Annals of Oncology2019;30(Suppl 3):iii52. EttlJ , QuekRG , LeeKH , RugoHS , HurvitzS , GonçalvesA , et al. Quality of life with talazoparib versus physician’s choice of chemotherapy in patients with advanced breast cancer and germline BRCA1/2 mutation: patient-reported outcomes from the EMBRACA phase III trial. Annals of Oncology2018;29(9):1939-47. FaschingPA , QuekRG , BhattacharyyaH , HurvitzSA , RugoHS , EttlJ . Impact of objective response (OR) on patient-reported outcomes (PRO) in patients (pts) with advanced breast cancer (ABC) and a germline BRCA1/2 (gBRCA) mutation in the phase III EMBRACA trial. Annals of Oncology2019;30(Suppl 3):iii49. GonçalvesA , EiermannW , RugoHS , EttlJ , HurvitzSA , YerushalmiR , et al. EMBRACA: Efficacy and safety in comparing talazoparib (TALA) with physician's choice of therapy (PCT) in patients (pts) with advanced breast cancer (aBC) and a germline BRCA mutation (gBRCAm); BRCA1/BRCA2 subgroup analysis. Annals of Oncology2018;29(Suppl 8):viii96–7. GoncalvesA , QuekRGW , BhattacharyyaH , EttlJ , HurvitzSA , RugoHS . Patient-reported outcomes (PRO) in patients (pts) with Her2-advanced breast cancer (ABC) receiving talazoparib (TALA) vs physician's choice chemotherapy (PCT): a focus on EMBRACA germline BRCA1 and BRCA2 mutation (gBRCA1/2m) subgroups. Breast2019;48(Suppl 2):S71. HurvitzSA , GoncalvesA , RugoHS , LeeKH , FehrenbacherL , MinaLA , et al. Talazoparib in patients with a germline BRCA-mutated advanced breast cancer: detailed safety analyses from the phase III EMBRACA Trial. Oncologist2019;25(3):e439-50. LeeKH , KimSB , SohnJ , GoodwinA , UsariT , LanzaloneS , et al. Talazoparib (TALA) vs physician’s choice of chemotherapy (PCT) in Asian patients (Pts) with HER2- advanced breast cancer (ABC) and a germline BRCA1/2 mutation (gBRCA1/2mut): data from phase III EMBRACA. Annals of Oncology2019;30(9):ix14. LittonJ , EttlJ , HurvitzSA , MinaLA , RugoHS , LeeKH , et al. A phase 3, open-label, randomized, 2-arm international study of the oral dual PARP inhibitor talazoparib in germline BRCA mutation subjects with locally advanced and/or metastatic breast cancer (EMBRACA). Cancer Research2017;77(Suppl 4):Abstract nr OT2-01-13. LittonJ , RugoHS , EttlJ , HurvitzS , GoncalvesA , LeeKH , et al. EMBRACA: a phase 3 trial comparing talazoparib, an oral PARP inhibitor, to physicianʼs choice of therapy in patients with advanced breast cancer and a germline BRCA mutation [abstract]. In: San Antonio Breast Cancer Symposium; 2017 Dec 5-9; San Antonio (TX). San Antonio (TX), 2017. LittonJK , HurvitzSA , MinaLA , RugoHS , LeeKH , GonçalvesA , et al. Talazoparib (TALA) in germline BRCA1/2 (gBRCA1/2)-mutated human epidermal growth factor receptor 2 negative (HER2-) advanced breast cancer (ABC): final overall survival (OS) results from randomized phase 3 EMBRACA trial. Cancer Research2020;80(Suppl 16):Abstract no. CT071. LittonJK , RugoHS , EttlJ , HurvitzSA , GonçalvesA , LeeKH , et al. Talazoparib in patients with advanced breast cancer and a germline BRCA mutation. New England Journal of Medicine2018;379(8):753-63. MartínM , EiermannW , RugoHS , EttlJ , HurvitzSA , GonçalvesA , et al. EMBRACA: Comparison of efficacy and safety of talazoparib (TALA) and physician's choice of therapy (PCT) in patients (pts) with advanced breast cancer (aBC), a germline BRCA1/2 mutation (gBRCAm), and prior platinum treatment. Annals of Oncology2018;29(Suppl 8):viii96. MinaL , LeeKH , GoncalvesA , WoodwardN , HurvitzSA , DiabS , et al. EMBRACA: efficacy and safety of talazoparib or physician's choice of therapy in patients with advanced breast cancer and a germline BRCA1/2 mutation: a regional analysis. Cancer Research2019;79(Suppl 4):Abstract nr P6-18-12. QuekR , BhattacharyyaH , HurvitzS , GoncalvesA , EttlJ , RugoH . Patient-reported outcomes in patients with HER2-advanced breast cancer and a germline BRCA1/2 mutation receiving talazoparib versus physician's choice chemotherapy: a focus on EMBRACA age subgroups. Journal of Managed Care and Specialty Pharmacy2019;25(Suppl 10A):S37-8. QuekRGW , BhattacharyyaH , GoncalvesA , RugoHS , HurvitzSA , EttlJ . Pcn491 Patient reported outcomes (PRO) of talazoparib (TALA) versus physician's choice of chemotherapy (PCT) in patients (pts) with advanced breast cancer (aBC) and a germline BRCA (gBRCa) mutation: a focus on Embraca pts with/without prior chemotherapy (CT) subgroups. Value in Health2019;22(Suppl 3):S532. RugoHS , EttlJ , HurvitzSA , GoncalvesA , LeeKH , FehrenbacherL , et al. Outcomes in clinically relevant patient subgroups from the EMBRACA study: talazoparib vs physician's choice standard-of-care chemotherapy. Journal of the National Cancer Institute Cancer Spectrum2020;4(1):pkz085. RugoHS , EttlJ , WoodwardNE , HurvitzSA , GoncalvesA , LeeKH , et al. EMBRACA: efficacy outcomes in clinically relevant subgroups comparing talazoparib (TALA), an oral poly ADP ribose polymerase (PARP) inhibitor, to physician's choice of therapy (PCT) in patients with advanced breast cancer and a germline BRCA mutation. Journal of Clinical Oncology2018;36(Suppl 15):1069. RugoHS , QuekR , EttlJ , HurvitzSA , BhattacharyyaH , HannahAL , et al. Patient-reported outcomes (PRO) in patients (pts) with advanced breast cancer and a germline BRCA1/2 mutation (gBRCAm) receiving talazoparib (TALA) vs physician’s choice chemotherapy treatment (PCT): a focus on the EMBRACA triple negative (TNBC) subpopulation. Annals of Oncology2018;29(Suppl 8):viii91. YuY , ElmeliegyM , LittonJK , TudorIC , CzibereA , ZhengJ , et al. Exposure-efficacy progression-free survival (PFS) analyses of breast cancer patients with germline BRCA1/2 mutations receiving talazoparib in the phase III EMBRACA trial. Annals of Oncology2018;29(Suppl 8):viii97. YuY , ElmeliegyM , LittonJK , TudorIC , CzibereA , ZhengJ , et al. Talazoparib exposure-efficacy analysis in patients with advanced breast cancer and germline BRCA1/2 mutations in the EMBRACA trial. Journal of Clinical Pharmacology2020;60(10):1324-33. ">EMBRACA</a>; <a href="./references#CD011395-bbs2-0006" title="DelalogeS , ContePF , ImS , Senkus-KonefkaE , XuB , DomchekSM , et al. OlympiAD: further efficacy outcomes in patients with HER2-negative metastatic breast cancer and a germline BRCA mutation receiving olaparib monotherapy vs standard single-agent chemotherapy treatment of physician’s choice. Annals of Oncology2017;28(Suppl 5):v74-v108. DomchekS , RobsonM , ImS , SenkusE , XuB , MasudaN , et al. Tolerability of olaparib monotherapy versus chemotherapy in patients with HER2-negative metastatic breast cancer and a germline BRCA mutation: OlympiAD. Cancer Research2018;78(Suppl 4):Abstract nr P5-21-12. ImSA , XuB , LiW , RobsonM , OuyangQ , YehDC , et al. Olaparib monotherapy for Asian patients with a germline BRCA mutation and HER2-negative metastatic breast cancer: OlympiAD randomized trial subgroup analysis. Scientific Reports2020;10(1):8753. ImSA , XuB , LiW , RobsonM , OuyangQ , YehDC , et al. Olaparib monotherapy versus chemotherapy for patients with HER2-negative metastatic breast cancer and a germline BRCA mutation: Asian subgroup analysis from the phase III OlympiAD trial. Cancer Research2018;78(Suppl 4):Abstract nr P5-21-13. MerensC , BannisterW , BergnerS , HettleR , McCreaC , McCutcheonS , et al. Impact of olaparib versus chemotherapy on the use of strong pain medications in gBRCA-mutated HER2-negative metastatic breast cancer and associated patient reported outcomes. Cancer Research2020;80(Suppl 4):Abstract nr P6-13-05. RobsonM , HettleR , DegboeA , SaundersO , CainT , KilvertH , et al. Estimating the health state utility of patients with HER2–gBRCA+ metastatic breast cancer treated with olaparib or chemotherapy via a mapping analysis of EORTC QLQ-C30 data collected in the Olympiad clinical trial. Value in Health2018;21(Suppl 1):S12. RobsonM , ImSA , SenkusE , XuB , DomchekS , MasudaN , et al. OlympiAD extended follow-up for overall survival and safety: olaparib versus chemotherapy treatment of physician’s choice in patients with a germline BRCA mutation and HER2-negative metastatic breast cancer. Cancer Research2020;80(Suppl 4):Abstract nr PD4-03. RobsonM , ImSA , SenkusE , XuB , DomchekSM , MasudaN , et al. Olaparib for metastatic breast cancer in patients with a germline BRCA mutation. New England Journal of Medicine2017;377(6):523-33. RobsonM , RuddyKJ , ImSA , SenkusE , XuB , DomchekSM , et al. Patient-reported outcomes in patients with a germline BRCA mutation and HER2-negative metastatic breast cancer receiving olaparib versus chemotherapy in the OlympiAD trial. European Journal of Cancer2019;120:20-30. RobsonM , RuddyKJ , ImSA , Senkus-KonefkaE , XuB , DomchekSM , et al. OlympiAD: health-related quality of life (HRQoL) in patients with HER2-negative metastatic breast cancer (mBC) and a germline BRCA mutation (gBRCAm) receiving olaparib monotherapy vs standard single-agent chemotherapy treatment of physician’s choice (TPC). Annals of Oncology2017;28(Suppl 5):v74-v108. RobsonME , ImSA , SenkusE , XuB , DomchekS , MasudaN , et al. Abstract CT038: OlympiAD final overall survival: olaparib versus chemotherapy treatment of physician's choice (TPC) in patients with HER2-negative metastatic breast cancer (mBC) and a germline BRCA mutation (gBRCAm). American Association for Cancer Research2018;78(Suppl 13):CT038. RobsonME , ImSA , SenkusE , XuB , DomchekSM , MasudaN , et al. OlympiAD: phase III trial of olaparib monotherapy versus chemotherapy for patients (pts) with HER2-negative metastatic breast cancer (mBC) and a germline BRCA mutation (gBRCAm). Journal of Clinical Oncology2017;35(Suppl 18):LBA4-LBA4. RobsonME , RuddyKJ , ImSA , Senkus-KonefkaE , XuB , DomchekSM , et al. EORTC QLQ-C30 (QLQ-C30) symptoms in patients (pts) with HER2-negative metastatic breast cancer (mBC) and a germline BRCA mutation (gBRCAm) receiving olaparib vs chemotherapy treatment of physician’s choice (TPC) in OlympiAD. Journal of Clinical Oncology2018;36(Suppl 15):1045. RobsonME , TungN , ConteP , ImSA , SenkusE , XuB , et al. OlympiAD final overall survival and tolerability results: olaparib versus chemotherapy treatment of physician’s choice in patients with a germline BRCA mutation and HER2-negative metastatic breast cancer. Annals of Oncology2019;30(4):558-66. Senkus-KonefkaE , DomchekSM , ImSA , XuB , ArmstrongA , MasudaN , et al. Subgroup analysis of olaparib monotherapy versus chemotherapy by hormone receptor and BRCA mutation status in patients with HER2-negative metastatic breast cancer and a germline BRCA mutation: OlympiAD. European Journal of Cancer2018;92:S19-20. TungNM , ImSA , Senkus-KonefkaE , XuB , DomchekSM , MasudaN , et al. Olaparib versus chemotherapy treatment of physician’s choice in patients with a germline BRCA mutation and HER2-negative metastatic breast cancer (OlympiAD): efficacy in patients with visceral metastases. Journal of Clinical Oncology2018;36(Suppl 15):1053. ">OLYMPIAD</a>) for meta‐analysis. We agree with their conclusions that PARP inhibitors were associated with significantly improved PFS and response rates. They found no difference in overall survival when analysing only these two studies. Also, use of single‐agent PARP inhibitors was associated with a significantly increased risk of anaemia and any grade of headache, but a reduced risk of neutropenia and any grade of palmar‐plantar erythrodysesthesia syndrome, as compared with chemotherapy. This study has similar methodology to ours, however, we are investigating a larger group and therefore have relevant findings for more breast cancer patients.<br/><br/>There is growing evidence regarding the role of immune checkpoint inhibitors, especially in triple‐negative metastatic breast cancer. Impassion130 (<a href="./references#CD011395-bbs2-0035" title="SchmidP , AdamsS , RugoHS , SchneeweissA , BarriosCH , IwataH , et al. Atezolizumab and nab-paclitaxel in advanced triple-negative breast cancer. New England Journal of Medicine2018;379(22):2108-21.">Schmid 2018</a>) showed a modest but statistically significant difference in progression‐free survival in favour of combination atezolizumab with nabpaclitaxel compared with nabpaclitaxel alone. However, the question remains whether PARP inhibitors or checkpoint inhibitors are more effective in metastatic BRCA mutated triple‐negative patients, or whether a combination may be superior.<br/><br/>From the current information available, including the addition of our systematic review results, it remains difficult to know which PARP inhibitor to choose for which patient. There are also two other PARP inhibitors on the market, niraparib and rucaparib, and these are under investigation for breast cancer patients. The phase 3 <a href="./references#CD011395-bbs2-0001" title="BalmanaJ , TryfonidisK , AudehW , GouliotiT , SlaetsL , AgarwalS , et al. A phase III, randomized, open-label, multicenter, controlled trial of niraparib versus physician's choice in previously-treated, HER2-negative, germline BRCA mutation-positive breast cancer patients. An EORTC-BIG intergroup study (BRAVO study). Cancer Research2016;76(Suppl 4):Abstract nr OT1-03-05. ">BRAVO</a> trial, assessing single‐agent niraparib in locally advanced or metastatic, HER2‐negative, BRCA1/2‐mutated breast cancer, ended prematurely (<a href="./references#CD011395-bbs2-0001" title="BalmanaJ , TryfonidisK , AudehW , GouliotiT , SlaetsL , AgarwalS , et al. A phase III, randomized, open-label, multicenter, controlled trial of niraparib versus physician's choice in previously-treated, HER2-negative, germline BRCA mutation-positive breast cancer patients. An EORTC-BIG intergroup study (BRAVO study). Cancer Research2016;76(Suppl 4):Abstract nr OT1-03-05. ">BRAVO</a>). But with more studies underway and the minimal chance of head‐to‐head studies being performed, it will likely come down to physician preference and drug availability. </p> </section> </section> </section> <div class="figures-list"> <div class="figure" id="CD011395-fig-0001"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD011395.pub2/media/CDSR/CD011395/urn:x-wiley:14651858:media:CD011395:CD011395-FIG-01" target="_blank"><b></b></a></p> </div><img alt="Study flow diagram." data-id="CD011395-fig-0001" src="/cdsr/doi/10.1002/14651858.CD011395.pub2/media/CDSR/CD011395/image_n/nCD011395-FIG-01.png"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD011395.pub2/media/CDSR/CD011395/image_t/tCD011395-FIG-01.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Figure 1</div> <div class="figure-caption"> <p>Study flow diagram.</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD011395.pub2/full#CD011395-fig-0001">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD011395.pub2/media/CDSR/CD011395/image_n/nCD011395-FIG-01.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD011395-fig-0002"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD011395.pub2/media/CDSR/CD011395/urn:x-wiley:14651858:media:CD011395:CD011395-FIG-02" target="_blank"><b></b></a></p> </div><img alt="Risk of bias summary: review authors' judgements about each risk of bias item for each included study." data-id="CD011395-fig-0002" src="/cdsr/doi/10.1002/14651858.CD011395.pub2/media/CDSR/CD011395/image_n/nCD011395-FIG-02.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD011395.pub2/media/CDSR/CD011395/image_t/tCD011395-FIG-02.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Figure 2</div> <div class="figure-caption"> <p>Risk of bias summary: review authors' judgements about each risk of bias item for each included study. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD011395.pub2/full#CD011395-fig-0002">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD011395.pub2/media/CDSR/CD011395/image_n/nCD011395-FIG-02.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD011395-fig-0003"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD011395.pub2/media/CDSR/CD011395/urn:x-wiley:14651858:media:CD011395:CD011395-FIG-03" target="_blank"><b></b></a></p> </div><img alt="Forest plot of comparison: 1 PARPi‐containing regimen vs non‐PARPi regimen, outcome: 1.1 Overall survival" data-id="CD011395-fig-0003" src="/cdsr/doi/10.1002/14651858.CD011395.pub2/media/CDSR/CD011395/image_n/nCD011395-FIG-03.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD011395.pub2/media/CDSR/CD011395/image_t/tCD011395-FIG-03.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Figure 3</div> <div class="figure-caption"> <p>Forest plot of comparison: 1 PARPi‐containing regimen vs non‐PARPi regimen, outcome: 1.1 Overall survival </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD011395.pub2/full#CD011395-fig-0003">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD011395.pub2/media/CDSR/CD011395/image_n/nCD011395-FIG-03.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD011395-fig-0004"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD011395.pub2/media/CDSR/CD011395/urn:x-wiley:14651858:media:CD011395:CD011395-FIG-04" target="_blank"><b></b></a></p> </div><img alt="Forest plot of comparison: 1 PARPi‐containing regimen vs non‐PARPi regimen, outcome: 1.2 Progression‐free survival" data-id="CD011395-fig-0004" src="/cdsr/doi/10.1002/14651858.CD011395.pub2/media/CDSR/CD011395/image_n/nCD011395-FIG-04.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD011395.pub2/media/CDSR/CD011395/image_t/tCD011395-FIG-04.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Figure 4</div> <div class="figure-caption"> <p>Forest plot of comparison: 1 PARPi‐containing regimen vs non‐PARPi regimen, outcome: 1.2 Progression‐free survival </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD011395.pub2/full#CD011395-fig-0004">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD011395.pub2/media/CDSR/CD011395/image_n/nCD011395-FIG-04.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD011395-fig-0005"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD011395.pub2/media/CDSR/CD011395/urn:x-wiley:14651858:media:CD011395:CD011395-FIG-05" target="_blank"><b></b></a></p> </div><img alt="Forest plot of comparison: 1 PARPi‐containing regimen vs non‐PARPi regimen, outcome: 1.3 Response rate" data-id="CD011395-fig-0005" src="/cdsr/doi/10.1002/14651858.CD011395.pub2/media/CDSR/CD011395/image_n/nCD011395-FIG-05.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD011395.pub2/media/CDSR/CD011395/image_t/tCD011395-FIG-05.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Figure 5</div> <div class="figure-caption"> <p>Forest plot of comparison: 1 PARPi‐containing regimen vs non‐PARPi regimen, outcome: 1.3 Response rate </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD011395.pub2/full#CD011395-fig-0005">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD011395.pub2/media/CDSR/CD011395/image_n/nCD011395-FIG-05.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD011395-fig-0006"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD011395.pub2/media/CDSR/CD011395/urn:x-wiley:14651858:media:CD011395:CD011395-FIG-06" target="_blank"><b></b></a></p> </div><img alt="Forest plot of comparison: 1 PARPi‐containing regimen vs non‐PARPi regimen, outcome: 1.4 Grade ≥ 3 AEs" data-id="CD011395-fig-0006" src="/cdsr/doi/10.1002/14651858.CD011395.pub2/media/CDSR/CD011395/image_n/nCD011395-FIG-06.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD011395.pub2/media/CDSR/CD011395/image_t/tCD011395-FIG-06.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Figure 6</div> <div class="figure-caption"> <p>Forest plot of comparison: 1 PARPi‐containing regimen vs non‐PARPi regimen, outcome: 1.4 Grade ≥ 3 AEs </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD011395.pub2/full#CD011395-fig-0006">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD011395.pub2/media/CDSR/CD011395/image_n/nCD011395-FIG-06.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD011395-fig-0007"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD011395.pub2/media/CDSR/CD011395/urn:x-wiley:14651858:media:CD011395:CD011395-CMP-001.01" target="_blank"><b></b></a></p> </div><img alt="Comparison 1: PARPi‐containing regimen vs non‐PARPi regimen, Outcome 1: Overall survival" data-id="CD011395-fig-0007" src="/cdsr/doi/10.1002/14651858.CD011395.pub2/media/CDSR/CD011395/image_n/nCD011395-CMP-001.01.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD011395.pub2/media/CDSR/CD011395/image_t/tCD011395-CMP-001.01.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.1</div> <div class="figure-caption"> <p>Comparison 1: PARPi‐containing regimen vs non‐PARPi regimen, Outcome 1: Overall survival</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD011395.pub2/references#CD011395-fig-0007">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD011395.pub2/media/CDSR/CD011395/image_n/nCD011395-CMP-001.01.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD011395-fig-0008"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD011395.pub2/media/CDSR/CD011395/urn:x-wiley:14651858:media:CD011395:CD011395-CMP-001.02" target="_blank"><b></b></a></p> </div><img alt="Comparison 1: PARPi‐containing regimen vs non‐PARPi regimen, Outcome 2: Progression‐free survival" data-id="CD011395-fig-0008" src="/cdsr/doi/10.1002/14651858.CD011395.pub2/media/CDSR/CD011395/image_n/nCD011395-CMP-001.02.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD011395.pub2/media/CDSR/CD011395/image_t/tCD011395-CMP-001.02.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.2</div> <div class="figure-caption"> <p>Comparison 1: PARPi‐containing regimen vs non‐PARPi regimen, Outcome 2: Progression‐free survival </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD011395.pub2/references#CD011395-fig-0008">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD011395.pub2/media/CDSR/CD011395/image_n/nCD011395-CMP-001.02.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD011395-fig-0009"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD011395.pub2/media/CDSR/CD011395/urn:x-wiley:14651858:media:CD011395:CD011395-CMP-001.03" target="_blank"><b></b></a></p> </div><img alt="Comparison 1: PARPi‐containing regimen vs non‐PARPi regimen, Outcome 3: Progression‐free survival: BRCA" data-id="CD011395-fig-0009" src="/cdsr/doi/10.1002/14651858.CD011395.pub2/media/CDSR/CD011395/image_n/nCD011395-CMP-001.03.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD011395.pub2/media/CDSR/CD011395/image_t/tCD011395-CMP-001.03.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.3</div> <div class="figure-caption"> <p>Comparison 1: PARPi‐containing regimen vs non‐PARPi regimen, Outcome 3: Progression‐free survival: BRCA </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD011395.pub2/references#CD011395-fig-0009">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD011395.pub2/media/CDSR/CD011395/image_n/nCD011395-CMP-001.03.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD011395-fig-0010"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD011395.pub2/media/CDSR/CD011395/urn:x-wiley:14651858:media:CD011395:CD011395-CMP-001.04" target="_blank"><b></b></a></p> </div><img alt="Comparison 1: PARPi‐containing regimen vs non‐PARPi regimen, Outcome 4: Progression‐free survival: receptor status" data-id="CD011395-fig-0010" src="/cdsr/doi/10.1002/14651858.CD011395.pub2/media/CDSR/CD011395/image_n/nCD011395-CMP-001.04.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD011395.pub2/media/CDSR/CD011395/image_t/tCD011395-CMP-001.04.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.4</div> <div class="figure-caption"> <p>Comparison 1: PARPi‐containing regimen vs non‐PARPi regimen, Outcome 4: Progression‐free survival: receptor status </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD011395.pub2/references#CD011395-fig-0010">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD011395.pub2/media/CDSR/CD011395/image_n/nCD011395-CMP-001.04.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD011395-fig-0011"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD011395.pub2/media/CDSR/CD011395/urn:x-wiley:14651858:media:CD011395:CD011395-CMP-001.05" target="_blank"><b></b></a></p> </div><img alt="Comparison 1: PARPi‐containing regimen vs non‐PARPi regimen, Outcome 5: Progression‐free survival: prior chemo for advanced breast cancer" data-id="CD011395-fig-0011" src="/cdsr/doi/10.1002/14651858.CD011395.pub2/media/CDSR/CD011395/image_n/nCD011395-CMP-001.05.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD011395.pub2/media/CDSR/CD011395/image_t/tCD011395-CMP-001.05.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.5</div> <div class="figure-caption"> <p>Comparison 1: PARPi‐containing regimen vs non‐PARPi regimen, Outcome 5: Progression‐free survival: prior chemo for advanced breast cancer </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD011395.pub2/references#CD011395-fig-0011">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD011395.pub2/media/CDSR/CD011395/image_n/nCD011395-CMP-001.05.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD011395-fig-0012"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD011395.pub2/media/CDSR/CD011395/urn:x-wiley:14651858:media:CD011395:CD011395-CMP-001.06" target="_blank"><b></b></a></p> </div><img alt="Comparison 1: PARPi‐containing regimen vs non‐PARPi regimen, Outcome 6: Progression‐free survival: prior platinum exposure" data-id="CD011395-fig-0012" src="/cdsr/doi/10.1002/14651858.CD011395.pub2/media/CDSR/CD011395/image_n/nCD011395-CMP-001.06.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD011395.pub2/media/CDSR/CD011395/image_t/tCD011395-CMP-001.06.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.6</div> <div class="figure-caption"> <p>Comparison 1: PARPi‐containing regimen vs non‐PARPi regimen, Outcome 6: Progression‐free survival: prior platinum exposure </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD011395.pub2/references#CD011395-fig-0012">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD011395.pub2/media/CDSR/CD011395/image_n/nCD011395-CMP-001.06.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD011395-fig-0013"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD011395.pub2/media/CDSR/CD011395/urn:x-wiley:14651858:media:CD011395:CD011395-CMP-001.07" target="_blank"><b></b></a></p> </div><img alt="Comparison 1: PARPi‐containing regimen vs non‐PARPi regimen, Outcome 7: Response rate" data-id="CD011395-fig-0013" src="/cdsr/doi/10.1002/14651858.CD011395.pub2/media/CDSR/CD011395/image_n/nCD011395-CMP-001.07.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD011395.pub2/media/CDSR/CD011395/image_t/tCD011395-CMP-001.07.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.7</div> <div class="figure-caption"> <p>Comparison 1: PARPi‐containing regimen vs non‐PARPi regimen, Outcome 7: Response rate</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD011395.pub2/references#CD011395-fig-0013">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD011395.pub2/media/CDSR/CD011395/image_n/nCD011395-CMP-001.07.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD011395-fig-0014"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD011395.pub2/media/CDSR/CD011395/urn:x-wiley:14651858:media:CD011395:CD011395-CMP-001.08" target="_blank"><b></b></a></p> </div><img alt="Comparison 1: PARPi‐containing regimen vs non‐PARPi regimen, Outcome 8: Grade ≥ 3 adverse events" data-id="CD011395-fig-0014" src="/cdsr/doi/10.1002/14651858.CD011395.pub2/media/CDSR/CD011395/image_n/nCD011395-CMP-001.08.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD011395.pub2/media/CDSR/CD011395/image_t/tCD011395-CMP-001.08.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.8</div> <div class="figure-caption"> <p>Comparison 1: PARPi‐containing regimen vs non‐PARPi regimen, Outcome 8: Grade ≥ 3 adverse events </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD011395.pub2/references#CD011395-fig-0014">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD011395.pub2/media/CDSR/CD011395/image_n/nCD011395-CMP-001.08.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD011395-fig-0015"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD011395.pub2/media/CDSR/CD011395/urn:x-wiley:14651858:media:CD011395:CD011395-CMP-001.09" target="_blank"><b></b></a></p> </div><img alt="Comparison 1: PARPi‐containing regimen vs non‐PARPi regimen, Outcome 9: Neutropenia (any grade)" data-id="CD011395-fig-0015" src="/cdsr/doi/10.1002/14651858.CD011395.pub2/media/CDSR/CD011395/image_n/nCD011395-CMP-001.09.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD011395.pub2/media/CDSR/CD011395/image_t/tCD011395-CMP-001.09.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.9</div> <div class="figure-caption"> <p>Comparison 1: PARPi‐containing regimen vs non‐PARPi regimen, Outcome 9: Neutropenia (any grade) </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD011395.pub2/references#CD011395-fig-0015">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD011395.pub2/media/CDSR/CD011395/image_n/nCD011395-CMP-001.09.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD011395-fig-0016"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD011395.pub2/media/CDSR/CD011395/urn:x-wiley:14651858:media:CD011395:CD011395-CMP-001.10" target="_blank"><b></b></a></p> </div><img alt="Comparison 1: PARPi‐containing regimen vs non‐PARPi regimen, Outcome 10: Anaemia (any grade)" data-id="CD011395-fig-0016" src="/cdsr/doi/10.1002/14651858.CD011395.pub2/media/CDSR/CD011395/image_n/nCD011395-CMP-001.10.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD011395.pub2/media/CDSR/CD011395/image_t/tCD011395-CMP-001.10.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.10</div> <div class="figure-caption"> <p>Comparison 1: PARPi‐containing regimen vs non‐PARPi regimen, Outcome 10: Anaemia (any grade) </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD011395.pub2/references#CD011395-fig-0016">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD011395.pub2/media/CDSR/CD011395/image_n/nCD011395-CMP-001.10.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD011395-fig-0017"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD011395.pub2/media/CDSR/CD011395/urn:x-wiley:14651858:media:CD011395:CD011395-CMP-001.11" target="_blank"><b></b></a></p> </div><img alt="Comparison 1: PARPi‐containing regimen vs non‐PARPi regimen, Outcome 11: Fatigue (any grade)" data-id="CD011395-fig-0017" src="/cdsr/doi/10.1002/14651858.CD011395.pub2/media/CDSR/CD011395/image_n/nCD011395-CMP-001.11.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD011395.pub2/media/CDSR/CD011395/image_t/tCD011395-CMP-001.11.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.11</div> <div class="figure-caption"> <p>Comparison 1: PARPi‐containing regimen vs non‐PARPi regimen, Outcome 11: Fatigue (any grade) </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD011395.pub2/references#CD011395-fig-0017">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD011395.pub2/media/CDSR/CD011395/image_n/nCD011395-CMP-001.11.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD011395-fig-0018"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD011395.pub2/media/CDSR/CD011395/urn:x-wiley:14651858:media:CD011395:CD011395-CMP-001.12" target="_blank"><b></b></a></p> </div><img alt="Comparison 1: PARPi‐containing regimen vs non‐PARPi regimen, Outcome 12: Thrombocytopenia (any grade)" data-id="CD011395-fig-0018" src="/cdsr/doi/10.1002/14651858.CD011395.pub2/media/CDSR/CD011395/image_n/nCD011395-CMP-001.12.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD011395.pub2/media/CDSR/CD011395/image_t/tCD011395-CMP-001.12.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.12</div> <div class="figure-caption"> <p>Comparison 1: PARPi‐containing regimen vs non‐PARPi regimen, Outcome 12: Thrombocytopenia (any grade) </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD011395.pub2/references#CD011395-fig-0018">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD011395.pub2/media/CDSR/CD011395/image_n/nCD011395-CMP-001.12.svg" target="_blank">Open in new tab</a></div> </div> </div> <div class="tables-list"> <div class="table"> <table class="summary-of-findings framed" data-id="CD011395-tbl-0001"> <div class="table-heading"><span class="table-label">Summary of findings 1.</span> <span class="table-title">PARPi‐containing regimen compared to non‐PARPi regimen for locally advanced or metastatic breast cancer</span></div> <tbody> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="7" rowspan="1" valign="top"> <p><b>PARPi‐containing regimen compared to non‐PARPi regimen for locally advanced or metastatic breast cancer</b> </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="7" rowspan="1" valign="top"> <p><b>Patient or population:</b> locally advanced or metastatic breast cancer<br/><b>Setting:</b> <br/><b>Intervention:</b> PARPi‐containing regimen<br/><b>Comparison:</b> non‐PARPi regimen </p> </td> </tr> <tr class="separated"> <th align="left" class="headercell" colspan="1" rowspan="2" scope="col" valign="top"> <p><b>Outcomes</b> </p> </th> <th align="left" class="headercell table-tint" colspan="2" rowspan="1" scope="col" valign="top"> <p><b>Anticipated absolute effects<sup>*</sup> (95% CI)</b> </p> </th> <th align="left" class="headercell" colspan="1" rowspan="2" scope="col" valign="top"> <p><b>Relative effect<br/>(95% CI)</b> </p> </th> <th align="left" class="headercell" colspan="1" rowspan="2" scope="col" valign="top"> <p><b>№ of participants<br/>(studies)</b> </p> </th> <th align="left" class="headercell" colspan="1" rowspan="2" scope="col" valign="top"> <p><b>Certainty of the evidence<br/>(GRADE)</b> </p> </th> <th align="left" class="headercell" colspan="1" rowspan="2" scope="col" valign="top"> <p><b>Comments</b> </p> </th> </tr> <tr class="separated"> <th align="left" class="headercell table-tint" colspan="1" rowspan="1" scope="col" valign="top"> <p><b>Risk with non‐PARPi regimen</b> </p> </th> <th align="left" class="headercell table-tint" colspan="1" rowspan="1" scope="col" valign="top"> <p><b>Risk with PARPi‐containing regimen</b> </p> </th> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>Overall Survival**<br/>follow up: 24 months </p> </td> <td align="left" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p>Study population</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>HR 0.84<br/>(0.76 to 1.00) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>1435<br/>(4 RCTs) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>⊕⊕⊕⊕<br/>HIGH <sup>1 2 3 4</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"></td> </tr> <tr class="separated"> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>550 per 1,000</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>497 per 1,000<br/>(446 to 550) </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>Progression Free Survival**<br/>follow up: 12 months </p> </td> <td align="left" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p>Study population</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>HR 0.63<br/>(0.56 to 0.71) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>1474<br/>(5 RCTs) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>⊕⊕⊕⊕<br/>HIGH <sup>1 3 5 6</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"></td> </tr> <tr class="separated"> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>625 per 1,000</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>461 per 1,000<br/>(423 to 502) </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>Response Rate</p> </td> <td align="left" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p>Study population</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>RR 1.39<br/>(1.24 to 1.54) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>1185<br/>(5 RCTs) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>⊕⊕⊝⊝<br/>LOW <sup>1 3 6 7</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"></td> </tr> <tr class="separated"> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>489 per 1,000</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>695 per 1,000<br/>(636 to 749) </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>Grade ≥3 AEs</p> </td> <td align="left" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p>Study population</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>RR 0.98<br/>(0.91 to 1.04) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>1443<br/>(5 RCTs) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>⊕⊕⊕⊝<br/>MODERATE <sup>1 3 8 9</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"></td> </tr> <tr class="separated"> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>645 per 1,000</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>620 per 1,000<br/>(555 to 684) </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p>*<b>The risk in the intervention group</b> (and its 95% confidence interval) is based on the assumed risk in the comparison group and the <b>relative effect</b> of the intervention (and its 95% CI). </p> <p>** Given i) overall survival and progression‐free survival are continuous endpoints in clinical practice but ii) that continuous measures are not easily quantifiable (even if the HR is available), we opted to estimate the percentage of patients with this outcome (e.g. death) at a predefined time interval to practically estimate the size of treatment benefit for readers. We extrapolated this information from Kaplan‐Meier curves from the included studies. We started with the OS at 2 years, then subtracted this from 1 to arrive at incidence of death at 2 years and similarly for PFS at 1 year (<a href="./references#CD011395-bbs2-0002" title="DiérasV , HanHS , RobsonME , PalacovaM , MarcomPK , JagerA , et al. Evaluation of veliparib (V) and temozolomide (TMZ) in a phase 2 randomized study of the efficacy and tolerability of V+TMZ or carboplatin (C) and paclitaxel (P) vs placebo (Plc)+C/P in patients (pts) with BRCA1 or BRCA2 mutations and metastatic breast cancer. Cancer Research2017;77(Suppl 4):Abstract nr SABCS16-P4-22-02. HanHS , DiérasV , RobsonM , PalácováM , MarcomPK , Jager A et al. Veliparib with temozolomide or carboplatin/paclitaxel versus placebo with carboplatin/paclitaxel in patients with BRCA1/2 locally recurrent/metastatic breast cancer: randomized phase II study. Annals of Oncology2018;29(1):154-61. HanHS , DiérasV , RobsonME , PalácováM , MarcomPK , JagerA , et al. Efficacy and tolerability of veliparib (V; ABT-888) in combination with carboplatin (C) and paclitaxel (P) vs placebo (Plc)+C/P in patients (pts) with BRCA1 or BRCA2 mutations and metastatic breast cancer: a randomized, phase 2 study. Cancer Research2017;77(Suppl 4):Abstract nr SABCS16-S2-05. IsakoffSJ , PuhallaS , DomchekSM , FriedlanderM , KaufmanB , RobsonM , et al. A randomized Phase II study of veliparib with temozolomide or carboplatin/paclitaxel versus placebo with carboplatin/paclitaxel in BRCA1/2 metastatic breast cancer: design and rationale. Future Oncology2017;13(4):307-20. ">BROCADE 2</a>; <a href="./references#CD011395-bbs2-0003" title="ArunBK , HanHS , KaufmanB , WildiersH , FriedlanderM , AyoubJP , et al. First-line veliparib plus carboplatin/paclitaxel in patients with HER2-negative advanced/metastatic gBRCA-associated breast cancer: planned subgroup analysis from the phase 3 BROCADE3 trial. Cancer Research2020;80(Suppl 4):Abstract nr PD4-01. AyoubJP , FriedlanderML , DierasVC , WildiersH , ArunB , HanHS , et al. Veliparib plus carboplatin-paclitaxel in patients with HER2-negative advanced/metastatic gBRCA-associated breast cancer: results in hormone receptor-positive and triple-negative breast cancer subgroups from the phase III BROCADE3 trial. Annals of Oncology2020;31(Suppl 2):S65. DierasV , HanH , KaufmanB , WildiersH , FriedlanderM , AyoubJ , et al. A Phase 3 randomized, placebo-controlled trial of carboplatin and paclitaxel with or without the PARP inhibitor veliparib (ABT-888) in HER2-negative metastatic or locally advanced unresectable BRCA-associated breast cancer. Annals of Oncology2019;30(Suppl 5):v851-v934. ">BROCADE 3</a>; <a href="./references#CD011395-bbs2-0004" title="DiabS , RugoHS , MinaLA , PuhallaS , MahtaniRL , HenryNL , et al. Efficacy and safety of talazoparib (TALA) or physician's choice of therapy (PCT) in United States patients (pts) with HER2- germline BRCA1/2-mutated (gBRCAm) locally advanced/metastatic breast cancer (LA/MBC) in the EMBRACA study. Journal of Clinical Oncology2019;37(Suppl 15):1044. EiermannW , RugoHS , DiabS , EttlJ , HurvitzSA , GoncalvesA , et al. Analysis of germline BRCA1/2 mutated (g BRCAmut) hormone receptor-positive (HR+) and triple-negative breast cancer (TNBC) treated with talazoparib (TALA). Journal of Clinical Oncology2018;36(Suppl 15):1070. EttlJ , HurvitzSA , RugoHS , LeeKH , MinaLA , WoodwardNE , et al. Outcomes of talazoparib (TALA) versus physician's choice of chemotherapy (PCT) in patients (pts) with advanced breast cancer (ABC) and a germline BRCA (gBRCA) mutation by line of chemotherapy (CT) in the EMBRACA trial. Journal of Clinical Oncology2019;37(Suppl 15):1071. EttlJ , QuekRG , BhattacharyyaH , RugoHS , HurvitzSA , GonçalvesA . Patient Reported Outcomes (PRO) in patients (pts) with HER2-advanced breast cancer (ABC) and a germline BRCA1/2 mutation (gBRCAm) receiving talazoparib (TALA) vs physician’s choice chemotherapy (PCT) in the EMBRACA trial: a focus on subgroups with/without visceral disease. Annals of Oncology2019;30(Suppl 5):v129–30. EttlJ , QuekRG , HurvitzSA , GoncalvesA , TudorIC , RugoHS . Hospitalization and supportive care medication (SCM) utilisation in patients (pts) with advanced breast cancer (ABC) and a germline BRCA1/2 mutation (gBRCAm) in EMBRACA. Annals of Oncology2019;30(Suppl 3):iii52. EttlJ , QuekRG , LeeKH , RugoHS , HurvitzS , GonçalvesA , et al. Quality of life with talazoparib versus physician’s choice of chemotherapy in patients with advanced breast cancer and germline BRCA1/2 mutation: patient-reported outcomes from the EMBRACA phase III trial. Annals of Oncology2018;29(9):1939-47. FaschingPA , QuekRG , BhattacharyyaH , HurvitzSA , RugoHS , EttlJ . Impact of objective response (OR) on patient-reported outcomes (PRO) in patients (pts) with advanced breast cancer (ABC) and a germline BRCA1/2 (gBRCA) mutation in the phase III EMBRACA trial. Annals of Oncology2019;30(Suppl 3):iii49. GonçalvesA , EiermannW , RugoHS , EttlJ , HurvitzSA , YerushalmiR , et al. EMBRACA: Efficacy and safety in comparing talazoparib (TALA) with physician's choice of therapy (PCT) in patients (pts) with advanced breast cancer (aBC) and a germline BRCA mutation (gBRCAm); BRCA1/BRCA2 subgroup analysis. Annals of Oncology2018;29(Suppl 8):viii96–7. GoncalvesA , QuekRGW , BhattacharyyaH , EttlJ , HurvitzSA , RugoHS . Patient-reported outcomes (PRO) in patients (pts) with Her2-advanced breast cancer (ABC) receiving talazoparib (TALA) vs physician's choice chemotherapy (PCT): a focus on EMBRACA germline BRCA1 and BRCA2 mutation (gBRCA1/2m) subgroups. Breast2019;48(Suppl 2):S71. HurvitzSA , GoncalvesA , RugoHS , LeeKH , FehrenbacherL , MinaLA , et al. Talazoparib in patients with a germline BRCA-mutated advanced breast cancer: detailed safety analyses from the phase III EMBRACA Trial. Oncologist2019;25(3):e439-50. LeeKH , KimSB , SohnJ , GoodwinA , UsariT , LanzaloneS , et al. Talazoparib (TALA) vs physician’s choice of chemotherapy (PCT) in Asian patients (Pts) with HER2- advanced breast cancer (ABC) and a germline BRCA1/2 mutation (gBRCA1/2mut): data from phase III EMBRACA. Annals of Oncology2019;30(9):ix14. LittonJ , EttlJ , HurvitzSA , MinaLA , RugoHS , LeeKH , et al. A phase 3, open-label, randomized, 2-arm international study of the oral dual PARP inhibitor talazoparib in germline BRCA mutation subjects with locally advanced and/or metastatic breast cancer (EMBRACA). Cancer Research2017;77(Suppl 4):Abstract nr OT2-01-13. LittonJ , RugoHS , EttlJ , HurvitzS , GoncalvesA , LeeKH , et al. EMBRACA: a phase 3 trial comparing talazoparib, an oral PARP inhibitor, to physicianʼs choice of therapy in patients with advanced breast cancer and a germline BRCA mutation [abstract]. In: San Antonio Breast Cancer Symposium; 2017 Dec 5-9; San Antonio (TX). San Antonio (TX), 2017. LittonJK , HurvitzSA , MinaLA , RugoHS , LeeKH , GonçalvesA , et al. Talazoparib (TALA) in germline BRCA1/2 (gBRCA1/2)-mutated human epidermal growth factor receptor 2 negative (HER2-) advanced breast cancer (ABC): final overall survival (OS) results from randomized phase 3 EMBRACA trial. Cancer Research2020;80(Suppl 16):Abstract no. CT071. LittonJK , RugoHS , EttlJ , HurvitzSA , GonçalvesA , LeeKH , et al. Talazoparib in patients with advanced breast cancer and a germline BRCA mutation. New England Journal of Medicine2018;379(8):753-63. MartínM , EiermannW , RugoHS , EttlJ , HurvitzSA , GonçalvesA , et al. EMBRACA: Comparison of efficacy and safety of talazoparib (TALA) and physician's choice of therapy (PCT) in patients (pts) with advanced breast cancer (aBC), a germline BRCA1/2 mutation (gBRCAm), and prior platinum treatment. Annals of Oncology2018;29(Suppl 8):viii96. MinaL , LeeKH , GoncalvesA , WoodwardN , HurvitzSA , DiabS , et al. EMBRACA: efficacy and safety of talazoparib or physician's choice of therapy in patients with advanced breast cancer and a germline BRCA1/2 mutation: a regional analysis. Cancer Research2019;79(Suppl 4):Abstract nr P6-18-12. QuekR , BhattacharyyaH , HurvitzS , GoncalvesA , EttlJ , RugoH . Patient-reported outcomes in patients with HER2-advanced breast cancer and a germline BRCA1/2 mutation receiving talazoparib versus physician's choice chemotherapy: a focus on EMBRACA age subgroups. Journal of Managed Care and Specialty Pharmacy2019;25(Suppl 10A):S37-8. QuekRGW , BhattacharyyaH , GoncalvesA , RugoHS , HurvitzSA , EttlJ . Pcn491 Patient reported outcomes (PRO) of talazoparib (TALA) versus physician's choice of chemotherapy (PCT) in patients (pts) with advanced breast cancer (aBC) and a germline BRCA (gBRCa) mutation: a focus on Embraca pts with/without prior chemotherapy (CT) subgroups. Value in Health2019;22(Suppl 3):S532. RugoHS , EttlJ , HurvitzSA , GoncalvesA , LeeKH , FehrenbacherL , et al. Outcomes in clinically relevant patient subgroups from the EMBRACA study: talazoparib vs physician's choice standard-of-care chemotherapy. Journal of the National Cancer Institute Cancer Spectrum2020;4(1):pkz085. RugoHS , EttlJ , WoodwardNE , HurvitzSA , GoncalvesA , LeeKH , et al. EMBRACA: efficacy outcomes in clinically relevant subgroups comparing talazoparib (TALA), an oral poly ADP ribose polymerase (PARP) inhibitor, to physician's choice of therapy (PCT) in patients with advanced breast cancer and a germline BRCA mutation. Journal of Clinical Oncology2018;36(Suppl 15):1069. RugoHS , QuekR , EttlJ , HurvitzSA , BhattacharyyaH , HannahAL , et al. Patient-reported outcomes (PRO) in patients (pts) with advanced breast cancer and a germline BRCA1/2 mutation (gBRCAm) receiving talazoparib (TALA) vs physician’s choice chemotherapy treatment (PCT): a focus on the EMBRACA triple negative (TNBC) subpopulation. Annals of Oncology2018;29(Suppl 8):viii91. YuY , ElmeliegyM , LittonJK , TudorIC , CzibereA , ZhengJ , et al. Exposure-efficacy progression-free survival (PFS) analyses of breast cancer patients with germline BRCA1/2 mutations receiving talazoparib in the phase III EMBRACA trial. Annals of Oncology2018;29(Suppl 8):viii97. YuY , ElmeliegyM , LittonJK , TudorIC , CzibereA , ZhengJ , et al. Talazoparib exposure-efficacy analysis in patients with advanced breast cancer and germline BRCA1/2 mutations in the EMBRACA trial. Journal of Clinical Pharmacology2020;60(10):1324-33. ">EMBRACA</a>; <a href="./references#CD011395-bbs2-0005" title="KummarS , WadeJL , OzaAM , SullivanD , ChenAP , GandaraDR , et al. Randomized phase II trial of cyclophosphamide and the oral poly (ADP-ribose) polymerase inhibitor veliparib in patients with recurrent, advanced triple-negative breast cancer. Investigational New Drugs2016;34(3):355–63. ">Kummar 2016</a>; <a href="./references#CD011395-bbs2-0006" title="DelalogeS , ContePF , ImS , Senkus-KonefkaE , XuB , DomchekSM , et al. OlympiAD: further efficacy outcomes in patients with HER2-negative metastatic breast cancer and a germline BRCA mutation receiving olaparib monotherapy vs standard single-agent chemotherapy treatment of physician’s choice. Annals of Oncology2017;28(Suppl 5):v74-v108. DomchekS , RobsonM , ImS , SenkusE , XuB , MasudaN , et al. Tolerability of olaparib monotherapy versus chemotherapy in patients with HER2-negative metastatic breast cancer and a germline BRCA mutation: OlympiAD. Cancer Research2018;78(Suppl 4):Abstract nr P5-21-12. ImSA , XuB , LiW , RobsonM , OuyangQ , YehDC , et al. Olaparib monotherapy for Asian patients with a germline BRCA mutation and HER2-negative metastatic breast cancer: OlympiAD randomized trial subgroup analysis. Scientific Reports2020;10(1):8753. ImSA , XuB , LiW , RobsonM , OuyangQ , YehDC , et al. Olaparib monotherapy versus chemotherapy for patients with HER2-negative metastatic breast cancer and a germline BRCA mutation: Asian subgroup analysis from the phase III OlympiAD trial. Cancer Research2018;78(Suppl 4):Abstract nr P5-21-13. MerensC , BannisterW , BergnerS , HettleR , McCreaC , McCutcheonS , et al. Impact of olaparib versus chemotherapy on the use of strong pain medications in gBRCA-mutated HER2-negative metastatic breast cancer and associated patient reported outcomes. Cancer Research2020;80(Suppl 4):Abstract nr P6-13-05. RobsonM , HettleR , DegboeA , SaundersO , CainT , KilvertH , et al. Estimating the health state utility of patients with HER2–gBRCA+ metastatic breast cancer treated with olaparib or chemotherapy via a mapping analysis of EORTC QLQ-C30 data collected in the Olympiad clinical trial. Value in Health2018;21(Suppl 1):S12. RobsonM , ImSA , SenkusE , XuB , DomchekS , MasudaN , et al. OlympiAD extended follow-up for overall survival and safety: olaparib versus chemotherapy treatment of physician’s choice in patients with a germline BRCA mutation and HER2-negative metastatic breast cancer. Cancer Research2020;80(Suppl 4):Abstract nr PD4-03. RobsonM , ImSA , SenkusE , XuB , DomchekSM , MasudaN , et al. Olaparib for metastatic breast cancer in patients with a germline BRCA mutation. New England Journal of Medicine2017;377(6):523-33. RobsonM , RuddyKJ , ImSA , SenkusE , XuB , DomchekSM , et al. Patient-reported outcomes in patients with a germline BRCA mutation and HER2-negative metastatic breast cancer receiving olaparib versus chemotherapy in the OlympiAD trial. European Journal of Cancer2019;120:20-30. RobsonM , RuddyKJ , ImSA , Senkus-KonefkaE , XuB , DomchekSM , et al. OlympiAD: health-related quality of life (HRQoL) in patients with HER2-negative metastatic breast cancer (mBC) and a germline BRCA mutation (gBRCAm) receiving olaparib monotherapy vs standard single-agent chemotherapy treatment of physician’s choice (TPC). Annals of Oncology2017;28(Suppl 5):v74-v108. RobsonME , ImSA , SenkusE , XuB , DomchekS , MasudaN , et al. Abstract CT038: OlympiAD final overall survival: olaparib versus chemotherapy treatment of physician's choice (TPC) in patients with HER2-negative metastatic breast cancer (mBC) and a germline BRCA mutation (gBRCAm). American Association for Cancer Research2018;78(Suppl 13):CT038. RobsonME , ImSA , SenkusE , XuB , DomchekSM , MasudaN , et al. OlympiAD: phase III trial of olaparib monotherapy versus chemotherapy for patients (pts) with HER2-negative metastatic breast cancer (mBC) and a germline BRCA mutation (gBRCAm). Journal of Clinical Oncology2017;35(Suppl 18):LBA4-LBA4. RobsonME , RuddyKJ , ImSA , Senkus-KonefkaE , XuB , DomchekSM , et al. EORTC QLQ-C30 (QLQ-C30) symptoms in patients (pts) with HER2-negative metastatic breast cancer (mBC) and a germline BRCA mutation (gBRCAm) receiving olaparib vs chemotherapy treatment of physician’s choice (TPC) in OlympiAD. Journal of Clinical Oncology2018;36(Suppl 15):1045. RobsonME , TungN , ConteP , ImSA , SenkusE , XuB , et al. OlympiAD final overall survival and tolerability results: olaparib versus chemotherapy treatment of physician’s choice in patients with a germline BRCA mutation and HER2-negative metastatic breast cancer. Annals of Oncology2019;30(4):558-66. Senkus-KonefkaE , DomchekSM , ImSA , XuB , ArmstrongA , MasudaN , et al. Subgroup analysis of olaparib monotherapy versus chemotherapy by hormone receptor and BRCA mutation status in patients with HER2-negative metastatic breast cancer and a germline BRCA mutation: OlympiAD. European Journal of Cancer2018;92:S19-20. TungNM , ImSA , Senkus-KonefkaE , XuB , DomchekSM , MasudaN , et al. Olaparib versus chemotherapy treatment of physician’s choice in patients with a germline BRCA mutation and HER2-negative metastatic breast cancer (OlympiAD): efficacy in patients with visceral metastases. Journal of Clinical Oncology2018;36(Suppl 15):1053. ">OLYMPIAD</a>).<br/><br/><b>CI:</b> Confidence interval; <b>HR:</b> Risk ratio; <b>OR:</b> Odds ratio; </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p><b>GRADE Working Group grades of evidence</b> <br/><b>High certainty:</b> We are very confident that the true effect lies close to that of the estimate of the effect<br/><b>Moderate certainty:</b> We are moderately confident in the effect estimate: The true effect is likely to be close to the estimate of the effect, but there is a possibility that it is substantially different<br/><b>Low certainty:</b> Our confidence in the effect estimate is limited: The true effect may be substantially different from the estimate of the effect<br/><b>Very low certainty:</b> We have very little confidence in the effect estimate: The true effect is likely to be substantially different from the estimate of effect </p> </td> </tr> </tbody> <tfoot> <tr> <td colspan="7"> <div class="table-footnote"> <p><sup>1</sup> All studies mostly graded as low to unclear risk of bias. This is based on the scores from each domain including 3/5 studies which had high risk of bias in terms of performance bias due to being open‐label. Also, detection bias for adverse events (3/5 studies) were judged as having high risk of bias. Overall, judged as unclear but not serious risk of bias. </p> <p><sup>2</sup> I<sup>2</sup>=0%, indicating low heterogeneity. </p> <p><sup>3</sup> No indirectness present. </p> <p><sup>4</sup> 95% CI did not extend past HR of 1.0 and the total number of patients exceeded 400. </p> <p><sup>5</sup> I<sup>2</sup>=2%, indicating low heterogeneity. </p> <p><sup>6</sup> 95% CI excluded a HR of 1.0 and the total number of events exceeded 400. </p> <p><sup>7</sup> Significant heterogeneity (I<sup>2</sup>=90%) without an obvious clinical explanation arising from differences in included trials. </p> <p><sup>8</sup> Significant heterogeneity (I<sup>2</sup>=73%). </p> <p><sup>9</sup> 95% CI crosses both 1 (the point of no effect) and 0.75 (the point of significantly reduced toxicity) </p> </div> </td> </tr> </tfoot> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Summary of findings 1.</span> <span class="table-title">PARPi‐containing regimen compared to non‐PARPi regimen for locally advanced or metastatic breast cancer</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD011395.pub2/full#CD011395-tbl-0001">Navigate to table in review</a></div> </div> <div class="table"> <table class="comparison" data-id="CD011395-tbl-0002"> <div class="table-heading"><span class="table-label">Comparison 1.</span> <span class="table-title">PARPi‐containing regimen vs non‐PARPi regimen</span></div> <thead> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>Outcome or subgroup title</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>No. of studies</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>No. of participants</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Statistical method</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Effect size</p> </td> </tr> </thead> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">1.1 Overall survival <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>4</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>1435</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Hazard Ratio (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.87 [0.76, 1.00]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">1.2 Progression‐free survival <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>5</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>1474</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Hazard Ratio (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.63 [0.56, 0.71]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">1.3 Progression‐free survival: BRCA <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>4</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>1414</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Hazard Ratio (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.63 [0.55, 0.73]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.3.1 BRCA 1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>4</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>717</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Hazard Ratio (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.65 [0.53, 0.78]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.3.2 BRCA 2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>4</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>697</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Hazard Ratio (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.62 [0.51, 0.76]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">1.4 Progression‐free survival: receptor status <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>4</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>1435</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Hazard Ratio (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.63 [0.54, 0.75]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.4.1 Not triple negative</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>4</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>771</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Hazard Ratio (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.66 [0.53, 0.82]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.4.2 Triple Negative</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>4</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>664</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Hazard Ratio (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.61 [0.47, 0.80]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">1.5 Progression‐free survival: prior chemo for advanced breast cancer <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>4</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>1435</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Hazard Ratio (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.65 [0.57, 0.74]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.5.1 Prior chemo</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>4</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>729</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Hazard Ratio (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.64 [0.53, 0.77]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.5.2 No prior chemo</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>4</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>706</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Hazard Ratio (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.66 [0.55, 0.79]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">1.6 Progression‐free survival: prior platinum exposure <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>1242</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Hazard Ratio (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.64 [0.55, 0.74]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.6.1 Previous platinum</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>205</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Hazard Ratio (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.71 [0.50, 1.01]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.6.2 No previous platinum</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>1037</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Hazard Ratio (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.63 [0.53, 0.73]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">1.7 Response rate <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>5</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>1185</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.39 [1.24, 1.54]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">1.8 Grade ≥ 3 adverse events <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>5</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>1443</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.98 [0.91, 1.04]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">1.9 Neutropenia (any grade) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>5</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>1443</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.67 [0.60, 0.76]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">1.10 Anaemia (any grade) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>5</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>1443</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.21 [1.04, 1.41]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">1.11 Fatigue (any grade) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>5</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>1443</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.90 [0.78, 1.05]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">1.12 Thrombocytopenia (any grade) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>4</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>1147</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.98 [0.84, 1.15]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> </tbody> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Comparison 1.</span> <span class="table-title">PARPi‐containing regimen vs non‐PARPi regimen</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD011395.pub2/references#CD011395-tbl-0002">Navigate to table in review</a></div> </div> </div> <noscript> <img height="1" src="/scolaris-auth/report/nonjs/fulltexthtmlreg?doi=10.1002%2F14651858.CD011395.pub2&amp;rf=&amp;articleType=CDSR" style="display:none" width="1"> </img></noscript> <section class="translation-notes-modal" data-modal-class="translation-notes" data-modal-title="Translation notes" data-ok-btn-selector=".ok-btn" style="display: none"> <div class="translation-notes"> <div class="section-language-toggles"> <nav class="section-languages"> <ul> <li class="section-languages-legend">Available in</li> <li class="section-language"> <a class="" href="es#CD011395-note-0011">Español</a> </li> <li class="section-language"> <a class="" href="fa#CD011395-note-0009">فارسی</a> </li> <li class="section-language"> <a class="" href="fr#CD011395-note-0010">Français</a> </li> <li class="section-language"> <a class="" href="ja#CD011395-note-0008">日本語</a> </li> <li class="section-language"> <a class="" href="ms#CD011395-note-0007">Bahasa Malaysia</a> </li> <li class="section-language"> <a class="" href="ru#CD011395-note-0005">Русский</a> </li> <li class="section-language"> <a class="" href="th#CD011395-note-0006">ภาษาไทย</a> </li> <li class="section-language"> <a class="" href="zh_HANS#CD011395-note-0004">简体中文</a> </li> </ul> </nav> </div> <section class="translation-notes-content"> </section> <button class="btn primary ok-btn pull-right" type="button">Close</button> </div> </section></article> </div> <div class="citation-modal" style="display: none"> <div class="export-citation-header"> <p class="inset-message" data-load-error="Unable to load citation data" id="citeProcText"></p> </div> <div class="export-citation-body row-fluid"> <div class="span12"> <div class="addthis_toolbox addthis_default_style addthis_16x16_style"> <nav class="inline-nav-list is-bordered"> <li> <h4 class="heading">Save citation to:</h4> </li> <li><a class="citation-btn-refworks at300b btn btn-link" href="#" id="refWorksCitationBtn"><span class="citation-icon refworks"></span>RefWorks</a></li> <li><a class="citation-btn-sciwheel at300b btn btn-link disabled" href="#" id="sciWheelCitationBtn" target="_blank"><span class="citation-icon sciwheel"></span>SciWheel</a></li> </nav> </div> </div> </div> <div class="row-fluid"> <div class="span12"> <div class="citation-format"> <h4>Copy or download citation</h4> <a href="/en/help/exporting-search-results" rel="noopener noreferrer" target="_blank">Export help</a> </div> <nav class="inline-nav-list has-dividers"> <li class="citation-option" data-option="plain"><button class="btn btn-link" type="button">Plain text</button></li> <li class="citation-option" data-option="endnote"><button class="btn btn-link" type="button">EndNote</button></li> <li class="citation-option" data-option="refmanager"><button class="btn btn-link" type="button">Reference Manager</button></li> <li class="citation-option" data-option="procite"><button class="btn btn-link" type="button">ProCite</button></li> <li class="citation-option" data-option="bibtex"><button class="btn btn-link" type="button">BibteX</button></li> <li class="citation-option" data-option="csv"><button class="btn btn-link" type="button">CSV (Excel)</button></li> </nav> <div class="citation-content"> <pre data-load-error="Unable to load citation data" id="citationContent" tabindex="0"></pre> </div> <div class="clearfix"> <form class="download-citation-form" data-citation-citeproc-url="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentdisplay_WAR_scolariscontentdisplay&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=citation-citeproc&amp;p_p_cacheability=cacheLevelPage&amp;p_p_col_id=column-1&amp;p_p_col_count=1" method="GET" target="citation-download-iframe"> <input id="siteId" name="siteId" type="hidden" value=""> <input id="downloadType" name="downloadType" type="hidden" value=""> <input id="style" name="style" type="hidden" value=""> <input id="articleId" name="articleId" type="hidden" value=""> <input name="p_p_id" type="hidden" value="scolariscontentdisplay_WAR_scolariscontentdisplay"><input name="p_p_lifecycle" type="hidden" value="2"><input name="p_p_state" type="hidden" value="normal"><input name="p_p_mode" type="hidden" value="view"/><input name="p_p_resource_id" type="hidden" value="citation-download"/><input name="p_p_cacheability" type="hidden" value="cacheLevelPage"/><input name="p_p_col_id" type="hidden" value="column-1"/><input name="p_p_col_count" type="hidden" value="1"/> <button class="btn primary wide pull-right" type="submit">Download</button> <div class="inline-checkbox pull-right"> <label title=" for=" withabstract"=""> <input checked="" class="checkbox" name="withAbstract" type="checkbox"/> <span class="checkbox-label">Include abstract</span> </label> </div> </input></input></input></input></input></input></input></form> <iframe aria-hidden="true" name="citation-download-iframe" src="" style="display: none; visibility: hidden" title="Citation download frame"></iframe> </div> </div> </div> </div> <div class="print-modal" data-modal-title="Print this review" style="display: none;"> <div class="print-options-wrapper"> <p><strong>All sections are selected by default</strong>, please select the sections you do not wish to print or use the select or deselect all button to add or remove sections.</p> <div class="print-options-controls"> <input checked="checked" class="print-options-select-all" title="Select/deselect all" type="checkbox"/> <span class="checkbox-label">Select/deselect all</span> </div> <ul class="print-options checkbox-list"> </ul> <button class="btn primary print-article pull-right"><i aria-hidden="true" class="fa fa-print"></i> Print</button> </div> </div> <div class="download-stats-data-modal" data-modal-title="Download data package" style="display: none;"> <div> <p> The data available are protected by copyright and may only be used in accordance with the <a class="external" href="/about/data-download" target="_blank">Terms and Conditions.</a> </p> <div class="hide-for-zip"> <p> <a class="external" href="https://revman.cochrane.org/#/rm5Converter" target="_blank">RevMan 5 files</a> can be converted to a <a class="external" href="https://links.cochrane.org/review-datapack-userguide" target="_blank">data package.</a> </p> </div> <p> Files in the data package can be imported to <a class="external" href="https://revman.cochrane.org/info" target="_blank">Review Manager software</a> or opened in other tools that support CSV and RIS. </p> <form class="download-stats-data-form" method="GET" target="_blank"> <input name="content-disposition" type="hidden" value="attachment"/> <input name="mime-type" type="hidden" value="application/octet-stream"/> <p class="print-options-controls"> <input aria-label="I agree to these terms and conditions" class="download-stats-data-toc-check-box" type="checkbox"/> <span aria-hidden="true" class="checkbox-label">I agree to these terms and conditions</span> <button class="btn primary download-stats-data pull-right" disabled=""><i aria-hidden="true" class="fa fa-download"></i> Download data</button> </p> </form> </div> </div> <div class="share-modal" data-modal-title="Share this review" style="display:none;"> </div> <div class="viewer-thumbnail-pane-html" style="display:none;"> <div class="figure-viewer-options"> <nav class="inline-nav-list"> <li class="figure-options-btn-container"><button class="btn btn-link" id="figureOptionBtn" type="button">Figures</button></li> <li class="table-options-btn-container"><button class="btn btn-link" id="tableOptionBtn" type="button">Tables</button></li> </nav> </div> <div class="figure-viewer-thumbnails"> <div class="figure-thumbnails is-visible" id="figureThumbnails"></div> <div class="table-thumbnails" id="tableThumbnails"></div> </div> </div> <div class="utilities-html" style="display:none;"> <div class="figure-viewer-utilities"> <a class="figure-viewer-menu-toggle" href="#"> <i class="fa fa-chevron-left"></i><span class="toggle-label" data-figure-hide-text="Hide thumbnails" data-figure-show-text="Show thumbnails" data-table-hide-text="Hide table list" data-table-show-text="Show table list">Hide thumbnails</span> </a> <a class="figure-viewer-navigateback" href="#"> <i class="fa fa-chevron-left"></i> </a> <a class="figure-viewer-rotate" href="#"> <i class="fa fa-undo"></i> </a> <a class="figure-viewer-download" href="#"> <i class="fa fa-download"></i> </a> <a class="figure-viewer-share" href="#"> <i class="fa fa-share-alt"></i> </a> <a class="figure-viewer-zoomin" href="#"> <i class="fa fa-plus"></i><span>zoom in</span> </a> <a class="figure-viewer-zoomout" href="#"> <i class="fa fa-minus"></i><span>zoom out</span> </a> </div> </div> <div class="controls-html" style="display:none;"> <div class="figure-viewer-navigation"> <a class="figure-viewer-nav previous" href="#"> <i class="fa fa-chevron-left"></i><span>left</span> </a> <a class="figure-viewer-nav next" href="#"> <i class="fa fa-chevron-right"></i><span>right</span> </a> </div> </div> <div class="mobile-thumbnail-selector-html" style="display:none;"> <div class="figure-viewer-mobile-thumbnails"> <select class="figure-selection"> <option>Figures</option> </select> <select class="table-selection"> <option>Tables</option> </select> </div> </div> </div> </div> </div> <div style="display:none"> <input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
</div>
</div>
</div>
</div>
<div class="portlet-boundary portlet-boundary_1_WAR_kaleodesignerportlet_ portlet-static portlet-static-end kaleo-designer-portlet" id="p_p_id_1_WAR_kaleodesignerportlet_">
<span id="p_1_WAR_kaleodesignerportlet"></span>
</div>
<form action="#" id="hrefFm" method="post" name="hrefFm">
<span></span>
</form>
</div>
<footer class="footer">
<div class="main-footer">
<div class="main-footer-wrapper container">
<div class="brand">
<p class="brand-name">Cochrane</p>
<a href="http://www.cochrane.org/" title="Cochrane logo">
<img alt="Cochrane logo" class="footer-logo logo-part-1" src="https://www.cochranelibrary.com/cochrane-theme/images/footer-logo-part-1.png"> <img alt="" class="footer-logo logo-part-2" src="https://www.cochranelibrary.com/cochrane-theme/images/footer-logo-part-2.png"> </img></img></a> </div> </div> </div> <div class="aux-footer"> <div class="aux-footer-nav-container container"> <nav class="aux-footer-nav"> <ul class="aux-footer-nav-list"> <li><a class="aux-footer-nav-link" href="https://onlinelibrary.wiley.com/">Browse Publications</a></li> <li><a class="aux-footer-nav-link" href="https://onlinelibrary.wiley.com/">Browse by Subject</a></li> </ul> <ul class="aux-footer-nav-list"> <li><a class="aux-footer-nav-link" href="https://onlinelibrary.wiley.com/advertisers">Advertisers &amp; Agents</a></li> <li><a class="aux-footer-nav-link" href="https://hub.wiley.com/community/support/cochrane-library">Contact Us</a></li> </ul> <ul class="aux-footer-nav-list"> <li><a class="aux-footer-nav-link" href="https://hub.wiley.com/community/support/cochrane-library">Help &amp; Support</a></li> <li><a class="aux-footer-nav-link" href="https://onlinelibrary.wiley.com/terms-and-conditions">Terms &amp; Conditions</a></li> </ul> </nav> </div> <div class="brand"> <div class="brand-container container"> <p class="copyright"> Copyright © 2000 - 2025 by <a class="" href="http://www.wiley.com">John Wiley &amp; Sons, Inc.</a> All Rights Reserved <br> Review our <a href="https://www.wiley.com/privacy"><strong>Privacy Policy</strong></a> <a href="https://www.wiley.com/cookies"><strong>Cookie Policy</strong></a> <a href="#" onclick="Osano.cm.showDrawer('osano-cm-dom-info-dialog-open')"><strong>Cookie Preferences</strong></a> </br></p> <a href="http://eu.wiley.com/"><img alt="Wiley logo" class="logo" src="https://www.cochranelibrary.com/cochrane-theme/images/en-US_wiley-footer-logo.png"/></a> </div> </div> <span class="wiley-semi-circle"></span> </div> <!--BEGIN QUALTRICS WEBSITE FEEDBACK SNIPPET--> <script type="text/javascript"> (function(){var g=function(e,h,f,g){ this.get=function(a){for(var a=a+"=",c=document.cookie.split(";"),b=0,e=c.length;b<e;b++){for(var d=c[b];" "==d.charAt(0);)d=d.substring(1,d.length);if(0==d.indexOf(a))return d.substring(a.length,d.length)}return null}; this.set=function(a,c){var b="",b=new Date;b.setTime(b.getTime()+6048E5);b="; expires="+b.toGMTString();document.cookie=a+"="+c+b+"; path=/; "}; this.check=function(){var a=this.get(f);if(a)a=a.split(":");else if(100!=e)"v"==h&&(e=Math.random()>=e/100?0:100),a=[h,e,0],this.set(f,a.join(":"));else return!0;var c=a[1];if(100==c)return!0;switch(a[0]){case "v":return!1;case "r":return c=a[2]%Math.floor(100/c),a[2]++,this.set(f,a.join(":")),!c}return!0}; this.go=function(){if(this.check()){var a=document.createElement("script");a.type="text/javascript";a.src=g;document.body&&document.body.appendChild(a)}}; this.start=function(){var t=this;"complete"!==document.readyState?window.addEventListener?window.addEventListener("load",function(){t.go()},!1):window.attachEvent&&window.attachEvent("onload",function(){t.go()}):t.go()};}; try{(new g(100,"r","QSI_S_ZN_cGCHHvWNpnJb1zf","https://zncgchhvwnpnjb1zf-wiley.siteintercept.qualtrics.com/SIE/?Q_ZID=ZN_cGCHHvWNpnJb1zf")).start()}catch(i){}})(); </script><div id="ZN_cGCHHvWNpnJb1zf"><!--DO NOT REMOVE-CONTENTS PLACED HERE--></div> <!--END WEBSITE FEEDBACK SNIPPET--> </footer> <div class="scolaris-modal-overlay"></div> <div class="scolaris-modal"> <div class="scolaris-modal-titlebar clearfix"> <p class="scolaris-modal-title"></p> <a class="scolaris-modal-close" href="#"><span>close</span><span class="icon fa fa-times"></span></a> <div class="scolaris-modal-ui"></div> </div> <!-- Static injection of addtoAny as dynamic injection not working properly--> <div class="scolaris-share-modal-content clearfix"> <div class="scolaris-modal-ui clearfix"> <div class="a2a_kit a2a_kit_size_32 a2a_default_style"> <a class="a2a_button_facebook share-button">  Facebook</a> <a class="a2a_button_x share-button">  X(Twitter)</a> <a class="a2a_button_whatsapp share-button">  WhatsApp</a> <a class="a2a_dd share-button">  View more</a> </div> </div> </div> <div class="scolaris-modal-content clearfix"> <div class="scolaris-modal-ui clearfix"></div> </div> <div class="scolaris-modal-ui clearfix"></div> </div> <div class="english-only-modal-wrapper" data-modal-class="english-only-modal" data-modal-title="Feature in English only" style="display: none"> <div class="english-only-modal"> <p class="message"></p> <button class="btn primary ok-btn pull-right" type="button">OK</button> <button class="btn primary border-only cancel-btn pull-right" type="button">Cancel</button> </div> </div> <!--[if gte IE 9]><!--> <script src="/cochrane-theme/vendor/ie9.js?t=1738734739000" type="text/javascript"></script> <!--<![endif]--> <script src="https://www.cochranelibrary.com/cochrane-theme/js/theme.js?t=1738734739000" type="text/javascript"></script> <script src="https://content.readcube.com/cochrane/checkout.js"></script> <script src="https://content.readcube.com/cochrane/epdf_linker.js" type="text/javascript"></script> <script src="https://crossmark-cdn.crossref.org/widget/v2.0/widget.js" type="text/javascript"></script> <script src="https://d1bxh8uas1mnw7.cloudfront.net/assets/embed.js" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/hit-highlighting.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773465000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/topics-lookup.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773465000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/institution.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773465000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/api-manager.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773465000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/pico.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773465000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/reference-linking.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773465000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/rightsLink.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773465000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/ui.submit.failed.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773465000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/ui.comment.form.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773465000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/safety-alerts.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773465000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/ui.translation-notes-modal.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773465000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/main.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773465000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/notifications-portlet/notifications/js/main.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773465000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-search/js/main.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773542000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-topics/js/main.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773465000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-language-portlet/js/main.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773471000" type="text/javascript"></script> <script type="text/javascript">Liferay.Util.addInputFocus();</script> <script type="text/javascript">Liferay.Portlet.register("scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header");Liferay.Portlet.onLoad({canEditTitle:false,columnPos:0,isStatic:"end",namespacedId:"p_p_id_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header_",portletId:"scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header",refreshURL:"\x2fen\x2fc\x2fportal\x2frender_portlet\x3fp_l_id\x3d20757\x26p_p_id\x3dscolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header\x26p_p_lifecycle\x3d0\x26p_t_lifecycle\x3d0\x26p_p_state\x3dnormal\x26p_p_mode\x3dview\x26p_p_col_id\x3dnull\x26p_p_col_pos\x3dnull\x26p_p_col_count\x3dnull\x26p_p_static\x3d1\x26p_p_isolated\x3d1\x26currentURL\x3d\x252Fweb\x252Fcochrane\x252Fcontent\x253FtemplateType\x253Dfull\x2526urlTitle\x253D\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD011395\x2epub2\x2526doi\x253D10\x2e1002\x252F14651858\x2eCD011395\x2epub2\x2526type\x253Dcdsr\x2526contentLanguage\x253D\x26templateType\x3dfull\x26urlTitle\x3d\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD011395\x2epub2\x26contentLanguage\x3d\x26type\x3dcdsr\x26doi\x3d10\x2e1002\x252F14651858\x2eCD011395\x2epub2"});Liferay.Portlet.register("scolariscontentdisplay_WAR_scolariscontentdisplay");Liferay.Portlet.onLoad({canEditTitle:false,columnPos:0,isStatic:"end",namespacedId:"p_p_id_scolariscontentdisplay_WAR_scolariscontentdisplay_",portletId:"scolariscontentdisplay_WAR_scolariscontentdisplay",refreshURL:"\x2fen\x2fc\x2fportal\x2frender_portlet\x3fp_l_id\x3d20757\x26p_p_id\x3dscolariscontentdisplay_WAR_scolariscontentdisplay\x26p_p_lifecycle\x3d0\x26p_t_lifecycle\x3d0\x26p_p_state\x3dnormal\x26p_p_mode\x3dview\x26p_p_col_id\x3dcolumn-1\x26p_p_col_pos\x3d0\x26p_p_col_count\x3d1\x26p_p_isolated\x3d1\x26currentURL\x3d\x252Fweb\x252Fcochrane\x252Fcontent\x253FtemplateType\x253Dfull\x2526urlTitle\x253D\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD011395\x2epub2\x2526doi\x253D10\x2e1002\x252F14651858\x2eCD011395\x2epub2\x2526type\x253Dcdsr\x2526contentLanguage\x253D"});Liferay.provide(Liferay.Util,"openKaleoDesignerPortlet",function(c){var b=AUI();var e=Liferay.PortletURL.createURL("https://www.cochranelibrary.com/en/content?p_p_id=2_WAR_kaleodesignerportlet&p_p_lifecycle=0");e.setParameter("mvcPath","/designer/edit_kaleo_draft_definition.jsp");e.setParameter("availableFields",c.availableFields);e.setParameter("availablePropertyModels",c.availablePropertyModels);e.setParameter("ddmStructureId",c.ddmStructureId);e.setParameter("draftVersion",c.draftVersion);e.setParameter("kaleoProcessId",c.kaleoProcessId);e.setParameter("name",c.name);e.setParameter("openerWindowName",c.openerWindowName);e.setParameter("portletResourceNamespace",c.portletResourceNamespace);e.setParameter("propertiesSaveCallback",c.propertiesSaveCallback);e.setParameter("refreshOpenerOnClose",c.refreshOpenerOnClose);e.setParameter("saveCallback",c.saveCallback);e.setParameter("version",c.version);e.setWindowState("pop_up");c.uri=e.toString();var d=c.dialog;if(!d){var f=b.one(Liferay.Util.getOpener()).get("region");d={destroyOnHide:true};c.dialog=d}if(!("align" in d)){d.align=Liferay.Util.Window.ALIGN_CENTER}var a=c.dialogIframe;if(!a){a={closeOnEscape:false};c.dialogIframe=a}Liferay.Util.openWindow(c)},["liferay-portlet-url"]);Liferay.Portlet.register("1_WAR_kaleodesignerportlet");Liferay.Portlet.onLoad({canEditTitle:false,columnPos:0,isStatic:"end",namespacedId:"p_p_id_1_WAR_kaleodesignerportlet_",portletId:"1_WAR_kaleodesignerportlet",refreshURL:"\x2fen\x2fc\x2fportal\x2frender_portlet\x3fp_l_id\x3d20757\x26p_p_id\x3d1_WAR_kaleodesignerportlet\x26p_p_lifecycle\x3d0\x26p_t_lifecycle\x3d0\x26p_p_state\x3dnormal\x26p_p_mode\x3dview\x26p_p_col_id\x3dnull\x26p_p_col_pos\x3dnull\x26p_p_col_count\x3dnull\x26p_p_static\x3d1\x26p_p_isolated\x3d1\x26currentURL\x3d\x252Fweb\x252Fcochrane\x252Fcontent\x253FtemplateType\x253Dfull\x2526urlTitle\x253D\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD011395\x2epub2\x2526doi\x253D10\x2e1002\x252F14651858\x2eCD011395\x2epub2\x2526type\x253Dcdsr\x2526contentLanguage\x253D\x26templateType\x3dfull\x26urlTitle\x3d\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD011395\x2epub2\x26contentLanguage\x3d\x26type\x3dcdsr\x26doi\x3d10\x2e1002\x252F14651858\x2eCD011395\x2epub2"});Liferay.Portlet.register("scolarissearchportlet_WAR_scolarissearch");Liferay.Portlet.onLoad({canEditTitle:false,columnPos:0,isStatic:"end",namespacedId:"p_p_id_scolarissearchportlet_WAR_scolarissearch_",portletId:"scolarissearchportlet_WAR_scolarissearch",refreshURL:"\x2fen\x2fc\x2fportal\x2frender_portlet\x3fp_l_id\x3d20757\x26p_p_id\x3dscolarissearchportlet_WAR_scolarissearch\x26p_p_lifecycle\x3d0\x26p_t_lifecycle\x3d0\x26p_p_state\x3dnormal\x26p_p_mode\x3dview\x26p_p_col_id\x3dnull\x26p_p_col_pos\x3dnull\x26p_p_col_count\x3dnull\x26p_p_static\x3d1\x26p_p_isolated\x3d1\x26currentURL\x3d\x252Fweb\x252Fcochrane\x252Fcontent\x253FtemplateType\x253Dfull\x2526urlTitle\x253D\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD011395\x2epub2\x2526doi\x253D10\x2e1002\x252F14651858\x2eCD011395\x2epub2\x2526type\x253Dcdsr\x2526contentLanguage\x253D\x26templateType\x3dfull\x26urlTitle\x3d\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD011395\x2epub2\x26contentLanguage\x3d\x26type\x3dcdsr\x26doi\x3d10\x2e1002\x252F14651858\x2eCD011395\x2epub2"});Liferay.Portlet.register("scolariscontentlanguagebanner_WAR_scolarislanguageportlet");Liferay.Portlet.onLoad({canEditTitle:false,columnPos:0,isStatic:"end",namespacedId:"p_p_id_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_",portletId:"scolariscontentlanguagebanner_WAR_scolarislanguageportlet",refreshURL:"\x2fen\x2fc\x2fportal\x2frender_portlet\x3fp_l_id\x3d20757\x26p_p_id\x3dscolariscontentlanguagebanner_WAR_scolarislanguageportlet\x26p_p_lifecycle\x3d0\x26p_t_lifecycle\x3d0\x26p_p_state\x3dnormal\x26p_p_mode\x3dview\x26p_p_col_id\x3dnull\x26p_p_col_pos\x3dnull\x26p_p_col_count\x3dnull\x26p_p_static\x3d1\x26p_p_isolated\x3d1\x26currentURL\x3d\x252Fweb\x252Fcochrane\x252Fcontent\x253FtemplateType\x253Dfull\x2526urlTitle\x253D\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD011395\x2epub2\x2526doi\x253D10\x2e1002\x252F14651858\x2eCD011395\x2epub2\x2526type\x253Dcdsr\x2526contentLanguage\x253D\x26templateType\x3dfull\x26urlTitle\x3d\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD011395\x2epub2\x26contentLanguage\x3d\x26type\x3dcdsr\x26doi\x3d10\x2e1002\x252F14651858\x2eCD011395\x2epub2"});AUI().use("aui-base","liferay-menu","liferay-notice","liferay-poller","liferay-session",function(a){(function(){Liferay.Util.addInputType();Liferay.Portlet.ready(function(b,c){Liferay.Util.addInputType(c)});if(a.UA.mobile){Liferay.Util.addInputCancel()}})();(function(){new Liferay.Menu();var b=Liferay.Data.notices;for(var c=1;c<b.length;c++){new Liferay.Notice(b[c])}})();(function(){Liferay.Session=new Liferay.SessionBase({autoExtend:true,sessionLength:1800,redirectOnExpire:false,redirectUrl:"https\x3a\x2f\x2fwww\x2ecochranelibrary\x2ecom\x2fweb\x2fcochrane",warningLength:0})})()});</script> <script src="https://www.cochranelibrary.com/cochrane-theme/js/main.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1738734739000" type="text/javascript"></script> <script type="text/javascript"></script> <div class="mobile-righthand-nav"> <a class="rh-nav-close-btn" href="#"> <span>Close</span> <span class="fa fa-chevron-down"></span> </a> <div class="wrapper"> </div> <a class="rh-nav-open-btn" href="#"> <span>Review tools &amp; navigation</span> </a> </div> <iframe aria-hidden="true" id="printframe" name="printframe" style="position: absolute; left: -2000px; top: 0;" title="Print frame"></iframe> <iframe aria-hidden="true" id="citationExportFrame" name="citationExportFrame" style="position: absolute; left: -2000px; top: 0;" title="scolaris.citation.export.frame"></iframe> <nav> <div class="mobile-navigation"> <div class="close-container"> <a aria-label="Navigate back" class="main-nav-back-btn" href="#"><i class="fa fa-chevron-left"></i></a> <a class="main-nav-close-btn" href="#" title="Close menu">Close menu <i class="fa fa-times"></i></a> </div> <div class="mobile-search basic-search-container"> <div class="portlet-boundary portlet-boundary_scolarissearchportlet_WAR_scolarissearch_ portlet-static portlet-static-end" id="p_p_id_scolarissearchportlet_WAR_scolarissearch_"> <span id="p_scolarissearchportlet_WAR_scolarissearch"></span> <section class="portlet" id="portlet_scolarissearchportlet_WAR_scolarissearch"> <header class="portlet-topper"> <h1 class="portlet-title"> <span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Search\x20Portlet')"> <img alt="" id="ymag__null__null" src="/scolaris-search/icon.png"> <span class="taglib-text hide-accessible">Scolaris Search Portlet</span> </img></span> <span class="portlet-title-text">Scolaris Search Portlet</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolarissearchportlet_WAR_scolarissearch" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <div class="header-search"> <form action="https://www.cochranelibrary.com/en/content?p_auth=EBp84H4P&amp;p_p_id=scolarissearchportlet_WAR_scolarissearch&amp;p_p_lifecycle=1&amp;p_p_state=normal&amp;p_p_mode=view&amp;_scolarissearchportlet_WAR_scolarissearch_scolarisAction=redirectSearchResult" method="post"> <input name="searchType" type="hidden" value="basic"> <input name="facetDisplayName" type="hidden" value=""> <input name="facetQueryTerm" type="hidden" value=""/> <input name="facetQueryField" type="hidden" value=""/> <input name="facetCategory" type="hidden" value=""/> <fieldset class="fieldset"> <legend class="sr-only">Basic Search</legend> <div class="select search-by"> <select aria-label="Search by options" class="custom-select-enabled search-type" name="searchBy" title="Search by options"> <option value="1">Title Abstract Keyword</option> <option value="2">Record Title</option> <option value="3">Abstract</option> <option value="4">Author</option> <option value="5">Keyword</option> <option value="6">All Text</option> <option value="7">Publication Type</option> <option value="8">Source</option> <option value="9">DOI</option> <option value="14">Language</option> <option value="10">Accession Number</option> <option value="11">Trial Registry Number</option> <option value="12">Cochrane Group</option> <option value="13">Cochrane Topic</option> </select> </div> <div class="search-select-crg-container select" style="display: none;"> <select class="search-select-crg-list"></select> </div> <div class="search-select-topic-container select" data-topic-list-url="https://www.cochranelibrary.com/en/content?p_p_id=scolaristopics_WAR_scolaristopics&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=topics-list&amp;p_p_cacheability=cacheLevelPage" style="display: none;"> <select class="search-select-topic-list"></select> </div> <div class="search-select-cl-container select" style="display: none;"> <select class="search-select-cl-list"></select> </div> <div class="search-text-container"> <div class="control-group control-group-inline search-input-wrapper"> <input aria-label="Enter search term" class="field browser-search search-text ui-autocomplete-input" id="searchText" name="searchText" placeholder="Search" size="30" type="text" value=""/>
<div id="autocomplete-results"></div>
</div>
<div class="control-group control-group-inline search-button-wrapper">
<button aria-label="Search" class="searchByBtn" type="submit">
<i aria-hidden="true" class="fa fa-search"></i>
</button>
</div>
</div>
</fieldset>
</input></input></form>
</div>
<script>
    window.displayResultURL = 'https://www.cochranelibrary.com/en/content?p_p_id=scolarissearchportlet_WAR_scolarissearch&p_p_lifecycle=2&p_p_state=normal&p_p_mode=view&p_p_resource_id=getSuggestions&p_p_cacheability=cacheLevelPage&_scolarissearchportlet_WAR_scolarissearch_templateType=full&_scolarissearchportlet_WAR_scolarissearch_urlTitle=%2Fcdsr%2Fdoi%2F10.1002%2F14651858.CD011395.pub2&_scolarissearchportlet_WAR_scolarissearch_contentLanguage=&_scolarissearchportlet_WAR_scolarissearch_type=cdsr&_scolarissearchportlet_WAR_scolarissearch_doi=10.1002%2F14651858.CD011395.pub2';
    window.searchByOption = '';
</script>
</div>
</div>
</div>
<div style="display:none">
<input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
<a class="btn secondary" href="/en/browse-by-topic">Browse </a>
<a class="btn secondary advanced-search-button" href="/en/advanced-search">Advanced search</a>
</div>
<div class="menu-items parent">
<div>
<div class="nav-root-item parent">
<a class="language-selection-title-link" href="#" title="Select language">
<span class="mobile-nav-language-title">Select your preferred language </span></a> <span class="icon fa fa-caret-down"></span>
<div class="mob-child">
<div class="portlet-boundary portlet-boundary_scolarislanguageselector_WAR_scolarislanguageportlet_ portlet-static portlet-static-end" id="p_p_id_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_mobilenav_">
<span id="p_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_mobilenav"></span>
<section class="portlet" id="portlet_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_mobilenav">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Language\x20Selector')">
<img alt="" id="fdkn__null__null" src="/scolaris-language-portlet/icon.png"> <span class="taglib-text hide-accessible">Scolaris Language Selector</span> </img></span> <span class="portlet-title-text">Scolaris Language Selector</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_mobilenav" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <div class="language-display" data-content-languages="[de, en, es, fa, fr, hi, hr, id, ja, ko, hu, ms, nl, pl, pt, ru, ro, ta, th, zh_HANT, zh_HANS]"> <a class="language-select-mobile" href="#" title="Select your preferred language"> <i class="fa fa-file-text"></i> English </a> <a class="language-select-mobile" href="#" title="Select your preferred language"> <i class="fa fa-globe"></i> English </a> </div> <div class="form-content language-selector-modal child"> <div class="row-fluid"> <h3><i class="fa fa-file-text"></i> Cochrane review language</h3> <p>Select your preferred language for Cochrane reviews and other content. Sections without translation will be in English.</p> <div class="dropdown-trigger" id="active-content-language"> <span>English</span> <i aria-hidden="true" class="fa fa-caret-down"></i> </div> <div class="language-selector-dropdown"> <a class="content-language-selector" data-languagecode="de" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=de">Deutsch</a> <a class="content-language-selector is-active" data-languagecode="en" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=en">English</a> <a class="content-language-selector" data-languagecode="es" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=es">Español</a> <a class="content-language-selector" data-languagecode="fa" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=fa">فارسی</a> <a class="content-language-selector" data-languagecode="fr" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=fr">Français</a> <a class="content-language-selector" data-languagecode="hi" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=hi">हिन्दी</a> <a class="content-language-selector" data-languagecode="hr" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=hr">Hrvatski</a> <a class="content-language-selector" data-languagecode="id" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=id">Bahasa Indonesia</a> <a class="content-language-selector" data-languagecode="ja" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=ja">日本語</a> <a class="content-language-selector" data-languagecode="ko" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=ko">한국어</a> <a class="content-language-selector" data-languagecode="hu" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=hu">Magyar</a> <a class="content-language-selector" data-languagecode="ms" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=ms">Bahasa Malaysia</a> <a class="content-language-selector" data-languagecode="nl" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=nl">Nederlands</a> <a class="content-language-selector" data-languagecode="pl" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=pl">Polski</a> <a class="content-language-selector" data-languagecode="pt" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=pt">Português</a> <a class="content-language-selector" data-languagecode="ru" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=ru">Русский</a> <a class="content-language-selector" data-languagecode="ro" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=ro">Română</a> <a class="content-language-selector" data-languagecode="ta" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=ta">தமிழ்</a> <a class="content-language-selector" data-languagecode="th" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=th">ภาษาไทย</a> <a class="content-language-selector" data-languagecode="zh_HANT" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=zh_HANT">繁體中文</a> <a class="content-language-selector" data-languagecode="zh_HANS" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=zh_HANS">简体中文</a> </div> </div> <div class="row-fluid"> <h3 class="portal-language-header"><i class="fa fa-globe"></i> Website language</h3> <p>Select your preferred language for the Cochrane Library website.</p> <div class="dropdown-trigger" id="active-portal-language"> <span>English</span> <i aria-hidden="true" class="fa fa-caret-down"></i> </div> <div class="language-selector-dropdown"> <a class="portal-language-selector is-active" data-portallanguage="en" href="/en/cdsr/doi/10.1002/14651858.CD011395.pub2/full/en">English</a> <a class="portal-language-selector" data-portallanguage="es" href="/es/cdsr/doi/10.1002/14651858.CD011395.pub2/full/es">Español</a> </div> </div> <a class="btn secondary ok-btn pull-right" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage">Save</a> </div> </div> </div> </div> <div style="display:none"> <input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
</div>
</div>
<div class="parent">
<a class="mobile-link signin" data-redirect="false" href="https://www.cochranelibrary.com/c/portal/login?p_l_id=20757&amp;redirect=%2Fcdsr%2Fdoi%2F10.1002%2F14651858.CD011395.pub2%2Ffull" rel="nofollow">
                        Sign In
                    </a>
</div>
</div>
<div class="menu-items-footer">
<div class="utility-links">
<a class="cochrane-link" href="http://www.cochrane.org/" target="_blank">Visit Cochrane.org</a>
</div>
</div>
</div>
<div class="menu-items child"></div>
</div>
</nav><div class="basic-login-form-content" data-modal-title="Sign in" style="display: none;">
<div class="form-content">
<div class="row-fluid">
<div class="span12">
<div class="portlet-boundary portlet-boundary_58_ portlet-static portlet-static-end portlet-login" id="p_p_id_58_INSTANCE_MODAL_">
<span id="p_58_INSTANCE_MODAL"></span>
<section class="portlet" id="portlet_58_INSTANCE_MODAL">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Sign\x20In')">
<img alt="" id="dbam__null__null" src="https://www.cochranelibrary.com/cochrane-theme/images/spacer.png" style="background-image: url('https://www.cochranelibrary.com/sprite/html/icons/_sprite.png'); background-position: 50% -592px; background-repeat: no-repeat; height: 16px; width: 16px;"> <span class="taglib-text hide-accessible">Sign In</span> </img></span> <span class="portlet-title-text">Sign In</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_58_INSTANCE_MODAL" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <form action="https://www.cochranelibrary.com/en/content?p_p_id=58_INSTANCE_MODAL&amp;p_p_lifecycle=1&amp;p_p_state=normal&amp;p_p_mode=view&amp;_58_INSTANCE_MODAL_struts_action=%2Flogin%2Flogin" autocomplete="on" class="form sign-in-form" id="_58_INSTANCE_MODAL_fm" method="post" name="_58_INSTANCE_MODAL_fm"> <fieldset class="input-container" disabled="disabled"> <legend class="sr-only">Cochrane Login</legend> <input name="_58_INSTANCE_MODAL_formDate" type="hidden" value="1740728667894"> <input class="field" id="_58_INSTANCE_MODAL_saveLastPath" name="_58_INSTANCE_MODAL_saveLastPath" type="hidden" value="false"> <input class="field" id="_58_INSTANCE_MODAL_redirect" name="_58_INSTANCE_MODAL_redirect" type="hidden" value="/cdsr/doi/10.1002/14651858.CD011395.pub2/full"> <input class="field" id="_58_INSTANCE_MODAL_doActionAfterLogin" name="_58_INSTANCE_MODAL_doActionAfterLogin" type="hidden" value="false"> <div class="control-group input-text-wrapper"> <label class="control-label" for="_58_INSTANCE_MODAL_login"> Email Address </label> <input class="field clearable" id="_58_INSTANCE_MODAL_login" name="_58_INSTANCE_MODAL_login" type="text" value=""> </input></div> <div class="control-group input-text-wrapper"> <label class="control-label" for="_58_INSTANCE_MODAL_password"> Password </label> <input class="field" id="_58_INSTANCE_MODAL_password" name="_58_INSTANCE_MODAL_password" type="password" value=""/> </div> <span id="_58_INSTANCE_MODAL_passwordCapsLockSpan" style="display: none;"> Caps Lock is on. </span> <div class="clearfix"> <div class="checkbox-list pull-left"> <div class="checkbox-list-item"> <div class="control-group form-inline input-checkbox-wrapper"> <label for="_58_INSTANCE_MODAL_rememberMeCheckbox"> <input id="_58_INSTANCE_MODAL_rememberMe" name="_58_INSTANCE_MODAL_rememberMe" type="hidden" value="true"/> <input checked="" class="field" id="_58_INSTANCE_MODAL_rememberMeCheckbox" name="_58_INSTANCE_MODAL_rememberMeCheckbox" onclick="Liferay.Util.updateCheckboxValue(this); " type="checkbox" value="true"/> Remember Me </label> </div> </div> </div> <div class="pull-right"> <a href="https://onlinelibrary.wiley.com/user/forgottenpassword" target="_blank">Forgotten password?</a> </div> </div> <div class="login-form-footer clearfix"> <div class="pull-left"> <button class="btn primary" type="submit">Sign in</button> <a class="btn secondary" href="https://onlinelibrary.wiley.com/user-registration" target="_blank">Register</a> </div> <div class="pull-right"> <a class="institutional-login-form-button" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentdisplay_WAR_scolariscontentdisplay&amp;p_p_lifecycle=0&amp;p_p_state=normal&amp;p_p_mode=view&amp;_scolariscontentdisplay_WAR_scolariscontentdisplay_action=institution-access">Institutional login</a> </div> </div> </input></input></input></input></fieldset> </form> </div> </div> </div> <div style="display:none"> <input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
</div>
</div>
</div></div>
<div class="institution-login-form-content" data-modal-title="Institutional login" style="display: none;">
<div class="form-content">
<div class="row-fluid access-content-wrapper">
<div class="span12">
<div class="section">
<div class="portlet-boundary portlet-boundary_scolariscontentdisplay_WAR_scolariscontentdisplay_ portlet-static portlet-static-end scolaris-content-display-portlet" id="p_p_id_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_combinedloginform_">
<span id="p_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_combinedloginform"></span>
<section class="portlet" id="portlet_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_combinedloginform">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Content\x20Display')">
<img alt="" id="obft__null__null" src="/scolaris-content-display/icon.png"> <span class="taglib-text hide-accessible">Scolaris Content Display</span> </img></span> <span class="portlet-title-text">Scolaris Content Display</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_combinedloginform" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <div class="access-content-section"> <div class="section-content"> <p>Search for your institution's name below to login via Shibboleth</p> <form action="/shibboleth" id="institutionLoginForm" method="post"> <div class="fieldset"> <div class="form-group access-input-wrapper"> <div class="ui-widget ui-front"> <label class="sr-only" for="institutionName">Institution name</label> <input class="field" id="institutionName" name="institutionName" type="text" value=""/>
</div>
<button class="btn primary" name="button" type="submit">Go</button>
</div>
<div class="message error" id="institutionLookupErrorDiv" style="display:none">
                        '<span id="enteredInstitionNameSpan"></span>' is not set up for this type of access on Wiley Online Library. Please contact your institution's administrator to ask about access.
                    </div>
</div>
<input id="entityId" name="entityId" type="hidden" value=""/>
</form>
<h4>Previously accessed institutions</h4>
<ul class="plain" id="previousInstitutions">
<li>(none)</li>
</ul>
</div>
<div class="section-content">
<div class="open-athens-login">
                Login using <a href="/openathens">OpenAthens</a>
</div>
</div>
</div>
</div>
</div>
</div>
<div style="display:none">
<input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
<div class="portlet-boundary portlet-boundary_58_ portlet-static portlet-static-end portlet-login" id="p_p_id_58_INSTANCE_4_">
<span id="p_58_INSTANCE_4"></span>
<section class="portlet" id="portlet_58_INSTANCE_4">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Sign\x20In')">
<img alt="" id="joiu__null__null" src="https://www.cochranelibrary.com/cochrane-theme/images/spacer.png" style="background-image: url('https://www.cochranelibrary.com/sprite/html/icons/_sprite.png'); background-position: 50% -592px; background-repeat: no-repeat; height: 16px; width: 16px;"> <span class="taglib-text hide-accessible">Sign In</span> </img></span> <span class="portlet-title-text">Sign In</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_58_INSTANCE_4" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <p>If you have a <strong>Wiley Online Library</strong> institutional username and password, enter them here.</p> <form action="https://www.cochranelibrary.com/en/content?p_p_id=58_INSTANCE_4&amp;p_p_lifecycle=1&amp;p_p_state=normal&amp;p_p_mode=view&amp;_58_INSTANCE_4_struts_action=%2Flogin%2Flogin" autocomplete="on" class="form sign-in-form" id="_58_INSTANCE_4_fm" method="post" name="_58_INSTANCE_4_fm"> <fieldset class="input-container" disabled="disabled"> <legend class="sr-only">Cochrane Login</legend> <input name="_58_INSTANCE_4_formDate" type="hidden" value="1740728667900"> <input class="field" id="_58_INSTANCE_4_saveLastPath" name="_58_INSTANCE_4_saveLastPath" type="hidden" value="false"> <input class="field" id="_58_INSTANCE_4_redirect" name="_58_INSTANCE_4_redirect" type="hidden" value="/cdsr/doi/10.1002/14651858.CD011395.pub2/full"> <input class="field" id="_58_INSTANCE_4_doActionAfterLogin" name="_58_INSTANCE_4_doActionAfterLogin" type="hidden" value="false"> <div class="control-group input-text-wrapper"> <label class="control-label" for="_58_INSTANCE_4_login"> Username </label> <input class="field clearable" id="_58_INSTANCE_4_login" name="_58_INSTANCE_4_login" type="text" value=""> </input></div> <div class="control-group input-text-wrapper"> <label class="control-label" for="_58_INSTANCE_4_password"> Password </label> <input class="field" id="_58_INSTANCE_4_password" name="_58_INSTANCE_4_password" type="password" value=""> </input></div> <input class="field" id="_58_INSTANCE_4_institutionalLogin" name="_58_INSTANCE_4_institutionalLogin" type="hidden" value="true"/> <span id="_58_INSTANCE_4_passwordCapsLockSpan" style="display: none;"> Caps Lock is on. </span> <div class="login-form-footer clearfix"> <div class="pull-left"> <button class="btn primary" type="submit">Sign in</button> </div> </div> </input></input></input></input></fieldset> </form> </div> </div> </div> <div style="display:none"> <input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
</div>
</div>
</div>
</div></div>
<div class="get-access-form-content" data-modal-title="Unlock gold-standard Cochrane evidence" style="display: none;">
<div class="portlet-boundary portlet-boundary_scolariscontentdisplay_WAR_scolariscontentdisplay_ portlet-static portlet-static-end scolaris-content-display-portlet" id="p_p_id_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_getaccessform_">
<span id="p_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_getaccessform"></span>
<section class="portlet" id="portlet_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_getaccessform">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Content\x20Display')">
<img alt="" id="wpdq__null__null" src="/scolaris-content-display/icon.png"> <span class="taglib-text hide-accessible">Scolaris Content Display</span> </img></span> <span class="portlet-title-text">Scolaris Content Display</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_getaccessform" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <div class="readcube-checkout-container-outer"> <div class="row-fluid access-content-wrapper"> <div class="span6 access-left-content"> <div class="section"> <div class="section-content"> <p>Improve your health decisions with access to trusted, independent evidence from the Cochrane Library. Unlock this review for uninterrupted access.</p> <p>Still deciding? <a href="https://m.info.wiley.com/webApp/cochranenewsletter"> Sign up to our newsletter to learn more </a> </p> </div> </div> <div class="section"> <div class="access-content-section"> <h3 class="title">Institutional users</h3> <div class="section-content"> <p>Search for your institution's name below to login via Shibboleth</p> <form action="/shibboleth" id="institutionLoginForm" method="post"> <div class="fieldset"> <div class="form-group access-input-wrapper"> <div class="ui-widget ui-front"> <label class="sr-only" for="institutionName">Institution name</label> <input class="field" id="institutionName" name="institutionName" type="text" value=""/> </div> <button class="btn primary" name="button" type="submit">Go</button> </div> <div class="message error" id="institutionLookupErrorDiv" style="display:none"> '<span id="enteredInstitionNameSpan"></span>' is not set up for this type of access on Wiley Online Library. Please contact your institution's administrator to ask about access. </div> </div> <input id="entityId" name="entityId" type="hidden" value=""/> </form> <h4>Previously accessed institutions</h4> <ul class="plain" id="previousInstitutions"> <li>(none)</li> </ul> </div> <div class="section-content"> <div class="open-athens-login"> Login using <a href="/openathens">OpenAthens</a> </div> </div> </div> </div> <div class="section"> <div class="access-content-section"> <h3 class="title"> Other access options </h3> <div class="section-content"> <ul class="plain"> <li> <a class="get-access-individual-login-button" href="/c/portal/login"> Individual access - via Wiley Online Library </a> </li> </ul> </div> </div> </div> </div> <div class="span6 access-right-content readcube-checkout-container"> <div class="section"> </div> </div> </div> </div> </div> </div> </div> <div style="display:none"> <input id="freelabel" name="freelabel" type="hidden" value="Free access"/> <input id="openlabel" name="openlabel" type="hidden" value="Open access"/> </div> </section> </div> </div> <!-- Scolaris Version: --> <script type="text/javascript">if(window._satellite){_satellite.pageBottom()};</script> </div> <script>(function(){function c(){var b=a.contentDocument||a.contentWindow.document;if(b){var d=b.createElement('script');d.innerHTML="window.__CF$cv$params={r:'918eca170be7f56f',t:'MTc0MDcyODY2OC4wMDAwMDA='};var a=document.createElement('script');a.nonce='';a.src='/cdn-cgi/challenge-platform/scripts/jsd/main.js';document.getElementsByTagName('head')[0].appendChild(a);";b.getElementsByTagName('head')[0].appendChild(d)}}if(document.body){var a=document.createElement('iframe');a.height=1;a.width=1;a.style.position='absolute';a.style.top=0;a.style.left=0;a.style.border='none';a.style.visibility='hidden';document.body.appendChild(a);if('loading'!==document.readyState)c();else if(window.addEventListener)document.addEventListener('DOMContentLoaded',c);else{var e=document.onreadystatechange||function(){};document.onreadystatechange=function(b){e(b);'loading'!==document.readyState&&(document.onreadystatechange=e,c())}}}})();</script></body> </html> 